1	Pharmacologic	O
2	aspects	O
3	of	O
4	neonatal	O
5	hyperbilirubinemia	O
6	.	O

1	Flurazepam	O
2	thus	O
3	appears	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	hypnotic	O
9	drug	O
10	with	O
11	the	O
12	optimum	O
13	dose	O
14	for	O
15	use	O
16	in	O
17	general	O
18	practice	O
19	being	O
20	15	O
21	mg	O
22	at	O
23	night	O
24	.	O

1	When	O
2	extracorporeal	O
3	CO2	O
4	removal	O
5	approximated	O
6	CO2	O
7	production	O
8	(	O
9	VCO2	O
10	),	O
11	alveolar	O
12	ventilation	O
13	almost	O
14	ceased	O
15	.	O

1	Serum	B
2	gamma	I
3	glutamyltransferase	I
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	Selective	O
2	stimulation	O
3	of	O
4	central	O
5	alpha	B
6	-	I
7	autoreceptors	I
8	following	O
9	treatment	O
10	with	O
11	alpha	O
12	-	O
13	methyldopa	O
14	and	O
15	FLA	O
16	136	O
17	.	O

1	Studies	O
2	on	O
3	immunoglobulin	B
4	E	I
5	:	O
6	the	O
7	impact	O
8	of	O
9	a	O
10	sojourn	O
11	with	O
12	Professor	O
13	Dan	O
14	H	O
15	.	O

1	Ten	O
2	out	O
3	-	O
4	patients	O
5	with	O
6	pustulosis	O
7	palmaris	O
8	et	O
9	plantaris	O
10	were	O
11	examined	O
12	with	O
13	direct	O
14	immunofluorescence	O
15	(	O
16	IF	O
17	)	O
18	technique	O
19	for	O
20	deposition	O
21	of	O
22	fibrinogen	B
23	,	O
24	fibrin	B
25	or	O
26	its	O
27	degradation	O
28	products	O
29	(	O
30	FR	B
31	-	I
32	antigen	I
33	)	O
34	in	O
35	affected	O
36	and	O
37	unaffected	O
38	skin	O
39	,	O
40	together	O
41	with	O
42	heparin	O
43	-	O
44	precipitable	O
45	fraction	O
46	(	O
47	HPF	O
48	),	O
49	cryoglobulin	B
50	and	O
51	total	O
52	plasma	O
53	fibrinogen	B
54	in	O
55	the	O
56	blood	O
57	.	O

1	False	O
2	positive	O
3	amniotic	B
4	fluid	I
5	alpha	I
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	Preface	O
2	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	According	O
2	to	O
3	their	O
4	functional	O
5	properties	O
6	the	O
7	latter	O
8	neurons	O
9	were	O
10	subdivided	O
11	into	O
12	:	O
13	(	O
14	a	O
15	)	O
16	neurons	O
17	responding	O
18	to	O
19	stimuli	O
20	near	O
21	the	O
22	eyes	O
23	;	O
24	(	O
25	b	O
26	)	O
27	neurons	O
28	triggered	O
29	by	O
30	complex	O
31	visual	O
32	stimuli	O
33	;	O
34	(	O
35	c	O
36	)	O
37	neurons	O
38	inhibited	O
39	by	O
40	visual	O
41	stimuli	O
42	.	O

1	Pb	O
2	foil	O
3	(	O
4	0	O
5	.	O
6	55	O
7	gcm	O
8	-	O
9	2	O
10	)	O
11	provided	O
12	the	O
13	best	O
14	overall	O
15	improvement	O
16	.	O

1	All	O
2	groups	O
3	were	O
4	tested	O
5	in	O
6	a	O
7	Hebb	O
8	-	O
9	Williams	O
10	maze	O
11	at	O
12	100	O
13	approximately	O
14	10	O
15	days	O
16	of	O
17	age	O
18	.	O

1	Imposed	O
2	angular	O
3	displacements	O
4	of	O
5	monkey	O
6	'	O
7	s	O
8	wrist	O
9	produce	O
10	three	O
11	major	O
12	peaks	O
13	of	O
14	activity	O
15	(	O
16	terms	O
17	M1	O
18	,	O
19	M2	O
20	,	O
21	and	O
22	M3	O
23	peaks	O
24	)	O
25	in	O
26	the	O
27	averaged	O
28	gross	O
29	EMG	O
30	activity	O
31	ot	O
32	the	O
33	stretched	O
34	muscles	O
35	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	The	O
2	maintenance	O
3	of	O
4	increased	O
5	myocardial	O
6	capillary	O
7	density	O
8	required	O
9	a	O
10	similar	O
11	amount	O
12	of	O
13	exercise	O
14	,	O
15	and	O
16	at	O
17	least	O
18	1	O
19	h	O
20	of	O
21	exercise	O
22	once	O
23	a	O
24	week	O
25	was	O
26	necessary	O
27	to	O
28	maintain	O
29	the	O
30	enlargement	O
31	of	O
32	ECA	O
33	.	O
34	20	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Prediction	O
2	of	O
3	the	O
4	times	O
5	of	O
6	sandfly	O
7	development	O

1	Native	O
2	human	B
3	fibrinogen	I
4	was	O
5	brought	O
6	to	O
7	coagulation	O
8	by	O
9	adding	O
10	thrombin	B
11	.	O

1	The	O
2	inner	O
3	ears	O
4	were	O
5	exposed	O
6	by	O
7	microdissection	O
8	,	O
9	and	O
10	the	O
11	vestibular	O
12	sensory	O
13	regions	O
14	were	O
15	either	O
16	sectioned	O
17	and	O
18	studied	O
19	with	O
20	light	O
21	or	O
22	electron	O
23	microscopy	O
24	,	O
25	or	O
26	prepared	O
27	and	O
28	studied	O
29	with	O
30	the	O
31	surface	O
32	specimen	O
33	technique	O
34	.	O

1	Steroid	O
2	glucuronides	O
3	in	O
4	amniotic	O
5	fluid	O
6	at	O
7	term	O
8	.	O

1	Innervation	O
2	of	O
3	the	O
4	ventral	O
5	diaphragm	O
6	of	O
7	the	O
8	locust	O
9	(	O
10	Locusta	O
11	migratoria	O
12	).	O

1	Ectopic	O
2	ACTH	B
3	syndrome	O
4	and	O
5	medullary	O
6	thyroid	O
7	carcinoma	O
8	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	B
18	contents	O
19	.	O

1	Chronic	O
2	hypophosphatemia	O
3	is	O
4	the	O
5	most	O
6	common	O
7	type	O
8	of	O
9	"	O
10	resistant	O
11	"	O
12	rickets	O
13	.	O

1	The	O
2	incidence	O
3	of	O
4	hepatitis	B
5	B	I
6	antigen	I
7	following	O
8	transfusion	O
9	was	O
10	about	O
11	2	O
12	.	O
13	8	O
14	per	O
15	cent	O
16	.	O

1	A	O
2	similar	O
3	phenomenon	O
4	has	O
5	been	O
6	reported	O
7	in	O
8	a	O
9	few	O
10	humans	O
11	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	Total	O
2	VO2	O
3	was	O
4	decreased	O
5	in	O
6	both	O
7	groups	O
8	during	O
9	severe	O
10	hypoxia	O
11	but	O
12	limb	O
13	VO2	O
14	was	O
15	maintained	O
16	in	O
17	the	O
18	beta	O
19	-	O
20	block	O
21	group	O
22	.	O
23	beta	O
24	-	O
25	Block	O
26	prevented	O
27	the	O
28	fall	O
29	in	O
30	total	O
31	and	O
32	limb	O
33	peripheral	O
34	resistance	O
35	seen	O
36	in	O
37	severe	O
38	hypoxia	O
39	but	O
40	did	O
41	not	O
42	alter	O
43	the	O
44	consistently	O
45	more	O
46	efficient	O
47	utilization	O
48	of	O
49	total	O
50	O2	O
51	delivery	O
52	shown	O
53	by	O
54	the	O
55	limb	O
56	in	O
57	comparison	O
58	to	O
59	the	O
60	whole	O
61	body	O
62	by	O
63	higher	O
64	O2	O
65	extraction	O
66	ratios	O
67	and	O
68	lower	O
69	venous	O
70	O2	O
71	pressure	O
72	.	O
73	beta	B
74	-	I
75	Vasodilator	I
76	receptors	I
77	evidently	O
78	played	O
79	an	O
80	active	O
81	part	O
82	in	O
83	the	O
84	vasodilatation	O
85	seen	O
86	during	O
87	severe	O
88	hypoxia	O
89	.	O

1	A	O
2	rapid	O
3	fluorimetric	O
4	procedure	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	the	O
10	fungicide	O
11	5	O
12	-	O
13	fluorocytosine	O
14	in	O
15	serum	O
16	is	O
17	described	O
18	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	Similarly	O
2	,	O
3	maternal	B
4	serum	I
5	somatomedin	I
6	A	I
7	was	O
8	significantly	O
9	reduced	O
10	in	O
11	rats	O
12	nursing	O
13	large	O
14	litters	O
15	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	serum	B
6	alpha1AT	I
7	quantitation	O
8	,	O
9	newborn	O
10	infants	O
11	may	O
12	be	O
13	separated	O
14	into	O
15	two	O
16	groups	O
17	,	O
18	characterized	O
19	respectively	O
20	by	O
21	concentrations	O
22	above	O
23	or	O
24	below	O
25	150	O
26	mg	O
27	%.	O

1	In	O
2	patients	O
3	who	O
4	were	O
5	not	O
6	vented	O
7	,	O
8	there	O
9	was	O
10	overall	O
11	significant	O
12	depression	O
13	of	O
14	function	O
15	(	O
16	67	O
17	+/-	O
18	5	O
19	%	O
20	of	O
21	control	O
22	;	O
23	range	O
24	,	O
25	91	O
26	--	O
27	45	O
28	%,	O
29	p	O
30	less	O
31	than	O
32	0	O
33	.	O
34	01	O
35	).	O

1	The	O
2	uterine	O
3	response	O
4	to	O
5	prostaglandin	O
6	E2	O
7	(	O
8	PGE2	O
9	)	O
10	and	O
11	prostaglandin	O
12	F2alpha	O
13	(	O
14	administered	O
15	by	O
16	intravenous	O
17	and	O
18	intrauterine	O
19	routes	O
20	)	O
21	was	O
22	evaluated	O
23	during	O
24	different	O
25	phases	O
26	of	O
27	the	O
28	menstrual	O
29	cycle	O
30	in	O
31	five	O
32	functionally	O
33	infertile	O
34	women	O
35	.	O

1	High	O
2	levels	O
3	of	O
4	serum	O
5	calcitonin	B
6	were	O
7	found	O
8	in	O
9	patients	O
10	with	O
11	chronic	O
12	renal	O
13	failure	O
14	.	O

1	Use	O
2	of	O
3	radioactive	O
4	isotopes	O
5	in	O
6	the	O
7	chemistry	O
8	of	O
9	proteins	O

1	(	O
2	Emeritus	O
3	)	O
4	John	O
5	Henri	O
6	Roosegaarde	O
7	Bisschop	O

1	Disrupted	O
2	vaccines	O
3	and	O
4	whole	O
5	-	O
6	virus	O
7	vaccines	O
8	containing	O
9	type	B
10	B	I
11	antigen	I
12	only	O
13	did	O
14	not	O
15	cause	O
16	significant	O
17	reactivity	O
18	.	O

1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	B
22	coli	I
23	endotoxin	I
24	intraperitoneally	O
25	.	O

1	Gonadal	O
2	dysfunction	O
3	in	O
4	patients	O
5	with	O
6	ataxia	O
7	telangiectasia	O
8	.	O

1	Bone	O
2	marrow	O
3	transplantation	O
4	-	O
5	1979	O
6	.	O

1	The	O
2	unilateral	O
3	vestibular	O
4	hypofunction	O
5	.	O

1	Inherent	O
2	hematology	O
3	of	O
4	old	O
5	age	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Immunologic	O
2	mechanisms	O
3	in	O
4	chronic	O
5	brucellosis	O
6	in	O
7	humans	O
8	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	Lethal	O
2	Tachmalcor	O
3	(	O
4	4	O
5	-(	O
6	3	O
7	'-	O
8	diethylamino	O
9	-	O
10	2	O
11	'-	O
12	hydroxypropyl	O
13	)-	O
14	ajmaline	O
15	)	O
16	poisoning	O
17	in	O
18	childhood	O

1	Serum	O
2	ferritin	B
3	concentration	O
4	and	O
5	bone	O
6	marrow	O
7	iron	O
8	stores	O
9	.	O

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	Data	O
2	were	O
3	processed	O
4	with	O
5	a	O
6	semi	O
7	-	O
8	automatic	O
9	computer	O
10	program	O
11	which	O
12	develops	O
13	an	O
14	averaged	O
15	-	O
16	volume	O
17	curve	O
18	from	O
19	an	O
20	assigned	O
21	LV	O
22	region	O
23	-	O
24	of	O
25	-	O
26	interest	O
27	.	O

1	Ultimate	O
2	strengthes	O
3	seem	O
4	to	O
5	be	O
6	reached	O
7	for	O
8	cast	O
9	cobalt	O
10	alloys	O
11	,	O
12	whereas	O
13	titanium	O
14	alloys	O
15	,	O
16	such	O
17	as	O
18	Ta	O
19	6	O
20	V	O
21	,	O
22	present	O
23	very	O
24	high	O
25	fatigue	O
26	limit	O
27	under	O
28	corrosion	O
29	.	O

1	Roentgenographically	O
2	,	O
3	the	O
4	lesion	O
5	was	O
6	usually	O
7	a	O
8	well	O
9	-	O
10	defined	O
11	and	O
12	benign	O
13	appearing	O
14	one	O
15	,	O
16	either	O
17	purely	O
18	lytic	O
19	(	O
20	3	O
21	cases	O
22	)	O
23	or	O
24	with	O
25	central	O
26	radiodensity	O
27	(	O
28	2	O
29	cases	O
30	).	O

1	Isolated	O
2	calcaneal	O
3	tuberculous	O
4	osteomyelitis	O
5	.	O

1	It	O
2	has	O
3	come	O
4	out	O
5	that	O
6	CAEC	O
7	is	O
8	between	O
9	CC	O
10	and	O
11	CIEC	O
12	and	O
13	that	O
14	attacks	O
15	of	O
16	biliary	O
17	fever	O
18	and	O
19	high	O
20	levels	O
21	of	O
22	alkaline	B
23	phosphatase	I
24	and	O
25	transaminases	O
26	in	O
27	the	O
28	serum	O
29	are	O
30	the	O
31	helpful	O
32	findings	O
33	for	O
34	preoperative	O
35	diagnosis	O
36	.	O

1	Changes	O
2	of	O
3	thirtynine	O
4	serum	O
5	protein	O
6	components	O
7	following	O
8	surgical	O
9	stress	O
10	.	O

1	All	O
2	13	O
3	patients	O
4	showed	O
5	endoscopic	O
6	evidence	O
7	of	O
8	oesophagitis	O
9	,	O
10	moderate	O
11	in	O
12	4	O
13	and	O
14	severe	O
15	in	O
16	9	O
17	.	O

1	Urinary	O
2	excretion	O
3	of	O
4	oestrone	O
5	,	O
6	oestradiol	O
7	-	O
8	17	O
9	beta	O
10	and	O
11	oestriol	O
12	in	O
13	pregnancies	O
14	complicated	O
15	by	O
16	steroid	B
17	sulphatase	I
18	deficiency	O
19	.	O

1	With	O
2	certain	O
3	exceptions	O
4	the	O
5	method	O
6	was	O
7	considered	O
8	suitable	O
9	in	O
10	the	O
11	routine	O
12	intravenous	O
13	cholangiography	O
14	.	O

1	(	O
2	5	O
3	)	O
4	No	O
5	changes	O
6	were	O
7	observed	O
8	in	O
9	the	O
10	gastric	O
11	venous	O
12	blood	O
13	flow	O
14	by	O
15	continuous	O
16	intravenous	O
17	injection	O
18	of	O
19	cimetidine	O
20	,	O
21	but	O
22	by	O
23	rapid	O
24	injection	O
25	both	O
26	the	O
27	flow	O
28	was	O
29	augmented	O
30	and	O
31	the	O
32	systemic	O
33	blood	O
34	pressure	O
35	decreased	O
36	transiently	O
37	.	O

1	Changes	O
2	in	O
3	ionic	O
4	content	O
5	of	O
6	the	O
7	mucous	O
8	suggest	O
9	that	O
10	cholinergic	O
11	mechanisms	O
12	affect	O
13	pressure	O
14	in	O
15	the	O
16	excretory	O
17	duct	O
18	of	O
19	the	O
20	gland	O
21	.	O

1	In	O
2	the	O
3	duodenum	O
4	a	O
5	small	O
6	part	O
7	of	O
8	the	O
9	administered	O
10	dose	O
11	was	O
12	transformed	O
13	to	O
14	3H	O
15	-	O
16	alpha	O
17	-	O
18	acetyldigoxin	O
19	.	O

1	Although	O
2	it	O
3	has	O
4	been	O
5	shown	O
6	that	O
7	it	O
8	is	O
9	possible	O
10	to	O
11	use	O
12	orally	O
13	administered	O
14	testosterone	O
15	to	O
16	maintain	O
17	se	O
18	-	O
19	T	O
20	levels	O
21	in	O
22	the	O
23	normal	O
24	male	O
25	range	O
26	,	O
27	the	O
28	convenience	O
29	to	O
30	the	O
31	patient	O
32	must	O
33	be	O
34	balanced	O
35	against	O
36	the	O
37	cost	O
38	and	O
39	possible	O
40	side	O
41	effects	O
42	of	O
43	the	O
44	large	O
45	doses	O
46	required	O
47	.	O

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Screening	O
2	of	O
3	asthma	O
4	patients	O
5	by	O
6	determination	O
7	of	O
8	IgE	B
9	and	O
10	by	O
11	comprehension	O
12	of	O
13	spectrum	O
14	of	O
15	allergospecific	B
16	IgE	I
17	antibodies	I

1	The	O
2	induction	O
3	of	O
4	seizures	O
5	in	O
6	"	O
7	Papio	O
8	papio	O
9	"	O
10	following	O
11	allylglycine	O
12	alone	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	intermittent	O
18	photic	O
19	stimulation	O

1	Serum	O
2	levels	O
3	of	O
4	IgG	B
5	and	O
6	IgM	B
7	were	O
8	also	O
9	raised	O
10	,	O
11	but	O
12	contrary	O
13	to	O
14	the	O
15	findings	O
16	of	O
17	other	O
18	observers	O
19	IgA	B
20	levels	O
21	were	O
22	normal	O
23	.	O

1	A	O
2	decrease	O
3	of	O
4	the	O
5	lysozyme	B
6	activity	O
7	coincided	O
8	with	O
9	the	O
10	clinical	O
11	improvement	O
12	of	O
13	the	O
14	bacterial	O
15	meningitis	O
16	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	1	O
2	The	O
3	effects	O
4	in	O
5	normal	O
6	subjects	O
7	of	O
8	a	O
9	single	O
10	oral	O
11	dose	O
12	of	O
13	Motival	O
14	(	O
15	one	O
16	tablet	O
17	,	O
18	containing	O
19	fluphenazine	O
20	0	O
21	.	O
22	5	O
23	mg	O
24	and	O
25	nortriptyline	O
26	10	O
27	mg	O
28	)	O
29	on	O
30	the	O
31	contingent	O
32	negative	O
33	variation	O
34	(	O
35	CNV	O
36	),	O
37	reaction	O
38	time	O
39	,	O
40	heart	O
41	rate	O
42	,	O
43	blood	O
44	pressure	O
45	and	O
46	self	O
47	-	O
48	rating	O
49	scales	O
50	for	O
51	alertness	O
52	,	O
53	anxiety	O
54	,	O
55	tension	O
56	,	O
57	detachment	O
58	and	O
59	depression	O
60	were	O
61	compared	O
62	with	O
63	those	O
64	of	O
65	diazepam	O
66	(	O
67	5	O
68	mg	O
69	and	O
70	7	O
71	.	O
72	5	O
73	mg	O
74	)	O
75	and	O
76	placebo	O
77	or	O
78	propranolol	O
79	(	O
80	60	O
81	mg	O
82	).	O

1	Smoking	O
2	was	O
3	regarded	O
4	as	O
5	the	O
6	major	O
7	contribution	O
8	to	O
9	pulmonary	O
10	dysfunction	O
11	.	O

1	The	O
2	malignity	O
3	of	O
4	nevoid	O
5	lentigo	O
6	.	O

1	Diuretics	O
2	:	O
3	basic	O
4	clinical	O
5	pharmacology	O
6	and	O
7	therapeutic	O
8	use	O
9	.	O

1	2	O
2	)	O
3	The	O
4	time	O
5	-	O
6	sharing	O
7	principle	O
8	was	O
9	applied	O
10	to	O
11	gain	O
12	high	O
13	stability	O
14	.	O

1	Increased	O
2	urinary	O
3	riboflavin	O
4	excretion	O
5	resulting	O
6	from	O
7	boric	O
8	acid	O
9	ingestion	O
10	.	O

1	Radionuclide	O
2	angiography	O
3	and	O
4	static	O
5	whole	O
6	body	O
7	imaging	O
8	performed	O
9	with	O
10	technetium	O
11	-	O
12	99m	O
13	-	O
14	labeled	O
15	particulates	O
16	can	O
17	clearly	O
18	demonstrate	O
19	differential	O
20	shunting	O
21	in	O
22	patients	O
23	with	O
24	patent	O
25	ductus	O
26	arteriosus	O
27	(	O
28	PDA	O
29	)	O
30	with	O
31	Eisenmenger	O
32	physiology	O
33	.	O

1	The	O
2	method	O
3	described	O
4	may	O
5	prove	O
6	useful	O
7	in	O
8	studying	O
9	the	O
10	physiology	O
11	of	O
12	the	O
13	nasal	O
14	cycle	O
15	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Angiotensin	B
2	effect	O
3	in	O
4	the	O
5	human	O
6	kidney	O
7	.	O

1	Procion	O
2	yellow	O
3	dye	O
4	was	O
5	injected	O
6	intracellularly	O
7	into	O
8	large	O
9	auditory	O
10	fibers	O
11	of	O
12	goldfish	O
13	to	O
14	investigate	O
15	the	O
16	relationship	O
17	between	O
18	the	O
19	response	O
20	type	O
21	of	O
22	these	O
23	fibers	O
24	and	O
25	their	O
26	site	O
27	of	O
28	termination	O
29	in	O
30	the	O
31	saccular	O
32	macula	O
33	.	O

1	Incidental	O
2	findings	O
3	in	O
4	the	O
5	epidermis	O
6	and	O
7	in	O
8	the	O
9	intraepidermal	O
10	eccrine	O
11	sweat	O
12	duct	O
13	units	O
14	.	O

1	Urine	O
2	antibodies	O
3	could	O
4	not	O
5	be	O
6	demonstrated	O
7	in	O
8	any	O
9	other	O
10	cases	O
11	.	O

1	The	O
2	mass	O
3	of	O
4	UO2	O
5	in	O
6	the	O
7	extrapulmonary	O
8	bronchi	O
9	and	O
10	first	O
11	bifurcation	O
12	decreased	O
13	more	O
14	slowly	O
15	over	O
16	0	O
17	--	O
18	8	O
19	d	O
20	after	O
21	inhalation	O
22	than	O
23	the	O
24	corresponding	O
25	mass	O
26	on	O
27	the	O
28	trachea	O
29	.	O

1	Pathogens	O
2	(	O
3	Staphylococcus	O
4	aureus	O
5	or	O
6	Gram	O
7	-	O
8	negative	O
9	bacilli	O
10	)	O
11	were	O
12	isolated	O
13	from	O
14	only	O
15	one	O
16	member	O
17	of	O
18	staff	O
19	in	O
20	small	O
21	numbers	O
22	and	O
23	irregularly	O
24	and	O
25	rarely	O
26	in	O
27	large	O
28	numbers	O
29	from	O
30	patients	O
31	.	O

1	The	O
2	histochemistry	O
3	and	O
4	ultrastructure	O
5	of	O
6	calcified	O
7	cerebellar	O
8	deposits	O
9	described	O
10	by	O
11	Tonge	O
12	et	O
13	al	O
14	.	O

1	Reaction	O
2	times	O
3	to	O
4	tachistoscopically	O
5	presented	O
6	stimuli	O
7	in	O
8	diabetics	O

1	The	O
2	results	O
3	of	O
4	a	O
5	quantitative	O
6	study	O
7	of	O
8	vasculosyncytial	O
9	membranes	O
10	in	O
11	123	O
12	placentas	O
13	are	O
14	presented	O
15	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	Avian	O
2	reproductive	O
3	system	O
4	:	O
5	daily	O
6	variations	O
7	in	O
8	responses	O
9	to	O
10	hormones	O
11	.	O

1	Biological	O
2	properties	O
3	of	O
4	sumithion	O
5	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	a	O
6	global	O
7	assessment	O
8	patients	O
9	showed	O
10	a	O
11	highly	O
12	significant	O
13	preference	O
14	for	O
15	imipramine	O
16	compared	O
17	with	O
18	placebo	O
19	as	O
20	adjunctive	O
21	therapy	O
22	.	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	Dialyzable	O
2	transfer	B
3	factor	I
4	.	O

1	The	O
2	effect	O
3	of	O
4	hydrostatic	O
5	pressure	O
6	on	O
7	the	O
8	swimming	O
9	activity	O
10	of	O
11	three	O
12	hyponeustonic	O
13	crustacea	O
14	,	O
15	Anomalocera	O
16	patersoni	O
17	,	O
18	Pontella	O
19	mediterranea	O
20	,	O
21	Labidocera	O
22	wollastoni	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	The	O
2	sense	O
3	of	O
4	self	O
5	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	The	O
2	acids	O
3	were	O
4	obtained	O
5	by	O
6	hydrolysis	O
7	of	O
8	the	O
9	corresponding	O
10	esters	O
11	,	O
12	and	O
13	their	O
14	anti	O
15	-	O
16	inflammatory	O
17	activity	O
18	was	O
19	tested	O
20	.	O

1	Evaluation	O
2	of	O
3	the	O
4	new	O
5	Gravigard	O
6	IUCD	O
7	inserter	O
8	.	O

1	Since	O
2	GAGs	O
3	are	O
4	the	O
5	components	O
6	of	O
7	cartilage	O
8	matrix	O
9	,	O
10	the	O
11	depletion	O
12	of	O
13	which	O
14	is	O
15	associated	O
16	with	O
17	osteoarthrosis	O
18	,	O
19	a	O
20	method	O
21	for	O
22	measuring	O
23	sulphated	O
24	GAG	O
25	synthesis	O
26	in	O
27	culture	O
28	has	O
29	been	O
30	investigated	O
31	.	O

1	Well	O
2	-	O
3	visualised	O
4	arteriograms	O
5	of	O
6	the	O
7	limbs	O
8	can	O
9	be	O
10	obtained	O
11	by	O
12	xeroradiography	O
13	after	O
14	rapid	O
15	manual	O
16	injection	O
17	of	O
18	contrast	O
19	-	O
20	medium	O
21	into	O
22	an	O
23	arm	O
24	vein	O
25	,	O
26	as	O
27	demonstrated	O
28	in	O
29	28	O
30	patients	O
31	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	Near	O
2	term	O
3	,	O
4	under	O
5	experimental	O
6	conditions	O
7	,	O
8	maternal	O
9	and	O
10	fetal	O
11	blood	O
12	gases	O
13	,	O
14	pH	O
15	,	O
16	uterine	O
17	and	O
18	umbilical	O
19	blood	O
20	flows	O
21	were	O
22	measured	O
23	or	O
24	calculated	O
25	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O

1	Scanning	O
2	electron	O
3	microscopic	O
4	investigations	O
5	on	O
6	the	O
7	formation	O
8	of	O
9	Reissner	O
10	'	O
11	s	O
12	fiber	O
13	in	O
14	Rattus	O
15	rattus	O

1	Iodine	O
2	-	O
3	123	O
4	was	O
5	satisfactorily	O
6	imaged	O
7	only	O
8	with	O
9	the	O
10	MEC	O
11	and	O
12	pinhole	O
13	collimators	O
14	,	O
15	which	O
16	in	O
17	turn	O
18	yielded	O
19	MTF	O
20	values	O
21	comparable	O
22	to	O
23	those	O
24	measured	O
25	for	O
26	99mTc	O
27	.	O

1	The	O
2	effect	O
3	of	O
4	food	O
5	on	O
6	procainamide	O
7	absorption	O
8	.	O

1	Does	O
2	afferent	O
3	loop	O
4	syndrome	O
5	exist	O
6	?]	O
7	It	O
8	is	O
9	the	O
10	author	O
11	'	O
12	s	O
13	opinion	O
14	that	O
15	diagnosis	O
16	of	O
17	the	O
18	"	O
19	adducent	O
20	loop	O
21	syndrome	O
22	"	O
23	is	O
24	unlikely	O
25	to	O
26	be	O
27	correct	O
28	in	O
29	patients	O
30	subjected	O
31	to	O
32	Billroth	O
33	-	O
34	II	O
35	gastrectomy	O
36	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	spontaneous	O
6	recovery	O
7	of	O
8	central	O
9	respiratory	O
10	function	O
11	after	O
12	intoxication	O
13	with	O
14	Soman	O
15	or	O
16	Sarin	O
17	may	O
18	not	O
19	be	O
20	related	O
21	to	O
22	the	O
23	return	O
24	of	O
25	AChE	B
26	activity	O
27	.	O

1	Also	O
2	,	O
3	samples	O
4	of	O
5	serum	O
6	were	O
7	absorbed	O
8	with	O
9	the	O
10	various	O
11	solid	O
12	-	O
13	phase	O
14	allergens	O
15	and	O
16	the	O
17	reactivity	O
18	of	O
19	the	O
20	remaining	O
21	IgE	B
22	antibodies	I
23	was	O
24	determined	O
25	.	O

1	Crisis	O
2	of	O
3	the	O
4	therapeutic	O
5	community	O
6	in	O
7	Great	O
8	Britain	O

1	It	O
2	is	O
3	possible	O
4	that	O
5	cyclic	O
6	variations	O
7	in	O
8	heme	O
9	turnover	O
10	are	O
11	related	O
12	to	O
13	changes	O
14	in	O
15	erythrocyte	O
16	characteristics	O
17	during	O
18	the	O
19	progesterone	O
20	phase	O
21	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	Extramedullary	O
2	plasmacytoma	O
3	of	O
4	the	O
5	parotid	O
6	gland	O

1	The	O
2	recovered	O
3	calves	O
4	were	O
5	tested	O
6	for	O
7	immunity	O
8	to	O
9	homologous	O
10	severe	O
11	challenge	O
12	,	O
13	50	O
14	or	O
15	73	O
16	days	O
17	after	O
18	the	O
19	first	O
20	infection	O
21	.	O

1	Primary	O
2	amenorrhoea	O
3	in	O
4	a	O
5	phenotypically	O
6	female	O
7	individual	O
8	with	O
9	a	O
10	karyotype	O
11	46	O
12	,	O
13	xy	O
14	and	O
15	bilateral	O
16	gonadoblastoma	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	Six	O
2	patients	O
3	with	O
4	the	O
5	diagnosis	O
6	of	O
7	acute	O
8	mania	O
9	were	O
10	treated	O
11	with	O
12	high	O
13	doses	O
14	of	O
15	the	O
16	beta	O
17	-	O
18	adrenergic	O
19	blocking	O
20	agent	O
21	propranolol	O
22	.	O

1	Effect	O
2	of	O
3	trauma	O
4	on	O
5	plasma	B
6	glucagon	I
7	and	O
8	insulin	B
9	concentrations	O
10	in	O
11	sheep	O
12	.	O

1	This	O
2	up	O
3	-	O
4	grading	O
5	of	O
6	the	O
7	final	O
8	score	O
9	by	O
10	the	O
11	CA	O
12	component	O
13	is	O
14	greater	O
15	(	O
16	3	O
17	-	O
18	8	O
19	%)	O
20	in	O
21	the	O
22	less	O
23	able	O
24	students	O
25	with	O
26	scores	O
27	below	O
28	the	O
29	mean	O
30	level	O
31	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	It	O
2	was	O
3	found	O
4	that	O
5	under	O
6	the	O
7	selected	O
8	conditions	O
9	a	O
10	linear	O
11	dependence	O
12	exists	O
13	between	O
14	the	O
15	betaI	O
16	%	O
17	value	O
18	and	O
19	lgC	O
20	within	O
21	the	O
22	range	O
23	of	O
24	0	O
25	.	O
26	5	O
27	--	O
28	10	O
29	mug	O
30	ruscogenin	O
31	.	O

1	Fibrin	B
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O

1	A	O
2	newly	O
3	synthesized	O
4	anti	O
5	-	O
6	inflammatory	O
7	agent	O
8	,	O
9	Y	O
10	-	O
11	8004	O
12	demonstrated	O
13	a	O
14	greater	O
15	inhibition	O
16	than	O
17	did	O
18	indomethacin	O
19	(	O
20	IM	O
21	).	O
22	on	O
23	inflammatory	O
24	response	O
25	such	O
26	as	O
27	ultraviolet	O
28	erythema	O
29	in	O
30	guinea	O
31	pigs	O
32	,	O
33	carrageenin	O
34	edema	O
35	,	O
36	evans	O
37	blue	O
38	and	O
39	carrageenin	O
40	-	O
41	induced	O
42	pleuritis	O
43	and	O
44	acetic	O
45	acid	O
46	-	O
47	induced	O
48	peritonitis	O
49	in	O
50	rats	O
51	.	O

1	Calcium	O
2	and	O
3	phosphorus	O
4	metabolism	O
5	in	O
6	chronic	O
7	uremia	O
8	.	O

1	IgG	B
2	levels	O
3	of	O
4	1	O
5	/	O
6	100	O
7	were	O
8	present	O
9	in	O
10	only	O
11	four	O
12	out	O
13	of	O
14	ten	O
15	samples	O
16	obtained	O
17	150	O
18	days	O
19	after	O
20	the	O
21	clinical	O
22	onset	O
23	.	O

1	The	O
2	discordant	O
3	behaviour	O
4	in	O
5	weakly	O
6	infected	O
7	mice	O
8	was	O
9	due	O
10	to	O
11	the	O
12	occurrence	O
13	in	O
14	some	O
15	animals	O
16	of	O
17	a	O
18	second	O
19	phase	O
20	of	O
21	more	O
22	rapid	O
23	increase	O
24	of	O
25	the	O
26	parasitemia	O
27	.	O

1	Thromboplastin	B
2	time	O
3	,	O
4	partial	O
5	thromboplastin	B
6	time	O
7	,	O
8	thrombin	B
9	time	O
10	,	O
11	heat	O
12	-	O
13	dependent	O
14	fibrin	B
15	,	O
16	clot	O
17	retraction	O
18	,	O
19	and	O
20	clotting	B
21	factors	I
22	II	I
23	,	I
24	V	I
25	,	I
26	VIII	I
27	,	I
28	IX	I
29	,	I
30	X	I
31	,	O
32	and	O
33	the	O
34	platelet	O
35	count	O
36	were	O
37	determined	O
38	.	O

1	Nerve	O
2	stimulation	O
3	(	O
4	1	O
5	.	O
6	5	O
7	-	O
8	12	O
9	cycles	O
10	/	O
11	s	O
12	)	O
13	produced	O
14	frequency	O
15	-	O
16	dependent	O
17	reductions	O
18	in	O
19	CBF	O
20	,	O
21	a	O
22	decrease	O
23	of	O
24	50	O
25	percent	O
26	occurring	O
27	with	O
28	the	O
29	highest	O
30	frequency	O
31	.	O

1	Liver	O
2	microsomes	O
3	of	O
4	the	O
5	shag	O
6	showed	O
7	smaller	O
8	than	O
9	8	O
10	%	O
11	of	O
12	the	O
13	epoxide	B
14	hydrase	I
15	activity	O
16	and	O
17	smaller	O
18	than	O
19	14	O
20	%	O
21	of	O
22	the	O
23	hydroxylating	O
24	capacity	O
25	of	O
26	liver	O
27	microsomes	O
28	from	O
29	the	O
30	rat	O
31	.	O

1	A	O
2	clinical	O
3	,	O
4	serological	O
5	and	O
6	prognostic	O
7	study	O

1	The	O
2	metabolic	O
3	clearance	O
4	rate	O
5	of	O
6	progesterone	O
7	was	O
8	295	O
9	+/-	O
10	49	O
11	(	O
12	S	O
13	.	O
14	E	O
15	.)	O
16	1	O
17	/	O
18	day	O
19	.	O

1	Editorial	O
2	:	O
3	Low	O
4	-	O
5	dose	O
6	heparin	O
7	and	O
8	the	O
9	prevention	O
10	of	O
11	venous	O
12	thromboembolic	O
13	disease	O
14	.	O

1	Prostaglandins	O
2	F	O
3	(	O
4	PGF	O
5	)	O
6	were	O
7	measured	O
8	in	O
9	uterine	O
10	vein	O
11	,	O
12	ovarian	O
13	artery	O
14	,	O
15	and	O
16	jugular	O
17	vein	O
18	plasma	O
19	and	O
20	in	O
21	the	O
22	endometrial	O
23	tissues	O
24	at	O
25	various	O
26	times	O
27	during	O
28	the	O
29	bovine	O
30	estrous	O
31	cycle	O
32	,	O
33	and	O
34	were	O
35	compared	O
36	to	O
37	peripheral	O
38	plasma	O
39	progesterone	O
40	levels	O
41	.	O

1	Before	O
2	this	O
3	date	O
4	,	O
5	the	O
6	drug	O
7	directly	O
8	inhibits	O
9	fetal	O
10	weight	O
11	gain	O
12	,	O
13	whereas	O
14	the	O
15	sensitivity	O
16	of	O
17	the	O
18	placenta	O
19	is	O
20	only	O
21	transient	O
22	at	O
23	day	O
24	16	O
25	resulting	O
26	in	O
27	maximum	O
28	weight	O
29	decrease	O
30	of	O
31	this	O
32	organ	O
33	24	O
34	h	O
35	later	O
36	.	O

1	Groups	O
2	of	O
3	ten	O
4	dependent	O
5	and	O
6	ten	O
7	saline	O
8	mice	O
9	were	O
10	singly	O
11	tested	O
12	in	O
13	both	O
14	light	O
15	and	O
16	dark	O
17	conditions	O
18	in	O
19	each	O
20	of	O
21	five	O
22	covered	O
23	cylinders	O
24	(	O
25	2	O
26	-	O
27	23	O
28	in	O
29	high	O
30	).	O

1	The	O
2	effects	O
3	initiated	O
4	from	O
5	the	O
6	nucleus	O
7	accumbens	O
8	septi	O
9	were	O
10	most	O
11	marked	O
12	.	O

1	Like	O
2	pineal	O
3	melatonin	O
4	,	O
5	serum	O
6	melatonin	O
7	was	O
8	high	O
9	at	O
10	mid	O
11	-	O
12	dark	O
13	and	O
14	low	O
15	at	O
16	mid	O
17	-	O
18	light	O
19	.	O

1	Caution	O
2	should	O
3	be	O
4	exercised	O
5	in	O
6	the	O
7	use	O
8	of	O
9	these	O
10	dyes	O
11	for	O
12	lymphograms	O
13	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Air	O
2	ion	O
3	action	O
4	on	O
5	bacteria	O
6	.	O

1	Following	O
2	retransfusion	O
3	,	O
4	the	O
5	affected	O
6	epithelial	O
7	lining	O
8	appeared	O
9	greatly	O
10	distended	O
11	over	O
12	the	O
13	oedematous	O
14	lamina	O
15	propria	O
16	,	O
17	with	O
18	almost	O
19	complete	O
20	loss	O
21	of	O
22	structural	O
23	detail	O
24	.	O

1	Characteristics	O
2	of	O
3	anesthesia	O
4	and	O
5	resuscitation	O
6	in	O
7	emergency	O
8	lung	O
9	surgery	O

1	Study	O
2	of	O
3	the	O
4	physico	O
5	-	O
6	chemical	O
7	state	O
8	of	O
9	plutonium	O
10	-	O
11	239	O
12	in	O
13	a	O
14	citrate	O
15	solution	O
16	-	O
17	blood	O
18	system	O

1	Tobramycin	O
2	60	O
3	mg	O
4	did	O
5	not	O
6	show	O
7	any	O
8	remarkable	O
9	effect	O
10	,	O
11	but	O
12	dibecacin	O
13	100	O
14	mg	O
15	produced	O
16	a	O
17	slight	O
18	potentiating	O
19	effect	O
20	on	O
21	the	O
22	action	O
23	of	O
24	d	O
25	-	O
26	tubocurarine	O
27	.	O

1	In	O
2	about	O
3	one	O
4	third	O
5	of	O
6	the	O
7	cases	O
8	this	O
9	operation	O
10	results	O
11	in	O
12	tonal	O
13	and	O
14	vocal	O
15	improvement	O
16	for	O
17	patients	O
18	suffering	O
19	from	O
20	progressive	O
21	perceptive	O
22	deafness	O
23	.	O

1	The	O
2	alterations	O
3	of	O
4	5	O
5	-	O
6	HT	O
7	and	O
8	5	O
9	-	O
10	HIAA	O
11	levels	O
12	in	O
13	several	O
14	regions	O
15	of	O
16	the	O
17	brain	O
18	under	O
19	the	O
20	conditions	O
21	examined	O
22	may	O
23	indicate	O
24	that	O
25	IDPN	O
26	'	O
27	s	O
28	neurotoxicity	O
29	primarily	O
30	affects	O
31	5	O
32	-	O
33	HT	O
34	-	O
35	containing	O
36	neurones	O
37	.	O

1	In	O
2	both	O
3	cases	O
4	,	O
5	at	O
6	the	O
7	end	O
8	of	O
9	exposure	O
10	the	O
11	same	O
12	level	O
13	of	O
14	blood	B
15	carboxyhemoglobin	I
16	(	O
17	COHb	B
18	)	O
19	(	O
20	about	O
21	50	O
22	%)	O
23	was	O
24	reached	O
25	.	O

1	Reduction	O
2	in	O
3	dosage	O
4	restored	O
5	normal	O
6	taste	O
7	sense	O
8	in	O
9	all	O
10	three	O
11	,	O
12	but	O
13	in	O
14	two	O
15	the	O
16	drug	O
17	had	O
18	to	O
19	be	O
20	discontinued	O
21	because	O
22	of	O
23	persisting	O
24	high	O
25	transaminase	O
26	levels	O
27	.	O

1	Biohydrogenation	O
2	of	O
3	linoleic	O
4	acid	O
5	into	O
6	octadecenoic	O
7	acid	O
8	was	O
9	observed	O
10	.	O

1	Rabbit	B
2	skeletal	I
3	muscle	I
4	glycogenin	I
5	.	O

1	For	O
2	the	O
3	first	O
4	group	O
5	,	O
6	the	O
7	maximal	O
8	decrease	O
9	in	O
10	plasma	O
11	potassium	O
12	elicited	O
13	by	O
14	salbutamol	O
15	was	O
16	0	O
17	.	O
18	80	O
19	+/-	O
20	0	O
21	.	O
22	19	O
23	,	O
24	0	O
25	.	O
26	48	O
27	+/-	O
28	0	O
29	.	O
30	22	O
31	,	O
32	and	O
33	0	O
34	.	O
35	78	O
36	+/-	O
37	0	O
38	.	O
39	46	O
40	mmol	O
41	/	O
42	l	O
43	,	O
44	and	O
45	for	O
46	the	O
47	second	O
48	group	O
49	,	O
50	maximal	O
51	decrement	O
52	was	O
53	1	O
54	.	O
55	31	O
56	+/-	O
57	0	O
58	.	O
59	37	O
60	,	O
61	0	O
62	.	O
63	70	O
64	+/-	O
65	0	O
66	.	O
67	24	O
68	,	O
69	and	O
70	0	O
71	.	O
72	84	O
73	+/-	O
74	0	O
75	.	O
76	17	O
77	mmol	O
78	/	O
79	l	O
80	for	O
81	the	O
82	iv	O
83	,	O
84	po	O
85	,	O
86	and	O
87	it	O
88	routes	O
89	,	O
90	respectively	O
91	.	O

1	The	O
2	two	O
3	drugs	O
4	increase	O
5	the	O
6	rate	O
7	of	O
8	early	O
9	diastolic	O
10	filling	O
11	.	O

1	The	O
2	method	O
3	was	O
4	adapted	O
5	for	O
6	the	O
7	determination	O
8	of	O
9	nadolol	O
10	racemate	O
11	A	O
12	by	O
13	a	O
14	change	O
15	in	O
16	mobile	O
17	phase	O
18	composition	O
19	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	In	O
2	7	O
3	of	O
4	9	O
5	cases	O
6	,	O
7	the	O
8	enhancer	O
9	is	O
10	fused	O
11	to	O
12	the	O
13	c	B
14	-	I
15	myc	I
16	bearing	I
17	sequences	I
18	of	O
19	chromosome	O
20	8	O
21	.	O

1	These	O
2	components	O
3	both	O
4	had	O
5	a	O
6	median	O
7	R2	O
8	of	O
9	0	O
10	.	O
11	84	O
12	,	O
13	compared	O
14	to	O
15	median	O
16	R2s	O
17	ranging	O
18	from	O
19	0	O
20	.	O
21	37	O
22	to	O
23	0	O
24	.	O
25	83	O
26	for	O
27	five	O
28	commonly	O
29	used	O
30	ad	O
31	hoc	O
32	EEG	O
33	components	O
34	.	O

1	66	O
2	:	O
3	469	O
4	-	O
5	479	O
6	,	O
7	1992	O
8	).	O

1	Possibly	O
2	,	O
3	the	O
4	scr1	B
5	-	I
6	1	I
7	mutation	I
8	does	O
9	not	O
10	affect	O
11	signal	O
12	recognition	O
13	or	O
14	translational	O
15	arrest	O
16	but	O
17	instead	O
18	results	O
19	in	O
20	maintenance	O
21	of	O
22	translational	O
23	arrest	O
24	of	O
25	AEP	B
26	synthesis	O
27	.	O

1	The	O
2	predicted	O
3	receptor	O
4	structure	O
5	includes	O
6	a	O
7	cysteine	O
8	-	O
9	rich	O
10	extracellular	O
11	domain	O
12	,	O
13	a	O
14	single	O
15	hydrophobic	O
16	transmembrane	O
17	domain	O
18	,	O
19	and	O
20	a	O
21	predicted	O
22	cytoplasmic	B
23	serine	I
24	/	I
25	threonine	I
26	kinase	I
27	domain	I
28	.	O

1	Analysis	O
2	of	O
3	the	O
4	entire	O
5	16	O
6	.	O
7	7	O
8	-	O
9	kb	O
10	mt	O
11	genome	O
12	determined	O
13	that	O
14	a	O
15	MDP1	B
16	mediates	O
17	cleavage	O
18	of	O
19	chick	O
20	mtDNA	O
21	in	O
22	vitro	O
23	at	O
24	three	O
25	H	O
26	-	O
27	and	O
28	two	O
29	L	O
30	-	O
31	strand	O
32	sequence	O
33	-	O
34	specific	O
35	target	O
36	sites	O
37	located	O
38	within	O
39	a	O
40	90	O
41	-	O
42	bp	O
43	A	O
44	+	O
45	T	O
46	-	O
47	rich	O
48	genomic	O
49	tract	O
50	,	O
51	theoretically	O
52	capable	O
53	of	O
54	forming	O
55	stable	O
56	secondary	O
57	structures	O
58	,	O
59	approximately	O
60	200	O
61	bases	O
62	upstream	O
63	from	O
64	the	O
65	H	O
66	-	O
67	strand	O
68	origin	O
69	(	O
70	OH	O
71	)	O
72	of	O
73	replication	O
74	.	O

1	The	O
2	phenotypes	O
3	of	O
4	the	O
5	ICP0	B
6	nonsense	O
7	mutants	O
8	were	O
9	intermediate	O
10	between	O
11	those	O
12	of	O
13	the	O
14	wild	O
15	-	O
16	type	O
17	virus	O
18	and	O
19	7134	O
20	in	O
21	that	O
22	the	O
23	more	O
24	ICP0	B
25	-	I
26	coding	I
27	sequence	I
28	expressed	O
29	by	O
30	a	O
31	given	O
32	nonsense	O
33	mutant	O
34	,	O
35	the	O
36	more	O
37	wild	O
38	type	O
39	-	O
40	like	O
41	was	O
42	its	O
43	phenotype	O
44	.	O

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O

1	Treatment	O
2	with	O
3	MK	O
4	-	O
5	801	O
6	induced	O
7	a	O
8	burst	O
9	suppression	O
10	in	O
11	the	O
12	EEG	O
13	and	O
14	a	O
15	transient	O
16	drop	O
17	(	O
18	11	O
19	.	O
20	4	O
21	+/-	O
22	6	O
23	.	O
24	5	O
25	mm	O
26	Hg	O
27	)	O
28	in	O
29	the	O
30	mean	O
31	arterial	O
32	pressure	O
33	.	O

1	Acad	O
2	.	O

1	The	O
2	ORF	O
3	4	O
4	gene	O
5	was	O
6	minimally	O
7	active	O
8	,	O
9	whereas	O
10	the	O
11	ORF	O
12	62	O
13	gene	O
14	gave	O
15	twofold	O
16	induction	O
17	;	O
18	both	O
19	genes	O
20	,	O
21	acting	O
22	together	O
23	,	O
24	gave	O
25	fivefold	O
26	induction	O
27	.	O

1	The	O
2	unphosphorylated	O
3	form	O
4	of	O
5	RNA	B
6	polymerase	I
7	II	I
8	is	O
9	designated	O
10	IIA	O
11	,	O
12	whereas	O
13	the	O
14	phosphorylated	O
15	form	O
16	is	O
17	designated	O
18	IIO	O
19	.	O

1	RNA	B
2	polymerase	I
3	IIA	I
4	was	O
5	recovered	O
6	in	O
7	transcriptionally	O
8	active	O
9	complexes	O
10	in	O
11	reactions	O
12	in	O
13	which	O
14	the	O
15	input	O
16	enzyme	O
17	was	O
18	RNA	B
19	polymerase	I
20	IIA	I
21	.	O

1	Tumor	O
2	cells	O
3	were	O
4	focally	O
5	immunoreactive	O
6	for	O
7	neuron	B
8	-	I
9	specific	I
10	enolase	I
11	,	O
12	insulin	B
13	,	O
14	glucagon	B
15	and	O
16	VIP	B
17	.	O

1	ROS	B
2	x	O
3	SRC	B
4	(	O
5	R	B
6	)	O
7	contains	O
8	a	O
9	16	O
10	-	O
11	amino	O
12	-	O
13	acid	O
14	deletion	O
15	that	O
16	includes	O
17	the	O
18	3	O
19	'	O
20	half	O
21	of	O
22	the	O
23	transmembrane	O
24	domain	O
25	of	O
26	ros	B
27	.	O

1	Possible	O
2	roles	O
3	of	O
4	RAD5	B
5	putative	O
6	ATPase	B
7	/	O
8	DNA	B
9	helicase	I
10	activity	O
11	in	O
12	DNA	O
13	repair	O
14	and	O
15	in	O
16	the	O
17	maintenance	O
18	of	O
19	wild	O
20	-	O
21	type	O
22	rates	O
23	of	O
24	instability	O
25	of	O
26	simple	O
27	repetitive	O
28	sequences	O
29	are	O
30	discussed	O
31	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	B
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	B
13	VIb	I
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O

1	The	O
2	minimal	O
3	promoter	O
4	of	O
5	the	O
6	RII	B
7	beta	I
8	gene	I
9	was	O
10	composed	O
11	of	O
12	two	O
13	adjacent	O
14	functional	O
15	elements	O
16	.	O

1	A	O
2	combination	O
3	of	O
4	comparative	O
5	sequence	O
6	analysis	O
7	and	O
8	thermodynamic	O
9	methods	O
10	reveals	O
11	the	O
12	conservation	O
13	of	O
14	tertiary	O
15	structure	O
16	elements	O
17	in	O
18	the	O
19	5	O
20	'	O
21	untranslated	O
22	region	O
23	(	O
24	UTR	O
25	)	O
26	of	O
27	human	O
28	enteroviruses	O
29	and	O
30	rhinoviruses	O
31	.	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	The	O
2	relationships	O
3	between	O
4	the	O
5	partial	O
6	pressures	O
7	of	O
8	O2	O
9	and	O
10	CO2	O
11	as	O
12	well	O
13	as	O
14	between	O
15	their	O
16	gradients	O
17	,	O
18	become	O
19	stronger	O
20	with	O
21	the	O
22	increase	O
23	of	O
24	the	O
25	ventilation	O
26	-	O
27	perfusion	O
28	ratio	O
29	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	total	O
7	protein	O
8	profiles	O
9	of	O
10	wild	O
11	-	O
12	type	O
13	S	O
14	.	O
15	entomophila	O
16	UC9	O
17	and	O
18	mutant	O
19	UC21	O
20	revealed	O
21	that	O
22	the	O
23	mutant	O
24	lacked	O
25	an	O
26	approximately	O
27	44	O
28	-	O
29	kDa	O
30	protein	O
31	and	O
32	overexpressed	O
33	an	O
34	approximately	O
35	20	O
36	-	O
37	kDa	O
38	protein	O
39	.	O

1	The	O
2	rationale	O
3	for	O
4	continuous	O
5	dopaminergic	O
6	stimulation	O
7	in	O
8	patients	O
9	with	O
10	Parkinson	O
11	'	O
12	s	O
13	disease	O
14	.	O

1	Effects	O
2	of	O
3	dioxins	O
4	on	O
5	thyroid	O
6	function	O
7	in	O
8	newborn	O
9	babies	O
10	.	O

1	cDNA	O
2	clones	O
3	encoding	O
4	Arabidopsis	O
5	thaliana	O
6	and	O
7	Zea	B
8	mays	I
9	mitochondrial	I
10	chaperonin	I
11	HSP60	I
12	and	O
13	gene	O
14	expression	O
15	during	O
16	seed	O
17	germination	O
18	and	O
19	heat	O
20	shock	O
21	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	B
11	and	I
12	Escherichia	I
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	The	O
2	single	O
3	site	O
4	of	O
5	glycosylation	O
6	is	O
7	located	O
8	near	O
9	the	O
10	C	O
11	-	O
12	terminus	O
13	in	O
14	the	O
15	N	O
16	-	O
17	glycosylation	O
18	sequon	O
19	-	O
20	Asn	O
21	-	O
22	Cys	O
23	-	O
24	Ser	O
25	-	O
26	in	O
27	which	O
28	Cys	O
29	forms	O
30	part	O
31	of	O
32	a	O
33	disulphide	O
34	bridge	O
35	.	O

1	The	O
2	subunit	O
3	protein	O
4	of	O
5	curli	B
6	was	O
7	highly	O
8	homologous	O
9	at	O
10	its	O
11	amino	O
12	terminus	O
13	to	O
14	SEF	B
15	-	I
16	17	I
17	,	O
18	the	O
19	subunit	O
20	protein	O
21	of	O
22	thin	O
23	,	O
24	aggregative	O
25	fimbriae	O
26	of	O
27	Salmonella	O
28	enteritidis	O
29	27655	O
30	strain	O
31	3b	O
32	,	O
33	suggesting	O
34	that	O
35	these	O
36	fibres	O
37	form	O
38	a	O
39	novel	O
40	class	O
41	of	O
42	surface	O
43	organelles	O
44	on	O
45	enterobacteria	O
46	.	O

1	Substitution	O
2	of	O
3	the	O
4	DR1	B
5	beta	I
6	chain	I
7	with	O
8	H	B
9	-	I
10	2E	I
11	beta	I
12	k	I
13	led	O
14	to	O
15	a	O
16	dramatic	O
17	loss	O
18	of	O
19	recognition	O
20	;	O
21	alpha	O
22	chain	O
23	substitution	O
24	had	O
25	a	O
26	less	O
27	marked	O
28	effect	O
29	.	O

1	Currents	O
2	aspects	O
3	of	O
4	H2	B
5	receptor	I
6	antagonists	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	ulcers	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	hGCSFR	B
6	gene	I
7	was	O
8	chromosomally	O
9	localized	O
10	by	O
11	Southern	O
12	blot	O
13	analysis	O
14	of	O
15	its	O
16	segregation	O
17	pattern	O
18	in	O
19	a	O
20	panel	O
21	of	O
22	rodent	O
23	-	O
24	human	O
25	hybrid	O
26	DNAs	O
27	using	O
28	the	O
29	radiolabeled	O
30	cDNA	O
31	probe	O
32	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	These	O
2	exons	O
3	,	O
4	further	O
5	identified	O
6	as	O
7	exons	O
8	9	O
9	,	O
10	10	O
11	,	O
12	and	O
13	11	O
14	,	O
15	together	O
16	encode	O
17	the	O
18	37	O
19	amino	O
20	acid	O
21	residues	O
22	present	O
23	in	O
24	alpha	B
25	s1	I
26	-	I
27	casein	I
28	variant	I
29	A	I
30	but	O
31	missing	O
32	in	O
33	variant	O
34	F	O
35	.	O

1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O

1	Between	O
2	acoR	B
3	and	O
4	acoXABC	B
5	,	O
6	two	O
7	different	O
8	types	O
9	of	O
10	sequences	O
11	with	O
12	dual	O
13	rotational	O
14	symmetry	O
15	[	O
16	CAC	O
17	-(	O
18	N11	O
19	to	O
20	N18	O
21	)-	O
22	GTG	O
23	and	O
24	TGT	O
25	-(	O
26	N10	O
27	to	O
28	N14	O
29	)-	O
30	ACA	O
31	]	O
32	were	O
33	found	O
34	;	O
35	these	O
36	sequences	O
37	are	O
38	similar	O
39	to	O
40	NtrC	B
41	and	O
42	NifA	B
43	upstream	I
44	activator	I
45	sequences	I
46	,	O
47	respectively	O
48	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	full	O
5	-	O
6	deletion	O
7	mutant	O
8	showed	O
9	a	O
10	strong	O
11	block	O
12	in	O
13	virus	O
14	release	O
15	,	O
16	suggesting	O
17	that	O
18	NC	B
19	is	O
20	involved	O
21	in	O
22	virus	O
23	assembly	O
24	.	O

1	Thirty	O
2	percent	O
3	of	O
4	patients	O
5	were	O
6	tapered	O
7	off	O
8	all	O
9	steroids	O
10	,	O
11	and	O
12	the	O
13	average	O
14	steroid	O
15	dose	O
16	in	O
17	the	O
18	group	O
19	who	O
20	received	O
21	steroids	O
22	was	O
23	8	O
24	.	O
25	6	O
26	mg	O
27	of	O
28	prednisone	O
29	per	O
30	day	O
31	.	O

1	T	B
2	antigen	I
3	contains	O
4	four	O
5	H	O
6	-	O
7	2Db	O
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	O
25	-	O
26	1	O
27	,	O
28	Y	O
29	-	O
30	2	O
31	,	O
32	Y	O
33	-	O
34	3	O
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	The	O
2	pulpal	O
3	tissues	O
4	of	O
5	the	O
6	permanent	O
7	mandibular	O
8	molars	O
9	were	O
10	amputated	O
11	and	O
12	then	O
13	dressed	O
14	with	O
15	calcium	O
16	hydrate	O
17	.	O

1	Interestingly	O
2	,	O
3	this	O
4	activation	O
5	occurred	O
6	only	O
7	when	O
8	the	O
9	regions	O
10	were	O
11	cloned	O
12	in	O
13	the	O
14	same	O
15	relative	O
16	orientation	O
17	in	O
18	which	O
19	they	O
20	exist	O
21	on	O
22	wild	O
23	-	O
24	type	O
25	pCF10	O
26	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	Again	O
2	residue	O
3	Glu	O
4	-	O
5	381	O
6	of	O
7	beta	O
8	was	O
9	notably	O
10	reduced	O
11	and	O
12	no	O
13	missing	O
14	residue	O
15	from	O
16	the	O
17	epsilon	O
18	peptide	O
19	could	O
20	be	O
21	identified	O
22	,	O
23	but	O
24	the	O
25	peptide	O
26	sequence	O
27	limited	O
28	the	O
29	possible	O
30	choices	O
31	to	O
32	Ser	O
33	-	O
34	106	O
35	,	O
36	Ser	O
37	-	O
38	107	O
39	,	O
40	or	O
41	Ser	O
42	-	O
43	108	O
44	.	O

1	Urease	B
2	activity	O
3	,	O
4	judged	O
5	as	O
6	the	O
7	amount	O
8	of	O
9	ammonia	O
10	production	O
11	from	O
12	urea	O
13	,	O
14	could	O
15	be	O
16	measured	O
17	at	O
18	25	O
19	ng	O
20	per	O
21	tube	O
22	(	O
23	S	O
24	/	O
25	N	O
26	=	O
27	1	O
28	.	O
29	5	O
30	)	O
31	with	O
32	Jack	B
33	bean	I
34	meal	I
35	urease	I
36	.	O

1	Consequently	O
2	,	O
3	significant	O
4	differences	O
5	between	O
6	the	O
7	measured	O
8	and	O
9	calculated	O
10	methods	O
11	were	O
12	noted	O
13	in	O
14	oxygen	O
15	uptake	O
16	(	O
17	213	O
18	+/-	O
19	41	O
20	ml	O
21	/	O
22	min	O
23	vs	O
24	193	O
25	+/-	O
26	25	O
27	ml	O
28	/	O
29	min	O
30	,	O
31	p	O
32	<	O
33	0	O
34	.	O
35	001	O
36	),	O
37	oxygen	O
38	delivery	O
39	(	O
40	780	O
41	+/-	O
42	297	O
43	ml	O
44	/	O
45	min	O
46	vs	O
47	716	O
48	+/-	O
49	296	O
50	ml	O
51	/	O
52	min	O
53	,	O
54	p	O
55	<	O
56	0	O
57	.	O
58	001	O
59	),	O
60	and	O
61	cardiac	O
62	output	O
63	(	O
64	5	O
65	.	O
66	8	O
67	+/-	O
68	2	O
69	.	O
70	2	O
71	L	O
72	/	O
73	min	O
74	vs	O
75	5	O
76	.	O
77	3	O
78	+/-	O
79	1	O
80	.	O
81	8	O
82	L	O
83	/	O
84	min	O
85	,	O
86	p	O
87	<	O
88	0	O
89	.	O
90	001	O
91	).	O

1	The	O
2	gene	O
3	sequence	O
4	also	O
5	identified	O
6	a	O
7	340	O
8	-	O
9	nucleotide	O
10	RNA	O
11	in	O
12	total	O
13	yeast	O
14	RNA	O
15	and	O
16	in	O
17	purified	O
18	RNase	B
19	MRP	I
20	enzyme	I
21	preparations	O
22	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	CBF	B
6	-	I
7	A	I
8	is	O
9	a	O
10	novel	O
11	CArG	O
12	box	O
13	-,	O
14	ssDNA	B
15	-	I
16	and	I
17	RNA	I
18	-	I
19	binding	I
20	protein	I
21	,	O
22	as	O
23	well	O
24	as	O
25	a	O
26	repressive	O
27	transcriptional	O
28	factor	O
29	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	Xenopus	B
5	U7	I
6	gene	I
7	contains	O
8	two	O
9	adjacent	O
10	octamer	O
11	-	O
12	binding	O
13	motifs	O
14	located	O
15	only	O
16	12	O
17	and	O
18	24	O
19	bp	O
20	upstream	O
21	from	O
22	the	O
23	PSE	B
24	,	O
25	instead	O
26	of	O
27	the	O
28	usual	O
29	location	O
30	around	O
31	150	O
32	-	O
33	200	O
34	bp	O
35	upstream	O
36	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	DR1	B
2	molecules	I
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O

1	Behind	O
2	the	O
3	ATPase	B
4	cluster	I
5	,	O
6	two	O
7	open	O
8	reading	O
9	frames	O
10	were	O
11	detected	O
12	that	O
13	are	O
14	not	O
15	homologous	O
16	to	O
17	any	O
18	known	O
19	chloroplast	O
20	gene	O
21	.	O

1	Autopsy	O
2	demonstrated	O
3	good	O
4	survival	O
5	of	O
6	the	O
7	transplanted	O
8	cells	O
9	with	O
10	good	O
11	integration	O
12	with	O
13	the	O
14	brain	O
15	of	O
16	the	O
17	recipient	O
18	and	O
19	traces	O
20	of	O
21	positive	O
22	immunocytochemical	O
23	reaction	O
24	for	O
25	tyrosine	B
26	hydroxylase	I
27	.	O

1	The	O
2	technique	O
3	of	O
4	the	O
5	TEE	O
6	visualization	O
7	of	O
8	the	O
9	proximal	O
10	coronary	O
11	arteries	O
12	is	O
13	described	O
14	.	O

1	Thus	O
2	,	O
3	chronic	O
4	hematocrit	O
5	decrease	O
6	induced	O
7	by	O
8	H	O
9	or	O
10	P	O
11	resulted	O
12	in	O
13	a	O
14	significant	O
15	fall	O
16	in	O
17	blood	O
18	pressure	O
19	compared	O
20	to	O
21	control	O
22	(	O
23	201	O
24	+/-	O
25	3	O
26	v	O
27	175	O
28	+/-	O
29	4	O
30	,	O
31	167	O
32	+/-	O
33	4	O
34	mm	O
35	Hg	O
36	,	O
37	respectively	O
38	;	O
39	P	O
40	<	O
41	.	O
42	05	O
43	).	O

1	The	O
2	TIMP	B
3	(-	O
4	59	O
5	/	O
6	-	O
7	53	O
8	)	O
9	AP1	B
10	site	O
11	is	O
12	a	O
13	promiscuous	O
14	motif	O
15	that	O
16	binds	O
17	c	B
18	-	I
19	Fos	I
20	/	O
21	c	B
22	-	I
23	Jun	I
24	AP1	I
25	translated	O
26	in	O
27	vitro	O
28	and	O
29	is	O
30	an	O
31	effective	O
32	competitor	O
33	for	O
34	binding	O
35	of	O
36	nuclear	B
37	AP1	I
38	factors	I
39	to	O
40	the	O
41	consensus	O
42	TRE	O
43	,	O
44	but	O
45	in	O
46	addition	O
47	it	O
48	binds	O
49	factors	O
50	that	O
51	do	O
52	not	O
53	associate	O
54	with	O
55	the	O
56	consensus	O
57	TRE	O
58	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	B
13	tissue	I
14	inhibitor	I
15	of	I
16	metalloproteinases	I
17	-	I
18	1	I
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	These	O
2	data	O
3	demonstrate	O
4	that	O
5	DMVA	O
6	does	O
7	not	O
8	cause	O
9	more	O
10	myocardial	O
11	trauma	O
12	than	O
13	CPB	O
14	when	O
15	used	O
16	to	O
17	provide	O
18	resuscitative	O
19	circulatory	O
20	support	O
21	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	total	O
7	pinealectomy	O
8	in	O
9	these	O
10	already	O
11	sympathectomized	O
12	blinded	O
13	rabbits	O
14	always	O
15	resulted	O
16	in	O
17	a	O
18	substantial	O
19	deceleration	O
20	of	O
21	the	O
22	rhythms	O
23	(	O
24	mean	O
25	delta	O
26	tau	O
27	=	O
28	+	O
29	0	O
30	.	O
31	23	O
32	h	O
33	).	O

1	4	O
2	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O

1	Disruption	O
2	of	O
3	microtubules	O
4	did	O
5	not	O
6	affect	O
7	the	O
8	fidelity	O
9	or	O
10	kinetics	O
11	of	O
12	vacuolar	O
13	protein	O
14	sorting	O
15	,	O
16	indicating	O
17	that	O
18	Vps1p	B
19	function	O
20	is	O
21	not	O
22	dependent	O
23	on	O
24	microtubules	O
25	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	B
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	B
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	Validation	O
2	of	O
3	automated	O
4	systems	O
5	--	O
6	system	O
7	definition	O
8	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	A	O
2	second	O
3	domain	O
4	,	O
5	located	O
6	in	O
7	the	O
8	C	O
9	-	O
10	terminal	O
11	437	O
12	amino	O
13	acids	O
14	of	O
15	IE1	B
16	,	O
17	is	O
18	required	O
19	for	O
20	inhibitory	O
21	and	O
22	DNA	O
23	-	O
24	binding	O
25	activities	O
26	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	the	O
6	blood	O
7	compatibility	O
8	of	O
9	autogenous	O
10	vein	O
11	graft	O
12	(	O
13	AVG	O
14	),	O
15	changes	O
16	in	O
17	prostacyclin	O
18	(	O
19	PGI2	O
20	)	O
21	production	O
22	following	O
23	harvesting	O
24	and	O
25	arterial	O
26	implantation	O
27	were	O
28	studied	O
29	experimentally	O
30	.	O

1	Nonreplicating	O
2	vaccinia	O
3	vector	O
4	efficiently	O
5	expresses	O
6	recombinant	O
7	genes	O
8	.	O

1	Interferon	B
2	type	I
3	I	I
4	in	O
5	protective	O
6	body	O
7	reactions	O
8	in	O
9	an	O
10	experimental	O
11	Klebsiella	O
12	infection	O

1	For	O
2	pressure	O
3	greater	O
4	than	O
5	121	O
6	atm	O
7	abs	O
8	,	O
9	an	O
10	increased	O
11	excitability	O
12	of	O
13	the	O
14	tadpoles	O
15	made	O
16	it	O
17	difficult	O
18	to	O
19	distinguish	O
20	the	O
21	righting	O
22	reflex	O
23	from	O
24	involuntary	O
25	movements	O
26	.	O

1	One	O
2	air	O
3	embolism	O
4	occurred	O
5	;	O
6	this	O
7	was	O
8	the	O
9	only	O
10	filter	O
11	-	O
12	or	O
13	retrieval	O
14	-	O
15	related	O
16	complication	O
17	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	B
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	O
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	I
37	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	B
8	protease	I
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	Comparisons	O
2	with	O
3	the	O
4	available	O
5	amino	O
6	acid	O
7	residue	O
8	(	O
9	aa	O
10	)	O
11	sequence	O
12	information	O
13	from	O
14	the	O
15	complete	O
16	CPMV	B
17	RNA	I
18	1	I
19	sequence	I
20	and	O
21	the	O
22	partial	O
23	sequence	O
24	of	O
25	red	B
26	clover	I
27	mottle	I
28	virus	I
29	RNA	I
30	1	I
31	suggest	O
32	that	O
33	CPSMV	B
34	RNA	I
35	1	I
36	specifies	O
37	the	O
38	expected	O
39	set	O
40	of	O
41	five	O
42	mature	O
43	proteins	O
44	:	O
45	32K	B
46	proteinase	I
47	cofactor	I
48	,	O
49	58K	B
50	presumed	I
51	helicase	I
52	,	O
53	VPg	B
54	5	I
55	'-	I
56	linked	I
57	protein	I
58	of	O
59	the	O
60	genomic	O
61	RNAs	O
62	,	O
63	24K	B
64	proteinase	I
65	,	O
66	and	O
67	87K	B
68	presumed	I
69	polymerase	I
70	,	O
71	separated	O
72	by	O
73	four	O
74	cleavage	O
75	sites	O
76	.	O

1	Pseudomonas	B
2	aeruginosa	I
3	exotoxin	I
4	A	I
5	:	O
6	its	O
7	role	O
8	in	O
9	retardation	O
10	of	O
11	wound	O
12	healing	O
13	:	O
14	the	O
15	1992	O
16	Lindberg	O
17	Award	O
18	.	O

1	GAL4	B
2	-	O
3	VP16	B
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	After	O
2	28	O
3	days	O
4	of	O
5	haloperidol	O
6	treatment	O
7	,	O
8	similar	O
9	changes	O
10	were	O
11	observed	O
12	for	O
13	delta	O
14	,	O
15	together	O
16	with	O
17	an	O
18	increase	O
19	of	O
20	alpha	O
21	1	O
22	,	O
23	and	O
24	a	O
25	decrease	O
26	of	O
27	fast	O
28	beta	O
29	.	O

1	A	O
2	case	O
3	of	O
4	chronic	O
5	hepatitis	O
6	C	O
7	with	O
8	primary	O
9	hypothyroidism	O
10	manifested	O
11	during	O
12	interferon	B
13	treatment	O

1	Since	O
2	CENP	B
3	-	I
4	B	I
5	gene	I
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	B
13	-	I
14	B	I
15	boxes	I
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Assay	O
2	of	O
3	urea	O
4	by	O
5	immobilized	O
6	urease	B
7	coupled	O
8	to	O
9	a	O
10	differential	O
11	pH	O
12	-	O
13	meter	O
14	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	O
12	serum	O
13	prolactin	B
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	The	O
2	CEM	O
3	receives	O
4	registration	O
5	updates	O
6	via	O
7	an	O
8	HL7	O
9	message	O
10	and	O
11	evaluates	O
12	data	O
13	dependencies	O
14	in	O
15	rules	O
16	via	O
17	an	O
18	interface	O
19	to	O
20	the	O
21	relational	O
22	database	O
23	.	O

1	Simultaneously	O
2	a	O
3	greater	O
4	NA	O
5	was	O
6	found	O
7	with	O
8	no	O
9	change	O
10	in	O
11	plasma	O
12	epinephrine	O
13	response	O
14	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	gene	O
6	segment	O
7	containing	O
8	the	O
9	mu	O
10	m	O
11	poly	O
12	(	O
13	A	O
14	)	O
15	signals	O
16	,	O
17	along	O
18	with	O
19	536	O
20	bp	O
21	of	O
22	downstream	O
23	flanking	O
24	sequence	O
25	,	O
26	acted	O
27	as	O
28	a	O
29	transcription	O
30	terminator	O
31	in	O
32	both	O
33	myeloma	O
34	cells	O
35	and	O
36	L	O
37	cell	O
38	fibroblasts	O
39	.	O

1	Alena	O
2	is	O
3	a	O
4	nurse	O
5	in	O
6	Prague	O
7	--	O
8	she	O
9	dreams	O
10	of	O
11	higher	O
12	wages	O
13	and	O
14	a	O
15	trip	O
16	across	O
17	the	O
18	ocean	O

1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O

1	ME1a1	B
2	,	O
3	a	O
4	16	O
5	-	O
6	base	O
7	-	O
8	pair	O
9	nuclear	O
10	factor	O
11	binding	O
12	site	O
13	residing	O
14	between	O
15	the	O
16	c	B
17	-	I
18	MYC	I
19	P1	I
20	and	I
21	P2	I
22	transcription	I
23	initiation	I
24	sites	I
25	,	O
26	is	O
27	required	O
28	for	O
29	P2	O
30	activity	O
31	.	O

1	During	O
2	V	O
3	-	O
4	A	O
5	bypass	O
6	,	O
7	hemodynamics	O
8	were	O
9	stable	O
10	.	O

1	Exposure	O
2	to	O
3	hepatitis	O
4	B	O
5	virus	O
6	in	O
7	the	O
8	general	O
9	population	O
10	of	O
11	Hisayama	O
12	,	O
13	Japan	O
14	:	O
15	significance	O
16	of	O
17	isolated	O
18	antibody	O
19	to	O
20	hepatitis	B
21	B	I
22	surface	I
23	antigen	I
24	in	O
25	general	O
26	population	O
27	.	O

1	High	O
2	-	O
3	resolution	O
4	computed	O
5	tomography	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	miliary	O
11	tuberculosis	O
12	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	O
6	GAL4	B
7	and	O
8	LexA	B
9	-	O
10	Bicoid	B
11	fusion	O
12	proteins	O
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	B
18	,	O
19	SNF5	B
20	,	O
21	and	O
22	SNF6	B
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	B
33	operators	I
34	.	O

1	NE	B
2	and	O
3	PR3	B
4	assist	O
5	in	O
6	the	O
7	destruction	O
8	of	O
9	phagocytosed	O
10	microorganisms	O
11	,	O
12	cleave	O
13	the	O
14	important	O
15	connective	B
16	-	I
17	tissue	I
18	protein	I
19	elastin	I
20	,	O
21	and	O
22	generate	O
23	chemotactic	O
24	activities	O
25	by	O
26	forming	O
27	alpha	B
28	1	I
29	-	I
30	proteinase	I
31	inhibitor	I
32	complexes	I
33	and	O
34	elastin	B
35	peptides	I
36	.	O

1	Mitochondria	O
2	-	O
3	lytic	O
4	action	O
5	of	O
6	warfarin	O
7	in	O
8	lymphocytes	O
9	.	O

1	Among	O
2	the	O
3	few	O
4	proteins	O
5	of	O
6	the	O
7	eukaryotic	O
8	nucleolus	O
9	that	O
10	have	O
11	been	O
12	characterized	O
13	,	O
14	four	O
15	proteins	O
16	,	O
17	nucleolin	B
18	,	O
19	fibrillarin	B
20	,	O
21	SSB1	B
22	and	O
23	NSR1	B
24	,	O
25	possess	O
26	a	O
27	common	O
28	structural	O
29	motif	O
30	,	O
31	the	O
32	GAR	O
33	domain	O
34	,	O
35	which	O
36	is	O
37	rich	O
38	in	O
39	glycine	O
40	and	O
41	arginine	O
42	residues	O
43	.	O

1	Thus	O
2	,	O
3	this	O
4	study	O
5	provides	O
6	evidence	O
7	that	O
8	a	O
9	novel	O
10	,	O
11	ubiquitous	O
12	factor	O
13	(	O
14	HF	B
15	-	I
16	1a	I
17	)	O
18	and	O
19	a	O
20	muscle	O
21	factor	O
22	(	O
23	HF	B
24	-	I
25	1b	I
26	/	O
27	MEF	B
28	-	I
29	2	I
30	)	O
31	can	O
32	form	O
33	a	O
34	novel	O
35	,	O
36	E	O
37	-	O
38	box	O
39	-	O
40	independent	O
41	pathway	O
42	for	O
43	muscle	O
44	-	O
45	specific	O
46	expression	O
47	in	O
48	ventricular	O
49	cardiac	O
50	muscle	O
51	cells	O
52	.	O

1	Mutations	O
2	in	O
3	either	O
4	gene	O
5	block	O
6	some	O
7	crucial	O
8	late	O
9	step	O
10	in	O
11	assembly	O
12	of	O
13	F1	B
14	,	O
15	causing	O
16	the	O
17	alpha	O
18	and	O
19	beta	O
20	subunits	O
21	to	O
22	accumulate	O
23	in	O
24	mitochondria	O
25	as	O
26	inactive	O
27	aggregates	O
28	(	O
29	Ackerman	O
30	,	O
31	S	O
32	.	O

1	Using	O
2	bovine	B
3	and	I
4	murine	I
5	c	I
6	-	I
7	myb	I
8	clones	O
9	,	O
10	no	O
11	change	O
12	in	O
13	the	O
14	rate	O
15	of	O
16	c	B
17	-	I
18	myb	I
19	gene	I
20	transcription	O
21	or	O
22	mRNA	O
23	stability	O
24	was	O
25	detected	O
26	during	O
27	the	O
28	cell	O
29	cycle	O
30	.	O

1	Of	O
2	the	O
3	drugs	O
4	orally	O
5	administered	O
6	,	O
7	WR	O
8	-	O
9	168643	O
10	was	O
11	the	O
12	best	O
13	protector	O
14	with	O
15	a	O
16	DMF	O
17	of	O
18	1	O
19	.	O
20	51	O
21	.	O

1	Comparison	O
2	of	O
3	the	O
4	genomic	O
5	DNA	O
6	sequence	O
7	with	O
8	that	O
9	of	O
10	the	O
11	four	O
12	different	O
13	mRNAs	O
14	indicates	O
15	that	O
16	these	O
17	transcripts	O
18	are	O
19	produced	O
20	by	O
21	alternative	O
22	splicing	O
23	of	O
24	the	O
25	murine	O
26	pre	O
27	-	O
28	mRNA	O
29	according	O
30	to	O
31	a	O
32	cassette	O
33	model	O
34	.	O

1	The	O
2	cardiac	B
3	myosin	I
4	light	I
5	chain	I
6	-	I
7	2	I
8	(	O
9	MLC	B
10	-	I
11	2	I
12	)	O
13	gene	O
14	promoter	O
15	contains	O
16	several	O
17	positive	O
18	and	O
19	negative	O
20	cis	O
21	-	O
22	acting	O
23	sequences	O
24	that	O
25	are	O
26	involved	O
27	in	O
28	the	O
29	regulation	O
30	of	O
31	its	O
32	expression	O
33	.	O

1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	B
8	early	I
9	meiotic	I
10	recombination	I
11	genes	I
12	REC102	I
13	and	O
14	REC107	B
15	/	O
16	MER2	B
17	.	O

1	The	O
2	MET4	B
3	gene	O
4	was	O
5	cloned	O
6	,	O
7	and	O
8	its	O
9	sequence	O
10	reveals	O
11	that	O
12	it	O
13	encodes	O
14	a	O
15	protein	O
16	related	O
17	to	O
18	the	O
19	family	O
20	of	O
21	the	O
22	bZIP	B
23	transcriptional	I
24	activators	I
25	.	O

1	GR63178A	O
2	is	O
3	a	O
4	water	O
5	-	O
6	soluble	O
7	analogue	O
8	of	O
9	mitoquidone	O
10	,	O
11	a	O
12	pentacyclic	O
13	pyrroloquinone	O
14	.	O

1	The	O
2	Klebsiella	B
3	aerogenes	I
4	gene	I
5	maoA	I
6	,	O
7	which	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	synthesis	O
13	of	O
14	monoamine	B
15	oxidase	I
16	,	O
17	was	O
18	induced	O
19	by	O
20	tyramine	O
21	and	O
22	the	O
23	related	O
24	compounds	O
25	,	O
26	subjected	O
27	to	O
28	catabolite	O
29	and	O
30	ammonium	O
31	ion	O
32	repression	O
33	,	O
34	and	O
35	cloned	O
36	.	O

1	To	O
2	determine	O
3	the	O
4	genetic	O
5	basis	O
6	for	O
7	the	O
8	differences	O
9	between	O
10	the	O
11	cardiac	O
12	and	O
13	brain	B
14	AE3	I
15	variants	I
16	,	O
17	we	O
18	isolated	O
19	and	O
20	characterized	O
21	the	O
22	rat	O
23	gene	O
24	.	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	From	O
2	March	O
3	5	O
4	through	O
5	October	O
6	26	O
7	,	O
8	1991	O
9	,	O
10	eight	O
11	persons	O
12	were	O
13	diagnosed	O
14	with	O
15	elevated	O
16	blood	O
17	lead	O
18	levels	O
19	(	O
20	BLLs	O
21	)	O
22	at	O
23	a	O
24	local	O
25	hospital	O
26	and	O
27	were	O
28	reported	O
29	to	O
30	the	O
31	notifiable	O
32	disease	O
33	surveillance	O
34	system	O
35	maintained	O
36	by	O
37	the	O
38	Alabama	O
39	Department	O
40	of	O
41	Public	O
42	Health	O
43	(	O
44	ADPH	O
45	).	O

1	The	O
2	SEN1	B
3	gene	I
4	corresponds	O
5	to	O
6	a	O
7	6	O
8	,	O
9	336	O
10	-	O
11	bp	O
12	open	O
13	reading	O
14	frame	O
15	coding	O
16	for	O
17	a	O
18	2	O
19	,	O
20	112	O
21	-	O
22	amino	O
23	-	O
24	acid	O
25	protein	O
26	(	O
27	molecular	O
28	mass	O
29	,	O
30	239	O
31	kDa	O
32	).	O

1	In	O
2	a	O
3	randomized	O
4	double	O
5	-	O
6	blind	O
7	cross	O
8	-	O
9	over	O
10	study	O
11	,	O
12	the	O
13	subjects	O
14	received	O
15	theophylline	O
16	5	O
17	mg	O
18	.	O
19	kg	O
20	-	O
21	1	O
22	per	O
23	day	O
24	with	O
25	omeprazole	O
26	20	O
27	mg	O
28	per	O
29	day	O
30	or	O
31	identical	O
32	placebo	O
33	during	O
34	two	O
35	periods	O
36	,	O
37	each	O
38	of	O
39	7	O
40	days	O
41	,	O
42	separated	O
43	by	O
44	a	O
45	washout	O
46	period	O
47	of	O
48	7	O
49	days	O
50	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	revealed	O
6	that	O
7	two	O
8	clusters	O
9	of	O
10	basic	O
11	amino	O
12	acids	O
13	within	O
14	a	O
15	conserved	O
16	basic	O
17	region	O
18	and	O
19	two	O
20	amphipathic	O
21	helices	O
22	within	O
23	the	O
24	adjacent	O
25	HLH	O
26	domain	O
27	are	O
28	essential	O
29	for	O
30	sequence	O
31	-	O
32	specific	O
33	DNA	O
34	binding	O
35	and	O
36	hetero	O
37	-	O
38	oligomerization	O
39	,	O
40	respectively	O
41	.	O

1	Dimerization	O
2	of	O
3	Myf	B
4	-	I
5	5	I
6	with	O
7	the	O
8	ubiquitously	O
9	expressed	O
10	bHLH	O
11	protein	O
12	E12	B
13	not	O
14	only	O
15	increases	O
16	the	O
17	affinity	O
18	for	O
19	DNA	O
20	but	O
21	also	O
22	stimulates	O
23	transactivation	O
24	independently	O
25	of	O
26	DNA	O
27	binding	O
28	.	O

1	SEA	O
2	was	O
3	recorded	O
4	with	O
5	bidirectional	O
6	filters	O
7	at	O
8	25	O
9	-	O
10	250	O
11	HZ	O
12	and	O
13	40	O
14	-	O
15	250	O
16	Hz	O
17	using	O
18	Simson	O
19	method	O
20	.	O

1	An	O
2	experiment	O
3	examined	O
4	the	O
5	effects	O
6	of	O
7	treatment	O
8	with	O
9	gonadotrophin	B
10	releasing	I
11	hormone	I
12	(	O
13	100	O
14	micrograms	O
15	GnRH	B
16	injected	O
17	24	O
18	h	O
19	after	O
20	progestagen	O
21	sponge	O
22	removal	O
23	),	O
24	season	O
25	of	O
26	treatment	O
27	(	O
28	autumn	O
29	v	O
30	.	O
31	spring	O
32	),	O
33	the	O
34	effect	O
35	of	O
36	supplementary	O
37	feeding	O
38	with	O
39	lupin	O
40	grain	O
41	(	O
42	in	O
43	autumn	O
44	only	O
45	,	O
46	from	O
47	12	O
48	days	O
49	before	O
50	until	O
51	8	O
52	days	O
53	after	O
54	sponge	O
55	removal	O
56	)	O
57	on	O
58	the	O
59	time	O
60	of	O
61	ovulation	O
62	in	O
63	182	O
64	mature	O
65	Merino	O
66	ewes	O
67	superovulated	O
68	with	O
69	a	O
70	combination	O
71	of	O
72	400	O
73	I	O
74	.	O
75	U	O
76	.	O
77	pregnant	B
78	mare	I
79	serum	I
80	gonadotrophin	I
81	(	O
82	PMSG	B
83	)	O
84	and	O
85	12	O
86	mg	O
87	follicle	B
88	stimulating	I
89	hormone	I
90	(	O
91	FSH	B
92	-	I
93	P	I
94	).	O

1	A	O
2	gene	O
3	homologous	O
4	to	O
5	the	O
6	Escherichia	B
7	coli	I
8	dnaA	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	Pseudomonas	O
14	putida	O
15	and	O
16	its	O
17	transcription	O
18	was	O
19	investigated	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	as	O
25	well	O
26	as	O
27	in	O
28	P	O
29	.	O
30	putida	O
31	.	O

1	Using	O
2	these	O
3	antibodies	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	define	O
10	the	O
11	conditions	O
12	to	O
13	completely	O
14	solubilize	O
15	the	O
16	Cdc25	B
17	protein	I
18	.	O

1	Eight	O
2	rabbits	O
3	were	O
4	exposed	O
5	to	O
6	0	O
7	.	O
8	7	O
9	+/-	O
10	0	O
11	.	O
12	4	O
13	mg	O
14	/	O
15	m3	O
16	Co2	O
17	+	O
18	as	O
19	CoCl2	O
20	and	O
21	1	O
22	.	O
23	2	O
24	+/-	O
25	0	O
26	.	O
27	7	O
28	mg	O
29	/	O
30	m3	O
31	Cr3	O
32	+	O
33	as	O
34	Cr	O
35	(	O
36	NO3	O
37	)	O
38	3	O
39	(	O
40	group	O
41	Co	O
42	+	O
43	Cr	O
44	),	O
45	eight	O
46	to	O
47	0	O
48	.	O
49	6	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	mg	O
55	/	O
56	m3	O
57	Co2	O
58	+	O
59	(	O
60	group	O
61	Co	O
62	),	O
63	and	O
64	eight	O
65	to	O
66	filtered	O
67	air	O
68	(	O
69	control	O
70	group	O
71	),	O
72	for	O
73	4	O
74	months	O
75	,	O
76	5	O
77	days	O
78	/	O
79	week	O
80	,	O
81	and	O
82	6	O
83	hr	O
84	/	O
85	day	O
86	.	O

1	Disruption	O
2	demonstrates	O
3	that	O
4	CDC14	B
5	is	O
6	an	O
7	essential	O
8	gene	O
9	.	O

1	Recent	O
2	investigations	O
3	have	O
4	detailed	O
5	a	O
6	selective	O
7	dye	O
8	release	O
9	technique	O
10	in	O
11	which	O
12	a	O
13	pulse	O
14	of	O
15	laser	O
16	light	O
17	induces	O
18	the	O
19	release	O
20	of	O
21	a	O
22	fluorescent	O
23	dye	O
24	from	O
25	temperature	O
26	-	O
27	sensitive	O
28	liposomes	O
29	circulating	O
30	in	O
31	the	O
32	retinal	O
33	vasculature	O
34	.	O

1	The	O
2	coating	O
3	materials	O
4	were	O
5	poloxamine	O
6	904	O
7	,	O
8	poloxamine	O
9	908	O
10	,	O
11	poloxamine	O
12	1508	O
13	,	O
14	poloxamer	O
15	338	O
16	,	O
17	and	O
18	Brij	O
19	35	O
20	.	O

1	His	O
2	HC	B
3	II	I
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	daughter	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O

1	Argatroban	O
2	may	O
3	be	O
4	more	O
5	effective	O
6	under	O
7	low	O
8	HC	B
9	II	I
10	conditions	O
11	because	O
12	of	O
13	its	O
14	potent	O
15	inhibition	O
16	of	O
17	thrombin	B
18	activity	O
19	at	O
20	sites	O
21	of	O
22	vascular	O
23	wall	O
24	damage	O
25	.	O

1	The	O
2	mean	O
3	minimum	O
4	steady	O
5	-	O
6	state	O
7	concentration	O
8	after	O
9	the	O
10	oral	O
11	regimen	O
12	(	O
13	23	O
14	micrograms	O
15	.	O
16	l	O
17	-	O
18	1	O
19	)	O
20	was	O
21	78	O
22	%	O
23	of	O
24	that	O
25	after	O
26	the	O
27	intramuscular	O
28	regime	O
29	(	O
30	29	O
31	micrograms	O
32	.	O
33	l	O
34	-	O
35	1	O
36	).	O

1	The	O
2	sequence	O
3	-	O
4	specific	O
5	interaction	O
6	of	O
7	nuclear	B
8	factor	I
9	HiNF	I
10	-	I
11	D	I
12	with	O
13	this	O
14	key	O
15	proximal	O
16	promoter	O
17	element	O
18	of	O
19	the	O
20	H4	B
21	-	I
22	FO108	I
23	gene	I
24	is	O
25	cell	O
26	cycle	O
27	regulated	O
28	in	O
29	normal	O
30	diploid	O
31	cells	O
32	(	O
33	J	O
34	.	O

1	UF	O
2	-	O
3	021	O
4	ophthalmic	O
5	solution	O
6	(	O
7	0	O
8	.	O
9	03	O
10	to	O
11	0	O
12	.	O
13	24	O
14	%),	O
15	when	O
16	topically	O
17	applied	O
18	to	O
19	the	O
20	eyes	O
21	of	O
22	rabbits	O
23	,	O
24	caused	O
25	dose	O
26	-	O
27	dependent	O
28	IOP	O
29	reduction	O
30	(	O
31	2	O
32	.	O
33	8	O
34	to	O
35	5	O
36	.	O
37	2	O
38	mmHg	O
39	),	O
40	without	O
41	transient	O
42	IOP	O
43	rise	O
44	.	O

1	In	O
2	the	O
3	Rett	O
4	syndrome	O
5	we	O
6	,	O
7	therefore	O
8	,	O
9	suspect	O
10	there	O
11	are	O
12	disturbances	O
13	in	O
14	the	O
15	brain	O
16	stem	O
17	functions	O
18	especially	O
19	in	O
20	the	O
21	ascending	O
22	reticular	O
23	activating	O
24	system	O
25	which	O
26	is	O
27	related	O
28	to	O
29	elevation	O
30	of	O
31	the	O
32	conscious	O
33	level	O
34	.	O

1	In	O
2	a	O
3	similar	O
4	experiment	O
5	,	O
6	simultaneous	O
7	nitrofurazone	O
8	administration	O
9	and	O
10	S	O
11	.	O
12	enteritidis	O
13	challenge	O
14	resulted	O
15	in	O
16	no	O
17	significant	O
18	differences	O
19	in	O
20	S	O
21	.	O
22	enteritidis	O
23	isolation	O
24	frequency	O
25	.	O

1	In	O
2	agreement	O
3	with	O
4	this	O
5	southern	O
6	blotting	O
7	of	O
8	mouse	O
9	DNA	O
10	with	O
11	SmN	B
12	probes	O
13	reveals	O
14	bands	O
15	,	O
16	additional	O
17	to	O
18	those	O
19	derived	O
20	from	O
21	the	O
22	pseudogene	O
23	,	O
24	which	O
25	are	O
26	characteristic	O
27	of	O
28	an	O
29	intron	O
30	-	O
31	containing	O
32	SmN	B
33	gene	I
34	.	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	O
10	of	O
11	the	O
12	tumor	O
13	was	O
14	obtained	O
15	.	O

1	The	O
2	DRF	B
3	-	I
4	2	I
5	nuclear	I
6	protein	I
7	has	O
8	characteristics	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	muscle	O
15	-	O
16	specific	O
17	regulatory	O
18	factor	O
19	,	O
20	MEF	B
21	-	I
22	2	I
23	(	O
24	Buskin	O
25	and	O
26	Hauschka	O
27	1989	O
28	;	O
29	Gossett	O
30	et	O
31	al	O
32	.,	O
33	1989	O
34	).	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	with	O
6	the	O
7	classical	O
8	'	O
9	oxygen	O
10	debt	O
11	hypothesis	O
12	',	O
13	which	O
14	states	O
15	that	O
16	the	O
17	oxygen	O
18	debt	O
19	and	O
20	lactate	O
21	clearance	O
22	are	O
23	linked	O
24	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	O
8	age	O
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	This	O
2	accurate	O
3	and	O
4	rapid	O
5	method	O
6	makes	O
7	the	O
8	MLPA	O
9	test	O
10	logistically	O
11	feasible	O
12	for	O
13	large	O
14	-	O
15	scale	O
16	screening	O
17	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	purified	O
7	and	O
8	characterized	O
9	the	O
10	recombinant	B
11	furin	I
12	from	O
13	the	O
14	conditioned	O
15	medium	O
16	of	O
17	these	O
18	cells	O
19	.	O

1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O

1	The	O
2	relation	O
3	between	O
4	myocardial	B
5	beta	I
6	-	I
7	adrenergic	I
8	receptor	I
9	and	O
10	left	O
11	ventricular	O
12	(	O
13	LV	O
14	)	O
15	function	O
16	was	O
17	studied	O
18	in	O
19	10	O
20	patients	O
21	,	O
22	aged	O
23	41	O
24	to	O
25	61	O
26	years	O
27	(	O
28	average	O
29	51	O
30	),	O
31	with	O
32	LV	O
33	volume	O
34	overload	O
35	mainly	O
36	due	O
37	to	O
38	chronic	O
39	mitral	O
40	regurgitation	O
41	.	O

1	Since	O
2	each	O
3	transcript	O
4	appears	O
5	to	O
6	encode	O
7	the	O
8	same	O
9	protein	O
10	,	O
11	this	O
12	complexity	O
13	may	O
14	reflect	O
15	the	O
16	need	O
17	for	O
18	lineage	O
19	-	O
20	specific	O
21	or	O
22	differentiation	O
23	-	O
24	dependent	O
25	control	O
26	of	O
27	expression	O
28	.	O

1	In	O
2	patients	O
3	with	O
4	limited	O
5	disease	O
6	,	O
7	the	O
8	survival	O
9	in	O
10	the	O
11	alternating	O
12	arm	O
13	was	O
14	significantly	O
15	superior	O
16	to	O
17	the	O
18	survival	O
19	in	O
20	the	O
21	CAV	O
22	arm	O
23	(	O
24	P	O
25	=	O
26	.	O
27	014	O
28	)	O
29	or	O
30	the	O
31	survival	O
32	in	O
33	the	O
34	PE	O
35	arm	O
36	(	O
37	P	O
38	=	O
39	.	O
40	023	O
41	).	O

1	In	O
2	similar	O
3	transient	O
4	transfection	O
5	experiments	O
6	in	O
7	HeLa	O
8	cells	O
9	,	O
10	overexpression	O
11	of	O
12	the	O
13	wt	B
14	human	I
15	retinoblastoma	I
16	susceptibility	I
17	gene	I
18	product	I
19	,	O
20	RB	B
21	,	O
22	was	O
23	found	O
24	to	O
25	repress	O
26	the	O
27	serum	O
28	-	O
29	induced	O
30	IL	B
31	-	I
32	6	I
33	(-	O
34	225	O
35	to	O
36	+	O
37	13	O
38	),	O
39	c	B
40	-	I
41	fos	I
42	(-	O
43	711	O
44	to	O
45	+	O
46	42	O
47	),	O
48	and	O
49	beta	B
50	-	I
51	actin	I
52	(-	O
53	3400	O
54	to	O
55	+	O
56	912	O
57	)	O
58	promoters	O
59	but	O
60	not	O
61	the	O
62	PRV	O
63	-	O
64	induced	O
65	IL	B
66	-	I
67	6	I
68	(-	O
69	110	O
70	to	O
71	+	O
72	13	O
73	)	O
74	or	O
75	the	O
76	serum	O
77	-	O
78	induced	O
79	MHC	B
80	(-	O
81	528	O
82	to	O
83	-	O
84	38	O
85	)	O
86	promoters	O
87	.	O

1	Recombination	O
2	between	O
3	feline	O
4	leukemia	O
5	virus	O
6	subgroup	O
7	B	O
8	or	O
9	C	O
10	and	O
11	endogenous	O
12	env	B
13	elements	O
14	alters	O
15	the	O
16	in	O
17	vitro	O
18	biological	O
19	activities	O
20	of	O
21	the	O
22	viruses	O
23	.	O

1	Therefore	O
2	,	O
3	the	O
4	strD	B
5	and	O
6	strE	B
7	genes	I
8	could	O
9	serve	O
10	as	O
11	universal	O
12	probes	O
13	indicative	O
14	of	O
15	the	O
16	presence	O
17	of	O
18	biosynthetic	O
19	capacity	O
20	for	O
21	6	O
22	-	O
23	deoxyhexose	O
24	moieties	O
25	.	O

1	Its	O
2	neuromuscular	O
3	effects	O
4	are	O
5	similar	O
6	to	O
7	a	O
8	single	O
9	ED90	O
10	dose	O
11	of	O
12	vecuronium	O
13	.	O

1	We	O
2	speculate	O
3	that	O
4	these	O
5	tumors	O
6	may	O
7	represent	O
8	congenital	O
9	hamartomatous	O
10	growths	O
11	.	O

1	Surprisingly	O
2	,	O
3	there	O
4	is	O
5	no	O
6	sequence	O
7	homology	O
8	between	O
9	this	O
10	region	O
11	of	O
12	Ly	B
13	-	I
14	6E	I
15	and	O
16	the	O
17	established	O
18	consensus	O
19	for	O
20	the	O
21	interferon	B
22	-	I
23	stimulated	I
24	response	I
25	element	I
26	,	O
27	which	O
28	has	O
29	been	O
30	shown	O
31	functionally	O
32	important	O
33	to	O
34	all	O
35	previously	O
36	characterized	O
37	alpha	B
38	/	I
39	beta	I
40	interferon	I
41	-	O
42	inducible	O
43	promoters	O
44	.	O

1	Relatively	O
2	large	O
3	DNA	O
4	rearrangements	O
5	spanning	O
6	the	O
7	region	O
8	with	O
9	tandem	O
10	direct	O
11	repeats	O
12	encoding	O
13	the	O
14	carboxy	O
15	-	O
16	terminal	O
17	histone	B
18	H1	I
19	-	I
20	like	I
21	structure	O
22	of	O
23	AlgP	B
24	were	O
25	detected	O
26	in	O
27	several	O
28	strains	O
29	upon	O
30	conversion	O
31	from	O
32	the	O
33	mucoid	O
34	to	O
35	the	O
36	nonmucoid	O
37	phenotype	O
38	.	O

1	(	O
2	1988	O
3	)	O
4	J	O
5	.	O

1	These	O
2	results	O
3	strongly	O
4	suggested	O
5	that	O
6	similar	O
7	,	O
8	if	O
9	not	O
10	identical	O
11	,	O
12	the	O
13	CArG	B
14	box	I
15	binding	I
16	proteins	I
17	interact	O
18	with	O
19	the	O
20	functionally	O
21	different	O
22	promoter	O
23	element	O
24	in	O
25	the	O
26	VLC1	B
27	,	O
28	cardiac	B
29	alpha	I
30	-	I
31	actin	I
32	,	O
33	and	O
34	c	B
35	-	I
36	fos	I
37	genes	I
38	.	O

1	Lymphoproliferative	O
2	disorders	O
3	arising	O
4	under	O
5	immunosuppression	O
6	with	O
7	FK	O
8	506	O
9	:	O
10	initial	O
11	observations	O
12	in	O
13	a	O
14	large	O
15	transplant	O
16	population	O
17	.	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	O
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	I
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	B
31	.	O

1	Chem	O
2	.	O

1	We	O
2	characterized	O
3	cDNA	O
4	clones	O
5	specific	O
6	for	O
7	the	O
8	extracellular	O
9	matrix	O
10	glycoprotein	O
11	undulin	B
12	.	O

1	Finally	O
2	,	O
3	some	O
4	point	O
5	mutations	O
6	in	O
7	the	O
8	Gag	B
9	-	O
10	Pol	B
11	PR	O
12	domain	O
13	inhibited	O
14	activation	O
15	of	O
16	RT	B
17	in	O
18	trans	O
19	by	O
20	a	O
21	wild	O
22	-	O
23	type	O
24	PR	B
25	,	O
26	suggesting	O
27	that	O
28	the	O
29	correct	O
30	conformation	O
31	of	O
32	the	O
33	PR	B
34	domain	O
35	in	O
36	Gag	B
37	-	O
38	Pol	B
39	is	O
40	prerequisite	O
41	for	O
42	activation	O
43	of	O
44	RT	B
45	.	O

1	The	O
2	alpha	B
3	inhibin	I
4	promoter	I
5	containing	O
6	a	O
7	mutated	O
8	CRE	O
9	was	O
10	not	O
11	regulated	O
12	by	O
13	forskolin	O
14	in	O
15	granulosa	O
16	cells	O
17	and	O
18	did	O
19	not	O
20	bind	O
21	the	O
22	CREB	B
23	protein	I
24	.	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	B
23	.	O

1	The	O
2	qualitative	O
3	concentrations	O
4	of	O
5	HCG	B
6	had	O
7	a	O
8	sensitivity	O
9	of	O
10	37	O
11	.	O
12	5	O
13	%	O
14	and	O
15	a	O
16	specificity	O
17	of	O
18	100	O
19	%.	O

1	The	O
2	activity	O
3	of	O
4	serum	B
5	lipase	I
6	and	O
7	amylase	B
8	distinctly	O
9	increased	O
10	at	O
11	3	O
12	h	O
13	and	O
14	went	O
15	up	O
16	to	O
17	the	O
18	maximum	O
19	at	O
20	12	O
21	h	O
22	after	O
23	injection	O
24	of	O
25	Na	O
26	-	O
27	Tc	O
28	.	O

1	These	O
2	risk	O
3	factors	O
4	can	O
5	be	O
6	divided	O
7	into	O
8	2	O
9	groups	O
10	:	O
11	local	O
12	vessel	O
13	wall	O
14	-	O
15	related	O
16	factors	O
17	,	O
18	and	O
19	local	O
20	(	O
21	focal	O
22	action	O
23	)	O
24	systemic	O
25	factors	O
26	.	O

1	86	O
2	:	O
3	3199	O
4	-	O
5	3203	O
6	)	O
7	or	O
8	G1	O
9	to	O
10	S	O
11	phase	O
12	(	O
13	Reilly	O
14	,	O
15	C	O
16	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	B
10	gene	I
11	32	I
12	protein	I
13	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	B
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	70	O
8	%	O
9	identity	O
10	to	O
11	that	O
12	of	O
13	Bacillus	B
14	stearothermophilus	I
15	TyrTS	I
16	and	O
17	55	O
18	%	O
19	identity	O
20	to	O
21	that	O
22	of	O
23	E	B
24	.	I
25	coli	I
26	TyrTS	I
27	,	O
28	while	O
29	identity	O
30	to	O
31	a	O
32	second	O
33	cryptic	O
34	B	B
35	.	I
36	subtilis	I
37	TyrTS	I
38	gene	I
39	,	O
40	designated	O
41	tyrZ	B
42	,	O
43	was	O
44	only	O
45	27	O
46	%.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	effectiveness	O
5	of	O
6	monoamine	B
7	oxidase	I
8	inhibitors	O
9	(	O
10	MAOIs	O
11	)	O
12	in	O
13	tricyclic	O
14	resistant	O
15	depression	O
16	has	O
17	received	O
18	surprisingly	O
19	little	O
20	systematic	O
21	study	O
22	.	O

1	Bone	O
2	and	O
3	bones	O
4	.	O

1	One	O
2	patients	O
3	had	O
4	plasma	B
5	C	I
6	-	I
7	peptide	I
8	greater	O
9	than	O
10	3	O
11	pM	O
12	and	O
13	was	O
14	therefore	O
15	excluded	O
16	from	O
17	analysis	O
18	.	O

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O

1	We	O
2	have	O
3	isolated	O
4	cDNAs	O
5	for	O
6	a	O
7	gene	O
8	coding	O
9	for	O
10	a	O
11	G	B
12	protein	I
13	alpha	I
14	subunit	I
15	from	I
16	tomato	I
17	(	O
18	Lycopersicon	O
19	esculentum	O
20	,	O
21	cv	O
22	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	I
15	activation	I
16	domain	I
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	Cardiac	O
2	output	O
3	(	O
4	CO	O
5	)	O
6	was	O
7	significantly	O
8	higher	O
9	(	O
10	p	O
11	less	O
12	than	O
13	0	O
14	.	O
15	0005	O
16	)	O
17	in	O
18	the	O
19	MBBF	O
20	group	O
21	.	O

1	As	O
2	an	O
3	initial	O
4	step	O
5	towards	O
6	the	O
7	characterization	O
8	of	O
9	replicative	O
10	DNA	B
11	polymerases	I
12	of	I
13	trypanosomes	I
14	,	O
15	we	O
16	have	O
17	cloned	O
18	,	O
19	sequenced	O
20	and	O
21	examined	O
22	the	O
23	expression	O
24	of	O
25	the	O
26	Trypanosoma	O
27	(	O
28	Trypanozoon	O
29	)	O
30	brucei	O
31	brucei	O
32	gene	O
33	that	O
34	encodes	O
35	the	O
36	DNA	B
37	polymerase	I
38	alpha	I
39	catalytic	I
40	core	I
41	(	O
42	pol	B
43	alpha	I
44	).	O

1	CONCLUSION	O
2	:	O
3	Monitoring	O
4	SpO2	O
5	at	O
6	the	O
7	nasal	O
8	septum	O
9	site	O
10	is	O
11	more	O
12	reliable	O
13	than	O
14	monitoring	O
15	it	O
16	at	O
17	the	O
18	finger	O
19	site	O
20	in	O
21	hypothermic	O
22	patients	O
23	.	O

1	Hence	O
2	,	O
3	the	O
4	uPA	B
5	promoter	I
6	contains	O
7	multiple	O
8	weak	O
9	cis	O
10	-	O
11	acting	O
12	elements	O
13	distributed	O
14	over	O
15	7	O
16	.	O
17	0	O
18	kb	O
19	5	O
20	'	O
21	to	O
22	the	O
23	translation	O
24	start	O
25	site	O
26	.	O

1	Substituting	O
2	a	O
3	Ser	O
4	for	O
5	Gly69	O
6	or	O
7	a	O
8	Glu	O
9	for	O
10	Lys	O
11	71	O
12	in	O
13	the	O
14	conserved	O
15	TGEK	B
16	tetrapeptide	I
17	in	O
18	finger	O
19	II	O
20	of	O
21	TFIIIA	B
22	resulted	O
23	in	O
24	the	O
25	loss	O
26	of	O
27	DNA	O
28	binding	O
29	.	O

1	In	O
2	Xenopus	O
3	laevis	O
4	,	O
5	the	O
6	gene	O
7	encoding	O
8	the	O
9	elongation	B
10	factor	I
11	1	I
12	-	I
13	alpha	I
14	variant	I
15	EF	I
16	-	I
17	1	I
18	alpha	I
19	O	I
20	,	O
21	where	O
22	O	O
23	stands	O
24	for	O
25	oocyte	O
26	,	O
27	is	O
28	expressed	O
29	in	O
30	oocytes	O
31	and	O
32	early	O
33	embryos	O
34	.	O

1	Antibodies	O
2	specific	O
3	to	O
4	rE12	B
5	and	O
6	rNFIL	B
7	-	I
8	6	I
9	disrupt	O
10	nucleoprotein	O
11	complexes	O
12	with	O
13	these	O
14	DNA	O
15	-	O
16	binding	O
17	sites	O
18	,	O
19	confirming	O
20	the	O
21	interaction	O
22	of	O
23	native	O
24	in	O
25	vivo	O
26	factors	O
27	.	O

1	Allergenic	O
2	activity	O
3	of	O
4	allergen	O
5	extract	O
6	Ambrosia	O
7	elatior	O
8	(	O
9	AE	O
10	)	O
11	was	O
12	tested	O
13	in	O
14	fifteen	O
15	volunteers	O
16	extremely	O
17	sensitive	O
18	to	O
19	the	O
20	allergen	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	After	O
2	PTCA	O
3	,	O
4	ejection	O
5	fraction	O
6	increased	O
7	from	O
8	54	O
9	+/-	O
10	8	O
11	%	O
12	to	O
13	59	O
14	+/-	O
15	8	O
16	%	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	05	O
24	)	O
25	and	O
26	regional	O
27	function	O
28	improved	O
29	significantly	O
30	(	O
31	maximal	O
32	standard	O
33	deviation	O
34	before	O
35	PTCA	O
36	:	O
37	2	O
38	.	O
39	8	O
40	+/-	O
41	0	O
42	.	O
43	8	O
44	;	O
45	after	O
46	PTCA	O
47	:	O
48	1	O
49	.	O
50	9	O
51	+/-	O
52	0	O
53	.	O
54	9	O
55	-	O
56	segments	O
57	below	O
58	the	O
59	first	O
60	standard	O
61	deviation	O
62	before	O
63	PTCA	O
64	:	O
65	31	O
66	+/-	O
67	16	O
68	;	O
69	after	O
70	PTCA	O
71	:	O
72	19	O
73	+/-	O
74	17	O
75	).	O

1	A	O
2	330	O
3	-	O
4	kb	O
5	YAC	O
6	,	O
7	A148A7	O
8	,	O
9	spanned	O
10	from	O
11	the	O
12	HLA	B
13	-	O
14	DQA1	B
15	locus	O
16	through	O
17	the	O
18	Y3	B
19	/	O
20	Ring	B
21	4	I
22	locus	O
23	and	O
24	extended	O
25	at	O
26	least	O
27	130	O
28	kb	O
29	centromeric	O
30	of	O
31	YAC	O
32	B1D12	O
33	.	O

1	Interspecific	O
2	backcross	O
3	analysis	O
4	using	O
5	progeny	O
6	derived	O
7	from	O
8	matings	O
9	of	O
10	(	O
11	C57BL	O
12	/	O
13	6J	O
14	x	O
15	Mus	O
16	spretus	O
17	)	O
18	F1	O
19	x	O
20	C57BL	O
21	/	O
22	6J	O
23	mice	O
24	indicates	O
25	that	O
26	the	O
27	thrombospondin	B
28	gene	I
29	is	O
30	tightly	O
31	linked	O
32	to	O
33	the	O
34	Fshb	B
35	,	O
36	Actcl	B
37	,	O
38	Ltk	B
39	,	O
40	and	O
41	B2M	B
42	loci	I
43	on	O
44	murine	O
45	chromosome	O
46	2	O
47	.	O

1	Using	O
2	an	O
3	image	O
4	-	O
5	processing	O
6	computer	O
7	,	O
8	regional	O
9	LV	O
10	time	O
11	-	O
12	density	O
13	curves	O
14	were	O
15	constructed	O
16	for	O
17	one	O
18	cardiac	O
19	cycle	O
20	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	O
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	I
29	unit	I
30	in	I
31	rhesus	I
32	macaque	I
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	O
39	repeat	O
40	,	O
41	Alu	B
42	3	I
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	O
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	O
70	repeat	O
71	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	repressor	O
6	locus	O
7	,	O
8	c	O
9	,	O
10	of	O
11	the	O
12	Streptomyces	O
13	temperate	O
14	phage	O
15	,	O
16	phi	O
17	C31	O
18	,	O
19	was	O
20	shown	O
21	previously	O
22	to	O
23	contain	O
24	an	O
25	open	O
26	reading	O
27	frame	O
28	encoding	O
29	a	O
30	74	O
31	kDa	O
32	protein	O
33	.	O

1	However	O
2	,	O
3	it	O
4	was	O
5	synthesized	O
6	at	O
7	both	O
8	temperatures	O
9	after	O
10	addition	O
11	of	O
12	A23187	O
13	.	O

1	Our	O
2	mapping	O
3	results	O
4	did	O
5	not	O
6	suggest	O
7	involvement	O
8	of	O
9	this	O
10	gene	O
11	in	O
12	previously	O
13	mapped	O
14	genetic	O
15	disorders	O
16	or	O
17	in	O
18	known	O
19	neoplasia	O
20	-	O
21	associated	O
22	translocation	O
23	breakpoints	O
24	.	O

1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	O
10	regardless	O
11	the	O
12	number	O
13	of	O
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	O
26	to	O
27	the	O
28	percentage	O
29	of	O
30	male	O
31	blood	O
32	donors	O
33	.	O

1	CT	O
2	abnormalities	O
3	noted	O
4	in	O
5	term	O
6	babies	O
7	included	O
8	hemorrhage	O
9	(	O
10	subarachnoid	O
11	5	O
12	.	O
13	8	O
14	%,	O
15	intracerebral	O
16	11	O
17	.	O
18	6	O
19	%),	O
20	hypodensity	O
21	(	O
22	mild	O
23	23	O
24	.	O
25	2	O
26	%,	O
27	moderate	O
28	11	O
29	.	O
30	6	O
31	%	O
32	severe	O
33	5	O
34	.	O
35	8	O
36	%);	O
37	hypodensity	O
38	with	O
39	hemorrhage	O
40	5	O
41	.	O
42	8	O
43	%	O
44	and	O
45	cerebral	O
46	atrophy	O
47	5	O
48	.	O
49	8	O
50	%.	O

1	A	O
2	two	O
3	phase	O
4	slug	O
5	flow	O
6	tubular	O
7	heat	O
8	exchanger	O
9	was	O
10	used	O
11	for	O
12	the	O
13	thermal	O
14	inactivation	O
15	of	O
16	Listeria	O
17	monocytogenes	O
18	in	O
19	natural	O
20	infected	O
21	milk	O
22	from	O
23	seven	O
24	cows	O
25	.	O

1	So	O
2	far	O
3	15	O
4	children	O
5	have	O
6	been	O
7	studied	O
8	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	identified	O
8	a	O
9	strong	O
10	positive	O
11	cis	O
12	-	O
13	regulatory	O
14	element	O
15	at	O
16	-	O
17	70	O
18	bp	O
19	to	O
20	-	O
21	75	O
22	bp	O
23	in	O
24	the	O
25	LpS1	B
26	beta	I
27	promoter	I
28	with	O
29	the	O
30	sequence	O
31	(	O
32	G	O
33	)	O
34	6	O
35	and	O
36	a	O
37	similar	O
38	,	O
39	more	O
40	distal	O
41	cis	O
42	-	O
43	element	O
44	at	O
45	-	O
46	721	O
47	bp	O
48	to	O
49	-	O
50	726	O
51	bp	O
52	.	O

1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	B
12	B	I
13	element	I
14	directly	O
15	and	O
16	specifically	O
17	.	O

1	The	O
2	Thr161Val	O
3	mutation	O
4	causes	O
5	a	O
6	lethal	O
7	phenotype	O
8	in	O
9	the	O
10	fission	O
11	yeast	O
12	Schizosaccharomyces	O
13	pombe	O
14	,	O
15	while	O
16	replacement	O
17	of	O
18	Thr161	O
19	with	O
20	glutamic	O
21	acid	O
22	,	O
23	potentially	O
24	mimicking	O
25	phosphorylation	O
26	,	O
27	causes	O
28	uncoordination	O
29	of	O
30	mitosis	O
31	and	O
32	multiple	O
33	cytokinesis	O
34	.	O

1	CREB	B
2	was	O
3	identified	O
4	as	O
5	one	O
6	of	O
7	the	O
8	protein	O
9	components	O
10	in	O
11	several	O
12	of	O
13	the	O
14	gel	O
15	shift	O
16	complexes	O
17	formed	O
18	with	O
19	the	O
20	variant	O
21	CRE	O
22	.	O

1	The	O
2	N	O
3	-	O
4	terminus	O
5	of	O
6	another	O
7	open	O
8	reading	O
9	frame	O
10	was	O
11	found	O
12	3	O
13	'	O
14	from	O
15	nifA	B
16	and	O
17	tentatively	O
18	identified	O
19	as	O
20	nifB	B
21	by	O
22	amino	O
23	acid	O
24	sequence	O
25	comparison	O
26	.	O

1	In	O
2	conclusion	O
3	,	O
4	we	O
5	observed	O
6	a	O
7	great	O
8	regeneration	O
9	ability	O
10	following	O
11	mechanical	O
12	injury	O
13	in	O
14	the	O
15	nasal	O
16	mucosa	O
17	.	O

1	However	O
2	,	O
3	the	O
4	relative	O
5	positions	O
6	of	O
7	the	O
8	VV	O
9	genes	O
10	(	O
11	genus	O
12	Orthopoxvirus	O
13	)	O
14	are	O
15	different	O
16	than	O
17	those	O
18	of	O
19	the	O
20	corresponding	O
21	ORFs	O
22	in	O
23	SFV	O
24	(	O
25	genus	O
26	Leporipoxvirus	O
27	),	O
28	indicating	O
29	complex	O
30	rearrangements	O
31	of	O
32	DNA	O
33	in	O
34	the	O
35	genome	O
36	of	O
37	one	O
38	or	O
39	both	O
40	of	O
41	these	O
42	viruses	O
43	subsequent	O
44	to	O
45	their	O
46	divergence	O
47	from	O
48	a	O
49	common	O
50	ancestor	O
51	.	O

1	Identification	O
2	and	O
3	nucleotide	O
4	sequence	O
5	of	O
6	Rhizobium	B
7	meliloti	I
8	insertion	I
9	sequence	I
10	ISRm3	I
11	:	O
12	similarity	O
13	between	O
14	the	O
15	putative	O
16	transposase	B
17	encoded	O
18	by	O
19	ISRm3	B
20	and	O
21	those	O
22	encoded	O
23	by	O
24	Staphylococcus	B
25	aureus	I
26	IS256	I
27	and	O
28	Thiobacillus	B
29	ferrooxidans	I
30	IST2	I
31	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	Premature	O
2	initiation	O
3	of	O
4	mitosis	O
5	in	O
6	yeast	O
7	lacking	O
8	RCC1	B
9	or	O
10	an	O
11	interacting	O
12	GTPase	B
13	.	O

1	Oculus	O
2	-	O
3	500	O
4	is	O
5	a	O
6	group	O
7	of	O
8	high	O
9	resolution	O
10	imaging	O
11	boards	O
12	for	O
13	use	O
14	with	O
15	IBM	O
16	-	O
17	AT	O
18	and	O
19	compatible	O
20	computers	O
21	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	each	O
6	of	O
7	the	O
8	three	O
9	proteins	O
10	has	O
11	about	O
12	70	O
13	%	O
14	homology	O
15	with	O
16	that	O
17	of	O
18	mouse	B
19	contrapsin	I
20	,	O
21	in	O
22	contrast	O
23	to	O
24	43	O
25	-	O
26	46	O
27	%	O
28	homology	O
29	with	O
30	that	O
31	of	O
32	rat	B
33	alpha	I
34	1	I
35	-	I
36	protease	I
37	inhibitor	O
38	.	O

1	Human	B
2	immunodeficiency	I
3	virus	I
4	type	I
5	1	I
6	(	I
7	HIV	I
8	-	I
9	1	I
10	)	I
11	IN	I
12	,	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	,	O
18	was	O
19	purified	O
20	to	O
21	near	O
22	homogeneity	O
23	.	O

1	Contributions	O
2	from	O
3	pairs	O
4	of	O
5	source	O
6	and	O
7	target	O
8	volume	O
9	elements	O
10	are	O
11	summed	O
12	for	O
13	the	O
14	S	O
15	values	O
16	between	O
17	the	O
18	tumor	O
19	and	O
20	itself	O
21	,	O
22	between	O
23	the	O
24	remaining	O
25	healthy	O
26	host	O
27	organ	O
28	and	O
29	itself	O
30	,	O
31	and	O
32	between	O
33	the	O
34	tumor	O
35	and	O
36	the	O
37	remaining	O
38	healthy	O
39	host	O
40	organ	O
41	,	O
42	with	O
43	the	O
44	reciprocity	O
45	theorem	O
46	assumed	O
47	for	O
48	the	O
49	last	O
50	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	O
10	p58	B
11	and	O
12	cdc2	B
13	/	O
14	p62	B
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	B
16	oxidase	I
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	For	O
2	SMX	O
3	at	O
4	pH	O
5	7	O
6	.	O
7	0	O
8	,	O
9	a	O
10	1	O
11	:	O
12	1	O
13	complex	O
14	is	O
15	formed	O
16	,	O
17	but	O
18	at	O
19	pH	O
20	7	O
21	.	O
22	5	O
23	HPCD	O
24	has	O
25	little	O
26	effect	O
27	on	O
28	the	O
29	solubility	O
30	of	O
31	the	O
32	highly	O
33	ionized	O
34	SMX	O
35	,	O
36	presumably	O
37	since	O
38	only	O
39	un	O
40	-	O
41	ionized	O
42	molecules	O
43	can	O
44	form	O
45	inclusion	O
46	complexes	O
47	with	O
48	the	O
49	HPCD	O
50	.	O

1	PO2	O
2	measurements	O
3	using	O
4	a	O
5	double	O
6	barrelled	O
7	recess	O
8	type	O
9	microelectrodes	O
10	were	O
11	measured	O
12	in	O
13	the	O
14	optic	O
15	nerve	O
16	head	O
17	of	O
18	miniature	O
19	pigs	O
20	in	O
21	normoxia	O
22	and	O
23	hyperoxia	O
24	.	O

1	The	O
2	IE0	B
3	gene	I
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O

1	3	O
2	cases	O

1	The	O
2	plasmid	O
3	shuffle	O
4	technique	O
5	was	O
6	used	O
7	to	O
8	replace	O
9	the	O
10	wild	O
11	-	O
12	type	O
13	gene	O
14	with	O
15	the	O
16	mutant	O
17	form	O
18	,	O
19	resulting	O
20	in	O
21	failure	O
22	of	O
23	the	O
24	yeast	O
25	cells	O
26	to	O
27	grow	O
28	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	Disruption	O
2	of	O
3	the	O
4	chromosomal	B
5	AAR1	I
6	gene	I
7	in	O
8	alpha	O
9	and	O
10	a	O
11	/	O
12	alpha	O
13	cells	O
14	conferred	O
15	the	O
16	nonmating	O
17	phenotype	O
18	,	O
19	and	O
20	the	O
21	a	O
22	/	O
23	alpha	O
24	diploids	O
25	could	O
26	not	O
27	sporulate	O
28	.	O

1	The	O
2	effect	O
3	of	O
4	ICRF	O
5	-	O
6	187	O
7	on	O
8	the	O
9	antitumor	O
10	response	O
11	induced	O
12	by	O
13	the	O
14	combination	O
15	of	O
16	ADR	O
17	and	O
18	WBH	O
19	was	O
20	also	O
21	investigated	O
22	in	O
23	order	O
24	to	O
25	assess	O
26	alterations	O
27	in	O
28	the	O
29	therapeutic	O
30	index	O
31	of	O
32	this	O
33	combined	O
34	therapeutic	O
35	modality	O
36	treatment	O
37	.	O

1	The	O
2	ORF	O
3	was	O
4	analyzed	O
5	for	O
6	secondary	O
7	structural	O
8	features	O
9	,	O
10	and	O
11	the	O
12	sequence	O
13	data	O
14	bases	O
15	were	O
16	searched	O
17	for	O
18	homologies	O
19	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	The	O
2	structural	O
3	changes	O
4	in	O
5	intra	O
6	-	O
7	acinar	O
8	artery	O
9	manifested	O
10	mainly	O
11	by	O
12	an	O
13	increase	O
14	in	O
15	number	O
16	of	O
17	muscular	O
18	artery	O
19	resulting	O
20	from	O
21	muscularization	O
22	of	O
23	precursor	O
24	cells	O
25	(	O
26	pericytes	O
27	and	O
28	intermediate	O
29	cells	O
30	)	O
31	located	O
32	within	O
33	partially	O
34	muscular	O
35	and	O
36	nonmuscular	O
37	arterial	O
38	wall	O
39	to	O
40	smooth	O
41	muscle	O
42	cell	O
43	,	O
44	and	O
45	by	O
46	the	O
47	medial	O
48	wall	O
49	thickened	O
50	due	O
51	to	O
52	hypertrophy	O
53	and	O
54	hyperplasia	O
55	of	O
56	smooth	O
57	muscle	O
58	cells	O
59	as	O
60	well	O
61	as	O
62	accumulation	O
63	of	O
64	a	O
65	large	O
66	amount	O
67	of	O
68	collagen	B
69	,	O
70	especially	O
71	the	O
72	type	B
73	1	I
74	collagen	I
75	.	O

1	Comparison	O
2	of	O
3	the	O
4	cDNA	O
5	-	O
6	predicted	O
7	avian	B
8	TnIcardiac	I
9	amino	I
10	acid	I
11	sequences	I
12	with	O
13	known	O
14	TnI	B
15	sequences	I
16	indicated	O
17	1	O
18	)	O
19	that	O
20	the	O
21	presence	O
22	of	O
23	an	O
24	N	O
25	-	O
26	terminal	O
27	extension	O
28	sequence	O
29	carrying	O
30	a	O
31	dual	O
32	protein	B
33	kinase	I
34	A	I
35	phosphorylation	O
36	target	O
37	site	O
38	and	O
39	an	O
40	adjacent	O
41	proline	O
42	-	O
43	rich	O
44	segment	O
45	is	O
46	an	O
47	ancient	O
48	cardiac	O
49	-	O
50	specific	O
51	feature	O
52	of	O
53	TnI	B
54	which	O
55	has	O
56	been	O
57	conserved	O
58	since	O
59	the	O
60	bird	O
61	/	O
62	mammal	O
63	divergence	O
64	,	O
65	2	O
66	)	O
67	that	O
68	features	O
69	of	O
70	the	O
71	near	O
72	-	O
73	N	O
74	-	O
75	terminal	O
76	troponin	B
77	C	I
78	(	O
79	TnC	B
80	)-	O
81	binding	O
82	site	O
83	sequence	O
84	suggest	O
85	isoform	O
86	-	O
87	specific	O
88	adaptation	O
89	of	O
90	TnI	B
91	and	O
92	TnC	B
93	,	O
94	and	O
95	3	O
96	)	O
97	that	O
98	the	O
99	avian	O
100	TnIcardiac	B
101	internal	O
102	actin	B
103	/	I
104	TnC	I
105	-	I
106	binding	I
107	,	I
108	actomyosin	I
109	-	I
110	inhibitory	I
111	,	I
112	domain	I
113	shows	O
114	significant	O
115	sequence	O
116	divergence	O
117	from	O
118	mammalian	B
119	TnIcardiac	I
120	sequences	I
121	,	O
122	including	O
123	the	O
124	absence	O
125	of	O
126	a	O
127	protein	B
128	kinase	I
129	C	I
130	target	O
131	site	O
132	which	O
133	is	O
134	a	O
135	cardiac	O
136	-	O
137	specific	O
138	feature	O
139	of	O
140	TnI	B
141	in	O
142	mammals	O
143	.	O

1	Habituation	O
2	of	O
3	completely	O
4	isolated	O
5	neurons	O
6	of	O
7	the	O
8	edible	O
9	snail	O
10	to	O
11	electrical	O
12	stimulation	O
13	.	O

1	Blood	O
2	flow	O
3	velocity	O
4	waveforms	O
5	were	O
6	recorded	O
7	by	O
8	pulsed	O
9	Doppler	O
10	examination	O
11	of	O
12	the	O
13	fetal	O
14	internal	O
15	carotid	O
16	and	O
17	middle	O
18	cerebral	O
19	arteries	O
20	using	O
21	the	O
22	established	O
23	transabdominal	O
24	route	O
25	as	O
26	well	O
27	as	O
28	a	O
29	new	O
30	transvaginal	O
31	approach	O
32	.	O

1	Position	O
2	22	O
3	is	O
4	an	O
5	isoleucine	O
6	in	O
7	the	O
8	complete	B
9	SsoL12	I
10	protein	I
11	sequence	I
12	,	O
13	coded	O
14	by	O
15	an	O
16	AUA	O
17	codon	O
18	.	O

1	Symptoms	O
2	due	O
3	to	O
4	the	O
5	action	O
6	of	O
7	mastocyte	O
8	mediators	O
9	were	O
10	observed	O
11	.	O

1	Of	O
2	these	O
3	179	O
4	samples	O
5	,	O
6	Mobiluncus	O
7	SP	O
8	was	O
9	observed	O
10	in	O
11	35	O
12	(	O
13	19	O
14	.	O
15	6	O
16	%)	O
17	using	O
18	Gram	O
19	staining	O
20	and	O
21	in	O
22	18	O
23	(	O
24	10	O
25	.	O
26	1	O
27	%)	O
28	this	O
29	microorganism	O
30	was	O
31	isolated	O
32	in	O
33	agar	O
34	RLK	O
35	and	O
36	anaerobic	O
37	atmosphere	O
38	.	O

1	Previous	O
2	investigators	O
3	have	O
4	suggested	O
5	that	O
6	subretinal	O
7	blood	O
8	damages	O
9	the	O
10	retina	O
11	in	O
12	part	O
13	because	O
14	of	O
15	its	O
16	solid	O
17	fibrin	B
18	meshwork	O
19	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	O
8	IGF	B
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	The	O
2	effect	O
3	of	O
4	salmon	B
5	calcitonin	I
6	nasal	O
7	spray	O
8	in	O
9	women	O
10	with	O
11	established	O
12	osteoporosis	O
13	has	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Skeletal	O
2	muscle	O
3	metaboreceptor	O
4	responses	O
5	are	O
6	impaired	O
7	in	O
8	heart	O
9	failure	O
10	.	O

1	Only	O
2	after	O
3	a	O
4	pretreatment	O
5	aimed	O
6	at	O
7	increasing	O
8	its	O
9	oxide	O
10	surface	O
11	layer	O
12	was	O
13	titanium	O
14	powder	O
15	found	O
16	to	O
17	accelerate	O
18	the	O
19	precipitation	O
20	from	O
21	solutions	O
22	containing	O
23	2	O
24	mmol	O
25	/	O
26	L	O
27	CaCl2	O
28	,	O
29	2	O
30	mmol	O
31	/	O
32	L	O
33	KH2PO4	O
34	,	O
35	50	O
36	mmol	O
37	/	O
38	L	O
39	Hepes	O
40	,	O
41	pH	O
42	7	O
43	.	O
44	2	O
45	,	O
46	and	O
47	to	O
48	induce	O
49	precipitation	O
50	from	O
51	metastable	O
52	solutions	O
53	containing	O
54	1	O
55	.	O
56	2	O
57	mmol	O
58	/	O
59	L	O
60	CaCl2	O
61	,	O
62	1	O
63	.	O
64	2	O
65	mmol	O
66	/	O
67	L	O
68	KH2PO4	O
69	,	O
70	50	O
71	mmol	O
72	/	O
73	L	O
74	Hepes	O
75	,	O
76	pH	O
77	7	O
78	.	O
79	2	O
80	,	O
81	at	O
82	37	O
83	degrees	O
84	C	O
85	.	O

1	Endothelial	O
2	cells	O
3	stored	O
4	with	O
5	University	O
6	of	O
7	Wisconsin	O
8	solution	O
9	excluded	O
10	trypan	O
11	blue	O
12	better	O
13	(	O
14	1	O
15	.	O
16	0	O
17	%	O
18	+/-	O
19	0	O
20	.	O
21	5	O
22	%	O
23	cells	O
24	stained	O
25	,	O
26	p	O
27	less	O
28	than	O
29	0	O
30	.	O
31	001	O
32	.	O

1	Fortunately	O
2	DDT	O
3	-,	O
4	HCH	O
5	-	O
6	and	O
7	HCB	O
8	-	O
9	levels	O
10	decreased	O
11	in	O
12	breast	O
13	milk	O
14	during	O
15	the	O
16	last	O
17	years	O
18	.	O

1	Dose	O
2	standardisation	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	Telomeres	O
2	prevent	O
3	end	O
4	-	O
5	to	O
6	-	O
7	end	O
8	fusions	O
9	and	O
10	exonucleolytic	O
11	degradation	O
12	,	O
13	enable	O
14	the	O
15	end	O
16	of	O
17	the	O
18	linear	O
19	DNA	O
20	molecule	O
21	to	O
22	replicate	O
23	,	O
24	and	O
25	function	O
26	in	O
27	cell	O
28	division	O
29	.	O

1	Early	O
2	cirrhosis	O
3	,	O
4	an	O
5	early	O
6	modality	O
7	of	O
8	the	O
9	evolution	O
10	of	O
11	acute	O
12	hepatitis	O
13	.	O

1	Seven	O
2	clones	O
3	encoding	O
4	interferon	B
5	response	I
6	element	I
7	binding	I
8	factors	I
9	have	O
10	been	O
11	isolated	O
12	from	O
13	a	O
14	mouse	O
15	fibroblast	O
16	lambda	O
17	gt11	O
18	cDNA	O
19	library	O
20	by	O
21	using	O
22	a	O
23	32P	O
24	end	O
25	-	O
26	labeled	O
27	tandem	O
28	trimer	O
29	of	O
30	the	O
31	mouse	B
32	(	I
33	2	I
34	'-	I
35	5	I
36	')	I
37	oligoadenylate	I
38	synthetase	I
39	gene	I
40	interferon	O
41	response	O
42	element	O
43	as	O
44	a	O
45	probe	O
46	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	B
12	-	I
13	bp	I
14	BAL	I
15	cDNA	I
16	structure	O
17	.	O

1	Alanine	B
2	aminotransferase	I
3	in	O
4	clinical	O
5	practice	O
6	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	I
8	PpG7	I
9	salicylate	I
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	B
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O

1	DNA	O
2	from	O
3	PCR	O
4	was	O
5	labeled	O
6	and	O
7	used	O
8	to	O
9	isolate	O
10	several	O
11	lambda	O
12	gt11	O
13	cDNA	O
14	clones	O
15	,	O
16	including	O
17	one	O
18	full	O
19	-	O
20	length	O
21	one	O
22	(	O
23	Dd	B
24	kinase	I
25	-	I
26	2	I
27	).	O

1	Salient	O
2	applications	O
3	of	O
4	PB	O
5	-	O
6	PK	O
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	The	O
2	cdr1	B
3	sequence	I
4	includes	O
5	an	O
6	additional	O
7	237	O
8	amino	O
9	acids	O
10	of	O
11	the	O
12	contiguous	O
13	fragment	O
14	and	O
15	encodes	O
16	a	O
17	product	O
18	of	O
19	predicted	O
20	Mr	O
21	67	O
22	,	O
23	000	O
24	.	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	O
26	alpha	B
27	-	I
28	IFN	I
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	No	O
2	positive	O
3	family	O
4	history	O
5	was	O
6	obtained	O
7	.	O

1	A	O
2	further	O
3	subdivision	O
4	of	O
5	Category	O
6	pN1	O
7	into	O
8	pN1a	O
9	(	O
10	metastasis	O
11	in	O
12	single	O
13	node	O
14	)	O
15	and	O
16	pN1b	O
17	(	O
18	two	O
19	or	O
20	more	O
21	nodes	O
22	)	O
23	is	O
24	recommended	O
25	.	O

1	To	O
2	identify	O
3	the	O
4	DNA	O
5	sequences	O
6	that	O
7	cis	O
8	-	O
9	regulate	O
10	the	O
11	expression	O
12	of	O
13	the	O
14	rat	B
15	liver	I
16	pyruvate	I
17	kinase	I
18	(	O
19	L	B
20	-	I
21	PK	I
22	)	O
23	genes	O
24	,	O
25	a	O
26	series	O
27	of	O
28	constructs	O
29	in	O
30	which	O
31	the	O
32	chloramphenicol	B
33	acetyltransferase	I
34	reporter	I
35	genes	I
36	is	O
37	driven	O
38	by	O
39	various	O
40	deleted	O
41	fragments	O
42	of	O
43	the	O
44	3200	O
45	base	O
46	pairs	O
47	(	O
48	bp	O
49	)	O
50	upstream	O
51	of	O
52	the	O
53	L	B
54	-	I
55	PK	I
56	gene	I
57	cap	I
58	site	I
59	have	O
60	been	O
61	assayed	O
62	for	O
63	transient	O
64	expression	O
65	after	O
66	introduction	O
67	into	O
68	hepatoma	O
69	HepG2	O
70	cells	O
71	,	O
72	rat	O
73	hepatocytes	O
74	in	O
75	primary	O
76	culture	O
77	,	O
78	fibroblast	O
79	LTK	O
80	-	O
81	cells	O
82	,	O
83	myogenic	O
84	C2C12	O
85	cells	O
86	,	O
87	and	O
88	CHO	O
89	cells	O
90	.	O

1	These	O
2	differences	O
3	involve	O
4	specific	O
5	hydrogen	O
6	-	O
7	bonding	O
8	interactions	O
9	between	O
10	the	O
11	protein	O
12	and	O
13	DNA	O
14	,	O
15	including	O
16	guanine	O
17	N7	O
18	sites	O
19	in	O
20	the	O
21	major	O
22	groove	O
23	of	O
24	DNA	O
25	,	O
26	and	O
27	alterations	O
28	in	O
29	DNA	O
30	phosphodiester	O
31	conformation	O
32	induced	O
33	by	O
34	protein	O
35	binding	O
36	.	O

1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	B
9	gene	I
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	B
18	-	I
19	1	I
20	LTR	I
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O

1	Differences	O
2	in	O
3	the	O
4	clinical	O
5	presentation	O
6	and	O
7	the	O
8	gross	O
9	appearance	O
10	of	O
11	the	O
12	two	O
13	cases	O
14	are	O
15	described	O
16	,	O
17	and	O
18	similarities	O
19	in	O
20	the	O
21	microscopic	O
22	features	O
23	are	O
24	discussed	O
25	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	The	O
7	two	O
8	groups	O
9	were	O
10	similar	O
11	on	O
12	entry	O
13	into	O
14	the	O
15	study	O
16	,	O
17	including	O
18	mean	O
19	FEV1	O
20	measurements	O
21	(	O
22	0	O
23	.	O
24	70	O
25	L	O
26	atropine	O
27	/	O
28	0	O
29	.	O
30	60	O
31	L	O
32	metaproterenol	O
33	,	O
34	P	O
35	greater	O
36	than	O
37	.	O
38	05	O
39	).	O

1	We	O
2	purified	O
3	a	O
4	Ca2	B
5	+/	I
6	calmodulin	I
7	(	I
8	CaM	I
9	)-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	CaM	B
15	kinase	I
16	)	O
17	from	O
18	the	O
19	yeast	O
20	Saccharomyces	O
21	cerevisiae	O
22	with	O
23	properties	O
24	similar	O
25	to	O
26	mammalian	B
27	type	I
28	II	I
29	CaM	I
30	kinases	I
31	.	O

1	Polymerase	O
2	chain	O
3	reaction	O
4	analysis	O
5	of	O
6	ETS1	B
7	cDNA	I
8	identified	O
9	several	O
10	amplified	O
11	products	O
12	,	O
13	indicating	O
14	alternative	O
15	splicing	O
16	.	O

1	The	O
2	alpha	B
3	4	I
4	gene	I
5	5	O
6	'	O
7	flanking	O
8	region	O
9	acted	O
10	as	O
11	a	O
12	promoter	O
13	in	O
14	transfection	O
15	assays	O
16	.	O

1	Two	O
2	homologues	O
3	of	O
4	the	O
5	rhombotin	B
6	gene	I
7	have	O
8	now	O
9	been	O
10	isolated	O
11	.	O

1	Angina	O
2	haemorrhagica	O
3	bullosa	O
4	causing	O
5	respiratory	O
6	obstruction	O
7	postoperatively	O
8	.	O

1	We	O
2	examined	O
3	the	O
4	effects	O
5	of	O
6	long	O
7	-	O
8	term	O
9	perfusion	O
10	with	O
11	pyridoxalated	O
12	hemoglobin	B
13	polyoxyethylene	O
14	conjugate	O
15	(	O
16	PHP	O
17	)	O
18	solution	O
19	on	O
20	cardiac	O
21	function	O
22	of	O
23	isolated	O
24	rat	O
25	hearts	O
26	.	O

1	A	O
2	single	O
3	case	O
4	of	O
5	an	O
6	adenocarcinoma	O
7	,	O
8	arising	O
9	in	O
10	a	O
11	retroperitoneal	O
12	enterogenous	O
13	cyst	O
14	and	O
15	which	O
16	presented	O
17	as	O
18	a	O
19	left	O
20	renal	O
21	cyst	O
22	,	O
23	is	O
24	reported	O
25	.	O

1	In	O
2	contrast	O
3	,	O
4	similar	O
5	rates	O
6	of	O
7	B	O
8	.	O
9	sphaericus	O
10	products	O
11	,	O
12	ABG	O
13	-	O
14	6184	O
15	technical	O
16	powder	O
17	and	O
18	BSP	O
19	-	O
20	2	O
21	flowable	O
22	concentrate	O
23	,	O
24	produced	O
25	no	O
26	significant	O
27	reduction	O
28	.	O

1	Hemorrhagic	O
2	shock	O
3	and	O
4	bacterial	O
5	translocation	O
6	in	O
7	a	O
8	swine	O
9	model	O
10	.	O

1	These	O
2	observations	O
3	,	O
4	together	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	putative	O
10	4	O
11	'-	O
12	phosphopantetheine	O
13	-	O
14	attachment	O
15	sites	O
16	and	O
17	a	O
18	putative	O
19	thioesterase	B
20	site	I
21	,	O
22	are	O
23	discussed	O
24	with	O
25	reference	O
26	to	O
27	the	O
28	reaction	O
29	sequence	O
30	leading	O
31	to	O
32	production	O
33	of	O
34	the	O
35	ACV	B
36	tripeptide	I
37	.	O

1	The	O
2	stimulus	O
3	threshold	O
4	for	O
5	EER	O
6	showed	O
7	a	O
8	less	O
9	individual	O
10	variation	O
11	than	O
12	amplitude	O
13	.	O

1	Analysis	O
2	of	O
3	electrically	O
4	evoked	O
5	response	O
6	(	O
7	EER	O
8	)	O
9	in	O
10	relation	O
11	to	O
12	the	O
13	central	O
14	visual	O
15	pathway	O
16	of	O
17	the	O
18	cat	O
19	(	O
20	1	O
21	).	O

1	In	O
2	all	O
3	cases	O
4	,	O
5	high	O
6	-	O
7	level	O
8	expression	O
9	of	O
10	the	O
11	truncated	B
12	avian	I
13	integrins	I
14	was	O
15	obtained	O
16	.	O

1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O

1	The	O
2	TCF	B
3	-	I
4	1	I
5	alpha	I
6	binding	I
7	site	I
8	was	O
9	also	O
10	required	O
11	for	O
12	TCR	B
13	alpha	I
14	enhancer	I
15	activity	O
16	in	O
17	transcriptionally	O
18	active	O
19	extracts	O
20	from	O
21	Jurkat	O
22	but	O
23	not	O
24	HeLa	O
25	cells	O
26	,	O
27	confirming	O
28	that	O
29	TCF	B
30	-	I
31	1	I
32	alpha	I
33	is	O
34	a	O
35	T	B
36	-	I
37	cell	I
38	-	I
39	specific	I
40	transcription	I
41	factor	I
42	.	O

1	A	O
2	new	O
3	semi	O
4	-	O
5	automatic	O
6	method	O
7	for	O
8	quantifying	O
9	regional	O
10	cerebral	O
11	uptake	O
12	of	O
13	99m	O
14	technetium	O
15	-	O
16	hexamethylpropylene	O
17	amine	O
18	oxime	O
19	(	O
20	99mTc	O
21	-	O
22	HMPAO	O
23	)	O
24	was	O
25	used	O
26	to	O
27	assess	O
28	single	O
29	photon	O
30	emission	O
31	tomograms	O
32	from	O
33	5	O
34	normal	O
35	subjects	O
36	,	O
37	14	O
38	patients	O
39	with	O
40	Alzheimer	O
41	'	O
42	s	O
43	disease	O
44	,	O
45	14	O
46	patients	O
47	with	O
48	dementia	O
49	of	O
50	frontal	O
51	lobe	O
52	type	O
53	and	O
54	4	O
55	patients	O
56	with	O
57	dementia	O
58	with	O
59	motor	O
60	neurone	O
61	disease	O
62	.	O

1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O

1	Diuresis	O
2	was	O
3	induced	O
4	by	O
5	scheduled	O
6	drinking	O
7	of	O
8	tea	O
9	(	O
10	150	O
11	ml	O
12	/	O
13	h	O
14	).	O

1	Spore	O
2	inocula	O
3	(	O
4	approximately	O
5	10	O
6	(	O
7	6	O
8	)/	O
9	coupon	O
10	)	O
11	were	O
12	dried	O
13	onto	O
14	0	O
15	.	O
16	5	O
17	-	O
18	in	O
19	.	O

1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	B
8	and	O
9	STE18	B
10	proteins	I
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	B
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	B
32	.	O

1	Inspired	O
2	CO2	O
3	causing	O
4	changes	O
5	from	O
6	hypo	O
7	-	O
8	to	O
9	normocapnia	O
10	has	O
11	previously	O
12	been	O
13	shown	O
14	to	O
15	improve	O
16	arterial	O
17	O2	O
18	tension	O
19	(	O
20	PaO2	O
21	)	O
22	and	O
23	to	O
24	reduce	O
25	alveolar	O
26	-	O
27	arterial	O
28	O2	O
29	difference	O
30	.	O

1	But	O
2	no	O
3	influence	O
4	was	O
5	observed	O
6	at	O
7	lower	O
8	concentrations	O
9	than	O
10	1	O
11	/	O
12	4	O
13	MIC	O
14	of	O
15	AMK	O
16	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	O
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	Gel	O
2	-	O
3	mobility	O
4	-	O
5	shift	O
6	assays	O
7	confirmed	O
8	that	O
9	the	O
10	Raji	O
11	nuclear	O
12	proteins	O
13	that	O
14	bound	O
15	to	O
16	W	O
17	and	O
18	V	O
19	elements	O
20	were	O
21	competed	O
22	with	O
23	by	O
24	an	O
25	HLA	B
26	-	I
27	DRA	I
28	X	I
29	-	I
30	box	I
31	oligonucleotide	I
32	.	O

1	Like	O
2	other	O
3	members	O
4	of	O
5	this	O
6	family	O
7	,	O
8	the	O
9	AP	B
10	-	I
11	4	I
12	HLH	O
13	motif	O
14	and	O
15	the	O
16	adjacent	O
17	basic	O
18	domain	O
19	are	O
20	necessary	O
21	and	O
22	sufficient	O
23	to	O
24	confer	O
25	site	O
26	-	O
27	specific	O
28	DNA	O
29	binding	O
30	.	O

1	Additionally	O
2	,	O
3	although	O
4	c	B
5	-	I
6	fos	I
7	and	O
8	egr	B
9	-	I
10	1	I
11	mRNAs	I
12	are	O
13	expressed	O
14	at	O
15	elevated	O
16	levels	O
17	in	O
18	stimulated	O
19	liver	O
20	cells	O
21	,	O
22	fos	B
23	-	I
24	B	I
25	,	O
26	fra	B
27	-	I
28	1	I
29	,	O
30	and	O
31	egr	B
32	-	I
33	2	I
34	are	O
35	not	O
36	,	O
37	which	O
38	suggests	O
39	that	O
40	factors	O
41	in	O
42	addition	O
43	to	O
44	the	O
45	serum	B
46	response	I
47	factor	I
48	participate	O
49	in	O
50	the	O
51	regulation	O
52	of	O
53	immediate	B
54	-	I
55	early	I
56	gene	I
57	induction	O
58	.	O

1	Although	O
2	no	O
3	Rh	B
4	-	I
5	antibodies	I
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	The	O
2	experimental	O
3	group	O
4	consisted	O
5	of	O
6	61	O
7	examinees	O
8	class	O
9	II	O
10	/	O
11	2	O
12	orthodontic	O
13	anomalies	O
14	.	O

1	Subjects	O
2	were	O
3	16	O
4	male	O
5	chronic	O
6	schizophrenics	O
7	consisting	O
8	of	O
9	8	O
10	DST	O
11	suppressors	O
12	and	O
13	8	O
14	nonsuppressors	O
15	.	O

1	In	O
2	a	O
3	highly	O
4	select	O
5	group	O
6	of	O
7	stable	O
8	hypertensive	O
9	patients	O
10	,	O
11	we	O
12	have	O
13	assessed	O
14	the	O
15	strength	O
16	of	O
17	association	O
18	between	O
19	various	O
20	blood	O
21	pressure	O
22	measurements	O
23	(	O
24	24	O
25	h	O
26	average	O
27	automated	O
28	ambulatory	O
29	blood	O
30	pressure	O
31	,	O
32	4	O
33	h	O
34	automated	O
35	ambulatory	O
36	morning	O
37	average	O
38	blood	O
39	pressure	O
40	,	O
41	multiple	O
42	office	O
43	visit	O
44	average	O
45	blood	O
46	pressure	O
47	,	O
48	and	O
49	a	O
50	single	O
51	office	O
52	visit	O
53	average	O
54	blood	O
55	pressure	O
56	)	O
57	and	O
58	various	O
59	echocardiographic	O
60	indices	O
61	of	O
62	hypertensive	O
63	cardiac	O
64	target	O
65	organ	O
66	damage	O
67	(	O
68	left	O
69	atrial	O
70	diameter	O
71	,	O
72	left	O
73	ventricular	O
74	end	O
75	diastolic	O
76	diameter	O
77	,	O
78	posterior	O
79	wall	O
80	thickness	O
81	,	O
82	combined	O
83	wall	O
84	thickness	O
85	,	O
86	relative	O
87	wall	O
88	thickness	O
89	,	O
90	left	O
91	ventricular	O
92	mass	O
93	and	O
94	mass	O
95	index	O
96	,	O
97	and	O
98	combined	O
99	wall	O
100	thickness	O
101	/	O
102	left	O
103	ventricular	O
104	diastolic	O
105	diameter	O
106	ratio	O
107	).	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	,	O
6	by	O
7	screening	O
8	a	O
9	lambda	O
10	gt11	O
11	expression	O
12	library	O
13	,	O
14	murine	B
15	protein	I
16	mXBP	I
17	,	O
18	which	O
19	binds	O
20	to	O
21	a	O
22	sequence	O
23	which	O
24	overlaps	O
25	the	O
26	3	O
27	'	O
28	end	O
29	of	O
30	the	O
31	murine	B
32	class	I
33	II	I
34	major	I
35	histocompatibility	I
36	complex	I
37	A	I
38	alpha	I
39	gene	I
40	X	I
41	box	I
42	,	O
43	a	O
44	conserved	O
45	transcription	O
46	element	O
47	found	O
48	upstream	O
49	of	O
50	all	O
51	class	O
52	II	O
53	genes	O
54	.	O

1	With	O
2	the	O
3	modified	O
4	fingertip	O
5	-	O
6	to	O
7	-	O
8	floor	O
9	(	O
10	MFTF	O
11	)	O
12	method	O
13	,	O
14	patients	O
15	stand	O
16	on	O
17	a	O
18	stool	O
19	and	O
20	forward	O
21	bend	O
22	so	O
23	that	O
24	measurements	O
25	can	O
26	be	O
27	taken	O
28	on	O
29	patients	O
30	who	O
31	are	O
32	able	O
33	to	O
34	touch	O
35	the	O
36	floor	O
37	or	O
38	reach	O
39	beyond	O
40	the	O
41	level	O
42	of	O
43	the	O
44	floor	O
45	.	O

1	No	O
2	significant	O
3	differences	O
4	could	O
5	be	O
6	seen	O
7	in	O
8	response	O
9	rates	O
10	according	O
11	to	O
12	the	O
13	concentration	O
14	of	O
15	estrogen	B
16	receptors	I
17	or	O
18	presence	O
19	of	O
20	progesteron	B
21	receptors	I
22	in	O
23	this	O
24	group	O
25	of	O
26	patients	O
27	.	O

1	Although	O
2	there	O
3	are	O
4	no	O
5	octamer	O
6	elements	O
7	in	O
8	the	O
9	adenovirus	O
10	genome	O
11	that	O
12	are	O
13	known	O
14	to	O
15	be	O
16	important	O
17	for	O
18	transcription	O
19	,	O
20	there	O
21	are	O
22	octamer	O
23	elements	O
24	in	O
25	the	O
26	viral	O
27	terminal	O
28	repeat	O
29	sequences	O
30	.	O

1	Regional	O
2	cerebral	O
3	blood	O
4	flow	O
5	was	O
6	measured	O
7	using	O
8	N	O
9	-	O
10	isopropyl	O
11	-	O
12	123I	O
13	-	O
14	iodoamphetamine	O
15	with	O
16	single	O
17	-	O
18	photon	O
19	emission	O
20	computed	O
21	tomography	O
22	(	O
23	CT	O
24	)	O
25	in	O
26	16	O
27	aged	O
28	patients	O
29	with	O
30	noninsulin	O
31	-	O
32	dependent	O
33	diabetes	O
34	mellitus	O
35	(	O
36	NIDDM	O
37	,	O
38	average	O
39	age	O
40	72	O
41	.	O
42	8	O
43	years	O
44	,	O
45	average	O
46	fasting	O
47	plasma	O
48	glucose	O
49	7	O
50	.	O
51	7	O
52	mmol	O
53	/	O
54	L	O
55	),	O
56	and	O
57	12	O
58	nondiabetic	O
59	subjects	O
60	(	O
61	71	O
62	.	O
63	6	O
64	years	O
65	,	O
66	5	O
67	.	O
68	3	O
69	mmol	O
70	/	O
71	L	O
72	).	O

1	This	O
2	result	O
3	indicates	O
4	that	O
5	separate	O
6	complexes	O
7	exist	O
8	containing	O
9	ankyrin	B
10	and	O
11	fodrin	B
12	with	O
13	either	O
14	uvomorulin	B
15	or	O
16	Na	B
17	+,	I
18	K	I
19	+-	I
20	ATPase	I
21	.	O

1	The	O
2	PC2	B
3	protein	I
4	also	O
5	shows	O
6	great	O
7	similarity	O
8	to	O
9	the	O
10	incomplete	O
11	NH2	O
12	-	O
13	terminal	O
14	sequence	O
15	of	O
16	the	O
17	human	B
18	furin	I
19	gene	I
20	product	I
21	,	O
22	a	O
23	putative	O
24	membrane	O
25	-	O
26	inserted	O
27	receptor	O
28	-	O
29	like	O
30	molecule	O
31	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	used	O
7	footprinting	O
8	and	O
9	gel	O
10	mobility	O
11	retardation	O
12	assays	O
13	to	O
14	reveal	O
15	that	O
16	bacterially	O
17	synthesized	O
18	Zta	B
19	fusion	I
20	proteins	I
21	bound	O
22	directly	O
23	to	O
24	six	O
25	TGTGCAA	O
26	-	O
27	like	O
28	motifs	O
29	within	O
30	DSL	B
31	.	O

1	The	O
2	zta	B
3	transactivator	I
4	involved	O
5	in	O
6	induction	O
7	of	O
8	lytic	O
9	cycle	O
10	gene	O
11	expression	O
12	in	O
13	Epstein	O
14	-	O
15	Barr	O
16	virus	O
17	-	O
18	infected	O
19	lymphocytes	O
20	binds	O
21	to	O
22	both	O
23	AP	B
24	-	I
25	1	I
26	and	O
27	ZRE	B
28	sites	I
29	in	O
30	target	O
31	promoter	O
32	and	O
33	enhancer	O
34	regions	O
35	.	O

1	Specific	O
2	binding	O
3	of	O
4	the	O
5	protein	O
6	factors	O
7	to	O
8	the	O
9	sites	O
10	,	O
11	possibly	O
12	to	O
13	the	O
14	three	O
15	Mt	O
16	sequences	O
17	,	O
18	may	O
19	play	O
20	an	O
21	important	O
22	role	O
23	in	O
24	the	O
25	coordinate	O
26	regulation	O
27	of	O
28	the	O
29	transcription	O
30	of	O
31	nuclear	O
32	genes	O
33	encoding	O
34	subunits	O
35	responsible	O
36	for	O
37	mitochondrial	O
38	oxidative	O
39	phosphorylation	O
40	.	O

1	This	O
2	points	O
3	to	O
4	a	O
5	specific	O
6	interference	O
7	with	O
8	HSV	O
9	-	O
10	induced	O
11	DNA	O
12	amplification	O
13	.	O

1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O

1	To	O
2	address	O
3	this	O
4	issue	O
5	,	O
6	the	O
7	gene	O
8	for	O
9	factor	B
10	Y	I
11	has	O
12	been	O
13	cloned	O
14	molecularly	O
15	and	O
16	its	O
17	DNA	O
18	sequence	O
19	has	O
20	been	O
21	determined	O
22	.	O

1	To	O
2	identify	O
3	these	O
4	sites	O
5	,	O
6	the	O
7	deduced	O
8	amino	O
9	acid	O
10	sequence	O
11	of	O
12	the	O
13	3T3	O
14	-	O
15	L1	O
16	adipocyte	B
17	insulin	I
18	receptor	I
19	of	O
20	the	O
21	mouse	O
22	was	O
23	determined	O
24	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	the	O
6	sequence	O
7	similarities	O
8	reflect	O
9	a	O
10	common	O
11	molecular	O
12	architecture	O
13	of	O
14	the	O
15	two	O
16	heme	O
17	binding	O
18	sites	O
19	and	O
20	of	O
21	a	O
22	copper	O
23	binding	O
24	site	O
25	in	O
26	these	O
27	enzymes	O
28	.	O

1	Our	O
2	studies	O
3	extend	O
4	these	O
5	findings	O
6	and	O
7	show	O
8	that	O
9	the	O
10	E2	B
11	transactivation	I
12	gene	I
13	is	O
14	expressed	O
15	from	O
16	multiple	O
17	promoters	O
18	.	O

1	Furthermore	O
2	,	O
3	analysis	O
4	of	O
5	the	O
6	E2	B
7	proteins	I
8	present	O
9	in	O
10	various	O
11	cell	O
12	lines	O
13	harboring	O
14	specific	O
15	BPV	O
16	-	O
17	1	O
18	mutants	O
19	,	O
20	including	O
21	the	O
22	2558	O
23	acceptor	O
24	mutant	O
25	,	O
26	proves	O
27	that	O
28	alternate	O
29	modes	O
30	of	O
31	E2	B
32	expression	O
33	exist	O
34	.	O

1	This	O
2	cohort	O
3	of	O
4	patients	O
5	was	O
6	selected	O
7	on	O
8	the	O
9	basis	O
10	of	O
11	clinical	O
12	stage	O
13	.	O

1	The	O
2	diagnosis	O
3	of	O
4	miliary	O
5	tuberculosis	O
6	should	O
7	be	O
8	systematically	O
9	considered	O
10	in	O
11	ARDS	O
12	of	O
13	unknown	O
14	origin	O
15	.	O

1	The	O
2	26S	B
3	rRNA	I
4	binding	I
5	ribosomal	I
6	protein	I
7	equivalent	O
8	to	O
9	bacterial	B
10	protein	I
11	L11	I
12	is	O
13	encoded	O
14	by	O
15	unspliced	O
16	duplicated	O
17	genes	O
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O

1	The	O
2	electrically	O
3	induced	O
4	motile	O
5	responses	O
6	were	O
7	not	O
8	suppressed	O
9	in	O
10	the	O
11	presence	O
12	of	O
13	dinitrophenol	O
14	or	O
15	cytochalasin	O
16	B	O
17	.	O

1	Blood	O
2	flow	O
3	and	O
4	velocity	O
5	(	O
6	measured	O
7	using	O
8	Doppler	O
9	ultrasound	O
10	)	O
11	gradually	O
12	decreased	O
13	during	O
14	diastole	O
15	and	O
16	ultimately	O
17	reversed	O
18	in	O
19	direction	O
20	as	O
21	cotyledon	O
22	resistance	O
23	was	O
24	increased	O
25	up	O
26	to	O
27	14	O
28	fold	O
29	.	O

1	A	O
2	total	O
3	of	O
4	112	O
5	patients	O
6	received	O
7	anistreplase	O
8	and	O
9	119	O
10	received	O
11	heparin	O
12	within	O
13	a	O
14	mean	O
15	period	O
16	of	O
17	188	O
18	+/-	O
19	62	O
20	min	O
21	following	O
22	the	O
23	onset	O
24	of	O
25	symptoms	O
26	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	14DM	I
5	gene	I
6	,	O
7	encoding	O
8	cytochrome	B
9	P450	I
10	lanosterol	I
11	14	I
12	alpha	I
13	-	I
14	demethylase	I
15	(	O
16	14DM	B
17	),	O
18	was	O
19	overexpressed	O
20	in	O
21	various	O
22	S	O
23	.	O
24	cerevisiae	O
25	strains	O
26	under	O
27	the	O
28	control	O
29	of	O
30	three	O
31	strong	O
32	heterologous	O
33	yeast	O
34	transcription	O
35	promoters	O
36	(	O
37	pADC1	B
38	,	O
39	pGPD	B
40	,	O
41	pPHO5	B
42	)	O
43	and	O
44	under	O
45	the	O
46	control	O
47	of	O
48	its	O
49	own	O
50	promoter	O
51	.	O

1	The	O
2	ANB1	B
3	locus	I
4	of	O
5	Saccharomyces	O
6	cerevisiae	O
7	encodes	O
8	the	O
9	protein	B
10	synthesis	I
11	initiation	I
12	factor	I
13	eIF	I
14	-	I
15	4D	I
16	.	O

1	R	O
2	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	O
11	protein	B
12	C	I
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O

1	Among	O
2	known	O
3	flea	O
4	larvae	O
5	,	O
6	the	O
7	genus	O
8	Anomiopsyllus	O
9	(	O
10	Anomiopsyllinae	O
11	,	O
12	Anomiopsyllini	O
13	)	O
14	is	O
15	as	O
16	distinctive	O
17	in	O
18	larval	O
19	form	O
20	as	O
21	are	O
22	the	O
23	adults	O
24	.	O

1	1	O
2	,	O
3	among	O
4	which	O
5	nine	O
6	have	O
7	been	O
8	cloned	O
9	and	O
10	two	O
11	(	O
12	potentially	O
13	functional	O
14	)	O
15	sequenced	O
16	.	O

1	Homozygous	O
2	protein	B
3	C	I
4	(	O
5	PC	B
6	)	O
7	deficiency	O
8	is	O
9	reported	O
10	in	O
11	two	O
12	siblings	O
13	(	O
14	girl	O
15	and	O
16	boy	O
17	)	O
18	who	O
19	received	O
20	their	O
21	proper	O
22	diagnoses	O
23	at	O
24	the	O
25	ages	O
26	of	O
27	7	O
28	4	O
29	/	O
30	12	O
31	and	O
32	1	O
33	3	O
34	/	O
35	12	O
36	years	O
37	respectively	O
38	.	O

1	The	O
2	urinary	O
3	protein	O
4	,	O
5	serum	O
6	albumin	B
7	,	O
8	BUN	O
9	and	O
10	SCr	O
11	all	O
12	had	O
13	very	O
14	significant	O
15	improvement	O
16	.	O

1	The	O
2	effects	O
3	of	O
4	coenzyme	O
5	Q10	O
6	(	O
7	CoQ	O
8	)	O
9	and	O
10	captopril	O
11	on	O
12	functional	O
13	capacity	O
14	,	O
15	hemodynamics	O
16	and	O
17	survival	O
18	were	O
19	studied	O
20	in	O
21	154	O
22	rats	O
23	that	O
24	recovered	O
25	after	O
26	experimental	O
27	myocardial	O
28	infarction	O
29	.	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	On	O
2	an	O
3	antithrombin	B
4	unit	O
5	basis	O
6	,	O
7	CY	O
8	216	O
9	and	O
10	CY	O
11	222	O
12	were	O
13	equivalent	O
14	and	O
15	more	O
16	potent	O
17	than	O
18	UH	O
19	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	The	O
2	protooncogene	O
3	c	B
4	-	I
5	myb	I
6	encodes	O
7	a	O
8	nuclear	O
9	transcription	O
10	factor	O
11	that	O
12	binds	O
13	to	O
14	DNA	O
15	in	O
16	a	O
17	sequence	O
18	-	O
19	specific	O
20	manner	O
21	and	O
22	transactivates	O
23	transcription	O
24	of	O
25	several	O
26	viral	O
27	and	O
28	cellular	O
29	genes	O
30	.	O

1	Presidential	O
2	address	O
3	1990	O
4	--	O
5	coming	O
6	in	O
7	from	O
8	the	O
9	cold	O
10	.	O

1	Perceptions	O
2	of	O
3	illness	O
4	intrusiveness	O
5	were	O
6	significantly	O
7	higher	O
8	when	O
9	both	O
10	muscle	O
11	cramp	O
12	and	O
13	headache	O
14	symptoms	O
15	occurred	O
16	during	O
17	one	O
18	or	O
19	more	O
20	assessment	O
21	intervals	O
22	as	O
23	compared	O
24	to	O
25	when	O
26	muscle	O
27	cramps	O
28	or	O
29	headaches	O
30	,	O
31	only	O
32	,	O
33	occurred	O
34	.	O

1	65	O
2	-	O
3	kilodalton	O
4	protein	O
5	phosphorylated	O
6	by	O
7	interleukin	B
8	2	I
9	stimulation	O
10	bears	O
11	two	O
12	putative	O
13	actin	B
14	-	I
15	binding	I
16	sites	I
17	and	O
18	two	O
19	calcium	O
20	-	O
21	binding	O
22	sites	O
23	.	O

1	The	O
2	circadian	O
3	rhythm	O
4	,	O
5	however	O
6	,	O
7	was	O
8	not	O
9	affected	O
10	and	O
11	the	O
12	difference	O
13	between	O
14	minimum	O
15	(	O
16	12	O
17	.	O
18	00	O
19	h	O
20	)	O
21	and	O
22	maximum	O
23	(	O
24	18	O
25	.	O
26	50	O
27	h	O
28	)	O
29	serum	O
30	concentrations	O
31	was	O
32	31	O
33	.	O
34	3	O
35	%.	O

1	Most	O
2	strains	O
3	(	O
4	95	O
5	%)	O
6	of	O
7	S	O
8	.	O
9	lugdunensis	O
10	produced	O
11	a	O
12	delta	B
13	hemolysin	I
14	like	O
15	that	O
16	seen	O
17	with	O
18	nine	O
19	other	O
20	species	O
21	of	O
22	CNS	O
23	.	O

1	First	O
2	,	O
3	each	O
4	lung	O
5	was	O
6	cut	O
7	into	O
8	slices	O
9	,	O
10	from	O
11	which	O
12	primary	O
13	disectors	O
14	were	O
15	sampled	O
16	systematically	O
17	with	O
18	a	O
19	known	O
20	sampling	O
21	fraction	O
22	.	O

1	Assuming	O
2	O2	O
3	consumption	O
4	of	O
5	the	O
6	isolated	O
7	skin	O
8	to	O
9	be	O
10	same	O
11	as	O
12	in	O
13	situ	O
14	,	O
15	calculations	O
16	showed	O
17	that	O
18	when	O
19	water	O
20	PO2	O
21	was	O
22	high	O
23	(	O
24	150	O
25	mm	O
26	Hg	O
27	),	O
28	about	O
29	40	O
30	%	O
31	of	O
32	total	O
33	cutaneous	O
34	O2	O
35	uptake	O
36	was	O
37	consumed	O
38	by	O
39	the	O
40	skin	O
41	.	O

1	Experiments	O
2	showed	O
3	that	O
4	temporary	O
5	arrest	O
6	of	O
7	pulmonary	O
8	circulation	O
9	under	O
10	conditions	O
11	of	O
12	extracorporeal	O
13	circulation	O
14	is	O
15	attended	O
16	by	O
17	the	O
18	development	O
19	of	O
20	ischemia	O
21	of	O
22	the	O
23	respiratory	O
24	pulmonary	O
25	tissue	O
26	.	O

1	The	O
2	survival	O
3	in	O
4	the	O
5	case	O
6	of	O
7	these	O
8	patients	O
9	was	O
10	studied	O
11	five	O
12	years	O
13	later	O
14	.	O

1	These	O
2	results	O
3	may	O
4	suggest	O
5	involvement	O
6	of	O
7	peripheral	O
8	enkephalins	O
9	in	O
10	pain	O
11	modulation	O
12	in	O
13	patients	O
14	with	O
15	episodic	O
16	cluster	O
17	headache	O
18	.	O

1	Common	O
2	foot	O
3	pathologies	O
4	are	O
5	heel	O
6	pain	O
7	,	O
8	metatarsalgia	O
9	,	O
10	hammertoes	O
11	and	O
12	clawtoes	O
13	,	O
14	bunions	O
15	,	O
16	hallux	O
17	rigidus	O
18	,	O
19	corns	O
20	and	O
21	calluses	O
22	,	O
23	nail	O
24	pathologies	O
25	,	O
26	arthritis	O
27	,	O
28	and	O
29	neuropathies	O
30	.	O

1	Liver	O
2	dysfunction	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	different	O
8	adverse	O
9	reactions	O
10	presented	O
11	with	O
12	a	O
13	higher	O
14	activity	O
15	in	O
16	the	O
17	blood	O
18	serum	O
19	of	O
20	indicator	O
21	liver	O
22	enzymes	O
23	and	O
24	its	O
25	impaired	O
26	protein	O
27	-	O
28	forming	O
29	function	O
30	.	O

1	Interlimb	O
2	coordination	O
3	during	O
4	fictive	O
5	locomotion	O
6	in	O
7	the	O
8	thalamic	O
9	cat	O
10	.	O

1	To	O
2	those	O
3	of	O
4	us	O
5	who	O
6	are	O
7	not	O
8	satisfied	O
9	with	O
10	the	O
11	present	O
12	outlook	O
13	there	O
14	is	O
15	much	O
16	to	O
17	be	O
18	investigated	O
19	and	O
20	much	O
21	to	O
22	be	O
23	contributed	O
24	.	O

1	The	O
2	introns	O
3	are	O
4	1	O
5	.	O
6	6	O
7	-	O
8	1	O
9	.	O
10	9	O
11	kbp	O
12	long	O
13	.	O

1	In	O
2	the	O
3	first	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	Sprague	O
9	-	O
10	Dawley	O
11	male	O
12	rats	O
13	were	O
14	implanted	O
15	unilaterally	O
16	with	O
17	guide	O
18	cannulas	O
19	aimed	O
20	at	O
21	the	O
22	lateral	O
23	ventricle	O
24	.	O

1	The	O
2	abscess	O
3	was	O
4	debrided	O
5	and	O
6	the	O
7	septum	O
8	was	O
9	patched	O
10	with	O
11	a	O
12	single	O
13	layer	O
14	of	O
15	autologous	O
16	pericardium	O
17	.	O

1	The	O
2	clinical	O
3	relevance	O
4	of	O
5	these	O
6	findings	O
7	is	O
8	strengthened	O
9	by	O
10	the	O
11	observation	O
12	that	O
13	similar	O
14	results	O
15	were	O
16	obtained	O
17	when	O
18	P	O
19	.	O
20	HCl	O
21	was	O
22	given	O
23	by	O
24	the	O
25	intravenous	O
26	route	O
27	.	O

1	The	O
2	alternative	O
3	exon	O
4	introduces	O
5	the	O
6	novel	O
7	carboxyl	O
8	terminus	O
9	and	O
10	a	O
11	new	O
12	translation	O
13	stop	O
14	signal	O
15	,	O
16	while	O
17	simultaneously	O
18	converting	O
19	the	O
20	coding	O
21	sequence	O
22	for	O
23	40	O
24	carboxyl	O
25	-	O
26	terminal	O
27	residues	O
28	in	O
29	CeCAT	B
30	alpha	I
31	into	O
32	3	O
33	'-	O
34	untranslated	O
35	nucleotides	O
36	.	O

1	Slowly	O
2	adapting	O
3	type	O
4	I	O
5	mechanoreceptor	O
6	discharge	O
7	as	O
8	a	O
9	function	O
10	of	O
11	dynamic	O
12	force	O
13	versus	O
14	dynamic	O
15	displacement	O
16	of	O
17	glabrous	O
18	skin	O
19	of	O
20	raccoon	O
21	and	O
22	squirrel	O
23	monkey	O
24	hand	O
25	.	O

1	Plasma	O
2	lecithin	B
3	/	I
4	cholesterol	I
5	acyltransferase	I
6	(	O
7	LCAT	B
8	)	O
9	activity	O
10	in	O
11	multiple	O
12	-	O
13	organ	O
14	donors	O
15	:	O
16	a	O
17	predictor	O
18	of	O
19	allograft	O
20	viability	O
21	in	O
22	clinical	O
23	liver	O
24	transplantation	O
25	.	O

1	The	O
2	application	O
3	of	O
4	these	O
5	microelectrodes	O
6	to	O
7	the	O
8	measurement	O
9	of	O
10	rapid	O
11	,	O
12	transient	O
13	changes	O
14	in	O
15	retinal	O
16	[	O
17	K	O
18	+]	O
19	o	O
20	is	O
21	presented	O
22	.	O

1	Expression	O
2	,	O
3	cellular	O
4	localization	O
5	and	O
6	in	O
7	vitro	O
8	transcription	O
9	studies	O
10	establish	O
11	that	O
12	cloned	B
13	hUBF	I
14	encodes	O
15	a	O
16	nucleolar	O
17	factor	O
18	that	O
19	binds	O
20	specifically	O
21	to	O
22	the	O
23	upstream	O
24	control	O
25	element	O
26	and	O
27	core	O
28	of	O
29	the	O
30	rRNA	O
31	gene	O
32	promoter	O
33	to	O
34	activate	O
35	transcription	O
36	in	O
37	a	O
38	binding	O
39	site	O
40	-	O
41	dependent	O
42	manner	O
43	.	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	O
9	(	O
10	EIA	O
11	)	O
12	while	O
13	breathing	O
14	WH	O
15	air	O
16	,	O
17	asthmatic	O
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	O
24	GH	O
25	increments	O
26	than	O
27	normal	O
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	O
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	We	O
2	have	O
3	synthesized	O
4	[	O
5	7	O
6	,	O
7	7	O
8	-	O
9	2H2	O
10	]-	O
11	19	O
12	-	O
13	OHA	O
14	with	O
15	high	O
16	deuterium	O
17	content	O
18	and	O
19	,	O
20	together	O
21	with	O
22	[	O
23	7	O
24	,	O
25	7	O
26	-	O
27	2H2	O
28	]	O
29	A	O
30	and	O
31	[	O
32	9	O
33	,	O
34	11	O
35	-	O
36	2H2	O
37	]	O
38	estrone	O
39	(	O
40	E1	O
41	),	O
42	have	O
43	developed	O
44	a	O
45	quantitative	O
46	assay	O
47	of	O
48	serum	O
49	level	O
50	19	O
51	-	O
52	OHA	O
53	,	O
54	A	O
55	,	O
56	and	O
57	E1	O
58	using	O
59	the	O
60	gas	O
61	chromatography	O
62	/	O
63	mass	O
64	spectrometry	O
65	-	O
66	mass	O
67	fragmentography	O
68	method	O
69	to	O
70	monitor	O
71	individual	O
72	subjects	O
73	throughout	O
74	pregnancy	O
75	.	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	Mean	O
2	(+/-	O
3	SE	O
4	)	O
5	measurements	O
6	of	O
7	clearance	O
8	(	O
9	24	O
10	.	O
11	5	O
12	+/-	O
13	2	O
14	.	O
15	06	O
16	v	O
17	26	O
18	.	O
19	5	O
20	+/-	O
21	2	O
22	.	O
23	05	O
24	mL	O
25	/	O
26	min	O
27	/	O
28	m2	O
29	),	O
30	half	O
31	-	O
32	life	O
33	(	O
34	5	O
35	.	O
36	7	O
37	+/-	O
38	0	O
39	.	O
40	5	O
41	v	O
42	6	O
43	.	O
44	4	O
45	+/-	O
46	0	O
47	.	O
48	5	O
49	hours	O
50	),	O
51	and	O
52	volume	O
53	of	O
54	distribution	O
55	(	O
56	12	O
57	.	O
58	4	O
59	+/-	O
60	1	O
61	.	O
62	1	O
63	v	O
64	13	O
65	.	O
66	7	O
67	+/-	O
68	1	O
69	.	O
70	6	O
71	L	O
72	/	O
73	m2	O
74	)	O
75	were	O
76	not	O
77	significantly	O
78	different	O
79	in	O
80	patients	O
81	with	O
82	jaundice	O
83	when	O
84	compared	O
85	with	O
86	controls	O
87	.	O

1	Attitudes	O
2	were	O
3	found	O
4	to	O
5	be	O
6	multidimensional	O
7	,	O
8	with	O
9	similar	O
10	dimensions	O
11	being	O
12	identified	O
13	in	O
14	both	O
15	samples	O
16	.	O

1	Environmental	O
2	factors	O
3	were	O
4	more	O
5	important	O
6	in	O
7	the	O
8	older	O
9	cohorts	O
10	(	O
11	perhaps	O
12	because	O
13	of	O
14	less	O
15	reliable	O
16	recall	O
17	).	O

1	Dopamine	O
2	SERS	O
3	spectra	O
4	from	O
5	these	O
6	electrodes	O
7	are	O
8	similar	O
9	to	O
10	those	O
11	obtained	O
12	at	O
13	uncoated	O
14	electrodes	O
15	.	O

1	The	O
2	results	O
3	suggest	O
4	followings	O
5	--	O
6	1	O
7	)	O
8	both	O
9	eosinophils	O
10	and	O
11	neutrophils	O
12	participate	O
13	in	O
14	hypersecretion	O
15	of	O
16	type	O
17	Ib	O
18	in	O
19	atopic	O
20	cases	O
21	,	O
22	and	O
23	only	O
24	eosinophils	O
25	in	O
26	non	O
27	-	O
28	atopic	O
29	cases	O
30	.	O

1	Of	O
2	the	O
3	remaining	O
4	seven	O
5	,	O
6	five	O
7	reacted	O
8	either	O
9	with	O
10	immediate	O
11	and	O
12	strong	O
13	symptoms	O
14	or	O
15	had	O
16	spontaneously	O
17	reduced	O
18	gluten	B
19	intake	O
20	,	O
21	or	O
22	had	O
23	an	O
24	acquired	O
25	IgA	B
26	deficiency	O
27	.	O

1	Dermal	O
2	toxicity	O
3	and	O
4	carcinogenicity	O
5	of	O
6	4	O
7	-	O
8	vinyl	O
9	-	O
10	1	O
11	-	O
12	cyclohexene	O
13	diepoxide	O
14	in	O
15	Fischer	O
16	rats	O
17	and	O
18	B6C3F1	O
19	mice	O
20	.	O

1	Transient	O
2	expression	O
3	of	O
4	human	B
5	and	I
6	chicken	I
7	progesterone	I
8	receptors	I
9	does	O
10	not	O
11	support	O
12	alternative	O
13	translational	O
14	initiation	O
15	from	O
16	a	O
17	single	O
18	mRNA	O
19	as	O
20	the	O
21	mechanism	O
22	generating	O
23	two	O
24	receptor	O
25	isoforms	O
26	.	O

1	The	O
2	Community	O
3	Adjustment	O
4	Scale	O
5	provided	O
6	outcome	O
7	data	O
8	related	O
9	to	O
10	the	O
11	subjects	O
12	'	O
13	degree	O
14	of	O
15	productivity	O
16	,	O
17	ability	O
18	to	O
19	maintain	O
20	close	O
21	relationships	O
22	,	O
23	and	O
24	presence	O
25	/	O
26	absence	O
27	of	O
28	symptomatology	O
29	an	O
30	average	O
31	of	O
32	32	O
33	years	O
34	after	O
35	initial	O
36	admission	O
37	.	O

1	The	O
2	eluent	O
3	from	O
4	the	O
5	column	O
6	was	O
7	mixed	O
8	with	O
9	the	O
10	chemiluminescent	O
11	solution	O
12	containing	O
13	lucigenin	B
14	and	O
15	Triton	O
16	X	O
17	-	O
18	100	O
19	and	O
20	a	O
21	0	O
22	.	O
23	28	O
24	M	O
25	KOH	O
26	solution	O
27	by	O
28	pumps	O
29	and	O
30	monitored	O
31	by	O
32	a	O
33	chemiluminescence	O
34	detector	O
35	.	O

1	The	O
2	same	O
3	trend	O
4	was	O
5	noted	O
6	between	O
7	YG	O
8	4	O
9	.	O
10	5	O
11	heifers	O
12	and	O
13	YG	O
14	5	O
15	.	O
16	5	O
17	steers	O
18	,	O
19	indicating	O
20	a	O
21	sex	O
22	-	O
23	related	O
24	deposition	O
25	of	O
26	seam	O
27	fat	O
28	in	O
29	fed	O
30	cattle	O
31	.	O

1	The	O
2	results	O
3	also	O
4	showed	O
5	that	O
6	although	O
7	oyster	O
8	shell	O
9	supplementation	O
10	generally	O
11	increased	O
12	alkaline	B
13	phosphatase	I
14	activity	O
15	,	O
16	bone	O
17	mineralization	O
18	was	O
19	relatively	O
20	uninfluenced	O
21	as	O
22	judged	O
23	by	O
24	the	O
25	low	O
26	coefficients	O
27	of	O
28	variation	O
29	(	O
30	CV	O
31	)	O
32	of	O
33	3	O
34	.	O
35	14	O
36	-	O
37	3	O
38	.	O
39	51	O
40	%	O
41	and	O
42	3	O
43	.	O
44	39	O
45	-	O
46	4	O
47	.	O
48	82	O
49	%	O
50	for	O
51	calcium	O
52	and	O
53	phosphorus	O
54	content	O
55	in	O
56	the	O
57	femur	O
58	and	O
59	tibia	O
60	respectively	O
61	.	O

1	The	O
2	pattern	O
3	for	O
4	catalytic	O
5	zinc	O
6	sites	O
7	included	O
8	two	O
9	ligands	O
10	close	O
11	in	O
12	sequence	O
13	,	O
14	a	O
15	sequence	O
16	-	O
17	distant	O
18	ligand	O
19	,	O
20	and	O
21	a	O
22	main	O
23	-	O
24	chain	O
25	hydrogen	O
26	bond	O
27	joining	O
28	two	O
29	ligands	O
30	.	O

1	Sprague	O
2	-	O
3	Dawley	O
4	newborn	O
5	rats	O
6	(	O
7	n	O
8	=	O
9	85	O
10	)	O
11	breathed	O
12	100	O
13	%	O
14	oxygen	O
15	(	O
16	O2	O
17	)	O
18	or	O
19	room	O
20	air	O
21	(	O
22	RA	O
23	)	O
24	during	O
25	the	O
26	first	O
27	8	O
28	days	O
29	of	O
30	life	O
31	,	O
32	and	O
33	then	O
34	RA	O
35	.	O

1	Antibodies	O
2	raised	O
3	against	O
4	a	O
5	bacterially	O
6	produced	O
7	beta	B
8	gal	I
9	-	O
10	trk	B
11	receptor	O
12	kinase	O
13	fusion	O
14	protein	O
15	recognized	O
16	a	O
17	44	O
18	kd	O
19	phosphoprotein	O
20	phosphorylated	O
21	on	O
22	serine	O
23	,	O
24	threonine	O
25	and	O
26	tyrosine	O
27	in	O
28	extracts	O
29	of	O
30	trk	B
31	-	I
32	2h	I
33	transformed	O
34	NIH3T3	O
35	cells	O
36	.	O

1	All	O
2	ABFI	B
3	-	I
4	binding	I
5	sites	I
6	,	O
7	regardless	O
8	of	O
9	origin	O
10	,	O
11	provided	O
12	weak	O
13	UAS	O
14	function	O
15	in	O
16	vivo	O
17	when	O
18	examined	O
19	in	O
20	test	O
21	plasmids	O
22	.	O

1	An	O
2	examination	O
3	of	O
4	the	O
5	properties	O
6	of	O
7	sequences	O
8	surrounding	O
9	ARS1	O
10	left	O
11	open	O
12	the	O
13	possibility	O
14	that	O
15	ABFI	B
16	enhances	O
17	the	O
18	initiation	O
19	of	O
20	DNA	O
21	replication	O
22	at	O
23	ARS1	O
24	by	O
25	transcriptional	O
26	activation	O
27	.	O

1	Likewise	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	the	O
7	hypotensive	O
8	action	O
9	of	O
10	converting	O
11	enzyme	O
12	inhibitors	O
13	is	O
14	age	O
15	-	O
16	related	O
17	is	O
18	as	O
19	yet	O
20	unknown	O
21	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	The	O
2	levels	O
3	of	O
4	both	O
5	MAP1	B
6	-	I
7	specific	I
8	and	I
9	MAP2	I
10	-	I
11	specific	I
12	mRNAs	I
13	decline	O
14	in	O
15	the	O
16	postnatal	O
17	developing	O
18	brain	O
19	;	O
20	the	O
21	level	O
22	of	O
23	MAP1	B
24	-	I
25	specific	I
26	mRNA	I
27	also	O
28	increases	O
29	slightly	O
30	in	O
31	rat	O
32	PC12	O
33	cells	O
34	upon	O
35	exposure	O
36	to	O
37	nerve	B
38	growth	I
39	factor	I
40	.	O

1	Colorimetric	O
2	method	O
3	of	O
4	determining	O
5	glycerin	O
6	in	O
7	the	O
8	blood	O

1	Rarely	O
2	,	O
3	patients	O
4	with	O
5	locally	O
6	advanced	O
7	,	O
8	uncontrollable	O
9	,	O
10	non	O
11	-	O
12	metastatic	O
13	prostatic	O
14	cancer	O
15	enjoy	O
16	prolonged	O
17	survival	O
18	.	O

1	The	O
2	first	O
3	involved	O
4	measurements	O
5	of	O
6	the	O
7	steady	O
8	state	O
9	levels	O
10	of	O
11	mRNAs	O
12	for	O
13	subunit	O
14	5	O
15	of	O
16	cytochrome	B
17	oxidase	I
18	and	O
19	the	O
20	beta	O
21	subunit	O
22	of	O
23	F1	B
24	ATPase	I
25	in	O
26	wild	O
27	type	O
28	and	O
29	in	O
30	a	O
31	hem2	B
32	mutant	I
33	.	O

1	ASL	O
2	-	O
3	8123	O
4	demonstrated	O
5	weak	O
6	competitive	O
7	beta	B
8	-	I
9	adrenoreceptor	I
10	blocking	O
11	activity	O
12	in	O
13	isolated	O
14	guinea	O
15	pig	O
16	right	O
17	atria	O
18	with	O
19	a	O
20	pA2	O
21	of	O
22	3	O
23	.	O
24	73	O
25	+/-	O
26	0	O
27	.	O
28	07	O
29	;	O
30	no	O
31	agonist	O
32	-	O
33	like	O
34	activity	O
35	was	O
36	observed	O
37	in	O
38	this	O
39	tissue	O
40	at	O
41	concentrations	O
42	of	O
43	ASL	O
44	-	O
45	8123	O
46	from	O
47	3	O
48	X	O
49	10	O
50	(-	O
51	5	O
52	)	O
53	to	O
54	1	O
55	X	O
56	10	O
57	(-	O
58	2	O
59	)	O
60	M	O
61	.	O

1	Prognosis	O
2	of	O
3	asymptomatic	O
4	multiple	O
5	myeloma	O
6	.	O

1	Svensson	O
2	et	O
3	al	O
4	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O

1	The	O
2	size	O
3	discrepancy	O
4	is	O
5	not	O
6	due	O
7	to	O
8	glycosylation	O
9	or	O
10	phosphorylation	O
11	of	O
12	Ag35	B
13	but	O
14	may	O
15	result	O
16	from	O
17	a	O
18	proline	O
19	-	O
20	rich	O
21	sequence	O
22	which	O
23	occurs	O
24	in	O
25	this	O
26	polypeptide	O
27	.	O

1	In	O
2	10	O
3	pentobarbitalized	O
4	dogs	O
5	,	O
6	plasma	O
7	viscosity	O
8	(	O
9	Ep	O
10	)	O
11	was	O
12	raised	O
13	fourfold	O
14	while	O
15	apparent	O
16	blood	O
17	viscosity	O
18	(	O
19	Ea	O
20	)	O
21	increased	O
22	about	O
23	twofold	O
24	by	O
25	two	O
26	steps	O
27	of	O
28	exchange	O
29	transfusion	O
30	of	O
31	200	O
32	ml	O
33	of	O
34	plasma	O
35	with	O
36	plasma	O
37	containing	O
38	high	O
39	molecular	O
40	weight	O
41	dextran	O
42	(	O
43	mol	O
44	wt	O
45	500	O
46	,	O
47	000	O
48	,	O
49	20	O
50	%	O
51	wt	O
52	/	O
53	vol	O
54	).	O

1	A	O
2	cDNA	O
3	encoding	O
4	a	O
5	new	O
6	human	O
7	lymphocyte	O
8	cell	O
9	surface	O
10	molecule	O
11	has	O
12	been	O
13	isolated	O
14	and	O
15	shown	O
16	to	O
17	identify	O
18	a	O
19	fourth	O
20	member	O
21	of	O
22	a	O
23	recently	O
24	discovered	O
25	family	O
26	of	O
27	adhesion	O
28	proteins	O
29	.	O

1	Spontaneous	O
2	sensitization	O
3	to	O
4	cross	O
5	-	O
6	reacting	O
7	chemicals	O
8	in	O
9	a	O
10	proportion	O
11	of	O
12	control	O
13	animals	O
14	is	O
15	strongly	O
16	suggested	O
17	,	O
18	somewhat	O
19	akin	O
20	to	O
21	spontaneous	O
22	sensitization	O
23	in	O
24	patients	O
25	with	O
26	anaphylactoid	O
27	reactions	O
28	to	O
29	neuromuscular	O
30	blockers	O
31	on	O
32	first	O
33	exposure	O
34	,	O
35	and	O
36	in	O
37	whom	O
38	IgE	B
39	antibodies	I
40	are	O
41	detected	O
42	.	O

1	This	O
2	approach	O
3	was	O
4	examined	O
5	utilizing	O
6	the	O
7	fetal	O
8	protein	O
9	,	O
10	HGB	B
11	F	I
12	.	O

1	The	O
2	84	B
3	.	I
4	1C	I
5	mAb	I
6	recognizes	O
7	a	O
8	site	O
9	on	O
10	IgE	B
11	which	O
12	is	O
13	identical	O
14	or	O
15	very	O
16	close	O
17	to	O
18	the	O
19	Fc	B
20	epsilon	I
21	R	I
22	binding	I
23	site	I
24	,	O
25	and	O
26	95	O
27	.	O
28	3	O
29	recognizes	O
30	a	O
31	site	O
32	on	O
33	IgE	B
34	which	O
35	is	O
36	related	O
37	,	O
38	but	O
39	not	O
40	identical	O
41	to	O
42	the	O
43	Fc	B
44	epsilon	I
45	R	I
46	binding	I
47	site	I
48	.	O

1	A	O
2	rapid	O
3	staining	O
4	technique	O
5	for	O
6	Leishmania	O
7	parasites	O
8	in	O
9	splenic	O
10	aspirate	O
11	smears	O
12	.	O

1	NIK	O
2	-	O
3	244	O
4	suppressed	O
5	coronary	O
6	ligation	O
7	-	O
8	and	O
9	digitalis	O
10	-	O
11	induced	O
12	arrhythmias	O
13	,	O
14	and	O
15	the	O
16	minimum	O
17	effective	O
18	plasma	O
19	concentrations	O
20	for	O
21	arrhythmias	O
22	induced	O
23	by	O
24	24	O
25	-	O
26	h	O
27	and	O
28	48	O
29	-	O
30	h	O
31	coronary	O
32	ligation	O
33	and	O
34	digitalis	O
35	were	O
36	0	O
37	.	O
38	41	O
39	+/-	O
40	0	O
41	.	O
42	10	O
43	(	O
44	by	O
45	1	O
46	mg	O
47	/	O
48	kg	O
49	i	O
50	.	O
51	v	O
52	.),	O
53	0	O
54	.	O
55	70	O
56	+/-	O
57	0	O
58	.	O
59	13	O
60	(	O
61	by	O
62	1	O
63	mg	O
64	/	O
65	kg	O
66	i	O
67	.	O
68	v	O
69	.),	O
70	and	O
71	0	O
72	.	O
73	21	O
74	+/-	O
75	0	O
76	.	O
77	08	O
78	(	O
79	by	O
80	0	O
81	.	O
82	5	O
83	mg	O
84	/	O
85	kg	O
86	i	O
87	.	O
88	v	O
89	.)	O
90	microgram	O
91	/	O
92	ml	O
93	,	O
94	respectively	O
95	(	O
96	mean	O
97	+/-	O
98	SD	O
99	of	O
100	the	O
101	mean	O
102	,	O
103	n	O
104	=	O
105	6	O
106	).	O

1	Structural	O
2	organization	O
3	and	O
4	expression	O
5	of	O
6	the	O
7	mouse	B
8	estrogen	I
9	receptor	I
10	.	O

1	When	O
2	considered	O
3	with	O
4	the	O
5	known	O
6	neurotoxic	O
7	effects	O
8	on	O
9	children	O
10	of	O
11	"	O
12	low	O
13	levels	O
14	"	O
15	of	O
16	exposure	O
17	to	O
18	lead	O
19	,	O
20	these	O
21	results	O
22	also	O
23	suggest	O
24	that	O
25	either	O
26	an	O
27	excessively	O
28	narrow	O
29	margin	O
30	of	O
31	safety	O
32	or	O
33	insufficient	O
34	safety	O
35	is	O
36	provided	O
37	by	O
38	present	O
39	U	O
40	.	O
41	S	O
42	.	O
43	guidelines	O
44	,	O
45	which	O
46	classify	O
47	an	O
48	elevated	O
49	blood	O
50	lead	O
51	concentration	O
52	as	O
53	25	O
54	micrograms	O
55	/	O
56	dl	O
57	or	O
58	greater	O
59	.	O

1	However	O
2	,	O
3	experiments	O
4	with	O
5	S1	B
6	mapping	O
7	of	O
8	in	O
9	vivo	O
10	transcripts	O
11	,	O
12	gene	O
13	disruptions	O
14	in	O
15	the	O
16	alpha	O
17	region	O
18	,	O
19	and	O
20	a	O
21	single	O
22	-	O
23	copy	O
24	transcriptional	O
25	fusion	O
26	vector	O
27	all	O
28	suggested	O
29	that	O
30	these	O
31	possible	O
32	promoters	O
33	were	O
34	largely	O
35	inactive	O
36	during	O
37	logarithmic	O
38	growth	O
39	,	O
40	that	O
41	the	O
42	major	O
43	promoter	O
44	for	O
45	the	O
46	alpha	O
47	operon	O
48	lay	O
49	upstream	O
50	from	O
51	the	O
52	region	O
53	cloned	O
54	,	O
55	and	O
56	that	O
57	the	O
58	genes	O
59	in	O
60	the	O
61	IF1	B
62	to	O
63	L17	B
64	interval	O
65	were	O
66	cotranscribed	O
67	.	O

1	Lowering	O
2	of	O
3	the	O
4	renal	O
5	blood	O
6	flow	O
7	alters	O
8	the	O
9	glomerular	O
10	and	O
11	tubular	O
12	excretion	O
13	processes	O
14	.	O

1	Fourth	O
2	,	O
3	sometime	O
4	between	O
5	4	O
6	and	O
7	24	O
8	hours	O
9	of	O
10	recovery	O
11	is	O
12	necessary	O
13	to	O
14	reverse	O
15	the	O
16	effect	O
17	of	O
18	chronic	O
19	hypoxia	O
20	on	O
21	cerebral	O
22	blood	O
23	flow	O
24	.	O

1	Kindling	O
2	of	O
3	the	O
4	primary	O
5	visual	O
6	cortex	O
7	(	O
8	VC	O
9	)	O
10	was	O
11	compared	O
12	with	O
13	that	O
14	of	O
15	the	O
16	amygdala	O
17	in	O
18	cats	O
19	.	O

1	Abundant	O
2	infiltration	O
3	of	O
4	lymphocytes	O
5	and	O
6	plasma	O
7	cells	O
8	was	O
9	also	O
10	wide	O
11	-	O
12	spread	O
13	beneath	O
14	the	O
15	carcinoma	O
16	in	O
17	situ	O
18	,	O
19	together	O
20	with	O
21	the	O
22	lymphoid	O
23	follicles	O
24	.	O

1	In	O
2	all	O
3	sessions	O
4	under	O
5	IFN	B
6	,	O
7	the	O
8	latency	O
9	of	O
10	the	O
11	P100	O
12	component	O
13	of	O
14	the	O
15	VEP	O
16	was	O
17	shortened	O
18	as	O
19	compared	O
20	to	O
21	baseline	O
22	conditions	O
23	.	O

1	Among	O
2	100	O
3	cases	O
4	of	O
5	post	O
6	-	O
7	transfusion	O
8	hepatitis	O
9	,	O
10	10	O
11	are	O
12	due	O
13	to	O
14	the	O
15	hepatitis	O
16	B	O
17	virus	O
18	(	O
19	despite	O
20	systematic	O
21	search	O
22	for	O
23	HBs	B
24	Ag	I
25	),	O
26	89	O
27	are	O
28	due	O
29	to	O
30	one	O
31	of	O
32	the	O
33	non	O
34	-	O
35	A	O
36	non	O
37	-	O
38	B	O
39	viruses	O
40	(	O
41	not	O
42	detectable	O
43	by	O
44	specific	O
45	serological	O
46	tests	O
47	)	O
48	and	O
49	1	O
50	to	O
51	several	O
52	viruses	O
53	,	O
54	specially	O
55	CMV	O
56	.	O

1	Recessive	O
2	lethal	O
3	mutations	O
4	were	O
5	isolated	O
6	based	O
7	upon	O
8	failure	O
9	to	O
10	complement	O
11	the	O
12	recessive	O
13	lethality	O
14	of	O
15	Df	O
16	(	O
17	3L	O
18	)	O
19	RR2	O
20	,	O
21	a	O
22	deletion	O
23	of	O
24	the	O
25	DRE	O
26	region	O
27	that	O
28	removes	O
29	16	O
30	-	O
31	18	O
32	polytene	O
33	chromosome	O
34	bands	O
35	.	O

1	This	O
2	paper	O
3	presents	O
4	the	O
5	reasons	O
6	why	O
7	countries	O
8	to	O
9	which	O
10	Chagas	O
11	disease	O
12	is	O
13	endemic	O
14	should	O
15	carry	O
16	out	O
17	the	O
18	relevant	O
19	research	O
20	themselves	O
21	.	O

1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O

1	Using	O
2	mutated	B
3	IL2R	I
4	alpha	I
5	promoter	I
6	constructs	I
7	in	O
8	transient	O
9	transfection	O
10	and	O
11	DNA	O
12	binding	O
13	assays	O
14	,	O
15	we	O
16	now	O
17	demonstrate	O
18	that	O
19	sequences	O
20	located	O
21	immediately	O
22	upstream	O
23	and	O
24	downstream	O
25	of	O
26	the	O
27	kappa	B
28	B	I
29	enhancer	I
30	also	O
31	contribute	O
32	to	O
33	the	O
34	regulation	O
35	of	O
36	IL2R	B
37	alpha	I
38	gene	I
39	expression	O
40	.	O

1	Palindromic	O
2	rheumatism	O

1	Xenopus	B
2	homolog	I
3	of	I
4	the	I
5	mos	I
6	protooncogene	I
7	transforms	O
8	mammalian	O
9	fibroblasts	O
10	and	O
11	induces	O
12	maturation	O
13	of	O
14	Xenopus	O
15	oocytes	O
16	.	O

1	Southern	O
2	blot	O
3	analyses	O
4	demonstrated	O
5	a	O
6	low	O
7	,	O
8	if	O
9	not	O
10	single	O
11	,	O
12	copy	O
13	number	O
14	for	O
15	this	O
16	gene	O
17	and	O
18	conservation	O
19	of	O
20	this	O
21	domain	O
22	in	O
23	other	O
24	vertebrates	O
25	.	O

1	Moreover	O
2	,	O
3	exons	O
4	2a	O
5	and	O
6	2b	O
7	share	O
8	the	O
9	same	O
10	5	O
11	'	O
12	sequence	O
13	but	O
14	differ	O
15	from	O
16	each	O
17	other	O
18	by	O
19	the	O
20	use	O
21	of	O
22	two	O
23	distinct	O
24	donor	O
25	splice	O
26	sites	O
27	171	O
28	bp	O
29	apart	O
30	in	O
31	the	O
32	gene	O
33	.	O

1	S1	B
2	nuclease	I
3	analysis	O
4	of	O
5	RNA	O
6	prepared	O
7	after	O
8	transfection	O
9	of	O
10	these	O
11	HIV	O
12	constructs	O
13	into	O
14	HeLa	O
15	cells	O
16	infected	O
17	with	O
18	wild	O
19	-	O
20	type	O
21	adenovirus	O
22	indicated	O
23	that	O
24	the	O
25	enhancer	O
26	,	O
27	SP1	B
28	,	O
29	TATA	O
30	,	O
31	and	O
32	a	O
33	portion	O
34	of	O
35	the	O
36	transactivation	O
37	-	O
38	responsive	O
39	element	O
40	were	O
41	each	O
42	required	O
43	for	O
44	complete	O
45	E1A	B
46	/	O
47	E1B	B
48	-	O
49	mediated	O
50	activation	O
51	of	O
52	the	O
53	HIV	B
54	LTR	I
55	.	O

1	In	O
2	supine	O
3	position	O
4	,	O
5	plasma	O
6	ANP	B
7	levels	O
8	ranged	O
9	from	O
10	12	O
11	pg	O
12	/	O
13	ml	O
14	to	O
15	51	O
16	.	O
17	5	O
18	pg	O
19	/	O
20	ml	O
21	,	O
22	with	O
23	an	O
24	average	O
25	level	O
26	of	O
27	35	O
28	.	O
29	3	O
30	+/-	O
31	11	O
32	.	O
33	5	O
34	pg	O
35	/	O
36	ml	O
37	.	O

1	Plasma	O
2	concentrations	O
3	of	O
4	ANF	B
5	(	O
6	pANF	B
7	),	O
8	aldosterone	O
9	(	O
10	PAC	O
11	)	O
12	and	O
13	renin	B
14	(	O
15	PRC	B
16	)	O
17	were	O
18	measured	O
19	daily	O
20	,	O
21	as	O
22	were	O
23	hemodynamic	O
24	parameters	O
25	.	O

1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	I
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	B
42	T1	I
43	gene	I
44	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	patients	O
6	who	O
7	undergo	O
8	postoperative	O
9	irradiation	O
10	for	O
11	low	O
12	grade	O
13	spinal	O
14	astrocytomas	O
15	and	O
16	localized	O
17	spinal	O
18	ependymomas	O
19	achieve	O
20	excellent	O
21	survival	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	(	O
5	a	O
6	)	O
7	the	O
8	likelihood	O
9	of	O
10	detecting	O
11	carcinoma	O
12	or	O
13	atypical	O
14	hyperplasia	O
15	exclusively	O
16	in	O
17	the	O
18	adipose	O
19	tissue	O
20	component	O
21	of	O
22	grossly	O
23	benign	O
24	breast	O
25	biopsies	O
26	is	O
27	extremely	O
28	low	O
29	,	O
30	and	O
31	(	O
32	b	O
33	)	O
34	a	O
35	possible	O
36	cost	O
37	-	O
38	effective	O
39	method	O
40	of	O
41	sampling	O
42	grossly	O
43	benign	O
44	breast	O
45	biopsies	O
46	consists	O
47	of	O
48	initially	O
49	submitting	O
50	a	O
51	maximum	O
52	of	O
53	10	O
54	blocks	O
55	of	O
56	fibrous	O
57	parenchyma	O
58	for	O
59	each	O
60	case	O
61	,	O
62	then	O
63	examining	O
64	the	O
65	remaining	O
66	tissue	O
67	histologically	O
68	only	O
69	if	O
70	carcinoma	O
71	or	O
72	atypical	O
73	hyperplasia	O
74	is	O
75	found	O
76	among	O
77	these	O
78	blocks	O
79	.	O

1	Synthetic	O
2	oligonucleotides	O
3	representing	O
4	the	O
5	19	O
6	bp	O
7	repeat	O
8	unit	O
9	strongly	O
10	reduced	O
11	the	O
12	activity	O
13	of	O
14	the	O
15	IE1	B
16	/	I
17	2	I
18	enhancer	I
19	/	I
20	promoter	I
21	in	O
22	cotransfection	O
23	assays	O
24	after	O
25	transient	O
26	expression	O
27	.	O

1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O

1	The	O
2	mustard	B
3	chloroplast	I
4	gene	I
5	rps16	I
6	is	O
7	split	O
8	by	O
9	an	O
10	887	O
11	bp	O
12	group	O
13	II	O
14	(	O
15	or	O
16	III	O
17	)	O
18	intron	O
19	.	O

1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	A	O
2	brief	O
3	account	O
4	of	O
5	the	O
6	1988	O
7	seminar	O
8	in	O
9	Shanghai	O
10	on	O
11	viral	O
12	hepatitis	O
13	A	O

1	Restriction	O
2	maps	O
3	of	O
4	the	O
5	cloned	O
6	plasmids	O
7	revealed	O
8	that	O
9	their	O
10	chromosomal	O
11	inserts	O
12	consisted	O
13	of	O
14	overlapping	O
15	fragments	O
16	.	O

1	First	O
2	,	O
3	a	O
4	pet54	B
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	B
19	introns	I
20	aI5	I
21	alpha	I
22	and	O
23	aI5	B
24	beta	I
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	B
30	gene	I
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	B
36	mRNA	I
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	B
7	-	O
8	related	O
9	sequences	O
10	and	O
11	a	O
12	small	B
13	Ig	I
14	-	I
15	related	I
16	sequence	I
17	.	O

1	Tyrosine	B
2	kinase	I
3	oncogenes	O
4	abrogate	O
5	interleukin	B
6	-	I
7	3	I
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	B
18	-	I
19	myc	I
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	B
25	-	I
26	myc	I
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	B
33	-	I
34	abl	I
35	.	O

1	To	O
2	assess	O
3	the	O
4	functional	O
5	importance	O
6	of	O
7	these	O
8	NBS	O
9	in	O
10	the	O
11	overall	O
12	drug	O
13	resistance	O
14	phenotype	O
15	conferred	O
16	by	O
17	mdr1	B
18	,	O
19	we	O
20	introduced	O
21	amino	O
22	acid	O
23	substitutions	O
24	in	O
25	the	O
26	core	O
27	consensus	O
28	sequence	O
29	for	O
30	nucleotide	O
31	binding	O
32	,	O
33	GXGKST	O
34	.	O

1	The	O
2	latency	O
3	time	O
4	for	O
5	the	O
6	lactate	O
7	concentration	O
8	to	O
9	reach	O
10	the	O
11	top	O
12	values	O
13	was	O
14	reduced	O
15	by	O
16	aerobic	O
17	training	O
18	(	O
19	T2	O
20	).	O

1	After	O
2	hepatitis	O
3	B	O
4	vaccine	O
5	immunization	O
6	,	O
7	serum	O
8	antibody	O
9	response	O
10	was	O
11	of	O
12	primary	O
13	type	O
14	in	O
15	33	O
16	cases	O
17	with	O
18	anti	B
19	-	I
20	HBs	I
21	less	O
22	than	O
23	2	O
24	.	O
25	1	O
26	S	O
27	/	O
28	N	O
29	(	O
30	S	O
31	/	O
32	N	O
33	Ratio	O
34	Unit	O
35	)	O
36	at	O
37	T0	O
38	,	O
39	the	O
40	anti	B
41	-	I
42	HBs	I
43	positive	O
44	rate	O
45	was	O
46	39	O
47	.	O
48	4	O
49	%,	O
50	84	O
51	.	O
52	8	O
53	%,	O
54	96	O
55	.	O
56	7	O
57	%	O
58	and	O
59	96	O
60	.	O
61	7	O
62	%	O
63	in	O
64	T1	O
65	,	O
66	T2	O
67	,	O
68	T0	O
69	and	O
70	T12	O
71	respectively	O
72	.	O

1	Analysis	O
2	of	O
3	the	O
4	inferred	O
5	1	B
6	,	I
7	859	I
8	-	I
9	residue	I
10	ama	I
11	-	I
12	1	I
13	product	I
14	showed	O
15	considerable	O
16	identity	O
17	with	O
18	the	O
19	largest	O
20	subunit	O
21	of	O
22	RNAP	B
23	II	I
24	from	O
25	other	O
26	organisms	O
27	,	O
28	including	O
29	the	O
30	presence	O
31	of	O
32	a	O
33	zinc	O
34	finger	O
35	motif	O
36	near	O
37	the	O
38	amino	O
39	terminus	O
40	,	O
41	and	O
42	a	O
43	carboxyl	O
44	-	O
45	terminal	O
46	domain	O
47	of	O
48	42	O
49	tandemly	O
50	reiterated	O
51	heptamers	O
52	with	O
53	the	O
54	consensus	O
55	Tyr	O
56	Ser	O
57	Pro	O
58	Thr	O
59	Ser	O
60	Pro	O
61	Ser	O
62	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	I
28	Type	I
29	Kappa	I
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	None	O
2	of	O
3	the	O
4	measured	O
5	parameters	O
6	(	O
7	heart	O
8	contents	O
9	of	O
10	neutral	O
11	lipids	O
12	,	O
13	total	O
14	phospholipids	O
15	,	O
16	phosphatidylcholine	O
17	,	O
18	phosphatidylethanolamine	O
19	,	O
20	diphosphatidylglycerol	O
21	,	O
22	sphingomyelin	O
23	and	O
24	fatty	O
25	acid	O
26	composition	O
27	of	O
28	each	O
29	phospholipid	O
30	class	O
31	)	O
32	appeared	O
33	to	O
34	be	O
35	related	O
36	with	O
37	the	O
38	grading	O
39	of	O
40	the	O
41	lesions	O
42	.	O

1	The	O
2	GALT	O
3	-	O
4	primed	O
5	calves	O
6	had	O
7	increased	O
8	serum	O
9	IgG	B
10	,	O
11	lavage	O
12	IgG	B
13	and	O
14	IgA	B
15	and	O
16	increased	O
17	LNA	B
18	titers	O
19	in	O
20	both	O
21	lavage	O
22	fluids	O
23	and	O
24	serum	O
25	following	O
26	the	O
27	SC	O
28	dose	O
29	of	O
30	killed	O
31	bacteria	O
32	.	O

1	The	O
2	present	O
3	studies	O
4	compare	O
5	the	O
6	biochemical	O
7	characteristics	O
8	,	O
9	Kanagawa	O
10	hemolysin	B
11	reactions	O
12	,	O
13	and	O
14	plasmid	O
15	profiles	O
16	of	O
17	13	O
18	patient	O
19	and	O
20	221	O
21	environmental	O
22	isolates	O
23	of	O
24	the	O
25	organism	O
26	.	O

1	A	O
2	fine	O
3	-	O
4	structure	O
5	deletion	O
6	map	O
7	of	O
8	human	O
9	chromosome	O
10	11p	O
11	:	O
12	analysis	O
13	of	O
14	J1	O
15	series	O
16	hybrids	O
17	.	O

1	Middle	O
2	-	O
3	latency	O
4	auditory	O
5	evoked	O
6	potentials	O
7	(	O
8	MAEPs	O
9	)	O
10	were	O
11	recorded	O
12	in	O
13	controls	O
14	and	O
15	patients	O
16	with	O
17	focal	O
18	lesions	O
19	in	O
20	dorsolateral	O
21	prefrontal	O
22	cortex	O
23	.	O

1	Specifically	O
2	,	O
3	they	O
4	were	O
5	performed	O
6	to	O
7	determine	O
8	whether	O
9	detection	O
10	of	O
11	envelope	O
12	phase	O
13	disparity	O
14	was	O
15	consistent	O
16	with	O
17	processing	O
18	within	O
19	a	O
20	single	O
21	channel	O
22	in	O
23	which	O
24	the	O
25	AM	O
26	tones	O
27	were	O
28	simply	O
29	added	O
30	.	O

1	Gel	O
2	retardation	O
3	assays	O
4	combined	O
5	with	O
6	DNase	B
7	I	I
8	footprinting	O
9	and	O
10	diethyl	O
11	pyrocarbonate	O
12	interference	O
13	showed	O
14	that	O
15	a	O
16	nuclear	O
17	factor	O
18	from	O
19	differentiated	O
20	C2	O
21	myotubes	O
22	and	O
23	BC3H1	O
24	myocytes	O
25	recognized	O
26	a	O
27	conserved	O
28	A	O
29	+	O
30	T	O
31	-	O
32	rich	O
33	sequence	O
34	within	O
35	the	O
36	peripheral	O
37	activating	O
38	region	O
39	.	O

1	Ventral	O
2	rhinotomy	O
3	is	O
4	no	O
5	more	O
6	difficult	O
7	than	O
8	dorsal	O
9	rhinotomy	O
10	,	O
11	has	O
12	less	O
13	patient	O
14	morbidity	O
15	and	O
16	fewer	O
17	postoperative	O
18	complications	O
19	,	O
20	and	O
21	is	O
22	more	O
23	cosmetically	O
24	acceptable	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	iron	O
5	intake	O
6	on	O
7	59Fe	O
8	absorption	O
9	throughout	O
10	pregnancy	O
11	,	O
12	and	O
13	on	O
14	maternal	O
15	and	O
16	fetal	O
17	Fe	O
18	status	O
19	towards	O
20	the	O
21	end	O
22	of	O
23	pregnancy	O
24	,	O
25	was	O
26	investigated	O
27	in	O
28	rats	O
29	.	O

1	Reagent	O
2	strips	O
3	are	O
4	frequently	O
5	used	O
6	in	O
7	the	O
8	practice	O
9	of	O
10	laboratory	O
11	medicine	O
12	as	O
13	well	O
14	as	O
15	outside	O
16	the	O
17	professional	O
18	laboratories	O
19	.	O

1	According	O
2	to	O
3	their	O
4	staining	O
5	affinity	O
6	for	O
7	anti	B
8	-	I
9	T	I
10	antibodies	I
11	,	O
12	the	O
13	glandular	O
14	tissue	O
15	cells	O
16	were	O
17	classified	O
18	as	O
19	T	B
20	-,	O
21	T	B
22	+,	O
23	T	B
24	++,	O
25	and	O
26	T	B
27	and	O
28	the	O
29	annual	O
30	changes	O
31	in	O
32	the	O
33	numbers	O
34	of	O
35	these	O
36	cell	O
37	populations	O
38	,	O
39	as	O
40	well	O
41	as	O
42	in	O
43	the	O
44	volume	O
45	occupied	O
46	by	O
47	the	O
48	glandular	O
49	tissue	O
50	,	O
51	were	O
52	calculated	O
53	.	O

1	Alkoxymetgyl	O
2	-	O
3	3	O
4	,	O
5	4	O
6	-	O
7	dimethylpyridinium	O
8	chlorides	O
9	were	O
10	synthetized	O
11	by	O
12	reacting	O
13	3	O
14	,	O
15	4	O
16	-	O
17	dimethylpyridine	O
18	with	O
19	chloromethyl	O
20	alkyl	O
21	ethers	O
22	,	O
23	while	O
24	1	O
25	-	O
26	ethyloxymethyl	O
27	-	O
28	3	O
29	-	O
30	alkylthiomethylimidazolium	O
31	chlorides	O
32	were	O
33	obtained	O
34	in	O
35	reactions	O
36	of	O
37	1	O
38	-	O
39	ethyloxymethylimidazol	O
40	with	O
41	chloromethyl	O
42	alkyl	O
43	sulfides	O
44	.	O

1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	O
16	-	O
17	R	O
18	-	O
19	R	O
20	pseudoisochromatic	O
21	plates	O
22	.	O

1	Serological	O
2	studies	O
3	at	O
4	the	O
5	early	O
6	relapse	O
7	stage	O
8	of	O
9	this	O
10	disease	O
11	showed	O
12	increased	O
13	serum	B
14	ANA	I
15	,	O
16	IgA	B
17	and	O
18	IgM	B
19	level	O
20	with	O
21	normal	O
22	IgG	B
23	and	O
24	decrease	O
25	of	O
26	C3	B
27	and	O
28	C4	B
29	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	B
6	-	I
7	kilodalton	I
8	major	I
9	integral	I
10	membrane	I
11	immunogen	I
12	of	I
13	Treponema	I
14	pallidum	I
15	.	O

1	In	O
2	Rat	O
3	-	O
4	1a	O
5	cells	O
6	the	O
7	expression	O
8	of	O
9	human	B
10	c	I
11	-	I
12	jun	I
13	mRNA	I
14	was	O
15	associated	O
16	with	O
17	the	O
18	ability	O
19	to	O
20	clone	O
21	in	O
22	soft	O
23	agarose	O
24	and	O
25	form	O
26	tumors	O
27	in	O
28	nude	O
29	mice	O
30	.	O

1	The	O
2	seventh	O
3	cysteine	O
4	residue	O
5	of	O
6	CTSE	B
7	is	O
8	located	O
9	within	O
10	the	O
11	activation	O
12	peptide	O
13	region	O
14	of	O
15	the	O
16	proenzyme	O
17	.	O

1	The	O
2	p34	B
3	.	I
4	8	I
5	gene	I
6	has	O
7	a	O
8	strong	O
9	codon	O
10	usage	O
11	bias	O
12	which	O
13	is	O
14	strikingly	O
15	different	O
16	from	O
17	that	O
18	of	O
19	the	O
20	polyhedrin	B
21	gene	I
22	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	S1	B
6	nuclease	I
7	protection	O
8	analysis	O
9	of	O
10	RNA	O
11	preparations	O
12	from	O
13	several	O
14	mouse	O
15	tissues	O
16	,	O
17	both	O
18	dhfr	B
19	and	O
20	divergent	O
21	genes	O
22	showed	O
23	similar	O
24	levels	O
25	of	O
26	expression	O
27	but	O
28	did	O
29	show	O
30	some	O
31	specificity	O
32	in	O
33	start	O
34	site	O
35	utilization	O
36	.	O

1	Mapping	O
2	results	O
3	suggested	O
4	that	O
5	the	O
6	complementation	O
7	group	O
8	identified	O
9	by	O
10	these	O
11	mutants	O
12	is	O
13	allelic	O
14	to	O
15	the	O
16	ag	B
17	alpha	I
18	1	I
19	mutation	O
20	identified	O
21	previously	O
22	.	O

1	The	O
2	R	B
3	.	I
4	meliloti	I
5	nifH	I
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	B
11	.	I
12	pneumoniae	I
13	nifH	I
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	O
19	dependent	O
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	Recently	O
2	,	O
3	an	O
4	alternatively	O
5	spliced	O
6	form	O
7	of	O
8	c	B
9	-	I
10	myb	I
11	-	I
12	encoded	I
13	mRNA	I
14	has	O
15	been	O
16	identified	O
17	in	O
18	murine	O
19	cells	O
20	containing	O
21	either	O
22	normal	O
23	or	O
24	rearranged	O
25	c	B
26	-	I
27	myb	I
28	genes	I
29	.	O

1	A	O
2	transcription	O
3	factor	O
4	exclusion	O
5	assay	O
6	was	O
7	used	O
8	to	O
9	show	O
10	that	O
11	the	O
12	PCF1	B
13	mutation	I
14	affects	O
15	two	O
16	distinct	O
17	stages	O
18	in	O
19	transcription	O
20	:	O
21	one	O
22	prior	O
23	to	O
24	and	O
25	one	O
26	after	O
27	stable	O
28	complex	O
29	formation	O
30	;	O
31	and	O
32	that	O
33	these	O
34	effects	O
35	are	O
36	mediated	O
37	by	O
38	a	O
39	component	O
40	of	O
41	the	O
42	stable	O
43	complex	O
44	.	O

1	Furthermore	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	untranslated	O
7	regions	O
8	of	O
9	pmGT10	B
10	display	O
11	a	O
12	marked	O
13	degree	O
14	of	O
15	homology	O
16	to	O
17	the	O
18	3	O
19	'	O
20	region	O
21	of	O
22	the	O
23	rat	B
24	Yb1	I
25	gene	I
26	,	O
27	while	O
28	this	O
29	region	O
30	of	O
31	pmGT2	B
32	displays	O
33	marked	O
34	homology	O
35	to	O
36	the	O
37	corresponding	O
38	region	O
39	of	O
40	the	O
41	rat	B
42	Yb2	I
43	gene	I
44	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	The	O
2	stereoselectivity	O
3	of	O
4	drug	O
5	action	O
6	.	O

1	Scotchbond	O
2	2	O
3	showed	O
4	the	O
5	least	O
6	dye	O
7	penetration	O
8	but	O
9	not	O
10	statistically	O
11	less	O
12	than	O
13	the	O
14	XR	O
15	bond	O
16	/	O
17	Silus	O
18	Plus	O
19	combination	O
20	.	O

1	Metformin	O
2	plasma	O
3	concentrations	O
4	remained	O
5	unchanged	O
6	except	O
7	for	O
8	patients	O
9	transferred	O
10	from	O
11	1	O
12	.	O
13	5	O
14	to	O
15	2	O
16	.	O
17	0	O
18	g	O
19	daily	O
20	to	O
21	850	O
22	mg	O
23	twice	O
24	daily	O
25	;	O
26	in	O
27	these	O
28	patients	O
29	plasma	O
30	concentrations	O
31	increased	O
32	from	O
33	1	O
34	.	O
35	83	O
36	+/-	O
37	0	O
38	.	O
39	87	O
40	to	O
41	2	O
42	.	O
43	50	O
44	+/-	O
45	0	O
46	.	O
47	89	O
48	micrograms	O
49	/	O
50	l	O
51	(	O
52	p	O
53	less	O
54	than	O
55	0	O
56	.	O
57	01	O
58	).	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	optimal	O
6	development	O
7	conditions	O
8	by	O
9	summary	O
10	oxygen	O
11	consumption	O

1	Swim	O
2	-	O
3	over	O
4	:	O
5	an	O
6	alternative	O
7	method	O
8	for	O
9	harvesting	O
10	motile	O
11	spermatozoa	O
12	.	O

1	Perfusion	O
2	washout	O
3	:	O
4	increasing	O
5	a	O
6	microvascular	O
7	free	O
8	flap	O
9	tolerance	O
10	to	O
11	ischemia	O
12	.	O

1	A	O
2	raised	O
3	amplitude	O
4	of	O
5	the	O
6	aggregation	O
7	of	O
8	plates	O
9	and	O
10	a	O
11	decrease	O
12	in	O
13	the	O
14	threshold	O
15	of	O
16	their	O
17	sensitivity	O
18	to	O
19	ADP	O
20	were	O
21	established	O
22	in	O
23	the	O
24	persons	O
25	with	O
26	types	O
27	IIa	O
28	and	O
29	IIb	O
30	HLP	O
31	and	O
32	in	O
33	CHD	O
34	without	O
35	HLP	O
36	.	O

1	Cosmid	O
2	clones	O
3	containing	O
4	both	O
5	VNTR	O
6	sequences	O
7	were	O
8	identified	O
9	,	O
10	and	O
11	restriction	O
12	mapping	O
13	showed	O
14	them	O
15	to	O
16	be	O
17	less	O
18	than	O
19	15	O
20	kb	O
21	apart	O
22	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	Endometrial	O
2	biopsies	O
3	and	O
4	plasma	O
5	oestradiol	O
6	(	O
7	E2	O
8	)	O
9	and	O
10	progesterone	O
11	(	O
12	P4	O
13	)	O
14	levels	O
15	in	O
16	23	O
17	patients	O
18	were	O
19	evaluated	O
20	during	O
21	26	O
22	replacement	O
23	therapy	O
24	cycles	O
25	for	O
26	premature	O
27	ovarian	O
28	failure	O
29	.	O

1	The	O
2	nature	O
3	of	O
4	the	O
5	process	O
6	formed	O
7	by	O
8	the	O
9	successive	O
10	occurrences	O
11	of	O
12	this	O
13	arrhythmia	O
14	was	O
15	studied	O
16	in	O
17	8	O
18	patients	O
19	with	O
20	a	O
21	history	O
22	of	O
23	symptomatic	O
24	paroxysmal	O
25	AF	O
26	.	O

1	This	O
2	would	O
3	have	O
4	had	O
5	the	O
6	effect	O
7	of	O
8	positioning	O
9	the	O
10	genes	O
11	currently	O
12	on	O
13	the	O
14	long	O
15	arm	O
16	adjacent	O
17	to	O
18	the	O
19	centromeric	O
20	heterochromatin	O
21	,	O
22	perhaps	O
23	resulting	O
24	in	O
25	a	O
26	"	O
27	position	O
28	effect	O
29	"	O
30	on	O
31	transcription	O
32	of	O
33	these	O
34	genes	O
35	.	O

1	Brain	B
2	cholinesterase	I
3	activity	O
4	of	O
5	nestling	O
6	great	O
7	egrets	O
8	,	O
9	snowy	O
10	egrets	O
11	and	O
12	black	O
13	-	O
14	crowned	O
15	night	O
16	-	O
17	herons	O
18	.	O
19	inhibition	O
20	of	O
21	brain	B
22	cholinesterase	I
23	(	O
24	ChE	B
25	)	O
26	activity	O
27	in	O
28	birds	O
29	is	O
30	often	O
31	used	O
32	to	O
33	diagnose	O
34	exposure	O
35	or	O
36	death	O
37	from	O
38	organophosphorus	O
39	or	O
40	carbamate	O
41	pesticides	O
42	.	O

1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O

1	Heating	O
2	cells	O
3	to	O
4	43	O
5	degrees	O
6	C	O
7	decreased	O
8	the	O
9	amount	O
10	of	O
11	newly	O
12	synthesized	O
13	rRNA	O
14	to	O
15	less	O
16	than	O
17	5	O
18	%	O
19	of	O
20	the	O
21	control	O
22	level	O
23	and	O
24	led	O
25	to	O
26	greater	O
27	than	O
28	95	O
29	%	O
30	inhibition	O
31	of	O
32	transcription	O
33	termination	O
34	at	O
35	a	O
36	region	O
37	355	O
38	to	O
39	362	O
40	nucleotides	O
41	downstream	O
42	of	O
43	the	O
44	3	O
45	'	O
46	end	O
47	of	O
48	28S	B
49	rRNA	I
50	,	O
51	with	O
52	readthrough	O
53	continuing	O
54	into	O
55	the	O
56	next	O
57	transcription	O
58	unit	O
59	.	O

1	Reye	O
2	'	O
3	s	O
4	syndrome	O
5	:	O
6	reports	O
7	of	O
8	7	O
9	cases	O
10	in	O
11	the	O
12	period	O
13	1982	O
14	-	O
15	1987	O

1	The	O
2	author	O
3	gives	O
4	an	O
5	account	O
6	of	O
7	antipsychotic	O
8	,	O
9	analgetic	O
10	,	O
11	myorelaxing	O
12	and	O
13	vasodilatating	O
14	effects	O
15	of	O
16	some	O
17	calcium	O
18	antagonists	O
19	,	O
20	and	O
21	their	O
22	clinical	O
23	application	O
24	is	O
25	discussed	O
26	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	1	O
2	-(	O
3	1	O
4	-	O
5	Naphthyl	O
6	)	O
7	piperazine	O
8	(	O
9	1	O
10	-	O
11	NP	O
12	)	O
13	has	O
14	been	O
15	reported	O
16	to	O
17	have	O
18	serotonin	O
19	antagonist	O
20	properties	O
21	at	O
22	the	O
23	5	B
24	-	I
25	HT2	I
26	subtype	I
27	of	O
28	receptor	O
29	,	O
30	and	O
31	it	O
32	has	O
33	been	O
34	suggested	O
35	that	O
36	it	O
37	may	O
38	have	O
39	agonist	O
40	actions	O
41	at	O
42	the	O
43	5	B
44	-	I
45	HT1	I
46	site	I
47	.	O

1	Histiocytic	O
2	panniculitis	O
3	was	O
4	observed	O
5	in	O
6	biopsy	O
7	specimens	O
8	with	O
9	cytophagocytosis	O
10	.	O

1	Oligosynaptic	O
2	EPSP	O
3	components	O
4	were	O
5	consistently	O
6	modulated	O
7	only	O
8	in	O
9	the	O
10	superficial	O
11	peroneal	O
12	responses	O
13	in	O
14	flexor	O
15	motoneurons	O
16	,	O
17	which	O
18	exhibited	O
19	enhanced	O
20	amplitude	O
21	during	O
22	the	O
23	flexion	O
24	phase	O
25	.	O

1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	O
23	trochoidea	O
24	Stein	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	O
53	(	O
54	25	O
55	microEin	O
56	m	O
57	-	O
58	2	O
59	s	O
60	-	O
61	1	O
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O

1	A	O
2	genomic	O
3	DNA	O
4	clone	O
5	encoding	O
6	oryzacystatin	B
7	(	O
8	Oc	B
9	),	O
10	a	O
11	cysteine	B
12	proteinase	I
13	inhibitor	O
14	(	O
15	cystatin	B
16	)	O
17	of	O
18	rice	O
19	,	O
20	was	O
21	isolated	O
22	from	O
23	a	O
24	lambda	O
25	EMBL3	O
26	phage	O
27	library	O
28	constructed	O
29	with	O
30	Sau3AI	B
31	partial	O
32	digests	O
33	of	O
34	rice	O
35	chromosomal	O
36	DNA	O
37	,	O
38	by	O
39	screening	O
40	with	O
41	an	O
42	oc	B
43	cDNA	I
44	as	O
45	a	O
46	probe	O
47	.	O

1	Male	B
2	-	I
3	enhanced	I
4	antigen	I
5	gene	I
6	is	O
7	phylogenetically	O
8	conserved	O
9	and	O
10	expressed	O
11	at	O
12	late	O
13	stages	O
14	of	O
15	spermatogenesis	O
16	.	O

1	In	O
2	rats	O
3	bearing	O
4	Walker	O
5	-	O
6	256	O
7	-	O
8	carcinosarcoma	O
9	4	O
10	-	O
11	EPI	O
12	was	O
13	effective	O
14	.(	O
15	ABSTRACT	O
16	TRUNCATED	O
17	AT	O
18	250	O
19	WORDS	O
20	)	O

1	The	O
2	subepicardial	O
3	lymphatic	O
4	capillaries	O
5	were	O
6	ramified	O
7	and	O
8	anastomosed	O
9	with	O
10	each	O
11	other	O
12	to	O
13	form	O
14	a	O
15	relatively	O
16	dense	O
17	network	O
18	which	O
19	extended	O
20	over	O
21	the	O
22	entire	O
23	surface	O
24	of	O
25	both	O
26	ventricles	O
27	.	O

1	The	O
2	major	O
3	inserted	O
4	DNA	O
5	has	O
6	no	O
7	significant	O
8	homology	O
9	to	O
10	published	O
11	human	O
12	nucleic	O
13	acid	O
14	sequences	O
15	.	O

1	We	O
2	have	O
3	also	O
4	found	O
5	that	O
6	the	O
7	in	O
8	vitro	O
9	interaction	O
10	between	O
11	the	O
12	SV40	O
13	octamer	O
14	motif	O
15	and	O
16	the	O
17	lymphoid	B
18	cell	I
19	-	I
20	specific	I
21	protein	I
22	oct	I
23	-	I
24	B2	I
25	was	O
26	negatively	O
27	modulated	O
28	by	O
29	a	O
30	component	O
31	present	O
32	in	O
33	the	O
34	nuclear	O
35	extracts	O
36	from	O
37	several	O
38	lymphoid	O
39	cell	O
40	lines	O
41	.	O

1	Anoxia	O
2	was	O
3	introduced	O
4	by	O
5	perfusing	O
6	the	O
7	gill	O
8	with	O
9	water	O
10	deprived	O
11	of	O
12	oxygen	O
13	or	O
14	by	O
15	halting	O
16	the	O
17	water	O
18	flow	O
19	to	O
20	the	O
21	gill	O
22	.	O

1	Thus	O
2	,	O
3	multiple	O
4	myogenic	O
5	factors	O
6	that	O
7	vary	O
8	qualitatively	O
9	and	O
10	quantitatively	O
11	may	O
12	be	O
13	responsible	O
14	for	O
15	the	O
16	different	O
17	and	O
18	complex	O
19	modulatory	O
20	programs	O
21	of	O
22	actin	B
23	gene	I
24	expression	O
25	observed	O
26	during	O
27	in	O
28	vivo	O
29	muscle	O
30	differentiation	O
31	.	O

1	Both	O
2	the	O
3	intact	B
4	A1	I
5	protein	I
6	and	O
7	its	O
8	proteolytic	O
9	fragment	O
10	,	O
11	the	O
12	UP1	B
13	protein	I
14	,	O
15	can	O
16	be	O
17	cleaved	O
18	by	O
19	Staphylococcus	B
20	aureus	I
21	V	I
22	-	I
23	8	I
24	protease	I
25	to	O
26	produce	O
27	two	O
28	polypeptides	O
29	of	O
30	92	O
31	amino	O
32	acids	O
33	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	The	O
2	lack	O
3	of	O
4	change	O
5	in	O
6	the	O
7	ratio	O
8	of	O
9	the	O
10	two	O
11	spliced	O
12	products	O
13	expressed	O
14	from	O
15	either	O
16	the	O
17	normal	O
18	or	O
19	the	O
20	5	B
21	'-	I
22	rearranged	I
23	myb	I
24	further	O
25	indicates	O
26	that	O
27	the	O
28	insertion	O
29	of	O
30	the	O
31	unique	O
32	121	O
33	amino	O
34	acids	O
35	in	O
36	the	O
37	larger	O
38	myb	B
39	transcripts	I
40	is	O
41	not	O
42	a	O
43	consequence	O
44	of	O
45	tumor	O
46	-	O
47	specific	O
48	activation	O
49	of	O
50	the	O
51	mouse	B
52	myb	I
53	oncogene	I
54	.	O

1	An	O
2	analysis	O
3	of	O
4	the	O
5	steady	O
6	state	O
7	RNA	O
8	levels	O
9	in	O
10	T	O
11	-	O
12	lymphoid	O
13	cell	O
14	lines	O
15	showed	O
16	that	O
17	at	O
18	least	O
19	three	O
20	different	O
21	incomplete	O
22	proviral	O
23	transcripts	O
24	and	O
25	their	O
26	spliced	O
27	products	O
28	made	O
29	up	O
30	the	O
31	majority	O
32	of	O
33	expressed	O
34	RD	B
35	-	I
36	114	I
37	mRNA	I
38	,	O
39	and	O
40	further	O
41	demonstrated	O
42	that	O
43	partially	O
44	deleted	O
45	proviral	O
46	loci	O
47	have	O
48	the	O
49	potential	O
50	to	O
51	be	O
52	transcriptionally	O
53	vigorous	O
54	in	O
55	certain	O
56	feline	O
57	cell	O
58	types	O
59	.	O

1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	Mo	O
2	+	O
3	SV	O
4	M	O
5	-	O
6	MuLV	O
7	-	O
8	inoculated	O
9	animals	O
10	became	O
11	moribund	O
12	at	O
13	3	O
14	to	O
15	13	O
16	months	O
17	postinoculation	O
18	,	O
19	whereas	O
20	delta	O
21	Mo	O
22	+	O
23	SV	O
24	M	O
25	-	O
26	MuLV	O
27	-	O
28	inoculated	O
29	animals	O
30	became	O
31	moribund	O
32	at	O
33	6	O
34	to	O
35	24	O
36	months	O
37	postinoculation	O
38	.	O

1	Accurate	O
2	evaluation	O
3	of	O
4	the	O
5	treatment	O
6	results	O
7	in	O
8	unresectable	O
9	lung	O
10	cancer	O
11	patients	O
12	must	O
13	take	O
14	the	O
15	strong	O
16	prognostic	O
17	factors	O
18	into	O
19	account	O
20	.	O

1	The	O
2	primary	O
3	structure	O
4	and	O
5	cotranscription	O
6	of	O
7	the	O
8	petCA	B
9	genes	I
10	encoding	O
11	the	O
12	Rieske	B
13	-	I
14	FeS	I
15	(	O
16	nuclear	B
17	encoded	I
18	in	I
19	plants	I
20	)	O
21	and	O
22	apocytochrome	B
23	f	I
24	proteins	I
25	has	O
26	been	O
27	described	O
28	previously	O
29	(	O
30	Kallas	O
31	,	O
32	T	O
33	.,	O
34	Spiller	O
35	,	O
36	S	O
37	.,	O
38	and	O
39	Malkin	O
40	,	O
41	R	O
42	.	O

1	The	O
2	Nostoc	O
3	petBD	B
4	genes	I
5	are	O
6	not	O
7	closely	O
8	linked	O
9	to	O
10	the	O
11	psbB	B
12	gene	I
13	(	O
14	encoding	O
15	the	O
16	51	O
17	-	O
18	kDa	O
19	photosystem	B
20	II	I
21	polypeptide	I
22	)	O
23	and	O
24	do	O
25	not	O
26	contain	O
27	introns	O
28	as	O
29	do	O
30	the	O
31	closely	O
32	related	O
33	chloroplast	O
34	genes	O
35	.	O

1	A	O
2	highly	O
3	hydrophobic	O
4	sequence	O
5	located	O
6	near	O
7	the	O
8	carboxyl	O
9	-	O
10	terminal	O
11	extremity	O
12	of	O
13	the	O
14	molecule	O
15	most	O
16	likely	O
17	constitutes	O
18	the	O
19	anchor	O
20	to	O
21	the	O
22	plasma	O
23	membrane	O
24	.	O

1	Poor	O
2	response	O
3	when	O
4	laboratory	O
5	recommended	O
6	range	O
7	for	O
8	serum	O
9	lithium	O
10	is	O
11	changed	O
12	.	O

1	Changes	O
2	in	O
3	dopamine	B
4	receptor	I
5	sensitivity	O
6	in	O
7	humans	O
8	after	O
9	heavy	O
10	alcohol	O
11	intake	O
12	.	O

1	Replacement	B
2	variant	I
3	histone	I
4	genes	I
5	contain	O
6	intervening	O
7	sequences	O
8	.	O

1	Output	O
2	of	O
3	99mTcO	O
4	-	O
5	4	O
6	by	O
7	the	O
8	parotid	O
9	gland	O
10	closely	O
11	mimicked	O
12	fluctuations	O
13	in	O
14	parotid	O
15	saliva	O
16	flow	O
17	rate	O
18	.	O

1	Present	O
2	results	O
3	reveal	O
4	a	O
5	frequency	O
6	-	O
7	dependent	O
8	inhibition	O
9	of	O
10	ganglionic	O
11	transmission	O
12	by	O
13	diltiazem	O
14	,	O
15	and	O
16	suggest	O
17	that	O
18	diltiazem	O
19	may	O
20	depress	O
21	excessive	O
22	sympathetic	O
23	activity	O
24	without	O
25	affecting	O
26	normal	O
27	ganglionic	O
28	transmission	O
29	.	O

1	Studies	O
2	were	O
3	performed	O
4	on	O
5	several	O
6	superficial	O
7	veins	O
8	from	O
9	the	O
10	rabbit	O
11	face	O
12	to	O
13	examine	O
14	the	O
15	relationship	O
16	between	O
17	beta	B
18	adrenoceptor	I
19	subtype	I
20	distribution	O
21	,	O
22	intrinsic	O
23	myogenic	O
24	tone	O
25	and	O
26	sympathetic	O
27	nerve	O
28	innervation	O
29	.	O

1	Somatostatin	B
2	-	O
3	producing	O
4	endocrine	O
5	pancreatic	O
6	tumor	O
7	in	O
8	Recklinghausen	O
9	'	O
10	s	O
11	neurofibromatosis	O
12	.	O

1	Seventy	O
2	-	O
3	one	O
4	supplementary	O
5	doses	O
6	of	O
7	vecuronium	O
8	were	O
9	used	O
10	for	O
11	muscle	O
12	relaxation	O
13	during	O
14	a	O
15	22	O
16	-	O
17	h	O
18	-	O
19	long	O
20	NLA	O
21	II	O
22	anaesthesia	O
23	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	properties	O
6	of	O
7	the	O
8	protein	O
9	encoded	O
10	by	O
11	neu	B
12	,	O
13	we	O
14	created	O
15	a	O
16	fusion	O
17	gene	O
18	that	O
19	joins	O
20	the	O
21	cytoplasmic	O
22	domain	O
23	of	O
24	neu	B
25	to	O
26	the	O
27	extracellular	O
28	portion	O
29	of	O
30	an	O
31	immunoglobulin	B
32	heavy	I
33	chain	I
34	.	O

1	Pharmacology	O
2	studies	O
3	with	O
4	potassium	O
5	chloride	O
6	and	O
7	acetylcholine	O
8	suggest	O
9	that	O
10	raveron	O
11	acts	O
12	as	O
13	a	O
14	calcium	O
15	antagonist	O
16	by	O
17	blocking	O
18	the	O
19	influx	O
20	of	O
21	extracellular	O
22	calcium	O
23	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	these	O
6	low	O
7	levels	O
8	studied	O
9	,	O
10	aluminum	O
11	accumulates	O
12	in	O
13	intestinal	O
14	tissue	O
15	,	O
16	and	O
17	that	O
18	this	O
19	accumulation	O
20	is	O
21	enhanced	O
22	by	O
23	citrate	O
24	ligand	O
25	.	O

1	Recently	O
2	,	O
3	an	O
4	electrical	O
5	-	O
6	mechanical	O
7	analog	O
8	model	O
9	of	O
10	heat	O
11	flow	O
12	within	O
13	the	O
14	brain	O
15	has	O
16	been	O
17	developed	O
18	from	O
19	which	O
20	an	O
21	expression	O
22	for	O
23	CBF	O
24	has	O
25	been	O
26	derived	O
27	:	O
28	CBF	O
29	=	O
30	Cb	O
31	/(	O
32	tau	O
33	rho	O
34	c	O
35	)	O
36	where	O
37	tau	O
38	is	O
39	the	O
40	thermal	O
41	decay	O
42	constant	O
43	,	O
44	rho	O
45	is	O
46	the	O
47	density	O
48	of	O
49	blood	O
50	,	O
51	and	O
52	c	O
53	is	O
54	its	O
55	specific	O
56	heat	O
57	.	O

1	Successful	O
2	use	O
3	of	O
4	transureteroureterostomy	O
5	to	O
6	salvage	O
7	ureterosigmoidostomy	O
8	after	O
9	anastomotic	O
10	failure	O
11	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	the	O
7	structure	O
8	of	O
9	the	O
10	Spec1	B
11	gene	I
12	in	O
13	the	O
14	sea	O
15	urchin	O
16	Strongylocentrotus	O
17	purpuratus	O
18	.	O

1	Group	O
2	A	O
3	was	O
4	treated	O
5	with	O
6	three	O
7	or	O
8	four	O
9	doses	O
10	of	O
11	hepatitis	B
12	B	I
13	immune	I
14	globulin	I
15	(	O
16	HBIG	B
17	)	O
18	in	O
19	one	O
20	of	O
21	three	O
22	different	O
23	schedules	O
24	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	effects	O
6	of	O
7	a	O
8	preparation	O
9	with	O
10	50	O
11	micrograms	O
12	ethinyl	O
13	estradiol	O
14	and	O
15	2	O
16	mg	O
17	cyproterone	O
18	acetate	O
19	on	O
20	gonadotropins	B
21	,	O
22	prolactin	B
23	,	O
24	testosterone	O
25	,	O
26	sex	B
27	hormone	I
28	binding	I
29	globulin	I
30	(	O
31	SHBG	B
32	),	O
33	androstenedione	O
34	,	O
35	and	O
36	calculated	O
37	free	O
38	testosterone	O
39	index	O
40	before	O
41	and	O
42	after	O
43	six	O
44	months	O
45	of	O
46	treatment	O
47	.	O

1	The	O
2	seco	O
3	-	O
4	steroid	O
5	hormone	O
6	1	O
7	,	O
8	25	O
9	-	O
10	dihydroxyvitamin	O
11	D3	O
12	is	O
13	known	O
14	to	O
15	induce	O
16	the	O
17	expression	O
18	of	O
19	a	O
20	calcium	O
21	binding	O
22	protein	O
23	termed	O
24	calbindin	B
25	-	I
26	D28K	I
27	in	O
28	a	O
29	variety	O
30	of	O
31	target	O
32	tissues	O
33	.	O

1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	B
9	proteins	I
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O

1	Most	O
2	patients	O
3	preferred	O
4	tablets	O
5	to	O
6	injection	O
7	both	O
8	on	O
9	day	O
10	1	O
11	(	O
12	313	O
13	v	O
14	200	O
15	)	O
16	and	O
17	at	O
18	follow	O
19	up	O
20	(	O
21	373	O
22	v	O
23	104	O
24	).	O

1	A	O
2	rare	O
3	chronic	O
4	course	O
5	of	O
6	Budd	O
7	-	O
8	Chiari	O
9	syndrome	O
10	associated	O
11	with	O
12	thrombosis	O
13	of	O
14	the	O
15	portal	O
16	vein	O
17	was	O
18	observed	O
19	in	O
20	a	O
21	30	O
22	-	O
23	year	O
24	-	O
25	old	O
26	male	O
27	patient	O
28	suffering	O
29	from	O
30	postmyocarditic	O
31	cardiosclerosis	O
32	.	O

1	Oligonucleotide	O
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	Phase	O
2	II	O
3	study	O
4	of	O
5	VP	O
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O

1	81	O
2	milk	O
3	samples	O
4	collected	O
5	from	O
6	35	O
7	donors	O
8	3	O
9	days	O
10	to	O
11	7	O
12	months	O
13	after	O
14	delivery	O
15	were	O
16	examined	O
17	for	O
18	the	O
19	occurrence	O
20	of	O
21	cytomegalovirus	O
22	(	O
23	CMV	O
24	).	O

1	Subcloning	O
2	of	O
3	DNA	O
4	fragments	O
5	from	O
6	the	O
7	8	O
8	.	O
9	5	O
10	-	O
11	kilobase	O
12	(	O
13	kb	O
14	)	O
15	insert	O
16	of	O
17	pAVO4	O
18	defined	O
19	a	O
20	4	O
21	-	O
22	kb	O
23	DNA	O
24	fragment	O
25	which	O
26	contained	O
27	the	O
28	functional	B
29	FBP	I
30	+	I
31	gene	I
32	and	O
33	its	O
34	regulatory	O
35	region	O
36	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	dopaminergic	O
6	regulation	O
7	of	O
8	adrenal	O
9	zona	O
10	glomerulosa	O
11	corticosteroid	O
12	and	O
13	renal	B
14	renin	I
15	secretion	O
16	is	O
17	absent	O
18	in	O
19	patients	O
20	with	O
21	high	O
22	spinal	O
23	cord	O
24	transections	O
25	,	O
26	suggesting	O
27	that	O
28	intact	O
29	neural	O
30	pathways	O
31	from	O
32	the	O
33	central	O
34	nervous	O
35	system	O
36	are	O
37	necessary	O
38	for	O
39	metoclopramide	O
40	stimulation	O
41	of	O
42	aldosterone	O
43	and	O
44	renin	B
45	secretion	O
46	in	O
47	men	O
48	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	enhancer	O
6	sequences	O
7	,	O
8	the	O
9	adenovirus	B
10	E1A	I
11	gene	I
12	can	O
13	not	O
14	stimulate	O
15	CATase	B
16	synthesis	O
17	.	O

1	This	O
2	L	B
3	-	I
4	myc	I
5	sequence	I
6	is	O
7	amplified	O
8	10	O
9	-	O
10	20	O
11	-	O
12	fold	O
13	in	O
14	four	O
15	SCLC	O
16	cell	O
17	line	O
18	DNAs	O
19	and	O
20	in	O
21	one	O
22	SCLC	O
23	tumour	O
24	specimen	O
25	taken	O
26	directly	O
27	from	O
28	a	O
29	patient	O
30	.	O

1	Alveolar	O
2	lymphocytes	O
3	were	O
4	surprisingly	O
5	increased	O
6	in	O
7	most	O
8	patients	O
9	with	O
10	AIDS	O
11	(	O
12	mean	O
13	26	O
14	.	O
15	1	O
16	+/-	O
17	21	O
18	.	O
19	9	O
20	%;	O
21	range	O
22	1	O
23	-	O
24	76	O
25	%)	O
26	and	O
27	CGL	O
28	(	O
29	mean	O
30	26	O
31	.	O
32	6	O
33	+/-	O
34	22	O
35	.	O
36	6	O
37	%;	O
38	range	O
39	3	O
40	-	O
41	76	O
42	%)	O
43	with	O
44	criteria	O
45	of	O
46	activation	O
47	contrasting	O
48	with	O
49	the	O
50	blood	O
51	lymphopenia	O
52	.	O

1	The	O
2	sequence	O
3	was	O
4	determined	O
5	for	O
6	a	O
7	4024	O
8	-	O
9	base	O
10	pair	O
11	(	O
12	bp	O
13	)	O
14	segment	O
15	that	O
16	extends	O
17	from	O
18	149	O
19	bp	O
20	5	O
21	'	O
22	to	O
23	the	O
24	cap	O
25	site	O
26	of	O
27	alpha	B
28	1	I
29	to	O
30	207	O
31	bp	O
32	3	O
33	'	O
34	to	O
35	psi	B
36	alpha	I
37	.	O

1	Comparison	O
2	with	O
3	a	O
4	recently	O
5	described	O
6	c	B
7	-	I
8	sis	I
9	cDNA	I
10	clone	I
11	(	O
12	Collins	O
13	et	O
14	al	O
15	.,	O
16	Nature	O
17	316	O
18	,	O
19	748	O
20	-	O
21	750	O
22	(	O
23	1985	O
24	))	O
25	revealed	O
26	that	O
27	the	O
28	1	O
29	.	O
30	9	O
31	kbp	O
32	DNA	O
33	region	O
34	contained	O
35	a	O
36	large	O
37	5	B
38	'	I
39	c	I
40	-	I
41	sis	I
42	exon	I
43	of	O
44	at	O
45	least	O
46	1050	O
47	bp	O
48	.	O

1	In	O
2	order	O
3	to	O
4	study	O
5	the	O
6	influence	O
7	of	O
8	iron	O
9	overload	O
10	on	O
11	the	O
12	polymorphonuclear	O
13	leucocyte	O
14	(	O
15	PMN	O
16	)	O
17	metabolism	O
18	of	O
19	patients	O
20	on	O
21	chronic	O
22	hemodialysis	O
23	,	O
24	generation	O
25	of	O
26	superoxide	O
27	anion	O
28	(	O
29	O2	O
30	-)	O
31	by	O
32	PMN	O
33	in	O
34	whole	O
35	blood	O
36	was	O
37	compared	O
38	in	O
39	two	O
40	groups	O
41	of	O
42	hemodialyzed	O
43	patients	O
44	:	O
45	group	O
46	A	O
47	consisted	O
48	of	O
49	twenty	O
50	-	O
51	one	O
52	individuals	O
53	with	O
54	serum	O
55	ferritin	B
56	levels	O
57	above	O
58	1000	O
59	ng	O
60	/	O
61	ml	O
62	and	O
63	group	O
64	B	O
65	of	O
66	nineteen	O
67	individuals	O
68	with	O
69	serum	O
70	ferritin	B
71	levels	O
72	below	O
73	1000	O
74	ng	O
75	/	O
76	ml	O
77	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	Analysis	O
2	of	O
3	glucocorticoid	O
4	unresponsive	O
5	cell	O
6	variants	O
7	using	O
8	a	O
9	mouse	B
10	glucocorticoid	I
11	receptor	I
12	complementary	O
13	DNA	O
14	clone	O
15	.	O

1	During	O
2	the	O
3	biosynthesis	O
4	of	O
5	all	O
6	three	O
7	mutant	O
8	polypeptides	O
9	,	O
10	the	O
11	signal	O
12	peptide	O
13	is	O
14	efficiently	O
15	and	O
16	accurately	O
17	cleaved	O
18	from	O
19	the	O
20	nascent	O
21	protein	O
22	,	O
23	even	O
24	though	O
25	in	O
26	mutants	O
27	X2	O
28	and	O
29	X3	O
30	the	O
31	cleavage	O
32	site	O
33	itself	O
34	has	O
35	been	O
36	altered	O
37	.	O

1	The	O
2	52	O
3	-	O
4	protein	O
5	subunit	O
6	of	O
7	T4	B
8	DNA	I
9	topoisomerase	I
10	is	O
11	homologous	O
12	to	O
13	the	O
14	gyrA	B
15	-	I
16	protein	I
17	of	O
18	gyrase	B
19	.	O

1	In	O
2	the	O
3	DNAs	O
4	of	O
5	all	O
6	Ph1	O
7	-	O
8	positive	O
9	chronic	O
10	myelocytic	O
11	leukemia	O
12	patients	O
13	studied	O
14	to	O
15	date	O
16	,	O
17	a	O
18	breakpoint	O
19	on	O
20	chromosome	O
21	22	O
22	(	O
23	the	O
24	Ph1	O
25	chromosome	O
26	)	O
27	can	O
28	be	O
29	demonstrated	O
30	with	O
31	a	O
32	probe	O
33	from	O
34	the	O
35	bcr	B
36	(	O
37	breakpoint	B
38	cluster	I
39	region	I
40	).	O

1	The	O
2	5	O
3	'-	O
4	nontranslated	O
5	sequences	O
6	and	O
7	parts	O
8	of	O
9	the	O
10	coding	O
11	sequences	O
12	of	O
13	various	O
14	yeast	O
15	genes	O
16	have	O
17	been	O
18	cloned	O
19	into	O
20	representative	O
21	lacZ	B
22	fusion	O
23	vectors	O
24	.	O

1	The	O
2	previously	O
3	described	O
4	four	O
5	sets	O
6	of	O
7	13	O
8	-	O
9	to	O
10	18	O
11	-	O
12	base	O
13	-	O
14	pair	O
15	interspersed	O
16	repeat	O
17	elements	O
18	between	O
19	-	O
20	55	O
21	and	O
22	-	O
23	580	O
24	provide	O
25	most	O
26	of	O
27	the	O
28	high	O
29	basal	O
30	transcriptional	O
31	strength	O
32	,	O
33	whereas	O
34	the	O
35	arrangement	O
36	of	O
37	further	O
38	upstream	O
39	tandemly	O
40	repeated	O
41	NF1	B
42	-	I
43	binding	I
44	sites	I
45	may	O
46	contribute	O
47	significantly	O
48	to	O
49	the	O
50	expanded	O
51	biological	O
52	host	O
53	range	O
54	for	O
55	expression	O
56	of	O
57	SCMV	B
58	IE94	I
59	compared	O
60	with	O
61	HCMV	B
62	IE68	I
63	.	O

1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	IR2	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	polymorphism	O
29	for	O
30	the	O
31	enzyme	B
32	SmaI	I
33	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	values	O
6	obtained	O
7	by	O
8	the	O
9	two	O
10	methods	O
11	were	O
12	in	O
13	agreement	O
14	for	O
15	each	O
16	species	O
17	of	O
18	epidermal	B
19	growth	I
20	factor	I
21	and	O
22	followed	O
23	the	O
24	order	O
25	:	O
26	wild	O
27	type	O
28	greater	O
29	than	O
30	Glu24	O
31	----	O
32	Gly	O
33	greater	O
34	than	O
35	Asp27	O
36	----	O
37	Gly	O
38	much	O
39	greater	O
40	than	O
41	Pro7	O
42	----	O
43	Thr	O
44	greater	O
45	than	O
46	Tyr29	O
47	----	O
48	Gly	O
49	greater	O
50	than	O
51	Leu47	O
52	----	O
53	His	O
54	.	O

1	We	O
2	also	O
3	found	O
4	an	O
5	eIF	B
6	-	I
7	4A	I
8	intronless	O
9	retroposon	O
10	which	O
11	,	O
12	when	O
13	compared	O
14	to	O
15	the	O
16	cDNA	O
17	,	O
18	contains	O
19	a	O
20	single	O
21	nucleotide	O
22	difference	O
23	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	In	O
2	view	O
3	of	O
4	these	O
5	results	O
6	,	O
7	simultaneous	O
8	pancreas	O
9	-	O
10	kidney	O
11	transplantation	O
12	appears	O
13	to	O
14	be	O
15	the	O
16	treatment	O
17	of	O
18	choice	O
19	for	O
20	Type	O
21	I	O
22	diabetic	O
23	patients	O
24	.	O

1	Administration	O
2	of	O
3	anticoagulants	O
4	,	O
5	i	O
6	.	O
7	e	O
8	.,	O
9	heparin	O
10	,	O
11	prostaglandin	O
12	E1	O
13	and	O
14	ticlopidine	O
15	seems	O
16	to	O
17	be	O
18	effective	O
19	in	O
20	alleviating	O
21	symptoms	O
22	and	O
23	might	O
24	prevent	O
25	further	O
26	deterioration	O
27	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	the	O
5	L1	B
6	binding	I
7	site	I
8	of	O
9	23S	B
10	rRNA	I
11	in	I
12	Escherichia	I
13	coli	I
14	.	O

1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O

1	After	O
2	a	O
3	survey	O
4	of	O
5	the	O
6	anatomical	O
7	and	O
8	physiological	O
9	basis	O
10	of	O
11	operative	O
12	treatment	O
13	of	O
14	behaviour	O
15	disorders	O
16	by	O
17	stereotactic	O
18	lesions	O
19	in	O
20	the	O
21	amygdala	O
22	and	O
23	the	O
24	posterior	O
25	medial	O
26	hypothalamus	O
27	the	O
28	author	O
29	describes	O
30	his	O
31	own	O
32	experiences	O
33	with	O
34	603	O
35	operations	O
36	for	O
37	control	O
38	of	O
39	conservatively	O
40	untreatable	O
41	aggressiveness	O
42	.	O

1	Histological	O
2	examination	O
3	revealed	O
4	a	O
5	small	O
6	simple	O
7	renal	O
8	cyst	O
9	associated	O
10	with	O
11	renal	O
12	cell	O
13	carcinoma	O
14	.	O

1	Although	O
2	large	O
3	epidemiologic	O
4	studies	O
5	are	O
6	best	O
7	able	O
8	to	O
9	identify	O
10	the	O
11	relative	O
12	contributions	O
13	of	O
14	specific	O
15	risk	O
16	factors	O
17	while	O
18	controlling	O
19	for	O
20	other	O
21	risk	O
22	factors	O
23	,	O
24	new	O
25	studies	O
26	need	O
27	to	O
28	focus	O
29	on	O
30	important	O
31	unresolved	O
32	questions	O
33	.	O

1	The	O
2	method	O
3	is	O
4	accurate	O
5	,	O
6	with	O
7	good	O
8	precision	O
9	and	O
10	adequate	O
11	sensitivity	O
12	.	O

1	Van	O
2	der	O
3	Ende	O
4	,	O
5	R	O
6	.	O

1	Statement	O
2	on	O
3	the	O
4	development	O
5	of	O
6	guidelines	O
7	for	O
8	the	O
9	prevention	O
10	of	O
11	AIDS	O
12	transmission	O
13	in	O
14	the	O
15	workplace	O
16	.	O

1	Intravenous	O
2	glucose	O
3	tolerance	O
4	tests	O
5	were	O
6	performed	O
7	before	O
8	operation	O
9	,	O
10	before	O
11	starting	O
12	CyA	O
13	and	O
14	after	O
15	3	O
16	weeks	O
17	.	O

1	This	O
2	gave	O
3	rise	O
4	to	O
5	RNA	O
6	molecules	O
7	with	O
8	3	O
9	'-	O
10	untranslated	O
11	regions	O
12	of	O
13	roughly	O
14	375	O
15	,	O
16	655	O
17	,	O
18	and	O
19	945	O
20	base	O
21	pairs	O
22	.	O

1	Also	O
2	,	O
3	the	O
4	BALB	B
5	/	I
6	c	I
7	gene	I
8	contains	O
9	a	O
10	single	O
11	substitution	O
12	in	O
13	a	O
14	conserved	O
15	octamer	O
16	sequence	O
17	approximately	O
18	equal	O
19	to	O
20	100	O
21	nucleotides	O
22	upstream	O
23	of	O
24	the	O
25	coding	O
26	region	O
27	,	O
28	which	O
29	could	O
30	affect	O
31	its	O
32	expression	O
33	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	greater	O
7	estrogenic	O
8	influence	O
9	associated	O
10	with	O
11	the	O
12	ethinyl	O
13	estradiol	O
14	-	O
15	containing	O
16	OC	O
17	resulted	O
18	in	O
19	inhibition	O
20	of	O
21	coronary	O
22	artery	O
23	atherosclerosis	O
24	despite	O
25	a	O
26	pronounced	O
27	progestin	O
28	-	O
29	induced	O
30	lowering	O
31	of	O
32	plasma	O
33	HDL	B
34	cholesterol	I
35	concentration	O
36	and	O
37	,	O
38	further	O
39	,	O
40	that	O
41	hormonal	O
42	balance	O
43	may	O
44	have	O
45	a	O
46	marked	O
47	influence	O
48	on	O
49	the	O
50	relationship	O
51	between	O
52	plasma	O
53	lipids	O
54	and	O
55	atherogenesis	O
56	.	O

1	40	O
2	.	O
3	3	O
4	+/-	O
5	10	O
6	.	O
7	1	O
8	mg	O
9	/	O
10	l	O
11	(	O
12	SD	O
13	)	O
14	vs	O
15	31	O
16	.	O
17	2	O
18	+/-	O
19	8	O
20	.	O
21	0	O
22	,	O
23	P	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	).	O
30	beta	B
31	2m	I
32	was	O
33	not	O
34	significantly	O
35	higher	O
36	in	O
37	patients	O
38	with	O
39	bone	O
40	cysts	O
41	(	O
42	37	O
43	.	O
44	7	O
45	+/-	O
46	11	O
47	.	O
48	4	O
49	mg	O
50	/	O
51	l	O
52	vs	O
53	37	O
54	.	O
55	0	O
56	+/-	O
57	10	O
58	.	O
59	0	O
60	),	O
61	but	O
62	median	O
63	duration	O
64	of	O
65	dialysis	O
66	was	O
67	significantly	O
68	(	O
69	P	O
70	less	O
71	than	O
72	0	O
73	.	O
74	01	O
75	)	O
76	longer	O
77	in	O
78	patients	O
79	with	O
80	bone	O
81	cysts	O
82	(	O
83	90	O
84	vs	O
85	57	O
86	months	O
87	).	O
88	beta	B
89	2m	I
90	was	O
91	lower	O
92	in	O
93	patients	O
94	maintained	O
95	on	O
96	dialysis	O
97	for	O
98	less	O
99	than	O
100	1	O
101	year	O
102	and	O
103	whose	O
104	residual	O
105	urine	O
106	volume	O
107	was	O
108	greater	O
109	than	O
110	0	O
111	.	O
112	1	O
113	litre	O
114	per	O
115	day	O
116	.	O

1	The	O
2	mean	O
3	percentage	O
4	of	O
5	linoleic	O
6	acid	O
7	in	O
8	the	O
9	triglycerides	O
10	of	O
11	the	O
12	subcutaneous	O
13	adipose	O
14	tissue	O
15	(	O
16	PLASAT	O
17	)	O
18	of	O
19	these	O
20	subjects	O
21	was	O
22	substantially	O
23	higher	O
24	than	O
25	that	O
26	in	O
27	a	O
28	similar	O
29	group	O
30	examined	O
31	in	O
32	1975	O
33	-	O
34	1976	O
35	.	O

1	Clinical	O
2	and	O
3	biological	O
4	correlates	O
5	of	O
6	panic	O
7	states	O
8	.	O

1	Human	B
2	rIL	I
3	-	I
4	3	I
5	expressed	O
6	in	O
7	COS7	O
8	cells	O
9	has	O
10	multipotential	O
11	CSF	B
12	activity	O
13	in	O
14	semisolid	O
15	cultures	O
16	of	O
17	bone	O
18	marrow	O
19	cells	O
20	,	O
21	and	O
22	selectively	O
23	induced	O
24	the	O
25	proliferation	O
26	of	O
27	My	O
28	-	O
29	10	O
30	+	O
31	marrow	O
32	or	O
33	cord	O
34	blood	O
35	cells	O
36	in	O
37	liquid	O
38	cultures	O
39	.	O

1	Apropos	O
2	of	O
3	a	O
4	case	O

1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	B
11	allotype	I
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O

1	HDL	B
2	-	I
3	cholesterol	I
4	(+	O
5	6	O
6	%,	O
7	P	O
8	less	O
9	than	O
10	.	O
11	01	O
12	)	O
13	and	O
14	apolipoprotein	B
15	A	I
16	-	I
17	I	I
18	(+	O
19	6	O
20	%,	O
21	P	O
22	less	O
23	than	O
24	.	O
25	01	O
26	)	O
27	concentrations	O
28	increased	O
29	significantly	O
30	only	O
31	in	O
32	the	O
33	young	O
34	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	sites	O
6	of	O
7	recombinational	O
8	resolution	O
9	is	O
10	inversely	O
11	correlated	O
12	with	O
13	that	O
14	of	O
15	the	O
16	gradient	O
17	of	O
18	sequence	O
19	divergence	O
20	,	O
21	with	O
22	only	O
23	approximately	O
24	7	O
25	%	O
26	of	O
27	the	O
28	X	O
29	recombinants	O
30	resolved	O
31	within	O
32	the	O
33	3	O
34	'	O
35	third	O
36	of	O
37	the	O
38	X	O
39	blocks	O
40	where	O
41	two	O
42	diverged	O
43	Alu	B
44	family	O
45	repeats	O
46	reside	O
47	.	O

1	Symptomatic	O
2	hyperventilators	O
3	had	O
4	a	O
5	larger	O
6	number	O
7	of	O
8	sighs	O
9	and	O
10	abnormally	O
11	wide	O
12	fluctuations	O
13	in	O
14	baseline	O
15	for	O
16	inspiratory	O
17	time	O
18	,	O
19	expiratory	O
20	time	O
21	,	O
22	and	O
23	PETCO2	O
24	.	O

1	The	O
2	central	O
3	visual	O
4	fields	O
5	of	O
6	2165	O
7	normal	O
8	and	O
9	106	O
10	glaucoma	O
11	eyes	O
12	were	O
13	measured	O
14	using	O
15	a	O
16	threshold	O
17	related	O
18	suprathreshold	O
19	strategy	O
20	.	O

1	Effect	O
2	of	O
3	chronic	O
4	undernutrition	O
5	on	O
6	susceptibility	O
7	to	O
8	cold	O
9	stress	O
10	in	O
11	young	O
12	adult	O
13	and	O
14	aged	O
15	rats	O
16	.	O

1	This	O
2	effect	O
3	and	O
4	the	O
5	fact	O
6	that	O
7	all	O
8	three	O
9	doses	O
10	were	O
11	toxic	O
12	to	O
13	the	O
14	dams	O
15	dictated	O
16	that	O
17	a	O
18	second	O
19	experiment	O
20	be	O
21	carried	O
22	out	O
23	at	O
24	lower	O
25	doses	O
26	.	O

1	The	O
2	CHARGE	O
3	association	O
4	is	O
5	a	O
6	collection	O
7	of	O
8	multisystem	O
9	congenital	O
10	anomalies	O
11	including	O
12	choanal	O
13	atresia	O
14	.	O

1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	O
26	from	O
27	adults	O
28	at	O
29	risk	O
30	for	O
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	O

1	Delayed	O
2	gallbladder	O
3	visualization	O
4	and	O
5	reduction	O
6	in	O
7	ejection	O
8	fraction	O
9	were	O
10	sensitive	O
11	but	O
12	nonspecific	O
13	indicators	O
14	of	O
15	biliary	O
16	disease	O
17	.	O

1	26	O
2	micrograms	O
3	PAF	B
4	or	O
5	placebo	O
6	was	O
7	sprayed	O
8	into	O
9	each	O
10	nasal	O
11	cavity	O
12	8	O
13	h	O
14	and	O
15	1	O
16	h	O
17	before	O
18	a	O
19	nasal	O
20	allergen	O
21	challenge	O
22	.	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	The	O
2	deduced	O
3	96	O
4	-	O
5	residue	O
6	amino	O
7	acid	O
8	coding	O
9	sequence	O
10	of	O
11	the	O
12	murine	O
13	HMG	B
14	-	I
15	I	I
16	(	I
17	Y	I
18	)	I
19	cDNA	O
20	is	O
21	very	O
22	similar	O
23	to	O
24	the	O
25	reported	O
26	amino	O
27	acid	O
28	sequence	O
29	of	O
30	human	O
31	HMG	B
32	-	I
33	I	I
34	,	O
35	except	O
36	that	O
37	it	O
38	lacks	O
39	11	O
40	internal	O
41	amino	O
42	acids	O
43	reported	O
44	in	O
45	the	O
46	human	O
47	protein	O
48	.	O

1	Interpersonal	O
2	style	O
3	differences	O
4	among	O
5	drug	O
6	abusers	O
7	were	O
8	explored	O
9	using	O
10	Ryan	O
11	'	O
12	s	O
13	(	O
14	1977	O
15	)	O
16	typological	O
17	system	O
18	of	O
19	FIRO	O
20	-	O
21	B	O
22	interpretation	O
23	.	O

1	There	O
2	were	O
3	gene	O
4	clusters	O
5	encoding	O
6	photosynthesis	O
7	components	O
8	such	O
9	as	O
10	the	O
11	psbB	B
12	-	O
13	psbH	B
14	-	O
15	petB	B
16	-	O
17	petD	B
18	and	O
19	the	O
20	psbE	O
21	-	O
22	psbF	O
23	clusters	O
24	.	O

1	Of	O
2	the	O
3	43	O
4	infants	O
5	with	O
6	a	O
7	(	O
8	probable	O
9	)	O
10	loss	O
11	18	O
12	were	O
13	examined	O
14	again	O
15	at	O
16	3	O
17	months	O
18	corrected	O
19	age	O
20	.	O

1	Although	O
2	not	O
3	consistently	O
4	identified	O
5	in	O
6	all	O
7	samples	O
8	,	O
9	secondary	O
10	Academic	O
11	,	O
12	Personal	O
13	Responsibility	O
14	,	O
15	and	O
16	Community	O
17	/	O
18	Vocational	O
19	dimensions	O
20	were	O
21	also	O
22	identified	O
23	.	O

1	The	O
2	temporal	O
3	and	O
4	static	O
5	plasma	O
6	concentration	O
7	-	O
8	effect	O
9	relationships	O
10	were	O
11	evaluated	O
12	by	O
13	pharmacodynamic	O
14	modeling	O
15	and	O
16	linear	O
17	regression	O
18	.	O

1	Many	O
2	children	O
3	with	O
4	BGC	O
5	are	O
6	delayed	O
7	in	O
8	their	O
9	development	O
10	,	O
11	but	O
12	calcifications	O
13	are	O
14	not	O
15	directly	O
16	related	O
17	to	O
18	specific	O
19	forms	O
20	of	O
21	neurologic	O
22	dysfunction	O
23	.	O

1	We	O
2	concluded	O
3	that	O
4	Ga	O
5	-	O
6	fbg	O
7	scintigraphy	O
8	is	O
9	a	O
10	very	O
11	simple	O
12	method	O
13	and	O
14	sufficiently	O
15	useful	O
16	for	O
17	detecting	O
18	active	O
19	left	O
20	ventricular	O
21	thrombi	O
22	and	O
23	for	O
24	monitoring	O
25	the	O
26	effect	O
27	of	O
28	anticoagulant	O
29	therapy	O
30	.	O

1	We	O
2	report	O
3	the	O
4	use	O
5	of	O
6	a	O
7	new	O
8	technetium	O
9	-	O
10	99m	O
11	-	O
12	albumin	B
13	colloid	O
14	white	O
15	blood	O
16	cell	O
17	(	O
18	TAC	O
19	-	O
20	WBC	O
21	)	O
22	scan	O
23	in	O
24	the	O
25	evaluation	O
26	of	O
27	appendicitis	O
28	.	O

1	The	O
2	SSB	B
3	-	O
4	poly	O
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O

1	The	O
2	putative	O
3	immunity	O
4	protein	O
5	was	O
6	detected	O
7	among	O
8	the	O
9	[	O
10	35S	O
11	]	O
12	methionine	O
13	-	O
14	labelled	O
15	proteins	O
16	produced	O
17	by	O
18	minicells	O
19	carrying	O
20	cni	B
21	cloned	O
22	under	O
23	lac	B
24	promoter	I
25	control	O
26	,	O
27	and	O
28	when	O
29	the	O
30	gene	O
31	was	O
32	subcloned	O
33	into	O
34	expression	O
35	vectors	O
36	under	O
37	the	O
38	control	O
39	of	O
40	a	O
41	bacteriophage	O
42	T7	O
43	promoter	O
44	.	O

1	Secretory	O
2	function	O
3	of	O
4	the	O
5	prostate	O
6	gland	O
7	.	O

1	Time	O
2	delay	O
3	effects	O
4	on	O
5	the	O
6	tensile	O
7	bond	O
8	strength	O
9	developed	O
10	by	O
11	the	O
12	Silicoater	O
13	.	O

1	Lysosomal	O
2	enzymes	O
3	that	O
4	degrade	O
5	cartilage	O
6	are	O
7	released	O
8	.	O

1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	B
11	and	I
12	beta	I
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O

1	There	O
2	is	O
3	a	O
4	cysteine	O
5	clustering	O
6	region	O
7	in	O
8	an	O
9	N	O
10	-	O
11	terminal	O
12	region	O
13	of	O
14	the	O
15	c	B
16	-	I
17	raf	I
18	(-	I
19	1	I
20	)	I
21	product	I
22	deduced	O
23	from	O
24	the	O
25	nucleotide	O
26	sequence	O
27	,	O
28	and	O
29	this	O
30	cysteine	O
31	clustering	O
32	region	O
33	was	O
34	found	O
35	to	O
36	be	O
37	highly	O
38	homologous	O
39	to	O
40	that	O
41	present	O
42	in	O
43	an	O
44	N	O
45	-	O
46	terminal	O
47	region	O
48	of	O
49	protein	B
50	kinase	I
51	C	I
52	,	O
53	although	O
54	,	O
55	in	O
56	the	O
57	latter	O
58	cysteine	O
59	clusters	O
60	are	O
61	present	O
62	in	O
63	duplicate	O
64	.	O

1	New	O
2	technologies	O
3	in	O
4	diagnosis	O
5	and	O
6	classification	O
7	of	O
8	malignancy	O
9	.	O

1	The	O
2	epidermal	B
3	growth	I
4	factor	I
5	(	I
6	EGF	I
7	)	I
8	receptor	I
9	,	O
10	which	O
11	exhibits	O
12	intrinsic	O
13	protein	B
14	tyrosine	I
15	kinase	I
16	activity	O
17	,	O
18	undergoes	O
19	a	O
20	rapid	O
21	,	O
22	intramolecular	O
23	self	O
24	-	O
25	phosphorylation	O
26	reaction	O
27	following	O
28	EGF	B
29	activation	O
30	.	O

1	We	O
2	have	O
3	improved	O
4	our	O
5	system	O
6	for	O
7	nuclear	O
8	contour	O
9	digitization	O
10	and	O
11	determined	O
12	its	O
13	theoretical	O
14	limitations	O
15	by	O
16	digitizing	O
17	standardized	O
18	objects	O
19	.	O

1	Recent	O
2	developments	O
3	in	O
4	drugs	O
5	antagonistic	O
6	to	O
7	factors	O
8	causing	O
9	peptic	O
10	ulcer	O
11	--	O
12	clinical	O
13	efficacy	O
14	and	O
15	problems	O
16	;	O
17	gastrin	B
18	receptor	I
19	blockaders	O

1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O

1	Psychological	O
2	disturbance	O
3	was	O
4	greater	O
5	in	O
6	the	O
7	high	O
8	life	O
9	stress	O
10	group	O
11	as	O
12	indicated	O
13	by	O
14	significant	O
15	elevations	O
16	on	O
17	the	O
18	global	O
19	severity	O
20	index	O
21	of	O
22	the	O
23	Symptom	O
24	Checklist	O
25	-	O
26	90	O
27	and	O
28	elevations	O
29	on	O
30	somatization	O
31	,	O
32	obsessive	O
33	compulsive	O
34	,	O
35	interpersonal	O
36	sensitivity	O
37	,	O
38	depression	O
39	,	O
40	anxiety	O
41	and	O
42	psychoticism	O
43	subscales	O
44	.	O

1	Statistical	O
2	analysis	O
3	of	O
4	the	O
5	degrees	O
6	of	O
7	secondary	O
8	spinal	O
9	cord	O
10	compression	O
11	was	O
12	performed	O
13	in	O
14	group	O
15	-	O
16	1	O
17	dogs	O
18	by	O
19	measuring	O
20	and	O
21	comparing	O
22	ratios	O
23	of	O
24	the	O
25	vertical	O
26	to	O
27	the	O
28	horizontal	O
29	diameters	O
30	of	O
31	the	O
32	transverse	O
33	spinal	O
34	cord	O
35	sections	O
36	from	O
37	locations	O
38	within	O
39	(	O
40	T12	O
41	to	O
42	L1	O
43	)	O
44	and	O
45	out	O
46	of	O
47	(	O
48	T11	O
49	,	O
50	T11	O
51	-	O
52	12	O
53	,	O
54	L1	O
55	-	O
56	2	O
57	,	O
58	and	O
59	L2	O
60	)	O
61	the	O
62	region	O
63	of	O
64	surgical	O
65	intervention	O
66	.	O

1	The	O
2	effects	O
3	produced	O
4	by	O
5	oral	O
6	administration	O
7	of	O
8	500	O
9	mg	O
10	/	O
11	kg	O
12	p	O
13	-	O
14	xylene	O
15	or	O
16	toluene	O
17	lasted	O
18	at	O
19	least	O
20	8	O
21	hr	O
22	,	O
23	while	O
24	the	O
25	effect	O
26	of	O
27	inhaled	O
28	p	O
29	-	O
30	xylene	O
31	dissipated	O
32	within	O
33	75	O
34	min	O
35	of	O
36	removal	O
37	from	O
38	the	O
39	exposure	O
40	.	O

1	PATIENTS	O
2	and	O
3	METHODS	O
4	:	O
5	Thallium	O
6	-	O
7	201	O
8	myocardial	O
9	scintigraphy	O
10	was	O
11	performed	O
12	at	O
13	rest	O
14	and	O
15	after	O
16	0	O
17	.	O
18	56	O
19	mg	O
20	/	O
21	kg	O
22	intravenous	O
23	dipyridamole	O
24	during	O
25	four	O
26	minutes	O
27	in	O
28	16	O
29	patients	O
30	with	O
31	sarcoidosis	O
32	.	O

1	The	O
2	incidence	O
3	of	O
4	cryptosporidiosis	O
5	in	O
6	young	O
7	children	O
8	was	O
9	determined	O
10	by	O
11	staining	O
12	of	O
13	faecal	O
14	specimens	O
15	with	O
16	a	O
17	modified	O
18	Kinyoun	O
19	stain	O
20	.	O

1	Seven	O
2	patients	O
3	(	O
4	8	O
5	.	O
6	3	O
7	percent	O
8	)	O
9	had	O
10	latent	O
11	hypothyroidism	O
12	only	O
13	discovered	O
14	by	O
15	hormonal	O
16	determinations	O
17	.	O

1	A	O
2	Golgi	O
3	study	O
4	of	O
5	the	O
6	sixth	O
7	layer	O
8	of	O
9	the	O
10	cerebral	O
11	cortex	O
12	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	The	O
2	diagnosis	O
3	of	O
4	amyloidosis	O
5	was	O
6	determined	O
7	from	O
8	a	O
9	labial	O
10	salivary	O
11	gland	O
12	biopsy	O
13	.	O

1	Emergency	O
2	treatment	O
3	of	O
4	facial	O
5	and	O
6	maxillary	O
7	/	O
8	mandibular	O
9	injuries	O

1	This	O
2	brief	O
3	hypercapnic	O
4	challenge	O
5	induced	O
6	a	O
7	rapid	O
8	increase	O
9	in	O
10	CBF	O
11	in	O
12	the	O
13	absence	O
14	of	O
15	any	O
16	change	O
17	in	O
18	MABP	O
19	.	O

1	Osteocalcin	B
2	(	O
3	serum	B
4	bone	I
5	-	I
6	Gla	I
7	protein	I
8	,	O
9	sBGP	B
10	),	O
11	serum	B
12	alkaline	I
13	phosphatase	I
14	(	O
15	sAP	B
16	)	O
17	and	O
18	urinary	O
19	hydroxyproline	O
20	/	O
21	creatinine	O
22	ratio	O
23	(	O
24	uOH	O
25	-	O
26	Prol	O
27	/	O
28	creatinine	O
29	)	O
30	have	O
31	been	O
32	measured	O
33	in	O
34	21	O
35	patients	O
36	with	O
37	primary	O
38	hyperparathyroidism	O
39	(	O
40	PHPT	O
41	)	O
42	and	O
43	in	O
44	nine	O
45	patients	O
46	with	O
47	hypercalcaemia	O
48	of	O
49	malignancy	O
50	(	O
51	HM	O
52	).	O

1	All	O
2	patients	O
3	then	O
4	received	O
5	suxamethonium	O
6	1	O
7	.	O
8	5	O
9	mg	O
10	kg	O
11	-	O
12	1	O
13	i	O
14	.	O
15	v	O
16	.	O

1	The	O
2	highest	O
3	postoperative	O
4	CK	B
5	-	I
6	MB	I
7	level	O
8	was	O
9	less	O
10	after	O
11	BC	O
12	(	O
13	BC	O
14	,	O
15	31	O
16	+/-	O
17	17	O
18	U	O
19	/	O
20	L	O
21	;	O
22	CC	O
23	,	O
24	56	O
25	+/-	O
26	13	O
27	U	O
28	/	O
29	L	O
30	;	O
31	p	O
32	less	O
33	than	O
34	0	O
35	.	O
36	05	O
37	).	O

1	High	O
2	trough	O
3	serum	O
4	TOB	O
5	concentrations	O
6	were	O
7	associated	O
8	with	O
9	death	O
10	and	O
11	very	O
12	low	O
13	levels	O
14	with	O
15	recovery	O
16	.	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	The	O
2	N	O
3	-	O
4	terminal	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	Mop	B
10	has	O
11	sequence	O
12	homology	O
13	with	O
14	DNA	O
15	binding	O
16	proteins	O
17	.	O

1	Acute	O
2	inhalation	O
3	toxicity	O
4	of	O
5	T	O
6	-	O
7	2	O
8	mycotoxin	O
9	in	O
10	mice	O
11	.	O

1	Similarly	O
2	,	O
3	actuarial	O
4	interpretations	O
5	for	O
6	the	O
7	second	O
8	protocols	O
9	were	O
10	not	O
11	more	O
12	frequently	O
13	selected	O
14	by	O
15	therapists	O
16	as	O
17	more	O
18	valid	O
19	,	O
20	regardless	O
21	of	O
22	treatment	O
23	condition	O
24	and	O
25	elevation	O
26	of	O
27	the	O
28	F	O
29	and	O
30	F	O
31	-	O
32	K	O
33	indices	O
34	on	O
35	the	O
36	first	O
37	MMPI	O
38	profile	O
39	.	O

1	The	O
2	study	O
3	disclosed	O
4	generalized	O
5	atrophy	O
6	and	O
7	diffuse	O
8	symmetric	O
9	white	O
10	matter	O
11	hypodensities	O
12	.	O

1	The	O
2	diagnosis	O
3	of	O
4	metachromatic	O
5	leukodystrophy	O
6	(	O
7	MLD	O
8	)	O
9	was	O
10	confirmed	O
11	by	O
12	the	O
13	finding	O
14	of	O
15	low	O
16	arylsulfatase	B
17	A	I
18	(	O
19	ASA	B
20	)	O
21	levels	O
22	in	O
23	cultured	O
24	fibroblasts	O
25	in	O
26	both	O
27	sisters	O
28	.	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	Thus	O
2	,	O
3	a	O
4	negative	O
5	test	O
6	is	O
7	compatible	O
8	with	O
9	low	O
10	disease	O
11	activity	O
12	and	O
13	/	O
14	or	O
15	efficacy	O
16	of	O
17	calcium	O
18	antagonist	O
19	treatment	O
20	.	O

1	The	O
2	nucleotide	O
3	sequences	O
4	of	O
5	the	O
6	human	B
7	and	I
8	murine	I
9	ornithine	I
10	decarboxylase	I
11	mRNAs	I
12	share	O
13	an	O
14	85	O
15	%	O
16	homology	O
17	,	O
18	even	O
19	in	O
20	their	O
21	3	O
22	'-	O
23	noncoding	O
24	regions	O
25	.	O

1	Cell	O
2	.	O

1	In	O
2	the	O
3	normal	O
4	,	O
5	basal	O
6	(	O
7	unstimulated	O
8	)	O
9	condition	O
10	there	O
11	were	O
12	no	O
13	significant	O
14	correlations	O
15	(	O
16	p	O
17	greater	O
18	than	O
19	0	O
20	.	O
21	05	O
22	)	O
23	between	O
24	the	O
25	systolic	O
26	blood	O
27	pressure	O
28	and	O
29	dopamine	O
30	(	O
31	r	O
32	=	O
33	0	O
34	.	O
35	09	O
36	),	O
37	norepinephrine	O
38	(	O
39	r	O
40	=	O
41	0	O
42	.	O
43	26	O
44	),	O
45	or	O
46	epinephrine	O
47	(	O
48	r	O
49	=	O
50	0	O
51	.	O
52	27	O
53	),	O
54	nor	O
55	were	O
56	there	O
57	significant	O
58	correlations	O
59	between	O
60	melatonin	O
61	and	O
62	dopamine	O
63	(	O
64	r	O
65	=	O
66	-	O
67	0	O
68	.	O
69	01	O
70	),	O
71	norepinephrine	O
72	(	O
73	r	O
74	=	O
75	-	O
76	0	O
77	.	O
78	26	O
79	),	O
80	or	O
81	growth	B
82	hormone	I
83	(	O
84	r	O
85	=	O
86	0	O
87	.	O
88	17	O
89	).	O

1	The	O
2	4	O
3	patients	O
4	with	O
5	carboxyhemoglobin	B
6	levels	O
7	in	O
8	excess	O
9	of	O
10	10	O
11	%	O
12	may	O
13	represent	O
14	occult	O
15	carbon	O
16	monoxide	O
17	poisoning	O
18	in	O
19	this	O
20	population	O
21	.	O

1	Hypoglycemic	O
2	action	O
3	of	O
4	"	O
5	he	O
6	xiang	O
7	zhuang	O
8	qi	O
9	gong	O
10	"	O
11	and	O
12	its	O
13	mechanism	O
14	on	O
15	diabetes	O
16	mellitus	O

1	Comparison	O
2	of	O
3	patients	O
4	receiving	O
5	phenytoin	O
6	and	O
7	those	O
8	who	O
9	were	O
10	not	O
11	showed	O
12	significantly	O
13	lower	O
14	serum	O
15	folate	O
16	in	O
17	the	O
18	sub	O
19	-	O
20	group	O
21	receiving	O
22	phenytoin	O
23	,	O
24	but	O
25	there	O
26	was	O
27	no	O
28	significant	O
29	difference	O
30	between	O
31	the	O
32	sub	O
33	-	O
34	groups	O
35	with	O
36	respect	O
37	to	O
38	vitamin	O
39	B12	O
40	or	O
41	behaviour	O
42	problem	O
43	rating	O
44	.	O

1	Effects	O
2	of	O
3	a	O
4	low	O
5	-	O
6	energy	O
7	laser	O
8	beam	O
9	on	O
10	the	O
11	cells	O
12	of	O
13	the	O
14	newt	O
15	embryo	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	less	O
6	antidopaminergic	O
7	activity	O
8	of	O
9	RHAL	O
10	in	O
11	this	O
12	neuroleptic	O
13	test	O
14	might	O
15	be	O
16	explained	O
17	by	O
18	the	O
19	lesser	O
20	conversion	O
21	of	O
22	RHAL	O
23	to	O
24	HAL	O
25	.	O

1	In	O
2	vivo	O
3	epiluminescence	O
4	microscopy	O
5	of	O
6	pigmented	O
7	skin	O
8	lesions	O
9	.	O

1	Endurance	O
2	training	O
3	resulted	O
4	in	O
5	an	O
6	increase	O
7	of	O
8	stiffness	O
9	associated	O
10	with	O
11	a	O
12	decrease	O
13	of	O
14	type	O
15	II	O
16	fibers	O
17	.	O

1	Two	O
2	new	O
3	glucosidase	B
4	inhibitors	O
5	(	O
6	BAY	O
7	m	O
8	1099	O
9	and	O
10	BAY	O
11	o	O
12	1248	O
13	)	O
14	were	O
15	studied	O
16	in	O
17	volunteers	O
18	and	O
19	type	O
20	II	O
21	diabetics	O
22	under	O
23	various	O
24	conditions	O
25	.	O

1	The	O
2	effect	O
3	of	O
4	a	O
5	beta	B
6	-	I
7	adrenoceptor	I
8	antagonist	O
9	,	O
10	pindolol	O
11	,	O
12	on	O
13	uterine	O
14	smooth	O
15	muscle	O
16	in	O
17	term	O
18	pregnant	O
19	women	O
20	was	O
21	studied	O
22	in	O
23	vitro	O
24	and	O
25	in	O
26	vivo	O
27	(	O
28	in	O
29	hypertensive	O
30	women	O
31	).	O

1	49	O
2	,	O
3	XXXXY	O
4	chromosome	O
5	anomaly	O
6	:	O
7	an	O
8	unusual	O
9	variant	O
10	of	O
11	Klinefelter	O
12	'	O
13	s	O
14	syndrome	O
15	.	O

1	The	O
2	effect	O
3	of	O
4	L	O
5	-	O
6	methionine	O
7	supplementation	O
8	on	O
9	the	O
10	utilization	O
11	of	O
12	a	O
13	soy	O
14	protein	O
15	isolate	O
16	(	O
17	SPI	O
18	)	O
19	was	O
20	evaluated	O
21	by	O
22	short	O
23	-	O
24	term	O
25	nitrogen	O
26	balance	O
27	studies	O
28	in	O
29	young	O
30	women	O
31	.	O

1	Adhesion	O
2	,	O
3	phagocytosis	O
4	,	O
5	chemotactic	O
6	and	O
7	random	O
8	migration	O
9	,	O
10	nitroblue	O
11	tetrazolium	O
12	dye	O
13	reduction	O
14	of	O
15	peritoneal	O
16	exudate	O
17	neutrophils	O
18	and	O
19	macrophages	O
20	,	O
21	fibrinogen	B
22	level	O
23	,	O
24	gelation	O
25	of	O
26	soluble	O
27	fibrin	B
28	and	O
29	serial	O
30	dilution	O
31	protamine	O
32	sulfate	O
33	test	O
34	were	O
35	investigated	O
36	in	O
37	115	O
38	New	O
39	Zealand	O
40	white	O
41	rabbits	O
42	with	O
43	experimentally	O
44	induced	O
45	Shwartzman	O
46	phenomenon	O
47	in	O
48	the	O
49	colon	O
50	,	O
51	and	O
52	in	O
53	control	O
54	animals	O
55	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	nerve	O
6	and	O
7	roots	O
8	differ	O
9	considerably	O
10	both	O
11	in	O
12	the	O
13	force	O
14	they	O
15	sustain	O
16	before	O
17	failure	O
18	and	O
19	in	O
20	the	O
21	other	O
22	biomechanics	O
23	they	O
24	exhibit	O
25	.	O

1	On	O
2	transition	O
3	from	O
4	high	O
5	to	O
6	low	O
7	voltage	O
8	there	O
9	was	O
10	a	O
11	significant	O
12	fall	O
13	in	O
14	arterial	O
15	pressure	O
16	(	O
17	7	O
18	%)	O
19	and	O
20	an	O
21	increase	O
22	in	O
23	flow	O
24	(	O
25	19	O
26	-	O
27	38	O
28	%)	O
29	to	O
30	areas	O
31	of	O
32	the	O
33	brain	O
34	corresponding	O
35	to	O
36	the	O
37	arborization	O
38	of	O
39	the	O
40	reticular	O
41	formation	O
42	,	O
43	i	O
44	.	O
45	e	O
46	.	O
47	excluding	O
48	the	O
49	cerebrum	O
50	and	O
51	cerebellum	O
52	.	O

1	Two	O
2	studies	O
3	assessed	O
4	two	O
5	types	O
6	of	O
7	reliability	O
8	of	O
9	the	O
10	student	O
11	Jenkins	O
12	Activity	O
13	Survey	O
14	(	O
15	JAS	O
16	;	O
17	a	O
18	questionnaire	O
19	measure	O
20	of	O
21	Type	O
22	A	O
23	behavior	O
24	).	O

1	Possibilities	O
2	and	O
3	outlook	O
4	for	O
5	wrist	O
6	joint	O
7	endoprosthesis	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	during	O
6	pregnancy	O
7	there	O
8	are	O
9	increases	O
10	in	O
11	bone	O
12	formation	O
13	rates	O
14	contributing	O
15	to	O
16	the	O
17	increases	O
18	in	O
19	skeletal	O
20	mass	O
21	.	O

1	Glucocorticoid	O
2	induced	O
3	hypertension	O
4	has	O
5	been	O
6	regarded	O
7	as	O
8	independent	O
9	of	O
10	sodium	O
11	(	O
12	Na	O
13	),	O
14	in	O
15	contrast	O
16	to	O
17	mineralocorticoid	O
18	induced	O
19	hypertension	O
20	,	O
21	which	O
22	is	O
23	Na	O
24	+-	O
25	dependent	O
26	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	An	O
2	exaggerated	O
3	tissue	O
4	response	O
5	adjacent	O
6	to	O
7	the	O
8	cyanoacrylate	O
9	site	O
10	suggested	O
11	a	O
12	potential	O
13	toxic	O
14	chemical	O
15	or	O
16	thermal	O
17	reaction	O
18	,	O
19	or	O
20	both	O
21	,	O
22	to	O
23	the	O
24	tissue	O
25	adhesive	O
26	,	O
27	but	O
28	there	O
29	was	O
30	no	O
31	evidence	O
32	of	O
33	any	O
34	distant	O
35	ocular	O
36	effects	O
37	.	O

1	Among	O
2	82	O
3	superficial	O
4	lesions	O
5	34	O
6	were	O
7	classified	O
8	as	O
9	showing	O
10	CR	O
11	and	O
12	another	O
13	23	O
14	as	O
15	showing	O
16	PR	O
17	,	O
18	with	O
19	a	O
20	response	O
21	rate	O
22	of	O
23	69	O
24	.	O
25	5	O
26	%.	O

1	Under	O
2	the	O
3	same	O
4	hematocrit	O
5	and	O
6	flow	O
7	conditions	O
8	,	O
9	the	O
10	rate	O
11	of	O
12	oxygen	O
13	saturation	O
14	decrease	O
15	was	O
16	significantly	O
17	higher	O
18	for	O
19	the	O
20	sickle	O
21	cells	O
22	than	O
23	for	O
24	normal	O
25	cells	O
26	.	O

1	These	O
2	fusion	O
3	proteins	O
4	also	O
5	allowed	O
6	the	O
7	localization	O
8	of	O
9	the	O
10	transcriptional	O
11	activation	O
12	and	O
13	DNA	O
14	binding	O
15	domains	O
16	of	O
17	the	O
18	ToxR	B
19	protein	I
20	to	O
21	its	O
22	cytoplasmically	O
23	located	O
24	N	O
25	-	O
26	terminal	O
27	portion	O
28	.	O

1	The	O
2	lethal	O
3	toxicity	O
4	of	O
5	inorganic	O
6	(	O
7	HgCl2	O
8	)	O
9	and	O
10	organic	O
11	(	O
12	CH3HgCl	O
13	)	O
14	mercury	O
15	chloride	O
16	was	O
17	compared	O
18	for	O
19	Coturnix	O
20	(	O
21	Japanese	O
22	quail	O
23	,	O
24	Coturnix	O
25	japonica	O
26	)	O
27	of	O
28	different	O
29	ages	O
30	from	O
31	hatch	O
32	through	O
33	adulthood	O
34	by	O
35	single	O
36	-	O
37	dose	O
38	acute	O
39	oral	O
40	and	O
41	intramuscular	O
42	injections	O
43	and	O
44	by	O
45	a	O
46	5	O
47	-	O
48	d	O
49	dietary	O
50	trial	O
51	.	O

1	Framingham	O
2	Type	O
3	A	O
4	behavior	O
5	was	O
6	positively	O
7	associated	O
8	with	O
9	diastolic	O
10	blood	O
11	pressure	O
12	(	O
13	r	O
14	=	O
15	0	O
16	.	O
17	17	O
18	,	O
19	p	O
20	less	O
21	than	O
22	0	O
23	.	O
24	05	O
25	)	O
26	among	O
27	the	O
28	women	O
29	.	O

1	The	O
2	M	B
3	reading	I
4	frame	I
5	differed	O
6	from	O
7	the	O
8	reported	O
9	sequence	O
10	by	O
11	a	O
12	single	O
13	nucleotide	O
14	corresponding	O
15	to	O
16	a	O
17	conservative	O
18	lysine	O
19	to	O
20	arginine	O
21	amino	O
22	acid	O
23	substitution	O
24	near	O
25	the	O
26	carboxy	O
27	-	O
28	terminus	O
29	conserved	O
30	among	O
31	the	O
32	M	B
33	proteins	I
34	of	O
35	paramyxoviruses	O
36	.	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	Autotransplantation	O
2	of	O
3	a	O
4	vein	O
5	segment	O
6	with	O
7	valve	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	deep	O
13	vein	O
14	valvular	O
15	insufficiency	O
16	of	O
17	the	O
18	lower	O
19	extremity	O

1	This	O
2	is	O
3	based	O
4	on	O
5	partitioning	O
6	an	O
7	underlying	O
8	multivariate	O
9	normal	O
10	distribution	O
11	.	O

1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O

1	Inhibition	O
2	of	O
3	histalog	O
4	-	O
5	stimulated	O
6	gastric	O
7	secretion	O
8	by	O
9	40	O
10	749	O
11	RP	O
12	,	O
13	a	O
14	new	O
15	long	O
16	-	O
17	acting	O
18	gastric	O
19	antisecretory	O
20	agent	O
21	.	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	Chemotherapy	O
2	of	O
3	metastasizing	O
4	breast	O
5	cancer	O

1	Eleven	O
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O

1	A	O
2	high	O
3	efficacy	O
4	of	O
5	the	O
6	combined	O
7	use	O
8	of	O
9	nontoxic	O
10	doses	O
11	of	O
12	two	O
13	pharmaceuticals	O
14	:	O
15	cystamine	O
16	(	O
17	50	O
18	mg	O
19	/	O
20	kg	O
21	)	O
22	and	O
23	mexamine	O
24	(	O
25	25	O
26	mg	O
27	/	O
28	kg	O
29	)	O
30	under	O
31	the	O
32	conditions	O
33	of	O
34	short	O
35	-	O
36	term	O
37	exogenous	O
38	hypoxia	O
39	(	O
40	7	O
41	.	O
42	5	O
43	%	O
44	O2	O
45	)	O
46	was	O
47	found	O
48	in	O
49	(	O
50	CBA	O
51	X	O
52	C57Bl	O
53	)	O
54	F1	O
55	mice	O
56	.	O

1	Laboratory	O
2	pyrolyses	O
3	have	O
4	indeed	O
5	shown	O
6	that	O
7	PCBs	O
8	give	O
9	significant	O
10	yields	O
11	of	O
12	PCDFs	O
13	,	O
14	and	O
15	chlorobenzenes	O
16	give	O
17	both	O
18	PCDFs	O
19	and	O
20	PCDDs	O
21	.	O

1	In	O
2	a	O
3	blind	O
4	controlled	O
5	trial	O
6	,	O
7	15	O
8	patients	O
9	with	O
10	COCM	O
11	(	O
12	NYHA	O
13	II	O
14	-	O
15	III	O
16	)	O
17	with	O
18	sinus	O
19	rhythm	O
20	and	O
21	a	O
22	left	O
23	ventricular	O
24	ejection	O
25	fraction	O
26	(	O
27	LV	O
28	-	O
29	EF	O
30	)	O
31	of	O
32	34	O
33	.	O
34	5	O
35	+/-	O
36	2	O
37	.	O
38	6	O
39	%	O
40	received	O
41	consecutively	O
42	D	O
43	(	O
44	0	O
45	.	O
46	25	O
47	-	O
48	0	O
49	.	O
50	5	O
51	mg	O
52	/	O
53	d	O
54	),	O
55	placebo	O
56	(	O
57	PLAC	O
58	),	O
59	P	O
60	(	O
61	slow	O
62	releases	O
63	=	O
64	SR	O
65	)	O
66	(	O
67	80	O
68	mg	O
69	/	O
70	d	O
71	SR	O
72	)	O
73	and	O
74	both	O
75	drugs	O
76	combined	O
77	in	O
78	respective	O
79	doses	O
80	.	O

1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O

1	The	O
2	possible	O
3	origin	O
4	and	O
5	role	O
6	of	O
7	CSF	B
8	prolactin	I
9	are	O
10	discussed	O
11	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	five	O
7	different	O
8	(	O
9	and	O
10	partially	O
11	overlapping	O
12	)	O
13	sry	B
14	messenger	I
15	RNAs	I
16	detectable	O
17	in	O
18	early	O
19	embryos	O
20	are	O
21	initiated	O
22	at	O
23	three	O
24	separate	O
25	sites	O
26	,	O
27	each	O
28	directly	O
29	upstream	O
30	from	O
31	one	O
32	of	O
33	the	O
34	three	O
35	protein	O
36	-	O
37	coding	O
38	regions	O
39	,	O
40	designated	O
41	(	O
42	in	O
43	5	O
44	'	O
45	to	O
46	3	O
47	'	O
48	order	O
49	)	O
50	beta	O
51	,	O
52	alpha	O
53	and	O
54	delta	O
55	.	O

1	Chronic	O
2	thyroiditis	O
3	as	O
4	a	O
5	risk	O
6	factor	O
7	of	O
8	B	O
9	-	O
10	cell	O
11	lymphoma	O
12	in	O
13	the	O
14	thyroid	O
15	gland	O
16	.	O

1	The	O
2	financial	O
3	impact	O
4	of	O
5	childhood	O
6	asthma	O
7	has	O
8	not	O
9	been	O
10	assessed	O
11	since	O
12	Vance	O
13	and	O
14	Taylor	O
15	reported	O
16	their	O
17	data	O
18	in	O
19	Annals	O
20	of	O
21	Allergy	O
22	13	O
23	years	O
24	ago	O
25	.	O

1	Hypersplenism	O

1	No	O
2	consistent	O
3	correlation	O
4	between	O
5	blood	O
6	pressure	O
7	change	O
8	and	O
9	SCR	O
10	-	O
11	change	O
12	was	O
13	seen	O
14	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	both	O
6	in	O
7	the	O
8	early	O
9	stages	O
10	(	O
11	0T	O
12	,	O
13	0N	O
14	)	O
15	and	O
16	in	O
17	more	O
18	severe	O
19	stages	O
20	of	O
21	VWF	O
22	(	O
23	stages	O
24	1	O
25	-	O
26	2	O
27	)	O
28	cold	O
29	induced	O
30	hyperreactivity	O
31	in	O
32	the	O
33	digital	O
34	vessels	O
35	and	O
36	Raynaud	O
37	'	O
38	s	O
39	syndrome	O
40	are	O
41	vascular	O
42	disorders	O
43	of	O
44	functional	O
45	origin	O
46	occurring	O
47	without	O
48	any	O
49	prethrombotic	O
50	alterations	O
51	.	O

1	However	O
2	,	O
3	kidneys	O
4	perfused	O
5	for	O
6	72	O
7	hr	O
8	demonstrated	O
9	more	O
10	similar	O
11	renal	O
12	functions	O
13	when	O
14	tested	O
15	by	O
16	either	O
17	IMPK	O
18	or	O
19	IBPK	O
20	.	O

1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O

1	In	O
2	metastasis	O
3	-	O
4	free	O
5	patients	O
6	,	O
7	the	O
8	best	O
9	results	O
10	were	O
11	obtained	O
12	with	O
13	tumor	O
14	diameters	O
15	under	O
16	2	O
17	cm	O
18	regardless	O
19	of	O
20	their	O
21	localization	O
22	in	O
23	lung	O
24	tissue	O
25	and	O
26	with	O
27	2	O
28	--	O
29	4	O
30	.	O
31	9	O
32	cm	O
33	tumors	O
34	embedded	O
35	in	O
36	lung	O
37	parenchyma	O
38	.	O

1	Since	O
2	1970	O
3	the	O
4	frequency	O
5	of	O
6	potassium	O
7	-	O
8	induced	O
9	ulceration	O
10	has	O
11	been	O
12	low	O
13	--	O
14	3	O
15	cases	O
16	per	O
17	100	O
18	000	O
19	patient	O
20	-	O
21	years	O
22	of	O
23	slow	O
24	-	O
25	release	O
26	tablet	O
27	use	O
28	.	O

1	Hydrocortisone	O
2	caused	O
3	lymphopenia	O
4	and	O
5	inhibited	O
6	the	O
7	blastogenic	O
8	response	O
9	of	O
10	peripheral	O
11	blood	O
12	lymphocytes	O
13	to	O
14	phytohemagglutinin	B
15	and	O
16	concanavalin	B
17	A	I
18	mitogens	O
19	.	O

1	To	O
2	test	O
3	the	O
4	feasibility	O
5	of	O
6	using	O
7	liposomes	O
8	to	O
9	deliver	O
10	therapeutic	O
11	agents	O
12	to	O
13	the	O
14	lungs	O
15	,	O
16	the	O
17	effect	O
18	of	O
19	liposome	O
20	-	O
21	encapsulated	O
22	superoxide	B
23	dismutase	I
24	(	O
25	SOD	B
26	)	O
27	or	O
28	catalase	B
29	on	O
30	pulmonary	O
31	oxygen	O
32	toxicity	O
33	was	O
34	studied	O
35	in	O
36	rats	O
37	.	O

1	Marrow	O
2	cell	O
3	necrosis	O
4	in	O
5	anorexia	O
6	nervosa	O
7	and	O
8	involuntary	O
9	starvation	O
10	.	O

1	55	O
2	+/-	O
3	11	O
4	%),	O
5	all	O
6	other	O
7	parameters	O
8	showed	O
9	a	O
10	significant	O
11	increase	O
12	:	O
13	RS	O
14	index	O
15	5	O
16	.	O
17	4	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	mVolt	O
23	to	O
24	6	O
25	.	O
26	0	O
27	+/-	O
28	1	O
29	.	O
30	7	O
31	mVolt	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	01	O
39	);	O
40	EDD	O
41	6	O
42	.	O
43	3	O
44	+/-	O
45	0	O
46	.	O
47	7	O
48	to	O
49	6	O
50	.	O
51	8	O
52	+/-	O
53	0	O
54	.	O
55	9	O
56	cm	O
57	(	O
58	p	O
59	less	O
60	than	O
61	0	O
62	.	O
63	001	O
64	);	O
65	HV	O
66	1017	O
67	+/-	O
68	151	O
69	ml	O
70	to	O
71	1099	O
72	+/-	O
73	261	O
74	ml	O
75	(	O
76	p	O
77	less	O
78	than	O
79	0	O
80	.	O
81	01	O
82	);	O
83	EDV	O
84	371	O
85	+/-	O
86	131	O
87	ml	O
88	to	O
89	441	O
90	+/-	O
91	175	O
92	ml	O
93	(	O
94	p	O
95	less	O
96	than	O
97	0	O
98	.	O
99	001	O
100	);	O
101	RBV	O
102	117	O
103	+/-	O
104	57	O
105	ml	O
106	to	O
107	151	O
108	+/-	O
109	77	O
110	ml	O
111	(	O
112	p	O
113	less	O
114	than	O
115	0	O
116	.	O
117	001	O
118	).	O

1	Individual	O
2	alcohol	O
3	reaction	O
4	profiles	O
5	.	O

1	A	O
2	high	O
3	degree	O
4	of	O
5	correlation	O
6	in	O
7	the	O
8	sense	O
9	of	O
10	the	O
11	classic	O
12	conception	O
13	of	O
14	brain	O
15	localization	O
16	of	O
17	neuropsychological	O
18	syndromes	O
19	was	O
20	found	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	B
22	triglyceride	I
23	lipase	I
24	activity	O
25	.	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	O
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	:	O
6	1	O
7	)	O
8	the	O
9	initial	O
10	response	O
11	to	O
12	tethering	O
13	varies	O
14	according	O
15	to	O
16	previous	O
17	penning	O
18	and	O
19	handling	O
20	experience	O
21	,	O
22	2	O
23	)	O
24	although	O
25	the	O
26	circadian	O
27	rhythm	O
28	of	O
29	cortisol	O
30	was	O
31	either	O
32	altered	O
33	or	O
34	disrupted	O
35	during	O
36	estrus	O
37	,	O
38	such	O
39	disruptions	O
40	were	O
41	not	O
42	influenced	O
43	by	O
44	type	O
45	of	O
46	penning	O
47	and	O
48	3	O
49	)	O
50	tether	O
51	stalls	O
52	may	O
53	chronically	O
54	increase	O
55	cortisol	O
56	concentrations	O
57	in	O
58	gilts	O
59	.	O

1	This	O
2	study	O
3	indicated	O
4	that	O
5	the	O
6	Japanese	O
7	quail	O
8	was	O
9	less	O
10	sensitive	O
11	to	O
12	particulate	O
13	Mn3O4	O
14	exposure	O
15	than	O
16	rodents	O
17	treated	O
18	comparably	O
19	.	O

1	Monitoring	O
2	changes	O
3	in	O
4	the	O
5	heart	O
6	rate	O
7	of	O
8	the	O
9	premature	O
10	fetus	O
11	during	O
12	tocolysis	O
13	with	O
14	the	O
15	beta	O
16	-	O
17	adrenomimetics	O
18	partusisten	O
19	and	O
20	Pre	O
21	-	O
22	par	O

1	Visidex	O
2	I	O
3	is	O
4	unsuitable	O
5	for	O
6	storage	O
7	and	O
8	re	O
9	-	O
10	reading	O
11	.	O

1	The	O
2	Cox	O
3	proportional	O
4	hazards	O
5	model	O
6	was	O
7	applied	O
8	to	O
9	the	O
10	data	O
11	in	O
12	order	O
13	to	O
14	determine	O
15	the	O
16	prognostic	O
17	factors	O
18	for	O
19	long	O
20	-	O
21	term	O
22	survival	O
23	.	O

1	National	O
2	Institutes	O
3	of	O
4	Health	O
5	Consensus	O
6	Development	O
7	Conference	O
8	Statement	O
9	.	O

1	Twenty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	80	O
7	,	O
8	6	O
9	%)	O
10	with	O
11	mixed	O
12	neoplasms	O
13	were	O
14	operated	O
15	on	O
16	by	O
17	total	O
18	conservative	O
19	parotidectomy	O
20	(	O
21	T	O
22	.	O
23	C	O
24	.	O
25	P	O
26	.),	O
27	3	O
28	(	O
29	9	O
30	,	O
31	7	O
32	%)	O
33	by	O
34	S	O
35	.	O
36	P	O
37	.	O
38	and	O
39	3	O
40	(	O
41	9	O
42	,	O
43	7	O
44	%)	O
45	by	O
46	En	O
47	.	O

1	The	O
2	weak	O
3	relationships	O
4	between	O
5	F	O
6	and	O
7	Zn	O
8	to	O
9	Mg	O
10	clearly	O
11	have	O
12	no	O
13	significant	O
14	effect	O
15	on	O
16	the	O
17	contents	O
18	of	O
19	these	O
20	elements	O
21	in	O
22	bone	O
23	.	O

1	Although	O
2	no	O
3	differences	O
4	were	O
5	noted	O
6	in	O
7	the	O
8	decrease	O
9	in	O
10	platelet	O
11	counts	O
12	between	O
13	the	O
14	two	O
15	groups	O
16	,	O
17	fibrinogen	B
18	levels	O
19	and	O
20	alpha	B
21	2	I
22	-	I
23	antiplasmin	I
24	levels	O
25	declined	O
26	less	O
27	drastically	O
28	in	O
29	the	O
30	antithrombin	B
31	-	O
32	treated	O
33	group	O
34	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	The	O
2	recommendation	O
3	is	O
4	made	O
5	that	O
6	specific	O
7	sub	O
8	-	O
9	groups	O
10	of	O
11	attempters	O
12	need	O
13	to	O
14	be	O
15	identified	O
16	and	O
17	may	O
18	warrant	O
19	specialized	O
20	intervention	O
21	strategies	O
22	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	secretor	O
7	status	O
8	and	O
9	clinical	O
10	status	O
11	,	O
12	spirometry	O
13	measurements	O
14	,	O
15	salivary	B
16	and	I
17	serum	I
18	lysozyme	I
19	levels	O
20	or	O
21	rates	O
22	of	O
23	respiratory	O
24	tract	O
25	colonization	O
26	with	O
27	P	O
28	.	O
29	aeruginosa	O
30	and	O
31	S	O
32	.	O
33	aureus	O
34	.	O

1	Gains	O
2	increased	O
3	3	O
4	.	O
5	5	O
6	%	O
7	(	O
8	P	O
9	less	O
10	than	O
11	.	O
12	10	O
13	)	O
14	and	O
15	feed	O
16	conversion	O
17	improved	O
18	5	O
19	.	O
20	9	O
21	%	O
22	(	O
23	P	O
24	less	O
25	than	O
26	.	O
27	07	O
28	)	O
29	in	O
30	steers	O
31	fed	O
32	.	O
33	28	O
34	%	O
35	AS	O
36	-	O
37	VFA	O
38	compared	O
39	with	O
40	gain	O
41	and	O
42	feed	O
43	conversion	O
44	of	O
45	the	O
46	control	O
47	steers	O
48	.	O

1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O

1	Renal	O
2	excretion	O
3	of	O
4	sulphadimidine	O
5	in	O
6	normal	O
7	and	O
8	uraemic	O
9	subjects	O
10	.	O

1	Experiences	O
2	with	O
3	the	O
4	clinical	O
5	and	O
6	experimental	O
7	use	O
8	of	O
9	Urat	O
10	-	O
11	I	O
12	lithotriptor	O
13	.	O

1	Formation	O
2	of	O
3	hyphae	O
4	and	O
5	chlamydospores	O
6	by	O
7	Cryptococcus	O
8	laurentii	O
9	.	O

1	Studies	O
2	on	O
3	alcoholic	O
4	liver	O
5	injury	O
6	.	O

1	Prevention	O
2	of	O
3	maternal	O
4	Rh	O
5	sensitization	O
6	:	O
7	anti	B
8	-	I
9	Rh	I
10	immune	I
11	globulin	I
12	.	O

1	Cerebrospinal	O
2	fluid	O
3	transferrin	B
4	II	I
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	High	O
2	dosages	O
3	of	O
4	D	O
5	-	O
6	penicillamine	O
7	in	O
8	pulmonary	O
9	fibroses	O

1	Laboratory	O
2	aspects	O
3	with	O
4	particular	O
5	reference	O
6	to	O
7	chemotherapy	O
8	and	O
9	control	O
10	.	O

1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O

1	Therapeutic	O
2	action	O
3	of	O
4	a	O
5	new	O
6	antibiotic	O
7	-	O
8	corticoid	O
9	association	O
10	used	O
11	for	O
12	instillations	O
13	in	O
14	otology	O

1	Clinico	O
2	-	O
3	physiological	O
4	experiment	O

1	Absence	O
2	of	O
3	action	O
4	potentials	O
5	in	O
6	frog	O
7	slow	O
8	muscle	O
9	fibres	O
10	paralysed	O
11	by	O
12	botulinum	B
13	toxin	I
14	.	O

1	A	O
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	B
7	receptors	I
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O

1	Kinetics	O
2	of	O
3	calcium	O
4	metabolism	O
5	.	O

1	Problems	O
2	common	O
3	to	O
4	pediatrics	O
5	and	O
6	anesthesiology	O

1	Treatment	O
2	and	O
3	care	O
4	of	O
5	adult	O
6	diabetes	O
7	mellitus	O
8	without	O
9	coma	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	I
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	Proceedings	O
2	:	O
3	Reversible	O
4	complete	O
5	heart	O
6	block	O
7	following	O
8	surgery	O
9	of	O
10	congenital	O
11	heart	O
12	defects	O

1	Blood	O
2	platelets	O
3	,	O
4	coagulation	O
5	factors	O
6	and	O
7	morphologic	O
8	organ	O
9	changes	O
10	following	O
11	scalding	O
12	shock	O
13	in	O
14	rhesus	O
15	monkeys	O

1	Temporal	O
2	relationships	O
3	and	O
4	the	O
5	development	O
6	phase	O
7	affected	O
8	.	O

1	Local	O
2	graft	O
3	irradiation	O
4	as	O
5	an	O
6	adjunct	O
7	to	O
8	pharmacologic	O
9	immunosuppression	O
10	.	O

1	Role	O
2	of	O
3	biocenosis	O
4	in	O
5	the	O
6	manifestation	O
7	of	O
8	Shigella	O
9	virulence	O

1	Cortical	O
2	afferents	O
3	to	O
4	the	O
5	entorhinal	O
6	cortex	O
7	of	O
8	the	O
9	Rhesus	O
10	monkey	O
11	.	O

1	Benign	O
2	intramural	O
3	tumors	O
4	of	O
5	the	O
6	esophagus	O

1	Methyl	O
2	mercury	O
3	intoxication	O
4	in	O
5	rat	O
6	kidneys	O
7	.	O

1	Compensative	O
2	justice	O
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	Estimation	O
2	of	O
3	renin	B
4	secretion	O
5	rate	O
6	and	O
7	renal	O
8	plasma	O
9	flow	O
10	from	O
11	peripheral	O
12	and	O
13	renal	B
14	vein	I
15	renin	I
16	levels	O
17	.	O

1	Disability	O
2	insurance	O
3	under	O
4	social	O
5	security	O
6	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	Lack	O
2	of	O
3	effect	O
4	of	O
5	the	O
6	appetite	O
7	stimulant	O
8	pizotifen	O
9	(	O
10	BC	O
11	105	O
12	)	O
13	on	O
14	the	O
15	absorption	O
16	of	O
17	isonicotinylhydrazine	O
18	.	O

1	Study	O
2	of	O
3	antinuclear	O
4	autoantibodies	O
5	by	O
6	immunofluorescence	O
7	technic	O
8	in	O
9	collagen	B
10	diseases	O

1	Labial	O
2	bar	O
3	.	O

1	The	O
2	metabolism	O
3	and	O
4	pharmacology	O
5	of	O
6	5	O
7	-	O
8	fluorouracil	O
9	.	O

1	Effects	O
2	of	O
3	temperature	O
4	and	O
5	moulting	O
6	cycle	O
7	on	O
8	melanin	O
9	synthesis	O
10	in	O
11	the	O
12	newt	O
13	,	O
14	Triturus	O
15	cristatus	O
16	.	O

1	A	O
2	comparative	O
3	study	O
4	of	O
5	the	O
6	cortical	O
7	end	O
8	of	O
9	the	O
10	auditory	O
11	analyzer	O
12	during	O
13	postnatal	O
14	ontogenesis	O
15	in	O
16	lower	O
17	monkeys	O
18	and	O
19	man	O

1	Nitrogen	O
2	-	O
3	hydrogen	O
4	tautomerism	O
5	in	O
6	porphyrins	O
7	and	O
8	chlorins	O
9	.	O

1	Angiography	O
2	of	O
3	aneurysmal	O
4	bone	O
5	cyst	O
6	.	O

1	Successful	O
2	treatment	O
3	of	O
4	candidiasis	O
5	with	O
6	transfer	B
7	factor	I
8	.	O

1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	The	O
2	status	O
3	of	O
4	education	O
5	and	O
6	training	O
7	programs	O
8	in	O
9	speech	O
10	pathology	O
11	and	O
12	audiology	O
13	--	O
14	1971	O
15	-	O
16	72	O
17	.	O

1	I	O
2	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pathologic	O
5	scars	O
6	of	O
7	myocardial	O
8	infarct	O

1	Sinusoidal	O
2	oscillations	O
3	of	O
4	a	O
5	gas	O
6	dilution	O
7	indicator	O

1	Successive	O
2	abdominal	O
3	scintillation	O
4	with	O
5	131	O
6	-	O
7	I	O
8	-	O
9	tagged	O
10	BSP	O
11	--	O
12	description	O
13	of	O
14	the	O
15	thyroid	O
16	gland	O
17	,	O
18	kidney	O
19	and	O
20	spleen	O
21	(	O
22	comparison	O
23	with	O
24	131	O
25	-	O
26	I	O
27	-	O
28	RB	O
29	)	O

1	Influence	O
2	of	O
3	cigarette	O
4	smoking	O
5	on	O
6	some	O
7	blood	O
8	coagulation	O
9	tests	O
10	.	O

1	Second	O
2	report	O
3	of	O
4	the	O
5	Norwegian	O
6	Cancer	O
7	Society	O
8	.	O

1	Comparative	O
2	study	O
3	on	O
4	acute	O
5	oral	O
6	overload	O
7	using	O
8	tolbutamide	O
9	and	O
10	tolazamide	O
11	in	O
12	normal	O
13	and	O
14	diabetic	O
15	subjects	O
16	.	O

1	Factors	O
2	influencing	O
3	in	O
4	vitro	O
5	skin	B
6	permeability	I
7	factor	I
8	production	O
9	by	O
10	Vibrio	O
11	cholerae	O
12	.	O

1	Pitfalls	O
2	in	O
3	the	O
4	use	O
5	of	O
6	chromosome	O
7	aberration	O
8	analysis	O
9	for	O
10	biological	O
11	radiation	O
12	dosimetry	O
13	.	O

1	The	O
2	effects	O
3	of	O
4	taloximine	O
5	and	O
6	aminophylline	O
7	on	O
8	isolated	O
9	human	O
10	smooth	O
11	muscle	O
12	.	O

1	The	O
2	exploratory	O
3	behaviour	O
4	in	O
5	normal	O
6	and	O
7	aggressive	O
8	mice	O
9	.	O

1	Genitography	O
2	in	O
3	intersexual	O
4	states	O
5	.	O

1	The	O
2	"	O
3	28	O
4	percent	O
5	"	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O

1	3	O
2	'-	O
3	Methyl	O
4	,	O
5	8	O
6	-	O
7	methyl	O
8	,	O
9	and	O
10	8	O
11	-	O
12	phenyl	O
13	derivatives	O
14	of	O
15	5	O
16	,	O
17	9	O
18	-	O
19	dimethyl	O
20	-	O
21	6	O
22	,	O
23	7	O
24	-	O
25	benzomorphans	O
26	.	O

1	Counter	O
2	-	O
3	current	O
4	heat	O
5	exchange	O
6	in	O
7	the	O
8	respiratory	O
9	passages	O
10	:	O
11	effect	O
12	on	O
13	water	O
14	and	O
15	heat	O
16	balance	O
17	.	O

1	Elimination	O
2	of	O
3	gamma	O
4	-	O
5	irradiation	O
6	induced	O
7	oxidation	O
8	in	O
9	aqueous	O
10	drug	O
11	preparations	O

1	Bimodal	O
2	cochlear	O
3	response	O
4	curves	O
5	in	O
6	rodents	O
7	.	O

1	CO2	O
2	assimilation	O
3	by	O
4	chloroplasts	O
5	illuminated	O
6	on	O
7	filter	O
8	paper	O
9	.	O

1	Foreign	O
2	profiles	O
3	in	O
4	air	O
5	pollution	O
6	control	O
7	activities	O
8	.	O

1	Effects	O
2	of	O
3	chronic	O
4	metaraminol	O
5	treatment	O
6	on	O
7	the	O
8	sympathetic	O
9	activity	O
10	of	O
11	intact	O
12	and	O
13	adrenal	O
14	demedullated	O
15	rats	O
16	kept	O
17	in	O
18	warm	O
19	or	O
20	cold	O
21	environments	O
22	.	O

1	Quantitation	O
2	of	O
3	exocrine	B
4	IgA	I
5	in	O
6	human	O
7	serum	O
8	in	O
9	health	O
10	and	O
11	disease	O
12	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	V	O
2	.	O

1	Morphogenesis	O
2	of	O
3	the	O
4	trochanter	O
5	produced	O
6	by	O
7	femoral	O
8	regeneration	O
9	in	O
10	the	O
11	phasmid	O
12	Carausius	O
13	morosus	O
14	Br	O

1	Two	O
2	Lab	O
3	8	O
4	computer	O
5	programmes	O
6	for	O
7	use	O
8	in	O
9	the	O
10	study	O
11	of	O
12	the	O
13	isometric	O
14	and	O
15	isotonic	O
16	contractile	O
17	characteristics	O
18	of	O
19	skeletal	O
20	muscle	O
21	.	O

1	Open	O
2	head	O
3	-	O
4	brain	O
5	injuries	O

1	The	O
2	modification	O
3	of	O
4	P32	O
5	uptake	O
6	into	O
7	the	O
8	Jensen	O
9	sarcoma	O
10	in	O
11	vitro	O
12	by	O
13	adding	O
14	of	O
15	peroxide	O
16	to	O
17	the	O
18	nutritive	O
19	medium	O

1	Nephrectomy	O
2	applied	O
3	to	O
4	cattle	O

1	Children	O
2	with	O
3	defective	O
4	vision	O

1	The	O
2	significance	O
3	of	O
4	structural	O
5	integrity	O
6	of	O
7	lymphoid	O
8	tissue	O
9	for	O
10	antibody	O
11	production	O
12	in	O
13	culture	O
14	in	O
15	vivo	O

1	Transformations	O
2	in	O
3	the	O
4	morphine	O
5	series	O
6	.	O

1	Caries	O
2	prevention	O
3	in	O
4	the	O
5	dental	O
6	office	O
7	.	O

1	Effect	O
2	of	O
3	castration	O
4	on	O
5	pituitary	B
6	and	I
7	serum	I
8	LH	I
9	and	O
10	FSH	B
11	in	O
12	testosterone	O
13	-	O
14	sterilized	O
15	rats	O
16	.	O

1	Effect	O
2	of	O
3	heparin	O
4	on	O
5	the	O
6	inactivation	O
7	of	O
8	serum	B
9	lipoprotein	I
10	lipase	I
11	by	O
12	the	O
13	liver	O
14	in	O
15	unanesthetized	O
16	dogs	O
17	.	O

1	On	O
2	the	O
3	character	O
4	of	O
5	changes	O
6	in	O
7	the	O
8	enzyme	O
9	activity	O
10	in	O
11	the	O
12	brain	O
13	tissue	O
14	during	O
15	reflex	O
16	epilepsy	O

1	Methoxyflurane	O
2	and	O
3	renal	O
4	function	O

1	On	O
2	the	O
3	diagnosis	O
4	of	O
5	bovine	O
6	leucosis	O
7	and	O
8	its	O
9	control	O
10	in	O
11	southern	O
12	Lower	O
13	Saxony	O

1	Studies	O
2	on	O
3	the	O
4	intracutaneous	O
5	infection	O
6	of	O
7	rabbits	O
8	by	O
9	Staphylococcus	O
10	aureus	O
11	.	O

1	Naphthalene	O
2	and	O
3	paradichlorobenzene	O
4	in	O
5	clinical	O
6	toxicology	O

1	Further	O
2	studies	O
3	on	O
4	a	O
5	"	O
6	new	O
7	"	O
8	human	O
9	isoprecipitin	B
10	system	O
11	(	O
12	Australia	O
13	antigen	O
14	).	O

1	The	O
2	3	O
3	-	O
4	hour	O
5	test	O
6	iodine	O
7	(	O
8	I	O
9	-	O
10	132	O
11	)	O
12	uptake	O
13	by	O
14	the	O
15	thyroid	O
16	in	O
17	children	O
18	with	O
19	growth	O
20	deficiency	O

1	Concussion	O
2	of	O
3	the	O
4	spinal	O
5	cord	O

1	Consanguinity	O
2	and	O
3	migration	O
4	in	O
5	the	O
6	marriages	O
7	of	O
8	the	O
9	region	O
10	of	O
11	Nunoa	O
12	,	O
13	Santiago	O
14	,	O
15	1850	O
16	-	O
17	1960	O

1	Further	O
2	observations	O
3	on	O
4	resorption	O
5	in	O
6	guinea	O
7	pigs	O
8	following	O
9	injections	O
10	of	O
11	trypan	O
12	blue	O
13	.	O

1	Retention	O
2	behavior	O
3	of	O
4	steroids	O
5	in	O
6	gas	O
7	chromatography	O
8	with	O
9	a	O
10	series	O
11	of	O
12	combination	O
13	columns	O
14	.	O

1	Two	O
2	hundred	O
3	forty	O
4	-	O
5	three	O
6	patients	O
7	have	O
8	received	O
9	WR	O
10	-	O
11	2721	O
12	in	O
13	Phase	O
14	I	O
15	-	O
16	II	O
17	studies	O
18	.	O

1	The	O
2	envelope	O
3	glycoproteins	O
4	of	O
5	Rous	O
6	sarcoma	O
7	virus	O
8	(	O
9	RSV	O
10	),	O
11	gp85	B
12	and	O
13	gp37	B
14	,	O
15	are	O
16	anchored	O
17	in	O
18	the	O
19	membrane	O
20	by	O
21	a	O
22	27	O
23	-	O
24	amino	O
25	acid	O
26	,	O
27	hydrophobic	O
28	domain	O
29	that	O
30	lies	O
31	adjacent	O
32	to	O
33	a	O
34	22	O
35	-	O
36	amino	O
37	acid	O
38	,	O
39	cytoplasmic	O
40	domain	O
41	at	O
42	the	O
43	carboxy	O
44	terminus	O
45	of	O
46	gp37	B
47	.	O

1	The	O
2	drug	O
3	was	O
4	given	O
5	in	O
6	a	O
7	daily	O
8	oral	O
9	dose	O
10	of	O
11	0	O
12	.	O
13	5	O
14	g	O
15	/	O
16	m2	O
17	,	O
18	3	O
19	.	O
20	5	O
21	h	O
22	prior	O
23	to	O
24	each	O
25	radiation	O
26	treatment	O
27	.	O

1	Mature	O
2	mRNA	O
3	for	O
4	cytosolic	B
5	phosphoenolpyruvate	I
6	carboxykinase	I
7	of	I
8	the	I
9	chicken	I
10	is	O
11	2	O
12	.	O
13	8	O
14	kilobases	O
15	in	O
16	length	O
17	,	O
18	similar	O
19	to	O
20	that	O
21	previously	O
22	noted	O
23	for	O
24	mRNA	O
25	coding	O
26	for	O
27	the	O
28	same	O
29	enzyme	O
30	in	O
31	the	O
32	rat	O
33	.	O

1	Upstream	O
2	activation	O
3	sites	O
4	of	O
5	the	O
6	CYC1	B
7	gene	I
8	of	O
9	Saccharomyces	O
10	cerevisiae	O
11	are	O
12	active	O
13	when	O
14	inverted	O
15	but	O
16	not	O
17	when	O
18	placed	O
19	downstream	O
20	of	O
21	the	O
22	"	O
23	TATA	O
24	box	O
25	".	O

1	The	O
2	results	O
3	presented	O
4	in	O
5	this	O
6	report	O
7	suggest	O
8	that	O
9	the	O
10	SV40	O
11	G	O
12	-	O
13	C	O
14	-	O
15	rich	O
16	sequences	O
17	can	O
18	function	O
19	as	O
20	independent	O
21	RNA	B
22	polymerase	I
23	II	I
24	transcriptional	O
25	-	O
26	control	O
27	elements	O
28	.	O

1	Propranolol	O
2	also	O
3	effectively	O
4	controlled	O
5	her	O
6	familial	O
7	tremor	O
8	.	O

1	Brief	O
2	report	O
3	.	O

1	Risk	O
2	of	O
3	HTLV	O
4	infection	O
5	in	O
6	patients	O
7	on	O
8	haemodialysis	O
9	.	O

1	Plasma	B
2	secretin	I
3	,	O
4	pancreozymin	B
5	,	O
6	and	O
7	somatostatin	B
8	-	I
9	like	I
10	hormone	I
11	in	O
12	chronic	O
13	renal	O
14	failure	O
15	patients	O
16	.	O

1	All	O
2	radiologists	O
3	using	O
4	the	O
5	machine	O
6	found	O
7	that	O
8	the	O
9	reporting	O
10	terminal	O
11	was	O
12	simple	O
13	to	O
14	operate	O
15	,	O
16	but	O
17	found	O
18	that	O
19	reporting	O
20	abnormalities	O
21	caused	O
22	an	O
23	increased	O
24	effort	O
25	and	O
26	took	O
27	a	O
28	longer	O
29	time	O
30	.	O

1	The	O
2	effect	O
3	of	O
4	echothiophate	O
5	on	O
6	the	O
7	biphasic	O
8	response	O
9	of	O
10	rabbit	O
11	ocular	O
12	pressure	O
13	to	O
14	dipivefrin	O
15	.	O

1	Unusual	O
2	course	O
3	of	O
4	plasmocytosis	O
5	.	O

1	These	O
2	fusions	O
3	are	O
4	contained	O
5	on	O
6	plasmids	O
7	which	O
8	have	O
9	both	O
10	yeast	O
11	and	O
12	E	O
13	.	O
14	coli	O
15	replication	O
16	origins	O
17	and	O
18	selectable	O
19	markers	O
20	and	O
21	,	O
22	therefore	O
23	,	O
24	can	O
25	be	O
26	used	O
27	to	O
28	transform	O
29	either	O
30	yeast	O
31	or	O
32	E	O
33	.	O
34	coli	O
35	cells	O
36	.	O

1	Therefore	O
2	,	O
3	it	O
4	was	O
5	concluded	O
6	that	O
7	thrombotic	O
8	tendency	O
9	certainly	O
10	existed	O
11	in	O
12	patients	O
13	with	O
14	MS	O
15	compared	O
16	to	O
17	those	O
18	with	O
19	non	O
20	RHD	O
21	and	O
22	that	O
23	it	O
24	was	O
25	one	O
26	of	O
27	the	O
28	causes	O
29	of	O
30	the	O
31	significantly	O
32	high	O
33	incidence	O
34	of	O
35	thromboembolism	O
36	in	O
37	comparison	O
38	with	O
39	non	O
40	RHD	O
41	.	O

1	Subdural	O
2	electrodes	O
3	may	O
4	yield	O
5	larger	O
6	VEP	O
7	amplitudes	O
8	than	O
9	skull	O
10	or	O
11	scalp	O
12	electrodes	O
13	.	O

1	Products	O
2	of	O
3	immune	O
4	cells	O
5	such	O
6	as	O
7	transfer	B
8	factor	I
9	and	O
10	lymphokines	O
11	form	O
12	the	O
13	third	O
14	and	O
15	possibly	O
16	most	O
17	important	O
18	group	O
19	of	O
20	immune	O
21	-	O
22	stimulating	O
23	agents	O
24	.	O

1	Five	O
2	of	O
3	the	O
4	patients	O
5	with	O
6	increased	O
7	L	O
8	-	O
9	L	O
10	size	O
11	had	O
12	a	O
13	normal	O
14	A	O
15	-	O
16	P	O
17	diameter	O
18	.	O

1	However	O
2	,	O
3	when	O
4	combined	O
5	with	O
6	mitomycin	O
7	C	O
8	given	O
9	with	O
10	1	O
11	to	O
12	5	O
13	-	O
14	days	O
15	interval	O
16	,	O
17	the	O
18	concurrent	O
19	administration	O
20	of	O
21	SPG	O
22	prolonged	O
23	significantly	O
24	the	O
25	life	O
26	-	O
27	span	O
28	of	O
29	the	O
30	tumor	O
31	-	O
32	bearing	O
33	mice	O
34	.	O

1	Fibrin	B
2	gels	O
3	and	O
4	their	O
5	possible	O
6	implication	O
7	for	O
8	surface	O
9	hemorheology	O
10	in	O
11	health	O
12	and	O
13	disease	O
14	.	O

1	Radiogallium	O
2	imaging	O
3	is	O
4	thus	O
5	of	O
6	limited	O
7	use	O
8	in	O
9	evaluation	O
10	of	O
11	suspected	O
12	giant	O
13	cell	O
14	tumors	O
15	of	O
16	bone	O
17	.	O

1	The	O
2	effect	O
3	of	O
4	treatment	O
5	may	O
6	thus	O
7	be	O
8	divided	O
9	into	O
10	two	O
11	main	O
12	phases	O
13	--	O
14	an	O
15	initial	O
16	phase	O
17	with	O
18	a	O
19	reduction	O
20	in	O
21	LV	O
22	mass	O
23	and	O
24	a	O
25	reduction	O
26	in	O
27	cardiac	O
28	output	O
29	and	O
30	no	O
31	change	O
32	in	O
33	total	O
34	peripheral	O
35	resistance	O
36	--	O
37	and	O
38	a	O
39	second	O
40	phase	O
41	with	O
42	a	O
43	constant	O
44	LV	O
45	mass	O
46	but	O
47	an	O
48	increase	O
49	in	O
50	cardiac	O
51	output	O
52	to	O
53	the	O
54	pretreatment	O
55	level	O
56	again	O
57	and	O
58	a	O
59	concomitant	O
60	decrease	O
61	in	O
62	total	O
63	peripheral	O
64	resistance	O
65	.	O

1	Selective	O
2	macrophage	O
3	inhibition	O
4	abolishes	O
5	warfarin	O
6	-	O
7	induced	O
8	reduction	O
9	of	O
10	metastasis	O
11	.	O

1	Thus	O
2	it	O
3	appears	O
4	that	O
5	insertion	O
6	of	O
7	a	O
8	transposable	O
9	element	O
10	near	O
11	the	O
12	5	O
13	'	O
14	terminus	O
15	of	O
16	the	O
17	structural	O
18	gene	O
19	can	O
20	produce	O
21	constitutive	O
22	expression	O
23	of	O
24	a	O
25	normally	O
26	glucose	O
27	-	O
28	repressed	O
29	enzyme	O
30	.	O

1	The	O
2	genome	O
3	of	O
4	avian	O
5	erythroblastosis	O
6	virus	O
7	contains	O
8	two	O
9	independently	O
10	expressed	O
11	genetic	O
12	loci	O
13	(	O
14	v	B
15	-	I
16	erbA	I
17	and	O
18	v	B
19	-	I
20	erbB	I
21	)	O
22	whose	O
23	activities	O
24	are	O
25	probably	O
26	responsible	O
27	for	O
28	oncogenesis	O
29	by	O
30	the	O
31	virus	O
32	.	O

1	Survey	O
2	on	O
3	antibody	O
4	against	O
5	egg	O
6	drop	O
7	syndrome	O
8	-	O
9	1976	O
10	virus	O
11	among	O
12	chicken	O
13	flocks	O
14	in	O
15	Japan	O
16	.	O

1	Two	O
2	mutations	O
3	that	O
4	affect	O
5	larval	B
6	cuticle	I
7	protein	I
8	gene	I
9	expression	O
10	in	O
11	the	O
12	2	O
13	/	O
14	3	O
15	variant	O
16	Drosophila	O
17	melanogaster	O
18	strain	O
19	were	O
20	investigated	O
21	.	O

1	The	O
2	ensembles	O
3	are	O
4	considered	O
5	to	O
6	be	O
7	one	O
8	of	O
9	the	O
10	forms	O
11	of	O
12	activity	O
13	of	O
14	the	O
15	structured	O
16	morphofunctional	O
17	cortical	O
18	units	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	columns	O
26	.	O

1	Lung	O
2	density	O
3	increased	O
4	in	O
5	quartz	O
6	-	O
7	exposed	O
8	,	O
9	but	O
10	not	O
11	in	O
12	volcanic	O
13	-	O
14	ash	O
15	-	O
16	exposed	O
17	animals	O
18	.	O

1	I	O
2	.	O

1	Viral	O
2	RNA	O
3	,	O
4	molecularly	O
5	cloned	O
6	proviral	O
7	DNA	O
8	,	O
9	and	O
10	virus	O
11	-	O
12	specific	O
13	protein	O
14	of	O
15	avian	O
16	retrovirus	O
17	MH2	O
18	were	O
19	analyzed	O
20	.	O

1	Plasmids	O
2	for	O
3	the	O
4	cloning	O
5	and	O
6	expression	O
7	of	O
8	full	O
9	-	O
10	length	O
11	double	O
12	-	O
13	stranded	O
14	cDNAs	O
15	under	O
16	control	O
17	of	O
18	the	O
19	SV40	B
20	early	I
21	or	O
22	late	B
23	gene	I
24	promoter	O
25	.	O

1	Supplementing	O
2	a	O
3	soybean	O
4	protein	O
5	and	O
6	sucrose	O
7	-	O
8	based	O
9	diet	O
10	with	O
11	levels	O
12	of	O
13	2	O
14	.	O
15	2	O
16	,	O
17	11	O
18	,	O
19	and	O
20	55	O
21	ppm	O
22	of	O
23	the	O
24	antibiotic	O
25	,	O
26	from	O
27	the	O
28	two	O
29	sources	O
30	each	O
31	with	O
32	two	O
33	different	O
34	purities	O
35	,	O
36	improved	O
37	weight	O
38	gain	O
39	of	O
40	chicks	O
41	an	O
42	average	O
43	of	O
44	23	O
45	%	O
46	and	O
47	improved	O
48	feed	O
49	efficiency	O
50	an	O
51	average	O
52	of	O
53	13	O
54	%	O
55	at	O
56	the	O
57	higher	O
58	levels	O
59	(	O
60	all	O
61	P	O
62	less	O
63	than	O
64	.	O
65	01	O
66	).	O

1	Overall	O
2	prevalences	O
3	of	O
4	antibody	O
5	were	O
6	70	O
7	per	O
8	cent	O
9	in	O
10	cattle	O
11	,	O
12	67	O
13	per	O
14	cent	O
15	in	O
16	sheep	O
17	and	O
18	76	O
19	per	O
20	cent	O
21	in	O
22	goats	O
23	as	O
24	assessed	O
25	by	O
26	an	O
27	immunodiffusion	O
28	test	O
29	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pulmonary	O
5	metastases	O
6	.	O

1	A	O
2	promoter	O
3	sequence	O
4	(	O
5	Goldberg	O
6	-	O
7	Hogness	O
8	or	O
9	TATA	O
10	box	O
11	)	O
12	is	O
13	situated	O
14	28	O
15	base	O
16	pairs	O
17	upstream	O
18	from	O
19	the	O
20	point	O
21	of	O
22	initiation	O
23	of	O
24	transcription	O
25	which	O
26	was	O
27	found	O
28	by	O
29	S1	B
30	nuclease	I
31	mapping	O
32	and	O
33	by	O
34	oligonucleotide	O
35	-	O
36	primed	O
37	reverse	O
38	transcription	O
39	of	O
40	rat	B
41	PTH	I
42	mRNA	I
43	.	O

1	The	O
2	12	B
3	,	I
4	000	I
5	MW	I
6	(	I
7	12K	I
8	)	I
9	IE	I
10	polypeptide	I
11	encoded	O
12	by	O
13	IEmRNA	B
14	-	I
15	5	I
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	USA	O
2	80	O
3	,	O
4	802	O
5	-	O
6	806	O
7	]	O
8	was	O
9	used	O
10	to	O
11	isolate	O
12	a	O
13	genomic	O
14	clone	O
15	lambda	O
16	PGK	B
17	-	I
18	1	I
19	containing	O
20	a	O
21	portion	O
22	of	O
23	an	O
24	autosomal	O
25	locus	O
26	for	O
27	phosphoglycerate	B
28	kinase	I
29	(	O
30	PGK	B
31	).	O

1	Tiaprofenic	O
2	acid	O
3	overdose	O
4	.	O

1	Blood	O
2	glucose	O
3	and	O
4	plasma	O
5	insulin	B
6	were	O
7	measured	O
8	at	O
9	zero	O
10	time	O
11	and	O
12	then	O
13	at	O
14	15	O
15	,	O
16	30	O
17	,	O
18	60	O
19	,	O
20	90	O
21	and	O
22	120	O
23	min	O
24	after	O
25	ingestion	O
26	of	O
27	25	O
28	g	O
29	glucose	O
30	,	O
31	fructose	O
32	or	O
33	lactose	O
34	,	O
35	or	O
36	30	O
37	g	O
38	honey	O
39	,	O
40	50	O
41	g	O
42	white	O
43	bread	O
44	,	O
45	125	O
46	g	O
47	white	O
48	rice	O
49	or	O
50	potatoes	O
51	,	O
52	150	O
53	g	O
54	apples	O
55	or	O
56	260	O
57	g	O
58	carrots	O
59	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	Induced	O
2	gamma	O
3	-	O
4	ray	O
5	spectroscopy	O

1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O

1	Resting	O
2	plasma	O
3	norepinephrine	O
4	(	O
5	NE	O
6	)	O
7	and	O
8	epinephrine	O
9	(	O
10	E	O
11	)	O
12	levels	O
13	were	O
14	lower	O
15	during	O
16	active	O
17	therapy	O
18	than	O
19	2	O
20	wk	O
21	after	O
22	withdrawal	O
23	(	O
24	guanfacine	O
25	and	O
26	control	O
27	:	O
28	plasma	O
29	NE	O
30	,	O
31	0	O
32	.	O
33	27	O
34	+/-	O
35	0	O
36	.	O
37	03	O
38	/	O
39	0	O
40	.	O
41	64	O
42	+/-	O
43	0	O
44	.	O
45	13	O
46	ng	O
47	/	O
48	ml	O
49	;	O
50	plasma	O
51	E	O
52	,	O
53	0	O
54	.	O
55	09	O
56	+/-	O
57	0	O
58	.	O
59	02	O
60	/	O
61	0	O
62	.	O
63	17	O
64	+/-	O
65	0	O
66	.	O
67	05	O
68	ng	O
69	/	O
70	ml	O
71	).	O

1	Eleven	O
2	biopsy	O
3	specimens	O
4	(	O
5	five	O
6	papules	O
7	and	O
8	six	O
9	dusky	O
10	or	O
11	crusted	O
12	lesions	O
13	)	O
14	from	O
15	four	O
16	patients	O
17	with	O
18	pityriasis	O
19	lichenoides	O
20	et	O
21	varioliformis	O
22	acuta	O
23	(	O
24	PLEVA	O
25	)	O
26	were	O
27	studied	O
28	by	O
29	direct	O
30	immunofluorescence	O
31	and	O
32	immunoperoxidase	B
33	technics	O
34	.	O

1	For	O
2	the	O
3	first	O
4	30	O
5	min	O
6	following	O
7	insulin	B
8	administration	O
9	,	O
10	the	O
11	rate	O
12	of	O
13	change	O
14	in	O
15	glucose	O
16	levels	O
17	was	O
18	significantly	O
19	less	O
20	among	O
21	the	O
22	patients	O
23	with	O
24	major	O
25	depressive	O
26	disorder	O
27	than	O
28	among	O
29	either	O
30	the	O
31	patients	O
32	with	O
33	dysthymic	O
34	disorder	O
35	or	O
36	the	O
37	normal	O
38	control	O
39	subjects	O
40	.	O

1	Results	O
2	of	O
3	a	O
4	controlled	O
5	study	O

1	Antithrombin	B
2	III	I
3	(	O
4	AT	B
5	III	I
6	)	O
7	is	O
8	a	O
9	plasma	O
10	protein	O
11	which	O
12	acts	O
13	as	O
14	the	O
15	principal	O
16	inhibitor	O
17	of	O
18	thrombin	B
19	and	O
20	is	O
21	a	O
22	major	O
23	modulator	O
24	of	O
25	intravascular	O
26	coagulation	O
27	.	O

1	Eighteen	O
2	patients	O
3	were	O
4	untreated	O
5	,	O
6	and	O
7	8	O
8	had	O
9	been	O
10	given	O
11	previous	O
12	treatment	O
13	with	O
14	depot	O
15	testosterone	O
16	100	O
17	mg	O
18	intramuscularly	O
19	every	O
20	2	O
21	-	O
22	3	O
23	weeks	O
24	for	O
25	an	O
26	average	O
27	duration	O
28	of	O
29	4	O
30	.	O
31	7	O
32	years	O
33	.	O

1	New	O
2	beta	O
3	-	O
4	blocking	O
5	drugs	O
6	have	O
7	been	O
8	introduced	O
9	which	O
10	may	O
11	prove	O
12	beneficial	O
13	in	O
14	certain	O
15	clinical	O
16	situations	O
17	since	O
18	they	O
19	exert	O
20	more	O
21	selective	O
22	blockade	O
23	of	O
24	the	O
25	cardiac	B
26	receptors	I
27	(	O
28	beta1	B
29	)	O
30	as	O
31	opposed	O
32	to	O
33	smooth	B
34	muscle	I
35	receptors	I
36	(	O
37	beta2	B
38	).	O

1	Total	O
2	cumulative	O
3	doses	O
4	of	O
5	doxorubicin	O
6	ranged	O
7	from	O
8	145	O
9	to	O
10	625	O
11	mg	O
12	./	O
13	m	O
14	.	O
15	2	O
16	.	O

1	Freezing	O
2	of	O
3	plasma	O
4	to	O
5	obtain	O
6	better	O
7	yield	O
8	of	O
9	factor	B
10	VIII	I
11	:	O
12	C	O
13	.	O

1	These	O
2	children	O
3	were	O
4	grouped	O
5	into	O
6	four	O
7	diagnostic	O
8	categories	O
9	:	O
10	1	O
11	)	O
12	idiopathic	O
13	GH	B
14	deficiency	O
15	(	O
16	n	O
17	=	O
18	10	O
19	);	O
20	2	O
21	)	O
22	organic	O
23	hypopituitarism	O
24	(	O
25	n	O
26	=	O
27	7	O
28	);	O
29	3	O
30	)	O
31	intrauterine	O
32	growth	O
33	retardation	O
34	(	O
35	n	O
36	=	O
37	5	O
38	);	O
39	and	O
40	4	O
41	)	O
42	constitutional	O
43	delay	O
44	of	O
45	growth	O
46	and	O
47	/	O
48	or	O
49	familial	O
50	short	O
51	stature	O
52	(	O
53	n	O
54	=	O
55	18	O
56	),	O
57	by	O
58	standard	O
59	clinical	O
60	criteria	O
61	and	O
62	physiological	O
63	and	O
64	pharmacological	O
65	tests	O
66	of	O
67	GH	B
68	reserve	O
69	.	O

1	These	O
2	changes	O
3	were	O
4	the	O
5	result	O
6	of	O
7	a	O
8	decrease	O
9	in	O
10	afterload	O
11	:	O
12	mean	O
13	aortic	O
14	pressure	O
15	fell	O
16	from	O
17	85	O
18	+/-	O
19	11	O
20	.	O
21	8	O
22	to	O
23	68	O
24	+/-	O
25	19	O
26	.	O
27	6	O
28	mmHg	O
29	(	O
30	p	O
31	less	O
32	than	O
33	0	O
34	.	O
35	01	O
36	)	O
37	and	O
38	systemic	O
39	arterial	O
40	resistance	O
41	fell	O
42	from	O
43	2	O
44	886	O
45	+/-	O
46	745	O
47	to	O
48	2	O
49	010	O
50	+/-	O
51	610	O
52	dynes	O
53	/	O
54	cm	O
55	-	O
56	5	O
57	/	O
58	sec	O
59	/	O
60	m	O
61	-	O
62	2	O
63	(	O
64	p	O
65	less	O
66	than	O
67	0	O
68	.	O
69	01	O
70	).	O

1	Regional	O
2	CBF	O
3	was	O
4	determined	O
5	by	O
6	clearance	O
7	of	O
8	xenon	O
9	133	O
10	in	O
11	67	O
12	patients	O
13	undergoing	O
14	coronary	O
15	bypass	O
16	grafting	O
17	procedures	O
18	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	axillo	O
6	-	O
7	axillary	O
8	by	O
9	-	O
10	pass	O
11	is	O
12	a	O
13	simple	O
14	solution	O
15	for	O
16	a	O
17	complex	O
18	haemodynamic	O
19	,	O
20	clinical	O
21	and	O
22	therapeutic	O
23	problem	O
24	.	O

1	Deformities	O
2	of	O
3	the	O
4	tip	O
5	of	O
6	the	O
7	olecranon	O
8	and	O
9	of	O
10	the	O
11	coronoid	O
12	process	O
13	are	O
14	also	O
15	described	O
16	(	O
17	De	O
18	Palma	O
19	1956	O
20	,	O
21	Jordan	O
22	1958	O
23	,	O
24	Ahlberg	O
25	1965	O
26	,	O
27	Weseloh	O
28	1973	O
29	).	O

1	Statokinesimetric	O
2	recording	O
3	in	O
4	Huntington	O
5	choreas	O

1	In	O
2	doses	O
3	of	O
4	0	O
5	.	O
6	03	O
7	-	O
8	0	O
9	.	O
10	3	O
11	mg	O
12	/	O
13	kg	O
14	i	O
15	.	O
16	v	O
17	.,	O
18	SG	O
19	-	O
20	75	O
21	did	O
22	not	O
23	significantly	O
24	affect	O
25	pulse	O
26	pressure	O
27	,	O
28	heart	O
29	rate	O
30	,	O
31	aortic	O
32	blood	O
33	flow	O
34	,	O
35	left	O
36	ventricular	O
37	pressure	O
38	(	O
39	LVP	O
40	)	O
41	and	O
42	LVdP	O
43	/	O
44	dt	O
45	max	O
46	.	O

1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O

1	The	O
2	response	O
3	chain	O
4	in	O
5	each	O
6	component	O
7	was	O
8	maintained	O
9	by	O
10	food	O
11	presentation	O
12	under	O
13	a	O
14	fixed	O
15	-	O
16	ratio	O
17	schedule	O
18	.	O

1	This	O
2	compares	O
3	favorably	O
4	to	O
5	results	O
6	of	O
7	similarly	O
8	sized	O
9	melanomas	O
10	treated	O
11	by	O
12	enucleation	O
13	.	O

1	Methods	O
2	of	O
3	clinical	O
4	and	O
5	experimental	O
6	algesimetry	O
7	are	O
8	described	O
9	that	O
10	have	O
11	been	O
12	used	O
13	to	O
14	evaluate	O
15	effects	O
16	of	O
17	peripherally	O
18	and	O
19	centrally	O
20	acting	O
21	analgesics	O
22	.	O

1	Human	B
2	thyroid	I
3	stimulator	I
4	(	O
5	HTS	B
6	)	O
7	in	O
8	thyroid	O
9	diseases	O

1	Brainstem	O
2	auditory	O
3	evoked	O
4	responses	O
5	(	O
6	BAERs	O
7	)	O
8	and	O
9	quantitative	O
10	saccadic	O
11	eye	O
12	movement	O
13	studies	O
14	provide	O
15	information	O
16	on	O
17	the	O
18	integrity	O
19	of	O
20	pathways	O
21	traversing	O
22	the	O
23	brainstem	O
24	.	O

1	Three	O
2	radiologists	O
3	without	O
4	knowledge	O
5	of	O
6	patients	O
7	'	O
8	data	O
9	and	O
10	treatment	O
11	analyzed	O
12	30	O
13	angiograms	O
14	with	O
15	and	O
16	30	O
17	examinations	O
18	without	O
19	PGF	O
20	.	O

1	In	O
2	a	O
3	man	O
4	with	O
5	myelomonocytic	O
6	leukemia	O
7	,	O
8	the	O
9	association	O
10	of	O
11	increased	O
12	prostatic	B
13	acid	I
14	phosphatase	I
15	activity	O
16	in	O
17	serum	O
18	and	O
19	the	O
20	presence	O
21	of	O
22	typical	O
23	bone	O
24	lesions	O
25	on	O
26	roentgenography	O
27	suggested	O
28	the	O
29	existence	O
30	of	O
31	disseminated	O
32	prostatic	O
33	carcinoma	O
34	.	O

1	Azygos	O
2	vein	O
3	abutting	O
4	the	O
5	posterior	O
6	wall	O
7	of	O
8	the	O
9	right	O
10	main	O
11	and	O
12	upper	O
13	lobe	O
14	bronchi	O
15	:	O
16	a	O
17	normal	O
18	CT	O
19	variant	O
20	.	O

1	Four	O
2	patients	O
3	(	O
4	group	O
5	1	O
6	)	O
7	had	O
8	type	O
9	I	O
10	basement	O
11	membrane	O
12	nephropathy	O
13	,	O
14	characterized	O
15	by	O
16	marked	O
17	thickening	O
18	and	O
19	lamellation	O
20	of	O
21	the	O
22	basement	O
23	membrane	O
24	in	O
25	a	O
26	pattern	O
27	resembling	O
28	that	O
29	of	O
30	Alport	O
31	'	O
32	s	O
33	syndrome	O
34	.	O

1	Introductory	O
2	remarks	O
3	.	O

1	After	O
2	clofelin	O
3	administration	O
4	the	O
5	autoregulation	O
6	borders	O
7	shifted	O
8	to	O
9	the	O
10	right	O
11	i	O
12	.	O
13	e	O
14	.	O
15	towards	O
16	higher	O
17	AP	O
18	levels	O
19	.	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	The	O
2	carcinogen	O
3	bioassay	O
4	therefore	O
5	is	O
6	a	O
7	very	O
8	important	O
9	component	O
10	of	O
11	the	O
12	battery	O
13	of	O
14	toxicological	O
15	tests	O
16	used	O
17	in	O
18	hazard	O
19	evaluation	O
20	.	O

1	Using	O
2	a	O
3	MOS	O
4	-	O
5	Hypersil	O
6	reversed	O
7	-	O
8	phase	O
9	column	O
10	with	O
11	a	O
12	phosphate	O
13	buffer	O
14	--	O
15	acetonitrile	O
16	mobile	O
17	phase	O
18	,	O
19	baseline	O
20	separation	O
21	of	O
22	antipyrine	O
23	,	O
24	its	O
25	metabolites	O
26	3	O
27	-	O
28	hydroxymethylantipyrine	O
29	,	O
30	norantipyrine	O
31	and	O
32	4	O
33	-	O
34	hydroxyantipyrine	O
35	,	O
36	and	O
37	the	O
38	internal	O
39	standard	O
40	,	O
41	phenacetin	O
42	,	O
43	was	O
44	achieved	O
45	within	O
46	6	O
47	min	O
48	.	O

1	These	O
2	results	O
3	confirming	O
4	the	O
5	high	O
6	validity	O
7	of	O
8	NOM	O
9	inhibiting	O
10	test	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	tumoural	O
16	hyperprolactinemic	O
17	states	O
18	,	O
19	reveal	O
20	contradictory	O
21	responses	O
22	to	O
23	CD	O
24	/	O
25	LD	O
26	,	O
27	LD	O
28	and	O
29	DOM	O
30	,	O
31	with	O
32	sustain	O
33	the	O
34	existence	O
35	of	O
36	2	O
37	sub	O
38	-	O
39	group	O
40	of	O
41	Prolactinomas	O
42	:	O
43	with	O
44	or	O
45	without	O
46	a	O
47	maintained	O
48	DA	O
49	central	O
50	tonus	O
51	supporting	O
52	the	O
53	possibility	O
54	of	O
55	different	O
56	etiopathogenetical	O
57	factors	O
58	in	O
59	inducing	O
60	a	O
61	tumoural	O
62	hyperprolactinemic	O
63	states	O
64	.	O

1	The	O
2	subgroup	O
3	innervating	O
4	the	O
5	medial	O
6	rectus	O
7	lies	O
8	exclusively	O
9	along	O
10	the	O
11	medial	O
12	face	O
13	of	O
14	the	O
15	oculomotor	O
16	nucleus	O
17	,	O
18	with	O
19	no	O
20	aberrant	O
21	neurons	O
22	in	O
23	the	O
24	medial	O
25	longitudinal	O
26	fasciculus	O
27	,	O
28	as	O
29	have	O
30	been	O
31	found	O
32	in	O
33	other	O
34	mammals	O
35	.	O

1	These	O
2	cells	O
3	averaged	O
4	17	O
5	microns	O
6	in	O
7	diameter	O
8	and	O
9	reproduced	O
10	by	O
11	fission	O
12	,	O
13	forming	O
14	clusters	O
15	of	O
16	two	O
17	or	O
18	four	O
19	daughter	O
20	cells	O
21	.	O

1	Dipetalonema	O
2	(	O
3	Alafilaria	O
4	)	O
5	hydrochoerus	O
6	subgen	O
7	.	O
8	et	O
9	sp	O
10	.	O
11	n	O
12	.	O

1	The	O
2	range	O
3	of	O
4	serum	O
5	concentrations	O
6	,	O
7	mean	O
8	values	O
9	,	O
10	median	O
11	values	O
12	,	O
13	and	O
14	standard	O
15	deviations	O
16	for	O
17	each	O
18	analyte	O
19	are	O
20	reported	O
21	for	O
22	males	O
23	and	O
24	females	O
25	and	O
26	for	O
27	three	O
28	age	O
29	groups	O
30	(	O
31	25	O
32	-	O
33	44	O
34	,	O
35	45	O
36	-	O
37	59	O
38	,	O
39	60	O
40	-	O
41	70	O
42	).	O

1	A	O
2	stable	O
3	interface	O
4	depends	O
5	on	O
6	overall	O
7	stress	O
8	and	O
9	microstress	O
10	distribution	O
11	on	O
12	the	O
13	bone	O
14	,	O
15	particularly	O
16	trabecular	O
17	bone	O
18	.	O

1	Plasma	O
2	NE	O
3	was	O
4	also	O
5	low	O
6	in	O
7	the	O
8	anephric	O
9	group	O
10	(	O
11	289	O
12	mg	O
13	/	O
14	liter	O
15	+/-	O
16	126	O
17	(	O
18	1	O
19	SD	O
20	)	O
21	vs	O
22	612	O
23	+/-	O
24	189	O
25	,	O
26	P	O
27	=	O
28	0	O
29	.	O
30	033	O
31	,	O
32	resting	O
33	).(	O
34	ABSTRACT	O
35	TRUNCATED	O
36	AT	O
37	250	O
38	WORDS	O
39	)	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	O
7	in	O
8	pallid	O
9	bats	O
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	Significant	O
2	immunoglobulinuria	O
3	developed	O
4	prior	O
5	to	O
6	the	O
7	development	O
8	of	O
9	azotemia	O
10	,	O
11	significantly	O
12	decreased	O
13	creatinine	O
14	clearance	O
15	,	O
16	significant	O
17	proteinuria	O
18	(	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	3	O
25	+	O
26	dipstick	O
27	or	O
28	greater	O
29	than	O
30	or	O
31	equal	O
32	to	O
33	5	O
34	gm	O
35	per	O
36	24	O
37	-	O
38	hour	O
39	urine	O
40	collection	O
41	),	O
42	or	O
43	oliguria	O
44	.	O

1	A	O
2	total	O
3	number	O
4	of	O
5	1628	O
6	cases	O
7	were	O
8	collected	O
9	from	O
10	135	O
11	medical	O
12	institutions	O
13	.	O

1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	the	O
6	sensitivity	O
7	of	O
8	the	O
9	3	O
10	given	O
11	guinea	O
12	pig	O
13	strains	O
14	was	O
15	comparable	O
16	.	O

1	Colorimetric	O
2	determination	O
3	of	O
4	urinary	O
5	iron	O
6	,	O
7	chelated	O
8	with	O
9	deferoxamine	O
10	B	O
11	,	O
12	using	O
13	a	O
14	single	O
15	reagent	O

1	Effects	O
2	of	O
3	dopamine	O
4	and	O
5	of	O
6	a	O
7	dopaminergic	O
8	blocker	O
9	,	O
10	haloperidol	O
11	,	O
12	on	O
13	the	O
14	responses	O
15	of	O
16	carotid	O
17	body	O
18	chemoreceptors	O
19	to	O
20	hypoxia	O
21	and	O
22	hypercapnia	O
23	were	O
24	investigated	O
25	in	O
26	16	O
27	anesthetized	O
28	cats	O
29	.	O

1	Trypanosoma	O
2	cruzi	O
3	.	O

1	The	O
2	alterations	O
3	in	O
4	differentiation	O
5	of	O
6	osteoprogenitor	O
7	cells	O
8	,	O
9	together	O
10	with	O
11	the	O
12	failure	O
13	of	O
14	mineralization	O
15	,	O
16	resulted	O
17	in	O
18	significantly	O
19	lower	O
20	rates	O
21	of	O
22	bone	O
23	formation	O
24	(	O
25	as	O
26	measured	O
27	by	O
28	fluorochrome	O
29	labeling	O
30	)	O
31	in	O
32	the	O
33	magnesium	O
34	-	O
35	deficient	O
36	rats	O
37	.	O

1	A	O
2	convenient	O
3	measure	O
4	of	O
5	this	O
6	impairment	O
7	may	O
8	be	O
9	obtained	O
10	using	O
11	the	O
12	ratio	O
13	of	O
14	urine	O
15	volume	O
16	(	O
17	V	O
18	)	O
19	divided	O
20	by	O
21	lithium	O
22	clearance	O
23	(	O
24	CLi	O
25	).	O

1	Production	O
2	of	O
3	C	B
4	mu	I
5	RNAs	I
6	,	O
7	unlike	O
8	mu	B
9	mRNAs	I
10	,	O
11	does	O
12	not	O
13	require	O
14	recombination	O
15	with	O
16	the	O
17	joining	B
18	region	I
19	(	O
20	JH	B
21	)	O
22	locus	O
23	.	O

1	Although	O
2	the	O
3	mechanism	O
4	of	O
5	action	O
6	of	O
7	ICRF	O
8	-	O
9	159	O
10	and	O
11	187	O
12	has	O
13	not	O
14	been	O
15	clearly	O
16	defined	O
17	,	O
18	it	O
19	is	O
20	evident	O
21	from	O
22	both	O
23	preclinical	O
24	and	O
25	early	O
26	clinical	O
27	studies	O
28	that	O
29	these	O
30	compounds	O
31	are	O
32	of	O
33	interest	O
34	.	O

1	There	O
2	is	O
3	now	O
4	a	O
5	significative	O
6	difference	O
7	between	O
8	age	O
9	group	O
10	1	O
11	-	O
12	5	O
13	and	O
14	the	O
15	others	O
16	(	O
17	p	O
18	Less	O
19	Than	O
20	0	O
21	,	O
22	02	O
23	).	O

1	The	O
2	sympathetic	O
3	neuroeffector	O
4	influence	O
5	on	O
6	the	O
7	myocardium	O
8	with	O
9	ATCI	O
10	depends	O
11	to	O
12	a	O
13	large	O
14	measure	O
15	on	O
16	the	O
17	intensity	O
18	of	O
19	the	O
20	neurotransmitter	O
21	biosynthesis	O
22	and	O
23	function	O
24	of	O
25	cardiomyocyte	O
26	adrenoreceptors	O
27	.	O

1	Lens	B
2	aldose	I
3	reductase	I
4	in	O
5	diabetic	O
6	and	O
7	galactosemic	O
8	cataracts	O
9	.	O

1	Fenfluramine	O
2	(	O
3	in	O
4	doses	O
5	ranging	O
6	from	O
7	0	O
8	.	O
9	0625	O
10	-	O
11	4	O
12	.	O
13	0	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	infusion	O
19	)	O
20	did	O
21	not	O
22	maintain	O
23	self	O
24	-	O
25	administration	O
26	behavior	O
27	at	O
28	or	O
29	above	O
30	the	O
31	minimum	O
32	requirement	O
33	(	O
34	FR	O
35	30	O
36	).	O

1	In	O
2	the	O
3	course	O
4	of	O
5	Hepatitis	B
6	A	I
7	HBs	I
8	-	I
9	and	I
10	HBe	I
11	-	I
12	antigen	I
13	as	O
14	well	O
15	as	O
16	HBc	B
17	(	I
18	IgM	I
19	and	I
20	IgG	I
21	)-,	I
22	HBs	I
23	-	I
24	and	I
25	HBe	I
26	-	I
27	antibodies	I
28	can	O
29	be	O
30	detected	O
31	.	O

1	The	O
2	already	O
3	elevated	O
4	prolactin	B
5	levels	O
6	in	O
7	nursing	O
8	women	O
9	were	O
10	not	O
11	influenced	O
12	by	O
13	chronic	O
14	oestradiol	O
15	administration	O
16	.	O

1	LCBF	O
2	in	O
3	normal	O
4	and	O
5	hypoxic	O
6	puppies	O
7	was	O
8	correlated	O
9	with	O
10	local	O
11	cerebral	O
12	glucose	O
13	utilization	O
14	(	O
15	LCGU	O
16	)	O
17	obtained	O
18	under	O
19	the	O
20	same	O
21	experimental	O
22	conditions	O
23	(	O
24	Duffy	O
25	et	O
26	al	O
27	,	O
28	1982	O
29	).	O

1	Detection	O
2	of	O
3	hemophilia	O
4	A	O
5	carriers	O
6	.	O

1	Bile	O
2	bilirubin	O
3	did	O
4	not	O
5	rise	O
6	within	O
7	12	O
8	h	O
9	after	O
10	haem	O
11	infusion	O
12	a	O
13	finding	O
14	which	O
15	warrants	O
16	further	O
17	investigation	O
18	.	O

1	Other	O
2	properties	O
3	of	O
4	Hg	O
5	-	O
6	and	O
7	Cd	O
8	-	O
9	spores	O
10	were	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	control	O
16	spores	O
17	.	O

1	Of	O
2	270	O
3	patients	O
4	with	O
5	well	O
6	-	O
7	defined	O
8	drug	O
9	reactions	O
10	,	O
11	190	O
12	(	O
13	70	O
14	per	O
15	cent	O
16	)	O
17	gave	O
18	a	O
19	positive	O
20	response	O
21	to	O
22	the	O
23	mast	O
24	cell	O
25	test	O
26	.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	It	O
2	then	O
3	merged	O
4	with	O
5	right	O
6	ventricular	O
7	wavefronts	O
8	ending	O
9	along	O
10	the	O
11	right	O
12	ventricular	O
13	anterior	O
14	atrioventricular	O
15	groove	O
16	and	O
17	outflow	O
18	tract	O
19	.	O

1	The	O
2	level	O
3	of	O
4	contamination	O
5	in	O
6	the	O
7	wound	O
8	can	O
9	be	O
10	determined	O
11	with	O
12	the	O
13	rapid	O
14	biopsy	O
15	fixation	O
16	technique	O
17	.	O

1	Copper	O
2	treatments	O
3	were	O
4	assigned	O
5	to	O
6	simulate	O
7	the	O
8	different	O
9	levels	O
10	of	O
11	copper	O
12	intake	O
13	that	O
14	might	O
15	result	O
16	from	O
17	differences	O
18	in	O
19	daily	O
20	feed	O
21	intake	O
22	similar	O
23	to	O
24	the	O
25	practice	O
26	followed	O
27	with	O
28	commercial	O
29	industry	O
30	.	O

1	Efficacy	O
2	of	O
3	cervical	O
4	spine	O
5	immobilization	O
6	methods	O
7	.	O

1	Pathogenetic	O
2	relationships	O
3	between	O
4	renal	O
5	tubular	O
6	acidosis	O
7	and	O
8	sodium	O
9	metabolism	O
10	alterations	O
11	in	O
12	liver	O
13	cirrhosis	O
14	.	O

1	In	O
2	the	O
3	ultramarathon	O
4	runner	O
5	the	O
6	testosterone	O
7	levels	O
8	sharply	O
9	rose	O
10	at	O
11	the	O
12	beginning	O
13	of	O
14	the	O
15	training	O
16	session	O
17	(	O
18	from	O
19	the	O
20	7	O
21	,	O
22	20	O
23	ng	O
24	/	O
25	ml	O
26	to	O
27	11	O
28	,	O
29	50	O
30	ng	O
31	/	O
32	ml	O
33	after	O
34	20	O
35	'	O
36	training	O
37	),	O
38	and	O
39	subsequently	O
40	decrease	O
41	after	O
42	3	O
43	hours	O
44	(	O
45	9	O
46	,	O
47	20	O
48	ng	O
49	/	O
50	ml	O
51	)	O
52	and	O
53	at	O
54	the	O
55	end	O
56	of	O
57	the	O
58	6	O
59	hours	O
60	training	O
61	(	O
62	4	O
63	,	O
64	60	O
65	ng	O
66	/	O
67	ml	O
68	).	O

1	In	O
2	visible	O
3	tumours	O
4	the	O
5	best	O
6	results	O
7	were	O
8	obtained	O
9	with	O
10	FB	O
11	(	O
12	85	O
13	%)	O
14	while	O
15	TBN	O
16	was	O
17	positive	O
18	in	O
19	65	O
20	%.	O

1	Normal	O
2	rates	O
3	of	O
4	weight	O
5	gain	O
6	were	O
7	seen	O
8	once	O
9	absorbed	O
10	energy	O
11	intakes	O
12	reached	O
13	100	O
14	-	O
15	110	O
16	%	O
17	of	O
18	requirements	O
19	.	O

1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O

1	Behcet	O
2	'	O
3	s	O
4	syndrome	O

1	Terbutaline	O
2	;	O
3	a	O
4	beta2	O
5	-	O
6	adrenergic	O
7	agonist	O
8	,	O
9	and	O
10	aminophyllin	O
11	,	O
12	a	O
13	phosphodiesterase	O
14	inhibitor	O
15	,	O
16	were	O
17	given	O
18	separately	O
19	,	O
20	or	O
21	in	O
22	combination	O
23	,	O
24	to	O
25	rabbit	O
26	fetuses	O
27	on	O
28	the	O
29	28th	O
30	day	O
31	of	O
32	gestation	O
33	.	O

1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O

1	Setting	O
2	takes	O
3	place	O
4	through	O
5	complex	O
6	formation	O
7	of	O
8	(	O
9	NH4Mg	O
10	PO4	O
11	.	O
12	6H2O	O
13	)	O
14	n	O
15	,	O
16	excess	O
17	reactants	O
18	,	O
19	and	O
20	water	O
21	.	O

1	Serum	B
2	IgE	I
3	levels	O
4	in	O
5	Tauranga	O
6	children	O
7	.	O

1	The	O
2	arginyl	O
3	peptide	O
4	bonds	O
5	that	O
6	are	O
7	cleaved	O
8	in	O
9	the	O
10	conversion	O
11	of	O
12	human	B
13	factor	I
14	IX	I
15	to	O
16	factor	B
17	IXa	I
18	by	O
19	factor	B
20	XIa	I
21	were	O
22	identified	O
23	as	O
24	Arg145	O
25	-	O
26	Ala146	O
27	and	O
28	Arg180	O
29	-	O
30	Val181	O
31	.	O

1	Contractile	O
2	responses	O
3	to	O
4	norepinephrine	O
5	,	O
6	serotonin	O
7	and	O
8	potassium	O
9	(	O
10	K	O
11	+)	O
12	and	O
13	relaxant	O
14	responses	O
15	to	O
16	isoproterenol	O
17	and	O
18	papaverine	O
19	were	O
20	studied	O
21	in	O
22	vitro	O
23	with	O
24	spirally	O
25	cut	O
26	thoracic	O
27	aortic	O
28	strips	O
29	from	O
30	aortic	O
31	coarcted	O
32	hypertensive	O
33	rats	O
34	(	O
35	AHR	O
36	)	O
37	2	O
38	,	O
39	6	O
40	,	O
41	14	O
42	and	O
43	28	O
44	days	O
45	postoperatively	O
46	and	O
47	compared	O
48	to	O
49	time	O
50	-	O
51	matched	O
52	,	O
53	sham	O
54	-	O
55	operated	O
56	normotensive	O
57	controls	O
58	.	O

1	The	O
2	effect	O
3	of	O
4	sodium	O
5	saccharin	O
6	in	O
7	the	O
8	diet	O
9	on	O
10	caecal	O
11	microflora	O
12	.	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	The	O
2	"	O
3	cracked	O
4	-	O
5	tooth	O
6	"	O
7	syndrome	O
8	.	O

1	Facts	O
2	on	O
3	the	O
4	Economic	O
5	Recovery	O
6	Tax	O
7	Act	O
8	of	O
9	1981	O
10	for	O
11	speech	O
12	-	O
13	language	O
14	pathologists	O
15	and	O
16	audiologists	O
17	.	O

1	Using	O
2	an	O
3	opsonophagocytic	O
4	bacterial	O
5	assay	O
6	and	O
7	a	O
8	suckling	O
9	rat	O
10	model	O
11	of	O
12	GBS	O
13	sepsis	O
14	,	O
15	we	O
16	analyzed	O
17	a	O
18	modified	O
19	human	B
20	immunoglobulin	I
21	for	O
22	opsonic	O
23	and	O
24	protective	O
25	antibody	O
26	.	O

1	When	O
2	vascular	O
3	pressure	O
4	(	O
5	Pvas	O
6	)	O
7	was	O
8	raised	O
9	abruptly	O
10	from	O
11	-	O
12	5	O
13	to	O
14	+	O
15	25	O
16	cmH2O	O
17	by	O
18	air	O
19	inflation	O
20	for	O
21	60	O
22	min	O
23	,	O
24	Px	O
25	(	O
26	f	O
27	)	O
28	became	O
29	abruptly	O
30	less	O
31	negative	O
32	,	O
33	then	O
34	remained	O
35	stable	O
36	.	O

1	(	O
2	1980	O
3	):	O
4	Science	O
5	210	O
6	,	O
7	77	O
8	-	O
9	72	O
10	)	O
11	that	O
12	stimulating	O
13	the	O
14	crossed	O
15	olivocochlear	O
16	bundle	O
17	(	O
18	COCB	O
19	)	O
20	can	O
21	change	O
22	the	O
23	magnitude	O
24	of	O
25	the	O
26	distortion	O
27	product	O
28	(	O
29	f2	O
30	-	O
31	f1	O
32	)	O
33	in	O
34	the	O
35	ear	O
36	-	O
37	canal	O
38	sound	O
39	pressure	O
40	.	O

1	When	O
2	the	O
3	l	O
4	-	O
5	methadone	O
6	-	O
7	sensitive	O
8	,	O
9	opioid	B
10	receptor	I
11	is	O
12	blocked	O
13	by	O
14	naloxone	O
15	or	O
16	tolerance	O
17	has	O
18	developed	O
19	,	O
20	than	O
21	l	O
22	-	O
23	methadone	O
24	can	O
25	produce	O
26	behavioral	O
27	effects	O
28	by	O
29	a	O
30	nonopioid	O
31	mechanism	O
32	.	O

1	Microwave	O
2	hyperthermia	O
3	-	O
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	A	O
2	simple	O
3	method	O
4	for	O
5	measuring	O
6	urinary	O
7	iron	O
8	following	O
9	the	O
10	administration	O
11	of	O
12	desferrioxamine	O
13	(	O
14	DF	O
15	)	O
16	is	O
17	described	O
18	.	O

1	Transvenous	O
2	serial	O
3	xeroradiography	O
4	.	O

1	Although	O
2	noninhibitory	O
3	fluid	O
4	had	O
5	higher	O
6	mean	O
7	concentrations	O
8	of	O
9	phosphorus	O
10	and	O
11	zinc	O
12	,	O
13	these	O
14	differences	O
15	did	O
16	not	O
17	hold	O
18	after	O
19	meconium	O
20	-	O
21	stained	O
22	samples	O
23	were	O
24	excluded	O
25	.	O

1	In	O
2	a	O
3	longitudinal	O
4	study	O
5	,	O
6	14	O
7	low	O
8	-	O
9	risk	O
10	fetuses	O
11	were	O
12	studied	O
13	at	O
14	2	O
15	-	O
16	week	O
17	intervals	O
18	from	O
19	32	O
20	weeks	O
21	of	O
22	gestation	O
23	onward	O
24	.	O

1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O

1	In	O
2	this	O
3	way	O
4	it	O
5	is	O
6	possible	O
7	to	O
8	simulate	O
9	the	O
10	growth	O
11	function	O
12	of	O
13	the	O
14	embryofetal	O
15	curve	O
16	of	O
17	the	O
18	length	O
19	'	O
20	increase	O
21	of	O
22	man	O
23	and	O
24	the	O
25	curve	O
26	of	O
27	the	O
28	mass	O
29	'	O
30	increase	O
31	of	O
32	rat	O
33	.	O

1	In	O
2	concept	O
3	II	O
4	62	O
5	patients	O
6	were	O
7	treated	O
8	with	O
9	selective	O
10	vagotomy	O
11	and	O
12	pyloroplasty	O
13	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	The	O
2	COP	O
3	-	O
4	PAWP	O
5	gradient	O
6	was	O
7	markedly	O
8	decreased	O
9	in	O
10	both	O
11	shock	O
12	and	O
13	non	O
14	-	O
15	shock	O
16	patients	O
17	with	O
18	pulmonary	O
19	edema	O
20	.	O

1	Administration	O
2	of	O
3	the	O
4	dopamine	O
5	agonist	O
6	bromocriptine	O
7	(	O
8	2	O
9	.	O
10	5	O
11	mg	O
12	three	O
13	times	O
14	a	O
15	day	O
16	for	O
17	4	O
18	days	O
19	)	O
20	suppressed	O
21	(	O
22	P	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	mean	O
30	24	O
31	-	O
32	h	O
33	plasma	O
34	18	O
35	-	O
36	OHB	O
37	levels	O
38	from	O
39	21	O
40	.	O
41	9	O
42	+/-	O
43	2	O
44	.	O
45	0	O
46	to	O
47	14	O
48	.	O
49	8	O
50	+/-	O
51	1	O
52	.	O
53	4	O
54	ng	O
55	/	O
56	dl	O
57	.	O

1	Restarting	O
2	time	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	magnesium	O
8	cardioplegia	O
9	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	The	O
2	favourable	O
3	effect	O
4	of	O
5	thymic	O
6	shielding	O
7	was	O
8	also	O
9	reflected	O
10	in	O
11	a	O
12	significant	O
13	increase	O
14	of	O
15	LD50	O
16	/	O
17	30	O
18	,	O
19	and	O
20	the	O
21	dose	O
22	reduction	O
23	factor	O
24	was	O
25	equal	O
26	to	O
27	2	O
28	.	O

1	The	O
2	cause	O
3	of	O
4	death	O
5	is	O
6	often	O
7	quite	O
8	apparent	O
9	from	O
10	the	O
11	pathological	O
12	and	O
13	toxicological	O
14	findings	O
15	;	O
16	however	O
17	,	O
18	the	O
19	manner	O
20	of	O
21	death	O
22	often	O
23	gives	O
24	the	O
25	examining	O
26	official	O
27	some	O
28	difficulty	O
29	.	O

1	Both	O
2	groups	O
3	rejected	O
4	pops	O
5	with	O
6	added	O
7	SOA	O
8	,	O
9	decreasing	O
10	mouthing	O
11	times	O
12	as	O
13	SOA	O
14	concentration	O
15	increased	O
16	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	After	O
2	successful	O
3	subtotal	O
4	parathyroidectomy	O
5	,	O
6	evident	O
7	by	O
8	the	O
9	decrease	O
10	of	O
11	serum	O
12	iPTH	B
13	levels	O
14	,	O
15	both	O
16	the	O
17	CL	O
18	of	O
19	group	O
20	2	O
21	PMNs	O
22	and	O
23	the	O
24	ability	O
25	of	O
26	group	O
27	2	O
28	sera	O
29	to	O
30	induce	O
31	augmented	O
32	CL	O
33	in	O
34	normal	O
35	PMNs	O
36	decreased	O
37	(	O
38	p	O
39	<	O
40	0	O
41	.	O
42	025	O
43	).	O

1	TCZ	O
2	provides	O
3	quick	O
4	,	O
5	inexpensive	O
6	,	O
7	noninvasive	O
8	indication	O
9	of	O
10	tissue	O
11	necrosis	O
12	,	O
13	moderate	O
14	-	O
15	to	O
16	-	O
17	severe	O
18	intracranial	O
19	hemorrhage	O
20	,	O
21	and	O
22	delayed	O
23	brain	O
24	maturation	O
25	.	O

1	Inhibition	O
2	of	O
3	Fusarium	O
4	moniliforme	O
5	var	O
6	.	O
7	subglutinans	O
8	,	O
9	the	O
10	causal	O
11	agent	O
12	of	O
13	pine	O
14	pitch	O
15	canker	O
16	,	O
17	by	O
18	the	O
19	soil	O
20	bacterium	O
21	Arthrobacter	O
22	sp	O
23	.	O

1	The	O
2	five	O
3	-	O
4	drug	O
5	combination	O
6	of	O
7	fluorouracil	O
8	imidazole	O
9	carboxamide	O
10	dimethyl	O
11	triazeno	O
12	,	O
13	vincristine	O
14	,	O
15	bis	O
16	-	O
17	chloroethyl	O
18	nitrosourea	O
19	,	O
20	and	O
21	prednisone	O
22	(	O
23	FIVB	O
24	+	O
25	P	O
26	)	O
27	was	O
28	given	O
29	to	O
30	120	O
31	women	O
32	with	O
33	metastatic	O
34	breast	O
35	cancer	O
36	.	O

1	To	O
2	evaluate	O
3	the	O
4	gas	O
5	chromatographic	O
6	electron	O
7	capture	O
8	detection	O
9	method	O
10	described	O
11	earlier	O
12	,	O
13	23	O
14	plasma	O
15	samples	O
16	have	O
17	been	O
18	analysed	O
19	by	O
20	both	O
21	techniques	O
22	.	O

1	Morphological	O
2	features	O
3	of	O
4	Jat	O
5	dentition	O
6	.	O

1	While	O
2	all	O
3	deletions	O
4	within	O
5	the	O
6	sequence	O
7	coding	O
8	for	O
9	the	O
10	mature	O
11	tRNA	O
12	led	O
13	to	O
14	inactivity	O
15	of	O
16	the	O
17	mutated	O
18	genes	O
19	,	O
20	substitution	O
21	of	O
22	the	O
23	central	O
24	portion	O
25	by	O
26	concatenated	B
27	Hind	I
28	III	I
29	linkers	I
30	produced	O
31	gene	O
32	units	O
33	active	O
34	in	O
35	transcription	O
36	.	O

1	Recording	O
2	of	O
3	the	O
4	digital	O
5	sphygmic	O
6	activity	O
7	in	O
8	the	O
9	lower	O
10	extremities	O
11	with	O
12	the	O
13	photoplethysmographic	O
14	and	O
15	strain	O
16	-	O
17	gauge	O
18	methods	O
19	.	O

1	Since	O
2	only	O
3	58	O
4	%	O
5	of	O
6	our	O
7	sample	O
8	could	O
9	be	O
10	adequately	O
11	classified	O
12	with	O
13	one	O
14	diagnosis	O
15	,	O
16	we	O
17	expect	O
18	that	O
19	the	O
20	ASDC	O
21	nosology	O
22	will	O
23	need	O
24	to	O
25	evolve	O
26	further	O
27	.	O

1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O

1	Effects	O
2	of	O
3	prostaglandin	O
4	inhibitors	O
5	on	O
6	the	O
7	onset	O
8	of	O
9	proteinuria	O
10	and	O
11	stroke	O
12	in	O
13	stroke	O
14	-	O
15	prone	O
16	spontaneously	O
17	hypertensive	O
18	rats	O
19	.	O

1	Survival	O
2	was	O
3	calculated	O
4	both	O
5	from	O
6	the	O
7	date	O
8	of	O
9	onset	O
10	and	O
11	from	O
12	the	O
13	date	O
14	of	O
15	diagnosis	O
16	.	O

1	Methisergide	O
2	(	O
3	0	O
4	.	O
5	5	O
6	mg	O
7	/	O
8	kg	O
9	,	O
10	i	O
11	.	O
12	p	O
13	.),	O
14	a	O
15	blocker	O
16	of	O
17	serotonin	B
18	receptors	I
19	,	O
20	prevented	O
21	the	O
22	development	O
23	of	O
24	the	O
25	antinociceptive	O
26	effect	O
27	of	O
28	serotonin	O
29	.	O

1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O

1	Similar	O
2	waves	O
3	were	O
4	seen	O
5	on	O
6	cross	O
7	-	O
8	correlating	O
9	a	O
10	motor	O
11	unit	O
12	with	O
13	an	O
14	electronic	O
15	oscillator	O
16	,	O
17	confirming	O
18	that	O
19	their	O
20	occurrence	O
21	does	O
22	not	O
23	necessarily	O
24	demonstrate	O
25	the	O
26	existence	O
27	of	O
28	active	O
29	neural	O
30	interactions	O
31	.	O

1	Current	O
2	status	O
3	of	O
4	chemotherapy	O
5	for	O
6	Hodgkin	O
7	'	O
8	s	O
9	disease	O

1	Forty	O
2	-	O
3	five	O
4	cases	O
5	were	O
6	surgically	O
7	by	O
8	direct	O
9	approach	O
10	to	O
11	the	O
12	tumour	O
13	,	O
14	while	O
15	two	O
16	cases	O
17	were	O
18	treated	O
19	only	O
20	with	O
21	a	O
22	shunt	O
23	.	O

1	The	O
2	known	O
3	B1	O
4	-	O
5	deficiency	O
6	reaches	O
7	excessive	O
8	high	O
9	values	O
10	with	O
11	light	O
12	exercise	O
13	.	O

1	Autotransfusion	O
2	was	O
3	performed	O
4	as	O
5	follows	O
6	:	O
7	Heparin	O
8	-	O
9	ACD	O
10	-	O
11	B	O
12	-	O
13	Heparin	O
14	-	O
15	DPD	O
16	-	O
17	Heparin	O
18	-	O
19	ACD	O
20	-	O
21	B	O
22	etc	O
23	.	O

1	Electron	O
2	microscopic	O
3	picture	O
4	of	O
5	the	O
6	cerebral	O
7	cortex	O
8	in	O
9	rats	O
10	cooled	O
11	to	O
12	22	O
13	degrees	O
14	C	O

1	A	O
2	simplified	O
3	thin	O
4	-	O
5	layer	O
6	chromatographic	O
7	determination	O
8	of	O
9	hippuric	O
10	acid	O
11	and	O
12	methylhippuric	O
13	acids	O
14	.	O

1	MSMS	O
2	Council	O
3	hears	O
4	new	O
5	public	O
6	health	O
7	director	O
8	.	O

1	The	O
2	quantitative	O
3	determination	O
4	of	O
5	HBSAG	B
6	--	O
7	a	O
8	valuable	O
9	aid	O
10	in	O
11	evaluating	O
12	the	O
13	infectiousness	O
14	of	O
15	hepatitis	O
16	B	O
17	virus	O
18	carriers	O

1	Arachnoid	O
2	cyst	O
3	.	O

1	100	O
2	more	O
3	than	O
4	in	O
5	the	O
6	summer	O
7	coat	O
8	).	O

1	Therefore	O
2	the	O
3	procedure	O
4	of	O
5	Lich	O
6	-	O
7	Gregoir	O
8	is	O
9	not	O
10	to	O
11	be	O
12	recommended	O
13	in	O
14	adults	O
15	.	O

1	Twenty	O
2	patients	O
3	aged	O
4	45	O
5	or	O
6	older	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	endogenous	O
12	depression	O
13	were	O
14	evaluated	O
15	in	O
16	terms	O
17	of	O
18	safety	O
19	and	O
20	efficacy	O
21	in	O
22	their	O
23	response	O
24	to	O
25	multiple	O
26	monitored	O
27	electroconvulsive	O
28	therapy	O
29	(	O
30	MMECT	O
31	)	O
32	versus	O
33	single	O
34	electroconvulsive	O
35	therapy	O
36	(	O
37	SECT	O
38	).	O

1	Two	O
2	new	O
3	artifacts	O
4	in	O
5	automated	O
6	coagulation	O
7	testing	O
8	.	O

1	This	O
2	relatively	O
3	simple	O
4	and	O
5	easily	O
6	performed	O
7	technique	O
8	of	O
9	measuring	O
10	deep	O
11	muscle	O
12	temperature	O
13	appears	O
14	to	O
15	be	O
16	a	O
17	useful	O
18	adjunct	O
19	in	O
20	choosing	O
21	the	O
22	amputation	O
23	level	O
24	.	O

1	Longitudinal	O
2	force	O
3	-	O
4	length	O
5	relationships	O
6	of	O
7	guinea	O
8	pig	O
9	ureter	O
10	were	O
11	studied	O
12	in	O
13	vitro	O
14	in	O
15	animals	O
16	3	O
17	weeks	O
18	,	O
19	3	O
20	months	O
21	,	O
22	and	O
23	3	O
24	years	O
25	of	O
26	age	O
27	.	O

1	Tests	O
2	of	O
3	the	O
4	method	O
5	indicate	O
6	(	O
7	1	O
8	)	O
9	the	O
10	Mossbauer	O
11	source	O
12	can	O
13	be	O
14	placed	O
15	on	O
16	the	O
17	basilar	O
18	membrane	O
19	without	O
20	altering	O
21	the	O
22	signal	O
23	-	O
24	transmission	O
25	properties	O
26	of	O
27	the	O
28	cochlea	O
29	,	O
30	and	O
31	(	O
32	2	O
33	)	O
34	the	O
35	source	O
36	adheres	O
37	to	O
38	the	O
39	basilar	O
40	membrane	O
41	.	O

1	The	O
2	authors	O
3	conclude	O
4	that	O
5	nonspecificity	O
6	of	O
7	low	O
8	platelet	B
9	MAO	I
10	as	O
11	a	O
12	possible	O
13	correlate	O
14	of	O
15	bipolar	O
16	affective	O
17	disorder	O
18	,	O
19	as	O
20	well	O
21	as	O
22	schizophrenia	O
23	,	O
24	increases	O
25	the	O
26	burden	O
27	of	O
28	proof	O
29	necessary	O
30	before	O
31	findings	O
32	of	O
33	low	O
34	platelet	B
35	MAO	I
36	can	O
37	be	O
38	accepted	O
39	as	O
40	primary	O
41	.	O

1	The	O
2	following	O
3	aspects	O
4	were	O
5	assessed	O
6	:	O
7	(	O
8	1	O
9	)	O
10	The	O
11	effect	O
12	on	O
13	the	O
14	cardiovascular	O
15	system	O
16	in	O
17	terms	O
18	of	O
19	brachial	O
20	arterial	O
21	pressure	O
22	,	O
23	pulse	O
24	rate	O
25	,	O
26	and	O
27	oxygen	O
28	consumption	O
29	(	O
30	VO2	O
31	)	O
32	during	O
33	exercise	O
34	in	O
35	5	O
36	health	O
37	volunteers	O
38	;	O
39	(	O
40	2	O
41	)	O
42	emg	O
43	activity	O
44	of	O
45	the	O
46	tibialis	O
47	anterior	O
48	and	O
49	gastrocnemius	O
50	muscles	O
51	during	O
52	exercise	O
53	in	O
54	the	O
55	same	O
56	5	O
57	volunteers	O
58	;	O
59	and	O
60	(	O
61	3	O
62	)	O
63	postexercise	O
64	ankle	O
65	pressure	O
66	changes	O
67	in	O
68	10	O
69	subjects	O
70	with	O
71	angiographically	O
72	proven	O
73	occlusive	O
74	arterial	O
75	diseases	O
76	of	O
77	the	O
78	lower	O
79	extremities	O
80	.	O

1	Blood	O
2	variables	O
3	measured	O
4	at	O
5	eight	O
6	intervals	O
7	before	O
8	,	O
9	during	O
10	,	O
11	and	O
12	after	O
13	operation	O
14	were	O
15	as	O
16	follows	O
17	:	O
18	seven	O
19	plasma	O
20	proteins	O
21	,	O
22	free	O
23	hemoglobin	B
24	,	O
25	formed	O
26	elements	O
27	,	O
28	and	O
29	clotting	O
30	functions	O
31	.	O

1	It	O
2	appears	O
3	that	O
4	the	O
5	pulmonary	O
6	gas	O
7	exchange	O
8	parenchyma	O
9	of	O
10	these	O
11	smallest	O
12	mammals	O
13	is	O
14	well	O
15	suited	O
16	to	O
17	supply	O
18	the	O
19	organism	O
20	with	O
21	the	O
22	comparatively	O
23	high	O
24	levels	O
25	of	O
26	O2	O
27	required	O
28	by	O
29	the	O
30	high	O
31	metabolic	O
32	rates	O
33	,	O
34	exhibiting	O
35	a	O
36	structural	O
37	adaptation	O
38	of	O
39	the	O
40	lung	O
41	to	O
42	higher	O
43	VO2	O
44	.	O

1	However	O
2	,	O
3	at	O
4	lower	O
5	temperature	O
6	the	O
7	positive	O
8	staircase	O
9	was	O
10	not	O
11	clear	O
12	and	O
13	rather	O
14	negative	O
15	staircase	O
16	appeared	O
17	(	O
18	1	O
19	--	O
20	3	O
21	Hz	O
22	).	O

1	A	O
2	16	O
3	-	O
4	year	O
5	follow	O
6	-	O
7	up	O
8	study	O
9	of	O
10	69	O
11	paraplegics	O
12	with	O
13	complete	O
14	lesions	O
15	from	O
16	T1	O
17	-	O
18	L3	O
19	is	O
20	presented	O
21	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	In	O
2	spite	O
3	of	O
4	this	O
5	and	O
6	other	O
7	complications	O
8	of	O
9	corticosteroids	O
10	,	O
11	she	O
12	made	O
13	a	O
14	full	O
15	recovery	O
16	from	O
17	the	O
18	fungal	O
19	infection	O
20	following	O
21	treatment	O
22	with	O
23	amphotericin	O
24	B	O
25	and	O
26	surgical	O
27	excision	O
28	of	O
29	the	O
30	lung	O
31	abscess	O
32	.	O

1	For	O
2	the	O
3	study	O
4	of	O
5	the	O
6	transition	O
7	of	O
8	long	O
9	to	O
10	short	O
11	waves	O
12	(	O
13	deep	O
14	-	O
15	water	O
16	waves	O
17	)	O
18	a	O
19	closed	O
20	-	O
21	form	O
22	solution	O
23	is	O
24	advantageous	O
25	;	O
26	this	O
27	can	O
28	,	O
29	however	O
30	,	O
31	only	O
32	be	O
33	obtained	O
34	at	O
35	the	O
36	cost	O
37	of	O
38	further	O
39	simplification	O
40	.	O

1	Fasting	O
2	plasma	O
3	and	O
4	lipoprotein	O
5	lipid	O
6	concentrations	O
7	,	O
8	adipose	B
9	tissue	I
10	lipoprotein	I
11	lipase	I
12	activity	O
13	,	O
14	anthropometric	O
15	data	O
16	,	O
17	alcohol	O
18	consumption	O
19	,	O
20	smoking	O
21	habits	O
22	,	O
23	weekly	O
24	mileage	O
25	run	O
26	and	O
27	performance	O
28	on	O
29	a	O
30	bicycle	O
31	ergometer	O
32	were	O
33	recorded	O
34	before	O
35	and	O
36	after	O
37	the	O
38	training	O
39	period	O
40	.	O

1	Thirty	O
2	cadaver	O
3	brains	O
4	were	O
5	examined	O
6	under	O
7	X	O
8	6	O
9	to	O
10	16	O
11	magnification	O
12	in	O
13	order	O
14	to	O
15	define	O
16	the	O
17	microsurgical	O
18	anatomy	O
19	of	O
20	the	O
21	pineal	O
22	region	O
23	,	O
24	particularly	O
25	the	O
26	relationship	O
27	of	O
28	the	O
29	pineal	O
30	body	O
31	,	O
32	posterior	O
33	cerebral	O
34	artery	O
35	,	O
36	superior	O
37	cerebellar	O
38	artery	O
39	,	O
40	vein	O
41	of	O
42	Galen	O
43	,	O
44	basal	O
45	vein	O
46	of	O
47	Rosenthal	O
48	,	O
49	internal	O
50	cerebral	O
51	vein	O
52	,	O
53	straight	O
54	sinus	O
55	,	O
56	bridging	O
57	vein	O
58	,	O
59	the	O
60	size	O
61	of	O
62	the	O
63	tentorial	O
64	notch	O
65	,	O
66	and	O
67	the	O
68	third	O
69	and	O
70	the	O
71	fourth	O
72	cranial	O
73	nerves	O
74	.	O

1	Serum	O
2	antibody	O
3	titre	O
4	was	O
5	not	O
6	significantly	O
7	associated	O
8	with	O
9	the	O
10	recurrence	O
11	rate	O
12	or	O
13	the	O
14	duration	O
15	of	O
16	infection	O
17	.	O

1	The	O
2	symptoms	O
3	and	O
4	objective	O
5	findings	O
6	were	O
7	caused	O
8	by	O
9	a	O
10	malignant	O
11	lymphoma	O
12	,	O
13	and	O
14	the	O
15	diagnosis	O
16	was	O
17	established	O
18	from	O
19	a	O
20	drill	O
21	biopsy	O
22	.	O

1	All	O
2	control	O
3	persons	O
4	had	O
5	a	O
6	normal	O
7	reaction	O
8	to	O
9	DNFB	O
10	.	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	All	O
2	lambs	O
3	with	O
4	B	O
5	breeding	O
6	had	O
7	significantly	O
8	higher	O
9	Hb	B
10	levels	O
11	at	O
12	the	O
13	end	O
14	of	O
15	the	O
16	experiment	O
17	than	O
18	did	O
19	NB	O
20	lambs	O
21	.	O
22	b	O
23	and	O
24	S	O
25	x	O
26	B	O
27	lambs	O
28	had	O
29	higher	O
30	(	O
31	P	O
32	<	O
33	.	O
34	05	O
35	)	O
36	Hb	B
37	levels	O
38	than	O
39	the	O
40	D	O
41	x	O
42	B	O
43	lambs	O
44	,	O
45	and	O
46	B	O
47	lambs	O
48	had	O
49	the	O
50	highest	O
51	(	O
52	P	O
53	<	O
54	.	O
55	05	O
56	)	O
57	mean	O
58	corpuscular	O
59	hemoglobin	B
60	concentrations	O
61	.	O

1	In	O
2	patients	O
3	,	O
4	the	O
5	effect	O
6	of	O
7	CCK	B
8	-	O
9	PZ	B
10	on	O
11	the	O
12	movement	O
13	of	O
14	the	O
15	terminal	O
16	part	O
17	of	O
18	the	O
19	bile	O
20	duct	O
21	was	O
22	measured	O
23	with	O
24	a	O
25	pressure	O
26	sensor	O
27	using	O
28	a	O
29	duodenofiberscope	O
30	.	O

1	In	O
2	11	O
3	patients	O
4	with	O
5	Horton	O
6	'	O
7	s	O
8	headache	O
9	morphological	O
10	investigations	O
11	(	O
12	differential	O
13	white	O
14	blood	O
15	cell	O
16	count	O
17	),	O
18	cytoenzymatic	O
19	determinations	O
20	(	O
21	alkaline	B
22	and	I
23	acid	I
24	phosphatase	I
25	,	O
26	non	B
27	-	I
28	specific	I
29	esterase	I
30	)	O
31	and	O
32	cytoimmunological	O
33	tests	O
34	(	O
35	IgM	B
36	and	O
37	IgG	B
38	binding	O
39	)	O
40	were	O
41	carried	O
42	out	O
43	on	O
44	capillary	O
45	blood	O
46	neutrophils	O
47	obtained	O
48	from	O
49	the	O
50	area	O
51	of	O
52	pain	O
53	,	O
54	non	O
55	-	O
56	painful	O
57	area	O
58	of	O
59	the	O
60	skin	O
61	on	O
62	the	O
63	head	O
64	on	O
65	the	O
66	contralateral	O
67	side	O
68	,	O
69	and	O
70	from	O
71	the	O
72	finger	O
73	.	O

1	At	O
2	4	O
3	wk	O
4	however	O
5	,	O
6	tumor	O
7	relapse	O
8	was	O
9	noted	O
10	in	O
11	6	O
12	of	O
13	7	O
14	group	O
15	4	O
16	responders	O
17	,	O
18	10	O
19	of	O
20	12	O
21	in	O
22	group	O
23	5	O
24	,	O
25	13	O
26	of	O
27	16	O
28	in	O
29	group	O
30	7	O
31	,	O
32	but	O
33	only	O
34	4	O
35	of	O
36	19	O
37	group	O
38	8	O
39	responders	O
40	(	O
41	p	O
42	less	O
43	than	O
44	.	O
45	001	O
46	group	O
47	8	O
48	versus	O
49	4	O
50	,	O
51	5	O
52	,	O
53	7	O
54	).	O

1	Early	O
2	infection	O
3	was	O
4	detected	O
5	in	O
6	one	O
7	of	O
8	50	O
9	control	O
10	women	O
11	who	O
12	gave	O
13	birth	O
14	to	O
15	a	O
16	healthy	O
17	infant	O
18	.	O

1	Family	O
2	planning	O
3	continues	O
4	to	O
5	play	O
6	a	O
7	minor	O
8	role	O
9	,	O
10	and	O
11	only	O
12	25	O
13	.	O
14	3	O
15	per	O
16	cent	O
17	of	O
18	all	O
19	patients	O
20	reviewed	O
21	took	O
22	to	O
23	oral	O
24	contraceptives	O
25	for	O
26	shorter	O
27	or	O
28	longer	O
29	periods	O
30	of	O
31	time	O
32	.	O
33	-	O
34	The	O
35	percentages	O
36	of	O
37	primiparae	O
38	and	O
39	secundiparae	O
40	in	O
41	all	O
42	births	O
43	as	O
44	well	O
45	as	O
46	the	O
47	high	O
48	percentage	O
49	of	O
50	multigravidity	O
51	are	O
52	parameters	O
53	by	O
54	which	O
55	the	O
56	approach	O
57	to	O
58	reproduction	O
59	differs	O
60	substantively	O
61	from	O
62	behaviour	O
63	patterns	O
64	in	O
65	Europe	O
66	.	O

1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	I
16	amino	I
17	acid	I
18	residues	I
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O

1	BSE	O
2	and	O
3	farmworkers	O
4	.	O

1	Peroxisome	B
2	proliferator	I
3	-	I
4	activated	I
5	receptors	I
6	(	O
7	PPARs	B
8	)	O
9	and	O
10	retinoid	B
11	X	I
12	receptors	I
13	(	O
14	RXRs	B
15	)	O
16	are	O
17	nuclear	B
18	hormone	I
19	receptors	I
20	that	O
21	are	O
22	activated	O
23	by	O
24	fatty	O
25	acids	O
26	and	O
27	9	O
28	-	O
29	cis	O
30	-	O
31	retinoic	O
32	acid	O
33	,	O
34	respectively	O
35	.	O

1	Some	O
2	strains	O
3	of	O
4	A	O
5	.	O
6	parasiticus	O
7	produced	O
8	all	O
9	four	O
10	aflatoxins	O
11	B1	O
12	B2	O
13	G1	O
14	G2	O
15	,	O
16	while	O
17	the	O
18	other	O
19	ones	O
20	produced	O
21	AF	O
22	B1	O
23	+	O
24	G1	O
25	only	O
26	,	O
27	with	O
28	concentrations	O
29	of	O
30	aflatoxins	O
31	from	O
32	0	O
33	.	O
34	1	O
35	to	O
36	450	O
37	mg	O
38	/	O
39	kg	O
40	.	O

1	These	O
2	HPV16	O
3	E6	B
4	/	O
5	E7	B
6	cDNAs	O
7	were	O
8	cloned	O
9	under	O
10	the	O
11	SV40	B
12	enhancer	I
13	/	I
14	promoter	I
15	and	O
16	the	O
17	MMTV	B
18	LTR	I
19	to	O
20	examine	O
21	the	O
22	activities	O
23	of	O
24	ras	B
25	-	O
26	collaborative	O
27	transformation	O
28	and	O
29	induction	O
30	of	O
31	cellular	O
32	DNA	O
33	synthesis	O
34	,	O
35	both	O
36	of	O
37	which	O
38	depend	O
39	on	O
40	the	O
41	E7	B
42	gene	I
43	product	O
44	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	IgE	B
6	,	O
7	and	O
8	asIgE	B
9	and	O
10	IgG	B
11	-	I
12	4	I
13	against	O
14	14	O
15	common	O
16	food	O
17	allergens	O
18	were	O
19	determined	O
20	.	O

1	The	O
2	influenza	O
3	virus	O
4	NS1	B
5	protein	O
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O

1	Comparison	O
2	to	O
3	other	O
4	coxI	B
5	genes	I
6	revealed	O
7	a	O
8	966	O
9	-	O
10	bp	O
11	group	O
12	I	O
13	intron	O
14	,	O
15	which	O
16	,	O
17	based	O
18	on	O
19	homology	O
20	with	O
21	the	O
22	related	O
23	yeast	B
24	coxI	I
25	intron	I
26	aI4	I
27	,	O
28	potentially	O
29	encodes	O
30	a	O
31	279	O
32	-	O
33	amino	O
34	-	O
35	acid	O
36	site	O
37	-	O
38	specific	O
39	DNA	B
40	endonuclease	I
41	.	O

1	The	O
2	promoter	O
3	mutation	O
4	is	O
5	complemented	O
6	in	O
7	trans	O
8	by	O
9	E1A	B
10	products	O
11	of	O
12	the	O
13	heterologous	O
14	helper	O
15	adenovirus	O
16	type	O
17	5	O
18	(	O
19	Ad5	O
20	).	O

1	Thus	O
2	,	O
3	as	O
4	expected	O
5	,	O
6	trans	O
7	-	O
8	splicing	O
9	depends	O
10	on	O
11	the	O
12	integrity	O
13	of	O
14	U2	B
15	,	O
16	U4	B
17	,	O
18	and	O
19	U6	B
20	snRNAs	I
21	.	O

1	Thus	O
2	,	O
3	transcriptional	O
4	regulation	O
5	,	O
6	splicing	O
7	,	O
8	kinase	O
9	interaction	O
10	sites	O
11	,	O
12	and	O
13	tyrosine	O
14	phosphorylation	O
15	of	O
16	the	O
17	LMP2A	B
18	homologs	I
19	have	O
20	been	O
21	conserved	O
22	despite	O
23	significant	O
24	sequences	O
25	heterogeneity	O
26	in	O
27	the	O
28	preterminal	O
29	repeat	O
30	regions	O
31	of	O
32	these	O
33	human	O
34	and	O
35	nonhuman	O
36	primate	O
37	EBVs	O
38	.	O

1	The	O
2	second	O
3	mutation	O
4	present	O
5	in	O
6	the	O
7	original	O
8	mutant	O
9	proved	O
10	to	O
11	be	O
12	an	O
13	allele	O
14	of	O
15	a	O
16	known	O
17	gene	O
18	,	O
19	PBS2	B
20	,	O
21	which	O
22	encodes	O
23	a	O
24	putative	O
25	protein	O
26	kinase	O
27	that	O
28	functions	O
29	in	O
30	the	O
31	high	O
32	osmolarity	O
33	stress	O
34	pathway	O
35	.	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	B
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	transiently	O
8	expressed	O
9	in	O
10	primary	O
11	cultures	O
12	of	O
13	rat	O
14	hepatocytes	O
15	plasmids	O
16	consisting	O
17	of	O
18	CYP3A1	B
19	5	I
20	'-	I
21	flanking	I
22	sequences	I
23	fused	O
24	to	O
25	a	O
26	chloramphenicol	B
27	acetyltransferase	I
28	reporter	I
29	plasmid	O
30	.	O

1	A	O
2	tobacco	O
3	homologue	O
4	(	O
5	trolC	B
6	)	O
7	of	O
8	the	O
9	rolC	B
10	gene	I
11	of	I
12	the	I
13	Agrobacterium	I
14	rhizogenes	I
15	Ri	I
16	-	I
17	plasmid	I
18	was	O
19	cloned	O
20	and	O
21	sequenced	O
22	from	O
23	Nicotiana	O
24	tabacum	O
25	L	O
26	.	O
27	cv	O
28	.	O

1	A	O
2	water	O
3	-	O
4	vapour	O
5	giga	O
6	-	O
7	maser	O
8	in	O
9	the	O
10	active	O
11	galaxy	O
12	TXFS2226	O
13	-	O
14	184	O
15	.	O

1	These	O
2	incisors	O
3	were	O
4	studied	O
5	by	O
6	scanning	O
7	electron	O
8	microscopy	O
9	-	O
10	energy	O
11	dispersive	O
12	spectroscopy	O
13	analysis	O
14	(	O
15	SEM	O
16	-	O
17	EDS	O
18	)	O
19	and	O
20	light	O
21	microscopy	O
22	to	O
23	examine	O
24	the	O
25	calciotraumatic	O
26	lines	O
27	of	O
28	strontium	O
29	in	O
30	the	O
31	rat	O
32	incisor	O
33	labial	O
34	dentin	O
35	.	O

1	We	O
2	have	O
3	also	O
4	tested	O
5	Src	B
6	SH2	I
7	mutants	O
8	for	O
9	their	O
10	binding	O
11	properties	O
12	and	O
13	have	O
14	interpreted	O
15	our	O
16	results	O
17	in	O
18	light	O
19	of	O
20	the	O
21	recent	O
22	crystal	O
23	structure	O
24	solution	O
25	for	O
26	the	O
27	Src	B
28	SH2	I
29	domain	O
30	.	O

1	Mechanism	O
2	of	O
3	enhancement	O
4	of	O
5	DNA	O
6	expression	O
7	consequent	O
8	to	O
9	cointernalization	O
10	of	O
11	a	O
12	replication	O
13	-	O
14	deficient	O
15	adenovirus	O
16	and	O
17	unmodified	O
18	plasmid	O
19	DNA	O
20	.	O

1	The	O
2	avidin	B
3	-	I
4	biotin	I
5	complex	I
6	peroxidase	I
7	(	O
8	ABC	B
9	-	I
10	P	I
11	)	O
12	method	O
13	was	O
14	used	O
15	to	O
16	detect	O
17	Mycobacterium	O
18	bovis	O
19	,	O
20	and	O
21	the	O
22	results	O
23	were	O
24	compared	O
25	with	O
26	those	O
27	obtained	O
28	by	O
29	the	O
30	Ziehl	O
31	-	O
32	Neelsen	O
33	(	O
34	ZN	O
35	)	O
36	technique	O
37	.	O

1	The	O
2	transforming	O
3	gene	O
4	of	O
5	the	O
6	avian	B
7	sarcoma	I
8	virus	I
9	CT10	I
10	encodes	O
11	a	O
12	fusion	O
13	protein	O
14	(	O
15	p47gag	B
16	-	O
17	crk	B
18	or	O
19	v	B
20	-	I
21	Crk	I
22	)	O
23	containing	O
24	viral	B
25	Gag	I
26	sequences	I
27	fused	O
28	to	O
29	cellular	O
30	sequences	O
31	consisting	O
32	primarily	O
33	of	O
34	Src	B
35	homology	I
36	regions	I
37	2	I
38	and	I
39	3	I
40	(	O
41	SH2	B
42	and	O
43	SH3	B
44	sequences	I
45	).	O

1	Long	O
2	-	O
3	range	O
4	mapping	O
5	of	O
6	the	O
7	11q23	O
8	region	O
9	involved	O
10	in	O
11	chromosome	O
12	aberrations	O
13	in	O
14	human	O
15	tumors	O
16	by	O
17	pulsed	O
18	-	O
19	field	O
20	gel	O
21	electrophoresis	O
22	with	O
23	a	O
24	yeast	O
25	artificial	O
26	chromosome	O
27	.	O

1	GTRE	O
2	,	O
3	TRE	O
4	,	O
5	and	O
6	CRE	O
7	oligonucleotides	O
8	all	O
9	compete	O
10	more	O
11	efficiently	O
12	for	O
13	protein	O
14	binding	O
15	to	O
16	their	O
17	labeled	O
18	congeners	O
19	than	O
20	for	O
21	protein	O
22	binding	O
23	to	O
24	either	O
25	of	O
26	the	O
27	other	O
28	labeled	O
29	oligonucleotides	O
30	,	O
31	suggesting	O
32	that	O
33	the	O
34	GTRE	O
35	,	O
36	TRE	O
37	,	O
38	and	O
39	CRE	O
40	oligonucleotides	O
41	,	O
42	suggesting	O
43	that	O
44	the	O
45	GTRE	O
46	,	O
47	TRE	O
48	,	O
49	and	O
50	CRE	O
51	oligonucleotides	O
52	each	O
53	bind	O
54	unique	O
55	as	O
56	well	O
57	as	O
58	common	O
59	proteins	O
60	,	O
61	likely	O
62	to	O
63	be	O
64	members	O
65	of	O
66	the	O
67	Jun	B
68	/	O
69	Fos	B
70	and	O
71	cAMP	B
72	-	I
73	responsive	I
74	element	I
75	-	I
76	binding	I
77	protein	I
78	/	O
79	activating	B
80	transcription	I
81	factors	I
82	(	O
83	CREB	B
84	/	O
85	ATF	B
86	)	O
87	families	O
88	of	O
89	transcription	O
90	factors	O
91	,	O
92	in	O
93	chromaffin	O
94	cells	O
95	.	O

1	The	O
2	lymph	O
3	nodes	O
4	from	O
5	two	O
6	of	O
7	the	O
8	patients	O
9	with	O
10	rheumatoid	O
11	arthritis	O
12	contained	O
13	numerous	O
14	sarcoid	O
15	like	O
16	granulomata	O
17	,	O
18	further	O
19	indicating	O
20	a	O
21	possible	O
22	association	O
23	between	O
24	sarcoidosis	O
25	and	O
26	rheumatoid	O
27	arthritis	O
28	.	O

1	Tyrosine	O
2	phosphorylation	O
3	of	O
4	cellular	O
5	proteins	O
6	is	O
7	the	O
8	earliest	O
9	identifiable	O
10	event	O
11	following	O
12	T	B
13	-	I
14	cell	I
15	antigen	I
16	receptor	I
17	(	O
18	TCR	B
19	)	O
20	stimulation	O
21	and	O
22	is	O
23	essential	O
24	for	O
25	activating	O
26	downstream	O
27	signaling	O
28	machinery	O
29	.	O

1	Moreover	O
2	,	O
3	Lck	B
4	was	O
5	reversibly	O
6	co	O
7	-	O
8	immunoprecipitated	O
9	with	O
10	p95Vav	B
11	,	O
12	and	O
13	the	O
14	stoichiometry	O
15	of	O
16	binding	O
17	increased	O
18	in	O
19	anti	B
20	-	I
21	CD3	I
22	-	O
23	treated	O
24	Jurkat	O
25	cells	O
26	.	O

1	In	O
2	contrast	O
3	,	O
4	injection	O
5	of	O
6	a	O
7	plasmid	O
8	encoding	O
9	simian	B
10	virus	I
11	40	I
12	small	I
13	t	I
14	antigen	I
15	,	O
16	which	O
17	interacts	O
18	with	O
19	PP2A	B
20	to	O
21	inhibit	O
22	its	O
23	activity	O
24	towards	O
25	several	O
26	phosphoprotein	O
27	substrates	O
28	,	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	the	O
34	phosphorylation	O
35	state	O
36	of	O
37	CREB	B
38	in	O
39	stimulated	O
40	or	O
41	unstimulated	O
42	NIH	O
43	3T3	O
44	cells	O
45	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	effect	O
6	of	O
7	proteolytic	O
8	processing	O
9	in	O
10	the	O
11	MVE	O
12	nonstructural	O
13	polyprotein	O
14	segment	O
15	mediated	O
16	by	O
17	the	O
18	viral	B
19	proteinase	I
20	NS3	I
21	on	O
22	antigen	O
23	processing	O
24	and	O
25	presentation	O
26	of	O
27	the	O
28	MVE	O
29	H	O
30	-	O
31	2Kk	O
32	-	O
33	restricted	O
34	T	O
35	cell	O
36	determinant	O
37	.	O

1	Two	O
2	promoters	O
3	were	O
4	identified	O
5	by	O
6	S1	B
7	nuclease	I
8	mapping	O
9	:	O
10	P1	O
11	,	O
12	which	O
13	lies	O
14	about	O
15	72	O
16	bp	O
17	upstream	O
18	from	O
19	the	O
20	structural	O
21	gene	O
22	;	O
23	and	O
24	P2	O
25	,	O
26	which	O
27	lies	O
28	about	O
29	35	O
30	bp	O
31	upstream	O
32	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	cells	O
7	containing	O
8	a	O
9	PTP1C	B
10	in	O
11	which	O
12	the	O
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	O
25	.	O

1	In	O
2	the	O
3	B6	O
4	-	O
5	derived	O
6	Db	B
7	mutant	I
8	B6	I
9	.	I
10	CH	I
11	-	I
12	2bm13	I
13	(	I
14	bm13	I
15	)	I
16	strain	O
17	,	O
18	part	O
19	of	O
20	the	O
21	class	B
22	I	I
23	Db	I
24	antigen	I
25	-	I
26	presenting	I
27	groove	I
28	is	O
29	shaped	O
30	by	O
31	a	O
32	class	B
33	I	I
34	Kb	I
35	-	I
36	encoded	I
37	sequence	I
38	.	O

1	Effects	O
2	of	O
3	alterations	O
4	of	O
5	primer	O
6	-	O
7	binding	O
8	site	O
9	sequences	O
10	on	O
11	human	O
12	immunodeficiency	O
13	virus	O
14	type	O
15	1	O
16	replication	O
17	.	O

1	The	O
2	results	O
3	revealed	O
4	a	O
5	hierarchy	O
6	of	O
7	ligand	O
8	affinities	O
9	that	O
10	mirrored	O
11	their	O
12	adhesive	O
13	activity	O
14	(	O
15	rsVCAM	B
16	-	I
17	1	I
18	>	O
19	fibronectin	B
20	variants	I
21	containing	O
22	CS1	B
23	>>	O
24	other	O
25	fibronectin	B
26	variants	I
27	).	O

1	Dilutions	O
2	of	O
3	H	B
4	-	I
5	2b	I
6	or	I
7	H	I
8	-	I
9	2d	I
10	NP	I
11	peptides	I
12	indicated	O
13	that	O
14	3	O
15	-	O
16	4	O
17	logs	O
18	less	O
19	H	B
20	-	I
21	2b	I
22	NP	I
23	peptide	I
24	was	O
25	required	O
26	to	O
27	sensitize	O
28	syngeneic	O
29	target	O
30	cells	O
31	for	O
32	CTL	O
33	-	O
34	specific	O
35	lysis	O
36	,	O
37	suggesting	O
38	that	O
39	the	O
40	differing	O
41	affinities	O
42	of	O
43	H	O
44	-	O
45	2b	O
46	and	O
47	H	O
48	-	O
49	2d	O
50	major	B
51	histocompatibility	I
52	complex	I
53	molecules	I
54	for	O
55	their	O
56	peptides	O
57	likely	O
58	account	O
59	for	O
60	the	O
61	total	O
62	removal	O
63	of	O
64	NP	O
65	CTL	O
66	in	O
67	the	O
68	H	O
69	-	O
70	2b	O
71	mice	O
72	but	O
73	only	O
74	partial	O
75	removal	O
76	in	O
77	H	O
78	-	O
79	2d	O
80	mice	O
81	made	O
82	to	O
83	express	O
84	thymic	O
85	NP	O
86	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	B
5	human	I
6	SLF	I
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	B
19	-	I
20	kit	I
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	Horvath	O
2	,	O
3	I	O
4	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	these	O
6	sequences	O
7	located	O
8	immediately	O
9	3	O
10	'	O
11	to	O
12	the	O
13	breakpoint	O
14	of	O
15	the	O
16	HPFH	B
17	-	I
18	3	I
19	deletion	I
20	,	O
21	exhibit	O
22	both	O
23	the	O
24	structure	O
25	and	O
26	the	O
27	function	O
28	of	O
29	an	O
30	enhancer	O
31	,	O
32	and	O
33	can	O
34	modify	O
35	the	O
36	developmental	O
37	specificity	O
38	of	O
39	the	O
40	fetal	B
41	gamma	I
42	-	I
43	globin	I
44	genes	I
45	,	O
46	resulting	O
47	in	O
48	their	O
49	continued	O
50	expression	O
51	during	O
52	adult	O
53	life	O
54	.	O

1	In	O
2	vivo	O
3	association	O
4	between	O
5	Shb	B
6	-	O
7	SH3	B
8	domain	O
9	proteins	O
10	v	B
11	-	I
12	Src	I
13	and	O
14	Eps8	B
15	was	O
16	detected	O
17	by	O
18	coimmunoprecipitation	O
19	.	O

1	Experiments	O
2	with	O
3	recombinant	O
4	proteins	O
5	showed	O
6	that	O
7	p50	B
8	/	O
9	p65	B
10	and	O
11	high	B
12	-	I
13	mobility	I
14	-	I
15	group	I
16	I	I
17	(	I
18	Y	I
19	)	I
20	protein	I
21	cooperatively	O
22	facilitated	O
23	the	O
24	binding	O
25	of	O
26	IRF	B
27	-	I
28	1	I
29	to	O
30	the	O
31	VCAM1	B
32	IRF	I
33	binding	I
34	site	I
35	and	O
36	that	O
37	IRF	B
38	-	I
39	1	I
40	physically	O
41	interacted	O
42	with	O
43	p50	B
44	and	O
45	with	O
46	high	B
47	-	I
48	mobility	I
49	-	I
50	group	I
51	I	I
52	(	I
53	Y	I
54	)	I
55	protein	I
56	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	the	O
7	isolation	O
8	of	O
9	a	O
10	Fab	B
11	fragment	I
12	(	O
13	Fab	B
14	A8	I
15	)	O
16	showing	O
17	a	O
18	high	O
19	relative	O
20	affinity	O
21	for	O
22	the	O
23	receptor	O
24	(	O
25	0	O
26	.	O
27	5	O
28	nM	O
29	).	O

1	The	O
2	fusion	O
3	proteins	O
4	were	O
5	tested	O
6	by	O
7	ELISA	O
8	for	O
9	reactivity	O
10	with	O
11	a	O
12	panel	O
13	of	O
14	human	B
15	anti	I
16	-	I
17	La	I
18	sera	I
19	in	O
20	order	O
21	to	O
22	define	O
23	the	O
24	nature	O
25	of	O
26	the	O
27	epitopes	O
28	.	O

1	GCD10	B
2	was	O
3	first	O
4	identified	O
5	genetically	O
6	as	O
7	a	O
8	translational	O
9	repressor	O
10	of	O
11	GCN4	B
12	.	O

1	Both	O
2	PPC	O
3	-	O
4	1	O
5	and	O
6	ALVA	O
7	-	O
8	31	O
9	cells	O
10	display	O
11	tumorigenesis	O
12	and	O
13	invasiveness	O
14	in	O
15	nude	O
16	mice	O
17	,	O
18	whereas	O
19	LNCap	O
20	cells	O
21	exhibit	O
22	a	O
23	less	O
24	malignant	O
25	phenotype	O
26	,	O
27	suggesting	O
28	a	O
29	correlation	O
30	between	O
31	CD44	B
32	variant	I
33	(	O
34	CD44v	B
35	)	O
36	expression	O
37	and	O
38	aggressive	O
39	prostate	O
40	tumor	O
41	behavior	O
42	.	O

1	The	O
2	gene	O
3	product	O
4	of	O
5	cotS	B
6	was	O
7	confirmed	O
8	to	O
9	be	O
10	identical	O
11	to	O
12	Cot40	B
13	-	I
14	2	I
15	by	O
16	SDS	O
17	-	O
18	PAGE	O
19	and	O
20	immunoblotting	O
21	from	O
22	Escherichia	O
23	coli	O
24	transformed	O
25	with	O
26	a	O
27	plasmid	O
28	containing	O
29	the	O
30	cotS	B
31	region	I
32	.	O

1	We	O
2	showed	O
3	previously	O
4	that	O
5	a	O
6	fusion	O
7	protein	O
8	(	O
9	GAL4	B
10	-	O
11	p40	B
12	)	O
13	containing	O
14	the	O
15	DNA	O
16	-	O
17	binding	O
18	domain	O
19	of	O
20	GAL4	B
21	and	O
22	sequences	O
23	of	O
24	chicken	B
25	l	I
26	kappa	I
27	B	I
28	-	I
29	alpha	I
30	(	O
31	p40	B
32	)	O
33	inhibits	O
34	growth	O
35	in	O
36	the	O
37	yeast	O
38	Saccharomyces	O
39	cerevisiae	O
40	.	O

1	Various	O
2	transcripts	O
3	are	O
4	generated	O
5	from	O
6	the	O
7	VCSA1	B
8	gene	I
9	by	O
10	alternative	O
11	splicing	O
12	and	O
13	poly	O
14	(	O
15	A	O
16	)	O
17	processing	O
18	in	O
19	the	O
20	rat	O
21	submandibular	O
22	gland	O
23	.	O

1	Closure	O
2	of	O
3	an	O
4	open	O
5	high	O
6	below	O
7	-	O
8	knee	O
9	guillotine	O
10	amputation	O
11	wound	O
12	using	O
13	a	O
14	skin	O
15	-	O
16	stretching	O
17	device	O
18	.	O

1	We	O
2	demonstrate	O
3	that	O
4	a	O
5	VT	O
6	+	O
7	peptide	O
8	was	O
9	specifically	O
10	phosphorylated	O
11	by	O
12	protein	B
13	kinase	I
14	C	I
15	(	O
16	PKC	B
17	)	O
18	in	O
19	vitro	O
20	,	O
21	but	O
22	not	O
23	by	O
24	protein	B
25	kinase	I
26	A	I
27	(	O
28	PKA	B
29	).	O

1	Indeed	O
2	,	O
3	ERM	B
4	and	O
5	c	B
6	-	I
7	Jun	I
8	synergistically	O
9	activated	O
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	R206S	B
6	HSF	I
7	substitution	O
8	exhibits	O
9	constitutive	O
10	transcriptional	O
11	activation	O
12	from	O
13	a	O
14	consensus	O
15	HSE	O
16	(	O
17	HSE2	O
18	).	O

1	The	O
2	range	O
3	of	O
4	eosinophils	O
5	was	O
6	22	O
7	-	O
8	56	O
9	%	O
10	of	O
11	the	O
12	number	O
13	of	O
14	peripheral	O
15	white	O
16	blood	O
17	cells	O
18	(	O
19	mean	O
20	nadir	O
21	33	O
22	%).	O

1	Here	O
2	we	O
3	demonstrate	O
4	genetically	O
5	that	O
6	plus	O
7	-	O
8	strand	O
9	DNA	O
10	synthesis	O
11	of	O
12	the	O
13	yeast	B
14	Ty1	I
15	element	I
16	is	O
17	initiated	O
18	at	O
19	two	O
20	sites	O
21	located	O
22	at	O
23	the	O
24	5	O
25	'	O
26	boundary	O
27	of	O
28	the	O
29	3	O
30	'	O
31	long	O
32	terminal	O
33	repeat	O
34	(	O
35	PPT1	B
36	)	O
37	and	O
38	near	O
39	the	O
40	middle	O
41	of	O
42	the	O
43	pol	B
44	gene	I
45	in	O
46	the	O
47	integrase	B
48	coding	I
49	sequence	I
50	(	O
51	PPT2	B
52	).	O

1	METHODS	O
2	:	O
3	We	O
4	obtained	O
5	maximal	O
6	inspiratory	O
7	and	O
8	expiratory	O
9	flow	O
10	-	O
11	volume	O
12	curves	O
13	in	O
14	41	O
15	unselected	O
16	patients	O
17	with	O
18	essential	O
19	tremor	O
20	(	O
21	14	O
22	males	O
23	,	O
24	27	O
25	females	O
26	,	O
27	age	O
28	61	O
29	.	O
30	7	O
31	+/-	O
32	2	O
33	.	O
34	14	O
35	years	O
36	).	O

1	The	O
2	hydropathy	O
3	plot	O
4	revealed	O
5	a	O
6	rather	O
7	hydrophilic	O
8	N	O
9	-	O
10	terminal	O
11	region	O
12	and	O
13	the	O
14	absence	O
15	of	O
16	a	O
17	hydrophobic	O
18	signal	O
19	peptide	O
20	.	O

1	Protein	O
2	electrophoresis	O
3	showed	O
4	decreased	O
5	albumin	B
6	levels	O
7	in	O
8	both	O
9	groups	O
10	,	O
11	with	O
12	lower	O
13	values	O
14	in	O
15	G2	O
16	.	O

1	An	O
2	abnormally	O
3	high	O
4	percentage	O
5	of	O
6	hypertensive	O
7	patients	O
8	(	O
9	approximately	O
10	30	O
11	%)	O
12	undergoing	O
13	cardiac	O
14	catheterization	O
15	because	O
16	of	O
17	anginal	O
18	pain	O
19	and	O
20	/	O
21	or	O
22	exercise	O
23	-	O
24	induced	O
25	ST	O
26	-	O
27	segment	O
28	depressions	O
29	has	O
30	angiographically	O
31	normal	O
32	coronary	O
33	arteries	O
34	.	O

1	cDNA	O
2	encoding	O
3	a	O
4	functional	O
5	feline	B
6	liver	I
7	/	I
8	bone	I
9	/	I
10	kidney	I
11	-	I
12	type	I
13	alkaline	I
14	phosphatase	I
15	.	O

1	Protein	B
2	kinase	I
3	C	I
4	(	O
5	PKC	B
6	),	O
7	a	O
8	widely	O
9	-	O
10	distributed	O
11	enzyme	O
12	implicated	O
13	in	O
14	the	O
15	regulation	O
16	of	O
17	many	O
18	physiological	O
19	processes	O
20	,	O
21	consists	O
22	of	O
23	a	O
24	family	O
25	of	O
26	at	O
27	least	O
28	twelve	O
29	isoenzymes	O
30	which	O
31	differ	O
32	in	O
33	tissue	O
34	distribution	O
35	,	O
36	subcellular	O
37	localization	O
38	,	O
39	regulatory	O
40	properties	O
41	,	O
42	etc	O
43	.	O

1	Here	O
2	we	O
3	focused	O
4	on	O
5	the	O
6	role	O
7	of	O
8	the	O
9	5	O
10	'	O
11	proximal	O
12	regulatory	O
13	cassette	O
14	(-	O
15	190	O
16	;	O
17	+	O
18	53	O
19	bp	O
20	)	O
21	of	O
22	the	O
23	rat	B
24	enkephalin	I
25	(	O
26	rENK	B
27	)	O
28	gene	O
29	in	O
30	the	O
31	developmental	O
32	regulation	O
33	of	O
34	the	O
35	enkephalin	B
36	phenotype	O
37	.	O

1	Estimated	O
2	daily	O
3	intakes	O
4	(	O
5	EDIs	O
6	)	O
7	per	O
8	person	O
9	were	O
10	0	O
11	.	O
12	56	O
13	microgram	O
14	for	O
15	total	O
16	HCH	O
17	,	O
18	0	O
19	.	O
20	20	O
21	microgram	O
22	for	O
23	gamma	O
24	-	O
25	HCH	O
26	,	O
27	0	O
28	.	O
29	09	O
30	microgram	O
31	for	O
32	dieldrin	O
33	,	O
34	1	O
35	.	O
36	42	O
37	micrograms	O
38	for	O
39	total	O
40	DDT	O
41	,	O
42	and	O
43	0	O
44	.	O
45	15	O
46	microgram	O
47	for	O
48	HCB	O
49	.	O

1	In	O
2	two	O
3	further	O
4	cases	O
5	(	O
6	one	O
7	type	O
8	I	O
9	and	O
10	one	O
11	type	O
12	III	O
13	SMA	O
14	),	O
15	de	O
16	novo	O
17	deletions	O
18	of	O
19	only	O
20	one	O
21	copy	O
22	of	O
23	Ag1	B
24	-	I
25	CA	I
26	and	O
27	C212	B
28	were	O
29	found	O
30	.	O

1	With	O
2	each	O
3	of	O
4	the	O
5	three	O
6	pairs	O
7	of	O
8	isolates	O
9	(	O
10	case	O
11	and	O
12	suspicious	O
13	case	O
14	),	O
15	identical	O
16	IS6110	O
17	banding	O
18	patterns	O
19	were	O
20	found	O
21	suggesting	O
22	identical	O
23	MTB	O
24	strains	O
25	.	O

1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	B
27	toxin	I
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O

1	These	O
2	early	O
3	structural	O
4	processes	O
5	are	O
6	assumed	O
7	to	O
8	be	O
9	subserved	O
10	by	O
11	the	O
12	anterior	O
13	parts	O
14	of	O
15	the	O
16	left	O
17	hemisphere	O
18	,	O
19	as	O
20	event	O
21	-	O
22	related	O
23	brain	O
24	potentials	O
25	show	O
26	this	O
27	area	O
28	to	O
29	be	O
30	maximally	O
31	activated	O
32	when	O
33	phrase	O
34	structure	O
35	violations	O
36	are	O
37	processed	O
38	and	O
39	as	O
40	circumscribed	O
41	lesions	O
42	in	O
43	this	O
44	area	O
45	lead	O
46	to	O
47	an	O
48	impairment	O
49	of	O
50	the	O
51	on	O
52	-	O
53	line	O
54	structural	O
55	assignment	O
56	.	O

1	Overexpression	O
2	of	O
3	wild	B
4	-	I
5	type	I
6	p53	I
7	also	O
8	induces	O
9	apoptosis	O
10	in	O
11	an	O
12	LCL	O
13	.	O

1	The	O
2	finding	O
3	that	O
4	the	O
5	chimeric	B
6	TdT	I
7	::	O
8	Pol	B
9	beta	I
10	protein	I
11	possessed	O
12	significant	O
13	template	O
14	-	O
15	dependent	O
16	polymerase	O
17	activity	O
18	suggests	O
19	that	O
20	aa	O
21	1	O
22	-	O
23	60	O
24	of	O
25	Pol	B
26	beta	I
27	are	O
28	involved	O
29	in	O
30	template	O
31	utilization	O
32	during	O
33	the	O
34	polymerization	O
35	reaction	O
36	,	O
37	as	O
38	suggested	O
39	by	O
40	the	O
41	previous	O
42	finding	O
43	that	O
44	the	O
45	8	O
46	-	O
47	kDa	O
48	N	O
49	-	O
50	terminal	O
51	domain	O
52	of	O
53	Pol	B
54	beta	I
55	possesses	O
56	ssDNA	O
57	-	O
58	binding	O
59	activity	O
60	[	O
61	Kumar	O
62	et	O
63	al	O
64	.,	O
65	J	O
66	.	O

1	Cholangiography	O
2	was	O
3	performed	O
4	in	O
5	all	O
6	cases	O
7	and	O
8	classified	O
9	by	O
10	a	O
11	scoring	O
12	system	O
13	specifically	O
14	developed	O
15	for	O
16	pediatric	O
17	patients	O
18	.	O

1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	O
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O

1	Altogether	O
2	our	O
3	data	O
4	indicate	O
5	that	O
6	PEDF	B
7	belongs	O
8	to	O
9	the	O
10	subgroup	O
11	of	O
12	noninhibitory	O
13	serpins	B
14	and	O
15	that	O
16	its	O
17	N	O
18	-	O
19	terminal	O
20	region	O
21	confers	O
22	a	O
23	neurite	O
24	-	O
25	promoting	O
26	activity	O
27	to	O
28	the	O
29	protein	O
30	.	O

1	We	O
2	conclude	O
3	that	O
4	this	O
5	new	O
6	measurement	O
7	technique	O
8	provides	O
9	an	O
10	easy	O
11	and	O
12	accurate	O
13	P0	O
14	.	O
15	1	O
16	measurement	O
17	using	O
18	standard	O
19	respiratory	O
20	equipment	O
21	when	O
22	tested	O
23	in	O
24	a	O
25	lung	O
26	model	O
27	.	O

1	After	O
2	cells	O
3	were	O
4	stably	O
5	transfected	O
6	with	O
7	CIITA	B
8	,	O
9	endogenous	O
10	MHC	B
11	class	I
12	II	I
13	genes	I
14	were	O
15	constitutively	O
16	expressed	O
17	,	O
18	and	O
19	MHC	B
20	class	I
21	II	I
22	promoters	I
23	,	O
24	delivered	O
25	by	O
26	transfection	O
27	,	O
28	were	O
29	actively	O
30	transcribed	O
31	in	O
32	CIITA	B
33	-	O
34	expressing	O
35	cells	O
36	.	O

1	The	O
2	peak	O
3	velocities	O
4	of	O
5	the	O
6	atrial	O
7	systolic	O
8	waves	O
9	of	O
10	the	O
11	transmitral	O
12	and	O
13	pulmonary	O
14	venous	O
15	flow	O
16	velocities	O
17	(	O
18	A	O
19	and	O
20	PVA	O
21	,	O
22	respectively	O
23	)	O
24	and	O
25	first	O
26	systolic	O
27	wave	O
28	(	O
29	PVS1	O
30	)	O
31	of	O
32	pulmonary	O
33	venous	O
34	flow	O
35	,	O
36	durations	O
37	of	O
38	both	O
39	atrial	O
40	systolic	O
41	waves	O
42	,	O
43	and	O
44	amplitude	O
45	of	O
46	interatrial	O
47	septal	O
48	motion	O
49	during	O
50	atrial	O
51	systole	O
52	increased	O
53	significantly	O
54	ten	O
55	days	O
56	after	O
57	cardioversion	O
58	compared	O
59	with	O
60	those	O
61	measured	O
62	within	O
63	a	O
64	day	O
65	of	O
66	cardioversion	O
67	in	O
68	all	O
69	patients	O
70	except	O
71	the	O
72	5	O
73	patients	O
74	with	O
75	dilated	O
76	cardiomyopathy	O
77	.	O

1	The	O
2	ORF3	O
3	probe	O
4	also	O
5	hybridized	O
6	to	O
7	a	O
8	540	O
9	bp	O
10	transcript	O
11	consistent	O
12	with	O
13	the	O
14	size	O
15	of	O
16	ORF3	O
17	alone	O
18	and	O
19	supportive	O
20	of	O
21	the	O
22	mutagenesis	O
23	data	O
24	of	O
25	non	O
26	-	O
27	linkage	O
28	.	O

1	We	O
2	conclude	O
3	that	O
4	pancreatic	O
5	polypeptide	O
6	and	O
7	motilin	B
8	responses	O
9	to	O
10	a	O
11	meal	O
12	are	O
13	different	O
14	in	O
15	encopretic	O
16	children	O
17	than	O
18	in	O
19	children	O
20	in	O
21	the	O
22	control	O
23	group	O
24	.	O

1	However	O
2	,	O
3	the	O
4	few	O
5	studies	O
6	that	O
7	address	O
8	antimicrobial	O
9	prophylaxis	O
10	in	O
11	bone	O
12	marrow	O
13	transplantation	O
14	have	O
15	not	O
16	always	O
17	shown	O
18	a	O
19	survival	O
20	benefit	O
21	.	O

1	By	O
2	in	O
3	vitro	O
4	immunoprecipitations	O
5	and	O
6	gel	O
7	shift	O
8	assays	O
9	,	O
10	we	O
11	identified	O
12	two	O
13	classes	O
14	of	O
15	high	O
16	affinity	O
17	Engrailed	B
18	-	I
19	binding	I
20	sites	I
21	upstream	O
22	of	O
23	each	O
24	of	O
25	the	O
26	two	O
27	polyhomeotic	O
28	transcription	O
29	units	O
30	.	O

1	Vestibular	O
2	adaptation	O
3	exercises	O
4	and	O
5	recovery	O
6	:	O
7	acute	O
8	stage	O
9	after	O
10	acoustic	O
11	neuroma	O
12	resection	O
13	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	also	O
5	reduced	O
6	at	O
7	week	O
8	12	O
9	by	O
10	17	O
11	.	O
12	0	O
13	%	O
14	(	O
15	20	O
16	mg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	15	O
22	.	O
23	7	O
24	%	O
25	(	O
26	20	O
27	-	O
28	30	O
29	mg	O
30	/	O
31	day	O
32	),	O
33	and	O
34	at	O
35	week	O
36	52	O
37	by	O
38	20	O
39	.	O
40	4	O
41	%	O
42	(<	O
43	or	O
44	=	O
45	20	O
46	mg	O
47	/	O
48	day	O
49	)	O
50	and	O
51	19	O
52	.	O
53	2	O
54	%	O
55	(>	O
56	or	O
57	=	O
58	30	O
59	mg	O
60	/	O
61	day	O
62	).	O

1	The	O
2	structural	O
3	gene	O
4	encoding	O
5	the	O
6	novel	O
7	lantibiotic	O
8	epilancin	B
9	K7	I
10	from	O
11	Staphylococcus	O
12	epidermidis	O
13	K7	O
14	was	O
15	cloned	O
16	and	O
17	its	O
18	nucleotide	O
19	sequence	O
20	was	O
21	determined	O
22	.	O

1	Increase	O
2	in	O
3	urinary	O
4	calcium	O
5	and	O
6	oxalate	O
7	after	O
8	fructose	O
9	infusion	O
10	.	O

1	To	O
2	discern	O
3	whether	O
4	these	O
5	disorders	O
6	of	O
7	GnRH	B
8	deficiency	O
9	are	O
10	associated	O
11	with	O
12	altered	O
13	melatonin	O
14	secretion	O
15	profiles	O
16	,	O
17	we	O
18	compared	O
19	untreated	O
20	young	O
21	males	O
22	IGD	O
23	(	O
24	n	O
25	=	O
26	7	O
27	)	O
28	and	O
29	DP	O
30	(	O
31	n	O
32	=	O
33	7	O
34	)	O
35	to	O
36	normal	O
37	pubertal	O
38	male	O
39	controls	O
40	(	O
41	n	O
42	=	O
43	6	O
44	).	O

1	Analysis	O
2	of	O
3	several	O
4	Tat	B
5	mutants	I
6	indicated	O
7	that	O
8	both	O
9	the	O
10	cysteine	O
11	-	O
12	rich	O
13	and	O
14	the	O
15	core	O
16	domains	O
17	of	O
18	this	O
19	transactivator	O
20	are	O
21	necessary	O
22	and	O
23	sufficient	O
24	to	O
25	activate	O
26	transcription	O
27	when	O
28	TBP	B
29	is	O
30	overexpressed	O
31	.	O

1	In	O
2	addition	O
3	,	O
4	depletion	O
5	of	O
6	Oct	B
7	-	I
8	1	I
9	from	O
10	the	O
11	nuclear	O
12	extract	O
13	by	O
14	using	O
15	Oct	B
16	-	I
17	1	I
18	-	O
19	specific	O
20	antiserum	O
21	or	O
22	a	O
23	sequence	O
24	-	O
25	specific	O
26	DNA	O
27	affinity	O
28	resin	O
29	decreased	O
30	in	O
31	vitro	O
32	transcription	O
33	from	O
34	the	O
35	wild	O
36	-	O
37	type	O
38	MMTV	O
39	promoter	O
40	to	O
41	a	O
42	level	O
43	identical	O
44	to	O
45	that	O
46	obtained	O
47	from	O
48	a	O
49	promoter	O
50	in	O
51	which	O
52	all	O
53	three	O
54	octamer	O
55	-	O
56	related	O
57	sequences	O
58	were	O
59	mutated	O
60	.	O

1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	prevalence	O
6	values	O
7	shows	O
8	clearly	O
9	that	O
10	the	O
11	global	O
12	MS	O
13	-	O
14	frequency	O
15	is	O
16	closer	O
17	related	O
18	to	O
19	the	O
20	geomagnetic	O
21	than	O
22	to	O
23	the	O
24	geographic	O
25	latitude	O
26	.	O

1	Both	O
2	mu	B
3	and	I
4	gamma	I
5	2b	I
6	heavy	I
7	chain	I
8	genes	I
9	cause	O
10	this	O
11	feedback	O
12	inhibition	O
13	of	O
14	heavy	O
15	chain	O
16	gene	O
17	rearrangement	O
18	.	O

1	The	O
2	Babcock	O
3	Surgical	O
4	Clinic	O
5	.	O

1	Histopathological	O
2	features	O
3	of	O
4	relapsed	O
5	leprosy	O
6	.	O

1	Regulation	O
2	of	O
3	Gax	B
4	homeobox	I
5	gene	I
6	transcription	O
7	by	O
8	a	O
9	combination	O
10	of	O
11	positive	O
12	factors	O
13	including	O
14	myocyte	B
15	-	I
16	specific	I
17	enhancer	I
18	factor	I
19	2	I
20	.	O

1	D	O
2	.	O

1	To	O
2	compare	O
3	the	O
4	PAX3	B
5	and	O
6	putative	O
7	PAX3	B
8	-	O
9	FKHR	B
10	transactivation	O
11	domains	O
12	,	O
13	we	O
14	fused	O
15	C	O
16	-	O
17	terminal	O
18	test	O
19	fragments	O
20	to	O
21	the	O
22	heterologous	O
23	GAL4	B
24	DNA	I
25	-	I
26	binding	I
27	domain	I
28	and	O
29	tested	O
30	activation	O
31	of	O
32	a	O
33	reporter	O
34	gene	O
35	co	O
36	-	O
37	transfected	O
38	into	O
39	four	O
40	cell	O
41	types	O
42	.	O

1	The	O
2	RAT3	B
3	gene	I
4	encodes	O
5	an	O
6	1157	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	without	O
12	similarity	O
13	to	O
14	other	O
15	known	O
16	proteins	O
17	.	O

1	Structural	O
2	organization	O
3	and	O
4	developmental	O
5	expression	O
6	pattern	O
7	of	O
8	the	O
9	mouse	B
10	WD	I
11	-	I
12	repeat	I
13	gene	I
14	DMR	I
15	-	I
16	N9	I
17	immediately	O
18	upstream	O
19	of	O
20	the	O
21	myotonic	B
22	dystrophy	I
23	locus	I
24	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	enzyme	O
9	(	O
10	CYP19	B
11	)	O
12	is	O
13	regulated	O
14	,	O
15	in	O
16	part	O
17	,	O
18	by	O
19	tissue	O
20	-	O
21	specific	O
22	promoters	O
23	through	O
24	the	O
25	use	O
26	of	O
27	alternative	O
28	-	O
29	splicing	O
30	mechanisms	O
31	.	O

1	To	O
2	investigate	O
3	the	O
4	potential	O
5	role	O
6	of	O
7	SP1	B
8	,	O
9	we	O
10	examined	O
11	nuclear	O
12	extracts	O
13	from	O
14	HCMV	O
15	-	O
16	infected	O
17	cells	O
18	.	O

1	From	O
2	May	O
3	1985	O
4	to	O
5	May	O
6	1989	O
7	,	O
8	126	O
9	necropsies	O
10	were	O
11	performed	O
12	at	O
13	the	O
14	Sao	O
15	Paulo	O
16	City	O
17	Morgue	O
18	on	O
19	cadavers	O
20	of	O
21	individuals	O
22	AIDS	O
23	victims	O
24	whose	O
25	unnatural	O
26	deaths	O
27	had	O
28	prompted	O
29	police	O
30	investigations	O
31	.	O

1	Thromboxane	O
2	B2	O
3	increased	O
4	(	O
5	97	O
6	+/-	O
7	105	O
8	versus	O
9	40	O
10	+/-	O
11	26	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	and	O
17	was	O
18	significantly	O
19	higher	O
20	during	O
21	heparin	O
22	free	O
23	hemodialysis	O
24	than	O
25	during	O
26	hemodialysis	O
27	with	O
28	heparin	O
29	(	O
30	p	O
31	=	O
32	0	O
33	.	O
34	01	O
35	,	O
36	Wilcoxon	O
37	matched	O
38	pairs	O
39	signed	O
40	rank	O
41	test	O
42	).	O

1	Conversely	O
2	,	O
3	treatment	O
4	of	O
5	human	B
6	protein	I
7	-	I
8	tyrosine	I
9	phosphatase	I
10	alpha	I
11	-	O
12	overexpressing	O
13	cells	O
14	with	O
15	phenylarsine	O
16	oxide	O
17	led	O
18	to	O
19	a	O
20	loss	O
21	of	O
22	the	O
23	constitutive	O
24	NF	B
25	-	I
26	kappa	I
27	B	I
28	activity	O
29	.	O

1	We	O
2	purified	O
3	both	O
4	proteins	O
5	from	O
6	human	O
7	platelet	O
8	membranes	O
9	using	O
10	DEAE	O
11	-	O
12	Sepharose	O
13	chromatography	O
14	followed	O
15	by	O
16	mAb	B
17	F11	I
18	affinity	O
19	chromatography	O
20	.	O

1	The	O
2	most	O
3	likely	O
4	explanation	O
5	for	O
6	this	O
7	is	O
8	that	O
9	gold	O
10	principally	O
11	accumulates	O
12	in	O
13	the	O
14	Kupffer	O
15	cells	O
16	and	O
17	renal	O
18	cortex	O
19	and	O
20	these	O
21	cells	O
22	do	O
23	not	O
24	express	O
25	Type	B
26	I	I
27	deiodinase	I
28	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	and	O
6	DNase	B
7	I	I
8	footprinting	O
9	experiments	O
10	using	O
11	purified	O
12	42	O
13	kDa	O
14	repressor	O
15	isoform	O
16	confirmed	O
17	that	O
18	CIRs	B
19	5	I
20	and	I
21	6	I
22	were	O
23	indeed	O
24	the	O
25	targets	O
26	for	O
27	binding	O
28	of	O
29	this	O
30	protein	O
31	.	O

1	Intrathecal	O
2	acetyl	B
3	cholinesterase	I
4	inhibitors	O
5	produce	O
6	analgesia	O
7	that	O
8	is	O
9	synergistic	O
10	with	O
11	morphine	O
12	and	O
13	clonidine	O
14	in	O
15	rats	O
16	.	O

1	The	O
2	yeast	O
3	enzyme	O
4	was	O
5	6	O
6	-	O
7	fold	O
8	slower	O
9	than	O
10	the	O
11	mammalian	O
12	enzymes	O
13	,	O
14	which	O
15	made	O
16	it	O
17	amenable	O
18	to	O
19	pre	O
20	-	O
21	steady	O
22	-	O
23	state	O
24	stopped	O
25	-	O
26	flow	O
27	spectroscopic	O
28	kinetic	O
29	analysis	O
30	at	O
31	30	O
32	degrees	O
33	C	O
34	and	O
35	pH	O
36	6	O
37	.	O
38	0	O
39	.	O

1	A	O
2	polymorphic	O
3	bipartite	O
4	motif	O
5	signals	O
6	nuclear	O
7	targeting	O
8	of	O
9	early	O
10	auxin	O
11	-	O
12	inducible	O
13	proteins	O
14	related	O
15	to	O
16	PS	O
17	-	O
18	IAA4	O
19	from	O
20	pea	O
21	(	O
22	Pisum	O
23	sativum	O
24	).	O

1	Transabdominal	O
2	repair	O
3	of	O
4	type	O
5	IV	O
6	thoraco	O
7	-	O
8	abdominal	O
9	aortic	O
10	aneurysms	O
11	.	O

1	EsaR	B
2	can	O
3	repress	O
4	its	O
5	own	O
6	expression	O
7	but	O
8	seems	O
9	not	O
10	to	O
11	regulate	O
12	the	O
13	expression	O
14	of	O
15	esaI	B
16	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	O
13	(	O
14	Zea	O
15	mays	O
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	Mean	O
2	longitudinal	O
3	extension	O
4	of	O
5	the	O
6	epidural	O
7	lesion	O
8	was	O
9	2	O
10	.	O
11	6	O
12	vertebral	O
13	segments	O
14	.	O

1	The	O
2	association	O
3	of	O
4	p255	B
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	B
15	CC3	I
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	O
23	pre	O
24	-	O
25	messenger	O
26	RNA	O
27	and	O
28	splicing	O
29	products	O
30	.	O

1	Genomic	O
2	structure	O
3	and	O
4	chromosomal	O
5	location	O
6	of	O
7	the	O
8	mouse	B
9	pre	I
10	-	I
11	T	I
12	-	I
13	cell	I
14	receptor	I
15	alpha	I
16	gene	I
17	.	O

1	A	O
2	single	O
3	-	O
4	case	O
5	experimental	O
6	ABAB	O
7	multiple	O
8	baseline	O
9	design	O
10	was	O
11	employed	O
12	to	O
13	test	O
14	for	O
15	treatment	O
16	effectiveness	O
17	.	O

1	The	O
2	hybridizing	O
3	clone	O
4	of	O
5	V	O
6	.	O
7	vulnificus	O
8	chromosomal	O
9	DNA	O
10	complemented	O
11	a	O
12	V	B
13	.	I
14	cholerae	I
15	fur	I
16	mutant	I
17	.	O

1	We	O
2	generated	O
3	transformed	O
4	B	O
5	lymphoblast	O
6	cell	O
7	lines	O
8	from	O
9	controls	O
10	,	O
11	from	O
12	four	O
13	patients	O
14	with	O
15	p47	B
16	-	O
17	phox	B
18	-	O
19	deficient	O
20	chronic	O
21	granulomatous	O
22	disease	O
23	,	O
24	and	O
25	from	O
26	three	O
27	parents	O
28	.	O

1	To	O
2	study	O
3	the	O
4	origin	O
5	of	O
6	different	O
7	fMLF	B
8	-	I
9	R	I
10	transcripts	I
11	,	O
12	the	O
13	genetic	O
14	linkage	O
15	of	O
16	chemotactic	O
17	receptor	O
18	genes	O
19	,	O
20	and	O
21	the	O
22	regulation	O
23	of	O
24	fMLF	B
25	-	I
26	R	I
27	gene	I
28	expression	O
29	,	O
30	we	O
31	determined	O
32	the	O
33	copy	O
34	number	O
35	,	O
36	chromosomal	O
37	location	O
38	,	O
39	structural	O
40	organization	O
41	,	O
42	and	O
43	5	O
44	'-	O
45	flanking	O
46	sequence	O
47	of	O
48	the	O
49	human	B
50	fMLF	I
51	-	I
52	R	I
53	gene	I
54	.	O

1	We	O
2	here	O
3	demonstrate	O
4	that	O
5	a	O
6	temperature	O
7	-	O
8	sensitive	O
9	fission	O
10	yeast	O
11	mutant	O
12	which	O
13	has	O
14	a	O
15	mutation	O
16	in	O
17	a	O
18	homologous	O
19	gene	O
20	,	O
21	and	O
22	two	O
23	of	O
24	three	O
25	additional	O
26	(	O
27	mtr1	B
28	/	O
29	prp20	B
30	/	O
31	srm1	B
32	)	O
33	mutants	O
34	accumulate	O
35	nuclear	O
36	poly	O
37	(	O
38	A	O
39	)+	O
40	RNA	O
41	at	O
42	37	O
43	degrees	O
44	C	O
45	.	O

1	BACKGROUND	O
2	:	O
3	Delineation	O
4	of	O
5	the	O
6	morphologic	O
7	aspects	O
8	of	O
9	age	O
10	-	O
11	related	O
12	macular	O
13	degeneration	O
14	(	O
15	ARMD	O
16	)	O
17	is	O
18	helpful	O
19	in	O
20	correlation	O
21	with	O
22	the	O
23	clinical	O
24	features	O
25	and	O
26	may	O
27	contribute	O
28	to	O
29	understanding	O
30	the	O
31	pathogenesis	O
32	.	O

1	To	O
2	determine	O
3	which	O
4	sequences	O
5	in	O
6	the	O
7	rat	B
8	P450c17	I
9	promoter	I
10	may	O
11	be	O
12	responsible	O
13	for	O
14	basal	O
15	and	O
16	cAMP	O
17	-	O
18	stimulated	O
19	gene	O
20	transcription	O
21	,	O
22	deletion	O
23	constructs	O
24	containing	O
25	between	O
26	-	O
27	1	O
28	,	O
29	560	O
30	and	O
31	-	O
32	53	O
33	base	O
34	pairs	O
35	of	O
36	5	O
37	'-	O
38	flanking	O
39	DNA	O
40	from	O
41	the	O
42	rat	B
43	P450c17	I
44	gene	I
45	were	O
46	ligated	O
47	to	O
48	plasmids	O
49	expressing	O
50	the	O
51	reporter	O
52	gene	O
53	luciferase	B
54	and	O
55	transfected	O
56	into	O
57	two	O
58	mouse	O
59	cell	O
60	lines	O
61	,	O
62	adrenal	O
63	Y	O
64	-	O
65	1	O
66	cells	O
67	,	O
68	and	O
69	testicular	O
70	Leydig	O
71	MA	O
72	-	O
73	10	O
74	cells	O
75	.	O

1	This	O
2	experimental	O
3	design	O
4	was	O
5	used	O
6	to	O
7	determine	O
8	the	O
9	effect	O
10	of	O
11	displacement	O
12	of	O
13	the	O
14	alpha	B
15	4	I
16	-	I
17	2	I
18	binding	I
19	site	I
20	on	O
21	the	O
22	repression	O
23	of	O
24	alpha	B
25	4	I
26	gene	I
27	transcription	O
28	by	O
29	ICP4	B
30	.	O

1	Immediate	O
2	-	O
3	early	O
4	transcription	O
5	from	O
6	the	O
7	channel	O
8	catfish	O
9	virus	O
10	genome	O
11	:	O
12	characterization	O
13	of	O
14	two	O
15	immediate	B
16	-	I
17	early	I
18	transcripts	I
19	.	O

1	The	O
2	GRE	O
3	at	O
4	nucleotide	O
5	7640	O
6	is	O
7	a	O
8	composite	O
9	GRE	O
10	(	O
11	cGRE	O
12	)	O
13	containing	O
14	an	O
15	overlapping	O
16	activator	B
17	protein	I
18	-	I
19	1	I
20	(	O
21	AP	B
22	-	I
23	1	I
24	)	O
25	motif	O
26	for	O
27	the	O
28	c	B
29	-	I
30	jun	I
31	homodimer	I
32	and	O
33	c	B
34	-	I
35	jun	I
36	/	O
37	c	B
38	-	I
39	fos	I
40	heterodimer	O
41	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	B
31	core	I
32	enhancer	I
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	B
38	enhancer	I
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	The	O
2	Oct	B
3	and	O
4	HMG2	B
5	proteins	I
6	also	O
7	interact	O
8	in	O
9	vivo	O
10	.	O

1	The	O
2	beta	O
3	subunit	O
4	of	O
5	the	O
6	Fc	B
7	epsilon	I
8	R1	I
9	is	O
10	a	O
11	33	O
12	-	O
13	kDa	O
14	tyrosine	O
15	phosphoprotein	O
16	,	O
17	but	O
18	the	O
19	p33	B
20	Grb2	I
21	-	I
22	binding	I
23	protein	I
24	described	O
25	in	O
26	the	O
27	present	O
28	report	O
29	is	O
30	not	O
31	the	O
32	Fc	B
33	epsilon	I
34	R1	I
35	beta	I
36	chain	I
37	and	O
38	its	O
39	identity	O
40	is	O
41	unknown	O
42	.	O

1	To	O
2	study	O
3	the	O
4	mechanisms	O
5	as	O
6	well	O
7	as	O
8	magnitude	O
9	of	O
10	the	O
11	transmembrane	O
12	transfer	O
13	of	O
14	bacterial	O
15	products	O
16	from	O
17	the	O
18	dialysate	O
19	,	O
20	we	O
21	developed	O
22	a	O
23	computerized	O
24	in	O
25	vitro	O
26	dialysis	O
27	model	O
28	which	O
29	provides	O
30	continuous	O
31	pressure	O
32	recording	O
33	from	O
34	the	O
35	arterial	O
36	,	O
37	venous	O
38	,	O
39	dialysate	O
40	inflow	O
41	and	O
42	outflow	O
43	ports	O
44	.	O

1	Each	O
2	dietary	O
3	treatment	O
4	was	O
5	fed	O
6	to	O
7	six	O
8	pen	O
9	replicates	O
10	of	O
11	five	O
12	chicks	O
13	per	O
14	pen	O
15	for	O
16	21	O
17	d	O
18	.	O

1	The	O
2	NarX	B
3	and	O
4	NarQ	B
5	proteins	I
6	with	O
7	amino	O
8	acid	O
9	substitutions	O
10	at	O
11	the	O
12	first	O
13	conserved	O
14	histidine	O
15	position	O
16	were	O
17	also	O
18	unable	O
19	to	O
20	dephosphorylate	O
21	NarL	B
22	-	O
23	phosphate	O
24	in	O
25	vitro	O
26	.	O

1	Because	O
2	ATF	B
3	-	I
4	1	I
5	and	O
6	CREM	B
7	are	O
8	known	O
9	to	O
10	bind	O
11	to	O
12	cAMP	O
13	response	O
14	elements	O
15	(	O
16	CRE	O
17	),	O
18	this	O
19	functional	O
20	sequence	O
21	was	O
22	named	O
23	the	O
24	kappa	O
25	E3	O
26	'-	O
27	CRE	O
28	.	O

1	The	O
2	Ng	B
3	/	I
4	RC3	I
5	and	O
6	PKC	B
7	-	I
8	gamma	I
9	genes	I
10	have	O
11	a	O
12	similar	O
13	expression	O
14	pattern	O
15	in	O
16	the	O
17	brain	O
18	during	O
19	development	O
20	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	known	O
8	largest	O
9	subunits	O
10	of	O
11	DdRPs	B
12	from	O
13	different	O
14	species	O
15	contain	O
16	highly	O
17	conserved	O
18	regions	O
19	.	O

1	Whole	O
2	bowel	O
3	irrigation	O
4	is	O
5	a	O
6	recently	O
7	described	O
8	technique	O
9	to	O
10	enhance	O
11	the	O
12	passage	O
13	of	O
14	drugs	O
15	already	O
16	beyond	O
17	the	O
18	pylorus	O
19	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	B
16	.	O

1	2	O
2	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SGC1	B
9	gene	I
10	product	I
11	includes	O
12	a	O
13	region	O
14	with	O
15	substantial	O
16	similarity	O
17	to	O
18	the	O
19	basic	O
20	-	O
21	helix	O
22	-	O
23	loop	O
24	-	O
25	helix	O
26	domain	O
27	of	O
28	the	O
29	Myc	B
30	family	I
31	of	O
32	DNA	O
33	-	O
34	binding	O
35	proteins	O
36	.	O

1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O

1	Analysis	O
2	of	O
3	Bcl	B
4	-	I
5	2	I
6	/	O
7	Bcl	B
8	-	I
9	2	I
10	homodimerization	O
11	using	O
12	both	O
13	in	O
14	vitro	O
15	binding	O
16	assays	O
17	as	O
18	well	O
19	as	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	method	O
26	provided	O
27	evidence	O
28	in	O
29	support	O
30	of	O
31	a	O
32	head	O
33	-	O
34	to	O
35	-	O
36	tail	O
37	model	O
38	for	O
39	Bcl	B
40	-	I
41	2	I
42	/	O
43	Bcl	B
44	-	I
45	2	I
46	homodimerization	O
47	and	O
48	revealed	O
49	that	O
50	sequences	O
51	within	O
52	the	O
53	NH2	O
54	-	O
55	terminal	O
56	A	O
57	domain	O
58	interact	O
59	with	O
60	a	O
61	structure	O
62	that	O
63	requires	O
64	the	O
65	presence	O
66	of	O
67	both	O
68	the	O
69	carboxyl	O
70	B	O
71	and	O
72	C	O
73	domains	O
74	in	O
75	combination	O
76	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O

1	Diagnosis	O
2	of	O
3	FHCS	O
4	has	O
5	been	O
6	weighed	O
7	upon	O
8	laparoscopic	O
9	findings	O
10	.	O

1	Restriction	O
2	mapping	O
3	analysis	O
4	localized	O
5	this	O
6	cDNA	O
7	to	O
8	the	O
9	HHV	B
10	-	I
11	6A	I
12	(	I
13	U1102	I
14	)	I
15	genomic	I
16	BamHI	I
17	G	I
18	fragment	I
19	,	O
20	at	O
21	the	O
22	right	O
23	end	O
24	of	O
25	the	O
26	unique	O
27	long	O
28	segment	O
29	of	O
30	the	O
31	genome	O
32	and	O
33	to	O
34	the	O
35	SalI	B
36	L	I
37	and	O
38	SalI	B
39	O	I
40	fragments	I
41	within	O
42	the	O
43	left	O
44	and	O
45	right	O
46	terminal	O
47	direct	O
48	repeat	O
49	regions	O
50	,	O
51	respectively	O
52	.	O

1	Coronary	O
2	T1	O
3	and	O
4	T2	O
5	weighted	O
6	images	O
7	were	O
8	obtained	O
9	.	O

1	The	O
2	smallest	O
3	active	B
4	FecR	I
5	derivative	I
6	contained	O
7	59	O
8	amino	O
9	acid	O
10	residues	O
11	as	O
12	compared	O
13	to	O
14	the	O
15	317	O
16	residues	O
17	of	O
18	wild	B
19	-	I
20	type	I
21	FecR	I
22	.	O

1	The	O
2	gene	O
3	pairs	O
4	psbB	B
5	-	O
6	psbT	B
7	and	O
8	psbH	B
9	-	O
10	psbN	B
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	contains	O
7	regions	O
8	identical	O
9	to	O
10	the	O
11	sequences	O
12	of	O
13	peptides	O
14	derived	O
15	from	O
16	bovine	B
17	liver	I
18	eIF	I
19	-	I
20	2B	I
21	alpha	I
22	subunit	I
23	.	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	B
14	eIF	I
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	Intrastriatal	O
2	grafts	O
3	of	O
4	nigral	O
5	and	O
6	adrenal	O
7	tissues	O
8	have	O
9	been	O
10	found	O
11	to	O
12	be	O
13	effective	O
14	in	O
15	alleviating	O
16	many	O
17	of	O
18	the	O
19	simple	O
20	motor	O
21	and	O
22	sensorimotor	O
23	deficits	O
24	associated	O
25	with	O
26	lesions	O
27	of	O
28	the	O
29	nigrostriatal	O
30	dopamine	O
31	system	O
32	.	O

1	Induction	O
2	in	O
3	AP	B
4	-	I
5	1	I
6	DNA	O
7	binding	O
8	correlates	O
9	with	O
10	a	O
11	concomitant	O
12	GH	B
13	trans	O
14	-	O
15	activation	O
16	of	O
17	c	B
18	-	I
19	jun	I
20	and	O
21	c	B
22	-	I
23	fos	I
24	genes	I
25	described	O
26	previously	O
27	.	O

1	Inactivation	O
2	of	O
3	MAP	B
4	kinases	I
5	occurs	O
6	via	O
7	a	O
8	specific	O
9	phosphatase	O
10	,	O
11	MKP	B
12	-	I
13	1	I
14	.	O

1	The	O
2	protein	O
3	expressed	O
4	from	O
5	the	O
6	cloned	O
7	cDNA	O
8	is	O
9	secreted	O
10	into	O
11	the	O
12	culture	O
13	medium	O
14	and	O
15	yields	O
16	of	O
17	up	O
18	to	O
19	40	O
20	mg	O
21	per	O
22	litre	O
23	have	O
24	been	O
25	obtained	O
26	.	O

1	The	O
2	timing	O
3	of	O
4	fla	B
5	gene	I
6	expression	O
7	in	O
8	the	O
9	cell	O
10	cycle	O
11	is	O
12	determined	O
13	by	O
14	specialized	O
15	forms	O
16	of	O
17	RNA	B
18	polymerase	I
19	and	O
20	the	O
21	appearance	O
22	and	O
23	/	O
24	or	O
25	activation	O
26	of	O
27	regulatory	O
28	proteins	O
29	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	EEA1	B
2	is	O
3	a	O
4	conserved	O
5	alpha	O
6	-	O
7	helical	O
8	peripheral	O
9	membrane	O
10	protein	O
11	flanked	O
12	by	O
13	cysteine	O
14	"	O
15	fingers	O
16	"	O
17	and	O
18	contains	O
19	a	O
20	calmodulin	B
21	-	I
22	binding	I
23	IQ	I
24	motif	I
25	.	O

1	Sensing	O
2	with	O
3	chemically	O
4	and	O
5	biologically	O
6	modified	O
7	carbon	O
8	electrodes	O
9	.	O

1	The	O
2	bHLH	B
3	proteins	I
4	function	O
5	as	O
6	potent	O
7	transcriptional	O
8	activators	O
9	of	O
10	tissue	O
11	-	O
12	specific	O
13	genes	O
14	by	O
15	forming	O
16	heterodimers	O
17	between	O
18	ubiquitous	O
19	and	O
20	cell	O
21	-	O
22	restricted	O
23	family	O
24	members	O
25	.	O

1	The	O
2	other	O
3	two	O
4	clones	O
5	,	O
6	Ash	B
7	-	I
8	m	I
9	and	I
10	-	I
11	s	I
12	,	O
13	had	O
14	nucleotide	O
15	sequences	O
16	identical	O
17	with	O
18	Ash	B
19	-	I
20	l	I
21	cDNA	O
22	in	O
23	the	O
24	amino	O
25	-	O
26	terminal	O
27	region	O
28	.	O

1	DNA	O
2	sequencing	O
3	and	O
4	Southern	O
5	blot	O
6	analyses	O
7	established	O
8	that	O
9	the	O
10	cDNA	O
11	clones	O
12	are	O
13	derived	O
14	from	O
15	two	O
16	different	O
17	genes	O
18	.	O

1	We	O
2	demonstrate	O
3	here	O
4	that	O
5	the	O
6	-	O
7	DEDDDL	O
8	sequence	O
9	stabilizes	O
10	GDP	O
11	binding	O
12	to	O
13	Ran	B
14	,	O
15	and	O
16	that	O
17	the	O
18	domain	O
19	is	O
20	required	O
21	for	O
22	high	O
23	affinity	O
24	interaction	O
25	with	O
26	a	O
27	Ran	B
28	-	I
29	binding	I
30	protein	I
31	,	O
32	HTF9A	B
33	/	O
34	RanBP1	B
35	.	O

1	Serial	O
2	followup	O
3	strength	O
4	data	O
5	for	O
6	2	O
7	patients	O
8	were	O
9	compared	O
10	to	O
11	change	O
12	in	O
13	creatinine	B
14	kinase	I
15	(	O
16	CK	B
17	)	O
18	levels	O
19	.	O

1	CodY	B
2	does	O
3	not	O
4	have	O
5	any	O
6	homologues	O
7	in	O
8	the	O
9	data	O
10	-	O
11	bases	O
12	.	O

1	Unlike	O
2	most	O
3	other	O
4	small	B
5	G	I
6	proteins	I
7	which	O
8	are	O
9	expressed	O
10	ubiquitously	O
11	,	O
12	TTF	B
13	was	O
14	transcribed	O
15	only	O
16	in	O
17	hemopoietic	O
18	cells	O
19	as	O
20	a	O
21	2	O
22	.	O
23	2	O
24	kb	O
25	transcript	O
26	.	O

1	The	O
2	provisional	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	macroscopic	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	supplementary	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	histochemistry	O
27	,	O
28	more	O
29	rarely	O
30	electron	O
31	microscopy	O
32	,	O
33	immunohistochemistry	O
34	and	O
35	/	O
36	or	O
37	microbiology	O
38	.	O

1	CPT	O
2	-	O
3	11	O
4	was	O
5	administered	O
6	as	O
7	a	O
8	30	O
9	-	O
10	minute	O
11	i	O
12	.	O
13	v	O
14	.	O
15	infusion	O
16	at	O
17	a	O
18	dose	O
19	of	O
20	350	O
21	mg	O
22	/	O
23	m2	O
24	diluted	O
25	in	O
26	250	O
27	ml	O
28	normal	O
29	saline	O
30	every	O
31	3	O
32	weeks	O
33	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	MTD	O
5	for	O
6	CPT	O
7	-	O
8	11	O
9	administered	O
10	in	O
11	a	O
12	3	O
13	consecutive	O
14	-	O
15	days	O
16	-	O
17	every	O
18	-	O
19	3	O
20	weeks	O
21	schedule	O
22	in	O
23	this	O
24	patient	O
25	population	O
26	is	O
27	115	O
28	mg	O
29	/	O
30	m2	O
31	/	O
32	day	O
33	.	O

1	The	O
2	absence	O
3	of	O
4	other	O
5	regions	O
6	of	O
7	hybridization	O
8	suggests	O
9	that	O
10	there	O
11	are	O
12	no	O
13	closely	O
14	related	O
15	sequences	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	reverse	O
22	transcribed	O
23	pseudogenes	O
24	)	O
25	scattered	O
26	throughout	O
27	the	O
28	genome	O
29	and	O
30	that	O
31	if	O
32	there	O
33	are	O
34	closely	O
35	related	O
36	genes	O
37	,	O
38	they	O
39	must	O
40	be	O
41	clustered	O
42	near	O
43	GSTT2	B
44	.	O

1	Antibodies	O
2	to	O
3	the	O
4	human	B
5	PTS1R	I
6	recognize	O
7	this	O
8	protein	O
9	in	O
10	human	O
11	,	O
12	monkey	O
13	,	O
14	rat	O
15	,	O
16	and	O
17	hamster	O
18	cells	O
19	.	O

1	Characterization	O
2	of	O
3	fus1	B
4	of	O
5	Schizosaccharomyces	O
6	pombe	O
7	:	O
8	a	O
9	developmentally	O
10	controlled	O
11	function	O
12	needed	O
13	for	O
14	conjugation	O
15	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	DNA	O
6	-	O
7	binding	O
8	domain	O
9	of	O
10	Pip	B
11	exhibits	O
12	a	O
13	high	O
14	degree	O
15	of	O
16	homology	O
17	to	O
18	the	O
19	DNA	O
20	-	O
21	binding	O
22	domains	O
23	of	O
24	members	O
25	of	O
26	the	O
27	interferon	B
28	regulatory	I
29	factor	I
30	(	O
31	IRF	B
32	)	O
33	family	O
34	,	O
35	which	O
36	includes	O
37	IRF	B
38	-	I
39	1	I
40	,	O
41	IRF	B
42	-	I
43	2	I
44	,	O
45	ICSBP	B
46	,	O
47	and	O
48	ISGF3	B
49	gamma	I
50	.	O

1	We	O
2	have	O
3	generated	O
4	various	O
5	base	O
6	substitutions	O
7	and	O
8	internal	O
9	deletions	O
10	in	O
11	and	O
12	around	O
13	DRE	O
14	(	O
15	nucleotide	O
16	positions	O
17	-	O
18	93	O
19	to	O
20	-	O
21	100	O
22	with	O
23	respect	O
24	to	O
25	the	O
26	transcription	O
27	initiation	O
28	site	O
29	)	O
30	of	O
31	the	O
32	PCNA	B
33	gene	I
34	in	O
35	vitro	O
36	and	O
37	subsequently	O
38	examined	O
39	their	O
40	effects	O
41	on	O
42	the	O
43	binding	O
44	to	O
45	DREF	B
46	(	O
47	DRE	B
48	-	I
49	binding	I
50	factor	I
51	)	O
52	and	O
53	PCNA	B
54	gene	I
55	promote	O
56	activity	O
57	in	O
58	cultured	O
59	Drosophila	O
60	Kc	O
61	cells	O
62	as	O
63	well	O
64	as	O
65	in	O
66	living	O
67	flies	O
68	.	O

1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	B
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	gene	O
18	expression	O
19	.	O

1	Reconstitution	O
2	of	O
3	complexes	O
4	containing	O
5	p62	B
6	and	O
7	the	O
8	src	B
9	family	I
10	kinase	I
11	p59fyn	I
12	in	O
13	HeLa	O
14	cells	O
15	demonstrated	O
16	that	O
17	complex	O
18	formation	O
19	resulted	O
20	in	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	p62	B
25	and	O
26	was	O
27	mediated	O
28	by	O
29	both	O
30	the	O
31	SH3	B
32	and	O
33	SH2	B
34	domains	I
35	of	O
36	p59fyn	B
37	.	O

1	Characterization	O
2	of	O
3	FIII	B
4	/	O
5	YY1	B
6	,	O
7	a	O
8	Xenopus	B
9	laevis	I
10	conserved	I
11	zinc	I
12	-	I
13	finger	I
14	protein	I
15	binding	O
16	to	O
17	the	O
18	first	O
19	exon	O
20	of	O
21	L1	B
22	and	O
23	L14	B
24	ribosomal	I
25	protein	I
26	genes	I
27	.	O

1	This	O
2	study	O
3	investigated	O
4	the	O
5	degree	O
6	to	O
7	which	O
8	racial	O
9	identity	O
10	influences	O
11	Mexican	O
12	-	O
13	Americans	O
14	'	O
15	performance	O
16	on	O
17	the	O
18	L	O
19	,	O
20	K	O
21	,	O
22	and	O
23	MF	O
24	scales	O
25	of	O
26	the	O
27	MMPI	O
28	-	O
29	2	O
30	.	O

1	In	O
2	broken	O
3	L	O
4	-	O
5	cell	O
6	membranes	O
7	expressing	O
8	wild	O
9	type	O
10	or	O
11	mutant	B
12	M6P	I
13	/	I
14	IGF	I
15	II	I
16	receptors	I
17	,	O
18	30	O
19	nM	O
20	IGF	B
21	II	I
22	also	O
23	failed	O
24	to	O
25	affect	O
26	the	O
27	pertussis	B
28	toxin	I
29	substrate	O
30	activity	O
31	.	O

1	Chem	O
2	.	O

1	Tumor	B
2	necrosis	I
3	factor	I
4	alpha	I
5	,	O
6	the	O
7	cytokine	O
8	that	O
9	participates	O
10	in	O
11	the	O
12	autocrine	O
13	growth	O
14	control	O
15	of	O
16	hairy	O
17	cell	O
18	leukemia	O
19	has	O
20	strong	O
21	bone	O
22	resorptive	O
23	properties	O
24	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	O
22	I	B
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	O
34	-	O
35	terminal	O
36	region	O
37	of	O
38	I	B
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	O
47	-	O
48	protein	O
49	binding	O
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	O
94	-	O
95	like	O
96	region	O
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	At	O
2	different	O
3	times	O
4	of	O
5	the	O
6	surgical	O
7	procedures	O
8	(	O
9	thorax	O
10	opening	O
11	and	O
12	closure	O
13	,	O
14	period	O
15	of	O
16	cardiopulmonary	O
17	bypass	O
18	)	O
19	67	O
20	to	O
21	100	O
22	%	O
23	of	O
24	the	O
25	patients	O
26	in	O
27	group	O
28	1	O
29	had	O
30	vancomycin	O
31	concentrations	O
32	in	O
33	the	O
34	studied	O
35	tissues	O
36	above	O
37	the	O
38	MIC	O
39	90	O
40	for	O
41	Staphylococcus	O
42	aureus	O
43	(	O
44	1	O
45	microgram	O
46	/	O
47	g	O
48	)	O
49	and	O
50	Staphylococcus	O
51	epidermidis	O
52	(	O
53	2	O
54	micrograms	O
55	/	O
56	g	O
57	).	O

1	Between	O
2	the	O
3	subgroups	O
4	of	O
5	dementia	O
6	disorders	O
7	there	O
8	were	O
9	no	O
10	significant	O
11	differences	O
12	in	O
13	basal	O
14	cortisol	O
15	levels	O
16	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	O
12	.	O

1	Integrated	O
2	mapping	O
3	analysis	O
4	of	O
5	the	O
6	Werner	O
7	syndrome	O
8	region	O
9	of	O
10	chromosome	O
11	8	O
12	.	O

1	The	O
2	region	O
3	between	O
4	DXS52	B
5	and	O
6	Factor	B
7	VIII	I
8	gene	I
9	in	O
10	the	O
11	human	O
12	Xq28	O
13	chromosomal	O
14	band	O
15	contains	O
16	a	O
17	G	O
18	+	O
19	C	O
20	-	O
21	rich	O
22	isochore	O
23	to	O
24	which	O
25	many	O
26	genes	O
27	have	O
28	been	O
29	mapped	O
30	.	O

1	To	O
2	further	O
3	our	O
4	knowledge	O
5	about	O
6	the	O
7	systemic	O
8	humoral	O
9	immune	O
10	system	O
11	response	O
12	to	O
13	weak	O
14	hapten	O
15	-	O
16	syngeneic	O
17	or	O
18	allogeneic	O
19	protein	O
20	conjugates	O
21	(	O
22	corrosion	O
23	and	O
24	wear	O
25	products	O
26	of	O
27	metallic	O
28	orthopedic	O
29	devices	O
30	),	O
31	a	O
32	sensitive	O
33	enzyme	O
34	-	O
35	linked	O
36	immunosorbent	O
37	assay	O
38	(	O
39	ELISA	O
40	)	O
41	method	O
42	for	O
43	testing	O
44	for	O
45	antibody	O
46	(	O
47	humoral	O
48	immunity	O
49	)	O
50	to	O
51	metals	O
52	was	O
53	developed	O
54	.	O

1	The	O
2	drug	O
3	sensitivity	O
4	was	O
5	100	O
6	%	O
7	for	O
8	vancomycin	O
9	(	O
10	VCM	O
11	),	O
12	30	O
13	%	O
14	for	O
15	imipenam	O
16	(	O
17	IMP	O
18	),	O
19	31	O
20	%	O
21	for	O
22	minomycin	O
23	(	O
24	MINO	O
25	),	O
26	31	O
27	%	O
28	for	O
29	amikacin	O
30	(	O
31	AMK	O
32	),	O
33	and	O
34	7	O
35	%	O
36	for	O
37	fosfomycin	O
38	(	O
39	FOM	O
40	).	O

1	Fraction	O
2	2	O
3	contains	O
4	1	O
5	,	O
6	25	O
7	(	O
8	OH	O
9	)	O
10	2	O
11	-	O
12	vitamin	O
13	D3	O
14	,	O
15	vitamin	O
16	D3	O
17	,	O
18	25	O
19	(	O
20	OH	O
21	)-	O
22	vitamin	O
23	D3	O
24	and	O
25	1	O
26	,	O
27	24	O
28	,	O
29	25	O
30	(	O
31	OH	O
32	)	O
33	3	O
34	-	O
35	vitamin	O
36	D3	O
37	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	was	O
6	88	O
7	%	O
8	homologous	O
9	to	O
10	that	O
11	of	O
12	hNUC	B
13	I	I
14	,	O
15	isolated	O
16	from	O
17	human	O
18	osteosarcoma	O
19	cells	O
20	.	O

1	To	O
2	understand	O
3	the	O
4	function	O
5	of	O
6	receptor	B
7	-	I
8	linked	I
9	tyrosine	I
10	phosphatases	I
11	in	O
12	neural	O
13	development	O
14	,	O
15	we	O
16	sought	O
17	to	O
18	identify	O
19	LAR	B
20	isoforms	I
21	preferentially	O
22	expressed	O
23	in	O
24	the	O
25	nervous	O
26	system	O
27	and	O
28	cellular	O
29	processes	O
30	regulating	O
31	LAR	B
32	alternative	O
33	splicing	O
34	.	O

1	They	O
2	also	O
3	reported	O
4	that	O
5	E	B
6	mu	I
7	pim	I
8	-	I
9	1	I
10	transgenic	O
11	mice	O
12	show	O
13	greatly	O
14	accelerated	O
15	lymphoma	O
16	development	O
17	when	O
18	infected	O
19	with	O
20	wild	O
21	-	O
22	type	O
23	M	O
24	-	O
25	MuLV	O
26	at	O
27	birth	O
28	.	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	Physical	O
2	analysis	O
3	maps	O
4	SAL6	B
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	B
10	and	O
11	spt14	B
12	.	O

1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O

1	Schnell	O
2	,	O
3	J	O
4	.	O

1	Removal	O
2	of	O
3	the	O
4	GST	B
5	domain	I
6	from	O
7	GST	B
8	-	O
9	Tax	B
10	by	O
11	thrombin	B
12	restores	O
13	Tax	B
14	'	O
15	s	O
16	ability	O
17	to	O
18	assemble	O
19	a	O
20	ternary	O
21	Tax	B
22	-	O
23	CREB	B
24	-	O
25	21	O
26	-	O
27	bp	O
28	-	O
29	repeat	O
30	complex	O
31	.(	O
32	ABSTRACT	O
33	TRUNCATED	O
34	AT	O
35	400	O
36	WORDS	O
37	)	O

1	The	O
2	pilE	B
3	gene	I
4	product	I
5	of	I
6	Pseudomonas	I
7	aeruginosa	I
8	,	O
9	required	O
10	for	O
11	pilus	O
12	biogenesis	O
13	,	O
14	shares	O
15	amino	O
16	acid	O
17	sequence	O
18	identity	O
19	with	O
20	the	O
21	N	O
22	-	O
23	termini	O
24	of	O
25	type	B
26	4	I
27	prepilin	I
28	proteins	I
29	.	O

1	A	O
2	comparative	O
3	study	O
4	by	O
5	holographic	O
6	interferometry	O
7	of	O
8	ten	O
9	porcine	O
10	bioprosthetic	O
11	valves	O
12	(	O
13	seven	O
14	Carpentier	O
15	-	O
16	Edwards	O
17	SAV	O
18	,	O
19	two	O
20	BioImplant	O
21	and	O
22	one	O
23	Valcor	O
24	)	O
25	with	O
26	five	O
27	human	O
28	aortic	O
29	valves	O
30	before	O
31	and	O
32	after	O
33	glutaraldehyde	O
34	treatment	O
35	is	O
36	presented	O
37	.	O

1	The	O
2	mean	O
3	jitter	O
4	and	O
5	the	O
6	fiber	O
7	density	O
8	did	O
9	not	O
10	change	O
11	significantly	O
12	from	O
13	day	O
14	0	O
15	(	O
16	30	O
17	.	O
18	1	O
19	+/-	O
20	3	O
21	.	O
22	6	O
23	microseconds	O
24	;	O
25	1	O
26	.	O
27	4	O
28	+/-	O
29	0	O
30	.	O
31	07	O
32	)	O
33	to	O
34	day	O
35	30	O
36	(	O
37	34	O
38	.	O
39	5	O
40	+/-	O
41	2	O
42	.	O
43	7	O
44	microseconds	O
45	;	O
46	1	O
47	.	O
48	6	O
49	+/-	O
50	0	O
51	.	O
52	13	O
53	).	O

1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	O
6	Cdk	B
7	complexes	O
8	in	O
9	Rb	B
10	-	O
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	B
19	/	O
20	MTS1	B
21	tumour	O
22	suppressor	O
23	gene	O
24	product	O
25	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	show	O
7	that	O
8	TEP	B
9	has	O
10	an	O
11	apparent	O
12	molecular	O
13	mass	O
14	of	O
15	approximately	O
16	65	O
17	kDa	O
18	.	O

1	In	O
2	the	O
3	presence	O
4	of	O
5	inositol	O
6	and	O
7	choline	O
8	(	O
9	repressing	O
10	),	O
11	the	O
12	product	O
13	of	O
14	the	O
15	OPI1	B
16	gene	I
17	represses	O
18	transcription	O
19	dictated	O
20	by	O
21	the	O
22	UASINO	O
23	element	O
24	.	O

1	The	O
2	Wilms	B
3	'	I
4	tumour	I
5	suppressor	I
6	protein	I
7	(	O
8	WT1	B
9	)	O
10	is	O
11	a	O
12	putative	O
13	transcriptional	O
14	regulatory	O
15	protein	O
16	with	O
17	four	O
18	zinc	O
19	fingers	O
20	,	O
21	the	O
22	last	O
23	three	O
24	of	O
25	which	O
26	have	O
27	extensive	O
28	sequence	O
29	homology	O
30	to	O
31	the	O
32	early	B
33	growth	I
34	response	I
35	-	I
36	1	I
37	(	O
38	EGR	B
39	-	I
40	1	I
41	)	O
42	protein	O
43	.	O

1	In	O
2	order	O
3	to	O
4	infer	O
5	shape	O
6	from	O
7	contour	O
8	,	O
9	the	O
10	human	O
11	visual	O
12	system	O
13	must	O
14	selectively	O
15	integrate	O
16	fragments	O
17	projecting	O
18	from	O
19	a	O
20	common	O
21	object	O
22	while	O
23	keeping	O
24	fragments	O
25	from	O
26	different	O
27	objects	O
28	separate	O
29	.	O

1	Gene	O
2	expression	O
3	occurs	O
4	in	O
5	a	O
6	circadian	O
7	rhythm	O
8	and	O
9	induced	O
10	by	O
11	light	O
12	in	O
13	leaves	O
14	of	O
15	dark	O
16	-	O
17	adapted	O
18	plants	O
19	.	O

1	Treatment	O
2	of	O
3	recurrent	O
4	FSGS	O
5	has	O
6	included	O
7	high	O
8	-	O
9	dose	O
10	steroids	O
11	,	O
12	high	O
13	-	O
14	dose	O
15	cyclosporine	O
16	(	O
17	CSA	O
18	),	O
19	plasmapheresis	O
20	,	O
21	and	O
22	ACE	B
23	inhibitors	O
24	with	O
25	mixed	O
26	results	O
27	.	O

1	Promoter	O
2	region	O
3	of	O
4	the	O
5	transcriptional	O
6	unit	O
7	for	O
8	human	B
9	alpha	I
10	1	I
11	-	I
12	chimaerin	I
13	,	O
14	a	O
15	neuron	B
16	-	I
17	specific	I
18	GTPase	I
19	-	I
20	activating	I
21	protein	I
22	for	O
23	p21rac	B
24	.	O
25	alpha	B
26	1	I
27	-	I
28	chimaerin	I
29	is	O
30	a	O
31	neuron	B
32	-	I
33	specific	I
34	GTPase	I
35	-	I
36	activating	I
37	protein	I
38	for	O
39	p21rac	B
40	,	O
41	a	O
42	protein	O
43	involved	O
44	in	O
45	morphological	O
46	events	O
47	.	O

1	During	O
2	ISO	O
3	+	O
4	AT	O
5	infusion	O
6	,	O
7	abdominal	O
8	fat	O
9	blood	O
10	flow	O
11	was	O
12	still	O
13	significantly	O
14	increased	O
15	as	O
16	compared	O
17	with	O
18	control	O
19	values	O
20	in	O
21	lean	O
22	and	O
23	obese	O
24	subjects	O
25	.	O

1	The	O
2	first	O
3	open	O
4	reading	O
5	frame	O
6	of	O
7	the	O
8	blueberry	O
9	scorch	O
10	carlavirus	O
11	(	O
12	BBScV	O
13	)	O
14	genome	O
15	encodes	O
16	a	O
17	putative	O
18	replication	O
19	-	O
20	associated	O
21	protein	O
22	of	O
23	223	O
24	kDa	O
25	(	O
26	p223	B
27	).	O

1	The	O
2	regions	O
3	of	O
4	the	O
5	tooth	O
6	fracture	O
7	are	O
8	determined	O
9	.	O

1	It	O
2	is	O
3	now	O
4	recognized	O
5	that	O
6	essentially	O
7	all	O
8	eukaryotic	O
9	and	O
10	prokaryotic	O
11	genes	O
12	whose	O
13	5	O
14	'-	O
15	flanking	O
16	regions	O
17	are	O
18	known	O
19	and	O
20	that	O
21	encode	O
22	barbiturate	O
23	-	O
24	inducible	O
25	proteins	O
26	contain	O
27	the	O
28	Barbie	O
29	box	O
30	element	O
31	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	a	O
6	study	O
7	of	O
8	low	O
9	dose	O
10	X	O
11	-	O
12	rays	O
13	effects	O
14	,	O
15	we	O
16	found	O
17	that	O
18	male	O
19	ICR	O
20	white	O
21	Swiss	O
22	mice	O
23	showed	O
24	remarkable	O
25	suppression	O
26	of	O
27	mounting	O
28	behavior	O
29	after	O
30	whole	O
31	body	O
32	irradiation	O
33	by	O
34	5	O
35	to	O
36	15	O
37	cGy	O
38	X	O
39	-	O
40	rays	O
41	.	O

1	Supplementary	O
2	Phase	O
3	Contraste	O
4	RSE	O
5	("	O
6	Rapid	O
7	Sequential	O
8	Excitation	O
9	")	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	0	O
2	.	O
3	61	O
4	+/-	O
5	0	O
6	.	O
7	04	O
8	).	O

1	Several	O
2	nuclear	O
3	factors	O
4	that	O
5	interact	O
6	with	O
7	sequences	O
8	in	O
9	the	O
10	5	O
11	'	O
12	flanking	O
13	region	O
14	of	O
15	the	O
16	mouse	B
17	tyrosinase	I
18	gene	I
19	were	O
20	identified	O
21	using	O
22	band	O
23	shift	O
24	and	O
25	methylation	O
26	interference	O
27	assays	O
28	.	O

1	TcPO2	O
2	measurement	O
3	appears	O
4	to	O
5	be	O
6	a	O
7	reliable	O
8	technique	O
9	that	O
10	can	O
11	influence	O
12	ischaemic	O
13	ulcer	O
14	management	O
15	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	Expression	O
2	of	O
3	h6	O
4	.	O
5	1	O
6	in	O
7	COS	O
8	-	O
9	1	O
10	cells	O
11	led	O
12	to	O
13	the	O
14	production	O
15	of	O
16	a	O
17	typical	O
18	type	B
19	IV	I
20	PDE	I
21	activity	O
22	in	O
23	that	O
24	cAMP	O
25	,	O
26	but	O
27	not	O
28	cGMP	O
29	,	O
30	served	O
31	as	O
32	substrate	O
33	and	O
34	its	O
35	activity	O
36	was	O
37	insensitive	O
38	to	O
39	either	O
40	Ca2	O
41	+/	O
42	CaM	B
43	or	O
44	cGMP	O
45	but	O
46	was	O
47	inhibited	O
48	by	O
49	low	O
50	concentrations	O
51	of	O
52	rolipram	O
53	.(	O
54	ABSTRACT	O
55	TRUNCATED	O
56	AT	O
57	400	O
58	WORDS	O
59	)	O

1	Computerized	O
2	detection	O
3	of	O
4	abnormal	O
5	asymmetry	O
6	in	O
7	digital	O
8	chest	O
9	radiographs	O
10	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	B
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O

1	Glomerular	O
2	hemodynamics	O
3	during	O
4	abortion	O
5	induced	O
6	by	O
7	RU	O
8	486	O
9	and	O
10	sepsis	O
11	in	O
12	rats	O
13	.	O

1	Involvement	O
2	of	O
3	early	B
4	growth	I
5	response	I
6	factor	I
7	Egr	I
8	-	I
9	1	I
10	in	O
11	apolipoprotein	B
12	AI	I
13	gene	I
14	transcription	O
15	.	O

1	Pregnancy	O
2	screening	O
3	by	O
4	uterine	O
5	artery	O
6	Doppler	O
7	velocimetry	O
8	--	O
9	which	O
10	criterion	O
11	performs	O
12	best	O
13	?	O
14	OBJECTIVE	O
15	:	O
16	To	O
17	test	O
18	whether	O
19	repeating	O
20	Doppler	O
21	studies	O
22	of	O
23	the	O
24	uteroplacental	O
25	circulation	O
26	late	O
27	in	O
28	gestation	O
29	will	O
30	improve	O
31	the	O
32	test	O
33	'	O
34	s	O
35	power	O
36	for	O
37	predicting	O
38	pregnancy	O
39	-	O
40	induced	O
41	hypertension	O
42	and	O
43	fetal	O
44	growth	O
45	restriction	O
46	(	O
47	FGR	O
48	),	O
49	and	O
50	whether	O
51	analysis	O
52	based	O
53	on	O
54	a	O
55	combination	O
56	of	O
57	quantitative	O
58	and	O
59	qualitative	O
60	assessments	O
61	of	O
62	the	O
63	uterine	O
64	arterial	O
65	waveforms	O
66	will	O
67	yield	O
68	better	O
69	results	O
70	than	O
71	analysis	O
72	based	O
73	on	O
74	either	O
75	alone	O
76	.	O

1	To	O
2	determine	O
3	whether	O
4	food	O
5	and	O
6	/	O
7	or	O
8	water	O
9	in	O
10	the	O
11	gastrointestinal	O
12	tract	O
13	affects	O
14	restitution	O
15	of	O
16	blood	O
17	volume	O
18	and	O
19	plasma	O
20	protein	O
21	after	O
22	hemorrhage	O
23	,	O
24	fed	O
25	and	O
26	24	O
27	-	O
28	h	O
29	-	O
30	fasted	O
31	awake	O
32	rats	O
33	received	O
34	a	O
35	20	O
36	ml	O
37	.	O
38	kg	O
39	-	O
40	1	O
41	x	O
42	3	O
43	min	O
44	-	O
45	1	O
46	hemorrhage	O
47	,	O
48	and	O
49	restitution	O
50	of	O
51	blood	O
52	volume	O
53	was	O
54	measured	O
55	by	O
56	Evans	O
57	blue	O
58	dye	O
59	and	O
60	dilution	O
61	of	O
62	hematocrit	O
63	.	O

1	We	O
2	took	O
3	advantage	O
4	of	O
5	the	O
6	high	O
7	degree	O
8	of	O
9	aa	O
10	sequence	O
11	homology	O
12	between	O
13	DAHPSs	B
14	from	O
15	several	O
16	species	O
17	to	O
18	isolate	O
19	ARO3	B
20	homologues	I
21	from	O
22	the	O
23	pathogenic	O
24	yeast	O
25	Candida	O
26	albicans	O
27	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	human	B
9	goosecoid	I
10	gene	I
11	(	O
12	GSC	B
13	)	O
14	from	O
15	a	O
16	genomic	O
17	library	O
18	and	O
19	the	O
20	sequence	O
21	of	O
22	its	O
23	encoded	O
24	protein	O
25	.	O

1	This	O
2	virus	O
3	is	O
4	not	O
5	merely	O
6	a	O
7	South	O
8	African	O
9	strain	O
10	of	O
11	passion	O
12	fruit	O
13	woodiness	O
14	virus	O
15	(	O
16	PWV	O
17	):	O
18	the	O
19	deduced	O
20	CP	B
21	sequence	I
22	is	O
23	only	O
24	distantly	O
25	related	O
26	to	O
27	CPs	B
28	of	O
29	other	O
30	sequenced	O
31	strains	O
32	of	O
33	PWV	O
34	,	O
35	although	O
36	it	O
37	is	O
38	part	O
39	of	O
40	a	O
41	distinct	O
42	subgroup	O
43	of	O
44	potyviruses	O
45	related	O
46	to	O
47	PWV	O
48	.	O

1	A	O
2	leucine	O
3	zipper	O
4	domain	O
5	of	O
6	the	O
7	suppressor	B
8	of	I
9	Hairy	I
10	-	I
11	wing	I
12	protein	I
13	mediates	O
14	its	O
15	repressive	O
16	effect	O
17	on	O
18	enhancer	O
19	function	O
20	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	CT	O
6	should	O
7	be	O
8	routinely	O
9	employed	O
10	in	O
11	patients	O
12	with	O
13	N1	O
14	-	O
15	N3	O
16	neck	O
17	disease	O
18	to	O
19	determine	O
20	the	O
21	proper	O
22	electron	O
23	-	O
24	energy	O
25	prescription	O
26	.	O

1	BACKGROUND	O
2	:	O
3	We	O
4	conducted	O
5	a	O
6	phase	O
7	I	O
8	study	O
9	with	O
10	MDL	O
11	73	O
12	,	O
13	147EF	O
14	,	O
15	a	O
16	new	O
17	5	B
18	hydroxytryptamine	I
19	3	I
20	(	I
21	5	I
22	-	I
23	HT3	I
24	)	I
25	receptor	I
26	antagonist	O
27	,	O
28	in	O
29	25	O
30	patients	O
31	requiring	O
32	emetogenic	O
33	chemotherapy	O
34	.	O

1	Expression	O
2	is	O
3	exclusively	O
4	limited	O
5	to	O
6	the	O
7	CNS	O
8	at	O
9	this	O
10	and	O
11	later	O
12	stages	O
13	.	O

1	The	O
2	expression	O
3	pattern	O
4	of	O
5	GL2	B
6	,	O
7	as	O
8	demonstrated	O
9	by	O
10	in	O
11	situ	O
12	hybridization	O
13	,	O
14	indicated	O
15	that	O
16	the	O
17	gene	O
18	is	O
19	expressed	O
20	in	O
21	trichome	O
22	progenitor	O
23	cells	O
24	and	O
25	at	O
26	stages	O
27	associated	O
28	with	O
29	trichome	O
30	development	O
31	.	O

1	The	O
2	DNA	O
3	sequence	O
4	adjacent	O
5	to	O
6	the	O
7	lacZ	B
8	gene	I
9	has	O
10	been	O
11	determined	O
12	for	O
13	91	O
14	vegetative	O
15	fusion	O
16	genes	O
17	whose	O
18	products	O
19	have	O
20	been	O
21	localized	O
22	and	O
23	for	O
24	43	O
25	meiotically	O
26	induced	O
27	fusions	O
28	.	O

1	DNA	O
2	sequence	O
3	and	O
4	functions	O
5	of	O
6	the	O
7	actVI	B
8	region	I
9	of	O
10	the	O
11	actinorhodin	O
12	biosynthetic	O
13	gene	O
14	cluster	O
15	of	O
16	Streptomyces	O
17	coelicolor	O
18	A3	O
19	(	O
20	2	O
21	).	O

1	Nine	O
2	new	O
3	naphthalene	O
4	related	O
5	compounds	O
6	(	O
7	I	O
8	,	O
9	IV	O
10	,	O
11	V	O
12	,	O
13	VII	O
14	-	O
15	XII	O
16	)	O
17	together	O
18	with	O
19	four	O
20	known	O
21	compounds	O
22	(	O
23	II	O
24	,	O
25	III	O
26	,	O
27	VI	O
28	,	O
29	XIII	O
30	)	O
31	were	O
32	isolated	O
33	from	O
34	the	O
35	root	O
36	bark	O
37	of	O
38	Oroxylum	O
39	indicum	O
40	Vent	O
41	.	O

1	As	O
2	shown	O
3	previously	O
4	,	O
5	EBNA2	B
6	transactivates	O
7	the	O
8	promoters	O
9	of	O
10	the	O
11	viral	B
12	latent	I
13	membrane	I
14	proteins	I
15	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	,	O
9	the	O
10	oncoprotein	O
11	of	O
12	the	O
13	avian	O
14	retrovirus	O
15	Rev	O
16	-	O
17	T	O
18	,	O
19	can	O
20	increase	O
21	expression	O
22	from	O
23	promoters	O
24	containing	O
25	binding	O
26	sites	O
27	for	O
28	the	O
29	cellular	O
30	transcription	O
31	factor	O
32	Sp1	B
33	in	O
34	chicken	O
35	embryo	O
36	fibroblasts	O
37	(	O
38	S	O
39	.	O

1	The	O
2	p55	B
3	mRNA	I
4	is	O
5	undetectable	O
6	in	O
7	non	O
8	-	O
9	EBV	O
10	-	O
11	infected	O
12	B	O
13	-	O
14	and	O
15	T	O
16	-	O
17	cell	O
18	lines	O
19	or	O
20	in	O
21	a	O
22	myelomonocytic	O
23	cell	O
24	line	O
25	(	O
26	U937	O
27	).	O

1	The	O
2	coordinated	O
3	expression	O
4	of	O
5	CD4	B
6	and	O
7	CD8	B
8	during	O
9	T	O
10	-	O
11	cell	O
12	development	O
13	is	O
14	tightly	O
15	coupled	O
16	with	O
17	the	O
18	maturation	O
19	state	O
20	of	O
21	the	O
22	T	O
23	cell	O
24	.	O

1	Expression	O
2	of	O
3	a	O
4	dominant	B
5	-	I
6	negative	I
7	ras	I
8	gene	I
9	also	O
10	blocks	O
11	TIS10	B
12	/	O
13	PGS2	B
14	induction	O
15	by	O
16	v	B
17	-	I
18	src	I
19	.	O

1	The	O
2	dying	O
3	tTG	B
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	Only	O
2	two	O
3	of	O
4	the	O
5	isoforms	O
6	possess	O
7	the	O
8	N	O
9	-	O
10	terminal	O
11	zinc	O
12	finger	O
13	domain	O
14	that	O
15	is	O
16	necessary	O
17	and	O
18	sufficient	O
19	for	O
20	TdT	B
21	promoter	I
22	binding	O
23	.	O

1	The	O
2	predominant	O
3	binding	O
4	activity	O
5	was	O
6	not	O
7	Ets	B
8	-	I
9	1	I
10	but	O
11	rather	O
12	two	O
13	independent	O
14	DNA	O
15	-	O
16	protein	O
17	complexes	O
18	that	O
19	comigrated	O
20	in	O
21	mobility	O
22	shift	O
23	assays	O
24	.	O

1	Using	O
2	this	O
3	method	O
4	,	O
5	we	O
6	were	O
7	able	O
8	to	O
9	select	O
10	strong	O
11	enhancer	O
12	-	O
13	type	O
14	activation	O
15	domains	O
16	from	O
17	the	O
18	immediate	B
19	early	I
20	regions	I
21	of	O
22	two	O
23	herpesviruses	O
24	,	O
25	namely	O
26	pseudorabies	O
27	virus	O
28	and	O
29	bovine	O
30	herpesvirus	O
31	1	O
32	.	O

1	Laser	O
2	therapy	O
3	of	O
4	penile	O
5	carcinoma	O

1	A	O
2	third	O
3	one	O
4	is	O
5	homologous	O
6	in	O
7	half	O
8	of	O
9	its	O
10	length	O
11	to	O
12	the	O
13	prokaryotic	B
14	hydantoinase	I
15	HyuA	I
16	and	O
17	in	O
18	the	O
19	other	O
20	half	O
21	to	O
22	hydatoinase	B
23	HyuB	I
24	.	O

1	It	O
2	was	O
3	shown	O
4	that	O
5	estradiol	O
6	concentrations	O
7	obtained	O
8	after	O
9	estradiol	O
10	valerate	O
11	and	O
12	micronized	O
13	estradiol	O
14	ingestion	O
15	were	O
16	dependent	O
17	on	O
18	the	O
19	patient	O
20	'	O
21	s	O
22	age	O
23	as	O
24	well	O
25	as	O
26	on	O
27	the	O
28	constitutional	O
29	type	O
30	.	O

1	Vibrio	O
2	cholerae	O
3	O139	O
4	in	O
5	Calcutta	O
6	.	O

1	The	O
2	site	O
3	-	O
4	directed	O
5	mutation	O
6	of	O
7	the	O
8	kappa	B
9	B	I
10	motif	I
11	in	O
12	IL	B
13	-	I
14	6	I
15	/	O
16	CAT	B
17	plasmid	O
18	resulted	O
19	in	O
20	the	O
21	complete	O
22	abrogation	O
23	of	O
24	IL	B
25	-	I
26	6	I
27	promoter	I
28	activity	O
29	in	O
30	these	O
31	cells	O
32	.	O

1	Lesion	O
2	diameters	O
3	of	O
4	greater	O
5	than	O
6	20	O
7	mm	O
8	and	O
9	the	O
10	large	O
11	sessile	O
12	-	O
13	type	O
14	configurations	O
15	were	O
16	factors	O
17	that	O
18	were	O
19	associated	O
20	with	O
21	incomplete	O
22	removal	O
23	.	O

1	Routinely	O
2	collected	O
3	,	O
4	processed	O
5	and	O
6	stored	O
7	breast	O
8	cancer	O
9	tissue	O
10	blocks	O
11	recovered	O
12	from	O
13	the	O
14	archives	O
15	of	O
16	the	O
17	Pathology	O
18	laboratory	O
19	in	O
20	Dar	O
21	es	O
22	Salaam	O
23	after	O
24	storage	O
25	of	O
26	up	O
27	to	O
28	3	O
29	years	O
30	were	O
31	analysed	O
32	by	O
33	a	O
34	flow	O
35	cytometry	O
36	for	O
37	DNA	O
38	ploidy	O
39	and	O
40	S	O
41	-	O
42	phase	O
43	fraction	O
44	.	O

1	In	O
2	general	O
3	,	O
4	the	O
5	filtration	O
6	rate	O
7	in	O
8	relevant	O
9	areas	O
10	appears	O
11	to	O
12	be	O
13	an	O
14	integrative	O
15	and	O
16	easily	O
17	determined	O
18	parameter	O
19	,	O
20	reflecting	O
21	hormonal	O
22	and	O
23	neurogenic	O
24	vascular	O
25	as	O
26	well	O
27	as	O
28	local	O
29	interstitial	O
30	control	O
31	of	O
32	the	O
33	Starling	O
34	forces	O
35	.	O

1	Interestingly	O
2	,	O
3	dTFIIA	B
4	-	I
5	L	I
6	/	I
7	S	I
8	is	O
9	also	O
10	able	O
11	to	O
12	significantly	O
13	enhance	O
14	transcriptional	O
15	activation	O
16	by	O
17	upstream	O
18	transcription	O
19	factors	O
20	including	O
21	Sp1	B
22	,	O
23	VP16	B
24	,	O
25	and	O
26	NTF	B
27	-	I
28	1	I
29	.	O

1	Furthermore	O
2	,	O
3	our	O
4	data	O
5	also	O
6	show	O
7	that	O
8	,	O
9	in	O
10	addition	O
11	to	O
12	TEF	B
13	-	I
14	1	I
15	,	O
16	another	O
17	HF	B
18	-	I
19	1a	I
20	-	I
21	related	I
22	factor	I
23	may	O
24	be	O
25	recognized	O
26	by	O
27	the	O
28	alpha	B
29	-	I
30	MHC	I
31	gene	I
32	EM	O
33	element	O
34	.	O

1	Recombinant	B
2	I	I
3	-	I
4	kappa	I
5	B	I
6	alpha	I
7	inhibited	O
8	kappa	B
9	B	I
10	motif	I
11	binding	O
12	by	O
13	nuclear	B
14	factor	I
15	-	I
16	kappa	I
17	B1	I
18	,	O
19	RelA	B
20	,	O
21	and	O
22	c	B
23	-	I
24	Rel	I
25	as	O
26	indicated	O
27	by	O
28	studies	O
29	using	O
30	UV	O
31	radiation	O
32	-	O
33	induced	O
34	covalent	O
35	cross	O
36	-	O
37	linking	O
38	to	O
39	a	O
40	bromodeoxyuridine	O
41	-	O
42	substituted	O
43	kappa	B
44	B	I
45	oligonucleotide	I
46	.	O

1	The	O
2	P131	O
3	ORF	O
4	is	O
5	followed	O
6	in	O
7	-	O
8	frame	O
9	by	O
10	a	O
11	second	O
12	ORF	O
13	which	O
14	is	O
15	probably	O
16	expressed	O
17	by	O
18	partial	O
19	readthrough	O
20	of	O
21	the	O
22	UGA	O
23	termination	O
24	codon	O
25	of	O
26	the	O
27	P131	O
28	ORF	O
29	to	O
30	produce	O
31	a	O
32	polypeptide	O
33	of	O
34	M	O
35	(	O
36	r	O
37	)	O
38	191044	O
39	(	O
40	P191	O
41	).	O

1	The	O
2	influence	O
3	of	O
4	patient	O
5	-	O
6	related	O
7	factors	O
8	on	O
9	inter	O
10	-	O
11	observer	O
12	variability	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	neurological	O
18	signs	O
19	was	O
20	investigated	O
21	.	O

1	The	O
2	defined	O
3	length	O
4	of	O
5	the	O
6	mRNA	O
7	,	O
8	1	O
9	,	O
10	838	O
11	nucleotides	O
12	,	O
13	was	O
14	in	O
15	agreement	O
16	with	O
17	that	O
18	of	O
19	a	O
20	1	O
21	.	O
22	9	O
23	-	O
24	kb	O
25	RNA	O
26	expressed	O
27	throughout	O
28	the	O
29	replication	O
30	cycle	O
31	,	O
32	starting	O
33	at	O
34	the	O
35	early	O
36	stages	O
37	of	O
38	infection	O
39	.	O

1	Articles	O
2	addressing	O
3	valvular	O
4	heart	O
5	disease	O
6	or	O
7	heart	O
8	failure	O
9	secondary	O
10	to	O
11	acute	O
12	myocardial	O
13	infarction	O
14	or	O
15	Chagas	O
16	'	O
17	disease	O
18	were	O
19	excluded	O
20	.	O

1	One	O
2	class	O
3	of	O
4	plasmids	O
5	contained	O
6	tRNA	B
7	(	I
8	His	I
9	)	I
10	genes	I
11	and	O
12	conferred	O
13	efficient	O
14	suppression	O
15	only	O
16	when	O
17	cells	O
18	were	O
19	starved	O
20	for	O
21	histidine	O
22	;	O
23	these	O
24	plasmids	O
25	suppressed	O
26	a	O
27	gcn2	B
28	deletion	O
29	much	O
30	less	O
31	efficiently	O
32	than	O
33	they	O
34	suppressed	O
35	gcn2	B
36	-	I
37	507	I
38	.	O

1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O

1	KRN2391	O
2	and	O
3	cromakalim	O
4	produced	O
5	a	O
6	dose	O
7	-	O
8	dependent	O
9	increase	O
10	in	O
11	aortic	O
12	and	O
13	coronary	O
14	blood	O
15	flow	O
16	.	O

1	Basal	O
2	plasma	O
3	AVP	B
4	levels	O
5	and	O
6	AVP	B
7	release	O
8	after	O
9	postural	O
10	change	O
11	were	O
12	assessed	O
13	,	O
14	and	O
15	plasma	O
16	NPY	B
17	levels	O
18	were	O
19	measured	O
20	in	O
21	the	O
22	same	O
23	samples	O
24	.	O

1	Sequence	O
2	analysis	O
3	revealed	O
4	:	O
5	1	O
6	)	O
7	a	O
8	kinase	O
9	catalytic	O
10	domain	O
11	most	O
12	characteristic	O
13	of	O
14	serine	B
15	/	I
16	threonine	I
17	kinases	I
18	but	O
19	hybrid	O
20	between	O
21	members	O
22	of	O
23	the	O
24	family	O
25	of	O
26	microtubule	B
27	-	I
28	associated	I
29	protein	I
30	kinase	I
31	kinase	I
32	kinases	I
33	and	O
34	the	O
35	fibroblast	B
36	growth	I
37	factor	I
38	receptor	I
39	family	I
40	;	O
41	2	O
42	)	O
43	two	O
44	putative	O
45	alpha	O
46	-	O
47	helical	O
48	leucine	O
49	zipper	O
50	motifs	O
51	separated	O
52	by	O
53	a	O
54	25	O
55	-	O
56	amino	O
57	acid	O
58	charged	O
59	intermediate	O
60	segment	O
61	but	O
62	lacking	O
63	an	O
64	NH2	O
65	-	O
66	terminal	O
67	basic	O
68	domain	O
69	;	O
70	and	O
71	3	O
72	)	O
73	COOH	O
74	-	O
75	terminal	O
76	and	O
77	NH2	O
78	-	O
79	terminal	O
80	proline	O
81	-	O
82	rich	O
83	domains	O
84	suggestive	O
85	of	O
86	src	B
87	homology	I
88	3	I
89	(	O
90	SH3	B
91	)	O
92	domain	O
93	binding	O
94	regions	O
95	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	The	O
2	treatment	O
3	of	O
4	hydronephrosis	O
5	in	O
6	children	O

1	In	O
2	reviewing	O
3	a	O
4	number	O
5	of	O
6	the	O
7	most	O
8	intensely	O
9	studied	O
10	environmentally	O
11	inducible	O
12	promoters	O
13	it	O
14	becomes	O
15	clear	O
16	that	O
17	the	O
18	presence	O
19	of	O
20	two	O
21	cis	O
22	-	O
23	acting	O
24	elements	O
25	are	O
26	critical	O
27	for	O
28	promoter	O
29	activity	O
30	,	O
31	one	O
32	of	O
33	which	O
34	is	O
35	the	O
36	G	O
37	-	O
38	box	O
39	(	O
40	CCACGTGG	O
41	).	O

1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	O
7	arrest	O
8	elongation	O
9	by	O
10	polIII	B
11	at	O
12	defined	O
13	positions	O
14	within	O
15	the	O
16	tRNA	O
17	gene	O
18	transcription	O
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	B
31	polIII	I
32	ternary	I
33	complexes	I
34	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	yeast	B
5	CEG1	I
6	demonstrated	O
7	that	O
8	four	O
9	of	O
10	the	O
11	five	O
12	conserved	O
13	motifs	O
14	are	O
15	essential	O
16	for	O
17	capping	B
18	enzyme	I
19	function	O
20	in	O
21	vivo	O
22	.	O

1	Transfer	O
2	also	O
3	correlated	O
4	inversely	O
5	with	O
6	gastric	O
7	juice	O
8	pH	O
9	(	O
10	r	O
11	=	O
12	-	O
13	0	O
14	.	O
15	619	O
16	,	O
17	P	O
18	<	O
19	0	O
20	.	O
21	02	O
22	).	O

1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	B
7	and	O
8	D9S5	B
9	and	O
10	between	O
11	FRDA	B
12	and	O
13	D9S15	B
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O

1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	O
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	O
12	kinase	O
13	TFIIH	B
14	/	O
15	TFIIK	B
16	.	O

1	I	O
2	hypothesize	O
3	that	O
4	white	B
5	gene	I
6	expression	O
7	from	O
8	P	B
9	[	I
10	en	I
11	]	I
12	is	O
13	repressed	O
14	by	O
15	the	O
16	formation	O
17	of	O
18	a	O
19	protein	O
20	complex	O
21	which	O
22	is	O
23	initiated	O
24	at	O
25	the	O
26	engrailed	B
27	PS	I
28	sites	I
29	and	O
30	also	O
31	requires	O
32	interactions	O
33	with	O
34	flanking	O
35	genomic	O
36	DNA	O
37	.	O

1	To	O
2	see	O
3	if	O
4	a	O
5	pulse	O
6	oximeter	O
7	can	O
8	monitor	O
9	the	O
10	fetus	O
11	during	O
12	labour	O
13	we	O
14	recruited	O
15	100	O
16	Caucasian	O
17	women	O
18	in	O
19	normal	O
20	uncomplicated	O
21	labour	O
22	.	O

1	The	O
2	IPL1	B
3	gene	I
4	is	O
5	required	O
6	for	O
7	high	O
8	-	O
9	fidelity	O
10	chromosome	O
11	segregation	O
12	in	O
13	the	O
14	budding	O
15	yeast	O
16	Saccharomyces	O
17	cerevisiae	O
18	.	O

1	No	O
2	drop	O
3	in	O
4	oxygen	O
5	saturation	O
6	(	O
7	SaO2	O
8	)	O
9	or	O
10	visual	O
11	evidence	O
12	of	O
13	transient	O
14	electroencephalographic	O
15	(	O
16	EEG	O
17	)	O
18	arousals	O
19	can	O
20	be	O
21	found	O
22	at	O
23	repeat	O
24	polysomnography	O
25	.	O

1	The	O
2	pentafluorobenzyl	O
3	derivative	O
4	of	O
5	clonidine	O
6	yields	O
7	an	O
8	intense	O
9	ion	O
10	fragment	O
11	at	O
12	m	O
13	/	O
14	z	O
15	354	O
16	,	O
17	and	O
18	the	O
19	lower	O
20	limit	O
21	of	O
22	detection	O
23	is	O
24	0	O
25	.	O
26	025	O
27	ng	O
28	/	O
29	ml	O
30	for	O
31	a	O
32	1	O
33	-	O
34	ml	O
35	plasma	O
36	sample	O
37	.	O

1	A	O
2	more	O
3	complete	O
4	analysis	O
5	of	O
6	dose	O
7	response	O
8	,	O
9	time	O
10	and	O
11	mode	O
12	of	O
13	Ga	O
14	administration	O
15	(	O
16	preinjury	O
17	or	O
18	postinjury	O
19	),	O
20	and	O
21	availability	O
22	of	O
23	Ga	O
24	across	O
25	the	O
26	blood	O
27	-	O
28	brain	O
29	barrier	O
30	is	O
31	needed	O
32	to	O
33	further	O
34	evaluate	O
35	the	O
36	efficacy	O
37	of	O
38	this	O
39	compound	O
40	.	O

1	The	O
2	presence	O
3	of	O
4	regulatory	O
5	sequences	O
6	for	O
7	the	O
8	binding	O
9	of	O
10	transcription	O
11	factors	O
12	such	O
13	as	O
14	NF	B
15	-	I
16	kappa	I
17	B	I
18	and	O
19	AP	B
20	-	I
21	2	I
22	,	O
23	whose	O
24	activation	O
25	is	O
26	associated	O
27	with	O
28	the	O
29	immediate	O
30	response	O
31	of	O
32	the	O
33	cell	O
34	to	O
35	an	O
36	injury	O
37	,	O
38	may	O
39	be	O
40	an	O
41	indication	O
42	of	O
43	the	O
44	important	O
45	role	O
46	which	O
47	HO	B
48	-	I
49	1	I
50	may	O
51	play	O
52	in	O
53	defense	O
54	mechanisms	O
55	against	O
56	tissue	O
57	injury	O
58	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	sought	O
6	to	O
7	test	O
8	the	O
9	hypothesis	O
10	that	O
11	,	O
12	when	O
13	equal	O
14	volumes	O
15	are	O
16	administered	O
17	intrathecally	O
18	,	O
19	significant	O
20	differences	O
21	exist	O
22	in	O
23	the	O
24	potential	O
25	to	O
26	three	O
27	commonly	O
28	used	O
29	anesthetic	O
30	solutions	O
31	to	O
32	induce	O
33	sensory	O
34	impairment	O
35	.	O

1	In	O
2	an	O
3	in	O
4	vitro	O
5	study	O
6	,	O
7	10	O
8	/	O
9	0	O
10	nylon	O
11	was	O
12	found	O
13	to	O
14	require	O
15	a	O
16	significantly	O
17	lower	O
18	laser	O
19	energy	O
20	density	O
21	to	O
22	produce	O
23	suture	O
24	lysis	O
25	following	O
26	a	O
27	single	O
28	shot	O
29	than	O
30	either	O
31	10	O
32	/	O
33	0	O
34	Dacron	O
35	or	O
36	10	O
37	/	O
38	0	O
39	prolene	O
40	.	O

1	However	O
2	,	O
3	by	O
4	an	O
5	NS35	B
6	-	I
7	specific	I
8	RNA	I
9	capture	O
10	assay	O
11	,	O
12	the	O
13	multimers	O
14	were	O
15	shown	O
16	to	O
17	possess	O
18	the	O
19	RNA	O
20	-	O
21	binding	O
22	activity	O
23	previously	O
24	demonstrated	O
25	for	O
26	NS35	B
27	.	O

1	CONCLUSION	O
2	:	O
3	Human	O
4	preterm	O
5	birth	O
6	is	O
7	associated	O
8	with	O
9	significantly	O
10	lower	O
11	progesterone	O
12	/	O
13	17	O
14	beta	O
15	-	O
16	estradiol	O
17	ratios	O
18	than	O
19	those	O
20	of	O
21	women	O
22	with	O
23	preterm	O
24	labor	O
25	delivered	O
26	at	O
27	term	O
28	.	O

1	The	O
2	mechanism	O
3	whereby	O
4	zeta	B
5	PKC	I
6	regulates	O
7	NF	B
8	-	I
9	kappa	I
10	B	I
11	most	O
12	probably	O
13	involves	O
14	the	O
15	activation	O
16	of	O
17	a	O
18	putative	O
19	I	B
20	kappa	I
21	B	I
22	kinase	I
23	of	O
24	molecular	O
25	mass	O
26	approximately	O
27	50	O
28	kDa	O
29	,	O
30	which	O
31	phosphorylates	O
32	and	O
33	inactivates	O
34	I	B
35	kappa	I
36	B	I
37	.	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	B
9	4	I
10	(	O
11	myosin	B
12	from	I
13	rat	I
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	O
28	myosin	B
29	I	I
30	.	O

1	However	O
2	,	O
3	each	O
4	promoter	O
5	activated	O
6	by	O
7	IEP86	B
8	was	O
9	synergistically	O
10	affected	O
11	by	O
12	the	O
13	addition	O
14	of	O
15	IEP72	B
16	.	O

1	We	O
2	speculate	O
3	that	O
4	mast	O
5	cell	O
6	degranulation	O
7	may	O
8	be	O
9	involved	O
10	in	O
11	the	O
12	pathogenesis	O
13	of	O
14	necrobiosis	O
15	by	O
16	altering	O
17	fibroblast	O
18	enzyme	O
19	activity	O
20	and	O
21	/	O
22	or	O
23	producing	O
24	prolonged	O
25	inflammatory	O
26	reactions	O
27	.	O

1	However	O
2	,	O
3	Southern	O
4	blot	O
5	and	O
6	karyotype	O
7	analyses	O
8	did	O
9	not	O
10	reveal	O
11	any	O
12	significant	O
13	changes	O
14	in	O
15	copy	O
16	number	O
17	or	O
18	gross	O
19	rearrangements	O
20	of	O
21	the	O
22	p53	B
23	gene	I
24	in	O
25	any	O
26	of	O
27	the	O
28	p53	B
29	-	I
30	cell	O
31	lines	O
32	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	IGF	B
2	I	I
3	and	O
4	insulin	B
5	receptors	I
6	are	O
7	homologous	O
8	proteins	O
9	that	O
10	function	O
11	in	O
12	distinct	O
13	physiological	O
14	pathways	O
15	.	O

1	We	O
2	have	O
3	found	O
4	a	O
5	satisfactory	O
6	reproducibility	O
7	in	O
8	vitro	O
9	(	O
10	T1	O
11	:	O
12	1	O
13	.	O
14	9	O
15	%;	O
16	T2	O
17	:	O
18	6	O
19	.	O
20	2	O
21	%),	O
22	while	O
23	the	O
24	reproducibility	O
25	was	O
26	less	O
27	satisfactory	O
28	in	O
29	vivo	O
30	(	O
31	T1	O
32	:	O
33	16	O
34	.	O
35	4	O
36	%;	O
37	T2	O
38	:	O
39	13	O
40	.	O
41	4	O
42	%).	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	diverse	O
7	set	O
8	of	O
9	carboxyl	O
10	-	O
11	terminal	O
12	sequence	O
13	motifs	O
14	and	O
15	posttranslational	O
16	modifications	O
17	lead	O
18	to	O
19	functional	O
20	Ras	B
21	proteins	I
22	in	O
23	yeast	O
24	.	O

1	An	O
2	in	O
3	vitro	O
4	binding	O
5	site	O
6	selection	O
7	procedure	O
8	was	O
9	used	O
10	to	O
11	determine	O
12	DNA	O
13	sequences	O
14	preferentially	O
15	bound	O
16	by	O
17	wild	B
18	-	I
19	type	I
20	HLF	I
21	and	O
22	chimeric	O
23	E2A	B
24	-	O
25	HLF	B
26	proteins	O
27	isolated	O
28	from	O
29	various	O
30	t	O
31	(	O
32	17	O
33	;	O
34	19	O
35	)-	O
36	bearing	O
37	leukemias	O
38	.	O

1	Ariga	O
2	,	O
3	Biochem	O
4	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	KRAB	B
7	domain	I
8	present	O
9	in	O
10	the	O
11	non	O
12	-	O
13	finger	O
14	region	O
15	of	O
16	many	O
17	ZFP	B
18	genes	I
19	quenches	O
20	transcription	O
21	possibly	O
22	due	O
23	to	O
24	specific	O
25	protein	O
26	-	O
27	protein	O
28	interactions	O
29	between	O
30	the	O
31	KRAB	B
32	-	I
33	A	I
34	domain	I
35	and	O
36	components	O
37	of	O
38	the	O
39	proximal	O
40	transcriptional	O
41	apparatus	O
42	.	O

1	Significant	O
2	alterations	O
3	in	O
4	CBC	O
5	results	O
6	and	O
7	serum	B
8	CRP	I
9	concentration	O
10	,	O
11	compared	O
12	with	O
13	baseline	O
14	values	O
15	,	O
16	were	O
17	lacking	O
18	in	O
19	dogs	O
20	of	O
21	the	O
22	control	O
23	group	O
24	.	O

1	CDC31	B
2	is	O
3	required	O
4	for	O
5	SPB	O
6	duplication	O
7	and	O
8	encodes	O
9	a	O
10	calmodulin	B
11	-	I
12	like	I
13	protein	I
14	that	O
15	is	O
16	most	O
17	closely	O
18	related	O
19	to	O
20	caltractin	B
21	/	O
22	centrin	B
23	,	O
24	a	O
25	protein	O
26	associated	O
27	with	O
28	the	O
29	Chlamydomonas	O
30	basal	O
31	body	O
32	.	O

1	During	O
2	transcript	O
3	elongation	O
4	,	O
5	the	O
6	sizes	O
7	of	O
8	the	O
9	DNA	O
10	footprint	O
11	and	O
12	the	O
13	single	O
14	-	O
15	stranded	O
16	transcription	O
17	bubble	O
18	vary	O
19	markedly	O
20	among	O
21	transcription	O
22	complexes	O
23	halted	O
24	at	O
25	different	O
26	template	O
27	positions	O
28	.	O

1	A	O
2	short	O
3	sequence	O
4	surrounding	O
5	the	O
6	major	O
7	JNK	B
8	phosphorylation	O
9	site	O
10	of	O
11	c	B
12	-	I
13	Jun	I
14	is	O
15	conserved	O
16	in	O
17	c	B
18	-	I
19	Fos	I
20	and	O
21	is	O
22	part	O
23	of	O
24	its	O
25	activation	O
26	domain	O
27	,	O
28	suggesting	O
29	that	O
30	c	B
31	-	I
32	Fos	I
33	may	O
34	be	O
35	similarly	O
36	regulated	O
37	.	O

1	A	O
2	new	O
3	generation	O
4	of	O
5	information	O
6	retrieval	O
7	tools	O
8	for	O
9	biologists	O
10	:	O
11	the	O
12	example	O
13	of	O
14	the	O
15	ExPASy	O
16	WWW	O
17	server	O
18	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	B
15	.	O

1	The	O
2	binding	O
3	of	O
4	transcription	O
5	factor	O
6	AP	B
7	-	I
8	1	I
9	and	O
10	vitamin	B
11	D	I
12	receptor	I
13	(	O
14	VDR	B
15	)	O
16	to	O
17	the	O
18	composite	O
19	AP	B
20	-	I
21	1	I
22	plus	I
23	vitamin	I
24	-	I
25	D	I
26	-	I
27	responsive	I
28	promoter	I
29	region	O
30	(	O
31	AP	B
32	-	I
33	1	I
34	+	I
35	VDRE	I
36	)	O
37	of	O
38	the	O
39	human	B
40	osteocalcin	I
41	gene	I
42	was	O
43	characterized	O
44	in	O
45	osteocalcin	B
46	-	O
47	producing	O
48	(	O
49	MG	O
50	-	O
51	63	O
52	)	O
53	and	O
54	non	O
55	-	O
56	producing	O
57	(	O
58	U2	O
59	-	O
60	Os	O
61	,	O
62	SaOs	O
63	-	O
64	2	O
65	)	O
66	human	O
67	osteosarcoma	O
68	cell	O
69	lines	O
70	.	O

1	Wild	B
2	type	I
3	and	I
4	mutant	I
5	Epo	I
6	cDNAs	I
7	were	O
8	transiently	O
9	expressed	O
10	at	O
11	high	O
12	levels	O
13	in	O
14	COS1	O
15	and	O
16	COS7	O
17	cells	O
18	.	O

1	OBJECTIVE	O
2	--	O
3	To	O
4	assess	O
5	the	O
6	risk	O
7	of	O
8	hepatitis	O
9	A	O
10	in	O
11	international	O
12	travelers	O
13	and	O
14	to	O
15	recommend	O
16	preventive	O
17	measures	O
18	.	O

1	This	O
2	mode	O
3	of	O
4	ternary	O
5	complex	O
6	formation	O
7	is	O
8	in	O
9	contrast	O
10	to	O
11	the	O
12	one	O
13	seen	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	the	O
19	c	B
20	-	I
21	fos	I
22	protooncogene	I
23	,	O
24	where	O
25	formation	O
26	of	O
27	the	O
28	ternary	O
29	complex	O
30	is	O
31	dependent	O
32	on	O
33	the	O
34	prior	O
35	assembly	O
36	of	O
37	the	O
38	serum	B
39	response	I
40	factor	I
41	-	I
42	DNA	I
43	binary	I
44	complex	I
45	.	O

1	The	O
2	LTR	O
3	-	O
4	binding	O
5	activities	O
6	of	O
7	VBP	B
8	,	O
9	a1	B
10	/	I
11	EBP	I
12	,	O
13	and	O
14	B	B
15	-	I
16	cell	I
17	nuclear	I
18	extract	I
19	protein	I
20	were	O
21	compared	O
22	and	O
23	mapped	O
24	by	O
25	gel	O
26	shift	O
27	,	O
28	DNase	B
29	I	I
30	footprinting	O
31	,	O
32	and	O
33	methylation	O
34	interference	O
35	assays	O
36	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	leader	O
6	-	O
7	mRNA	O
8	fusion	O
9	in	O
10	coronavirus	O
11	transcription	O
12	does	O
13	not	O
14	require	O
15	direct	O
16	RNA	O
17	-	O
18	RNA	O
19	interaction	O
20	between	O
21	complementary	O
22	sequences	O
23	.	O

1	Demographic	O
2	characteristics	O
3	and	O
4	risk	O
5	factor	O
6	data	O
7	for	O
8	76	O
9	,	O
10	672	O
11	clients	O
12	were	O
13	studied	O
14	to	O
15	characterize	O
16	the	O
17	distribution	O
18	of	O
19	infection	O
20	with	O
21	human	O
22	immunodeficiency	O
23	virus	O
24	(	O
25	HIV	O
26	)	O
27	and	O
28	the	O
29	use	O
30	of	O
31	counseling	O
32	and	O
33	testing	O
34	facilities	O
35	in	O
36	Houston	O
37	,	O
38	Tex	O
39	.	O

1	Results	O
2	indicate	O
3	that	O
4	KNM	O
5	-	O
6	LU	O
7	335	O
8	differs	O
9	from	O
10	both	O
11	human	O
12	and	O
13	chimpanzee	O
14	M1s	O
15	in	O
16	relative	O
17	distances	O
18	(	O
19	measured	O
20	in	O
21	three	O
22	dimensions	O
23	)	O
24	between	O
25	crown	O
26	fissure	O
27	termini	O
28	.	O

1	Comparison	O
2	with	O
3	the	O
4	bovine	O
5	gene	O
6	showed	O
7	that	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	hATP1	B
16	gene	I
17	has	O
18	an	O
19	unconserved	O
20	guanine	O
21	-	O
22	cytosine	O
23	(	O
24	GC	O
25	)	O
26	rich	O
27	region	O
28	,	O
29	including	O
30	several	O
31	binding	O
32	motifs	O
33	of	O
34	transcriptional	O
35	factors	O
36	,	O
37	such	O
38	as	O
39	Sp1	B
40	,	O
41	AP	B
42	-	I
43	2	I
44	,	O
45	and	O
46	GCF	B
47	.	O

1	The	O
2	polyubiquitin	B
3	gene	I
4	was	O
5	transcribed	O
6	throughout	O
7	the	O
8	Volvox	O
9	life	O
10	cycle	O
11	with	O
12	peaks	O
13	in	O
14	the	O
15	1	O
16	.	O
17	6	O
18	-	O
19	kb	O
20	mRNA	O
21	levels	O
22	during	O
23	pre	O
24	-	O
25	cleavage	O
26	,	O
27	cleavage	O
28	,	O
29	and	O
30	post	O
31	-	O
32	inversion	O
33	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	DNA	B
6	polymerase	I
7	delta	I
8	of	I
9	Saccharomyces	I
10	cerevisiae	I
11	,	O
12	an	O
13	enzyme	O
14	that	O
15	is	O
16	essential	O
17	for	O
18	viability	O
19	and	O
20	chromosomal	O
21	replication	O
22	,	O
23	is	O
24	also	O
25	required	O
26	for	O
27	base	O
28	excision	O
29	repair	O
30	of	O
31	exogenous	O
32	DNA	O
33	methylation	O
34	damage	O
35	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	Marek	O
6	'	O
7	s	O
8	Disease	O
9	Virus	O
10	(	O
11	MDV	O
12	)	O
13	genes	O
14	within	O
15	the	O
16	EcoRI	B
17	-	I
18	B	I
19	fragment	I
20	of	O
21	MDV	O
22	-	O
23	GA	O
24	genomic	O
25	DNA	O
26	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	microsatellite	O
6	repeat	O
7	polymorphism	O
8	with	O
9	a	O
10	heterozygosity	O
11	of	O
12	71	O
13	%	O
14	at	O
15	the	O
16	RET	B
17	locus	I
18	and	O
19	a	O
20	restriction	O
21	fragment	O
22	length	O
23	polymorphism	O
24	with	O
25	a	O
26	heterozygosity	O
27	of	O
28	42	O
29	%	O
30	detected	O
31	by	O
32	a	O
33	lambda	O
34	clone	O
35	from	O
36	the	O
37	D10S94	B
38	locus	I
39	have	O
40	been	O
41	developed	O
42	for	O
43	high	O
44	-	O
45	resolution	O
46	genetic	O
47	linkage	O
48	mapping	O
49	and	O
50	predictive	O
51	diagnostic	O
52	testing	O
53	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	Salazopyrine	O
2	desensitization	O

1	We	O
2	show	O
3	that	O
4	HRI	B
5	and	O
6	dsRNA	B
7	-	I
8	PK	I
9	phosphorylate	O
10	yeast	B
11	eIF	I
12	-	I
13	2	I
14	alpha	I
15	in	O
16	vitro	O
17	and	O
18	in	O
19	vivo	O
20	and	O
21	functionally	O
22	substitute	O
23	for	O
24	GCN2	B
25	protein	I
26	to	O
27	stimulate	O
28	GCN4	B
29	translation	O
30	in	O
31	yeast	O
32	.	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	Tobacco	O
2	mosaic	O
3	virus	O
4	-	O
5	infected	O
6	tobacco	O
7	(	O
8	Nicotiana	O
9	tabacum	O
10	var	O
11	.	O

1	Fenoldopam	O
2	,	O
3	a	O
4	dopamine	B
5	receptor	I
6	agonist	O
7	,	O
8	has	O
9	been	O
10	shown	O
11	,	O
12	in	O
13	animal	O
14	experiments	O
15	,	O
16	to	O
17	improve	O
18	renal	O
19	perfusion	O
20	.	O

1	The	O
2	approach	O
3	derives	O
4	from	O
5	a	O
6	recently	O
7	described	O
8	strategy	O
9	for	O
10	making	O
11	recombinants	O
12	from	O
13	five	O
14	overlapping	O
15	EBV	O
16	cosmid	O
17	-	O
18	cloned	O
19	DNAs	O
20	(	O
21	B	O
22	.	O

1	Comparative	O
2	analysis	O
3	with	O
4	an	O
5	antiandrogen	O
6	niftolid	O
7	and	O
8	synthetic	B
9	GnRH	I
10	was	O
11	carried	O
12	out	O
13	in	O
14	22	O
15	normal	O
16	subjects	O
17	,	O
18	14	O
19	patients	O
20	with	O
21	primary	O
22	and	O
23	20	O
24	ones	O
25	with	O
26	secondary	O
27	hypogonadism	O
28	,	O
29	and	O
30	in	O
31	5	O
32	patients	O
33	with	O
34	clinical	O
35	signs	O
36	of	O
37	gonadal	O
38	insufficiency	O
39	and	O
40	obscure	O
41	diagnosis	O
42	in	O
43	order	O
44	to	O
45	elucidate	O
46	the	O
47	pituitary	B
48	gonadotropin	I
49	reserves	O
50	.	O

1	Increasing	O
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O

1	Western	O
2	blotting	O
3	(	O
4	immunoblotting	O
5	)	O
6	with	O
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	SOD	B
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	masses	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O

1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O

1	Deletion	O
2	analyses	O
3	of	O
4	the	O
5	pCD41	B
6	ORF	I
7	-	I
8	A	I
9	and	O
10	the	O
11	use	O
12	of	O
13	promoter	O
14	constructs	O
15	further	O
16	mapped	O
17	an	O
18	internal	O
19	functional	O
20	promoter	O
21	within	O
22	the	O
23	pCD41	B
24	sequence	I
25	that	O
26	can	O
27	direct	O
28	the	O
29	synthesis	O
30	of	O
31	the	O
32	trans	O
33	-	O
34	activating	O
35	protein	O
36	.	O

1	The	O
2	inferred	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	cyanobacterial	B
9	HemB	I
10	protein	I
11	indicates	O
12	a	O
13	significant	O
14	difference	O
15	in	O
16	the	O
17	metal	O
18	cofactor	O
19	requirement	O
20	from	O
21	the	O
22	higher	O
23	-	O
24	plant	O
25	enzymes	O
26	,	O
27	which	O
28	was	O
29	confirmed	O
30	by	O
31	overexpression	O
32	and	O
33	biochemical	O
34	analysis	O
35	.	O

1	Although	O
2	inactive	O
3	in	O
4	cells	O
5	under	O
6	normal	O
7	conditions	O
8	,	O
9	the	O
10	CHOP	B
11	gene	I
12	is	O
13	markedly	O
14	induced	O
15	by	O
16	a	O
17	variety	O
18	of	O
19	cellular	O
20	stresses	O
21	,	O
22	including	O
23	nutrient	O
24	deprivation	O
25	and	O
26	metabolic	O
27	perturbations	O
28	.	O

1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O

1	Expression	O
2	of	O
3	the	O
4	dibasic	O
5	proprotein	O
6	processing	O
7	enzyme	O
8	furin	B
9	is	O
10	directed	O
11	by	O
12	multiple	O
13	promoters	O
14	.	O

1	MSSP	B
2	-	I
3	1	I
4	produced	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	as	O
10	a	O
11	fusion	O
12	protein	O
13	with	O
14	GST	B
15	specifically	O
16	interacted	O
17	with	O
18	single	O
19	-	O
20	stranded	O
21	TCTTAT	O
22	(	O
23	plus	O
24	myc	B
25	(	O
26	H	O
27	-	O
28	P	O
29	)	O
30	21	O
31	)	O
32	and	O
33	ACT	O
34	-	O
35	ATT	O
36	(	O
37	in	O
38	minus	O
39	myc	B
40	(	O
41	H	O
42	-	O
43	P	O
44	)	O
45	21	O
46	),	O
47	the	O
48	consensus	O
49	of	O
50	which	O
51	can	O
52	be	O
53	referred	O
54	to	O
55	as	O
56	A	O
57	/	O
58	TCTA	O
59	/	O
60	TA	O
61	/	O
62	TT	O
63	.	O

1	Varieties	O
2	of	O
3	envious	O
4	experience	O
5	.	O

1	A	O
2	segment	O
3	of	O
4	mRNA	O
5	encoding	O
6	the	O
7	leader	O
8	peptide	O
9	of	O
10	the	O
11	CPA1	B
12	gene	I
13	confers	O
14	repression	O
15	by	O
16	arginine	O
17	on	O
18	a	O
19	heterologous	O
20	yeast	O
21	gene	O
22	transcript	O
23	.	O

1	RNP1	B
2	,	O
3	a	O
4	new	O
5	ribonucleoprotein	O
6	gene	O
7	of	O
8	the	O
9	yeast	O
10	Saccharomyces	O
11	cerevisiae	O
12	.	O

1	Digestion	O
2	of	O
3	NF	B
4	-	I
5	IL6	I
6	with	O
7	endoprotease	B
8	Asp	I
9	-	I
10	N	I
11	produced	O
12	a	O
13	domain	O
14	smaller	O
15	than	O
16	the	O
17	TCD	B
18	(	O
19	NF	B
20	-	I
21	IL6	I
22	bZIP	I
23	domains	I
24	(	O
25	NFBD	B
26	)	O
27	(	O
28	272	O
29	-	O
30	345	O
31	)),	O
32	a	O
33	domain	O
34	identified	O
35	either	O
36	in	O
37	the	O
38	absence	O
39	or	O
40	the	O
41	presence	O
42	of	O
43	DNA	O
44	.	O

1	With	O
2	a	O
3	cutoff	O
4	level	O
5	for	O
6	TSST	B
7	-	I
8	1	I
9	of	O
10	less	O
11	than	O
12	100	O
13	pg	O
14	/	O
15	ml	O
16	,	O
17	28	O
18	samples	O
19	obtained	O
20	from	O
21	12	O
22	patients	O
23	were	O
24	positive	O
25	for	O
26	TSST	B
27	-	I
28	1	I
29	.	O

1	Mapping	O
2	of	O
3	intracellular	O
4	localization	O
5	domains	O
6	and	O
7	evidence	O
8	for	O
9	colocalization	O
10	interactions	O
11	between	O
12	the	O
13	IE110	B
14	and	O
15	IE175	B
16	nuclear	O
17	transactivator	O
18	proteins	O
19	of	O
20	herpes	O
21	simplex	O
22	virus	O
23	.	O

1	Dotarizine	O
2	produced	O
3	arterial	O
4	dilation	O
5	in	O
6	both	O
7	systemic	O
8	and	O
9	pulmonary	O
10	circulation	O
11	:	O
12	the	O
13	total	O
14	peripheral	O
15	resistance	O
16	dropped	O
17	,	O
18	and	O
19	femoral	O
20	artery	O
21	flow	O
22	rose	O
23	;	O
24	aortic	O
25	and	O
26	pulmonary	O
27	artery	O
28	mean	O
29	and	O
30	diastolic	O
31	pressures	O
32	declined	O
33	,	O
34	and	O
35	systolic	O
36	pressures	O
37	remained	O
38	almost	O
39	stable	O
40	.	O

1	The	O
2	usefulness	O
3	of	O
4	the	O
5	lambda	O
6	PG15	O
7	and	O
8	the	O
9	lambda	O
10	AD5	O
11	cloning	O
12	vectors	O
13	was	O
14	demonstrated	O
15	by	O
16	constructing	O
17	large	O
18	Neurospora	O
19	crassa	O
20	cDNA	O
21	libraries	O
22	.	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	APS1	I
5	gene	I
6	encodes	O
7	a	O
8	homolog	O
9	of	O
10	the	O
11	small	O
12	subunit	O
13	of	O
14	the	O
15	mammalian	B
16	clathrin	I
17	AP	I
18	-	I
19	1	I
20	complex	I
21	:	O
22	evidence	O
23	for	O
24	functional	O
25	interaction	O
26	with	O
27	clathrin	B
28	at	O
29	the	O
30	Golgi	O
31	complex	O
32	.	O

1	Retrogradely	O
2	labelled	O
3	neurons	O
4	significantly	O
5	prevailed	O
6	in	O
7	the	O
8	ipsilateral	O
9	substantia	O
10	nigra	O
11	pars	O
12	compacta	O
13	.	O

1	Therefore	O
2	,	O
3	the	O
4	amino	O
5	-	O
6	terminal	O
7	sequence	O
8	of	O
9	the	O
10	purified	O
11	carA	B
12	product	I
13	is	O
14	identical	O
15	to	O
16	that	O
17	derived	O
18	from	O
19	the	O
20	nucleotide	O
21	sequence	O
22	in	O
23	both	O
24	organisms	O
25	,	O
26	P	O
27	.	O
28	stutzeri	O
29	having	O
30	four	O
31	additional	O
32	amino	O
33	acids	O
34	.	O

1	Location	O
2	and	O
3	orientation	O
4	of	O
5	an	O
6	activating	O
7	region	O
8	in	O
9	the	O
10	Escherichia	O
11	coli	O
12	transcription	O
13	factor	O
14	,	O
15	FNR	B
16	.	O

1	We	O
2	have	O
3	used	O
4	these	O
5	modified	O
6	assay	O
7	conditions	O
8	to	O
9	extend	O
10	studies	O
11	on	O
12	the	O
13	transposition	O
14	pathway	O
15	.	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	ICP10	B
6	constitutively	O
7	increases	O
8	ras	B
9	activity	O
10	,	O
11	and	O
12	its	O
13	TM	O
14	segment	O
15	plays	O
16	a	O
17	critical	O
18	role	O
19	in	O
20	transformation	O
21	-	O
22	related	O
23	signaling	O
24	pathways	O
25	.	O

1	Exposure	O
2	to	O
3	higher	O
4	TPA	O
5	concentrations	O
6	decreased	O
7	the	O
8	content	O
9	of	O
10	these	O
11	transcripts	O
12	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	B
8	and	O
9	NQO1	B
10	gene	I
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	B
17	gene	I
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O

1	The	O
2	experiment	O
3	included	O
4	6	O
5	male	O
6	and	O
7	4	O
8	female	O
9	healthy	O
10	subjects	O
11	who	O
12	,	O
13	during	O
14	a	O
15	24	O
16	-	O
17	hour	O
18	stay	O
19	in	O
20	the	O
21	respiration	O
22	chambers	O
23	,	O
24	performed	O
25	,	O
26	in	O
27	the	O
28	morning	O
29	and	O
30	afternoon	O
31	,	O
32	15	O
33	min	O
34	cycling	O
35	with	O
36	the	O
37	total	O
38	work	O
39	of	O
40	6	O
41	,	O
42	750	O
43	kg	O
44	m	O
45	.	O

1	These	O
2	rearrangements	O
3	result	O
4	in	O
5	the	O
6	formation	O
7	of	O
8	chimeric	O
9	genes	O
10	showing	O
11	the	O
12	tyrosine	B
13	kinase	I
14	domain	I
15	of	O
16	ret	B
17	fused	O
18	with	O
19	the	O
20	5	O
21	'	O
22	end	O
23	sequences	O
24	of	O
25	different	O
26	genes	O
27	.	O

1	DESIGN	O
2	--	O
3	A	O
4	randomised	O
5	study	O
6	was	O
7	conducted	O
8	in	O
9	all	O
10	women	O
11	aged	O
12	50	O
13	-	O
14	70	O
15	years	O
16	who	O
17	were	O
18	eligible	O
19	for	O
20	breast	O
21	cancer	O
22	screening	O
23	and	O
24	living	O
25	in	O
26	the	O
27	city	O
28	of	O
29	Utrecht	O
30	.	O

1	Gel	O
2	electrophoresis	O
3	and	O
4	Western	O
5	immunoblot	O
6	analyses	O
7	of	O
8	intracellular	O
9	fractions	O
10	derived	O
11	from	O
12	infected	O
13	cells	O
14	revealed	O
15	that	O
16	large	O
17	amounts	O
18	of	O
19	NS53	B
20	were	O
21	present	O
22	in	O
23	the	O
24	cytosol	O
25	and	O
26	in	O
27	association	O
28	with	O
29	the	O
30	cytoskeletal	O
31	matrix	O
32	.	O

1	Thrombotic	O
2	thrombocytopenic	O
3	purpura	O
4	in	O
5	systemic	O
6	lupus	O
7	erythematosus	O
8	.	O

1	CONCLUSIONS	O
2	:	O
3	Serum	B
4	prolactin	I
5	concentrations	O
6	show	O
7	age	O
8	related	O
9	variations	O
10	in	O
11	presumably	O
12	fertile	O
13	men	O
14	.	O

1	Eight	O
2	highly	O
3	trained	O
4	male	O
5	kayakers	O
6	were	O
7	studied	O
8	to	O
9	determine	O
10	the	O
11	relationship	O
12	between	O
13	critical	O
14	power	O
15	(	O
16	CP	O
17	)	O
18	and	O
19	the	O
20	onset	O
21	of	O
22	blood	O
23	lactate	O
24	accumulation	O
25	(	O
26	OBLA	O
27	).	O

1	As	O
2	in	O
3	S	O
4	.	O
5	cerevisiae	O
6	,	O
7	the	O
8	sequence	O
9	of	O
10	rhp51	B
11	+	I
12	showed	O
13	two	O
14	MluI	B
15	cell	I
16	-	I
17	cycle	I
18	boxes	I
19	and	O
20	a	O
21	putative	O
22	DNA	O
23	damage	O
24	-	O
25	responsive	O
26	element	O
27	in	O
28	its	O
29	upstream	O
30	region	O
31	.	O

1	A	O
2	partial	O
3	cDNA	O
4	sequence	O
5	indicated	O
6	that	O
7	the	O
8	T	B
9	lymphocyte	I
10	early	I
11	-	I
12	activation	I
13	gene	I
14	(	O
15	Tea	B
16	)	O
17	encodes	O
18	a	O
19	protein	O
20	related	O
21	to	O
22	the	O
23	dual	O
24	-	O
25	function	O
26	ecotropic	B
27	retrovirus	I
28	receptor	I
29	/	O
30	cationic	B
31	amino	I
32	acid	I
33	transporter	I
34	(	O
35	ecoR	B
36	/	O
37	CAT1	B
38	),	O
39	and	O
40	RNA	O
41	blots	O
42	suggested	O
43	highest	O
44	Tea	B
45	expression	O
46	in	O
47	T	O
48	lymphocytes	O
49	and	O
50	liver	O
51	(	O
52	MacLeod	O
53	,	O
54	C	O
55	.	O
56	L	O
57	.,	O
58	Finley	O
59	,	O
60	K	O
61	.,	O
62	Kakuda	O
63	,	O
64	D	O
65	.	O

1	This	O
2	strategy	O
3	was	O
4	used	O
5	to	O
6	place	O
7	both	O
8	the	O
9	Tn903	B
10	neo	I
11	gene	I
12	and	O
13	the	O
14	Rhodosporidium	B
15	toruloides	I
16	phenylalanine	I
17	ammonia	I
18	lyase	I
19	(	O
20	PAL	B
21	)-	O
22	encoding	O
23	gene	O
24	under	O
25	the	O
26	transcriptional	O
27	control	O
28	of	O
29	pPGK	B
30	::	O
31	REP2	B
32	.	O

1	A	O
2	-	O
3	69	O
4	-	O
5	year	O
6	-	O
7	old	O
8	patient	O
9	with	O
10	postoperative	O
11	small	O
12	-	O
13	bowel	O
14	obstruction	O
15	underwent	O
16	laparotomy	O
17	three	O
18	times	O
19	.	O

1	A	O
2	total	O
3	of	O
4	7	O
5	(	O
6	4	O
7	males	O
8	and	O
9	3	O
10	females	O
11	)	O
12	patients	O
13	were	O
14	included	O
15	in	O
16	this	O
17	retrospective	O
18	study	O
19	to	O
20	determine	O
21	the	O
22	sensitivity	O
23	of	O
24	radioimmunoscintigraphy	O
25	with	O
26	I	O
27	-	O
28	131	O
29	labeled	O
30	anti	B
31	CEA	I
32	/	O
33	CA	B
34	19	I
35	-	I
36	9	I
37	monoclonal	O
38	antibodies	O
39	.	O

1	Simultaneous	O
2	,	O
3	bilateral	O
4	and	O
5	permanent	O
6	ventilation	O
7	with	O
8	a	O
9	diaphragm	O
10	pacing	O
11	in	O
12	childhood	O
13	:	O
14	the	O
15	implantation	O
16	technique	O
17	and	O
18	indications	O

1	Also	O
2	,	O
3	HR21ap	B
4	as	O
5	well	O
6	as	O
7	HR21Xap	B
8	are	O
9	specific	O
10	in	O
11	their	O
12	inhibition	O
13	of	O
14	Sp1	B
15	binding	O
16	.	O

1	Open	O
2	reading	O
3	frames	O
4	in	O
5	a	O
6	4556	O
7	nucleotide	O
8	sequence	O
9	within	O
10	MDV	B
11	-	I
12	1	I
13	BamHI	I
14	-	I
15	D	I
16	DNA	I
17	fragment	I
18	:	O
19	evidence	O
20	for	O
21	splicing	O
22	of	O
23	mRNA	O
24	from	O
25	a	O
26	new	O
27	viral	O
28	glycoprotein	O
29	gene	O
30	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	a	O
6	tat	B
7	expressing	O
8	plasmid	O
9	with	O
10	these	O
11	viruses	O
12	containing	O
13	the	O
14	tat	B
15	ORF	I
16	mutations	O
17	resulted	O
18	in	O
19	higher	O
20	levels	O
21	of	O
22	virus	O
23	production	O
24	demonstrating	O
25	that	O
26	the	O
27	effects	O
28	of	O
29	both	O
30	mutants	O
31	are	O
32	tat	B
33	specific	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	gag	B
5	and	O
6	rev	B
7	proteins	I
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	O
19	in	O
20	cells	O
21	transfected	O
22	with	O
23	the	O
24	tat	B
25	mutants	I
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	O
36	in	O
37	trans	O
38	with	O
39	a	O
40	tat	B
41	expression	O
42	vector	O
43	.	O

1	To	O
2	determine	O
3	whether	O
4	the	O
5	excess	O
6	prevalence	O
7	of	O
8	human	O
9	immunodeficiency	O
10	virus	O
11	type	O
12	1	O
13	(	O
14	HIV	O
15	-	O
16	1	O
17	)	O
18	infection	O
19	in	O
20	US	O
21	black	O
22	and	O
23	Hispanic	O
24	homosexual	O
25	men	O
26	relative	O
27	to	O
28	white	O
29	men	O
30	can	O
31	be	O
32	explained	O
33	by	O
34	differences	O
35	in	O
36	sociodemographic	O
37	factors	O
38	,	O
39	history	O
40	of	O
41	sexually	O
42	transmitted	O
43	diseases	O
44	,	O
45	or	O
46	sexual	O
47	and	O
48	drug	O
49	-	O
50	use	O
51	behaviors	O
52	,	O
53	the	O
54	authors	O
55	conducted	O
56	a	O
57	cross	O
58	-	O
59	sectional	O
60	analysis	O
61	of	O
62	baseline	O
63	HIV	O
64	-	O
65	1	O
66	seroprevalence	O
67	and	O
68	HIV	O
69	-	O
70	1	O
71	risk	O
72	factors	O
73	among	O
74	4	O
75	,	O
76	475	O
77	non	O
78	-	O
79	Hispanic	O
80	white	O
81	,	O
82	234	O
83	Hispanic	O
84	white	O
85	,	O
86	and	O
87	194	O
88	black	O
89	homosexual	O
90	men	O
91	from	O
92	four	O
93	centers	O
94	in	O
95	the	O
96	United	O
97	States	O
98	(	O
99	Baltimore	O
100	/	O
101	Washington	O
102	,	O
103	DC	O
104	,	O
105	Pittsburgh	O
106	,	O
107	Chicago	O
108	,	O
109	and	O
110	Los	O
111	Angeles	O
112	).	O

1	The	O
2	patients	O
3	in	O
4	one	O
5	group	O
6	had	O
7	intrauterine	O
8	catheters	O
9	inserted	O
10	and	O
11	oxytocin	B
12	was	O
13	titrated	O
14	to	O
15	achieve	O
16	the	O
17	75th	O
18	percentile	O
19	of	O
20	uterine	O
21	activity	O
22	observed	O
23	in	O
24	spontaneous	O
25	normal	O
26	labour	O
27	according	O
28	to	O
29	parity	O
30	.	O

1	The	O
2	ultrastructure	O
3	of	O
4	retinal	O
5	vessels	O
6	was	O
7	examined	O
8	in	O
9	three	O
10	eyes	O
11	from	O
12	diabetic	O
13	patients	O
14	and	O
15	two	O
16	eyes	O
17	from	O
18	control	O
19	subjects	O
20	.	O

1	The	O
2	yeast	B
3	SSS1	I
4	gene	I
5	is	O
6	essential	O
7	for	O
8	secretory	O
9	protein	O
10	translocation	O
11	and	O
12	encodes	O
13	a	O
14	conserved	O
15	protein	O
16	of	O
17	the	O
18	endoplasmic	O
19	reticulum	O
20	.	O

1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	of	O
6	rat	B
7	EFIA	I
8	(	O
9	gene	O
10	encoding	O
11	enhancer	B
12	factor	I
13	I	I
14	subunit	I
15	A	I
16	)	O
17	reveals	O
18	a	O
19	complex	O
20	band	O
21	pattern	O
22	when	O
23	cDNA	O
24	subfragment	O
25	probes	O
26	are	O
27	used	O
28	.	O

1	[	B
2	Ala85	I
3	]	I
4	Dk	I
5	(	I
6	69	I
7	-	I
8	85	I
9	)	I
10	retains	O
11	full	O
12	biological	O
13	activity	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	QLMI	O
6	questionnaire	O
7	has	O
8	good	O
9	potential	O
10	as	O
11	an	O
12	instrument	O
13	for	O
14	assessing	O
15	QL	O
16	in	O
17	post	O
18	-	O
19	AMI	O
20	patients	O
21	and	O
22	that	O
23	it	O
24	can	O
25	be	O
26	successfully	O
27	self	O
28	-	O
29	administered	O
30	.	O

1	RESULTS	O
2	:	O
3	In	O
4	an	O
5	18	O
6	moth	O
7	period	O
8	and	O
9	out	O
10	of	O
11	a	O
12	total	O
13	of	O
14	284	O
15	positive	O
16	blood	O
17	cultures	O
18	(	O
19	154	O
20	significant	O
21	isolations	O
22	)	O
23	14	O
24	episodes	O
25	of	O
26	bacteremia	O
27	by	O
28	M	O
29	.	O
30	tuberculosis	O
31	were	O
32	studied	O
33	in	O
34	12	O
35	prison	O
36	patients	O
37	coinfected	O
38	by	O
39	the	O
40	human	O
41	immunodeficiency	O
42	virus	O
43	with	O
44	associated	O
45	severe	O
46	immunosuppression	O
47	(	O
48	mean	O
49	of	O
50	CD4	B
51	=	O
52	0	O
53	.	O
54	068	O
55	x	O
56	10	O
57	(	O
58	9	O
59	)/	O
60	l	O
61	).	O

1	Similar	O
2	synergistic	O
3	activation	O
4	was	O
5	observed	O
6	in	O
7	the	O
8	IL	B
9	-	I
10	8	I
11	promoter	I
12	,	O
13	which	O
14	also	O
15	contains	O
16	both	O
17	NF	B
18	-	I
19	IL6	I
20	and	O
21	NF	B
22	-	I
23	kappa	I
24	B	I
25	binding	I
26	sites	I
27	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	Effects	O
2	of	O
3	diltiazem	O
4	on	O
5	netilmicin	O
6	-	O
7	induced	O
8	nephrotoxicity	O
9	in	O
10	rabbits	O
11	.	O

1	About	O
2	20	O
3	%	O
4	of	O
5	single	O
6	-	O
7	stranded	O
8	DNA	O
9	binding	O
10	was	O
11	observed	O
12	in	O
13	the	O
14	presence	O
15	of	O
16	MgdTDP	O
17	,	O
18	but	O
19	none	O
20	was	O
21	detectable	O
22	in	O
23	the	O
24	absence	O
25	of	O
26	nucleotides	O
27	.	O

1	Three	O
2	cysteine	O
3	and	O
4	four	O
5	tryptophan	O
6	residues	O
7	,	O
8	previously	O
9	identified	O
10	as	O
11	conserved	O
12	amongst	O
13	nitrous	B
14	-	I
15	oxide	I
16	reductases	I
17	,	O
18	are	O
19	found	O
20	in	O
21	the	O
22	Paracoccus	O
23	enzyme	O
24	.	O

1	Recombinant	B
2	Leishmania	I
3	surface	I
4	glycoprotein	I
5	GP63	I
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	B
17	.	O

1	Hepatitis	O
2	B	O
3	and	O
4	liver	O
5	transplantation	O
6	.	O

1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	B
31	gene	I
32	expression	O
33	.	O

1	Clipping	O
2	resulted	O
3	in	O
4	a	O
5	serious	O
6	mislocalization	O
7	of	O
8	the	O
9	position	O
10	of	O
11	the	O
12	peak	O
13	of	O
14	the	O
15	epicortical	O
16	potential	O
17	field	O
18	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	The	O
2	promoter	O
3	and	O
4	upstream	O
5	region	O
6	of	O
7	the	O
8	Brassica	B
9	napus	I
10	2S	I
11	storage	I
12	protein	I
13	napA	I
14	gene	I
15	were	O
16	studied	O
17	to	O
18	identify	O
19	cis	O
20	-	O
21	acting	O
22	sequences	O
23	involved	O
24	in	O
25	developmental	O
26	seed	O
27	-	O
28	specific	O
29	expression	O
30	.	O

1	A	O
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	B
16	G	I
17	(	O
18	IgG	B
19	)	O
20	are	O
21	now	O
22	commercially	O
23	available	O
24	.	O

1	This	O
2	intron	O
3	occupies	O
4	a	O
5	conserved	O
6	position	O
7	corresponding	O
8	to	O
9	that	O
10	of	O
11	intron	O
12	1	O
13	in	O
14	the	O
15	transit	O
16	peptide	O
17	region	O
18	of	O
19	chloroplast	B
20	GAPDH	I
21	genes	I
22	(	O
23	GapA	B
24	and	O
25	GapB	B
26	)	O
27	of	O
28	higher	O
29	plants	O
30	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	largest	O
7	subunit	O
8	of	O
9	RNA	B
10	polymerase	I
11	II	I
12	and	O
13	TFIIB	B
14	are	O
15	important	O
16	determinants	O
17	of	O
18	transcription	O
19	start	O
20	site	O
21	selection	O
22	in	O
23	S	O
24	.	O
25	cerevisiae	O
26	and	O
27	suggest	O
28	that	O
29	this	O
30	function	O
31	might	O
32	be	O
33	conferred	O
34	by	O
35	interaction	O
36	between	O
37	these	O
38	two	O
39	proteins	O
40	.	O

1	Val	O
2	-->	O
3	Ala	O
4	mutations	O
5	selectively	O
6	alter	O
7	helix	O
8	-	O
9	helix	O
10	packing	O
11	in	O
12	the	O
13	transmembrane	O
14	segment	O
15	of	O
16	phage	B
17	M13	I
18	coat	I
19	protein	I
20	.	O

1	The	O
2	therapeutic	O
3	action	O
4	of	O
5	cyclosporin	O
6	A	O
7	(	O
8	Sandimmun	O
9	):	O
10	its	O
11	application	O
12	in	O
13	rheumatoid	O
14	arthritis	O
15	.	O

1	In	O
2	a	O
3	retrospective	O
4	analysis	O
5	of	O
6	first	O
7	-	O
8	time	O
9	total	O
10	colonoscopies	O
11	in	O
12	685	O
13	patients	O
14	,	O
15	we	O
16	investigated	O
17	the	O
18	relationship	O
19	between	O
20	hyperplastic	O
21	and	O
22	adenomatous	O
23	polyps	O
24	.	O

1	The	O
2	kinase	O
3	inhibitor	O
4	staurosporine	O
5	(	O
6	1	O
7	microM	O
8	)	O
9	blocks	O
10	LPA	O
11	-	O
12	induced	O
13	,	O
14	but	O
15	not	O
16	epidermal	O
17	growth	O
18	factor	O
19	-	O
20	induced	O
21	,	O
22	activation	O
23	of	O
24	p21ras	B
25	and	O
26	MAP	B
27	kinase	I
28	,	O
29	consistent	O
30	with	O
31	an	O
32	intermediate	O
33	protein	O
34	kinase	O
35	linking	O
36	the	O
37	LPA	B
38	receptor	I
39	to	O
40	p21ras	B
41	activation	O
42	.	O

1	267	O
2	,	O
3	4870	O
4	-	O
5	4877	O
6	))	O
7	indicates	O
8	an	O
9	overall	O
10	identity	O
11	of	O
12	58	O
13	and	O
14	56	O
15	%,	O
16	respectively	O
17	,	O
18	with	O
19	a	O
20	91	O
21	and	O
22	92	O
23	%	O
24	identity	O
25	in	O
26	the	O
27	highly	O
28	conserved	O
29	transmembrane	O
30	and	O
31	cytoplasmic	O
32	domains	O
33	.	O

1	Mothers	O
2	with	O
3	severe	O
4	anatomical	O
5	abnormalities	O
6	,	O
7	who	O
8	are	O
9	HIV	O
10	positive	O
11	,	O
12	have	O
13	active	O
14	TB	O
15	or	O
16	whose	O
17	children	O
18	have	O
19	inherited	O
20	mono	O
21	-	O
22	or	O
23	disaccharide	O
24	intolerances	O
25	should	O
26	not	O
27	breastfeed	O
28	.	O

1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O

1	Interleukin	B
2	-	I
3	6	I
4	may	O
5	possibly	O
6	potentiate	O
7	metastasis	O
8	of	O
9	cardiac	O
10	myxoma	O
11	.	O

1	Plasma	O
2	,	O
3	LDL	B
4	and	O
5	liver	O
6	cholesterol	O
7	concentrations	O
8	were	O
9	higher	O
10	in	O
11	the	O
12	hyperlipidemic	O
13	control	O
14	than	O
15	the	O
16	nonhyperlipidemic	O
17	control	O
18	and	O
19	lower	O
20	in	O
21	the	O
22	groups	O
23	fed	O
24	diets	O
25	containing	O
26	pectin	B
27	or	O
28	prune	O
29	fiber	O
30	than	O
31	in	O
32	the	O
33	hyperlipidemic	O
34	control	O
35	group	O
36	.	O

1	A	O
2	single	O
3	1	O
4	.	O
5	8	O
6	-	O
7	kb	O
8	transcript	O
9	mRNA	O
10	was	O
11	detected	O
12	by	O
13	Northern	O
14	(	O
15	RNA	O
16	)	O
17	blot	O
18	analysis	O
19	,	O
20	and	O
21	its	O
22	5	O
23	'	O
24	end	O
25	maps	O
26	to	O
27	a	O
28	position	O
29	51	O
30	bp	O
31	upstream	O
32	from	O
33	the	O
34	site	O
35	of	O
36	initiation	O
37	of	O
38	protein	O
39	synthesis	O
40	.	O

1	We	O
2	found	O
3	that	O
4	T3	O
5	(	O
6	10	O
7	(-	O
8	8	O
9	)	O
10	M	O
11	)	O
12	selectively	O
13	stimulates	O
14	transcription	O
15	from	O
16	rGH	B
17	-	O
18	TRE	O
19	-	O
20	and	O
21	TREpal	O
22	-,	O
23	but	O
24	not	O
25	ME	O
26	-	O
27	TRE	O
28	-	O
29	and	O
30	F2	O
31	-	O
32	TRE	O
33	-,	O
34	containing	O
35	templates	O
36	in	O
37	which	O
38	these	O
39	TREs	O
40	are	O
41	linked	O
42	in	O
43	front	O
44	of	O
45	the	O
46	rGH	B
47	minimal	I
48	promoter	I
49	containing	O
50	only	O
51	the	O
52	TATA	B
53	box	I
54	binding	I
55	protein	I
56	,	O
57	but	O
58	not	O
59	any	O
60	other	O
61	proximal	O
62	binding	O
63	protein	O
64	,	O
65	sequence	O
66	.	O

1	A	O
2	complementary	O
3	DNA	O
4	was	O
5	isolated	O
6	from	O
7	Caenorhabditis	O
8	elegans	O
9	that	O
10	encoded	O
11	a	O
12	polypeptide	O
13	of	O
14	1438	O
15	amino	O
16	acid	O
17	residues	O
18	,	O
19	CeGAP	B
20	,	O
21	which	O
22	contains	O
23	a	O
24	domain	O
25	with	O
26	sequence	O
27	similarity	O
28	to	O
29	the	O
30	COOH	B
31	-	I
32	terminal	I
33	segment	I
34	(	I
35	GTPase	I
36	-	I
37	activating	I
38	protein	I
39	region	I
40	)	I
41	of	O
42	Bcr	B
43	and	O
44	other	O
45	known	O
46	GTPase	B
47	-	I
48	activating	I
49	proteins	I
50	of	O
51	the	O
52	Rho	B
53	subfamily	I
54	.	O

1	Additional	O
2	exonuclease	B
3	III	I
4	protection	O
5	was	O
6	observed	O
7	beyond	O
8	the	O
9	core	O
10	region	O
11	on	O
12	both	O
13	the	O
14	5	O
15	'	O
16	and	O
17	3	O
18	'	O
19	sides	O
20	,	O
21	suggesting	O
22	that	O
23	E1	B
24	interacted	O
25	with	O
26	more	O
27	distal	O
28	sequences	O
29	as	O
30	well	O
31	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	rep	B
6	strongly	O
7	enhances	O
8	the	O
9	function	O
10	of	O
11	negative	O
12	regulatory	O
13	elements	O
14	of	O
15	the	O
16	LTR	O
17	.	O

1	The	O
2	Oct	B
3	-	I
4	3	I
5	/	I
6	4	I
7	gene	I
8	product	I
9	,	O
10	which	O
11	belongs	O
12	to	O
13	the	O
14	POU	B
15	family	I
16	of	I
17	transcription	I
18	factors	I
19	,	O
20	is	O
21	a	O
22	good	O
23	candidate	O
24	for	O
25	regulating	O
26	initial	O
27	differentiation	O
28	decisions	O
29	.	O

1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	I
10	TFs	I
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	B
20	embryonic	I
21	stem	I
22	cell	I
23	-	I
24	specific	I
25	enhancer	I
26	.	O

1	To	O
2	our	O
3	knowledge	O
4	,	O
5	type	O
6	IV	O
7	renal	O
8	tubular	O
9	acidosis	O
10	has	O
11	not	O
12	been	O
13	reported	O
14	previously	O
15	in	O
16	association	O
17	with	O
18	Alport	O
19	'	O
20	s	O
21	syndrome	O
22	in	O
23	an	O
24	adult	O
25	patient	O
26	.	O

1	A	O
2	cDNA	O
3	clone	O
4	was	O
5	isolated	O
6	from	O
7	a	O
8	chicken	O
9	embryo	O
10	cDNA	O
11	library	O
12	employing	O
13	a	O
14	PCR	O
15	-	O
16	generated	O
17	radiolabeled	O
18	probe	O
19	specific	O
20	for	O
21	the	O
22	U3	B
23	region	I
24	of	O
25	the	O
26	Rous	B
27	sarcoma	I
28	virus	I
29	LTR	I
30	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SAP	B
9	-	I
10	1	I
11	cDNA	I
12	showed	O
13	that	O
14	mature	B
15	SAP	I
16	-	I
17	1	I
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	B
26	-	I
27	type	I
28	PTP	I
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	B
35	-	I
36	conserved	I
37	domain	I
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O

1	Several	O
2	features	O
3	of	O
4	10	O
5	.	O
6	24	O
7	.	O
8	6	O
9	cells	O
10	suggest	O
11	that	O
12	the	O
13	mutation	O
14	disrupts	O
15	normal	O
16	intracellular	O
17	formation	O
18	of	O
19	peptide	B
20	/	I
21	DR	I
22	complexes	I
23	.	O

1	The	O
2	Harleco	O
3	apparatus	O
4	is	O
5	a	O
6	simple	O
7	,	O
8	useful	O
9	,	O
10	cost	O
11	-	O
12	effective	O
13	adjunct	O
14	to	O
15	the	O
16	diagnosis	O
17	and	O
18	treatment	O
19	of	O
20	this	O
21	life	O
22	-	O
23	threatening	O
24	condition	O
25	.	O

1	The	O
2	inserted	O
3	region	O
4	,	O
5	which	O
6	represents	O
7	an	O
8	intron	O
9	in	O
10	brain	O
11	and	O
12	muscle	O
13	,	O
14	is	O
15	expressed	O
16	in	O
17	the	O
18	tumor	O
19	cell	O
20	lines	O
21	either	O
22	as	O
23	a	O
24	"	O
25	readthrough	O
26	"	O
27	form	O
28	or	O
29	with	O
30	78	O
31	residues	O
32	deleted	O
33	from	O
34	its	O
35	5	O
36	'	O
37	end	O
38	.	O

1	Regression	O
2	line	O
3	slopes	O
4	of	O
5	IBDQ	O
6	scores	O
7	were	O
8	significantly	O
9	different	O
10	in	O
11	patients	O
12	who	O
13	deteriorated	O
14	from	O
15	those	O
16	who	O
17	remained	O
18	stable	O
19	([	O
20	b	O
21	]	O
22	<	O
23	0	O
24	.	O
25	15	O
26	;	O
27	P	O
28	<	O
29	0	O
30	.	O
31	0001	O
32	).	O

1	This	O
2	region	O
3	is	O
4	required	O
5	for	O
6	activation	O
7	of	O
8	DNA	O
9	binding	O
10	of	O
11	MyoD	B
12	and	O
13	E12	B
14	homodimers	I
15	and	O
16	E12	B
17	/	O
18	MyoD	B
19	heterodimers	O
20	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	Recovery	O
2	of	O
3	carbimazole	O
4	-	O
5	induced	O
6	agranulocytosis	O
7	following	O
8	recombinant	B
9	granulocyte	I
10	-	I
11	macrophage	I
12	colony	I
13	stimulating	I
14	factor	I
15	(	O
16	rhGM	B
17	-	I
18	CSF	I
19	)	O
20	administration	O
21	.	O

1	The	O
2	neglect	O
3	of	O
4	Richards	O
5	'	O
6	s	O
7	theory	O
8	demonstrates	O
9	the	O
10	range	O
11	of	O
12	factors	O
13	,	O
14	other	O
15	than	O
16	the	O
17	strictly	O
18	scientific	O
19	,	O
20	which	O
21	can	O
22	be	O
23	important	O
24	in	O
25	determining	O
26	the	O
27	influence	O
28	or	O
29	otherwise	O
30	of	O
31	a	O
32	psychological	O
33	theory	O
34	.	O

1	It	O
2	could	O
3	be	O
4	detected	O
5	exclusively	O
6	in	O
7	the	O
8	culture	O
9	medium	O
10	of	O
11	cDNA	O
12	-	O
13	transfected	O
14	COS	O
15	cells	O
16	.	O

1	There	O
2	was	O
3	no	O
4	clear	O
5	correlation	O
6	between	O
7	the	O
8	MFA	O
9	and	O
10	the	O
11	severity	O
12	of	O
13	the	O
14	UTS	O
15	phenotype	O
16	.	O

1	These	O
2	lesions	O
3	were	O
4	asymptomatic	O
5	,	O
6	but	O
7	both	O
8	were	O
9	characterized	O
10	clinically	O
11	by	O
12	central	O
13	ulceration	O
14	.	O

1	Neither	O
2	RD19	B
3	nor	O
4	RD21	B
5	mRNA	I
6	synthesis	O
7	was	O
8	responsive	O
9	to	O
10	cold	O
11	or	O
12	to	O
13	heat	O
14	stress	O
15	.	O

1	One	O
2	member	O
3	of	O
4	this	O
5	multigene	O
6	family	O
7	,	O
8	GATA	B
9	-	I
10	3	I
11	,	O
12	is	O
13	most	O
14	abundantly	O
15	expressed	O
16	in	O
17	T	O
18	lymphocytes	O
19	,	O
20	a	O
21	cellular	O
22	target	O
23	for	O
24	human	O
25	immunodeficiency	O
26	virus	O
27	type	O
28	1	O
29	(	O
30	HIV	O
31	-	O
32	1	O
33	)	O
34	infection	O
35	and	O
36	replication	O
37	.	O

1	Indeed	O
2	,	O
3	significant	O
4	level	O
5	of	O
6	CAT	B
7	activity	O
8	was	O
9	observed	O
10	in	O
11	human	O
12	lung	O
13	adenocarcinoma	O
14	(	O
15	A549	O
16	-	O
17	1	O
18	)	O
19	cells	O
20	which	O
21	had	O
22	been	O
23	incubated	O
24	with	O
25	a	O
26	complex	O
27	of	O
28	T7	B
29	RNA	I
30	polymerase	I
31	,	O
32	pT7	B
33	-	I
34	EMC	I
35	-	I
36	CAT	I
37	DNA	I
38	and	O
39	DC	O
40	-	O
41	chol	O
42	cationic	O
43	liposomes	O
44	.	O

1	To	O
2	begin	O
3	to	O
4	examine	O
5	the	O
6	mechanism	O
7	controlling	O
8	expression	O
9	of	O
10	this	O
11	gene	O
12	during	O
13	the	O
14	cell	O
15	-	O
16	cycle	O
17	,	O
18	a	O
19	mouse	B
20	B	I
21	-	I
22	myb	I
23	5	I
24	'	I
25	flanking	I
26	sequence	I
27	was	O
28	isolated	O
29	from	O
30	a	O
31	cosmid	O
32	library	O
33	and	O
34	shown	O
35	to	O
36	promote	O
37	efficiently	O
38	the	O
39	transcription	O
40	of	O
41	a	O
42	luciferase	B
43	reporter	I
44	gene	I
45	when	O
46	transfected	O
47	into	O
48	NIH3T3	O
49	fibroblasts	O
50	.	O

1	The	O
2	number	O
3	of	O
4	bacteria	O
5	in	O
6	the	O
7	lung	O
8	,	O
9	peripheral	O
10	white	O
11	blood	O
12	cell	O
13	and	O
14	BAL	O
15	fluid	O
16	cell	O
17	also	O
18	decreased	O
19	by	O
20	the	O
21	administration	O
22	of	O
23	FN	B
24	.	O

1	The	O
2	equivalent	O
3	of	O
4	the	O
5	third	O
6	ligand	O
7	,	O
8	H	O
9	-	O
10	87	O
11	,	O
12	is	O
13	T	O
14	-	O
15	47	O
16	in	O
17	the	O
18	PSTAIRE	O
19	sequence	O
20	motif	O
21	.	O

1	Although	O
2	antisperm	O
3	antibodies	O
4	are	O
5	associated	O
6	with	O
7	infertility	O
8	,	O
9	many	O
10	hospital	O
11	laboratories	O
12	do	O
13	not	O
14	test	O
15	for	O
16	these	O
17	antibodies	O
18	.	O

1	The	O
2	phosphorylation	O
3	efficiency	O
4	is	O
5	improved	O
6	by	O
7	increasing	O
8	the	O
9	number	O
10	of	O
11	N	O
12	-	O
13	terminal	O
14	arginine	O
15	residues	O
16	and	O
17	by	O
18	moving	O
19	the	O
20	arginyl	O
21	cluster	O
22	one	O
23	residue	O
24	further	O
25	away	O
26	from	O
27	the	O
28	serine	O
29	,	O
30	the	O
31	nonapeptide	O
32	(	O
33	Arg	O
34	)	O
35	4	O
36	-	O
37	Ala	O
38	-	O
39	Ala	O
40	-	O
41	Ser	O
42	-	O
43	Val	O
44	-	O
45	Ala	O
46	being	O
47	the	O
48	best	O
49	substrate	O
50	among	O
51	all	O
52	the	O
53	short	O
54	peptides	O
55	tested	O
56	(	O
57	Km	O
58	=	O
59	15	O
60	microM	O
61	).	O

1	The	O
2	Saccharomyces	B
3	cerevisiae	I
4	GAL1	I
5	and	O
6	GAL10	B
7	genes	I
8	are	O
9	controlled	O
10	in	O
11	response	O
12	to	O
13	the	O
14	availability	O
15	of	O
16	galactose	O
17	and	O
18	glucose	O
19	by	O
20	multiple	O
21	activating	O
22	and	O
23	repressing	O
24	proteins	O
25	bound	O
26	at	O
27	adjacent	O
28	or	O
29	overlapping	O
30	sites	O
31	in	O
32	UASG	O
33	.	O

1	Sex	O
2	of	O
3	calf	O
4	(	O
5	variate	O
6	2	O
7	)	O
8	was	O
9	associated	O
10	most	O
11	closely	O
12	with	O
13	width	O
14	of	O
15	muzzle	O
16	and	O
17	head	O
18	.	O

1	We	O
2	suggest	O
3	that	O
4	the	O
5	ER	O
6	lumenal	O
7	variable	O
8	domain	O
9	of	O
10	gp19K	B
11	has	O
12	a	O
13	specific	O
14	tertiary	O
15	structure	O
16	that	O
17	is	O
18	important	O
19	for	O
20	binding	O
21	to	O
22	the	O
23	polymorphic	O
24	alpha	O
25	1	O
26	and	O
27	alpha	O
28	2	O
29	domains	O
30	of	O
31	class	B
32	I	I
33	heavy	I
34	(	I
35	alpha	I
36	)	I
37	chains	I
38	.	O

1	We	O
2	recently	O
3	found	O
4	that	O
5	17	O
6	beta	O
7	-	O
8	estradiol	O
9	(	O
10	E2	O
11	)	O
12	not	O
13	only	O
14	suppresses	O
15	bone	O
16	resorption	O
17	but	O
18	also	O
19	stimulates	O
20	bone	O
21	formation	O
22	in	O
23	the	O
24	cancellous	O
25	bone	O
26	of	O
27	female	O
28	rats	O
29	.	O

1	ST	O
2	elevation	O
3	occurs	O
4	in	O
5	5	O
6	patients	O
7	(	O
8	55	O
9	.	O
10	5	O
11	%)	O
12	of	O
13	subgroup	O
14	A	O
15	and	O
16	in	O
17	no	O
18	patient	O
19	of	O
20	the	O
21	subgroup	O
22	B	O
23	.	O

1	Furthermore	O
2	,	O
3	a	O
4	p21X	B
5	protein	I
6	lacking	O
7	the	O
8	N	O
9	-	O
10	terminus	O
11	of	O
12	Rex1	B
13	was	O
14	expressed	O
15	at	O
16	high	O
17	levels	O
18	;	O
19	our	O
20	data	O
21	indicate	O
22	that	O
23	p21X	B
24	is	O
25	translated	O
26	from	O
27	the	O
28	1	O
29	.	O
30	6	O
31	-	O
32	kb	O
33	mRNA	O
34	which	O
35	is	O
36	derived	O
37	primarily	O
38	from	O
39	deleted	O
40	proviruses	O
41	.	O

1	HTLV	O
2	-	O
3	1	O
4	gene	O
5	expression	O
6	by	O
7	defective	O
8	proviruses	O
9	in	O
10	an	O
11	infected	O
12	T	O
13	-	O
14	cell	O
15	line	O
16	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	the	O
7	structures	O
8	of	O
9	the	O
10	b	O
11	-	O
12	Zip	O
13	domain	O
14	are	O
15	well	O
16	conserved	O
17	among	O
18	these	O
19	Maf	B
20	-	I
21	related	I
22	proteins	I
23	.	O

1	These	O
2	contain	O
3	a	O
4	single	O
5	1977	O
6	-	O
7	bp	O
8	exon	O
9	that	O
10	encodes	O
11	900	O
12	bp	O
13	of	O
14	the	O
15	5	O
16	'	O
17	and	O
18	3	O
19	'	O
20	untranslated	O
21	sequences	O
22	in	O
23	addition	O
24	to	O
25	a	O
26	1077	O
27	-	O
28	bp	O
29	open	O
30	reading	O
31	frame	O
32	identical	O
33	to	O
34	that	O
35	found	O
36	in	O
37	vascular	B
38	smooth	I
39	muscle	I
40	cell	I
41	AT1a	I
42	receptor	I
43	cDNAs	I
44	.	O

1	The	O
2	binding	O
3	specificity	O
4	of	O
5	this	O
6	protein	O
7	was	O
8	compared	O
9	to	O
10	that	O
11	of	O
12	human	B
13	E2F	I
14	using	O
15	a	O
16	number	O
17	of	O
18	mutant	B
19	E2F	I
20	sites	I
21	as	O
22	competitors	O
23	.	O

1	To	O
2	analyze	O
3	the	O
4	VH	O
5	regions	O
6	of	O
7	polyreactive	O
8	antibodies	O
9	,	O
10	with	O
11	particular	O
12	attention	O
13	at	O
14	their	O
15	somatically	O
16	mutated	O
17	status	O
18	,	O
19	we	O
20	generated	O
21	five	O
22	IgG	B
23	(	O
24	three	O
25	IgG1	B
26	and	O
27	two	O
28	IgG3	B
29	)	O
30	mAb	O
31	(	O
32	using	O
33	B	O
34	cells	O
35	from	O
36	a	O
37	healthy	O
38	subject	O
39	,	O
40	a	O
41	patient	O
42	with	O
43	insulin	B
44	-	O
45	dependent	O
46	diabetes	O
47	mellitus	O
48	and	O
49	a	O
50	patient	O
51	with	O
52	SLE	O
53	),	O
54	which	O
55	bound	O
56	with	O
57	various	O
58	efficiencies	O
59	a	O
60	number	O
61	of	O
62	different	O
63	self	O
64	and	O
65	foreign	O
66	Ag	O
67	.	O

1	McCann	O
2	III	O
3	,	O
4	F	O
5	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	to	O
6	what	O
7	extent	O
8	this	O
9	interaction	O
10	might	O
11	contribute	O
12	to	O
13	tumor	O
14	induction	O
15	by	O
16	the	O
17	virus	O
18	,	O
19	we	O
20	have	O
21	introduced	O
22	two	O
23	different	O
24	point	O
25	mutations	O
26	within	O
27	the	O
28	putative	O
29	pRb	B
30	-	I
31	binding	I
32	sequence	I
33	of	O
34	large	B
35	T	I
36	antigen	I
37	,	O
38	and	O
39	as	O
40	a	O
41	preliminary	O
42	to	O
43	in	O
44	vivo	O
45	experiments	O
46	we	O
47	have	O
48	studied	O
49	their	O
50	effects	O
51	in	O
52	vitro	O
53	on	O
54	some	O
55	biological	O
56	activities	O
57	relevant	O
58	to	O
59	tumor	O
60	induction	O
61	.	O

1	Since	O
2	the	O
3	-	O
4	172	O
5	/-	O
6	148	O
7	element	O
8	also	O
9	conferred	O
10	estrogen	O
11	and	O
12	thyroid	O
13	hormone	O
14	responsiveness	O
15	,	O
16	it	O
17	can	O
18	be	O
19	considered	O
20	a	O
21	composite	O
22	hormone	O
23	response	O
24	element	O
25	.	O

1	Optimal	O
2	activation	O
3	of	O
4	T	O
5	cells	O
6	requires	O
7	at	O
8	least	O
9	two	O
10	signals	O
11	.	O

1	One	O
2	of	O
3	these	O
4	genes	O
5	,	O
6	REC114	B
7	,	O
8	is	O
9	described	O
10	here	O
11	,	O
12	and	O
13	the	O
14	data	O
15	confirm	O
16	that	O
17	REC114	B
18	is	O
19	a	O
20	meiosis	O
21	-	O
22	specific	O
23	recombination	O
24	gene	O
25	with	O
26	no	O
27	detectable	O
28	function	O
29	in	O
30	mitosis	O
31	.	O

1	Growth	O
2	factor	O
3	stimulation	O
4	rapidly	O
5	induces	O
6	a	O
7	reversible	O
8	change	O
9	in	O
10	the	O
11	electrophoretic	O
12	mobility	O
13	of	O
14	the	O
15	ternary	O
16	complex	O
17	,	O
18	accompanied	O
19	by	O
20	increased	O
21	phosphorylation	O
22	of	O
23	the	O
24	Elk	B
25	-	I
26	1	I
27	C	I
28	-	I
29	terminal	I
30	region	I
31	and	O
32	by	O
33	the	O
34	activation	O
35	of	O
36	a	O
37	42	B
38	kd	I
39	cellular	I
40	Elk	I
41	-	I
42	1	I
43	kinase	I
44	.	O

1	Furthermore	O
2	,	O
3	a	O
4	mutant	O
5	receptor	O
6	(	O
7	Y977F	O
8	/	O
9	Y989F	O
10	[	O
11	PLC	B
12	gamma	I
13	-	O
14	binding	O
15	sites	O
16	])	O
17	could	O
18	fully	O
19	activate	O
20	Ras	B
21	,	O
22	and	O
23	the	O
24	direct	O
25	activation	O
26	of	O
27	protein	B
28	kinase	I
29	C	I
30	and	O
31	calcium	O
32	mobilization	O
33	had	O
34	almost	O
35	no	O
36	effect	O
37	on	O
38	the	O
39	GDP	O
40	/	O
41	GTP	O
42	state	O
43	of	O
44	Ras	B
45	in	O
46	this	O
47	cell	O
48	line	O
49	.	O

1	This	O
2	observation	O
3	suggests	O
4	that	O
5	the	O
6	methyl	O
7	-	O
8	directed	O
9	repair	O
10	system	O
11	utilizes	O
12	the	O
13	proximal	O
14	d	O
15	(	O
16	GATC	O
17	)	O
18	sequence	O
19	to	O
20	direct	O
21	correction	O
22	.	O

1	Uracil	B
2	DNA	I
3	glycosylase	I
4	catalyzes	O
5	the	O
6	initial	O
7	step	O
8	in	O
9	the	O
10	repair	O
11	pathway	O
12	that	O
13	removes	O
14	potentially	O
15	mutagenic	O
16	uracil	O
17	from	O
18	duplex	O
19	DNA	O
20	.	O

1	Lithium	O
2	phthalocyanine	O
3	(	O
4	LiPc	O
5	)	O
6	is	O
7	a	O
8	prototype	O
9	of	O
10	another	O
11	generation	O
12	of	O
13	synthetic	O
14	,	O
15	metallic	O
16	-	O
17	organic	O
18	,	O
19	paramagnetic	O
20	crystallites	O
21	that	O
22	appear	O
23	very	O
24	useful	O
25	for	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	electron	O
32	paramagnetic	O
33	resonance	O
34	oximetry	O
35	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	Losses	O
2	during	O
3	the	O
4	complete	O
5	procedure	O
6	are	O
7	corrected	O
8	for	O
9	using	O
10	radioactive	O
11	estrogen	O
12	conjugates	O
13	during	O
14	the	O
15	first	O
16	steps	O
17	and	O
18	later	O
19	by	O
20	adding	O
21	deuterated	O
22	internal	O
23	standards	O
24	of	O
25	all	O
26	compounds	O
27	measured	O
28	(	O
29	matairesinol	O
30	,	O
31	enterodiol	O
32	,	O
33	enterolactone	O
34	,	O
35	daidzein	O
36	,	O
37	O	O
38	-	O
39	desmethylangolensin	O
40	,	O
41	equol	O
42	,	O
43	and	O
44	genistein	O
45	).	O

1	IE2	B
2	-	O
3	IE2	B
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	The	O
2	conserved	O
3	ninth	O
4	C	O
5	-	O
6	terminal	O
7	heptad	O
8	in	O
9	thyroid	O
10	hormone	O
11	and	O
12	retinoic	B
13	acid	I
14	receptors	I
15	mediates	O
16	diverse	O
17	responses	O
18	by	O
19	affecting	O
20	heterodimer	O
21	but	O
22	not	O
23	homodimer	O
24	formation	O
25	.	O

1	Several	O
2	lines	O
3	of	O
4	evidence	O
5	demonstrate	O
6	that	O
7	this	O
8	growth	O
9	inhibition	O
10	requires	O
11	active	O
12	PKA	B
13	subunits	I
14	and	O
15	cAMP	O
16	:	O
17	(	O
18	i	O
19	)	O
20	this	O
21	phenotype	O
22	is	O
23	dependent	O
24	on	O
25	cAMP	O
26	since	O
27	it	O
28	is	O
29	not	O
30	seen	O
31	in	O
32	a	O
33	strain	O
34	lacking	O
35	adenylyl	B
36	cyclase	I
37	activity	O
38	,	O
39	but	O
40	the	O
41	growth	O
42	rate	O
43	of	O
44	these	O
45	transformants	O
46	is	O
47	slower	O
48	when	O
49	exogenous	O
50	cAMP	O
51	is	O
52	added	O
53	;	O
54	(	O
55	ii	O
56	)	O
57	normal	O
58	growth	O
59	occurs	O
60	when	O
61	wild	O
62	-	O
63	type	O
64	RI	B
65	cDNA	O
66	is	O
67	replaced	O
68	by	O
69	a	O
70	mutant	B
71	RI	I
72	cDNA	I
73	encoding	O
74	a	O
75	RI	B
76	protein	I
77	with	O
78	reduced	O
79	cAMP	O
80	binding	O
81	;	O
82	and	O
83	(	O
84	iii	O
85	)	O
86	the	O
87	growth	O
88	-	O
89	inhibited	O
90	phenotype	O
91	of	O
92	the	O
93	transformed	O
94	BL21	O
95	(	O
96	DE3	O
97	)	O
98	cells	O
99	requires	O
100	soluble	O
101	,	O
102	active	O
103	C	B
104	alpha	I
105	protein	I
106	.	O

1	Liu	O
2	,	O
3	B	O
4	.	O

1	BCR	B
2	-	O
3	ABL	B
4	and	O
5	v	B
6	-	I
7	abl	I
8	oncogenes	I
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	thymic	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	subsets	O
19	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	B
37	B	I
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	Regulated	O
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	B
13	corticotropin	I
14	-	I
15	releasing	I
16	hormone	I
17	gene	I
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O

1	French	O
2	bean	O
3	contains	O
4	a	O
5	small	O
6	family	O
7	of	O
8	genes	B
9	encoding	I
10	PAL	I
11	and	O
12	two	O
13	of	O
14	these	O
15	genes	O
16	,	O
17	PAL2	B
18	and	O
19	PAL3	B
20	,	O
21	have	O
22	been	O
23	shown	O
24	to	O
25	be	O
26	differentially	O
27	expressed	O
28	at	O
29	the	O
30	mRNA	O
31	level	O
32	in	O
33	bean	O
34	tissues	O
35	.	O

1	When	O
2	introduced	O
3	into	O
4	recJ	B
5	+	I
6	strains	O
7	,	O
8	srjA	B
9	mutations	O
10	conferred	O
11	hyperrecombinational	O
12	and	O
13	hyper	B
14	-	I
15	UVr	I
16	phenotypes	O
17	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	1	O
2	)	O
3	CFDN	O
4	,	O
5	AMPC	O
6	and	O
7	MNZ	O
8	showed	O
9	a	O
10	potent	O
11	antimicrobial	O
12	activity	O
13	against	O
14	H	O
15	.	O
16	pylori	O
17	,	O
18	and	O
19	especially	O
20	,	O
21	AMPC	O
22	showed	O
23	a	O
24	marked	O
25	bactericidal	O
26	activity	O
27	in	O
28	a	O
29	short	O
30	time	O
31	.	O

1	A	O
2	high	O
3	mean	O
4	intensity	O
5	of	O
6	CLTPA	O
7	(	O
8	standardized	O
9	multivariate	O
10	regression	O
11	coefficient	O
12	beta	O
13	-	O
14	0	O
15	.	O
16	059	O
17	,	O
18	p	O
19	=	O
20	0	O
21	.	O
22	020	O
23	)	O
24	and	O
25	a	O
26	high	O
27	maximal	O
28	oxygen	O
29	uptake	O
30	(	O
31	beta	O
32	-	O
33	0	O
34	.	O
35	163	O
36	,	O
37	p	O
38	<	O
39	0	O
40	.	O
41	001	O
42	)	O
43	were	O
44	associated	O
45	with	O
46	reduced	O
47	plasma	B
48	fibrinogen	I
49	when	O
50	adjusting	O
51	for	O
52	the	O
53	strongest	O
54	covariates	O
55	.	O

1	The	O
2	scr	B
3	regulon	I
4	of	O
5	pUR400	O
6	and	O
7	the	O
8	chromosomally	B
9	encoded	I
10	scr	I
11	regulon	I
12	of	I
13	Klebsiella	I
14	pneumoniae	I
15	KAY2026	I
16	are	O
17	both	O
18	negatively	O
19	controlled	O
20	by	O
21	a	O
22	specific	O
23	repressor	O
24	(	O
25	ScrR	B
26	).	O

1	Genomic	O
2	Southern	O
3	blot	O
4	analysis	O
5	and	O
6	chromosome	O
7	mapping	O
8	showed	O
9	that	O
10	GPRK6	B
11	hybridizes	O
12	to	O
13	two	O
14	closely	O
15	related	O
16	genes	O
17	located	O
18	on	O
19	chromosomes	O
20	5	O
21	and	O
22	13	O
23	and	O
24	are	O
25	,	O
26	therefore	O
27	,	O
28	distinct	O
29	from	O
30	the	O
31	GPRK	B
32	located	O
33	near	O
34	the	O
35	Huntington	B
36	disease	I
37	locus	I
38	on	O
39	chromosome	O
40	4	O
41	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	B
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	B
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	L	O
2	.,	O
3	Stange	O
4	,	O
5	G	O
6	.,	O
7	Markovich	O
8	,	O
9	D	O
10	.,	O
11	Biber	O
12	,	O
13	J	O
14	.,	O
15	Testar	O
16	,	O
17	X	O
18	.,	O
19	Zorzano	O
20	,	O
21	A	O
22	.,	O
23	Palacin	O
24	,	O
25	M	O
26	.,	O
27	and	O
28	Murer	O
29	,	O
30	H	O
31	.	O

1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	B
5	S	I
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O

1	The	O
2	obvious	O
3	functional	O
4	necessity	O
5	for	O
6	editing	O
7	in	O
8	kinetoplastid	O
9	mitochondria	O
10	is	O
11	the	O
12	formation	O
13	of	O
14	translatable	O
15	mRNAs	O
16	.	O

1	Localization	O
2	of	O
3	the	O
4	intronless	O
5	gene	O
6	coding	O
7	for	O
8	calmodulin	B
9	-	I
10	like	I
11	protein	I
12	CLP	I
13	to	O
14	human	O
15	chromosome	O
16	10p13	O
17	-	O
18	ter	O
19	.	O

1	In	O
2	wandering	O
3	stage	O
4	larvae	O
5	,	O
6	the	O
7	OBP	B
8	transcript	I
9	appeared	O
10	to	O
11	be	O
12	at	O
13	least	O
14	250	O
15	-	O
16	fold	O
17	less	O
18	abundant	O
19	than	O
20	ribosomal	O
21	RNA	O
22	.	O

1	This	O
2	promoter	O
3	could	O
4	direct	O
5	the	O
6	constitutive	O
7	expression	O
8	of	O
9	the	O
10	reporter	O
11	beta	B
12	-	I
13	galactosidase	I
14	at	O
15	high	O
16	frequency	O
17	in	O
18	transfected	O
19	colonies	O
20	of	O
21	transformed	O
22	cells	O
23	that	O
24	express	O
25	L	B
26	-	I
27	plastin	I
28	constitutively	O
29	;	O
30	by	O
31	contrast	O
32	,	O
33	this	O
34	promoter	O
35	was	O
36	virtually	O
37	inactive	O
38	in	O
39	transfected	O
40	colonies	O
41	of	O
42	normal	O
43	fibroblasts	O
44	and	O
45	it	O
46	exhibited	O
47	a	O
48	low	O
49	frequency	O
50	of	O
51	constitutive	O
52	activation	O
53	in	O
54	transfected	O
55	colonies	O
56	of	O
57	in	O
58	vitro	O
59	SV40	O
60	-	O
61	transformed	O
62	fibroblasts	O
63	which	O
64	did	O
65	not	O
66	exhibit	O
67	L	B
68	-	I
69	plastin	I
70	expression	O
71	.	O

1	The	O
2	DNase	B
3	I	I
4	footprint	O
5	extended	O
6	5	O
7	'	O
8	in	O
9	the	O
10	silencer	O
11	region	O
12	to	O
13	include	O
14	an	O
15	inverted	O
16	repeat	O
17	of	O
18	a	O
19	six	O
20	-	O
21	nucleotide	O
22	motif	O
23	(	O
24	epsilon	O
25	-	O
26	267	O
27	to	O
28	-	O
29	278	O
30	bp	O
31	)	O
32	which	O
33	shares	O
34	5	O
35	of	O
36	6	O
37	bases	O
38	with	O
39	the	O
40	GATA	B
41	-	I
42	1	I
43	consensus	I
44	sequence	I
45	.	O

1	These	O
2	data	O
3	establish	O
4	Smd1p	B
5	as	O
6	a	O
7	required	O
8	component	O
9	of	O
10	the	O
11	cellular	O
12	splicing	O
13	apparatus	O
14	and	O
15	a	O
16	factor	O
17	in	O
18	snRNA	O
19	maturation	O
20	and	O
21	stability	O
22	.	O

1	The	O
2	activity	O
3	of	O
4	the	O
5	coat	B
6	protein	I
7	promoter	I
8	of	O
9	chloris	O
10	striate	O
11	mosaic	O
12	virus	O
13	is	O
14	enhanced	O
15	by	O
16	its	O
17	own	O
18	and	O
19	C1	B
20	-	O
21	C2	B
22	gene	O
23	products	O
24	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	alignment	O
6	of	O
7	TC	B
8	II	I
9	with	O
10	that	O
11	of	O
12	other	O
13	Cbl	B
14	binding	I
15	proteins	I
16	(	O
17	rat	B
18	intrinsic	I
19	factor	I
20	,	O
21	human	B
22	transcobalamin	I
23	I	I
24	and	O
25	porcine	B
26	haptocorrin	I
27	)	O
28	revealed	O
29	only	O
30	33	O
31	%	O
32	overall	O
33	homology	O
34	.	O

1	In	O
2	mitogen	O
3	-	O
4	stimulated	O
5	splenocytes	O
6	,	O
7	Gfi	B
8	-	I
9	1	I
10	expression	O
11	begins	O
12	to	O
13	rise	O
14	at	O
15	12	O
16	h	O
17	after	O
18	stimulation	O
19	and	O
20	reaches	O
21	very	O
22	high	O
23	levels	O
24	after	O
25	50	O
26	h	O
27	,	O
28	suggesting	O
29	that	O
30	it	O
31	may	O
32	be	O
33	functionally	O
34	involved	O
35	in	O
36	events	O
37	occurring	O
38	after	O
39	the	O
40	interaction	O
41	of	O
42	IL	B
43	-	I
44	2	I
45	with	O
46	its	O
47	receptor	O
48	,	O
49	perhaps	O
50	during	O
51	the	O
52	transition	O
53	from	O
54	the	O
55	G1	O
56	to	O
57	the	O
58	S	O
59	phase	O
60	of	O
61	the	O
62	cell	O
63	cycle	O
64	.	O

1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	I
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O

1	In	O
2	order	O
3	to	O
4	investigate	O
5	how	O
6	these	O
7	expression	O
8	patterns	O
9	are	O
10	established	O
11	,	O
12	we	O
13	fused	O
14	promoter	O
15	regions	O
16	of	O
17	an	O
18	acidic	O
19	and	O
20	a	O
21	basic	O
22	glucanase	B
23	gene	I
24	to	O
25	the	O
26	beta	B
27	-	I
28	glucuronidase	I
29	(	O
30	GUS	B
31	)	O
32	reporter	O
33	gene	O
34	and	O
35	examined	O
36	expression	O
37	of	O
38	these	O
39	constructs	O
40	in	O
41	transgenic	O
42	tobacco	O
43	plants	O
44	.	O

1	Southern	O
2	blot	O
3	analysis	O
4	using	O
5	probes	O
6	from	O
7	the	O
8	3	O
9	'	O
10	portions	O
11	of	O
12	the	O
13	genomic	O
14	and	O
15	B	B
16	.	I
17	napus	I
18	MA	I
19	and	O
20	MB	B
21	cDNA	I
22	clones	O
23	showed	O
24	that	O
25	MA	B
26	type	I
27	myrosinases	I
28	are	O
29	encoded	O
30	by	O
31	approximately	O
32	4	O
33	genes	O
34	,	O
35	while	O
36	MB	B
37	type	I
38	myrosinases	I
39	are	O
40	encoded	O
41	by	O
42	more	O
43	than	O
44	10	O
45	genes	O
46	in	O
47	B	O
48	.	O
49	napus	O
50	.	O

1	Second	O
2	,	O
3	the	O
4	transcription	B
5	factor	I
6	Gal	I
7	-	I
8	ER	I
9	was	O
10	rendered	O
11	more	O
12	potent	O
13	and	O
14	less	O
15	susceptible	O
16	to	O
17	cell	O
18	type	O
19	-	O
20	specific	O
21	variation	O
22	by	O
23	fusing	O
24	the	O
25	strong	O
26	activating	O
27	domain	O
28	of	O
29	the	O
30	herpesvirus	B
31	protein	I
32	VP16	I
33	onto	O
34	its	O
35	C	O
36	terminus	O
37	.	O

1	Following	O
2	seizure	O
3	induction	O
4	,	O
5	MABP	O
6	increased	O
7	to	O
8	105	O
9	mm	O
10	Hg	O
11	and	O
12	brain	O
13	pHi	O
14	fell	O
15	to	O
16	6	O
17	.	O
18	79	O
19	+/-	O
20	0	O
21	.	O
22	03	O
23	within	O
24	15	O
25	min	O
26	and	O
27	remained	O
28	at	O
29	this	O
30	level	O
31	for	O
32	1	O
33	h	O
34	(	O
35	P	O
36	<	O
37	0	O
38	.	O
39	001	O
40	).	O

1	Ig	B
2	-	I
3	alpha	I
4	and	O
5	Ig	B
6	-	I
7	beta	I
8	contain	O
9	extended	O
10	cytoplasmic	O
11	structure	O
12	(	O
13	61	O
14	and	O
15	48	O
16	amino	O
17	acids	O
18	,	O
19	respectively	O
20	)	O
21	and	O
22	associate	O
23	with	O
24	cytoplasmic	O
25	effectors	O
26	indicating	O
27	that	O
28	they	O
29	are	O
30	directly	O
31	involved	O
32	in	O
33	signal	O
34	transduction	O
35	.	O

1	This	O
2	study	O
3	evaluates	O
4	the	O
5	feasibility	O
6	of	O
7	indirect	O
8	mesenteric	O
9	lymphangiography	O
10	as	O
11	a	O
12	colonoscopic	O
13	technique	O
14	in	O
15	a	O
16	canine	O
17	model	O
18	.	O

1	Air	O
2	lead	O
3	was	O
4	not	O
5	a	O
6	significant	O
7	explanatory	O
8	variable	O
9	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	regulation	O
6	of	O
7	flaN	B
8	transcription	O
9	in	O
10	vivo	O
11	depends	O
12	on	O
13	a	O
14	sigma	B
15	54	I
16	promoter	I
17	and	O
18	two	O
19	ftr	O
20	elements	O
21	located	O
22	downstream	O
23	of	O
24	the	O
25	transcription	O
26	start	O
27	site	O
28	at	O
29	+	O
30	86	O
31	(	O
32	ftr2	O
33	)	O
34	and	O
35	+	O
36	120	O
37	(	O
38	ftr3	O
39	).	O

1	Group	O
2	I	O
3	consisted	O
4	of	O
5	six	O
6	noncholestatic	O
7	patients	O
8	;	O
9	group	O
10	II	O
11	consisted	O
12	of	O
13	nine	O
14	mildly	O
15	cholestatic	O
16	patients	O
17	with	O
18	mild	O
19	hepatic	O
20	impairment	O
21	(	O
22	conjugated	O
23	bilirubin	O
24	,	O
25	47	O
26	mumol	O
27	liter	O
28	-	O
29	1	O
30	;	O
31	alkaline	B
32	phosphatase	I
33	,	O
34	280	O
35	IU	O
36	liter	O
37	-	O
38	1	O
39	;	O
40	gamma	B
41	-	I
42	glutamyltranspeptidase	I
43	,	O
44	190	O
45	IU	O
46	liter	O
47	-	O
48	1	O
49	);	O
50	group	O
51	III	O
52	consisted	O
53	of	O
54	six	O
55	benign	O
56	intrahepatic	O
57	cholestatic	O
58	patients	O
59	with	O
60	high	O
61	isolated	O
62	conjugated	O
63	hyperbilirubinemia	O
64	(	O
65	98	O
66	.	O
67	1	O
68	mumol	O
69	liter	O
70	-	O
71	1	O
72	).	O

1	Nuclear	B
2	beta	I
3	II	I
4	PKC	I
5	,	O
6	like	O
7	p34cdc2	B
8	kinase	I
9	,	O
10	may	O
11	function	O
12	to	O
13	regulate	O
14	nuclear	O
15	lamina	O
16	structural	O
17	stability	O
18	during	O
19	cell	O
20	cycle	O
21	.	O

1	A	O
2	rat	O
3	cDNA	O
4	that	O
5	encodes	O
6	eIF	B
7	-	I
8	5	I
9	has	O
10	been	O
11	isolated	O
12	and	O
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	to	O
18	yield	O
19	a	O
20	catalytically	O
21	active	O
22	eIF	B
23	-	I
24	5	I
25	protein	I
26	.	O

1	Mutational	O
2	analyses	O
3	have	O
4	demonstrated	O
5	the	O
6	importance	O
7	of	O
8	sequences	O
9	within	O
10	the	O
11	327	O
12	bp	O
13	segment	O
14	that	O
15	contain	O
16	a	O
17	putative	O
18	cyclic	B
19	AMP	I
20	responsive	I
21	element	I
22	binding	I
23	protein	I
24	(	O
25	CREB	B
26	)	O
27	binding	O
28	site	O
29	for	O
30	TGF	B
31	-	I
32	beta	I
33	1	I
34	and	O
35	PMA	O
36	responsiveness	O
37	and	O
38	putative	O
39	PU	B
40	-	I
41	1	I
42	and	O
43	Sp1	B
44	binding	I
45	sites	I
46	for	O
47	basal	O
48	promoter	O
49	activity	O
50	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	a	O
6	25	O
7	-	O
8	bp	O
9	promoter	O
10	element	O
11	previously	O
12	shown	O
13	to	O
14	be	O
15	important	O
16	for	O
17	the	O
18	G1	O
19	-	O
20	S	O
21	activation	O
22	of	O
23	the	O
24	human	B
25	thymidine	I
26	kinase	I
27	(	O
28	htk	B
29	)	O
30	promoter	O
31	in	O
32	growth	O
33	-	O
34	stimulated	O
35	cells	O
36	is	O
37	a	O
38	cellular	O
39	target	O
40	of	O
41	cyclin	B
42	A	I
43	and	O
44	the	O
45	p33cdk2	B
46	complexes	I
47	.	O

1	These	O
2	protective	O
3	influences	O
4	were	O
5	observed	O
6	throughout	O
7	the	O
8	range	O
9	of	O
10	filling	O
11	pressures	O
12	measured	O
13	,	O
14	from	O
15	0	O
16	to	O
17	30	O
18	mmHg	O
19	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	with	O
5	rat	O
6	liver	O
7	nuclear	O
8	extracts	O
9	identified	O
10	7	O
11	major	O
12	protein	O
13	-	O
14	binding	O
15	domains	O
16	termed	O
17	P1	O
18	through	O
19	P7	O
20	in	O
21	a	O
22	796	O
23	base	O
24	pair	O
25	DNA	O
26	fragment	O
27	(	O
28	base	O
29	pairs	O
30	-	O
31	763	O
32	to	O
33	+	O
34	33	O
35	).	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	B
16	p53	I
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	Both	O
2	inhaled	O
3	and	O
4	superfused	O
5	isoflurane	O
6	dilated	O
7	the	O
8	baseline	O
9	vein	O
10	diameter	O
11	before	O
12	stimulation	O
13	.	O

1	By	O
2	applying	O
3	the	O
4	potentiometric	O
5	method	O
6	,	O
7	in	O
8	aqueous	O
9	medium	O
10	of	O
11	ionic	O
12	strength	O
13	mu	O
14	=	O
15	0	O
16	.	O
17	2	O
18	,	O
19	the	O
20	stability	O
21	constants	O
22	,	O
23	log	O
24	beta	O
25	1	O
26	=	O
27	4	O
28	.	O
29	42	O
30	and	O
31	log	O
32	beta	O
33	2	O
34	=	O
35	8	O
36	.	O
37	57	O
38	were	O
39	obtained	O
40	.	O

1	The	O
2	bcl	B
3	-	I
4	2	I
5	gene	I
6	can	O
7	potentially	O
8	encode	O
9	26	O
10	-	O
11	and	O
12	22	O
13	-	O
14	kDa	O
15	proteins	O
16	that	O
17	differ	O
18	only	O
19	in	O
20	their	O
21	carboxyl	O
22	tails	O
23	because	O
24	of	O
25	an	O
26	alternative	O
27	splicing	O
28	mechanism	O
29	.	O

1	Subsequent	O
2	cloning	O
3	and	O
4	nucleotide	O
5	sequence	O
6	analysis	O
7	of	O
8	the	O
9	S	B
10	.	I
11	pombe	I
12	adenylate	I
13	kinase	I
14	gene	I
15	,	O
16	adk1	B
17	,	O
18	revealed	O
19	a	O
20	coding	O
21	region	O
22	of	O
23	660	O
24	nucleotides	O
25	.	O

1	Calcification	O
2	of	O
3	a	O
4	cariogenic	O
5	Streptococcus	O
6	and	O
7	of	O
8	Corynebacterium	O
9	(	O
10	Bacterionema	O
11	)	O
12	matruchotii	O
13	.	O

1	Sequence	O
2	analysis	O
3	and	O
4	identification	O
5	of	O
6	two	O
7	hyp	B
8	regulatory	I
9	mutants	I
10	.	O

1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	O
8	GCN1	B
9	interacts	O
10	with	O
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	B
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O

1	NF	B
2	-	I
3	HB	I
4	(	O
5	BSAP	B
6	)	O
7	is	O
8	a	O
9	repressor	O
10	of	O
11	the	O
12	murine	B
13	immunoglobulin	I
14	heavy	I
15	-	I
16	chain	I
17	3	I
18	'	I
19	alpha	I
20	enhancer	I
21	at	O
22	early	O
23	stages	O
24	of	O
25	B	O
26	-	O
27	cell	O
28	differentiation	O
29	.	O

1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	B
22	gene	I
23	,	O
24	confirming	O
25	that	O
26	FtsN	B
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O

1	Against	O
2	200	O
3	strains	O
4	of	O
5	methicillin	O
6	-	O
7	resistant	O
8	Staphylococcus	O
9	aureus	O
10	(	O
11	MRSA	O
12	)	O
13	isolated	O
14	from	O
15	1990	O
16	to	O
17	1991	O
18	,	O
19	minimum	O
20	inhibitory	O
21	concentrations	O
22	(	O
23	MICs	O
24	)	O
25	of	O
26	a	O
27	total	O
28	of	O
29	15	O
30	antibacterial	O
31	agents	O
32	including	O
33	arbekacin	O
34	(	O
35	ABK	O
36	)	O
37	were	O
38	determined	O
39	.	O

1	RESULTS	O
2	:	O
3	Statistically	O
4	significant	O
5	differences	O
6	were	O
7	obtained	O
8	between	O
9	group	O
10	I	O
11	and	O
12	II	O
13	concerning	O
14	the	O
15	number	O
16	of	O
17	patients	O
18	in	O
19	whom	O
20	induced	O
21	atrial	O
22	fibrillation	O
23	with	O
24	conduction	O
25	by	O
26	the	O
27	accessory	O
28	pathway	O
29	and	O
30	RR	O
31	<	O
32	or	O
33	=	O
34	250	O
35	msec	O
36	was	O
37	found	O
38	(	O
39	0	O
40	vs	O
41	6	O
42	,	O
43	p	O
44	=	O
45	0	O
46	.	O
47	0045	O
48	).	O

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	O
8	on	O
9	the	O
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	B
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	O
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	O
31	beta	O
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	B
43	locus	I
44	was	O
45	not	O
46	deleted	O
47	.	O

1	Cloning	O
2	and	O
3	sequencing	O
4	revealed	O
5	that	O
6	dMax	B
7	contains	O
8	a	O
9	deletion	O
10	spanning	O
11	the	O
12	basic	O
13	region	O
14	and	O
15	helix	O
16	1	O
17	and	O
18	the	O
19	loop	O
20	of	O
21	the	O
22	helix	O
23	-	O
24	loop	O
25	-	O
26	helix	O
27	region	O
28	,	O
29	presumably	O
30	as	O
31	a	O
32	result	O
33	of	O
34	alternative	O
35	splicing	O
36	of	O
37	max	B
38	RNA	I
39	.	O

1	I	O
2	report	O
3	here	O
4	that	O
5	induction	O
6	of	O
7	HSP82	B
8	is	O
9	regulated	O
10	by	O
11	the	O
12	early	O
13	meiotic	O
14	IME1	B
15	-	O
16	IME2	B
17	transcriptional	O
18	cascade	O
19	.	O

1	The	O
2	domain	O
3	structure	O
4	of	O
5	bovine	B
6	LTBP	I
7	-	I
8	2	I
9	is	O
10	very	O
11	similar	O
12	to	O
13	that	O
14	of	O
15	the	O
16	human	B
17	LTBP	I
18	-	I
19	2	I
20	,	O
21	containing	O
22	20	O
23	examples	O
24	of	O
25	6	O
26	-	O
27	cysteine	O
28	epidermal	B
29	growth	I
30	factor	I
31	-	I
32	like	I
33	repeats	I
34	,	O
35	16	O
36	of	O
37	which	O
38	have	O
39	the	O
40	consensus	O
41	sequence	O
42	for	O
43	calcium	O
44	binding	O
45	,	O
46	together	O
47	with	O
48	4	O
49	examples	O
50	of	O
51	8	O
52	-	O
53	cysteine	O
54	motifs	O
55	characteristic	O
56	of	O
57	fibrillins	B
58	and	O
59	LTBP	B
60	-	I
61	1	I
62	.	O

1	We	O
2	now	O
3	report	O
4	the	O
5	isolation	O
6	and	O
7	expression	O
8	of	O
9	cDNAs	O
10	encoding	O
11	PTF	B
12	gamma	I
13	and	O
14	PTF	B
15	delta	I
16	,	O
17	as	O
18	well	O
19	as	O
20	functional	O
21	studies	O
22	with	O
23	cognate	O
24	antibodies	O
25	that	O
26	recognize	O
27	the	O
28	native	O
29	PTF	B
30	complex	I
31	in	O
32	HeLa	O
33	extracts	O
34	.	O

1	Results	O
2	from	O
3	the	O
4	mechanism	O
5	study	O
6	have	O
7	revealed	O
8	that	O
9	YY1	B
10	is	O
11	able	O
12	to	O
13	inhibit	O
14	transactivation	O
15	mediated	O
16	by	O
17	either	O
18	AP1	B
19	or	O
20	the	O
21	Sp1	B
22	-	I
23	related	I
24	protein	I
25	,	O
26	and	O
27	YY1	B
28	suppressive	O
29	activity	O
30	is	O
31	DNA	O
32	binding	O
33	dependent	O
34	.	O

1	Striking	O
2	sequence	O
3	similarities	O
4	(	O
5	57	O
6	and	O
7	53	O
8	%)	O
9	were	O
10	observed	O
11	with	O
12	yeast	O
13	mitochondrial	O
14	proteins	O
15	,	O
16	SMF1	B
17	and	O
18	SMF2	B
19	,	O
20	especially	O
21	within	O
22	putative	O
23	functional	O
24	domains	O
25	:	O
26	exon	O
27	6	O
28	encoding	O
29	the	O
30	second	O
31	transmembrane	O
32	spanning	O
33	domain	O
34	,	O
35	site	O
36	of	O
37	the	O
38	murine	B
39	susceptibility	I
40	mutation	O
41	;	O
42	and	O
43	exon	O
44	11	O
45	encoding	O
46	a	O
47	conserved	O
48	transport	O
49	motif	O
50	.	O

1	The	O
2	human	B
3	gp39	I
4	promoter	I
5	.	O

1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	B
9	orphan	I
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	O
26	beta	O
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O

1	In	O
2	this	O
3	paper	O
4	we	O
5	describe	O
6	properties	O
7	of	O
8	the	O
9	cdc10	B
10	-	O
11	C4	O
12	mutant	O
13	of	O
14	the	O
15	fission	O
16	yeast	O
17	Schizosaccharomyces	O
18	pombe	O
19	.	O

1	The	O
2	predicted	O
3	protein	O
4	products	O
5	of	O
6	ORFs	B
7	N2417	I
8	and	O
9	N2403	B
10	present	O
11	similarities	O
12	with	O
13	domains	O
14	from	O
15	proteins	O
16	of	O
17	other	O
18	organisms	O
19	:	O
20	the	O
21	Candida	O
22	maltosa	O
23	cycloheximide	B
24	-	I
25	resistance	I
26	protein	I
27	,	O
28	the	O
29	human	O
30	interleukin	B
31	enhancer	I
32	-	I
33	binding	I
34	factor	I
35	(	O
36	ILF	B
37	-	I
38	2	I
39	).	O

1	In	O
2	particular	O
3	,	O
4	the	O
5	highly	O
6	expressed	O
7	ADH1	B
8	gene	I
9	is	O
10	represented	O
11	in	O
12	this	O
13	database	O
14	by	O
15	no	O
16	less	O
17	than	O
18	20	O
19	EST	O
20	sequences	O
21	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	I
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	All	O
2	three	O
3	NR	B
4	isoforms	O
5	are	O
6	expressed	O
7	in	O
8	cv	O
9	.	O

1	Interestingly	O
2	,	O
3	internal	O
4	and	O
5	5	O
6	'	O
7	deletions	O
8	revealed	O
9	tha	O
10	the	O
11	distal	O
12	promoter	O
13	was	O
14	not	O
15	required	O
16	for	O
17	full	O
18	transcriptional	O
19	activity	O
20	and	O
21	that	O
22	the	O
23	first	O
24	631	O
25	base	O
26	pairs	O
27	of	O
28	WNT	B
29	-	I
30	5A	I
31	harbored	O
32	the	O
33	strongest	O
34	promoter	O
35	activity	O
36	.	O

1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	B
15	-	I
16	finger	I
17	protein	I
18	(	O
19	THZif	B
20	-	I
21	1	I
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	B
62	-	I
63	hypersensitive	I
64	element	I
65	(	O
66	NHE	B
67	)	O
68	of	O
69	the	O
70	human	B
71	c	I
72	-	I
73	myc	I
74	gene	I
75	.	O

1	Erythrocyte	O
2	AA	O
3	in	O
4	FO	O
5	+	O
6	EPO	B
7	-	O
8	supplemented	O
9	infants	O
10	remained	O
11	low	O
12	and	O
13	below	O
14	breast	O
15	-	O
16	and	O
17	placebo	O
18	formula	O
19	-	O
20	fed	O
21	levels	O
22	.	O

1	The	O
2	XS2	B
3	gene	I
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	B
14	genes	I
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O

1	Diabetes	O
2	care	O
3	:	O
4	a	O
5	guideline	O
6	to	O
7	the	O
8	facilities	O
9	needed	O
10	to	O
11	support	O
12	internationally	O
13	endorsed	O
14	standards	O
15	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	around	O
7	the	O
8	transcriptional	O
9	start	O
10	points	O
11	(	O
12	tsp	O
13	),	O
14	as	O
15	determined	O
16	by	O
17	primer	O
18	extension	O
19	analysis	O
20	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	In	O
2	vivo	O
3	,	O
4	selective	O
5	activation	O
6	of	O
7	SAPKs	B
8	stimulates	O
9	formation	O
10	of	O
11	the	O
12	ternary	O
13	complex	O
14	containing	O
15	Elk	B
16	-	I
17	1	I
18	,	O
19	serum	B
20	response	I
21	factor	I
22	and	O
23	the	O
24	serum	O
25	response	O
26	element	O
27	,	O
28	and	O
29	enhances	O
30	Elk	B
31	-	I
32	1	I
33	-	O
34	dependent	O
35	transcription	O
36	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	Upstream	O
2	of	O
3	the	O
4	dra	B
5	gene	I
6	an	O
7	open	O
8	reading	O
9	frame	O
10	of	O
11	313	O
12	amino	O
13	acids	O
14	was	O
15	identified	O
16	.	O

1	Oligodeoxynucleotides	O
2	antisense	O
3	to	O
4	the	O
5	predicted	O
6	translation	O
7	initiation	O
8	regions	O
9	of	O
10	ICP4	B
11	and	O
12	pp38	B
13	mRNAs	I
14	inhibited	O
15	proliferation	O
16	of	O
17	MSB1	O
18	cells	O
19	but	O
20	not	O
21	MDCC	O
22	-	O
23	CU91	O
24	(	O
25	CU91	O
26	)	O
27	reticuloendotheliosis	O
28	virus	O
29	-	O
30	transformed	O
31	cells	O
32	.	O

1	Paf1p	B
2	may	O
3	therefore	O
4	be	O
5	required	O
6	for	O
7	both	O
8	positive	O
9	and	O
10	negative	O
11	regulation	O
12	of	O
13	subsets	O
14	of	O
15	yeast	O
16	genes	O
17	.	O

1	Clones	O
2	that	O
3	expressed	O
4	DBD	O
5	exhibited	O
6	a	O
7	dominant	O
8	negative	O
9	phenotype	O
10	and	O
11	did	O
12	not	O
13	elicit	O
14	antiviral	O
15	activity	O
16	against	O
17	vesicular	O
18	stomatitis	O
19	virus	O
20	(	O
21	VSV	O
22	)	O
23	infection	O
24	upon	O
25	IFN	B
26	treatment	O
27	.	O

1	Identification	O
2	,	O
3	purification	O
4	,	O
5	and	O
6	molecular	O
7	cloning	O
8	of	O
9	autonomously	B
10	replicating	I
11	sequence	I
12	-	I
13	binding	I
14	protein	I
15	1	I
16	from	I
17	fission	I
18	yeast	I
19	Schizosaccharomyces	I
20	pombe	I
21	.	O

1	Liposomal	O
2	Amphotericin	O
3	-	O
4	B	O
5	failed	O
6	in	O
7	6	O
8	/	O
9	7	O
10	patients	O
11	with	O
12	culture	O
13	-	O
14	proven	O
15	mycosis	O
16	who	O
17	died	O
18	from	O
19	infection	O
20	with	O
21	Aspergillus	O
22	(	O
23	n	O
24	=	O
25	2	O
26	)	O
27	and	O
28	Candida	O
29	(	O
30	n	O
31	=	O
32	4	O
33	),	O
34	respectively	O
35	.	O

1	Transgenic	O
2	tobacco	O
3	plants	O
4	(	O
5	ppa	B
6	-	I
7	1	I
8	)	O
9	constitutively	O
10	expressing	O
11	Escherichia	B
12	coli	I
13	pyrophosphatase	I
14	behind	O
15	the	O
16	35S	B
17	CaMV	I
18	promoter	I
19	accumulate	O
20	high	O
21	levels	O
22	of	O
23	soluble	O
24	sugars	O
25	in	O
26	their	O
27	leaves	O
28	[	O
29	27	O
30	].	O

1	High	O
2	fibrinogen	B
3	levels	O
4	could	O
5	thus	O
6	be	O
7	a	O
8	risk	O
9	for	O
10	perioperative	O
11	thrombosis	O
12	.	O

1	Strontium	O
2	chloride	O
3	Sr	O
4	89	O
5	is	O
6	costly	O
7	,	O
8	but	O
9	preliminary	O
10	analysis	O
11	indicates	O
12	that	O
13	it	O
14	may	O
15	reduce	O
16	management	O
17	expenditures	O
18	overall	O
19	.(	O
20	ABSTRACT	O
21	TRUNCATED	O
22	AT	O
23	250	O
24	WORDS	O
25	)	O

1	In	O
2	our	O
3	opinion	O
4	,	O
5	the	O
6	SM	O
7	-	O
8	CMA	O
9	system	O
10	is	O
11	,	O
12	despite	O
13	some	O
14	shortcomings	O
15	in	O
16	its	O
17	user	O
18	-	O
19	interface	O
20	,	O
21	a	O
22	useful	O
23	and	O
24	versatile	O
25	instrument	O
26	for	O
27	examination	O
28	of	O
29	human	O
30	semen	O
31	samples	O
32	,	O
33	with	O
34	desirable	O
35	features	O
36	.	O

1	The	O
2	method	O
3	has	O
4	been	O
5	satisfactorily	O
6	applied	O
7	to	O
8	the	O
9	determination	O
10	of	O
11	paracetamol	O
12	in	O
13	pharmaceutical	O
14	formulations	O
15	and	O
16	biological	O
17	fluids	O
18	.	O

1	Suppressors	O
2	of	O
3	defective	O
4	silencing	O
5	in	O
6	yeast	O
7	:	O
8	effects	O
9	on	O
10	transcriptional	O
11	repression	O
12	at	O
13	the	O
14	HMR	B
15	locus	I
16	,	O
17	cell	O
18	growth	O
19	and	O
20	telomere	O
21	structure	O
22	.	O

1	With	O
2	current	O
3	methodology	O
4	beta	B
5	-	I
6	2	I
7	transferrin	I
8	does	O
9	not	O
10	appear	O
11	to	O
12	be	O
13	a	O
14	reliable	O
15	clinical	O
16	marker	O
17	for	O
18	perilymph	O
19	in	O
20	the	O
21	operative	O
22	setting	O
23	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	indicated	O
6	that	O
7	at	O
8	least	O
9	four	O
10	nuclear	O
11	proteins	O
12	with	O
13	distinct	O
14	biochemical	O
15	and	O
16	binding	O
17	properties	O
18	possess	O
19	the	O
20	ability	O
21	to	O
22	bind	O
23	the	O
24	3	O
25	beta	O
26	I	O
27	-	O
28	A	O
29	element	O
30	to	O
31	produce	O
32	four	O
33	DNA	O
34	-	O
35	protein	O
36	complexes	O
37	(	O
38	R1	O
39	to	O
40	R4	O
41	).	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	Regressing	O
2	microaneurysms	O
3	in	O
4	5	O
5	cases	O
6	of	O
7	hepatitis	O
8	B	O
9	virus	O
10	related	O
11	polyarteritis	O
12	nodosa	O
13	.	O

1	Effects	O
2	of	O
3	repeated	O
4	exposures	O
5	of	O
6	hydrogen	O
7	sulphide	O
8	on	O
9	rat	O
10	hippocampal	O
11	EEG	O
12	.	O

1	The	O
2	evidence	O
3	presented	O
4	here	O
5	suggests	O
6	that	O
7	the	O
8	p40	B
9	complex	I
10	is	O
11	a	O
12	ribonucleoprotein	O
13	complex	O
14	containing	O
15	L1Hs	B
16	RNA	I
17	(	I
18	s	I
19	)	I
20	and	O
21	that	O
22	protein	O
23	-	O
24	protein	O
25	interactions	O
26	in	O
27	which	O
28	alpha	O
29	-	O
30	helix	O
31	structures	O
32	participate	O
33	,	O
34	for	O
35	example	O
36	coiled	O
37	-	O
38	coils	O
39	,	O
40	may	O
41	occur	O
42	in	O
43	the	O
44	complex	O
45	.	O

1	In	O
2	conclusion	O
3	,	O
4	IgM	B
5	class	O
6	CIC	O
7	is	O
8	the	O
9	predominant	O
10	CIC	O
11	in	O
12	acute	O
13	hepatitis	O
14	A	O
15	and	O
16	correlated	O
17	with	O
18	disease	O
19	activity	O
20	.	O

1	Epitope	O
2	mapping	O
3	revealed	O
4	that	O
5	these	O
6	three	O
7	clones	O
8	appear	O
9	to	O
10	recognize	O
11	an	O
12	identical	O
13	epitope	O
14	domain	O
15	present	O
16	on	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	RNP	O
22	motif	O
23	of	O
24	the	O
25	U1A	B
26	protein	I
27	.	O

1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O

1	SUMMARY	O
2	OF	O
3	REVIEW	O
4	:	O
5	We	O
6	discuss	O
7	the	O
8	criteria	O
9	that	O
10	make	O
11	such	O
12	studies	O
13	comparable	O
14	,	O
15	drawing	O
16	on	O
17	the	O
18	experiences	O
19	of	O
20	recent	O
21	studies	O
22	performed	O
23	around	O
24	the	O
25	world	O
26	.	O

1	RESULTS	O
2	:	O
3	Basal	O
4	plasma	B
5	IGF	I
6	-	I
7	I	I
8	levels	O
9	as	O
10	well	O
11	as	O
12	body	O
13	mass	O
14	index	O
15	(	O
16	BMI	O
17	)	O
18	were	O
19	lower	O
20	in	O
21	amenorrheic	O
22	patients	O
23	than	O
24	in	O
25	healthy	O
26	controls	O
27	.	O

1	The	O
2	two	O
3	different	O
4	phosphoforms	O
5	of	O
6	STAT5	B
7	have	O
8	identical	O
9	in	O
10	vitro	O
11	DNA	O
12	binding	O
13	specificity	O
14	and	O
15	reactivity	O
16	with	O
17	tyrosine	O
18	phosphopeptides	O
19	,	O
20	but	O
21	differ	O
22	in	O
23	their	O
24	cellular	O
25	localization	O
26	.	O

1	However	O
2	,	O
3	while	O
4	the	O
5	sequence	O
6	similarity	O
7	between	O
8	the	O
9	membrane	O
10	exons	O
11	of	O
12	avian	B
13	mIgY	I
14	and	O
15	mammalian	B
16	mIgG	I
17	and	I
18	IgE	I
19	is	O
20	striking	O
21	,	O
22	the	O
23	overall	O
24	similarity	O
25	with	O
26	Xenopus	B
27	mIgY	I
28	is	O
29	very	O
30	low	O
31	.	O

1	Control	O
2	of	O
3	transcription	O
4	of	O
5	the	O
6	erbB	B
7	-	I
8	2	I
9	gene	I
10	is	O
11	an	O
12	important	O
13	determinant	O
14	of	O
15	receptor	O
16	expression	O
17	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	selective	O
6	expression	O
7	of	O
8	the	O
9	receptor	O
10	,	O
11	FL	B
12	expression	O
13	was	O
14	detected	O
15	in	O
16	90	O
17	-	O
18	100	O
19	%	O
20	of	O
21	the	O
22	various	O
23	cell	O
24	types	O
25	of	O
26	leukemia	O
27	cell	O
28	lines	O
29	from	O
30	all	O
31	hematopoietic	O
32	cell	O
33	lineages	O
34	.	O

1	Further	O
2	analysis	O
3	of	O
4	this	O
5	domain	O
6	by	O
7	in	O
8	vitro	O
9	mutagenesis	O
10	pointed	O
11	to	O
12	a	O
13	core	O
14	of	O
15	hydrophobic	O
16	and	O
17	acidic	O
18	residues	O
19	as	O
20	critical	O
21	for	O
22	the	O
23	activity	O
24	.	O

1	The	O
2	neural	O
3	mechanism	O
4	of	O
5	parkinsonian	O
6	motor	O
7	symptoms	O
8	,	O
9	i	O
10	.	O
11	e	O
12	.,	O
13	rigidity	O
14	,	O
15	tremor	O
16	and	O
17	akinesia	O
18	,	O
19	which	O
20	are	O
21	the	O
22	result	O
23	of	O
24	nigrostriatal	O
25	dopamine	O
26	deficiency	O
27	,	O
28	is	O
29	interpreted	O
30	from	O
31	long	O
32	-	O
33	term	O
34	observations	O
35	on	O
36	the	O
37	effect	O
38	of	O
39	surgical	O
40	and	O
41	pharmacological	O
42	treatment	O
43	of	O
44	the	O
45	disease	O
46	in	O
47	relation	O
48	to	O
49	the	O
50	neuropathological	O
51	findings	O
52	within	O
53	the	O
54	substantia	O
55	nigra	O
56	zona	O
57	compacta	O
58	(	O
59	SNc	O
60	).	O

1	Protein	O
2	splicing	O
3	:	O
4	evidence	O
5	for	O
6	an	O
7	N	O
8	-	O
9	O	O
10	acyl	O
11	rearrangement	O
12	as	O
13	the	O
14	initial	O
15	step	O
16	in	O
17	the	O
18	splicing	O
19	process	O
20	.	O

1	In	O
2	agreement	O
3	with	O
4	these	O
5	data	O
6	,	O
7	western	O
8	blot	O
9	experiments	O
10	using	O
11	an	O
12	antibody	O
13	directed	O
14	against	O
15	the	O
16	carboxy	O
17	-	O
18	terminal	O
19	portion	O
20	of	O
21	the	O
22	mouse	O
23	c	B
24	-	I
25	kit	I
26	protein	I
27	showed	O
28	that	O
29	a	O
30	polypeptide	O
31	,	O
32	of	O
33	the	O
34	size	O
35	predicted	O
36	by	O
37	the	O
38	open	O
39	reading	O
40	frame	O
41	of	O
42	the	O
43	spermatid	B
44	-	I
45	specific	I
46	c	I
47	-	I
48	kit	I
49	cDNA	I
50	,	O
51	accumulates	O
52	in	O
53	the	O
54	latest	O
55	stages	O
56	of	O
57	spermatogenesis	O
58	and	O
59	in	O
60	epididymal	O
61	spermatozoa	O
62	.	O

1	Both	O
2	P5CDh	B
3	cDNA	I
4	clones	O
5	detect	O
6	a	O
7	single	O
8	3	O
9	.	O
10	2	O
11	-	O
12	kb	O
13	transcript	O
14	on	O
15	Northern	O
16	blots	O
17	of	O
18	multiple	O
19	human	O
20	tissues	O
21	,	O
22	indicating	O
23	the	O
24	long	O
25	cDNA	O
26	containing	O
27	the	O
28	3	O
29	'-	O
30	untranslated	O
31	intron	O
32	represents	O
33	the	O
34	predominant	O
35	transcript	O
36	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	O
20	.	O

1	An	O
2	AP	B
3	-	I
4	1	I
5	binding	I
6	sequence	I
7	is	O
8	essential	O
9	for	O
10	regulation	O
11	of	O
12	the	O
13	human	B
14	alpha2	I
15	(	I
16	I	I
17	)	I
18	collagen	I
19	(	O
20	COL1A2	B
21	)	O
22	promoter	O
23	activity	O
24	by	O
25	transforming	B
26	growth	I
27	factor	I
28	-	I
29	beta	I
30	.	O

1	Only	O
2	two	O
3	patients	O
4	(	O
5	0	O
6	.	O
7	3	O
8	%)	O
9	had	O
10	a	O
11	CA	B
12	125	I
13	response	O
14	at	O
15	the	O
16	time	O
17	of	O
18	clinical	O
19	progression	O
20	.	O

1	These	O
2	results	O
3	illuminate	O
4	a	O
5	hitherto	O
6	unanticipated	O
7	function	O
8	of	O
9	U6	B
10	RNA	I
11	:	O
12	the	O
13	modulation	O
14	of	O
15	a	O
16	phosphorylation	O
17	-	O
18	dephosphorylation	O
19	cycle	O
20	of	O
21	C1	B
22	hnRNP	I
23	protein	I
24	that	O
25	influences	O
26	the	O
27	binding	O
28	affinity	O
29	of	O
30	this	O
31	protein	O
32	for	O
33	pre	O
34	-	O
35	mRNA	O
36	.	O

1	Lyn	B
2	kinase	I
3	immunoprecipitated	O
4	from	O
5	lysates	O
6	of	O
7	irradiated	O
8	BCP	O
9	as	O
10	well	O
11	as	O
12	a	O
13	full	O
14	-	O
15	length	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	(	O
21	GST	B
22	)-	O
23	Lyn	B
24	fusion	O
25	protein	O
26	-	O
27	phosphorylated	O
28	recombinant	B
29	human	I
30	p34cdc2	I
31	on	O
32	tyrosine	O
33	15	O
34	.	O

1	Mutations	O
2	within	O
3	conserved	O
4	region	O
5	2	O
6	(	O
7	CR2	O
8	)	O
9	of	O
10	E1A	B
11	that	O
12	inhibit	O
13	the	O
14	binding	O
15	of	O
16	E1A	B
17	to	O
18	the	O
19	retinoblastoma	B
20	gene	I
21	product	I
22	(	O
23	pRb	B
24	)	O
25	further	O
26	enhanced	O
27	the	O
28	stimulation	O
29	of	O
30	transcription	O
31	from	O
32	the	O
33	PEPCK	B
34	promoter	I
35	by	O
36	2	O
37	3	O
38	-	O
39	fold	O
40	compared	O
41	with	O
42	wild	B
43	type	I
44	E1A	I
45	.	O

1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O

1	EMSA	O
2	competition	O
3	experiments	O
4	showed	O
5	that	O
6	mutations	O
7	within	O
8	the	O
9	direct	O
10	repeats	O
11	failed	O
12	to	O
13	compete	O
14	for	O
15	binding	O
16	of	O
17	the	O
18	nuclear	O
19	proteins	O
20	to	O
21	labeled	O
22	wild	O
23	type	O
24	oligonucleotide	O
25	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	100	O
6	-	O
7	bp	O
8	Col2a1	B
9	enhancer	I
10	revealed	O
11	several	O
12	sequence	O
13	motifs	O
14	similar	O
15	to	O
16	motifs	O
17	present	O
18	within	O
19	the	O
20	regulatory	O
21	region	O
22	of	O
23	the	O
24	link	B
25	protein	I
26	gene	I
27	,	O
28	another	O
29	cartilage	O
30	gene	O
31	.	O

1	Vertebrate	B
2	synapsins	I
3	constitute	O
4	a	O
5	family	O
6	of	O
7	synaptic	O
8	proteins	O
9	that	O
10	participate	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	neurotransmitter	O
16	release	O
17	.	O

1	Electrophoretic	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	crude	O
7	extracts	O
8	from	O
9	FREJ4	O
10	cells	O
11	revealed	O
12	the	O
13	binding	O
14	of	O
15	a	O
16	member	O
17	(	O
18	s	O
19	)	O
20	of	O
21	the	O
22	Ets	B
23	family	I
24	of	I
25	transcription	I
26	factors	I
27	to	O
28	the	O
29	P4	B
30	EBS	I
31	,	O
32	as	O
33	well	O
34	as	O
35	the	O
36	interaction	O
37	of	O
38	two	O
39	members	O
40	of	O
41	the	O
42	Sp1	B
43	family	I
44	,	O
45	Sp1	B
46	and	O
47	Sp3	B
48	,	O
49	with	O
50	the	O
51	adjacent	O
52	GC	O
53	box	O
54	.	O

1	UV	O
2	cross	O
3	-	O
4	linking	O
5	experiments	O
6	demonstrated	O
7	that	O
8	HSV	O
9	infection	O
10	caused	O
11	enhanced	O
12	binding	O
13	of	O
14	protein	O
15	factors	O
16	,	O
17	including	O
18	the	O
19	64	B
20	-	I
21	kDa	I
22	component	I
23	of	I
24	cleavage	I
25	stimulation	I
26	factor	I
27	(	O
28	CstF	B
29	),	O
30	to	O
31	poly	O
32	(	O
33	A	O
34	)	O
35	site	O
36	RNAs	O
37	from	O
38	virus	O
39	genes	O
40	of	O
41	all	O
42	temporal	O
43	classes	O
44	and	O
45	that	O
46	this	O
47	enhanced	O
48	binding	O
49	required	O
50	expression	O
51	of	O
52	IE63	B
53	.	O

1	As	O
2	pH	O
3	and	O
4	Hb	B
5	can	O
6	also	O
7	affect	O
8	mixed	O
9	venous	O
10	CO2	O
11	content	O
12	,	O
13	the	O
14	effect	O
15	on	O
16	Q	O
17	was	O
18	also	O
19	assessed	O
20	.	O

1	Identification	O
2	of	O
3	this	O
4	region	O
5	as	O
6	the	O
7	E	B
8	.	I
9	coli	I
10	tmk	I
11	gene	I
12	was	O
13	confirmed	O
14	by	O
15	functional	O
16	complementation	O
17	of	O
18	a	O
19	yeast	B
20	dTMP	I
21	kinase	I
22	temperature	O
23	-	O
24	sensitive	O
25	mutant	O
26	and	O
27	by	O
28	in	O
29	vitro	O
30	enzyme	O
31	assay	O
32	of	O
33	the	O
34	thymidylate	B
35	kinase	I
36	activity	O
37	in	O
38	cell	O
39	extracts	O
40	of	O
41	E	O
42	.	O
43	coli	O
44	by	O
45	use	O
46	of	O
47	tmk	B
48	-	O
49	overproducing	O
50	plasmids	O
51	.	O

1	This	O
2	interaction	O
3	is	O
4	mediated	O
5	by	O
6	the	O
7	SH2	B
8	domain	I
9	of	O
10	Crk	B
11	and	O
12	can	O
13	be	O
14	inhibited	O
15	with	O
16	a	O
17	phosphopeptide	O
18	containing	O
19	the	O
20	Crk	B
21	-	O
22	SH2	B
23	binding	O
24	motif	O
25	.	O

1	Consistent	O
2	with	O
3	ErbB	B
4	-	I
5	2	I
6	being	O
7	a	O
8	shared	O
9	receptor	O
10	subunit	O
11	,	O
12	its	O
13	tyrosine	O
14	phosphorylation	O
15	was	O
16	increased	O
17	by	O
18	both	O
19	heterologous	O
20	ligands	O
21	and	O
22	it	O
23	mediated	O
24	a	O
25	trans	O
26	-	O
27	inhibitory	O
28	effect	O
29	of	O
30	NDF	B
31	on	O
32	EGF	B
33	binding	O
34	.	O

1	The	O
2	cDNA	O
3	corresponding	O
4	to	O
5	the	O
6	FPS1	B
7	gene	I
8	was	O
9	isolated	O
10	by	O
11	functional	O
12	complementation	O
13	of	O
14	a	O
15	mutant	O
16	yeast	O
17	strain	O
18	defective	O
19	in	O
20	FPS	B
21	activity	O
22	(	O
23	Delourme	O
24	,	O
25	D	O
26	.,	O
27	Lacroute	O
28	,	O
29	F	O
30	.,	O
31	and	O
32	Karst	O
33	,	O
34	F	O
35	.	O

1	The	O
2	members	O
3	of	O
4	the	O
5	Myb	B
6	family	I
7	of	I
8	transcription	I
9	factors	I
10	are	O
11	defined	O
12	by	O
13	homology	O
14	in	O
15	the	O
16	DNA	O
17	-	O
18	binding	O
19	domain	O
20	;	O
21	all	O
22	bind	O
23	the	O
24	Myb	B
25	-	I
26	binding	I
27	site	I
28	(	O
29	MBS	B
30	)	O
31	sequence	O
32	(	O
33	YG	O
34	(	O
35	A	O
36	/	O
37	G	O
38	)	O
39	C	O
40	(	O
41	A	O
42	/	O
43	C	O
44	/	O
45	G	O
46	)	O
47	GTT	O
48	(	O
49	G	O
50	/	O
51	A	O
52	)).	O

1	The	O
2	specificity	O
3	of	O
4	action	O
5	of	O
6	C	B
7	/	I
8	EBP	I
9	family	I
10	members	I
11	may	O
12	be	O
13	derived	O
14	from	O
15	the	O
16	characteristics	O
17	of	O
18	each	O
19	factor	O
20	,	O
21	including	O
22	the	O
23	expression	O
24	profiles	O
25	,	O
26	the	O
27	DNA	O
28	binding	O
29	affinities	O
30	,	O
31	the	O
32	cofactors	O
33	,	O
34	and	O
35	so	O
36	on	O
37	,	O
38	in	O
39	addition	O
40	to	O
41	the	O
42	DNA	O
43	binding	O
44	specificities	O
45	.	O

1	A	O
2	DNA	O
3	fragment	O
4	carrying	O
5	1	O
6	,	O
7	100	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	of	O
17	the	O
18	UGT1A1	B
19	gene	I
20	was	O
21	enough	O
22	for	O
23	MC	O
24	induction	O
25	.	O

1	Two	O
2	XPG	B
3	regions	I
4	with	O
5	putative	O
6	NLS	O
7	[	O
8	amino	O
9	acid	O
10	(	O
11	AA	O
12	)	O
13	coordinates	O
14	:	O
15	NLS	O
16	-	O
17	B	O
18	(	O
19	AA	O
20	1057	O
21	-	O
22	1074	O
23	)	O
24	and	O
25	NLS	O
26	-	O
27	C	O
28	(	O
29	AA	O
30	1171	O
31	-	O
32	1185	O
33	)]	O
34	were	O
35	each	O
36	shown	O
37	to	O
38	independently	O
39	localize	O
40	the	O
41	beta	B
42	-	I
43	gal	I
44	extensively	O
45	(>	O
46	80	O
47	%)	O
48	to	O
49	the	O
50	nucleus	O
51	of	O
52	HeLa	O
53	cells	O
54	.	O

1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	O
9	surface	O
10	and	O
11	bound	O
12	insulin	B
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	autophosphorylation	O
20	in	O
21	response	O
22	to	O
23	insulin	B
24	.	O

1	Results	O
2	were	O
3	supported	O
4	by	O
5	the	O
6	agar	O
7	diffusion	O
8	method	O
9	for	O
10	Y	O
11	.	O
12	enterocolitica	O
13	,	O
14	whereas	O
15	inhibition	O
16	activity	O
17	was	O
18	not	O
19	found	O
20	for	O
21	A	O
22	.	O
23	hydrophila	O
24	.	O

1	OND	O
2	8	O
3	mg	O
4	tid	O
5	days	O
6	2	O
7	-	O
8	3	O
9	,	O
10	and	O
11	8	O
12	mg	O
13	tid	O
14	prn	O
15	days	O
16	4	O
17	-	O
18	5	O
19	and	O
20	prednisolone	O
21	75	O
22	-	O
23	100	O
24	mg	O
25	qds	O
26	days	O
27	2	O
28	-	O
29	5	O
30	and	O
31	2	O
32	)	O
33	MCP	O
34	30	O
35	mg	O
36	/	O
37	metylprednisolone	O
38	80	O
39	mg	O
40	i	O
41	.	O
42	v	O
43	.	O
44	before	O
45	CT	O
46	and	O
47	MCP	O
48	20	O
49	mg	O
50	p	O
51	.	O
52	r	O
53	.	O
54	after	O
55	4	O
56	and	O
57	8	O
58	h	O
59	respectively	O
60	.	O

1	When	O
2	overexpressed	O
3	in	O
4	an	O
5	appropriate	O
6	cell	O
7	line	O
8	,	O
9	TAN	B
10	-	I
11	1C	I
12	prevented	O
13	kappa	B
14	B	I
15	-	O
16	dependent	O
17	transactivation	O
18	in	O
19	transient	O
20	reporter	O
21	gene	O
22	assays	O
23	in	O
24	a	O
25	fashion	O
26	similar	O
27	to	O
28	the	O
29	structurally	O
30	related	O
31	protein	O
32	,	O
33	Bcl	B
34	-	I
35	3	I
36	.	O

1	Thus	O
2	,	O
3	a	O
4	critical	O
5	question	O
6	is	O
7	how	O
8	HOX	B
9	proteins	I
10	select	O
11	the	O
12	correct	O
13	sets	O
14	of	O
15	target	O
16	genes	O
17	in	O
18	vivo	O
19	.	O

1	This	O
2	region	O
3	includes	O
4	verA	B
5	,	O
6	a	O
7	structural	O
8	gene	O
9	previously	O
10	shown	O
11	to	O
12	be	O
13	required	O
14	for	O
15	ST	O
16	biosynthesis	O
17	,	O
18	and	O
19	24	O
20	additional	O
21	closely	O
22	spaced	O
23	transcripts	O
24	ranging	O
25	in	O
26	size	O
27	from	O
28	0	O
29	.	O
30	6	O
31	to	O
32	7	O
33	.	O
34	2	O
35	kb	O
36	that	O
37	are	O
38	coordinately	O
39	induced	O
40	only	O
41	under	O
42	ST	O
43	-	O
44	producing	O
45	conditions	O
46	.	O

1	Subcellular	O
2	localizations	O
3	of	O
4	the	O
5	wild	B
6	-	I
7	type	I
8	CBFbeta	I
9	and	O
10	the	O
11	CBFbeta	B
12	-	O
13	SMMHC	B
14	fusion	O
15	protein	O
16	were	O
17	determined	O
18	by	O
19	immunofluorescence	O
20	of	O
21	NIH	O
22	3T3	O
23	cells	O
24	that	O
25	overexpress	O
26	wild	O
27	-	O
28	type	O
29	or	O
30	fusion	O
31	protein	O
32	.	O

1	Escherichia	O
2	coli	O
3	BL21	O
4	(	O
5	DE3	O
6	)	O
7	plysS	O
8	,	O
9	harbouring	O
10	a	O
11	recombinant	O
12	plasmid	O
13	containing	O
14	the	O
15	catalase	B
16	-	O
17	peroxidase	B
18	gene	O
19	,	O
20	produced	O
21	a	O
22	large	O
23	amount	O
24	of	O
25	proteins	O
26	that	O
27	co	O
28	-	O
29	migrated	O
30	on	O
31	SDS	O
32	/	O
33	PAGE	O
34	with	O
35	the	O
36	native	O
37	enzyme	O
38	.	O

1	The	O
2	Cdk2	B
3	-	O
4	cyclin	B
5	-	I
6	D1	I
7	complex	O
8	did	O
9	not	O
10	phosphorylate	O
11	any	O
12	tested	O
13	substrates	O
14	,	O
15	such	O
16	as	O
17	H1	B
18	histone	I
19	,	O
20	pRB	B
21	,	O
22	SV40	B
23	large	I
24	T	I
25	antigen	I
26	,	O
27	p53	B
28	,	O
29	E2F	B
30	-	I
31	1	I
32	or	O
33	a	O
34	preparation	O
35	of	O
36	nuclear	O
37	proteins	O
38	from	O
39	HeLa	O
40	cells	O
41	;	O
42	in	O
43	contrast	O
44	,	O
45	Cdk2	B
46	-	O
47	cyclin	B
48	-	I
49	E	I
50	and	O
51	Cdk2	B
52	-	O
53	cyclin	B
54	-	I
55	A	I
56	phosphorylated	O
57	these	O
58	proteins	O
59	.	O

1	Two	O
2	overlapping	O
3	clones	O
4	contained	O
5	the	O
6	complete	O
7	Adh	B
8	-	I
9	2	I
10	gene	I
11	composed	O
12	of	O
13	nine	O
14	exons	O
15	in	O
16	a	O
17	12	O
18	-	O
19	kb	O
20	region	O
21	,	O
22	with	O
23	the	O
24	placement	O
25	of	O
26	introns	O
27	matching	O
28	that	O
29	observed	O
30	in	O
31	other	O
32	mammalian	B
33	ADH	I
34	genes	I
35	.	O

1	Northern	O
2	blot	O
3	hybridization	O
4	demonstrated	O
5	that	O
6	HEP	B
7	-	O
8	COP	B
9	was	O
10	expressed	O
11	in	O
12	a	O
13	wide	O
14	range	O
15	of	O
16	human	O
17	adult	O
18	and	O
19	fetal	O
20	tissues	O
21	.	O

1	A	O
2	human	O
3	cytoplasmic	O
4	signaling	O
5	protein	O
6	has	O
7	been	O
8	cloned	O
9	that	O
10	possesses	O
11	the	O
12	same	O
13	structural	O
14	arrangement	O
15	of	O
16	SH3	B
17	-	O
18	SH2	B
19	-	O
20	SH3	B
21	domains	O
22	as	O
23	Grb2	B
24	.	O

1	E3	B
2	/	I
3	19K	I
4	resides	O
5	in	O
6	the	O
7	endoplasmic	O
8	reticulum	O
9	where	O
10	it	O
11	binds	O
12	to	O
13	MHC	B
14	class	I
15	I	I
16	molecules	I
17	,	O
18	thereby	O
19	preventing	O
20	their	O
21	transport	O
22	to	O
23	the	O
24	cell	O
25	surface	O
26	.	O

1	Among	O
2	the	O
3	LE6	B
4	deletions	O
5	,	O
6	only	O
7	one	O
8	had	O
9	a	O
10	reduced	O
11	transformation	O
12	efficiency	O
13	,	O
14	while	O
15	seven	O
16	transformed	O
17	cells	O
18	at	O
19	least	O
20	as	O
21	efficiently	O
22	as	O
23	wild	B
24	-	I
25	type	I
26	LE6	I
27	.	O

1	Clb2	B
2	/	O
3	Cdc28	B
4	kinase	O
5	is	O
6	not	O
7	required	O
8	for	O
9	the	O
10	repression	O
11	of	O
12	MCB	B
13	-	I
14	binding	I
15	factor	I
16	transcriptional	O
17	activity	O
18	in	O
19	G2	O
20	and	O
21	M	O
22	phase	O
23	.	O

1	The	O
2	carboxy	O
3	terminus	O
4	of	O
5	Mbp1	B
6	is	O
7	sufficient	O
8	for	O
9	interaction	O
10	with	O
11	Swi6	B
12	,	O
13	and	O
14	the	O
15	carboxy	O
16	terminus	O
17	of	O
18	Swi6	B
19	is	O
20	required	O
21	for	O
22	interaction	O
23	with	O
24	Mbp1	B
25	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	analyzed	O
6	human	B
7	CTCF	I
8	cDNA	I
9	clones	O
10	and	O
11	show	O
12	here	O
13	that	O
14	the	O
15	ubiquitously	O
16	expressed	O
17	11	B
18	-	I
19	zinc	I
20	-	I
21	finger	I
22	factor	I
23	CTCF	I
24	is	O
25	an	O
26	exceptionally	O
27	highly	O
28	conserved	O
29	protein	O
30	displaying	O
31	93	O
32	%	O
33	identity	O
34	between	O
35	avian	O
36	and	O
37	human	O
38	amino	O
39	acid	O
40	sequences	O
41	.	O

1	The	O
2	growth	O
3	defect	O
4	of	O
5	a	O
6	reg1	B
7	reg2	I
8	double	I
9	mutant	I
10	is	O
11	alleviated	O
12	by	O
13	a	O
14	loss	O
15	-	O
16	of	O
17	-	O
18	function	O
19	mutation	O
20	in	O
21	the	O
22	SNF1	B
23	-	I
24	encoded	I
25	protein	I
26	kinase	I
27	.	O

1	A	O
2	developmentally	O
3	modulated	O
4	chromatin	O
5	structure	O
6	at	O
7	the	O
8	mouse	B
9	immunoglobulin	I
10	kappa	I
11	3	I
12	'	I
13	enhancer	I
14	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	further	O
7	investigated	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	synthesis	O
13	of	O
14	the	O
15	c	B
16	-	I
17	mos	I
18	oncogene	I
19	product	I
20	,	O
21	which	O
22	is	O
23	necessary	O
24	for	O
25	the	O
26	activation	O
27	of	O
28	Cdc2	B
29	.	O

1	Transcriptional	O
2	regulators	O
3	utilizing	O
4	the	O
5	POU	B
6	domain	I
7	DNA	I
8	-	I
9	binding	I
10	motif	I
11	have	O
12	been	O
13	shown	O
14	to	O
15	form	O
16	multi	O
17	-	O
18	protein	O
19	complexes	O
20	dependent	O
21	on	O
22	the	O
23	POU	B
24	domain	I
25	itself	O
26	and	O
27	its	O
28	flexible	O
29	recognition	O
30	of	O
31	various	O
32	octamer	O
33	sequence	O
34	elements	O
35	.	O

1	We	O
2	found	O
3	strand	O
4	selective	O
5	repair	O
6	in	O
7	DNA	O
8	fragments	O
9	within	O
10	two	O
11	active	O
12	genes	O
13	,	O
14	DHFR	B
15	and	O
16	an	O
17	unknown	O
18	gene	O
19	adjacent	O
20	to	O
21	DHFR	B
22	.	O

1	The	O
2	mMIWC1	B
3	promoter	I
4	was	O
5	identified	O
6	and	O
7	contained	O
8	TATA	O
9	,	O
10	CAAT	O
11	,	O
12	GATA	O
13	,	O
14	and	O
15	AP	B
16	-	I
17	2	I
18	elements	I
19	;	O
20	primer	O
21	extension	O
22	revealed	O
23	mMIWC	B
24	transcription	O
25	initiation	O
26	at	O
27	621	O
28	bp	O
29	upstream	O
30	from	O
31	the	O
32	mMIWC1	B
33	translational	O
34	initiation	O
35	site	O
36	.	O

1	Human	B
2	MN	I
3	/	I
4	CA9	I
5	gene	I
6	,	O
7	a	O
8	novel	O
9	member	O
10	of	O
11	the	O
12	carbonic	B
13	anhydrase	I
14	family	I
15	:	O
16	structure	O
17	and	O
18	exon	O
19	to	O
20	protein	O
21	domain	O
22	relationships	O
23	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	B
15	mRNA	I
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	We	O
2	have	O
3	obtained	O
4	the	O
5	human	B
6	EP4	I
7	receptor	I
8	gene	I
9	sequence	I
10	and	O
11	determined	O
12	its	O
13	structure	O
14	relative	O
15	to	O
16	EP4R	B
17	cDNA	I
18	synthesized	O
19	from	O
20	peripheral	O
21	blood	O
22	lymphocytes	O
23	.	O

1	Hydropathy	O
2	analysis	O
3	of	O
4	KCC1	B
5	indicates	O
6	structural	O
7	homology	O
8	to	O
9	NKCC	B
10	,	O
11	including	O
12	12	O
13	transmembrane	O
14	domains	O
15	,	O
16	a	O
17	large	O
18	extracellular	O
19	loop	O
20	with	O
21	potential	O
22	N	O
23	-	O
24	linked	O
25	glycosylation	O
26	sites	O
27	,	O
28	and	O
29	cytoplasmic	O
30	N	O
31	-	O
32	and	O
33	C	O
34	-	O
35	terminal	O
36	regions	O
37	.	O

1	This	O
2	protein	O
3	with	O
4	a	O
5	hydrophobic	O
6	amino	O
7	terminus	O
8	appears	O
9	to	O
10	be	O
11	a	O
12	secreted	O
13	protein	O
14	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	human	B
10	DSG3	I
11	gene	I
12	and	O
13	examined	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	its	O
19	expression	O
20	.	O

1	Vacuolar	O
2	membrane	O
3	vesicles	O
4	from	O
5	hum1	B
6	mutants	I
7	lack	O
8	all	O
9	Ca2	O
10	+/	O
11	H	O
12	+	O
13	antiport	O
14	activity	O
15	,	O
16	demonstrating	O
17	that	O
18	Hum1p	B
19	catalyzes	O
20	the	O
21	exchange	O
22	of	O
23	Ca2	O
24	+	O
25	for	O
26	H	O
27	+	O
28	across	O
29	the	O
30	yeast	O
31	vacuolar	O
32	membrane	O
33	.	O

1	Detailed	O
2	mutagenesis	O
3	of	O
4	the	O
5	element	O
6	'	O
7	s	O
8	rare	O
9	-	O
10	codon	O
11	/	O
12	AU	O
13	-	O
14	rich	O
15	sequence	O
16	boundary	O
17	revealed	O
18	that	O
19	the	O
20	destabilizing	O
21	activity	O
22	of	O
23	the	O
24	MATalpha1	B
25	IE	I
26	is	O
27	observed	O
28	when	O
29	the	O
30	terminal	O
31	codon	O
32	of	O
33	the	O
34	element	O
35	'	O
36	s	O
37	rare	O
38	-	O
39	codon	O
40	interval	O
41	is	O
42	translated	O
43	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	63	O
2	.	O
3	3	O
4	micromol	O
5	/	O
6	1	O
7	,	O
8	p	O
9	<	O
10	0	O
11	.	O
12	01	O
13	)	O
14	and	O
15	area	O
16	under	O
17	the	O
18	plasma	O
19	concentration	O
20	-	O
21	time	O
22	curve	O
23	extrapolated	O
24	to	O
25	infinity	O
26	AUC	O
27	9	O
28	(	O
29	0	O
30	-	O
31	infinity	O
32	)(	O
33	518	O
34	.	O
35	7	O
36	vs	O
37	.	O

1	DNA	B
2	polymerase	I
3	E	I
4	,	O
5	DNA	B
6	ligase	I
7	III	I
8	and	O
9	a	O
10	DNA	O
11	structure	O
12	-	O
13	specific	O
14	endonuclease	O
15	co	O
16	-	O
17	purify	O
18	with	O
19	the	O
20	five	O
21	polypeptide	O
22	complex	O
23	.	O

1	By	O
2	using	O
3	reporter	O
4	gene	O
5	constructs	O
6	,	O
7	it	O
8	is	O
9	shown	O
10	that	O
11	upstream	O
12	sequences	O
13	of	O
14	the	O
15	P1	O
16	promoter	O
17	contain	O
18	several	O
19	regions	O
20	that	O
21	modulate	O
22	the	O
23	expression	O
24	either	O
25	positively	O
26	or	O
27	negatively	O
28	.	O

1	RESULTS	O
2	:	O
3	The	O
4	bilinear	O
5	model	O
6	provided	O
7	a	O
8	significantly	O
9	better	O
10	fit	O
11	to	O
12	the	O
13	acuity	O
14	outcome	O
15	data	O
16	.	O

1	However	O
2	,	O
3	one	O
4	3	O
5	'	O
6	splice	O
7	site	O
8	,	O
9	located	O
10	at	O
11	nucleotide	O
12	(	O
13	nt	O
14	)	O
15	3225	O
16	,	O
17	is	O
18	used	O
19	for	O
20	the	O
21	processing	O
22	of	O
23	most	O
24	BPV	O
25	-	O
26	1	O
27	pre	O
28	-	O
29	mRNAs	O
30	in	O
31	BPV	O
32	-	O
33	1	O
34	-	O
35	transformed	O
36	C127	O
37	cells	O
38	and	O
39	at	O
40	early	O
41	to	O
42	intermediate	O
43	times	O
44	in	O
45	productively	O
46	infected	O
47	warts	O
48	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	recombinant	B
7	CREB	I
8	and	O
9	activating	B
10	transcription	I
11	factor	I
12	proteins	I
13	bound	O
14	the	O
15	junB	B
16	CRE	O
17	-	O
18	like	O
19	site	O
20	,	O
21	but	O
22	did	O
23	not	O
24	interact	O
25	with	O
26	a	O
27	mutant	O
28	CRE	O
29	-	O
30	like	O
31	site	O
32	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	B
11	kinase	I
12	A	I
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	B
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O

1	Three	O
2	ORFs	O
3	(	O
4	9765orfR002	O
5	,	O
6	9765orfR011	O
7	and	O
8	9765orfR013	O
9	)	O
10	were	O
11	found	O
12	to	O
13	be	O
14	homologous	O
15	with	O
16	Schizosaccharomyces	O
17	pombe	O
18	polyadenylate	B
19	binding	I
20	protein	I
21	,	O
22	Escherichia	O
23	coli	O
24	hypothetical	O
25	38	O
26	.	O
27	1	O
28	-	O
29	kDa	O
30	protein	O
31	in	O
32	the	O
33	BCR	B
34	5	O
35	'	O
36	region	O
37	,	O
38	and	O
39	transcription	O
40	regulatory	O
41	protein	O
42	Swi3	B
43	,	O
44	respectively	O
45	.	O

1	Limited	O
2	role	O
3	for	O
4	PCR	O
5	-	O
6	based	O
7	diagnosis	O
8	of	O
9	Whipple	O
10	'	O
11	s	O
12	disease	O
13	from	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	.	O

1	The	O
2	ability	O
3	of	O
4	A20	B
5	to	O
6	block	O
7	NF	B
8	-	I
9	kappaB	I
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O

1	By	O
2	using	O
3	a	O
4	DNA	O
5	sequence	O
6	selected	O
7	for	O
8	its	O
9	ability	O
10	to	O
11	bind	O
12	recombinant	B
13	BCL	I
14	-	I
15	6	I
16	in	O
17	vitro	O
18	,	O
19	we	O
20	show	O
21	here	O
22	that	O
23	BCL	B
24	-	I
25	6	I
26	is	O
27	present	O
28	in	O
29	DNA	O
30	-	O
31	binding	O
32	complexes	O
33	in	O
34	nuclear	O
35	extracts	O
36	from	O
37	various	O
38	B	O
39	-	O
40	cell	O
41	lines	O
42	.	O

1	We	O
2	previously	O
3	described	O
4	the	O
5	purification	O
6	of	O
7	an	O
8	83	B
9	-	I
10	kDa	I
11	phosphatidic	I
12	acid	I
13	phosphatase	I
14	(	O
15	PAP	B
16	)	O
17	from	O
18	the	O
19	porcine	O
20	thymus	O
21	membranes	O
22	(	O
23	Kanoh	O
24	,	O
25	H	O
26	.,	O
27	Imai	O
28	,	O
29	S	O
30	.-	O
31	i	O
32	.,	O
33	Yamada	O
34	,	O
35	K	O
36	.	O
37	and	O
38	Sakane	O
39	,	O
40	F	O
41	.(	O
42	1992	O
43	)	O
44	J	O
45	.	O

1	In	O
2	order	O
3	to	O
4	delineate	O
5	structural	O
6	motifs	O
7	regulating	O
8	substrate	O
9	affinity	O
10	and	O
11	recognition	O
12	for	O
13	the	O
14	human	B
15	dopamine	I
16	transporter	I
17	(	O
18	DAT	B
19	),	O
20	we	O
21	assessed	O
22	[	O
23	3H	O
24	]	O
25	dopamine	O
26	uptake	O
27	kinetics	O
28	and	O
29	[	O
30	3H	O
31	]	O
32	CFT	O
33	binding	O
34	characteristics	O
35	of	O
36	COS	O
37	-	O
38	7	O
39	cells	O
40	transiently	O
41	expressing	O
42	mutant	B
43	DATs	I
44	in	O
45	which	O
46	the	O
47	COOH	O
48	terminus	O
49	was	O
50	truncated	O
51	or	O
52	substituted	O
53	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	elements	O
6	that	O
7	control	O
8	promoter	O
9	activity	O
10	include	O
11	binding	O
12	sites	O
13	for	O
14	transcription	O
15	factors	O
16	Sp1	B
17	and	O
18	alphaCbf	B
19	,	O
20	a	O
21	60	B
22	-	I
23	kDa	I
24	CCAAT	I
25	box	I
26	-	I
27	binding	I
28	protein	I
29	.	O

1	RESULTS	O
2	:	O
3	The	O
4	LV	O
5	maximum	O
6	brightness	O
7	and	O
8	area	O
9	under	O
10	the	O
11	curve	O
12	showed	O
13	significant	O
14	negative	O
15	correlations	O
16	(	O
17	p	O
18	=	O
19	<	O
20	0	O
21	.	O
22	004	O
23	)	O
24	with	O
25	the	O
26	FIO2	O
27	,	O
28	while	O
29	the	O
30	minimum	O
31	brightness	O
32	showed	O
33	a	O
34	significant	O
35	positive	O
36	correlation	O
37	(	O
38	p	O
39	=	O
40	<	O
41	0	O
42	.	O
43	002	O
44	).	O

1	Aggravating	O
2	process	O
3	induced	O
4	by	O
5	indomethacin	O
6	on	O
7	chronic	O
8	gastric	O
9	lesion	O
10	in	O
11	rat	O
12	.	O

1	Our	O
2	studies	O
3	also	O
4	excluded	O
5	the	O
6	possibility	O
7	that	O
8	the	O
9	phosphorylation	O
10	of	O
11	Ser	O
12	-	O
13	2	O
14	,	O
15	Ser	O
16	-	O
17	123	O
18	,	O
19	or	O
20	Ser	O
21	-	O
22	210	O
23	,	O
24	had	O
25	roles	O
26	in	O
27	the	O
28	trans	O
29	-	O
30	suppression	O
31	activity	O
32	of	O
33	the	O
34	large	B
35	HDAg	I
36	,	O
37	in	O
38	the	O
39	assembly	O
40	of	O
41	empty	O
42	virus	B
43	-	I
44	like	I
45	HDAg	I
46	particle	I
47	,	O
48	and	O
49	in	O
50	the	O
51	nuclear	O
52	transport	O
53	of	O
54	HDAgs	B
55	.	O

1	We	O
2	have	O
3	been	O
4	studying	O
5	the	O
6	interaction	O
7	of	O
8	the	O
9	oncogenic	O
10	human	O
11	polyomavirus	O
12	BK	O
13	(	O
14	BKV	O
15	)	O
16	with	O
17	the	O
18	tumor	B
19	-	I
20	suppressor	I
21	protein	I
22	p53	I
23	to	O
24	understand	O
25	the	O
26	biology	O
27	of	O
28	this	O
29	virus	O
30	as	O
31	well	O
32	as	O
33	to	O
34	understand	O
35	the	O
36	basic	O
37	mechanisms	O
38	of	O
39	p53	B
40	transactivation	O
41	.	O

1	Unaided	O
2	attempts	O
3	to	O
4	quit	O
5	smoking	O
6	are	O
7	generally	O
8	unsuccessful	O
9	.	O

1	Blood	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	was	O
7	measured	O
8	with	O
9	a	O
10	spectrophotometer	O
11	,	O
12	using	O
13	a	O
14	modification	O
15	of	O
16	a	O
17	previously	O
18	described	O
19	assay	O
20	.	O

1	STUDY	O
2	DESIGN	O
3	.	O

1	The	O
2	mature	O
3	chromosome	O
4	4	O
5	FRG1	B
6	transcript	I
7	is	O
8	1042	O
9	bp	O
10	in	O
11	length	O
12	and	O
13	contains	O
14	nine	O
15	exons	O
16	which	O
17	encode	O
18	a	O
19	putative	O
20	protein	O
21	of	O
22	258	O
23	amino	O
24	acid	O
25	residues	O
26	.	O

1	The	O
2	predicted	O
3	protein	O
4	,	O
5	Seb1p	B
6	,	O
7	consists	O
8	of	O
9	82	O
10	amino	O
11	acids	O
12	and	O
13	contains	O
14	one	O
15	potential	O
16	membrane	O
17	-	O
18	spanning	O
19	region	O
20	at	O
21	the	O
22	C	O
23	-	O
24	terminus	O
25	but	O
26	no	O
27	N	O
28	-	O
29	terminal	O
30	signal	O
31	sequence	O
32	.	O

1	The	O
2	most	O
3	frequent	O
4	causes	O
5	of	O
6	the	O
7	meningitis	O
8	was	O
9	the	O
10	external	O
11	ventricular	O
12	drainage	O
13	(	O
14	14	O
15	.	O
16	8	O
17	%),	O
18	post	O
19	-	O
20	neurosurgical	O
21	(	O
22	0	O
23	.	O
24	8	O
25	%)	O
26	and	O
27	head	O
28	injury	O
29	(	O
30	0	O
31	.	O
32	0007	O
33	%).	O

1	In	O
2	3	O
3	treatments	O
4	the	O
5	diet	O
6	was	O
7	supplemented	O
8	with	O
9	0	O
10	,	O
11	100	O
12	and	O
13	150	O
14	mg	O
15	probiotic	O
16	/	O
17	kg	O
18	food	O
19	.	O

1	Furthermore	O
2	,	O
3	cpxA	B
4	*	I
5	mutations	O
6	suppress	O
7	the	O
8	toxicity	O
9	conferred	O
10	by	O
11	the	O
12	LamB	B
13	-	O
14	LacZ	B
15	hybrid	O
16	protein	O
17	,	O
18	which	O
19	exerts	O
20	its	O
21	effects	O
22	in	O
23	the	O
24	cytoplasm	O
25	,	O
26	sequestered	O
27	from	O
28	DegP	B
29	.	O

1	This	O
2	caused	O
3	severe	O
4	cortical	O
5	damage	O
6	and	O
7	neuronal	O
8	loss	O
9	in	O
10	hippocampus	O
11	subfields	O
12	CA1	O
13	,	O
14	CA3	O
15	,	O
16	and	O
17	hilus	O
18	.	O

1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	B
22	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	O
20	.	O

1	Cognitive	O
2	visual	O
3	dysfunction	O
4	in	O
5	a	O
6	child	O
7	with	O
8	cerebral	O
9	damage	O
10	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	isolate	O
6	genes	O
7	with	O
8	down	O
9	-	O
10	regulated	O
11	expression	O
12	at	O
13	the	O
14	mRNA	O
15	level	O
16	during	O
17	oncogenic	O
18	transformation	O
19	of	O
20	human	O
21	mammary	O
22	epithelial	O
23	cells	O
24	(	O
25	MECs	O
26	),	O
27	we	O
28	performed	O
29	subtractive	O
30	hybridization	O
31	between	O
32	normal	O
33	MEC	O
34	strain	O
35	76N	O
36	and	O
37	its	O
38	radiation	O
39	-	O
40	transformed	O
41	tumorigenic	O
42	derivative	O
43	76R	O
44	-	O
45	30	O
46	.	O

1	The	O
2	P	B
3	-	I
4	wr	I
5	and	O
6	P	B
7	-	I
8	rr	I
9	cDNA	I
10	sequences	I
11	are	O
12	very	O
13	similar	O
14	in	O
15	their	O
16	5	O
17	'	O
18	regions	O
19	.	O

1	OBJECTIVES	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	the	O
7	study	O
8	was	O
9	to	O
10	analyze	O
11	the	O
12	clinical	O
13	characteristics	O
14	,	O
15	treatment	O
16	and	O
17	outcome	O
18	of	O
19	310	O
20	patients	O
21	with	O
22	hydatidiform	O
23	mole	O
24	.	O

1	Are	O
2	low	O
3	P300	O
4	amplitudes	O
5	a	O
6	marker	O
7	for	O
8	schizophrenia	O
9	.	O

1	Improved	O
2	methods	O
3	have	O
4	been	O
5	developed	O
6	for	O
7	maintaining	O
8	and	O
9	breeding	O
10	the	O
11	neotropical	O
12	short	O
13	-	O
14	tailed	O
15	fruit	O
16	bat	O
17	,	O
18	Carollia	O
19	perspicillata	O
20	,	O
21	in	O
22	an	O
23	easily	O
24	-	O
25	reproduced	O
26	,	O
27	laboratory	O
28	setting	O
29	.	O

1	DESIGN	O
2	:	O
3	A	O
4	cross	O
5	-	O
6	sectional	O
7	study	O
8	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	B
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	O
20	fos	B
21	gene	O
22	family	O
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	Its	O
2	transcription	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	induced	O
9	40	O
10	-	O
11	50	O
12	-	O
13	fold	O
14	in	O
15	response	O
16	to	O
17	oxygen	O
18	or	O
19	heme	O
20	deficiency	O
21	,	O
22	in	O
23	part	O
24	through	O
25	relief	O
26	of	O
27	repression	O
28	exerted	O
29	by	O
30	Rox1p	B
31	and	O
32	in	O
33	part	O
34	by	O
35	activation	O
36	mediated	O
37	by	O
38	an	O
39	upstream	O
40	activation	O
41	sequence	O
42	(	O
43	UAS	O
44	).	O

1	Lck	B
2	has	O
3	been	O
4	postulated	O
5	to	O
6	dimerize	O
7	through	O
8	the	O
9	SH2	B
10	and	O
11	SH3	B
12	domains	I
13	.	O

1	Five	O
2	-	O
3	year	O
4	survivals	O
5	amounted	O
6	to	O
7	100	O
8	%,	O
9	86	O
10	.	O
11	2	O
12	%,	O
13	59	O
14	.	O
15	4	O
16	%,	O
17	29	O
18	.	O
19	8	O
20	%,	O
21	and	O
22	20	O
23	%	O
24	for	O
25	stages	O
26	I	O
27	,	O
28	II	O
29	,	O
30	III	O
31	,	O
32	IVA	O
33	and	O
34	IVB	O
35	respectively	O
36	.	O

1	The	O
2	partial	O
3	categories	O
4	of	O
5	the	O
6	SIP	O
7	that	O
8	were	O
9	more	O
10	affected	O
11	were	O
12	work	O
13	,	O
14	recreation	O
15	and	O
16	pastimes	O
17	,	O
18	home	O
19	management	O
20	,	O
21	and	O
22	sleep	O
23	and	O
24	rest	O
25	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	isolated	O
6	genomic	O
7	clone	O
8	revealed	O
9	that	O
10	the	O
11	DNA	O
12	binding	O
13	domain	O
14	of	O
15	this	O
16	orphan	O
17	receptor	O
18	is	O
19	most	O
20	homologous	O
21	to	O
22	the	O
23	human	B
24	TR2	I
25	receptor	I
26	.	O

1	Melatonin	O
2	and	O
3	seasonality	O
4	:	O
5	filling	O
6	the	O
7	gap	O
8	.	O

1	A	O
2	1	O
3	.	O
4	8	O
5	-	O
6	kb	O
7	cDNA	O
8	clone	O
9	(	O
10	designed	O
11	hKID	B
12	,	O
13	gene	B
14	symbol	I
15	AQP2L	I
16	)	O
17	with	O
18	homology	O
19	to	O
20	the	O
21	aquaporins	B
22	was	O
23	isolated	O
24	from	O
25	a	O
26	human	O
27	kidney	O
28	cDNA	O
29	library	O
30	.	O

1	Thus	O
2	,	O
3	the	O
4	multidomained	O
5	ROK	B
6	alpha	I
7	appears	O
8	to	O
9	be	O
10	involved	O
11	in	O
12	reorganization	O
13	of	O
14	the	O
15	cytoskeleton	O
16	,	O
17	with	O
18	the	O
19	N	O
20	and	O
21	C	O
22	termini	O
23	acting	O
24	as	O
25	positive	O
26	and	O
27	negative	O
28	regulators	O
29	,	O
30	respectively	O
31	,	O
32	of	O
33	the	O
34	kinase	O
35	domain	O
36	whose	O
37	activity	O
38	is	O
39	crucial	O
40	for	O
41	formation	O
42	of	O
43	stress	O
44	fibers	O
45	and	O
46	focal	O
47	adhesion	O
48	complexes	O
49	.	O

1	These	O
2	findings	O
3	and	O
4	the	O
5	differential	O
6	tissue	O
7	distribution	O
8	of	O
9	p54	B
10	suggest	O
11	that	O
12	this	O
13	novel	O
14	SR	B
15	protein	I
16	may	O
17	participate	O
18	in	O
19	regulation	O
20	of	O
21	alternative	O
22	splicing	O
23	in	O
24	a	O
25	tissue	O
26	-	O
27	and	O
28	substrate	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	An	O
2	interaction	O
3	screen	O
4	with	O
5	the	O
6	repression	O
7	domain	O
8	of	O
9	the	O
10	orphan	B
11	receptor	I
12	RevErb	I
13	identified	O
14	N	B
15	-	I
16	CoR	I
17	,	O
18	the	O
19	corepressor	O
20	for	O
21	thyroid	B
22	hormone	I
23	receptor	I
24	(	O
25	TR	B
26	)	O
27	and	O
28	retinoic	B
29	acid	I
30	receptor	I
31	(	O
32	RAR	B
33	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	inhibition	O
6	of	O
7	Jun	B
8	kinase	I
9	activation	O
10	was	O
11	sufficient	O
12	to	O
13	inhibit	O
14	Ras	B
15	transformation	O
16	even	O
17	in	O
18	the	O
19	presence	O
20	of	O
21	activated	O
22	Erk	B
23	-	I
24	2	I
25	.	O

1	In	O
2	transient	O
3	cotransfections	O
4	E1A	B
5	could	O
6	induce	O
7	the	O
8	activity	O
9	of	O
10	the	O
11	p53	B
12	promoter	I
13	to	O
14	a	O
15	high	O
16	level	O
17	;	O
18	12S	B
19	E1A	I
20	was	O
21	threefold	O
22	as	O
23	efficient	O
24	as	O
25	13S	B
26	E1A	I
27	in	O
28	this	O
29	activity	O
30	,	O
31	and	O
32	YY1	B
33	bound	O
34	to	O
35	the	O
36	composite	O
37	element	O
38	was	O
39	shown	O
40	to	O
41	mediate	O
42	55	O
43	%	O
44	of	O
45	this	O
46	induction	O
47	.	O

1	Titration	O
2	of	O
3	the	O
4	human	O
5	and	O
6	porcine	O
7	proteins	O
8	with	O
9	2	O
10	-	O
11	nitro	O
12	-	O
13	5	O
14	-	O
15	thiosulfabenzoate	O
16	indicates	O
17	that	O
18	membrane	B
19	dipeptidase	I
20	additionally	O
21	possesses	O
22	two	O
23	intrachain	O
24	disulfide	O
25	bonds	O
26	.	O

1	Therapy	O
2	with	O
3	dietary	O
4	modification	O
5	and	O
6	triglyceride	O
7	lowering	O
8	drugs	O
9	resulted	O
10	in	O
11	resolution	O
12	of	O
13	symptoms	O
14	and	O
15	parotid	O
16	swelling	O
17	in	O
18	one	O
19	patient	O
20	.	O

1	Chernoff	O
2	,	O
3	submitted	O
4	for	O
5	publication	O
6	).	O

1	We	O
2	have	O
3	cloned	O
4	a	O
5	novel	O
6	protein	O
7	kinase	O
8	,	O
9	termed	O
10	hematopoietic	B
11	progenitor	I
12	kinase	I
13	1	I
14	(	O
15	HPK1	B
16	),	O
17	that	O
18	is	O
19	expressed	O
20	predominantly	O
21	in	O
22	hematopoietic	O
23	cells	O
24	,	O
25	including	O
26	early	O
27	progenitor	O
28	cells	O
29	.	O

1	Human	O
2	ESP1	B
3	/	O
4	CRP2	B
5	protein	O
6	has	O
7	two	O
8	LIM	B
9	domains	O
10	,	O
11	and	O
12	each	O
13	shares	O
14	35	O
15	.	O
16	1	O
17	%	O
18	and	O
19	77	O
20	or	O
21	79	O
22	%	O
23	identical	O
24	residues	O
25	with	O
26	human	B
27	cysteine	I
28	-	I
29	rich	I
30	protein	I
31	(	O
32	CRP	B
33	)	O
34	and	O
35	rat	B
36	CRIP	I
37	,	O
38	respectively	O
39	.	O

1	Linkage	O
2	studies	O
3	have	O
4	shown	O
5	locus	O
6	heterogeneity	O
7	with	O
8	one	O
9	TSC	B
10	gene	I
11	mapped	O
12	to	O
13	chromosome	O
14	9q34	O
15	and	O
16	a	O
17	second	O
18	to	O
19	16p13	O
20	.	O
21	3	O
22	.	O

1	The	O
2	initial	O
3	inpatient	O
4	experience	O
5	for	O
6	individuals	O
7	with	O
8	HIV	O
9	-	O
10	related	O
11	TB	O
12	may	O
13	be	O
14	pivotal	O
15	to	O
16	the	O
17	acceptance	O
18	of	O
19	and	O
20	participation	O
21	in	O
22	ongoing	O
23	TB	O
24	care	O
25	.	O

1	Analysis	O
2	of	O
3	human	O
4	genomic	O
5	DNA	O
6	reveals	O
7	an	O
8	intronless	O
9	sequence	O
10	with	O
11	strong	O
12	homology	O
13	to	O
14	human	B
15	G	I
16	alpha	I
17	q	I
18	cDNA	I
19	.	O

1	The	O
2	use	O
3	of	O
4	primary	O
5	GE	O
6	cells	O
7	thus	O
8	provides	O
9	a	O
10	convenient	O
11	in	O
12	vitro	O
13	system	O
14	for	O
15	further	O
16	study	O
17	of	O
18	the	O
19	endocrine	O
20	,	O
21	paracrine	O
22	,	O
23	and	O
24	autocrine	O
25	factors	O
26	regulating	O
27	endometrial	O
28	gene	O
29	expression	O
30	during	O
31	pregnancy	O
32	.	O

1	Proximal	O
2	CBD	O
3	was	O
4	inversely	O
5	correlated	O
6	with	O
7	bone	B
8	alkaline	I
9	phosphatase	I
10	(	O
11	r	O
12	=	O
13	-	O
14	0	O
15	.	O
16	71	O
17	,	O
18	p	O
19	<	O
20	0	O
21	.	O
22	01	O
23	)	O
24	and	O
25	intact	O
26	PTH	B
27	(	O
28	r	O
29	=	O
30	-	O
31	0	O
32	.	O
33	59	O
34	,	O
35	p	O
36	<	O
37	0	O
38	.	O
39	05	O
40	).	O

1	The	O
2	CD4	B
3	count	O
4	at	O
5	which	O
6	remission	O
7	occurs	O
8	may	O
9	reflect	O
10	severe	O
11	immunodeficiency	O
12	such	O
13	that	O
14	risk	O
15	for	O
16	AIDS	O
17	-	O
18	related	O
19	infection	O
20	is	O
21	high	O
22	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	these	O
8	subdomains	O
9	in	O
10	PRL	B
11	binding	O
12	and	O
13	signal	O
14	transduction	O
15	,	O
16	deletion	O
17	mutants	O
18	of	O
19	S1	O
20	or	O
21	/	O
22	and	O
23	S2	O
24	subdomains	O
25	were	O
26	constructed	O
27	.	O

1	OKA	O
2	and	O
3	calyculin	O
4	A	O
5	do	O
6	not	O
7	decrease	O
8	OCFRE	B
9	DNA	O
10	-	O
11	protein	O
12	interactions	O
13	,	O
14	suggesting	O
15	that	O
16	important	O
17	protein	O
18	-	O
19	protein	O
20	interactions	O
21	are	O
22	phosphatase	O
23	regulated	O
24	.	O

1	The	O
2	detection	O
3	ratio	O
4	peaked	O
5	at	O
6	ages	O
7	30	O
8	to	O
9	34	O
10	and	O
11	decreased	O
12	heavily	O
13	during	O
14	the	O
15	next	O
16	15	O
17	years	O
18	of	O
19	age	O
20	.	O

1	Two	O
2	techniques	O
3	based	O
4	on	O
5	assay	O
6	coefficients	O
7	of	O
8	variation	O
9	were	O
10	employed	O
11	to	O
12	characterize	O
13	a	O
14	normal	O
15	circadian	O
16	pattern	O
17	of	O
18	cortisol	O
19	.	O

1	Previous	O
2	work	O
3	showed	O
4	that	O
5	repA	B
6	(	O
7	initiator	O
8	protein	O
9	)	O
10	expression	O
11	requires	O
12	tap	B
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	O
18	.	O

1	This	O
2	paper	O
3	gives	O
4	an	O
5	overview	O
6	of	O
7	the	O
8	global	O
9	pattern	O
10	of	O
11	casualties	O
12	in	O
13	earthquakes	O
14	which	O
15	occurred	O
16	during	O
17	the	O
18	30	O
19	-	O
20	month	O
21	period	O
22	from	O
23	1	O
24	September	O
25	1993	O
26	to	O
27	29	O
28	February	O
29	1996	O
30	.	O

1	The	O
2	reconstituted	O
3	RNA	B
4	polymerases	I
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	B
20	-	I
21	CRP	I
22	and	O
23	the	O
24	rrnBP1	B
25	UP	I
26	element	I
27	.	O

1	A	O
2	decrease	O
3	of	O
4	erythrocyte	O
5	Mn	O
6	with	O
7	age	O
8	,	O
9	expressed	O
10	in	O
11	nmol	O
12	/	O
13	L	O
14	,	O
15	was	O
16	noted	O
17	(	O
18	p	O
19	<	O
20	0	O
21	.	O
22	02	O
23	).	O

1	Gene	B
2	1	I
3	has	O
4	been	O
5	completely	O
6	sequenced	O
7	.	O

1	Five	O
2	of	O
3	these	O
4	eight	O
5	patients	O
6	in	O
7	group	O
8	II	O
9	also	O
10	received	O
11	8	O
12	-	O
13	in	O
14	-	O
15	1	O
16	chemotherapy	O
17	.	O

1	However	O
2	,	O
3	an	O
4	intrinsic	O
5	DNA	O
6	-	O
7	binding	O
8	subunit	O
9	for	O
10	HiNF	B
11	-	I
12	D	I
13	was	O
14	not	O
15	identified	O
16	.	O

1	Recently	O
2	,	O
3	a	O
4	distantly	O
5	related	O
6	UmuC	B
7	-	I
8	homolog	I
9	,	O
10	DinB	B
11	,	O
12	has	O
13	also	O
14	been	O
15	identified	O
16	in	O
17	E	O
18	.	O
19	coli	O
20	.	O

1	The	O
2	intranodal	O
3	mesothelial	O
4	cells	O
5	occupied	O
6	the	O
7	sinusoids	O
8	of	O
9	the	O
10	lymph	O
11	nodes	O
12	and	O
13	were	O
14	initially	O
15	suspected	O
16	of	O
17	being	O
18	metastatic	O
19	from	O
20	the	O
21	ovarian	O
22	tumor	O
23	in	O
24	each	O
25	case	O
26	.	O

1	The	O
2	gene	B
3	ccpA	I
4	encoding	O
5	the	O
6	catabolite	B
7	control	I
8	protein	I
9	CcpA	I
10	of	O
11	Staphylococcus	O
12	xylosus	O
13	has	O
14	been	O
15	cloned	O
16	and	O
17	characterized	O
18	.	O

1	Using	O
2	anchored	O
3	PCR	O
4	,	O
5	a	O
6	VL	B
7	element	I
8	rearranged	O
9	to	O
10	CL2	B
11	was	O
12	isolated	O
13	.	O

1	Sodium	O
2	polystyrene	O
3	sulfonate	O
4	treatment	O
5	for	O
6	lithium	O
7	toxicity	O
8	:	O
9	effects	O
10	on	O
11	serum	O
12	potassium	O
13	concentrations	O
14	.	O

1	Interferon	B
2	stimulated	I
3	gene	I
4	factor	I
5	3	I
6	(	O
7	ISGF3	B
8	)	O
9	is	O
10	a	O
11	trimeric	O
12	transcription	O
13	factor	O
14	activated	O
15	on	O
16	treatment	O
17	of	O
18	cells	O
19	with	O
20	interferon	B
21	-	I
22	alpha	I
23	and	I
24	beta	I
25	(	O
26	type	B
27	I	I
28	IFNs	I
29	).	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	B
13	,	O
14	but	O
15	activated	O
16	TC21	B
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	O
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	Mutations	O
2	at	O
3	two	O
4	neighboring	O
5	sites	O
6	,	O
7	serine	O
8	242	O
9	and	O
10	threonine	O
11	255	O
12	,	O
13	exacerbated	O
14	the	O
15	effect	O
16	.	O

1	In	O
2	contrast	O
3	,	O
4	cotransfection	O
5	of	O
6	TFIIB	B
7	and	O
8	IRF	B
9	-	I
10	1	I
11	into	O
12	NIH	O
13	3T3	O
14	cells	O
15	resulted	O
16	in	O
17	a	O
18	dose	O
19	-	O
20	dependent	O
21	repression	O
22	of	O
23	promoter	O
24	activation	O
25	which	O
26	occurred	O
27	in	O
28	a	O
29	TATA	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	The	O
2	requirement	O
3	of	O
4	Tyr	O
5	-	O
6	19	O
7	dephosphorylation	O
8	for	O
9	spindle	O
10	assembly	O
11	is	O
12	also	O
13	observed	O
14	under	O
15	conditions	O
16	in	O
17	which	O
18	spindle	O
19	formation	O
20	is	O
21	independent	O
22	of	O
23	mitosis	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	involvement	O
29	of	O
30	Cdc28	B
31	/	O
32	Clb	B
33	kinase	O
34	in	O
35	SPB	O
36	separation	O
37	is	O
38	direct	O
39	.	O

1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	E1A	B
8	binds	O
9	several	O
10	high	O
11	molecular	O
12	weight	O
13	proteins	O
14	and	O
15	inhibits	O
16	the	O
17	transcriptional	O
18	coactivator	O
19	function	O
20	of	O
21	p300	B
22	and	O
23	the	O
24	homologous	O
25	cAMP	B
26	response	I
27	element	I
28	(	I
29	CRE	I
30	)-	I
31	binding	I
32	protein	I
33	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	reporter	O
6	gene	O
7	constructs	O
8	containing	O
9	various	O
10	lengths	O
11	of	O
12	the	O
13	5	B
14	'	I
15	mdr1b	I
16	sequences	I
17	revealed	O
18	that	O
19	the	O
20	sequence	O
21	located	O
22	between	O
23	-	O
24	247	O
25	to	O
26	-	O
27	126	O
28	bp	O
29	was	O
30	important	O
31	for	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	reporter	O
37	gene	O
38	in	O
39	many	O
40	different	O
41	cell	O
42	lines	O
43	.	O

1	When	O
2	this	O
3	DNA	O
4	fragment	O
5	was	O
6	placed	O
7	upstream	O
8	of	O
9	the	O
10	chloramphenicol	B
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	O
15	reporter	O
16	gene	O
17	and	O
18	transfected	O
19	into	O
20	a	O
21	carp	O
22	CF	O
23	cell	O
24	line	O
25	,	O
26	it	O
27	could	O
28	drive	O
29	the	O
30	synthesis	O
31	of	O
32	CAT	B
33	enzyme	I
34	16	O
35	times	O
36	more	O
37	efficiently	O
38	than	O
39	the	O
40	promoterless	O
41	pCAT	B
42	-	I
43	Basic	I
44	.	O

1	Physiol	O
2	.	O

1	The	O
2	objective	O
3	of	O
4	this	O
5	study	O
6	was	O
7	to	O
8	examine	O
9	the	O
10	influence	O
11	of	O
12	HHCA	O
13	and	O
14	other	O
15	serological	O
16	factors	O
17	upon	O
18	the	O
19	development	O
20	of	O
21	VGS	O
22	.	O

1	T	O
2	.,	O
3	Patel	O
4	,	O
5	S	O
6	.	O

1	The	O
2	up	O
3	-	O
4	regulation	O
5	of	O
6	E	B
7	-	I
8	selectin	I
9	,	O
10	one	O
11	of	O
12	the	O
13	adhesion	O
14	molecules	O
15	on	O
16	the	O
17	endothelium	O
18	,	O
19	is	O
20	an	O
21	important	O
22	event	O
23	in	O
24	the	O
25	mediation	O
26	of	O
27	the	O
28	inflammatory	O
29	response	O
30	.	O

1	The	O
2	majority	O
3	of	O
4	the	O
5	cases	O
6	with	O
7	0	O
8	-	O
9	I	O
10	or	O
11	0	O
12	-	O
13	III	O
14	components	O
15	were	O
16	sm	O
17	.	O
18	cancer	O
19	.	O

1	Moloney	O
2	murine	O
3	leukemia	O
4	virus	O
5	(	O
6	MMLV	O
7	)-	O
8	derived	O
9	pUCMoTiN	O
10	-	O
11	based	O
12	retroviral	O
13	vectors	O
14	were	O
15	engineered	O
16	to	O
17	allow	O
18	constitutive	O
19	and	O
20	Tat	B
21	(	O
22	trans	B
23	-	I
24	activator	I
25	of	I
26	transcription	I
27	)-	O
28	inducible	O
29	expression	O
30	of	O
31	five	O
32	hammerhead	O
33	ribozymes	O
34	targeted	O
35	against	O
36	highly	O
37	conserved	O
38	sequences	O
39	within	O
40	the	O
41	group	B
42	antigen	I
43	(	O
44	Gag	B
45	),	O
46	protease	B
47	(	O
48	Pro	B
49	),	O
50	reverse	B
51	transcriptase	I
52	(	O
53	RT	B
54	),	O
55	tat	B
56	,	O
57	and	O
58	envelope	B
59	(	O
60	Env	B
61	)	O
62	coding	O
63	regions	O
64	of	O
65	human	O
66	immunodeficiency	O
67	virus	O
68	type	O
69	-	O
70	1	O
71	(	O
72	HIV	O
73	-	O
74	1	O
75	)	O
76	RNA	O
77	.	O

1	The	O
2	same	O
3	ligands	O
4	also	O
5	exhibit	O
6	a	O
7	similar	O
8	inhibitory	O
9	effect	O
10	on	O
11	PDGF	B
12	-	I
13	BB	I
14	-	O
15	dependent	O
16	[	O
17	3H	O
18	]	O
19	thymidine	O
20	incorporation	O
21	in	O
22	PAE	O
23	cells	O
24	expressing	O
25	the	O
26	PDGF	B
27	beta	I
28	-	I
29	receptors	I
30	.	O

1	We	O
2	analyzed	O
3	serial	O
4	biopsy	O
5	specimens	O
6	from	O
7	eight	O
8	patients	O
9	with	O
10	FL	O
11	for	O
12	secondary	O
13	alterations	O
14	of	O
15	the	O
16	rearranged	B
17	bcl	I
18	-	I
19	2	I
20	gene	I
21	in	O
22	the	O
23	breakpoint	O
24	and	O
25	open	O
26	reading	O
27	frame	O
28	(	O
29	ORF	O
30	)	O
31	regions	O
32	.	O

1	Kss1	B
2	binds	O
3	specifically	O
4	to	O
5	a	O
6	GST	B
7	-	O
8	Dig1	B
9	fusion	O
10	in	O
11	the	O
12	absence	O
13	of	O
14	any	O
15	other	O
16	yeast	O
17	protein	O
18	.	O

1	The	O
2	current	O
3	study	O
4	defines	O
5	the	O
6	vinculin	B
7	-	O
8	and	O
9	FAK	B
10	-	I
11	interaction	I
12	domains	I
13	on	O
14	paxillin	B
15	and	O
16	identifies	O
17	the	O
18	principal	O
19	paxillin	B
20	focal	O
21	adhesion	O
22	targeting	O
23	motif	O
24	.	O

1	Jerseys	O
2	had	O
3	higher	O
4	hepatic	O
5	Cu	O
6	concentrations	O
7	than	O
8	did	O
9	Holsteins	O
10	on	O
11	d	O
12	60	O
13	(	O
14	346	O
15	vs	O
16	.	O

1	When	O
2	the	O
3	E1A	B
4	N	I
5	-	I
6	terminus	I
7	is	O
8	used	O
9	as	O
10	a	O
11	competitor	O
12	in	O
13	squelshing	O
14	experiments	O
15	it	O
16	abolishes	O
17	CBP	B
18	-	O
19	induced	O
20	activation	O
21	of	O
22	E2F1	B
23	/	O
24	DP1	B
25	,	O
26	whereas	O
27	an	O
28	E1A	B
29	mutant	I
30	lacking	O
31	CBP	B
32	binding	O
33	ability	O
34	fails	O
35	to	O
36	do	O
37	so	O
38	.	O

1	The	O
2	nm23	B
3	-	I
4	H1	I
5	/	O
6	nm23	B
7	-	I
8	H2	I
9	gene	O
10	transcriptional	O
11	activity	O
12	ratio	O
13	varied	O
14	depending	O
15	on	O
16	the	O
17	cell	O
18	line	O
19	.	O

1	Histological	O
2	changes	O
3	,	O
4	including	O
5	cortical	O
6	cell	O
7	involution	O
8	and	O
9	hemorrhage	O
10	occurring	O
11	during	O
12	the	O
13	neonatal	O
14	period	O
15	,	O
16	would	O
17	seem	O
18	to	O
19	have	O
20	crucial	O
21	relevance	O
22	to	O
23	the	O
24	remodeling	O
25	of	O
26	the	O
27	adrenal	O
28	vasculature	O
29	.	O

1	Furthermore	O
2	,	O
3	co	O
4	-	O
5	expression	O
6	of	O
7	both	O
8	p46	B
9	and	O
10	p54	B
11	subunits	I
12	markedly	O
13	altered	O
14	the	O
15	subcellular	O
16	distribution	O
17	of	O
18	p46	B
19	;	O
20	co	O
21	-	O
22	expressed	O
23	p46	B
24	was	O
25	transported	O
26	into	O
27	the	O
28	nucleus	O
29	as	O
30	efficiently	O
31	as	O
32	p54	B
33	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	both	O
8	the	O
9	N	O
10	-	O
11	and	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	talin	B
18	bind	O
19	actin	B
20	,	O
21	the	O
22	properties	O
23	of	O
24	these	O
25	two	O
26	regions	O
27	of	O
28	the	O
29	protein	O
30	are	O
31	distinct	O
32	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	fodrin	B
6	proteolysis	O
7	in	O
8	vivo	O
9	may	O
10	reflect	O
11	the	O
12	activity	O
13	of	O
14	multiple	O
15	ICE	B
16	/	O
17	Ced	B
18	-	I
19	3	I
20	proteases	O
21	whose	O
22	partial	O
23	sensitivity	O
24	to	O
25	DEVD	O
26	-	O
27	CHO	O
28	reflects	O
29	a	O
30	limited	O
31	contribution	O
32	from	O
33	CPP32	B
34	,	O
35	or	O
36	an	O
37	ICE	B
38	/	O
39	Ced	B
40	-	I
41	3	I
42	protease	O
43	less	O
44	sensitive	O
45	than	O
46	CPP32	B
47	to	O
48	DEVD	O
49	-	O
50	CHO	O
51	inhibition	O
52	.	O

1	Replacing	O
2	residues	O
3	405	O
4	-	O
5	419	O
6	on	O
7	delta419	O
8	with	O
9	the	O
10	conserved	O
11	AF	O
12	-	O
13	2	O
14	domain	O
15	from	O
16	the	O
17	vitamin	B
18	D3	I
19	receptor	I
20	or	O
21	the	O
22	estrogen	B
23	receptor	I
24	results	O
25	in	O
26	a	O
27	receptor	O
28	with	O
29	wild	O
30	-	O
31	type	O
32	or	O
33	low	O
34	transcriptional	O
35	activity	O
36	,	O
37	respectively	O
38	.	O

1	But	O
2	,	O
3	as	O
4	Theriault	O
5	explains	O
6	,	O
7	improvements	O
8	in	O
9	assessing	O
10	exposure	O
11	have	O
12	not	O
13	yet	O
14	translated	O
15	into	O
16	clear	O
17	and	O
18	consistent	O
19	findings	O
20	.	O

1	The	O
2	effects	O
3	of	O
4	oral	O
5	vanadyl	O
6	sulfate	O
7	(	O
8	VOSO4	O
9	)	O
10	(	O
11	0	O
12	.	O
13	5	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	on	O
21	anthropometry	O
22	,	O
23	body	O
24	composition	O
25	,	O
26	and	O
27	performance	O
28	were	O
29	investigated	O
30	in	O
31	a	O
32	12	O
33	-	O
34	week	O
35	,	O
36	double	O
37	-	O
38	blind	O
39	,	O
40	placebo	O
41	-	O
42	controlled	O
43	trial	O
44	involving	O
45	weight	O
46	-	O
47	training	O
48	volunteers	O
49	.	O

1	Disruption	O
2	of	O
3	re	O
4	-	O
5	replication	O
6	control	O
7	by	O
8	overexpression	O
9	of	O
10	human	B
11	ORC1	I
12	in	O
13	fission	O
14	yeast	O
15	.	O

1	Recombinant	O
2	,	O
3	bacterially	O
4	expressed	O
5	PIP5KIalpha	B
6	possessed	O
7	PIP5K	B
8	activity	O
9	and	O
10	was	O
11	immunoreactive	O
12	with	O
13	erythroid	B
14	PIP5KI	I
15	antibodies	I
16	.	O

1	Two	O
2	classes	O
3	of	O
4	mutations	O
5	were	O
6	obtained	O
7	:	O
8	(	O
9	i	O
10	)	O
11	those	O
12	that	O
13	altered	O
14	the	O
15	coding	O
16	region	O
17	of	O
18	HOL1	B
19	,	O
20	conferring	O
21	the	O
22	ability	O
23	to	O
24	take	O
25	up	O
26	histidinol	O
27	;	O
28	and	O
29	(	O
30	ii	O
31	)	O
32	cis	O
33	-	O
34	acting	O
35	mutations	O
36	(	O
37	selected	O
38	in	O
39	a	O
40	mutant	O
41	HOL1	B
42	-	I
43	1	I
44	background	O
45	)	O
46	that	O
47	increased	O
48	expression	O
49	of	O
50	the	O
51	Hol1	B
52	protein	I
53	.	O

1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	vasculitis	O
7	(	O
8	cutaneous	O
9	and	O
10	neurologic	O
11	)	O
12	which	O
13	led	O
14	to	O
15	the	O
16	discovery	O
17	of	O
18	a	O
19	selective	O
20	immunodeficit	O
21	towards	O
22	EBV	O
23	,	O
24	similar	O
25	to	O
26	Purtilo	O
27	'	O
28	s	O
29	syndrome	O
30	.	O

1	Filter	O
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O

1	These	O
2	data	O
3	do	O
4	not	O
5	support	O
6	the	O
7	use	O
8	of	O
9	LDD	O
10	to	O
11	reduce	O
12	risk	O
13	of	O
14	progression	O
15	to	O
16	MSOF	O
17	in	O
18	sepsis	O
19	.	O

1	In	O
2	contrast	O
3	,	O
4	extracts	O
5	of	O
6	the	O
7	mutant	O
8	virions	O
9	catalyze	O
10	the	O
11	wild	O
12	-	O
13	type	O
14	level	O
15	of	O
16	transcription	O
17	from	O
18	an	O
19	exogenous	O
20	template	O
21	containing	O
22	an	O
23	early	O
24	promoter	O
25	.	O

1	The	O
2	SCMV	B
3	SNE	I
4	sites	I
5	contain	O
6	potential	O
7	overlapping	O
8	core	O
9	recognition	O
10	binding	O
11	motifs	O
12	for	O
13	SRF	B
14	,	O
15	Rel	B
16	/	O
17	NFkappaB	B
18	,	O
19	ETS	B
20	,	O
21	and	O
22	YY1	B
23	class	I
24	transcription	I
25	factors	I
26	but	O
27	fail	O
28	to	O
29	respond	O
30	to	O
31	either	O
32	serum	O
33	or	O
34	tumor	B
35	necrosis	I
36	factor	I
37	alpha	I
38	.	O

1	Fas	B
2	has	O
3	been	O
4	shown	O
5	to	O
6	require	O
7	ICE	B
8	(	O
9	interleukin	B
10	-	I
11	1	I
12	beta	I
13	-	I
14	converting	I
15	enzyme	I
16	)	O
17	family	O
18	proteases	O
19	to	O
20	induce	O
21	apoptosis	O
22	from	O
23	studies	O
24	utilizing	O
25	the	O
26	cowpox	O
27	ICE	B
28	inhibitor	I
29	protein	I
30	CrmA	I
31	,	O
32	the	O
33	synthetic	O
34	tetrapeptide	O
35	ICE	B
36	inhibitor	O
37	YVAD	B
38	-	I
39	CMK	I
40	,	O
41	and	O
42	the	O
43	tripeptide	O
44	pan	O
45	-	O
46	ICE	B
47	inhibitor	O
48	Z	B
49	-	I
50	VAD	I
51	-	I
52	FMK	I
53	.	O

1	Complementary	O
2	DNAs	O
3	encompassing	O
4	the	O
5	coat	B
6	protein	I
7	coding	O
8	and	O
9	adjacent	O
10	regions	O
11	of	O
12	Agropyron	O
13	mosaic	O
14	virus	O
15	(	O
16	AgMV	O
17	)	O
18	and	O
19	Hordeum	O
20	mosaic	O
21	virus	O
22	(	O
23	HoMV	O
24	)	O
25	were	O
26	cloned	O
27	and	O
28	sequenced	O
29	.	O

1	Several	O
2	cDNAs	O
3	corresponding	O
4	to	O
5	the	O
6	human	B
7	PWP2	I
8	gene	I
9	were	O
10	identified	O
11	and	O
12	partially	O
13	sequenced	O
14	.	O

1	However	O
2	,	O
3	we	O
4	did	O
5	not	O
6	observe	O
7	a	O
8	correlation	O
9	between	O
10	serum	O
11	and	O
12	seminal	B
13	plasma	I
14	PSA	I
15	levels	O
16	.	O

1	Mutants	O
2	lacking	O
3	any	O
4	tyrosine	O
5	residues	O
6	in	O
7	the	O
8	cytoplasmic	O
9	domain	O
10	maintain	O
11	their	O
12	ability	O
13	to	O
14	activate	O
15	STAT5	B
16	and	O
17	STAT1	B
18	but	O
19	cannot	O
20	activate	O
21	STAT3	B
22	,	O
23	implying	O
24	that	O
25	STAT5	B
26	and	O
27	STAT1	B
28	activation	O
29	does	O
30	not	O
31	require	O
32	receptor	O
33	tyrosine	O
34	phosphorylation	O
35	.	O

1	This	O
2	establishes	O
3	Rad3	B
4	/	O
5	Mec1	B
6	as	O
7	the	O
8	only	O
9	conserved	O
10	protein	O
11	which	O
12	is	O
13	required	O
14	for	O
15	all	O
16	the	O
17	DNA	O
18	structure	O
19	checkpoints	O
20	in	O
21	both	O
22	yeast	O
23	model	O
24	systems	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	double	O
5	mutants	O
6	with	O
7	either	O
8	dim1	B
9	-	I
10	delta	I
11	or	O
12	dim2	B
13	-	I
14	1	I
15	and	O
16	the	O
17	endocytosis	O
18	mutants	B
19	end4	I
20	-	I
21	1	I
22	or	O
23	act1	B
24	-	I
25	1	I
26	displayed	O
27	synthetic	O
28	growth	O
29	defects	O
30	,	O
31	indicating	O
32	that	O
33	the	O
34	DIM	B
35	gene	I
36	products	I
37	function	O
38	in	O
39	a	O
40	common	O
41	or	O
42	parallel	O
43	endocytic	O
44	pathway	O
45	.	O

1	Mortality	O
2	on	O
3	the	O
4	last	O
5	ranch	O
6	was	O
7	particularly	O
8	severe	O
9	among	O
10	certain	O
11	segregated	O
12	groups	O
13	of	O
14	turkeys	O
15	that	O
16	included	O
17	toms	O
18	,	O
19	heavier	O
20	birds	O
21	,	O
22	and	O
23	birds	O
24	undergoing	O
25	a	O
26	stressful	O
27	event	O
28	such	O
29	as	O
30	artificial	O
31	insemination	O
32	.	O

1	Further	O
2	,	O
3	the	O
4	PIP2	O
5	content	O
6	of	O
7	the	O
8	85	O
9	-	O
10	90	O
11	kDa	O
12	protein	O
13	appeared	O
14	to	O
15	decrease	O
16	with	O
17	CSF	B
18	-	I
19	1	I
20	treatment	O
21	.	O

1	The	O
2	first	O
3	identification	O
4	of	O
5	the	O
6	active	O
7	37LRP	B
8	/	O
9	p40	B
10	gene	O
11	presented	O
12	in	O
13	this	O
14	study	O
15	is	O
16	a	O
17	critical	O
18	step	O
19	toward	O
20	the	O
21	isolation	O
22	of	O
23	the	O
24	corresponding	O
25	human	O
26	gene	O
27	and	O
28	the	O
29	understanding	O
30	of	O
31	the	O
32	molecular	O
33	mechanisms	O
34	involved	O
35	in	O
36	the	O
37	up	O
38	-	O
39	regulation	O
40	of	O
41	its	O
42	expression	O
43	during	O
44	tumor	O
45	invasion	O
46	and	O
47	metastasis	O
48	.	O

1	The	O
2	promoter	O
3	region	O
4	(	O
5	P1	O
6	)	O
7	corresponding	O
8	to	O
9	the	O
10	main	O
11	group	O
12	of	O
13	transcription	O
14	initiation	O
15	sites	O
16	is	O
17	devoid	O
18	of	O
19	TATA	O
20	and	O
21	CAAT	O
22	boxes	O
23	but	O
24	has	O
25	putative	O
26	binding	O
27	sites	O
28	for	O
29	the	O
30	transcription	B
31	factor	I
32	SP1	I
33	and	O
34	is	O
35	embedded	O
36	in	O
37	a	O
38	large	O
39	G	O
40	+	O
41	C	O
42	-	O
43	rich	O
44	domain	O
45	of	O
46	a	O
47	CpG	O
48	island	O
49	,	O
50	features	O
51	shared	O
52	by	O
53	the	O
54	promoters	O
55	of	O
56	constitutively	O
57	expressed	O
58	housekeeping	O
59	genes	O
60	.	O

1	Children	O
2	born	O
3	from	O
4	chronic	O
5	alcoholic	O
6	mothers	O
7	have	O
8	shown	O
9	behavioral	O
10	teratogenic	O
11	effects	O
12	more	O
13	frequently	O
14	than	O
15	morphological	O
16	malformations	O
17	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	Apo	B
5	-	I
6	3	I
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O

1	The	O
2	results	O
3	demonstrate	O
4	that	O
5	(	O
6	i	O
7	)	O
8	no	O
9	intact	O
10	capsids	O
11	were	O
12	assembled	O
13	when	O
14	the	O
15	full	O
16	-	O
17	length	O
18	or	O
19	a	O
20	truncated	O
21	(	O
22	missing	O
23	the	O
24	C	O
25	-	O
26	terminal	O
27	65	O
28	amino	O
29	acids	O
30	)	O
31	UL80	B
32	.	I
33	5	I
34	protein	I
35	was	O
36	tested	O
37	;	O
38	(	O
39	ii	O
40	)	O
41	when	O
42	the	O
43	C	O
44	-	O
45	terminal	O
46	65	O
47	amino	O
48	acids	O
49	of	O
50	the	O
51	UL80	B
52	.	I
53	5	I
54	protein	I
55	were	O
56	replaced	O
57	with	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	25	O
63	amino	O
64	acids	O
65	of	O
66	the	O
67	UL26	B
68	.	I
69	5	I
70	protein	I
71	,	O
72	intact	O
73	capsids	O
74	were	O
75	made	O
76	and	O
77	direct	O
78	interaction	O
79	of	O
80	the	O
81	UL80	B
82	.	I
83	5	I
84	protein	I
85	with	O
86	VP5	B
87	was	O
88	detected	O
89	;	O
90	(	O
91	iii	O
92	)	O
93	assembly	O
94	of	O
95	intact	O
96	capsids	O
97	was	O
98	demonstrated	O
99	when	O
100	the	O
101	sequence	O
102	of	O
103	the	O
104	last	O
105	12	O
106	amino	O
107	acids	O
108	of	O
109	the	O
110	UL80	B
111	.	I
112	5	I
113	protein	I
114	was	O
115	changed	O
116	from	O
117	RRIFVA	O
118	ALNKLE	O
119	to	O
120	RRIFVAAMMKLE	O
121	;	O
122	(	O
123	iv	O
124	)	O
125	self	O
126	-	O
127	interaction	O
128	of	O
129	the	O
130	scaffold	O
131	proteins	O
132	is	O
133	mediated	O
134	by	O
135	sequences	O
136	N	O
137	terminal	O
138	to	O
139	the	O
140	maturation	O
141	cleavage	O
142	site	O
143	;	O
144	and	O
145	(	O
146	v	O
147	)	O
148	the	O
149	UL26	B
150	.	I
151	5	I
152	and	O
153	UL80	B
154	.	I
155	5	I
156	proteins	I
157	will	O
158	not	O
159	coassemble	O
160	into	O
161	scaffold	O
162	structures	O
163	.	O

1	C	B
2	/	I
3	EBP	I
4	beta	I
5	V	I
6	>	O
7	A	O
8	selectively	O
9	binds	O
10	only	O
11	the	O
12	subset	O
13	of	O
14	C	B
15	/	I
16	EBP	I
17	sites	I
18	that	O
19	are	O
20	also	O
21	DBP	B
22	sites	I
23	,	O
24	both	O
25	as	O
26	oligonucleotides	O
27	and	O
28	within	O
29	the	O
30	natural	O
31	contexts	O
32	of	O
33	the	O
34	albumin	B
35	and	O
36	cholesterol	B
37	hydroxylase	I
38	promoters	I
39	.	O

1	Specific	O
2	IgG	B
3	,	O
4	specific	O
5	IgE	B
6	and	O
7	total	O
8	IgE	B
9	immunoglobulins	I
10	against	O
11	Toxocara	B
12	canis	I
13	excretory	I
14	/	I
15	secretory	I
16	antigens	I
17	(	O
18	TES	B
19	)	O
20	were	O
21	detected	O
22	by	O
23	using	O
24	ELISA	O
25	technique	O
26	.	O

1	Its	O
2	transcription	O
3	product	O
4	,	O
5	a	O
6	1	O
7	.	O
8	3	O
9	kb	O
10	mRNA	O
11	,	O
12	is	O
13	polyadenylated	O
14	at	O
15	a	O
16	site	O
17	containing	O
18	consensus	O
19	eukaryotic	O
20	polyadenylation	O
21	signals	O
22	and	O
23	mapping	O
24	87	O
25	bp	O
26	downstream	O
27	of	O
28	the	O
29	translation	O
30	termination	O
31	codon	O
32	for	O
33	CG30	B
34	.	O

1	The	O
2	resurgence	O
3	of	O
4	drug	O
5	-	O
6	resistant	O
7	malaria	O
8	makes	O
9	urgent	O
10	the	O
11	evaluation	O
12	of	O
13	new	O
14	antimalarial	O
15	agents	O
16	.	O

1	Prevalence	O
2	of	O
3	sleep	O
4	-	O
5	disordered	O
6	breathing	O
7	(	O
8	SDB	O
9	)	O
10	is	O
11	reported	O
12	to	O
13	increase	O
14	in	O
15	menopausal	O
16	women	O
17	.	O

1	BCL	B
2	-	I
3	2	I
4	,	O
5	an	O
6	inhibitor	O
7	of	O
8	apoptosis	O
9	in	O
10	a	O
11	wide	O
12	variety	O
13	of	O
14	cell	O
15	types	O
16	,	O
17	has	O
18	been	O
19	reported	O
20	to	O
21	prevent	O
22	oxidative	O
23	stress	O
24	-	O
25	induced	O
26	cell	O
27	death	O
28	.	O

1	In	O
2	vitro	O
3	translation	O
4	of	O
5	the	O
6	mTRF1	B
7	cDNA	I
8	resulted	O
9	in	O
10	a	O
11	56	O
12	kDa	O
13	protein	O
14	that	O
15	binds	O
16	to	O
17	TTAGGG	O
18	repeat	O
19	arrays	O
20	.	O
21	mTRF1	B
22	displayed	O
23	the	O
24	same	O
25	sequence	O
26	specificity	O
27	as	O
28	hTRF1	B
29	,	O
30	preferring	O
31	arrays	O
32	of	O
33	TTAGGG	O
34	repeats	O
35	as	O
36	a	O
37	binding	O
38	substrate	O
39	over	O
40	TTAGGC	O
41	and	O
42	TTGGGG	O
43	repeats	O
44	.	O

1	The	O
2	results	O
3	demonstrate	O
4	(	O
5	i	O
6	)	O
7	that	O
8	the	O
9	selenocysteine	O
10	-	O
11	specific	O
12	UGA	O
13	codon	O
14	is	O
15	readily	O
16	suppressed	O
17	under	O
18	conditions	O
19	where	O
20	the	O
21	homologous	B
22	SelB	I
23	protein	I
24	is	O
25	absent	O
26	and	O
27	(	O
28	ii	O
29	)	O
30	that	O
31	apart	O
32	from	O
33	the	O
34	specificity	O
35	of	O
36	the	O
37	SelB	B
38	-	I
39	mRNA	I
40	interaction	O
41	,	O
42	a	O
43	structural	O
44	compatibility	O
45	of	O
46	the	O
47	quaternary	O
48	complex	O
49	with	O
50	the	O
51	ribosome	O
52	is	O
53	required	O
54	.	O

1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	B
9	gene	I
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	B
19	RNA	I
20	polymerase	I
21	promoter	I
22	.	O

1	PrpB	B
2	showed	O
3	homology	O
4	to	O
5	carboxyphosphonoenolpyruvate	B
6	phosphonomutase	I
7	of	I
8	Streptomyces	I
9	hygroscopicus	I
10	and	O
11	to	O
12	its	O
13	homolog	O
14	in	O
15	the	O
16	carnation	O
17	Dianthus	O
18	caryophyllus	O
19	;	O
20	PrpC	B
21	was	O
22	homologous	O
23	to	O
24	both	O
25	archaeal	B
26	and	I
27	bacterial	I
28	citrate	I
29	synthases	I
30	;	O
31	PrpD	B
32	showed	O
33	homology	O
34	to	O
35	yeast	O
36	and	O
37	Bacillus	O
38	subtilis	O
39	proteins	O
40	of	O
41	unknown	O
42	function	O
43	;	O
44	PrpE	B
45	showed	O
46	homology	O
47	to	O
48	acetyl	B
49	coenzyme	I
50	A	I
51	synthetases	I
52	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	cDNA	O
6	encoding	O
7	human	B
8	MEKK3	I
9	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	O
17	gene	O
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	B
28	RXRgamma2	I
29	isoform	I
30	was	O
31	characterized	O
32	.	O

1	Mutant	O
2	enzyme	O
3	forms	O
4	were	O
5	prepared	O
6	to	O
7	eliminate	O
8	the	O
9	initial	O
10	autoprocessing	O
11	site	O
12	and	O
13	thus	O
14	form	O
15	an	O
16	active	O
17	single	O
18	-	O
19	chain	O
20	protein	O
21	for	O
22	structure	O
23	-	O
24	function	O
25	studies	O
26	.	O

1	The	O
2	primer	O
3	is	O
4	generated	O
5	by	O
6	a	O
7	cleavage	O
8	that	O
9	occurs	O
10	between	O
11	bases	O
12	11	O
13	and	O
14	12	O
15	of	O
16	the	O
17	Tf1	B
18	mRNA	I
19	.	O

1	Cholesterol	B
2	side	I
3	-	I
4	chain	I
5	cleavage	I
6	cytochrome	I
7	P450	I
8	(	O
9	CYP11A	B
10	;	O
11	P450scc	B
12	)	O
13	gene	O
14	expression	O
15	is	O
16	regulated	O
17	by	O
18	gonadotropins	B
19	via	O
20	cAMP	O
21	in	O
22	the	O
23	ovary	O
24	and	O
25	by	O
26	ACTH	B
27	via	O
28	cAMP	O
29	in	O
30	adrenal	O
31	cortical	O
32	cells	O
33	.	O

1	Both	O
2	HEF1	B
3	and	O
4	Cas	B
5	were	O
6	found	O
7	to	O
8	complex	O
9	with	O
10	the	O
11	related	B
12	adhesion	I
13	focal	I
14	tyrosine	I
15	kinase	I
16	(	O
17	RAFTK	B
18	),	O
19	and	O
20	when	O
21	tyrosine	O
22	phosphorylated	O
23	,	O
24	with	O
25	the	O
26	adapter	O
27	molecule	O
28	CrkL	B
29	.	O

1	Complexes	O
2	of	O
3	qTBP42	B
4	with	O
5	each	O
6	complementary	O
7	strand	O
8	of	O
9	telomeric	O
10	DNA	O
11	and	O
12	with	O
13	quadruplex	O
14	forms	O
15	of	O
16	the	O
17	guanine	O
18	-	O
19	rich	O
20	strand	O
21	had	O
22	3	O
23	.	O
24	7	O
25	-	O
26	14	O
27	.	O
28	6	O
29	nM	O
30	dissociation	O
31	constants	O
32	,	O
33	Kd	O
34	,	O
35	whereas	O
36	complexes	O
37	with	O
38	double	O
39	-	O
40	stranded	O
41	telomeric	O
42	DNA	O
43	had	O
44	up	O
45	to	O
46	100	O
47	-	O
48	fold	O
49	higher	O
50	Kd	O
51	values	O
52	.	O

1	Because	O
2	L	B
3	-	I
4	plastin	I
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	O
52	L	B
53	-	I
54	plastin	I
55	gene	O
56	promoters	O
57	.	O

1	OBJECTIVE	O
2	:	O
3	Our	O
4	goal	O
5	was	O
6	to	O
7	determine	O
8	whether	O
9	chlamydia	O
10	-	O
11	infected	O
12	women	O
13	have	O
14	a	O
15	higher	O
16	rate	O
17	of	O
18	febrile	O
19	complications	O
20	after	O
21	postpartum	O
22	tubal	O
23	ligation	O
24	.	O

1	A	O
2	heterologous	O
3	promoter	O
4	construct	O
5	containing	O
6	three	O
7	repeats	O
8	of	O
9	a	O
10	consensus	O
11	Sp1	B
12	site	I
13	,	O
14	cloned	O
15	upstream	O
16	of	O
17	a	O
18	single	O
19	copy	O
20	of	O
21	the	O
22	ZII	B
23	(	O
24	CREB	B
25	/	I
26	AP1	I
27	)	O
28	element	O
29	from	O
30	the	O
31	BZLF1	B
32	promoter	I
33	linked	O
34	to	O
35	the	O
36	beta	B
37	-	I
38	globin	I
39	TATA	O
40	box	O
41	,	O
42	exhibited	O
43	phorbol	O
44	ester	O
45	inducibility	O
46	.	O

1	How	O
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	Together	O
2	,	O
3	the	O
4	data	O
5	suggest	O
6	that	O
7	cAMP	O
8	-	O
9	dependent	O
10	control	O
11	of	O
12	the	O
13	amounts	O
14	of	O
15	the	O
16	activator	O
17	SF	B
18	-	I
19	1	I
20	vs	O
21	.	O
22	the	O
23	repressor	O
24	COUP	B
25	-	I
26	TF	I
27	could	O
28	influence	O
29	CRS2	O
30	-	O
31	dependent	O
32	transcription	O
33	.	O

1	Object	O
2	relations	O
3	,	O
4	affect	O
5	management	O
6	,	O
7	and	O
8	psychic	O
9	structure	O
10	formation	O
11	.	O

1	Constitutive	O
2	activation	O
3	of	O
4	Rac1	B
5	and	O
6	RhoA	B
7	causes	O
8	tumorigenic	O
9	transformation	O
10	of	O
11	NIH	O
12	3T3	O
13	cells	O
14	,	O
15	and	O
16	their	O
17	functions	O
18	may	O
19	be	O
20	required	O
21	for	O
22	full	O
23	Ras	B
24	transformation	O
25	.	O

1	Overexpression	O
2	of	O
3	the	O
4	bZip	O
5	interaction	O
6	domain	O
7	of	O
8	CBP	B
9	specifically	O
10	abolishes	O
11	the	O
12	positive	O
13	cross	O
14	talk	O
15	between	O
16	TR	B
17	and	O
18	p45	B
19	/	O
20	NF	B
21	-	I
22	E2	I
23	.	O

1	In	O
2	summary	O
3	,	O
4	p56	B
5	(	O
6	lck	B
7	)	O
8	activity	O
9	stimulates	O
10	G1	O
11	/	O
12	S	O
13	transition	O
14	in	O
15	immature	O
16	thymoblasts	O
17	and	O
18	maintains	O
19	cell	O
20	viability	O
21	via	O
22	transduction	O
23	of	O
24	constitutive	O
25	activation	O
26	signals	O
27	downstream	O
28	to	O
29	components	O
30	of	O
31	the	O
32	Ras	B
33	/	O
34	Raf	B
35	/	O
36	MAPK	B
37	pathway	O
38	.	O

1	Clinically	O
2	meaningful	O
3	decreases	O
4	due	O
5	to	O
6	alkalinization	O
7	alone	O
8	within	O
9	30	O
10	minutes	O
11	are	O
12	unlikely	O
13	.	O

1	Acetoin	O
2	-	O
3	dependent	O
4	expression	O
5	of	O
6	the	O
7	acoABCD	B
8	operon	I
9	could	O
10	be	O
11	restored	O
12	in	O
13	the	O
14	E	B
15	.	I
16	coli	I
17	acoK	I
18	mutants	I
19	by	O
20	supplying	O
21	a	O
22	plasmid	O
23	carrying	O
24	an	O
25	intact	O
26	acoK	B
27	,	O
28	suggesting	O
29	a	O
30	transactivating	O
31	function	O
32	of	O
33	the	O
34	gene	O
35	product	O
36	.	O

1	Marinol	O
2	/	O
3	marijuana	O
4	usage	O
5	was	O
6	associated	O
7	with	O
8	depressed	O
9	CD4	B
10	+	I
11	counts	O
12	and	O
13	elevated	O
14	amylase	B
15	levels	O
16	within	O
17	the	O
18	DDI	O
19	subgroup	O
20	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	I
10	2	I
11	but	O
12	not	O
13	an	O
14	Egr	B
15	-	I
16	1	I
17	expression	O
18	vector	O
19	activated	O
20	VPF	B
21	/	O
22	VEGF	B
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	I
30	2	I
31	protein	I
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	B
37	alpha	I
38	-	O
39	induced	O
40	VPF	B
41	/	O
42	VEGF	B
43	gene	O
44	expression	O
45	.	O

1	The	O
2	HBP	B
3	gene	I
4	is	O
5	composed	O
6	of	O
7	eight	O
8	exons	O
9	covering	O
10	19	O
11	.	O
12	5	O
13	kb	O
14	on	O
15	the	O
16	short	O
17	arm	O
18	of	O
19	chromosome	O
20	4	O
21	.	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	O
13	virally	O
14	encoded	O
15	proteases	O
16	which	O
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	B
23	factor	I
24	eIF4G	I
25	.	O

1	The	O
2	best	O
3	endometrial	O
4	ablation	O
5	was	O
6	seen	O
7	when	O
8	SnET2	O
9	was	O
10	given	O
11	by	O
12	intrauterine	O
13	administration	O
14	with	O
15	light	O
16	treatment	O
17	at	O
18	150	O
19	J	O
20	/	O
21	cm	O
22	24	O
23	hours	O
24	later	O
25	.	O

1	Unlike	O
2	class	O
3	II	O
4	-	O
5	and	O
6	III	O
7	-	O
8	specific	O
9	TBP	B
10	-	O
11	TAF	B
12	complexes	O
13	,	O
14	the	O
15	corresponding	O
16	murine	O
17	and	O
18	human	O
19	class	O
20	I	O
21	-	O
22	specific	O
23	transcription	O
24	initiation	O
25	factor	O
26	TIF	B
27	-	I
28	IB	I
29	/	O
30	SL1	B
31	exhibits	O
32	a	O
33	pronounced	O
34	selectivity	O
35	for	O
36	its	O
37	homologous	O
38	promoter	O
39	.	O

1	We	O
2	now	O
3	describe	O
4	the	O
5	identification	O
6	of	O
7	DEK	B
8	as	O
9	this	O
10	43	B
11	-	I
12	kDa	I
13	pets	I
14	factor	I
15	.	O

1	Transient	O
2	cotransfection	O
3	of	O
4	tat	B
5	cDNA	I
6	in	O
7	sense	O
8	orientation	O
9	(	O
10	tat	B
11	/	I
12	S	I
13	),	O
14	together	O
15	with	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	c	B
21	-	I
22	fos	I
23	promoter	I
24	(	O
25	FC3	B
26	,	O
27	from	O
28	-	O
29	711	O
30	to	O
31	+	O
32	42	O
33	)	O
34	in	O
35	front	O
36	of	O
37	the	O
38	bacterial	B
39	chloramphenicol	I
40	acetyltransferase	I
41	(	O
42	CAT	B
43	)	O
44	gene	O
45	significantly	O
46	enhanced	O
47	CAT	B
48	activity	O
49	in	O
50	Jurkat	O
51	cells	O
52	activated	O
53	by	O
54	the	O
55	addition	O
56	of	O
57	15	O
58	%	O
59	fetal	O
60	calf	O
61	serum	O
62	(	O
63	FCS	O
64	)	O
65	or	O
66	5	O
67	micrograms	O
68	/	O
69	mL	O
70	phytohemagglutinin	B
71	plus	O
72	10	O
73	(-	O
74	7	O
75	)	O
76	mol	O
77	/	O
78	L	O
79	phorbol	O
80	myristate	O
81	acetate	O
82	(	O
83	PMA	O
84	)	O
85	and	O
86	U937	O
87	cells	O
88	activated	O
89	by	O
90	15	O
91	%	O
92	FCS	O
93	or	O
94	10	O
95	(-	O
96	7	O
97	)	O
98	mol	O
99	/	O
100	L	O
101	PMA	O
102	.	O

1	Derepression	O
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	B
15	lyase	I
16	gene	I
17	of	I
18	Candida	I
19	tropicalis	I
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	cis	O
6	elements	O
7	positioned	O
8	between	O
9	the	O
10	alpha	B
11	3	I
12	and	O
13	beta	B
14	4	I
15	coding	O
16	regions	O
17	are	O
18	important	O
19	for	O
20	establishing	O
21	part	O
22	of	O
23	the	O
24	restricted	O
25	CNS	O
26	patterns	O
27	of	O
28	beta	B
29	4	I
30	,	O
31	alpha	B
32	3	I
33	,	O
34	and	O
35	alpha	B
36	5	I
37	gene	I
38	transcription	O
39	.	O

1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O

1	These	O
2	changes	O
3	in	O
4	virus	O
5	entry	O
6	features	O
7	may	O
8	result	O
9	in	O
10	coronaviruses	O
11	with	O
12	novel	O
13	pathogenic	O
14	properties	O
15	.	O

1	RESULTS	O
2	:	O
3	Among	O
4	women	O
5	,	O
6	the	O
7	age	O
8	-	O
9	related	O
10	decline	O
11	in	O
12	BMD	O
13	at	O
14	all	O
15	non	O
16	-	O
17	spine	O
18	skeletal	O
19	sites	O
20	was	O
21	significantly	O
22	different	O
23	from	O
24	zero	O
25	,	O
26	with	O
27	the	O
28	largest	O
29	decline	O
30	seen	O
31	at	O
32	the	O
33	femoral	O
34	neck	O
35	(-.	O
36	0038	O
37	g	O
38	/	O
39	cm2	O
40	/	O
41	y	O
42	,	O
43	p	O
44	<	O
45	.	O
46	001	O
47	)	O
48	and	O
49	the	O
50	smallest	O
51	at	O
52	the	O
53	trochanter	O
54	of	O
55	the	O
56	hip	O
57	(-.	O
58	0023	O
59	g	O
60	/	O
61	cm2	O
62	/	O
63	y	O
64	,	O
65	p	O
66	=	O
67	.	O
68	03	O
69	).	O

1	Relief	O
2	from	O
3	autoinhibition	O
4	and	O
5	a	O
6	subsequent	O
7	10	O
8	-	O
9	60	O
10	-	O
11	fold	O
12	increase	O
13	in	O
14	V	O
15	(	O
16	max	O
17	)	O
18	have	O
19	been	O
20	observed	O
21	upon	O
22	N	B
23	-	I
24	SH2	I
25	domain	I
26	engagement	O
27	by	O
28	a	O
29	specific	O
30	phosphotyrosyl	O
31	ligand	O
32	or	O
33	upon	O
34	deletion	O
35	of	O
36	the	O
37	SH2	B
38	domains	I
39	to	O
40	yield	O
41	the	O
42	catalytic	O
43	PTPase	B
44	domain	I
45	.	O

1	The	O
2	addition	O
3	of	O
4	zidovudine	O
5	did	O
6	not	O
7	influence	O
8	this	O
9	transfer	O
10	.	O

1	Antisense	O
2	transcription	O
3	of	O
4	a	O
5	murine	B
6	FGFR	I
7	-	I
8	3	I
9	psuedogene	I
10	during	O
11	fetal	O
12	developement	O
13	.	O

1	Type	O
2	IV	O
3	splice	O
4	pattern	O
5	,	O
6	containing	O
7	exon	O
8	U3	O
9	and	O
10	S	O
11	was	O
12	found	O
13	both	O
14	in	O
15	kidney	O
16	and	O
17	ovary	O
18	.	O

1	Recognition	O
2	mechanisms	O
3	of	O
4	the	O
5	minus	O
6	-	O
7	strand	O
8	origin	O
9	of	O
10	phage	O
11	f1	O
12	by	O
13	Escherichia	B
14	coli	I
15	RNA	I
16	polymerase	I
17	.	O

1	Some	O
2	8	O
3	.	O
4	8	O
5	kb	O
6	of	O
7	the	O
8	Lactobacillus	O
9	sake	O
10	plasmid	O
11	pCIM1	O
12	was	O
13	sequenced	O
14	,	O
15	revealing	O
16	eight	O
17	tightly	O
18	clustered	O
19	open	O
20	reading	O
21	frames	O
22	(	O
23	ORFs	O
24	)	O
25	downstream	O
26	from	O
27	lasA	B
28	,	O
29	which	O
30	encodes	O
31	pre	B
32	-	I
33	lactocin	I
34	S	I
35	.	O

1	Purified	B
2	Pra	I
3	was	O
4	also	O
5	shown	O
6	to	O
7	physically	O
8	interact	O
9	with	O
10	pyruvate	B
11	kinase	I
12	(	O
13	Pk	B
14	);	O
15	Pk	B
16	and	O
17	Pra	B
18	can	O
19	form	O
20	a	O
21	complex	O
22	,	O
23	but	O
24	when	O
25	the	O
26	12	B
27	-	I
28	kDa	I
29	Ndk	I
30	,	O
31	Pk	B
32	,	O
33	and	O
34	Pra	B
35	are	O
36	all	O
37	present	O
38	,	O
39	Pk	B
40	has	O
41	a	O
42	higher	O
43	affinity	O
44	than	O
45	Pra	B
46	for	O
47	forming	O
48	a	O
49	complex	O
50	with	O
51	the	O
52	12	B
53	-	I
54	kDa	I
55	Ndk	I
56	.	O

1	Thirty	O
2	-	O
3	five	O
4	patients	O
5	were	O
6	included	O
7	.	O

1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	B
12	,	O
13	encoding	O
14	3	B
15	-	I
16	isopropylmalate	I
17	dehydrogenase	I
18	;	O
19	asd	B
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	B
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	B
41	proteins	I
42	from	I
43	Vibrio	I
44	spp	I
45	.	O

1	Transcriptional	O
2	activity	O
3	was	O
4	measured	O
5	by	O
6	slot	O
7	-	O
8	blot	O
9	hybridization	O
10	with	O
11	steady	O
12	-	O
13	state	O
14	RNA	O
15	isolated	O
16	from	O
17	lacZ	B
18	+	I
19	M	I
20	.	I
21	smegmatis	I
22	clones	O
23	.	O

1	Hovenitin	O
2	I	O
3	and	O
4	(+)-	O
5	ampelopsin	O
6	,	O
7	both	O
8	of	O
9	which	O
10	were	O
11	principal	O
12	ingredients	O
13	of	O
14	the	O
15	active	O
16	fractions	O
17	from	O
18	this	O
19	natural	O
20	medicine	O
21	,	O
22	were	O
23	found	O
24	to	O
25	show	O
26	an	O
27	inhibitory	O
28	activity	O
29	on	O
30	the	O
31	ethanol	O
32	-	O
33	induced	O
34	muscle	O
35	relaxation	O
36	in	O
37	rats	O
38	.	O

1	It	O
2	is	O
3	also	O
4	homologous	O
5	to	O
6	other	O
7	sugar	O
8	carriers	O
9	from	O
10	human	O
11	,	O
12	mouse	O
13	and	O
14	Escherichia	O
15	coli	O
16	.	O

1	Analysis	O
2	of	O
3	homologous	O
4	DNA	O
5	sequences	O
6	within	O
7	the	O
8	first	O
9	intron	O
10	of	O
11	the	O
12	mouse	B
13	and	I
14	human	I
15	mts1	I
16	genes	I
17	:	O
18	kB	B
19	-	I
20	like	I
21	site	I
22	and	O
23	microsatellite	O
24	DNA	O

1	These	O
2	studies	O
3	point	O
4	to	O
5	the	O
6	involvement	O
7	of	O
8	the	O
9	MAP	B
10	kinase	I
11	pathway	O
12	in	O
13	the	O
14	activation	O
15	of	O
16	monocytic	O
17	cells	O
18	during	O
19	transmigration	O
20	to	O
21	inflammatory	O
22	sites	O
23	.	O

1	This	O
2	site	O
3	is	O
4	upstream	O
5	from	O
6	the	O
7	TATA	O
8	box	O
9	used	O
10	in	O
11	somatic	O
12	cells	O
13	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	O
18	Cdks	B
19	.	O

1	Coliphage	B
2	186	I
3	B	I
4	is	O
5	a	O
6	72	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	belonging	O
12	to	O
13	the	O
14	Ogr	B
15	family	O
16	of	O
17	analogous	O
18	transcription	O
19	factors	O
20	present	O
21	in	O
22	P2	O
23	-	O
24	like	O
25	phage	O
26	,	O
27	which	O
28	contain	O
29	a	O
30	Cys	O
31	-	O
32	X2	O
33	-	O
34	Cys	O
35	-	O
36	X22	O
37	-	O
38	Cys	O
39	-	O
40	X4	O
41	-	O
42	Cys	O
43	presumptive	O
44	zinc	O
45	-	O
46	finger	O
47	motif	O
48	.	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	O
39	epsilon	O
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Chronic	O
2	renal	O
3	failure	O
4	patients	O
5	essentially	O
6	die	O
7	from	O
8	cardiovascular	O
9	causes	O
10	,	O
11	and	O
12	the	O
13	frequency	O
14	of	O
15	malignant	O
16	disease	O
17	responsible	O
18	for	O
19	death	O
20	is	O
21	estimated	O
22	to	O
23	be	O
24	10	O
25	%.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	myofibrillar	O
9	disarray	O
10	seen	O
11	in	O
12	HCM	O
13	patients	O
14	which	O
15	harbor	O
16	either	O
17	of	O
18	these	O
19	two	O
20	mutations	O
21	may	O
22	not	O
23	be	O
24	directly	O
25	due	O
26	to	O
27	the	O
28	failure	O
29	of	O
30	the	O
31	mutant	B
32	myosin	I
33	heavy	I
34	chain	I
35	protein	I
36	to	O
37	assemble	O
38	and	O
39	form	O
40	normal	O
41	sarcomeres	O
42	,	O
43	but	O
44	may	O
45	rather	O
46	be	O
47	a	O
48	secondary	O
49	effect	O
50	possibly	O
51	resulting	O
52	from	O
53	the	O
54	chronic	O
55	stress	O
56	of	O
57	decreased	O
58	beta	B
59	MHC	I
60	function	O
61	.	O

1	The	O
2	capacity	O
3	to	O
4	repair	O
5	8	O
6	-	O
7	OxoG	O
8	has	O
9	been	O
10	measured	O
11	in	O
12	cell	O
13	-	O
14	free	O
15	extracts	O
16	of	O
17	wild	O
18	-	O
19	type	O
20	and	O
21	ogg1	B
22	strains	O
23	using	O
24	a	O
25	34mer	O
26	DNA	O
27	fragment	O
28	containing	O
29	a	O
30	single	O
31	8	O
32	-	O
33	OxoG	O
34	residue	O
35	paired	O
36	with	O
37	a	O
38	cytosine	O
39	(	O
40	8	O
41	-	O
42	OxoG	O
43	/	O
44	C	O
45	)	O
46	as	O
47	a	O
48	substrate	O
49	.	O

1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	I
11	myc	I
12	mRNA	I
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	B
25	myc	I
26	genes	I
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	B
34	sequences	I
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	B
40	beta	I
41	-	I
42	globin	I
43	gene	I
44	or	O
45	to	O
46	the	O
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	O
51	CAT	B
52	)	O
53	gene	O
54	.	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	O
25	C	B
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	Thus	O
2	,	O
3	depending	O
4	on	O
5	their	O
6	location	O
7	,	O
8	psoralen	O
9	cross	O
10	-	O
11	links	O
12	affected	O
13	different	O
14	steps	O
15	in	O
16	the	O
17	initiation	O
18	process	O
19	.	O

1	Domain	O
2	switch	O
3	experiments	O
4	reveal	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	beta	I
10	proteins	I
11	containing	O
12	either	O
13	the	O
14	leucine	O
15	zipper	O
16	or	O
17	the	O
18	activation	O
19	domain	O
20	of	O
21	C	B
22	/	I
23	EBP	I
24	alpha	I
25	are	O
26	unable	O
27	to	O
28	stimulate	O
29	the	O
30	2D5	B
31	promoter	I
32	yet	O
33	are	O
34	fully	O
35	capable	O
36	of	O
37	transactivating	O
38	an	O
39	artificial	O
40	promoter	O
41	bearing	O
42	a	O
43	high	O
44	-	O
45	affinity	O
46	C	B
47	/	I
48	EBP	I
49	site	I
50	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	RA	O
6	-	O
7	mediated	O
8	repression	O
9	of	O
10	the	O
11	hMGP	B
12	gene	I
13	is	O
14	due	O
15	to	O
16	binding	O
17	of	O
18	liganded	O
19	RAR	B
20	/	O
21	RXR	B
22	to	O
23	a	O
24	novel	O
25	negative	O
26	RA	O
27	response	O
28	element	O
29	.	O

1	The	O
2	electromyographically	O
3	recorded	O
4	responses	O
5	consisted	O
6	of	O
7	an	O
8	early	O
9	R1	O
10	response	O
11	in	O
12	the	O
13	orbicularis	O
14	oculi	O
15	muscle	O
16	ipsilateral	O
17	to	O
18	the	O
19	side	O
20	of	O
21	stimulation	O
22	,	O
23	a	O
24	bilateral	O
25	late	O
26	response	O
27	(	O
28	ipsilateral	O
29	R2	O
30	and	O
31	contralateral	O
32	Rc	O
33	)	O
34	and	O
35	a	O
36	third	O
37	,	O
38	R3	O
39	response	O
40	,	O
41	in	O
42	the	O
43	ipsilateral	O
44	orbicularis	O
45	oculi	O
46	muscle	O
47	.	O

1	Further	O
2	support	O
3	for	O
4	a	O
5	direct	O
6	interaction	O
7	of	O
8	Tub4p	B
9	,	O
10	Spc98p	B
11	and	O
12	Spc97p	B
13	comes	O
14	from	O
15	the	O
16	toxicity	O
17	of	O
18	strong	O
19	SPC97	B
20	overexpression	O
21	which	O
22	is	O
23	suppressed	O
24	by	O
25	co	O
26	-	O
27	overexpression	O
28	of	O
29	TUB4	B
30	or	O
31	SPC98	B
32	.	O

1	The	O
2	atp	B
3	1	I
4	and	O
5	atp	B
6	2	I
7	types	O
8	of	O
9	cDNA	O
10	sequences	O
11	were	O
12	the	O
13	most	O
14	redundant	O
15	among	O
16	the	O
17	28	O
18	different	O
19	isoperoxidases	B
20	identified	O
21	among	O
22	about	O
23	200	O
24	peroxidase	B
25	encoding	I
26	ESTs	I
27	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	constitutively	O
6	active	O
7	Mek1	B
8	could	O
9	activate	O
10	p96h2bk	B
11	in	O
12	the	O
13	absence	O
14	of	O
15	oncogenic	B
16	Ras	I
17	.	O

1	The	O
2	sequencing	O
3	of	O
4	Stellate	B
5	copies	O
6	located	O
7	along	O
8	the	O
9	discontinuous	O
10	cluster	O
11	revealed	O
12	a	O
13	complex	O
14	pattern	O
15	of	O
16	diversification	O
17	.	O

1	CTF1alpha	B
2	,	O
3	expressed	O
4	in	O
5	Escherichia	O
6	coli	O
7	,	O
8	showed	O
9	specific	O
10	binding	O
11	to	O
12	the	O
13	palindrome	O
14	2	O
15	DNA	O
16	fragment	O
17	but	O
18	not	O
19	to	O
20	palindrome	O
21	1	O
22	or	O
23	mutant	O
24	palindrome	O
25	2	O
26	DNA	O
27	fragments	O
28	,	O
29	suggesting	O
30	specific	O
31	binding	O
32	of	O
33	CTF1alpha	B
34	to	O
35	palindrome	O
36	2	O
37	.	O

1	Cyclin	B
2	G2	I
3	is	O
4	highly	O
5	expressed	O
6	in	O
7	the	O
8	immune	O
9	system	O
10	where	O
11	immunologic	O
12	tolerance	O
13	subjects	O
14	self	O
15	-	O
16	reactive	O
17	lymphocytes	O
18	to	O
19	negative	O
20	selection	O
21	and	O
22	clonal	O
23	deletion	O
24	via	O
25	apoptosis	O
26	.	O

1	Thus	O
2	,	O
3	the	O
4	P	O
5	.	O
6	aeruginosa	O
7	orfX	O
8	and	O
9	vfr	B
10	promoters	I
11	are	O
12	arranged	O
13	in	O
14	a	O
15	back	O
16	-	O
17	to	O
18	-	O
19	back	O
20	orientation	O
21	rather	O
22	than	O
23	the	O
24	face	O
25	-	O
26	to	O
27	-	O
28	face	O
29	orientation	O
30	of	O
31	the	O
32	dorf	O
33	and	O
34	crp	B
35	promoters	I
36	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	Anabaena	O
6	strain	O
7	7120	O
8	leuA	B
9	gene	O
10	did	O
11	not	O
12	complement	O
13	the	O
14	nifV	B
15	mutation	I
16	of	O
17	R229I	O
18	efficiently	O
19	.	O

1	Respiratory	O
2	chain	O
3	enzyme	O
4	activity	O
5	was	O
6	normal	O
7	.	O

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	One	O
2	P1	O
3	genomic	O
4	clone	O
5	and	O
6	six	O
7	subsequent	O
8	plasmid	O
9	subclones	O
10	were	O
11	isolated	O
12	and	O
13	analyzed	O
14	for	O
15	the	O
16	exon	O
17	-	O
18	intron	O
19	organization	O
20	of	O
21	the	O
22	Ctpct	B
23	gene	I
24	.	O

1	We	O
2	also	O
3	review	O
4	the	O
5	role	O
6	of	O
7	grains	O
8	in	O
9	the	O
10	formation	O
11	of	O
12	complex	O
13	molecules	O
14	in	O
15	interstellar	O
16	molecular	O
17	clouds	O
18	.	O

1	Like	O
2	the	O
3	elicitors	O
4	of	O
5	the	O
6	hypersensitive	O
7	reaction	O
8	(	O
9	HR	O
10	)	O
11	produced	O
12	by	O
13	E	O
14	.	O
15	chrysanthemi	O
16	(	O
17	HarpinEch	O
18	)	O
19	and	O
20	E	O
21	.	O
22	amylovora	O
23	(	O
24	HarpinEa	O
25	),	O
26	the	O
27	deduced	O
28	36	O
29	-	O
30	kDa	O
31	protein	O
32	does	O
33	not	O
34	possess	O
35	a	O
36	typical	O
37	signal	O
38	sequence	O
39	,	O
40	but	O
41	it	O
42	contains	O
43	a	O
44	putative	O
45	membrane	O
46	-	O
47	spanning	O
48	domain	O
49	.	O

1	Positional	O
2	cloning	O
3	has	O
4	already	O
5	produced	O
6	the	O
7	sequences	O
8	of	O
9	more	O
10	than	O
11	70	O
12	human	O
13	genes	O
14	associated	O
15	with	O
16	specific	O
17	diseases	O
18	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	data	O
6	establish	O
7	that	O
8	the	O
9	previously	O
10	reported	O
11	human	B
12	MAdCAM	I
13	-	I
14	1	I
15	cDNA	I
16	does	O
17	indeed	O
18	encode	O
19	the	O
20	human	O
21	homologue	O
22	of	O
23	mouse	B
24	MAdCAM	I
25	-	I
26	1	I
27	,	O
28	despite	O
29	gross	O
30	dissimilarities	O
31	in	O
32	the	O
33	MAdCAM	B
34	-	I
35	1	I
36	C	O
37	-	O
38	terminal	O
39	structures	O
40	.	O

1	MATERIAL	O
2	AND	O
3	METHODS	O
4	:	O
5	The	O
6	authors	O
7	analyzed	O
8	41	O
9	persons	O
10	formerly	O
11	submitted	O
12	to	O
13	surgery	O
14	(	O
15	after	O
16	8	O
17	years	O
18	and	O
19	4	O
20	months	O
21	,	O
22	as	O
23	a	O
24	mean	O
25	),	O
26	31	O
27	to	O
28	highly	O
29	selective	O
30	vagotomy	O
31	,	O
32	and	O
33	10	O
34	to	O
35	truncal	O
36	or	O
37	selective	O
38	vagotomy	O
39	plus	O
40	gastroduodenal	O
41	drainage	O
42	.	O

1	This	O
2	region	O
3	does	O
4	not	O
5	contain	O
6	an	O
7	identifiable	O
8	TATA	O
9	element	O
10	,	O
11	indicating	O
12	that	O
13	transcription	O
14	of	O
15	the	O
16	glutaminase	B
17	gene	I
18	is	O
19	driven	O
20	by	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	.	O

1	A	O
2	xylE	B
3	transcriptional	I
4	fusion	I
5	to	O
6	the	O
7	putative	O
8	mxbD	B
9	promoter	I
10	showed	O
11	low	O
12	-	O
13	level	O
14	expression	O
15	in	O
16	wild	O
17	-	O
18	type	O
19	cells	O
20	grown	O
21	on	O
22	one	O
23	-	O
24	carbon	O
25	(	O
26	C1	O
27	)	O
28	compounds	O
29	and	O
30	no	O
31	detectable	O
32	expression	O
33	in	O
34	cells	O
35	grown	O
36	on	O
37	succinate	O
38	.	O

1	These	O
2	six	O
3	amino	O
4	acids	O
5	are	O
6	part	O
7	of	O
8	an	O
9	amphipathic	O
10	helix	O
11	that	O
12	is	O
13	highly	O
14	conserved	O
15	among	O
16	nuclear	B
17	hormone	I
18	receptors	I
19	and	O
20	contains	O
21	the	O
22	core	O
23	domain	O
24	of	O
25	the	O
26	ligand	O
27	-	O
28	dependent	O
29	transactivation	O
30	function	O
31	,	O
32	AF	O
33	-	O
34	2	O
35	.	O

1	Based	O
2	on	O
3	the	O
4	occurrence	O
5	of	O
6	several	O
7	transcription	O
8	signals	O
9	in	O
10	the	O
11	Thermus	B
12	pyr	I
13	promoter	I
14	region	I
15	and	O
16	strong	O
17	amino	O
18	acid	O
19	sequence	O
20	identities	O
21	(	O
22	about	O
23	60	O
24	%)	O
25	between	O
26	Thermus	B
27	PyrR	I
28	and	O
29	the	O
30	PyrR	B
31	attenuation	I
32	proteins	I
33	of	O
34	two	O
35	Bacillus	O
36	sp	O
37	.,	O
38	we	O
39	propose	O
40	a	O
41	regulatory	O
42	mechanism	O
43	involving	O
44	transcriptional	O
45	attenuation	O
46	to	O
47	control	O
48	pyr	B
49	gene	I
50	expression	O
51	in	O
52	Thermus	O
53	.	O

1	Thus	O
2	,	O
3	the	O
4	B	O
5	-	O
6	S	O
7	mutant	O
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	B
14	GAPDHs	I
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	B
58	GAPDH	I
59	.	O

1	EGF	B
2	acts	O
3	primarily	O
4	by	O
5	means	O
6	of	O
7	transactivation	O
8	domain	O
9	AF	O
10	-	O
11	1	O
12	,	O
13	whereas	O
14	cAMP	O
15	acts	O
16	via	O
17	transactivation	O
18	domain	O
19	AF	O
20	-	O
21	2	O
22	of	O
23	the	O
24	ER	B
25	.	O

1	SPP	B
2	also	O
3	induced	O
4	transient	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	focal	B
9	adhesion	I
10	kinase	I
11	(	O
12	p125	B
13	(	O
14	FAK	B
15	)),	O
16	a	O
17	cytosolic	B
18	tyrosine	I
19	kinase	I
20	that	O
21	localizes	O
22	in	O
23	focal	O
24	adhesions	O
25	,	O
26	and	O
27	of	O
28	the	O
29	cytoskeleton	B
30	-	I
31	associated	I
32	protein	I
33	paxillin	I
34	.	O

1	Using	O
2	a	O
3	conditional	O
4	-	O
5	lethal	O
6	mutant	O
7	allele	O
8	of	O
9	SUP45	B
10	(	O
11	sup45	B
12	-	I
13	2	I
14	)	O
15	and	O
16	a	O
17	combination	O
18	of	O
19	in	O
20	vivo	O
21	and	O
22	in	O
23	vitro	O
24	approaches	O
25	,	O
26	we	O
27	demonstrate	O
28	that	O
29	the	O
30	product	O
31	of	O
32	the	O
33	SUP45	B
34	gene	I
35	(	O
36	Sup45p	B
37	or	O
38	eRF1	B
39	)	O
40	is	O
41	a	O
42	factor	O
43	required	O
44	for	O
45	translation	O
46	termination	O
47	in	O
48	yeast	O
49	.	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	B
8	-	I
9	3a	I
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	She	O
2	was	O
3	able	O
4	to	O
5	stand	O
6	unaided	O
7	by	O
8	3	O
9	years	O
10	of	O
11	age	O
12	with	O
13	then	O
14	progressive	O
15	worsening	O
16	of	O
17	motor	O
18	abilities	O
19	.	O

1	Organization	O
2	of	O
3	the	O
4	human	B
5	LU	I
6	gene	I
7	and	O
8	molecular	O
9	basis	O
10	of	O
11	the	O
12	Lu	O
13	(	O
14	a	O
15	)/	O
16	Lu	B
17	(	I
18	b	I
19	)	I
20	blood	O
21	group	O
22	polymorphism	O
23	.	O

1	Cytological	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	transgenes	O
7	associate	O
8	with	O
9	a	O
10	nucleolus	O
11	.	O

1	Sequence	O
2	divergence	O
3	is	O
4	observed	O
5	in	O
6	untranslated	O
7	regions	O
8	which	O
9	allows	O
10	the	O
11	definition	O
12	of	O
13	gene	O
14	-	O
15	specific	O
16	probes	O
17	.	O

1	Secretion	O
2	in	O
3	milk	O
4	and	O
5	transplacental	O
6	transfer	O
7	of	O
8	two	O
9	iodized	O
10	oils	O
11	,	O
12	Lipiodol	O
13	UF	O
14	and	O
15	Oriodol	O
16	,	O
17	in	O
18	rabbits	O
19	.	O

1	The	O
2	coding	O
3	region	O
4	of	O
5	mkh1	B
6	is	O
7	contained	O
8	within	O
9	a	O
10	single	O
11	exon	O
12	encoding	O
13	a	O
14	1	O
15	,	O
16	116	O
17	-	O
18	amino	O
19	-	O
20	acid	O
21	protein	O
22	.	O

1	With	O
2	a	O
3	view	O
4	to	O
5	identifying	O
6	other	O
7	important	O
8	U14	B
9	interactions	O
10	,	O
11	a	O
12	stem	O
13	-	O
14	loop	O
15	domain	O
16	required	O
17	for	O
18	activity	O
19	of	O
20	Saccharomyces	B
21	cerevisiae	I
22	U14	I
23	RNAs	I
24	(	O
25	the	O
26	Y	O
27	domain	O
28	)	O
29	was	O
30	first	O
31	subjected	O
32	to	O
33	detailed	O
34	mutational	O
35	analysis	O
36	.	O

1	In	O
2	12	O
3	cases	O
4	(	O
5	3	O
6	.	O
7	1	O
8	%),	O
9	a	O
10	change	O
11	in	O
12	stage	O
13	resulted	O
14	.	O

1	Spatial	O
2	zones	O
3	for	O
4	muscle	O
5	coactivation	O
6	and	O
7	the	O
8	control	O
9	of	O
10	postural	O
11	stability	O
12	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pDHL1	O
5	from	O
6	Debaryomyces	O
7	hansenii	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	pGKL1	B
16	-	I
17	plasmid	I
18	DNA	I
19	polymerase	I
20	.	O

1	The	O
2	RNA	O
3	-	O
4	binding	O
5	and	O
6	RNA	B
7	-	I
8	DNA	I
9	helicase	I
10	activities	O
11	of	O
12	the	O
13	Escherichia	B
14	coli	I
15	transcription	I
16	termination	I
17	factor	I
18	rho	I
19	have	O
20	been	O
21	investigated	O
22	using	O
23	natural	O
24	RNA	O
25	molecules	O
26	that	O
27	are	O
28	255	O
29	and	O
30	391	O
31	nucleotide	O
32	residues	O
33	in	O
34	length	O
35	and	O
36	that	O
37	contain	O
38	the	O
39	trp	B
40	t	I
41	'	I
42	rho	I
43	-	I
44	dependent	I
45	termination	I
46	sequence	I
47	of	O
48	E	O
49	.	O
50	coli	O
51	.	O

1	This	O
2	study	O
3	describes	O
4	a	O
5	new	O
6	MADS	B
7	box	I
8	gene	I
9	,	O
10	nmhC5	B
11	,	O
12	which	O
13	along	O
14	with	O
15	nmh7	B
16	(	O
17	J	O
18	.	O

1	Sternocleidomastoid	O
2	,	O
3	neck	O
4	or	O
5	facial	O
6	muscles	O
7	wasting	O
8	were	O
9	also	O
10	found	O
11	in	O
12	three	O
13	cases	O
14	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	B
13	carboxypeptidases	I
14	.	O

1	However	O
2	,	O
3	we	O
4	could	O
5	not	O
6	find	O
7	the	O
8	homologous	O
9	regions	O
10	with	O
11	guanine	B
12	nucleotide	I
13	exchange	I
14	factors	I
15	or	O
16	GTPase	B
17	-	I
18	activating	I
19	proteins	I
20	in	O
21	the	O
22	c	B
23	-	I
24	cbl	I
25	gene	I
26	.	O

1	However	O
2	,	O
3	using	O
4	ATL	O
5	-	O
6	16T	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	that	O
13	GATA	B
14	-	I
15	4	I
16	is	O
17	the	O
18	only	O
19	GATA	B
20	-	I
21	binding	I
22	protein	I
23	that	O
24	forms	O
25	specific	O
26	DNA	O
27	-	O
28	protein	O
29	complex	O
30	with	O
31	the	O
32	-	O
33	70	O
34	GATA	O
35	site	O
36	.	O

1	Surveillance	O
2	for	O
3	preeclampsia	O
4	was	O
5	conducted	O
6	by	O
7	personnel	O
8	unaware	O
9	of	O
10	treatment	O
11	-	O
12	group	O
13	assignments	O
14	,	O
15	using	O
16	standardized	O
17	measurements	O
18	of	O
19	blood	O
20	pressure	O
21	and	O
22	urinary	O
23	protein	O
24	excretion	O
25	at	O
26	uniformly	O
27	scheduled	O
28	prenatal	O
29	visits	O
30	,	O
31	protocols	O
32	for	O
33	monitoring	O
34	these	O
35	measurements	O
36	during	O
37	the	O
38	hospitalization	O
39	for	O
40	delivery	O
41	,	O
42	and	O
43	reviews	O
44	of	O
45	medical	O
46	records	O
47	of	O
48	unscheduled	O
49	outpatient	O
50	visits	O
51	and	O
52	all	O
53	hospitalizations	O
54	.	O

1	Aryl	B
2	hydrocarbon	I
3	receptor	I
4	nuclear	I
5	translocator	I
6	(	O
7	ARNT	B
8	)	O
9	is	O
10	a	O
11	component	O
12	of	O
13	the	O
14	transcription	O
15	factors	O
16	,	O
17	aryl	B
18	hydrocarbon	I
19	receptor	I
20	(	O
21	AhR	B
22	)	O
23	and	O
24	hypoxia	B
25	-	I
26	inducible	I
27	factor	I
28	1	I
29	,	O
30	which	O
31	transactivate	O
32	their	O
33	target	O
34	genes	O
35	,	O
36	such	O
37	as	O
38	CYP1A1	B
39	and	O
40	erythropoietin	B
41	,	O
42	in	O
43	response	O
44	to	O
45	xenobiotic	O
46	aromatic	O
47	hydrocarbons	O
48	and	O
49	to	O
50	low	O
51	O2	O
52	concentration	O
53	,	O
54	respectively	O
55	.	O

1	We	O
2	also	O
3	provide	O
4	evidence	O
5	that	O
6	gar2	B
7	is	O
8	phosphorylated	O
9	in	O
10	vitro	O
11	by	O
12	a	O
13	p13	B
14	(	O
15	suc1	B
16	)-	O
17	Sepharose	O
18	-	O
19	bound	O
20	kinase	O
21	from	O
22	Schizosaccharomyces	O
23	pombe	O
24	extracts	O
25	that	O
26	displays	O
27	cell	O
28	cycle	O
29	-	O
30	regulated	O
31	activity	O
32	similar	O
33	to	O
34	that	O
35	of	O
36	the	O
37	p34	B
38	(	O
39	cdc2	B
40	(	O
41	kinase	O
42	.	O

1	Here	O
2	,	O
3	we	O
4	correlate	O
5	Dox	O
6	effects	O
7	on	O
8	cell	O
9	cycle	O
10	with	O
11	changes	O
12	of	O
13	E2F	B
14	/	O
15	DP	B
16	complexes	O
17	and	O
18	activity	O
19	in	O
20	differentiating	O
21	C2C12	O
22	myocytes	O
23	.	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	B
13	levels	O
14	in	O
15	humans	O
16	".	O

1	Liver	O
2	regional	O
3	blood	O
4	volume	O
5	(	O
6	LRBV	O
7	)	O
8	is	O
9	altered	O
10	by	O
11	several	O
12	disease	O
13	states	O
14	and	O
15	various	O
16	drugs	O
17	.	O

1	Chloramphenicol	B
2	acetyltransferase	I
3	assays	O
4	examining	O
5	the	O
6	ability	O
7	of	O
8	IE86	B
9	to	O
10	repress	O
11	activity	O
12	from	O
13	the	O
14	HCMV	O
15	major	O
16	IE	B
17	promoter	I
18	or	O
19	activate	O
20	the	O
21	HCMV	B
22	early	I
23	promoter	I
24	for	O
25	the	O
26	2	O
27	.	O
28	2	O
29	-	O
30	kb	O
31	class	O
32	of	O
33	RNAs	O
34	demonstrated	O
35	the	O
36	functional	O
37	integrity	O
38	of	O
39	the	O
40	IE86	B
41	protein	I
42	.	O

1	The	O
2	frequency	O
3	of	O
4	positive	O
5	anti	B
6	-	I
7	GM1	I
8	antibody	I
9	titers	O
10	in	O
11	the	O
12	Guillain	O
13	-	O
14	Barre	O
15	syndrome	O
16	patients	O
17	with	O
18	PEN	O
19	19	O
20	isolates	O
21	was	O
22	higher	O
23	than	O
24	that	O
25	in	O
26	the	O
27	Guillain	O
28	-	O
29	Barre	O
30	syndrome	O
31	and	O
32	Fisher	O
33	'	O
34	s	O
35	syndrome	O
36	patients	O
37	without	O
38	PEN	O
39	19	O
40	isolates	O
41	.	O

1	The	O
2	following	O
3	technique	O
4	describes	O
5	a	O
6	modification	O
7	to	O
8	a	O
9	bar	O
10	superstructure	O
11	that	O
12	provided	O
13	the	O
14	advantages	O
15	of	O
16	convenience	O
17	,	O
18	security	O
19	,	O
20	and	O
21	consistent	O
22	positioning	O
23	even	O
24	though	O
25	one	O
26	implant	O
27	was	O
28	lost	O
29	and	O
30	the	O
31	angulation	O
32	of	O
33	implants	O
34	limited	O
35	accuracy	O
36	.	O

1	We	O
2	have	O
3	separated	O
4	a	O
5	dermatan	O
6	sulfate	O
7	proteoglycan	O
8	,	O
9	epiphycan	O
10	,	O
11	from	O
12	decorin	B
13	and	O
14	biglycan	O
15	by	O
16	using	O
17	dissociative	O
18	extraction	O
19	of	O
20	bovine	O
21	fetal	O
22	epiphyseal	O
23	cartilage	O
24	,	O
25	followed	O
26	by	O
27	sequential	O
28	ion	O
29	-	O
30	exchange	O
31	,	O
32	gel	O
33	permeation	O
34	,	O
35	hydrophobic	O
36	,	O
37	and	O
38	Zn2	O
39	+	O
40	chelate	O
41	chromatographic	O
42	steps	O
43	.	O

1	The	O
2	selective	O
3	5	B
4	-	I
5	HT3	I
6	receptor	I
7	antagonists	O
8	ramosetron	O
9	(	O
10	YM060	O
11	),	O
12	YM114	O
13	(	O
14	KAE	O
15	-	O
16	393	O
17	),	O
18	granisetron	O
19	and	O
20	ondansetron	O
21	,	O
22	and	O
23	the	O
24	substituted	O
25	benzamides	O
26	(	O
27	5	B
28	-	I
29	HT4	I
30	receptor	I
31	agonist	O
32	/	O
33	5	B
34	-	I
35	HT3	I
36	receptor	I
37	antagonists	O
38	)	O
39	cisapride	O
40	mosapride	O
41	and	O
42	SC	O
43	-	O
44	53116	O
45	dose	O
46	-	O
47	dependently	O
48	enhanced	O
49	gastric	O
50	emptying	O
51	in	O
52	normal	O
53	rats	O
54	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	characteristic	O
6	expression	O
7	pattern	O
8	of	O
9	DJ	B
10	protein	I
11	and	O
12	its	O
13	conspicuous	O
14	repeat	O
15	units	O
16	possible	O
17	functional	O
18	roles	O
19	are	O
20	discussed	O
21	.	O

1	Second	O
2	,	O
3	plasmid	O
4	-	O
5	derived	O
6	transgenes	O
7	and	O
8	gene	O
9	targeting	O
10	of	O
11	the	O
12	endogenous	B
13	Hnf3g	I
14	gene	I
15	locus	I
16	were	O
17	used	O
18	to	O
19	demonstrate	O
20	that	O
21	the	O
22	3	O
23	'-	O
24	flanking	O
25	region	O
26	of	O
27	the	O
28	gene	O
29	is	O
30	necessary	O
31	and	O
32	sufficient	O
33	to	O
34	direct	O
35	reporter	O
36	gene	O
37	expression	O
38	in	O
39	liver	O
40	,	O
41	pancreas	O
42	,	O
43	stomach	O
44	and	O
45	small	O
46	intestine	O
47	.	O

1	This	O
2	regulation	O
3	requires	O
4	two	O
5	HMG	B
6	-	I
7	box	I
8	proteins	I
9	:	O
10	the	O
11	ubiquitous	O
12	Ste11	B
13	transcription	I
14	factor	I
15	and	O
16	the	O
17	M	O
18	cell	O
19	-	O
20	controlling	O
21	protein	O
22	Mat1	B
23	-	I
24	Mc	I
25	.	O

1	Upstream	O
2	activating	O
3	sequences	O
4	(	O
5	UASs	O
6	)	O
7	derived	O
8	from	O
9	known	O
10	Ste12p	B
11	-	O
12	dependent	O
13	genes	O
14	have	O
15	previously	O
16	been	O
17	characterized	O
18	to	O
19	require	O
20	either	O
21	multiple	O
22	PREs	O
23	or	O
24	a	O
25	single	O
26	PRE	O
27	coupled	O
28	to	O
29	a	O
30	binding	O
31	site	O
32	for	O
33	a	O
34	second	O
35	protein	O
36	.	O

1	JNK	B
2	is	O
3	additionally	O
4	regulated	O
5	by	O
6	the	O
7	Ras	B
8	-	O
9	related	O
10	G	B
11	proteins	I
12	Rac	I
13	and	O
14	Cdc42	B
15	.	O

1	While	O
2	important	O
3	for	O
4	ligand	O
5	-	O
6	dependent	O
7	transactivation	O
8	,	O
9	this	O
10	interaction	O
11	surface	O
12	is	O
13	not	O
14	directly	O
15	involved	O
16	in	O
17	transrepression	O
18	of	O
19	AP	B
20	-	I
21	1	I
22	activity	O
23	.	O

1	A	O
2	2	O
3	years	O
4	and	O
5	9	O
6	months	O
7	old	O
8	female	O
9	patient	O
10	,	O
11	with	O
12	the	O
13	diagnosis	O
14	of	O
15	Weaver	O
16	syndrome	O
17	is	O
18	reported	O
19	.	O

1	Confirming	O
2	measures	O
3	made	O
4	by	O
5	nurses	O
6	and	O
7	additionally	O
8	,	O
9	ABPM	O
10	for	O
11	women	O
12	,	O
13	seem	O
14	to	O
15	lessen	O
16	this	O
17	effect	O
18	.	O

1	Sustained	O
2	activation	O
3	of	O
4	p21	B
5	expression	O
6	is	O
7	proposed	O
8	to	O
9	be	O
10	a	O
11	distinguishing	O
12	feature	O
13	of	O
14	the	O
15	activity	O
16	of	O
17	NGF	B
18	that	O
19	contributes	O
20	to	O
21	PC12	O
22	growth	O
23	arrest	O
24	during	O
25	differentiation	O

1	The	O
2	remaining	O
3	80	O
4	patients	O
5	underwent	O
6	recordings	O
7	of	O
8	ECG	O
9	,	O
10	beat	O
11	-	O
12	to	O
13	-	O
14	beat	O
15	arterial	O
16	oxygen	O
17	saturation	O
18	(	O
19	SaO2	O
20	),	O
21	and	O
22	respiration	O
23	during	O
24	both	O
25	spontaneous	O
26	and	O
27	controlled	O
28	breathing	O
29	.	O

1	In	O
2	all	O
3	experimental	O
4	eyes	O
5	,	O
6	there	O
7	was	O
8	a	O
9	marked	O
10	reduction	O
11	,	O
12	but	O
13	never	O
14	a	O
15	complete	O
16	absence	O
17	of	O
18	adrenergic	O
19	nerves	O
20	in	O
21	the	O
22	iris	O
23	.	O

1	It	O
2	is	O
3	present	O
4	in	O
5	the	O
6	nucleus	O
7	of	O
8	the	O
9	cells	O
10	in	O
11	which	O
12	it	O
13	is	O
14	expressed	O
15	and	O
16	can	O
17	phosphorylate	O
18	and	O
19	activate	O
20	the	O
21	cyclic	B
22	AMP	I
23	response	I
24	element	I
25	binding	I
26	proteins	I
27	CREB	I
28	and	O
29	CREM	B
30	tau	I
31	in	O
32	a	O
33	manner	O
34	analogous	O
35	to	O
36	protein	B
37	kinase	I
38	A	I
39	.	O

1	Both	O
2	of	O
3	these	O
4	dogs	O
5	had	O
6	low	O
7	serum	O
8	IgG	B
9	(	O
10	3	O
11	.	O
12	5	O
13	to	O
14	7	O
15	.	O
16	2	O
17	mg	O
18	/	O
19	ml	O
20	)	O
21	and	O
22	the	O
23	second	O
24	littermate	O
25	also	O
26	had	O
27	reduced	O
28	serum	O
29	IgA	B
30	(<	O
31	0	O
32	.	O
33	1	O
34	to	O
35	0	O
36	.	O
37	15	O
38	mg	O
39	/	O
40	ml	O
41	).	O

1	The	O
2	Ogg1	B
3	protein	I
4	efficiently	O
5	cleaves	O
6	a	O
7	DNA	O
8	duplex	O
9	where	O
10	a	O
11	preformed	O
12	AP	B
13	site	I
14	is	O
15	placed	O
16	opposite	O
17	a	O
18	cytosine	O
19	(	O
20	AP	O
21	/	O
22	C	O
23	).	O

1	METHODS	O
2	:	O
3	Four	O
4	hundred	O
5	fifty	O
6	patients	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	squamous	O
12	cell	O
13	carcinoma	O
14	of	O
15	the	O
16	oral	O
17	cavity	O
18	received	O
19	their	O
20	primary	O
21	treatment	O
22	at	O
23	Roswell	O
24	Park	O
25	Cancer	O
26	Center	O
27	(	O
28	RPCI	O
29	)	O
30	from	O
31	1971	O
32	to	O
33	1991	O
34	.	O

1	Cell	O
2	49	O
3	,	O
4	753	O
5	-	O
6	761	O
7	].	O

1	Patients	O
2	received	O
3	either	O
4	diltiazem	O
5	CD	O
6	180	O
7	mg	O
8	or	O
9	placebo	O
10	once	O
11	/	O
12	day	O
13	in	O
14	combination	O
15	with	O
16	existing	O
17	antianginal	O
18	therapy	O
19	.	O

1	They	O
2	also	O
3	interact	O
4	with	O
5	GTPase	B
6	activating	I
7	proteins	I
8	encoded	O
9	by	O
10	IRA1	B
11	and	O
12	IRA2	B
13	.	O

1	Furthermore	O
2	,	O
3	the	O
4	PH	B
5	and	O
6	PTB	O
7	domains	O
8	are	O
9	highly	O
10	homologous	O
11	(	O
12	at	O
13	least	O
14	40	O
15	%	O
16	identical	O
17	)	O
18	to	O
19	those	O
20	found	O
21	in	O
22	insulin	B
23	receptor	I
24	substrates	I
25	1	I
26	,	I
27	2	I
28	,	I
29	and	I
30	3	I
31	(	O
32	IRS	B
33	-	I
34	1	I
35	,	O
36	IRS	B
37	-	I
38	2	I
39	,	O
40	and	O
41	IRS	B
42	-	I
43	3	I
44	).	O

1	As	O
2	demonstrated	O
3	by	O
4	gel	O
5	mobility	O
6	shift	O
7	analysis	O
8	and	O
9	supershift	O
10	experiments	O
11	,	O
12	FIRE1	B
13	,	O
14	located	O
15	between	O
16	-	O
17	516	O
18	and	O
19	-	O
20	498	O
21	,	O
22	is	O
23	responsible	O
24	for	O
25	binding	O
26	NF	B
27	-	I
28	Y	I
29	.	O

1	Eight	O
2	induced	O
3	cDNA	O
4	sequences	O
5	were	O
6	identified	O
7	and	O
8	designated	O
9	message	B
10	up	I
11	-	I
12	regulated	I
13	during	I
14	death	I
15	(	I
16	mud	I
17	)-	I
18	1	I
19	-	I
20	8	I
21	.	O

1	DNase	B
2	I	I
3	and	O
4	1	O
5	,	O
6	10	O
7	-	O
8	phenanthroline	O
9	-	O
10	copper	O
11	footprinting	O
12	of	O
13	MURA	B
14	-	O
15	Mu1	B
16	TIR	O
17	complexes	O
18	indicate	O
19	that	O
20	MURA	B
21	binds	O
22	to	O
23	a	O
24	conserved	O
25	approximately	O
26	32	O
27	-	O
28	bp	O
29	region	O
30	in	O
31	the	O
32	TIR	O
33	of	O
34	Mu1	B
35	.	O

1	Various	O
2	assays	O
3	demonstrate	O
4	promoter	O
5	activity	O
6	in	O
7	this	O
8	sequence	O
9	that	O
10	reproduces	O
11	the	O
12	normal	O
13	control	O
14	of	O
15	E2F2	B
16	expression	O
17	during	O
18	a	O
19	growth	O
20	stimulation	O
21	.	O

1	The	O
2	MCAD	B
3	nuclear	I
4	receptor	I
5	response	I
6	element	I
7	1	I
8	(	O
9	NRRE	B
10	-	I
11	1	I
12	)	O
13	interacts	O
14	in	O
15	vitro	O
16	with	O
17	ERR	B
18	alpha	I
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	7	O
24	cells	O
25	.	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	The	O
2	pattern	O
3	and	O
4	timing	O
5	of	O
6	CARP	B
7	mRNA	I
8	expression	O
9	,	O
10	including	O
11	transient	O
12	expression	O
13	in	O
14	the	O
15	tongue	O
16	at	O
17	14	O
18	.	O
19	5	O
20	days	O
21	p	O
22	.	O
23	c	O
24	.,	O
25	coincides	O
26	with	O
27	that	O
28	of	O
29	Nkx2	B
30	.	I
31	5	I
32	/	O
33	Csx	B
34	(	O
35	a	O
36	putative	O
37	homolog	O
38	of	O
39	tinman	B
40	,	O
41	the	O
42	Drosophila	O
43	melanogaster	O
44	gene	O
45	responsible	O
46	for	O
47	cardiac	O
48	development	O
49	).	O

1	Examination	O
2	of	O
3	the	O
4	MMP	B
5	-	I
6	2	I
7	RE1	I
8	sequence	I
9	revealed	O
10	an	O
11	incomplete	O
12	Y	O
13	-	O
14	box	O
15	sequence	O
16	(	O
17	CTGCTGGGCAAG	O
18	),	O
19	which	O
20	specifically	O
21	interacted	O
22	with	O
23	recombinant	B
24	YB	I
25	-	I
26	1	I
27	on	O
28	DMS	O
29	protection	O
30	footprinting	O
31	analysis	O
32	.	O

1	Hence	O
2	,	O
3	scs32	B
4	only	O
5	partially	O
6	suppressed	O
7	the	O
8	ts	O
9	phenotype	O
10	and	O
11	was	O
12	unable	O
13	to	O
14	suppress	O
15	the	O
16	Ino	O
17	-	O
18	phenotype	O
19	of	O
20	rpo26	B
21	-	I
22	31	I
23	.	O

1	4	O
2	.	O

1	Area	O
2	under	O
3	the	O
4	drug	O
5	concentration	O
6	-	O
7	time	O
8	curves	O
9	(	O
10	AUC0	O
11	-	O
12	24	O
13	hr	O
14	)	O
15	for	O
16	MTX	O
17	were	O
18	2379	O
19	and	O
20	3534	O
21	ng	O
22	*	O
23	hr	O
24	/	O
25	ml	O
26	from	O
27	PG	O
28	-	O
29	2	O
30	.	O
31	5	O
32	%	O
33	Azone	O
34	and	O
35	PG	O
36	-	O
37	7	O
38	.	O
39	5	O
40	%	O
41	Azone	O
42	systems	O
43	respectively	O
44	.	O

1	To	O
2	address	O
3	mechanisms	O
4	that	O
5	define	O
6	interactions	O
7	of	O
8	Site	B
9	II	I
10	regulatory	I
11	factors	I
12	with	O
13	this	O
14	cell	O
15	cycle	O
16	control	O
17	element	O
18	,	O
19	we	O
20	have	O
21	investigated	O
22	these	O
23	determinants	O
24	of	O
25	transcriptional	O
26	regulation	O
27	at	O
28	the	O
29	G1	O
30	/	O
31	S	O
32	phase	O
33	transition	O
34	in	O
35	FDC	O
36	-	O
37	P1	O
38	hematopoietic	O
39	progenitor	O
40	cells	O
41	.	O

1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	ArgR	B
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O

1	Among	O
2	38	O
3	patients	O
4	with	O
5	inducible	O
6	reentrant	O
7	VTs	O
8	who	O
9	underwent	O
10	electrophysiologic	O
11	study	O
12	(	O
13	EPS	O
14	),	O
15	10	O
16	VTs	O
17	of	O
18	six	O
19	patients	O
20	were	O
21	selected	O
22	.	O

1	Transient	O
2	hyperammonaemia	O
3	in	O
4	an	O
5	adult	O
6	German	O
7	shepherd	O
8	dog	O
9	.	O

1	Proteasomes	O
2	are	O
3	the	O
4	multisubunit	O
5	protease	O
6	involved	O
7	in	O
8	the	O
9	generation	O
10	of	O
11	peptides	O
12	presented	O
13	by	O
14	MHC	B
15	class	I
16	I	I
17	molecules	I
18	.	O

1	For	O
2	sputum	B
3	interleukin	I
4	-	I
5	8	I
6	there	O
7	was	O
8	an	O
9	estimated	O
10	true	O
11	treatment	O
12	median	O
13	difference	O
14	of	O
15	142	O
16	pg	O
17	/	O
18	ml	O
19	(	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	(	O
25	CI	O
26	)	O
27	8	O
28	to	O
29	2866	O
30	pg	O
31	/	O
32	ml	O
33	)	O
34	in	O
35	favour	O
36	of	O
37	placebo	O
38	;	O
39	while	O
40	for	O
41	maximal	O
42	expiratory	O
43	flow	O
44	at	O
45	25	O
46	%	O
47	(	O
48	MEF25	O
49	%)	O
50	remaining	O
51	forced	O
52	vital	O
53	capacity	O
54	predicted	O
55	for	O
56	sex	O
57	and	O
58	height	O
59	there	O
60	was	O
61	a	O
62	15	O
63	percentage	O
64	points	O
65	(	O
66	pp	O
67	)	O
68	(	O
69	95	O
70	%	O
71	CI	O
72	4	O
73	to	O
74	26	O
75	pp	O
76	)	O
77	mean	O
78	treatment	O
79	difference	O
80	in	O
81	favour	O
82	of	O
83	placebo	O
84	.	O

1	Overexpression	O
2	of	O
3	BAG	B
4	-	I
5	1	I
6	also	O
7	protected	O
8	certain	O
9	cell	O
10	lines	O
11	from	O
12	heat	O
13	shock	O
14	-	O
15	induced	O
16	cell	O
17	death	O
18	.	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	contains	O
7	potential	O
8	binding	O
9	sites	O
10	for	O
11	TATA	B
12	-	I
13	binding	I
14	protein	I
15	,	O
16	Sp1	B
17	,	O
18	nuclear	B
19	factor	I
20	1	I
21	(	O
22	NF1	B
23	),	O
24	CAAT	B
25	-	I
26	box	I
27	binding	I
28	protein	I
29	(	O
30	C	B
31	/	I
32	EBP	I
33	),	O
34	hepatocyte	B
35	nuclear	I
36	factors	I
37	1	I
38	and	I
39	5	I
40	(	O
41	HNF1	B
42	,	O
43	HNF5	B
44	)	O
45	and	O
46	activator	B
47	proteins	I
48	1	I
49	and	I
50	2	I
51	(	O
52	AP1	B
53	,	O
54	AP2	B
55	).	O

1	Evidence	O
2	for	O
3	such	O
4	peak	O
5	shifts	O
6	has	O
7	been	O
8	found	O
9	in	O
10	the	O
11	responses	O
12	of	O
13	auditory	O
14	nerve	O
15	fibers	O
16	,	O
17	cochlear	O
18	microphonics	O
19	,	O
20	and	O
21	the	O
22	responses	O
23	of	O
24	outer	O
25	hair	O
26	cells	O
27	and	O
28	supporting	O
29	cells	O
30	in	O
31	the	O
32	cochlea	O
33	,	O
34	as	O
35	well	O
36	as	O
37	in	O
38	basilar	O
39	membrane	O
40	vibration	O
41	measurements	O
42	,	O
43	and	O
44	indirectly	O
45	,	O
46	in	O
47	psychophysical	O
48	data	O
49	.	O

1	Mnt	B
2	:	O
3	Max	B
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	O
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	In	O
2	the	O
3	United	O
4	States	O
5	high	O
6	-	O
7	MW	O
8	HES	O
9	480	O
10	which	O
11	is	O
12	difficult	O
13	to	O
14	degrade	O
15	is	O
16	most	O
17	frequently	O
18	used	O
19	and	O
20	results	O
21	in	O
22	a	O
23	larger	O
24	in	O
25	vivo	O
26	MW	O
27	and	O
28	subsequent	O
29	decrease	O
30	in	O
31	factor	B
32	VIII	I
33	/	O
34	von	B
35	Willebrand	I
36	factor	I
37	levels	O
38	.	O

1	The	O
2	distributed	O
3	current	O
4	density	O
5	J	O
6	is	O
7	calculated	O
8	within	O
9	the	O
10	volume	O
11	defined	O
12	by	O
13	the	O
14	motor	O
15	unit	O
16	.	O

1	Involvement	O
2	of	O
3	AP	B
4	-	I
5	2	I
6	in	O
7	regulation	O
8	of	O
9	the	O
10	R	B
11	-	I
12	FABP	I
13	gene	I
14	in	O
15	the	O
16	developing	O
17	chick	O
18	retina	O
19	.	O

1	However	O
2	,	O
3	Cbf5p	B
4	was	O
5	found	O
6	to	O
7	be	O
8	nucleolar	O
9	and	O
10	is	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	rat	B
16	nucleolar	I
17	protein	I
18	NAP57	I
19	,	O
20	which	O
21	coimmunoprecipitates	O
22	with	O
23	Nopp140	B
24	and	O
25	which	O
26	is	O
27	postulated	O
28	to	O
29	be	O
30	involved	O
31	in	O
32	nucleolar	O
33	-	O
34	cytoplasmic	O
35	shuttling	O
36	(	O
37	U	O
38	.	O

1	Ig	B
2	heavy	I
3	chain	I
4	class	O
5	switching	O
6	is	O
7	directed	O
8	by	O
9	cytokines	O
10	inducing	O
11	transcription	O
12	from	O
13	unrearranged	O
14	CH	B
15	genes	I
16	.	O

1	We	O
2	found	O
3	that	O
4	multiple	O
5	tumor	O
6	suppressor	O
7	genes	O
8	(	O
9	e	O
10	.	O
11	g	O
12	.,	O
13	p53	B
14	,	O
15	DCC	B
16	,	O
17	APC	B
18	,	O
19	MCC	B
20	,	O
21	BRCA1	B
22	,	O
23	and	O
24	WAF1	B
25	/	O
26	CIP1	B
27	)	O
28	were	O
29	inactivated	O
30	at	O
31	different	O
32	frequencies	O
33	via	O
34	various	O
35	mechanisms	O
36	[	O
37	e	O
38	.	O
39	g	O
40	.,	O
41	loss	O
42	of	O
43	heterozygosity	O
44	(	O
45	LOH	O
46	),	O
47	loss	O
48	of	O
49	expression	O
50	(	O
51	LOE	O
52	),	O
53	mutation	O
54	,	O
55	and	O
56	inactivation	O
57	by	O
58	cellular	O
59	binding	O
60	protein	O
61	].	O

1	Because	O
2	the	O
3	deletion	O
4	included	O
5	the	O
6	TK	B
7	gene	I
8	,	O
9	selection	O
10	with	O
11	gancyclovir	O
12	against	O
13	cells	O
14	not	O
15	having	O
16	undergone	O
17	recombination	O
18	was	O
19	possible	O
20	.	O

1	The	O
2	sequenced	O
3	cDNA	O
4	predicts	O
5	a	O
6	704	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	80	O
12	%	O
13	identical	O
14	to	O
15	human	B
16	progelatinase	I
17	B	I
18	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	this	O
5	region	O
6	revealed	O
7	three	O
8	eight	O
9	-	O
10	bp	O
11	repetitive	O
12	elements	O
13	,	O
14	the	O
15	deletion	O
16	of	O
17	which	O
18	restored	O
19	wild	O
20	-	O
21	type	O
22	levels	O
23	of	O
24	luciferase	B
25	activity	O
26	to	O
27	the	O
28	-	O
29	916	O
30	-	O
31	bp	O
32	reporter	O
33	plasmid	O
34	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	study	O
6	in	O
7	which	O
8	mutation	O
9	screening	O
10	has	O
11	been	O
12	performed	O
13	for	O
14	both	O
15	the	O
16	EXT1	B
17	and	O
18	EXT2	B
19	genes	I
20	prior	O
21	to	O
22	any	O
23	linkage	O
24	analysis	O
25	.	O

1	The	O
2	growth	O
3	-	O
4	promoting	O
5	properties	O
6	of	O
7	the	O
8	retroviral	B
9	v	I
10	-	I
11	erbA	I
12	oncogene	I
13	,	O
14	a	O
15	highly	O
16	mutated	O
17	version	O
18	of	O
19	the	O
20	chicken	B
21	thyroid	I
22	hormone	I
23	receptor	I
24	(	I
25	TR	I
26	)	I
27	alpha	I
28	,	O
29	have	O
30	so	O
31	far	O
32	exclusively	O
33	been	O
34	linked	O
35	to	O
36	dominant	O
37	repression	O
38	of	O
39	the	O
40	antimitogenic	O
41	roles	O
42	of	O
43	TR	B
44	and	O
45	retinoic	B
46	acid	I
47	receptors	I
48	.	O

1	Null	O
2	mutations	O
3	in	O
4	daf	B
5	-	I
6	3	I
7	suppress	O
8	mutations	O
9	in	O
10	genes	O
11	encoding	O
12	this	O
13	TGF	B
14	-	I
15	beta	I
16	signal	O
17	,	O
18	its	O
19	receptors	O
20	,	O
21	and	O
22	associated	O
23	Smad	B
24	signal	I
25	transduction	I
26	proteins	I
27	.	O
28	daf	B
29	-	I
30	3	I
31	encodes	O
32	a	O
33	Smad	B
34	protein	I
35	that	O
36	is	O
37	most	O
38	closely	O
39	related	O
40	to	O
41	mammalian	B
42	DPC4	I
43	,	O
44	and	O
45	is	O
46	expressed	O
47	throughout	O
48	development	O
49	in	O
50	many	O
51	of	O
52	the	O
53	tissues	O
54	that	O
55	are	O
56	remodeled	O
57	during	O
58	dauer	O
59	development	O
60	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	B
9	EGF	I
10	receptor	I
11	DER	I
12	/	O
13	Egfr	B
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	B
25	.	O

1	We	O
2	have	O
3	measured	O
4	the	O
5	kinetics	O
6	of	O
7	the	O
8	recovery	O
9	of	O
10	mRNA	O
11	synthesis	O
12	in	O
13	the	O
14	inducible	O
15	GAL10	B
16	and	O
17	RNR3	B
18	genes	I
19	after	O
20	exposure	O
21	of	O
22	yeast	O
23	cells	O
24	to	O
25	ultraviolet	O
26	(	O
27	UV	O
28	)	O
29	radiation	O
30	.	O

1	The	O
2	medium	O
3	chains	O
4	of	O
5	these	O
6	complexes	O
7	,	O
8	mu1	B
9	and	O
10	mu2	B
11	,	O
12	have	O
13	been	O
14	implicated	O
15	in	O
16	two	O
17	types	O
18	of	O
19	interaction	O
20	:	O
21	assembly	O
22	with	O
23	the	O
24	beta1	B
25	and	I
26	beta2	I
27	chains	I
28	of	O
29	the	O
30	corresponding	O
31	complexes	O
32	and	O
33	recognition	O
34	of	O
35	tyrosine	O
36	-	O
37	based	O
38	sorting	O
39	signals	O
40	.	O

1	Osmotic	O
2	shock	O
3	stimulates	O
4	GLUT4	B
5	translocation	O
6	in	O
7	3T3L1	O
8	adipocytes	O
9	by	O
10	a	O
11	novel	O
12	tyrosine	B
13	kinase	I
14	pathway	O
15	.	O

1	Furthermore	O
2	,	O
3	deletion	O
4	and	O
5	mutation	O
6	analyses	O
7	of	O
8	the	O
9	VCAM	B
10	-	I
11	1	I
12	promoter	I
13	performed	O
14	with	O
15	chloramphenicol	B
16	acetyltransferase	I
17	constructs	I
18	revealed	O
19	that	O
20	Tax	B
21	was	O
22	trans	O
23	activating	O
24	the	O
25	VCAM	B
26	-	I
27	1	I
28	promoter	I
29	via	O
30	two	O
31	NF	B
32	-	I
33	kappaB	I
34	sites	I
35	present	O
36	at	O
37	bp	O
38	-	O
39	72	O
40	and	O
41	-	O
42	57	O
43	in	O
44	the	O
45	VCAM	B
46	-	I
47	1	I
48	gene	I
49	promoter	I
50	,	O
51	with	O
52	both	O
53	of	O
54	them	O
55	being	O
56	required	O
57	for	O
58	the	O
59	Tax	B
60	-	O
61	induced	O
62	expression	O
63	of	O
64	this	O
65	adhesion	O
66	molecule	O
67	.	O

1	Likewise	O
2	,	O
3	rad6	B
4	-	I
5	delta	I
6	reduces	O
7	silencing	O
8	of	O
9	the	O
10	telomere	B
11	-	I
12	located	I
13	RNAP	I
14	II	I
15	-	I
16	transcribed	I
17	genes	I
18	URA3	I
19	and	O
20	ADE2	B
21	.	O

1	The	O
2	amplitude	O
3	of	O
4	detrusor	O
5	contractions	O
6	at	O
7	6	O
8	,	O
9	12	O
10	,	O
11	and	O
12	24	O
13	hours	O
14	showed	O
15	no	O
16	significant	O
17	difference	O
18	from	O
19	that	O
20	in	O
21	the	O
22	controls	O
23	.	O

1	Thus	O
2	,	O
3	ZNF74	B
4	sublocalization	O
5	in	O
6	nuclear	O
7	domains	O
8	enriched	O
9	in	O
10	pre	O
11	-	O
12	mRNA	O
13	maturating	O
14	factors	O
15	,	O
16	its	O
17	RNA	O
18	binding	O
19	activity	O
20	,	O
21	and	O
22	its	O
23	direct	O
24	phosphodependent	O
25	interaction	O
26	with	O
27	the	O
28	pol	B
29	IIo	I
30	,	O
31	a	O
32	form	O
33	of	O
34	the	O
35	RNA	B
36	polymerase	I
37	functionally	O
38	associated	O
39	with	O
40	pre	O
41	-	O
42	mRNA	O
43	processing	O
44	,	O
45	suggest	O
46	a	O
47	role	O
48	for	O
49	this	O
50	member	O
51	of	O
52	the	O
53	KRAB	B
54	multifinger	I
55	protein	I
56	family	I
57	in	O
58	RNA	O
59	processing	O
60	.	O

1	The	O
2	cellular	O
3	rate	O
4	of	O
5	anticoagulant	B
6	heparan	I
7	sulfate	I
8	proteoglycan	I
9	(	O
10	HSPGact	B
11	)	O
12	generation	O
13	is	O
14	determined	O
15	by	O
16	the	O
17	level	O
18	of	O
19	a	O
20	kinetically	O
21	limiting	O
22	microsomal	O
23	activity	O
24	,	O
25	HSact	O
26	conversion	O
27	activity	O
28	,	O
29	which	O
30	is	O
31	predominantly	O
32	composed	O
33	of	O
34	the	O
35	long	O
36	sought	O
37	heparan	B
38	sulfate	I
39	D	I
40	-	I
41	glucosaminyl	I
42	3	I
43	-	I
44	O	I
45	-	I
46	sulfotransferase	I
47	(	O
48	3	B
49	-	I
50	OST	I
51	)	O
52	(	O
53	Shworak	O
54	,	O
55	N	O
56	.	O

1	It	O
2	thus	O
3	appears	O
4	that	O
5	MAPK	B
6	functions	O
7	in	O
8	meiotic	O
9	maturation	O
10	by	O
11	preventing	O
12	unfertilized	O
13	eggs	O
14	from	O
15	proceeding	O
16	into	O
17	parthenogenetic	O
18	development	O
19	.	O

1	(	O
2	ii	O
3	)	O
4	An	O
5	AF	O
6	G	B
7	-	I
8	CSF	I
9	level	O
10	>	O
11	2000	O
12	pg	O
13	/	O
14	ml	O
15	is	O
16	a	O
17	strong	O
18	positive	O
19	predictor	O
20	of	O
21	CAM	O
22	.	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	O
29	-	O
30	Starry	O
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	20	O
2	%	O
3	of	O
4	total	O
5	HSL	B
6	transcripts	I
7	in	O
8	human	O
9	subcutaneous	O
10	adipocytes	O
11	.	O

1	These	O
2	residues	O
3	,	O
4	Ile244	O
5	at	O
6	the	O
7	extracellular	O
8	end	O
9	of	O
10	transmembrane	O
11	helix	O
12	3	O
13	,	O
14	and	O
15	Tyr318	O
16	at	O
17	the	O
18	COOH	O
19	-	O
20	terminal	O
21	portion	O
22	of	O
23	extracellular	O
24	loop	O
25	2	O
26	,	O
27	are	O
28	replaced	O
29	by	O
30	Leu	O
31	and	O
32	Ile	O
33	in	O
34	the	O
35	PTH	B
36	-	I
37	1	I
38	receptor	I
39	,	O
40	respectively	O
41	.	O

1	We	O
2	have	O
3	now	O
4	shown	O
5	that	O
6	in	O
7	vivo	O
8	phosphorylation	O
9	of	O
10	14	B
11	-	I
12	3	I
13	-	I
14	3	I
15	zeta	I
16	at	O
17	the	O
18	CKIalpha	B
19	site	I
20	(	I
21	Thr	I
22	-	I
23	233	I
24	)	I
25	negatively	O
26	regulates	O
27	its	O
28	binding	O
29	to	O
30	c	B
31	-	I
32	Raf	I
33	,	O
34	and	O
35	may	O
36	be	O
37	important	O
38	in	O
39	Raf	B
40	-	O
41	mediated	O
42	signal	O
43	transduction	O
44	.	O

1	Re	O
2	:	O
3	"	O
4	Assessing	O
5	the	O
6	direction	O
7	of	O
8	causality	O
9	in	O
10	cross	O
11	-	O
12	sectional	O
13	studies	O
14	".	O

1	Transfection	O
2	analyses	O
3	indicated	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Tbxas1	B
9	is	O
10	controlled	O
11	by	O
12	a	O
13	short	O
14	(	O
15	70	O
16	-	O
17	bp	O
18	)	O
19	positive	O
20	regulatory	O
21	sequence	O
22	and	O
23	several	O
24	upstream	O
25	repressive	O
26	elements	O
27	.	O

1	Thus	O
2	,	O
3	unlike	O
4	other	O
5	proteins	O
6	reported	O
7	to	O
8	inhibit	O
9	SRF	B
10	activity	O
11	,	O
12	the	O
13	repressor	O
14	activity	O
15	associated	O
16	with	O
17	the	O
18	GC	O
19	-	O
20	rich	O
21	element	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	function	O
27	through	O
28	direct	O
29	inhibition	O
30	of	O
31	SRF	B
32	binding	O
33	.	O

1	The	O
2	mHIF	B
3	-	I
4	1	I
5	alpha	I
6	structural	I
7	gene	I
8	is	O
9	composed	O
10	of	O
11	15	O
12	exons	O
13	.	O

1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	O
9	-	O
10	responsive	O
11	gene	O
12	,	O
13	rd22	B
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O

1	Unlike	O
2	most	O
3	other	O
4	members	O
5	of	O
6	the	O
7	Bcl	B
8	-	I
9	2	I
10	family	I
11	,	O
12	BAD	B
13	(	O
14	Bcl	B
15	-	I
16	xL	I
17	/	I
18	Bcl	I
19	-	I
20	2	I
21	associated	I
22	death	I
23	promoter	I
24	),	O
25	a	O
26	death	B
27	enhancer	I
28	,	O
29	has	O
30	no	O
31	C	O
32	-	O
33	terminal	O
34	transmembrane	O
35	domain	O
36	for	O
37	targeting	O
38	to	O
39	the	O
40	outer	O
41	mitochondrial	O
42	membrane	O
43	and	O
44	nuclear	O
45	envelope	O
46	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	a	O
7	region	O
8	encoding	O
9	a	O
10	lipase	B
11	operon	I
12	and	O
13	a	O
14	putative	O
15	,	O
16	previously	O
17	uncharacterized	O
18	metalloprotease	B
19	of	I
20	Vibrio	I
21	cholerae	I
22	O1	I
23	.	O

1	We	O
2	previously	O
3	described	O
4	two	O
5	alanine	O
6	cluster	O
7	mutations	O
8	,	O
9	R77	O
10	to	O
11	A	O
12	(	O
13	R77A	O
14	)-	O
15	K79A	O
16	and	O
17	E192A	O
18	-	O
19	E194A	O
20	,	O
21	which	O
22	selectively	O
23	inactivated	O
24	the	O
25	triphosphatase	O
26	component	O
27	.	O

1	The	O
2	proposed	O
3	mechanism	O
4	of	O
5	effect	O
6	states	O
7	that	O
8	mono	O
9	(	O
10	2	O
11	-	O
12	ethylhexyl	O
13	)	O
14	phthalate	O
15	(	O
16	MEHP	O
17	),	O
18	the	O
19	primary	O
20	hydrolysis	O
21	product	O
22	of	O
23	DEHP	O
24	,	O
25	mimics	O
26	the	O
27	inducing	O
28	prostaglandins	O
29	(	O
30	PG	O
31	)	O
32	PGD	O
33	(	O
34	2	O
35	),	O
36	9alpha	O
37	,	O
38	11betaPGF2	O
39	,	O
40	and	O
41	PGF2alpha	O
42	,	O
43	and	O
44	thromboxanes	O
45	in	O
46	the	O
47	lungs	O
48	,	O
49	thereby	O
50	increasing	O
51	the	O
52	risk	O
53	of	O
54	inducing	O
55	inflammation	O
56	in	O
57	the	O
58	airways	O
59	,	O
60	which	O
61	is	O
62	a	O
63	characteristic	O
64	of	O
65	asthma	O
66	.	O

1	Glutathione	B
2	S	I
3	-	I
4	transferase	I
5	(	O
6	GST	B
7	)-	O
8	E2F	B
9	and	O
10	GST	B
11	-	O
12	DP	B
13	fusion	O
14	proteins	O
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	B
25	sites	I
26	in	O
27	the	O
28	DNA	B
29	polymerase	I
30	alpha	I
31	gene	I
32	promoter	I
33	in	O
34	vitro	O
35	.	O

1	Furthermore	O
2	,	O
3	DNA	O
4	-	O
5	bound	O
6	LAZ3	B
7	/	O
8	BCL6	B
9	recruits	O
10	SMRT	B
11	in	O
12	vivo	O
13	,	O
14	and	O
15	both	O
16	overexpressed	O
17	proteins	O
18	completely	O
19	colocalize	O
20	in	O
21	nuclear	O
22	dots	O
23	.	O

1	Ask	O
2	AONE	O
3	'	O
4	s	O
5	experts	O
6	...	O
7	about	O
8	productivity	O
9	indicators	O
10	.	O

1	The	O
2	amplitudes	O
3	of	O
4	DPOAE	O
5	also	O
6	recovered	O
7	to	O
8	a	O
9	greater	O
10	extent	O
11	and	O
12	outer	O
13	hair	O
14	cell	O
15	losses	O
16	were	O
17	less	O
18	severe	O
19	in	O
20	the	O
21	R	O
22	-	O
23	PIA	O
24	-	O
25	treated	O
26	ears	O
27	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	B
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	B
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	B
35	were	O
36	constructed	O
37	.	O

1	Western	O
2	blot	O
3	analysis	O
4	of	O
5	various	O
6	bovine	O
7	tissues	O
8	with	O
9	human	O
10	NMT	B
11	peptide	I
12	antibody	I
13	indicated	O
14	a	O
15	common	O
16	prominent	O
17	immunoreactive	O
18	band	O
19	with	O
20	an	O
21	apparent	O
22	molecular	O
23	mass	O
24	of	O
25	48	O
26	.	O
27	5	O
28	-	O
29	50	O
30	kDa	O
31	in	O
32	all	O
33	tissues	O
34	.	O

1	Transcription	O
2	start	O
3	sites	O
4	of	O
5	the	O
6	plastid	O
7	ACCase	B
8	genes	I
9	were	O
10	estimated	O
11	from	O
12	the	O
13	longest	O
14	cDNA	O
15	clones	O
16	obtained	O
17	by	O
18	5	O
19	'-	O
20	RACE	O
21	(	O
22	rapid	O
23	amplification	O
24	of	O
25	cDNA	O
26	ends	O
27	).	O

1	Thus	O
2	,	O
3	Fis	B
4	acts	O
5	as	O
6	an	O
7	accessory	O
8	transcriptional	O
9	activator	O
10	at	O
11	the	O
12	mar	B
13	promoter	I
14	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	O
13	tRNA	O
14	can	O
15	confer	O
16	a	O
17	mutator	O
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	B
29	and	O
30	mutC	B
31	cells	O
32	.	O

1	CKbeta4GT	B
2	-	I
3	II	I
4	is	O
5	predicted	O
6	to	O
7	encode	O
8	a	O
9	type	B
10	II	I
11	transmembrane	I
12	glycoprotein	I
13	of	O
14	43	O
15	kDa	O
16	with	O
17	five	O
18	potential	O
19	N	O
20	-	O
21	linked	O
22	glycosylation	O
23	sites	O
24	.	O

1	Thus	O
2	,	O
3	the	O
4	absence	O
5	of	O
6	residual	O
7	infarct	O
8	-	O
9	zone	O
10	viability	O
11	discriminates	O
12	patients	O
13	who	O
14	develop	O
15	progressive	O
16	left	O
17	ventricular	O
18	dilation	O
19	after	O
20	reperfused	O
21	AMI	O
22	from	O
23	those	O
24	who	O
25	maintain	O
26	normal	O
27	left	O
28	ventricular	O
29	geometry	O
30	.	O

1	The	O
2	proofreading	O
3	domain	O
4	of	O
5	Escherichia	B
6	coli	I
7	DNA	I
8	polymerase	I
9	I	I
10	and	O
11	other	O
12	DNA	B
13	and	I
14	/	I
15	or	I
16	RNA	I
17	exonuclease	I
18	domains	I
19	.	O

1	SCID	O
2	V	B
3	(	O
4	D	B
5	)	O
6	J	B
7	recombination	O
8	can	O
9	be	O
10	partly	O
11	rescued	O
12	in	O
13	T	O
14	-	O
15	lymphocytes	O
16	by	O
17	either	O
18	DNA	O
19	-	O
20	damaging	O
21	agents	O
22	(	O
23	gamma	O
24	-	O
25	irradiation	O
26	and	O
27	bieomycin	O
28	)	O
29	or	O
30	a	O
31	null	O
32	mutation	O
33	of	O
34	the	O
35	p53	B
36	gene	I
37	,	O
38	possibly	O
39	because	O
40	of	O
41	transiently	O
42	elevated	O
43	DNA	O
44	repair	O
45	activity	O
46	in	O
47	response	O
48	to	O
49	DNA	O
50	damage	O
51	or	O
52	to	O
53	delayed	O
54	apoptosis	O
55	in	O
56	the	O
57	absence	O
58	of	O
59	p53	B
60	.	O

1	An	O
2	even	O
3	greater	O
4	inflammatory	O
5	response	O
6	was	O
7	observed	O
8	after	O
9	intratracheal	O
10	instillation	O
11	of	O
12	ufCB	O
13	,	O
14	but	O
15	not	O
16	after	O
17	CB	O
18	instillation	O
19	.	O

1	Interestingly	O
2	,	O
3	the	O
4	avirulent	O
5	strain	O
6	H37Ra	O
7	showed	O
8	weak	O
9	hybridization	O
10	with	O
11	these	O
12	two	O
13	probes	O
14	,	O
15	suggesting	O
16	that	O
17	these	O
18	genes	O
19	might	O
20	have	O
21	been	O
22	deleted	O
23	in	O
24	the	O
25	avirulent	O
26	strain	O
27	or	O
28	are	O
29	present	O
30	in	O
31	limited	O
32	copy	O
33	numbers	O
34	as	O
35	opposed	O
36	to	O
37	those	O
38	in	O
39	the	O
40	virulent	O
41	strain	O
42	H37Rv	O
43	.	O

1	At	O
2	60	O
3	days	O
4	the	O
5	amount	O
6	of	O
7	gangliosides	O
8	was	O
9	on	O
10	average	O
11	lower	O
12	in	O
13	females	O
14	than	O
15	in	O
16	males	O
17	,	O
18	even	O
19	if	O
20	with	O
21	some	O
22	exception	O
23	.	O

1	During	O
2	the	O
3	conditioning	O
4	procedure	O
5	,	O
6	the	O
7	C	O
8	-	O
9	fiber	O
10	reflex	O
11	was	O
12	facilitated	O
13	(	O
14	wind	O
15	-	O
16	up	O
17	)	O
18	in	O
19	a	O
20	stimulus	O
21	-	O
22	dependent	O
23	fashion	O
24	in	O
25	intact	O
26	,	O
27	anesthetized	O
28	animals	O
29	during	O
30	the	O
31	application	O
32	of	O
33	the	O
34	first	O
35	seven	O
36	conditioning	O
37	stimuli	O
38	;	O
39	thereafter	O
40	,	O
41	the	O
42	magnitude	O
43	of	O
44	the	O
45	responses	O
46	reached	O
47	a	O
48	plateau	O
49	and	O
50	then	O
51	decreased	O
52	.	O

1	Upon	O
2	UV	O
3	damage	O
4	,	O
5	Crb2	B
6	is	O
7	transiently	O
8	modified	O
9	,	O
10	probably	O
11	phosphorylated	O
12	,	O
13	with	O
14	a	O
15	similar	O
16	timing	O
17	of	O
18	phosphorylation	O
19	in	O
20	Chk1	B
21	kinase	I
22	,	O
23	which	O
24	is	O
25	reported	O
26	to	O
27	restrain	O
28	Cdc2	B
29	activation	O
30	.	O

1	Bilateral	O
2	basal	O
3	arteries	O
4	were	O
5	measured	O
6	by	O
7	the	O
8	transtemporal	O
9	approach	O
10	with	O
11	a	O
12	2	O
13	MHz	O
14	pulsed	O
15	Doppler	O
16	instrument	O
17	(	O
18	TC	O
19	-	O
20	2	O
21	64B	O
22	EME	O
23	).	O

1	At	O
2	the	O
3	genomic	O
4	level	O
5	,	O
6	the	O
7	sequences	O
8	of	O
9	two	O
10	members	O
11	of	O
12	this	O
13	family	O
14	are	O
15	known	O
16	in	O
17	the	O
18	rat	O
19	Rattus	O
20	norvegicus	O
21	:	O
22	the	O
23	VCSA1	B
24	gene	I
25	,	O
26	encoding	O
27	the	O
28	prohormone	B
29	-	I
30	like	I
31	polypeptide	I
32	SMR1	I
33	,	O
34	and	O
35	the	O
36	VCSB1	B
37	gene	I
38	,	O
39	encoding	O
40	a	O
41	salivary	O
42	Pro	O
43	-	O
44	rich	O
45	polypeptide	O
46	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	and	O
5	super	O
6	-	O
7	shift	O
8	assays	O
9	using	O
10	liver	O
11	nuclear	O
12	extracts	O
13	from	O
14	either	O
15	rat	O
16	liver	O
17	or	O
18	DDT1MF	O
19	-	O
20	2	O
21	cells	O
22	demonstrated	O
23	that	O
24	the	O
25	CRE	O
26	in	O
27	the	O
28	alpha	B
29	1B	I
30	-	I
31	AR	I
32	gene	I
33	bound	O
34	CRE	B
35	binding	I
36	protein	I
37	.	O

1	In	O
2	accordance	O
3	with	O
4	clinical	O
5	improvement	O
6	we	O
7	found	O
8	a	O
9	decrease	O
10	of	O
11	laboratory	O
12	indicators	O
13	of	O
14	inflammation	O
15	(	O
16	C	B
17	-	I
18	reactive	I
19	protein	I
20	,	O
21	alpha	B
22	2	I
23	-	I
24	globuline	I
25	,	O
26	prostaglandin	O
27	E2	O
28	).	O

1	The	O
2	multidomain	O
3	structure	O
4	includes	O
5	a	O
6	cysteine	O
7	-	O
8	rich	O
9	motif	O
10	resembling	O
11	those	O
12	of	O
13	protein	B
14	kinase	I
15	C	I
16	and	O
17	n	B
18	-	I
19	chimaerin	I
20	and	O
21	a	O
22	putative	O
23	pleckstrin	B
24	homology	I
25	domain	I
26	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	STAT	B
8	activation	O
9	in	O
10	a	O
11	panel	O
12	of	O
13	rodent	O
14	fibroblast	O
15	cell	O
16	lines	O
17	stably	O
18	transformed	O
19	by	O
20	diverse	O
21	viral	O
22	oncoproteins	O
23	.	O

1	In	O
2	serum	O
3	-	O
4	stimulated	O
5	cells	O
6	,	O
7	the	O
8	binding	O
9	of	O
10	NF	B
11	-	I
12	Y	I
13	/	O
14	CBF	B
15	to	O
16	TKC1	B
17	increased	O
18	gradually	O
19	,	O
20	reaching	O
21	a	O
22	plateau	O
23	at	O
24	the	O
25	S	O
26	phase	O
27	.	O

1	MpB	B
2	GroEL	I
3	has	O
4	extensive	O
5	sequence	O
6	similarity	O
7	(	O
8	92	O
9	%)	O
10	with	O
11	Escherichia	B
12	coli	I
13	GroEL	I
14	and	O
15	other	O
16	members	O
17	of	O
18	the	O
19	chaperonin	B
20	-	I
21	60	I
22	family	I
23	.	O

1	The	O
2	critical	O
3	mutations	O
4	were	O
5	likely	O
6	to	O
7	have	O
8	been	O
9	multiple	O
10	and	O
11	dispersed	O
12	,	O
13	including	O
14	elongation	O
15	of	O
16	the	O
17	TM	O
18	and	O
19	Nef	B
20	coding	I
21	sequences	I
22	;	O
23	changes	O
24	in	O
25	RNA	O
26	splice	O
27	donor	O
28	and	O
29	acceptor	O
30	sites	O
31	,	O
32	TATA	O
33	box	O
34	sites	O
35	,	O
36	and	O
37	Sp1	B
38	sites	I
39	;	O
40	multiple	O
41	changes	O
42	in	O
43	the	O
44	V2	B
45	region	O
46	of	O
47	SU	B
48	,	O
49	including	O
50	a	O
51	consensus	O
52	neutralization	O
53	epitope	O
54	;	O
55	and	O
56	five	O
57	new	O
58	N	O
59	-	O
60	linked	O
61	glycosylation	O
62	sites	O
63	in	O
64	SU	B
65	.	O

1	To	O
2	investigate	O
3	the	O
4	requirements	O
5	for	O
6	CBF2	B
7	binding	O
8	,	O
9	we	O
10	synthesized	O
11	a	O
12	series	O
13	of	O
14	oligonucleotides	O
15	carrying	O
16	double	O
17	transversion	O
18	mutations	O
19	spanning	O
20	both	O
21	the	O
22	conserved	O
23	core	O
24	sequence	O
25	and	O
26	outside	O
27	flanking	O
28	sequences	O
29	.	O

1	These	O
2	and	O
3	other	O
4	comparisons	O
5	suggest	O
6	that	O
7	,	O
8	during	O
9	evolution	O
10	,	O
11	both	O
12	the	O
13	RNA	B
14	-	I
15	polymerase	I
16	specificity	O
17	of	O
18	telomerase	B
19	RNA	I
20	-	I
21	gene	I
22	promoters	I
23	and	O
24	,	O
25	more	O
26	recently	O
27	,	O
28	the	O
29	position	O
30	of	O
31	the	O
32	template	O
33	sequence	O
34	in	O
35	the	O
36	telomerase	B
37	RNA	I
38	changed	O
39	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	catalytically	O
6	inactive	O
7	version	O
8	of	O
9	the	O
10	Src	B
11	family	I
12	member	O
13	,	O
14	Lck	B
15	(	O
16	lymphoid	B
17	cell	I
18	kinase	I
19	),	O
20	was	O
21	expressed	O
22	,	O
23	purified	O
24	,	O
25	and	O
26	evaluated	O
27	as	O
28	a	O
29	Csk	B
30	substrate	O
31	.	O

1	Neuronal	O
2	mechanisms	O
3	underlying	O
4	stimulus	O
5	-	O
6	response	O
7	(	O
8	S	O
9	-	O
10	R	O
11	)	O
12	associations	O
13	in	O
14	S	O
15	-	O
16	R	O
17	compatibility	O
18	tasks	O
19	were	O
20	identified	O
21	in	O
22	2	O
23	experiments	O
24	with	O
25	monkeys	O
26	.	O

1	The	O
2	c	B
3	-	I
4	myc	I
5	/	O
6	TGF	B
7	-	I
8	alpha	I
9	HCCs	O
10	were	O
11	also	O
12	characterized	O
13	by	O
14	a	O
15	particularly	O
16	strong	O
17	expression	O
18	of	O
19	TGF	B
20	-	I
21	alpha	I
22	and	O
23	very	O
24	low	O
25	apoptotic	O
26	index	O
27	in	O
28	contrast	O
29	to	O
30	high	O
31	levels	O
32	of	O
33	apoptosis	O
34	in	O
35	peritumorous	O
36	tissues	O
37	and	O
38	c	B
39	-	I
40	myc	I
41	HCCs	O
42	.	O

1	The	O
2	well	O
3	-	O
4	known	O
5	Rel	B
6	/	O
7	NF	B
8	-	I
9	kappaB	I
10	family	O
11	of	O
12	vertebrate	O
13	transcription	O
14	factors	O
15	comprises	O
16	a	O
17	number	O
18	of	O
19	structurally	O
20	related	O
21	,	O
22	interacting	O
23	proteins	O
24	that	O
25	bind	O
26	DNA	O
27	as	O
28	dimers	O
29	and	O
30	whose	O
31	activity	O
32	is	O
33	regulated	O
34	by	O
35	subcellular	O
36	location	O
37	.	O

1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	O
6	saccharopine	B
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	Small	O
2	-	O
3	molecule	O
4	control	O
5	of	O
6	insulin	B
7	and	O
8	PDGF	B
9	receptor	I
10	signaling	O
11	and	O
12	the	O
13	role	O
14	of	O
15	membrane	O
16	attachment	O
17	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	mutant	B
5	EphB1	I
6	receptors	I
7	(	O
8	Y594F	O
9	)	O
10	blocked	O
11	Nck	B
12	recruitment	O
13	to	O
14	EphB1	B
15	,	O
16	attenuated	O
17	downstream	O
18	JNK	B
19	activation	O
20	,	O
21	and	O
22	blocked	O
23	cell	O
24	attachment	O
25	responses	O
26	.	O

1	Clinical	O
2	value	O
3	of	O
4	the	O
5	estimation	O
6	of	O
7	growth	O
8	kinetics	O
9	of	O
10	primary	O
11	ovarian	O
12	cancer	O
13	recurrences	O
14	by	O
15	CA125	B
16	doubling	O
17	time	O

1	Normal	O
2	baseline	O
3	(	O
4	day	O
5	-	O
6	8	O
7	)	O
8	PC	O
9	levels	O
10	(	O
11	86	O
12	and	O
13	89	O
14	%)	O
15	were	O
16	markedly	O
17	reduced	O
18	in	O
19	both	O
20	patients	O
21	at	O
22	the	O
23	time	O
24	of	O
25	VOD	O
26	manifestation	O
27	on	O
28	day	O
29	20	O
30	and	O
31	40	O
32	,	O
33	respectively	O
34	(	O
35	26	O
36	and	O
37	31	O
38	%).	O

1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	B
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	O
28	gene	O
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O

1	(	O
2	1997	O
3	)	O
4	Science	O
5	275	O
6	,	O
7	1927	O
8	-	O
9	1930	O
10	).	O

1	CES4	B
2	on	O
3	a	O
4	multicopy	O
5	plasmid	O
6	was	O
7	unable	O
8	to	O
9	suppress	O
10	tif1	B
11	-	I
12	A79V	I
13	.	O

1	A	O
2	fusion	O
3	protein	O
4	composed	O
5	of	O
6	beta	B
7	-	I
8	galactosidase	I
9	and	O
10	full	B
11	-	I
12	length	I
13	Ahr	I
14	translocates	O
15	from	O
16	the	O
17	cytoplasm	O
18	to	O
19	the	O
20	nucleus	O
21	in	O
22	a	O
23	ligand	O
24	-	O
25	dependent	O
26	manner	O
27	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	B
13	(	O
14	MyrSos1	B
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	B
28	C	I
29	terminus	I
30	(	O
31	MyrSos1	B
32	-	I
33	deltaC	I
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	Genetic	O
2	analysis	O
3	has	O
4	subsequently	O
5	identified	O
6	subpathways	O
7	of	O
8	the	O
9	DNA	O
10	structure	O
11	checkpoints	O
12	,	O
13	including	O
14	the	O
15	reversible	O
16	arrest	O
17	of	O
18	DNA	O
19	synthesis	O
20	.	O

1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O

1	Interleukin	B
2	-	I
3	6	I
4	(	O
5	IL	B
6	-	I
7	6	I
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O

1	Our	O
2	purpose	O
3	was	O
4	to	O
5	determine	O
6	if	O
7	intact	O
8	perianal	O
9	(	O
10	S4	O
11	-	O
12	5	O
13	)	O
14	pin	O
15	sensation	O
16	(	O
17	PPS	O
18	)	O
19	and	O
20	bulbocavernosus	O
21	(	O
22	S2	O
23	-	O
24	4	O
25	)	O
26	reflex	O
27	(	O
28	BCR	O
29	)	O
30	shortly	O
31	after	O
32	spinal	O
33	cord	O
34	injury	O
35	(	O
36	SCI	O
37	)	O
38	are	O
39	predictive	O
40	of	O
41	bladder	O
42	function	O
43	recovery	O
44	.	O

1	ALT	B
2	levels	O
3	in	O
4	responders	O
5	were	O
6	lowered	O
7	by	O
8	46	O
9	%	O
10	and	O
11	AST	B
12	levels	O
13	were	O
14	lowered	O
15	by	O
16	35	O
17	%	O
18	after	O
19	12	O
20	weeks	O
21	of	O
22	vitamin	O
23	E	O
24	treatment	O
25	.	O

1	Pao2	O
2	increased	O
3	from	O
4	15	O
5	.	O
6	5	O
7	+/-	O
8	5	O
9	.	O
10	6	O
11	kPa	O
12	(	O
13	116	O
14	+/-	O
15	42	O
16	mm	O
17	Hg	O
18	)	O
19	to	O
20	17	O
21	.	O
22	3	O
23	+/-	O
24	6	O
25	.	O
26	3	O
27	kPa	O
28	(	O
29	130	O
30	+/-	O
31	47	O
32	mm	O
33	Hg	O
34	)	O
35	(	O
36	P	O
37	<	O
38	0	O
39	.	O
40	05	O
41	).	O

1	Training	O
2	for	O
3	audit	O
4	.	O

1	Expression	O
2	and	O
3	characterization	O
4	of	O
5	recombinant	B
6	single	I
7	-	I
8	chain	I
9	Fv	I
10	and	O
11	Fv	B
12	fragments	I
13	derived	O
14	from	O
15	a	O
16	set	O
17	of	O
18	catalytic	O
19	antibodies	O
20	.	O

1	Platelet	O
2	aggregation	O
3	in	O
4	response	O
5	to	O
6	10	O
7	micrograms	O
8	collagen	B
9	/	O
10	ml	O
11	was	O
12	decreased	O
13	in	O
14	parallel	O
15	after	O
16	treatment	O
17	with	O
18	ASA	O
19	.	O

1	Sibling	O
2	aggregation	O
3	of	O
4	low	B
5	-	I
6	and	I
7	high	I
8	-	I
9	density	I
10	lipoprotein	I
11	cholesterol	I
12	and	O
13	apolipoproteins	B
14	B	I
15	and	I
16	A	I
17	-	I
18	I	I
19	levels	O
20	in	O
21	black	O
22	and	O
23	white	O
24	children	O
25	:	O
26	the	O
27	Bogalusa	O
28	Heart	O
29	Study	O
30	.	O

1	The	O
2	CAPLC1	B
3	protein	I
4	also	O
5	exhibited	O
6	several	O
7	unique	O
8	features	O
9	,	O
10	including	O
11	a	O
12	novel	O
13	stretch	O
14	of	O
15	18	O
16	-	O
17	19	O
18	amino	O
19	acid	O
20	residues	O
21	within	O
22	the	O
23	X	O
24	domain	O
25	and	O
26	an	O
27	unusually	O
28	long	O
29	N	O
30	-	O
31	terminus	O
32	which	O
33	did	O
34	not	O
35	contain	O
36	a	O
37	recognizable	O
38	EF	O
39	-	O
40	hand	O
41	Ca	O
42	(	O
43	2	O
44	+)-	O
45	binding	O
46	domain	O
47	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	I
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	B
45	2m	I
46	.	O

1	In	O
2	the	O
3	tissues	O
4	tested	O
5	,	O
6	except	O
7	brain	O
8	,	O
9	the	O
10	message	O
11	for	O
12	CLIP	B
13	-	I
14	170	I
15	was	O
16	more	O
17	abundant	O
18	than	O
19	that	O
20	for	O
21	Restin	B
22	.	O

1	The	O
2	cloned	O
3	alcR	B
4	gene	I
5	provided	O
6	in	O
7	trans	O
8	restored	O
9	these	O
10	siderophore	O
11	system	O
12	activities	O
13	to	O
14	the	O
15	mutants	O
16	.	O

1	Substrates	O
2	for	O
3	p210	B
4	(	O
5	bcr	B
6	-	O
7	abl	B
8	)	O
9	are	O
10	likely	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	the	O
16	pathogenesis	O
17	of	O
18	CML	O
19	.	O

1	Soluble	O
2	FasR	B
3	ligand	O
4	-	O
5	binding	O
6	domain	O
7	:	O
8	high	O
9	-	O
10	yield	O
11	production	O
12	of	O
13	active	O
14	fusion	O
15	and	O
16	non	O
17	-	O
18	fusion	O
19	recombinant	O
20	proteins	O
21	using	O
22	the	O
23	baculovirus	O
24	/	O
25	insect	O
26	cell	O
27	system	O
28	.	O

1	The	O
2	inhibition	O
3	of	O
4	focus	O
5	formation	O
6	observed	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	C3G	B
12	was	O
13	not	O
14	due	O
15	to	O
16	toxic	O
17	effects	O
18	on	O
19	cell	O
20	viability	O
21	,	O
22	since	O
23	transfected	O
24	C3G	B
25	cells	O
26	exhibited	O
27	the	O
28	same	O
29	survival	O
30	and	O
31	growth	O
32	rates	O
33	as	O
34	untransfected	O
35	NIH3T3	O
36	cells	O
37	or	O
38	cells	O
39	transfected	O
40	with	O
41	plasmid	O
42	vector	O
43	alone	O
44	.	O

1	C	O
2	.	O
3	D2	O
4	-	O
5	Chr	O
6	4	O
7	congenic	O
8	strains	O
9	harboring	O
10	DBA	O
11	/	O
12	2	O
13	alleles	O
14	associated	O
15	with	O
16	the	O
17	Pctr1	B
18	locus	I
19	contained	O
20	DBA	O
21	/	O
22	2	O
23	"	O
24	resistant	O
25	"	O
26	alleles	O
27	of	O
28	the	O
29	CDK4	B
30	/	O
31	CDK6	B
32	inhibitors	O
33	p16	B
34	and	O
35	p15	B
36	.	O

1	This	O
2	resulted	O
3	in	O
4	a	O
5	complete	O
6	inhibition	O
7	of	O
8	Site	O
9	-	O
10	1	O
11	cleavage	O
12	that	O
13	was	O
14	restored	O
15	by	O
16	concomitant	O
17	overexpression	O
18	of	O
19	full	O
20	-	O
21	length	O
22	SCAP	B
23	.	O

1	To	O
2	determine	O
3	the	O
4	true	O
5	molecular	O
6	identity	O
7	of	O
8	SFD	B
9	,	O
10	both	O
11	the	O
12	50	O
13	-	O
14	and	O
15	57	O
16	-	O
17	kDa	O
18	polypeptides	O
19	were	O
20	directly	O
21	sequenced	O
22	.	O

1	Localized	O
2	fluorescence	O
3	was	O
4	detectable	O
5	only	O
6	in	O
7	cells	O
8	containing	O
9	a	O
10	visible	O
11	midcell	O
12	constriction	O
13	,	O
14	suggesting	O
15	that	O
16	FtsK	B
17	targeting	O
18	normally	O
19	occurs	O
20	only	O
21	at	O
22	a	O
23	late	O
24	stage	O
25	of	O
26	septation	O
27	.	O

1	Structural	O
2	and	O
3	evolutionary	O
4	studies	O
5	on	O
6	sterol	B
7	14	I
8	-	I
9	demethylase	I
10	P450	I
11	(	O
12	CYP51	B
13	),	O
14	the	O
15	most	O
16	conserved	O
17	P450	B
18	monooxygenase	I
19	:	O
20	I	O
21	.	O

1	The	O
2	DSF	O
3	regimen	O
4	appears	O
5	to	O
6	have	O
7	significant	O
8	activity	O
9	in	O
10	patients	O
11	who	O
12	have	O
13	metastatic	O
14	pancreatic	O
15	islet	O
16	-	O
17	cell	O
18	carcinoma	O
19	,	O
20	and	O
21	patient	O
22	tolerance	O
23	of	O
24	the	O
25	regimen	O
26	is	O
27	excellent	O
28	,	O
29	thus	O
30	warranting	O
31	further	O
32	investigation	O
33	.	O

1	Activation	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	is	O
12	a	O
13	primary	O
14	consequence	O
15	of	O
16	Ras	B
17	activation	O
18	and	O
19	plays	O
20	a	O
21	key	O
22	role	O
23	in	O
24	mediating	O
25	Ras	B
26	signal	O
27	transduction	O
28	.	O

1	Histone	B
2	acetylation	O
3	levels	O
4	in	O
5	cells	O
6	result	O
7	from	O
8	a	O
9	dynamic	O
10	equilibrium	O
11	between	O
12	competing	O
13	histone	B
14	acetylases	I
15	and	I
16	deacetylases	I
17	.	O

1	We	O
2	also	O
3	present	O
4	evidence	O
5	that	O
6	human	B
7	HYAL1	I
8	is	O
9	identical	O
10	to	O
11	an	O
12	uncharacterized	O
13	gene	O
14	positionally	O
15	cloned	O
16	by	O
17	others	O
18	from	O
19	chromosome	O
20	3p21	O
21	.	O
22	3	O
23	that	O
24	is	O
25	homozygously	O
26	deleted	O
27	in	O
28	several	O
29	small	O
30	-	O
31	cell	O
32	lung	O
33	carcinoma	O
34	cell	O
35	lines	O
36	.	O

1	Randomised	O
2	comparison	O
3	of	O
4	addition	O
5	of	O
6	autologous	O
7	bone	O
8	-	O
9	marrow	O
10	transplantation	O
11	to	O
12	intensive	O
13	chemotherapy	O
14	for	O
15	acute	O
16	myeloid	O
17	leukaemia	O
18	in	O
19	first	O
20	remission	O
21	:	O
22	results	O
23	of	O
24	MRC	O
25	AML	O
26	10	O
27	trial	O
28	.	O

1	A	O
2	review	O
3	of	O
4	studies	O
5	published	O
6	between	O
7	1983	O
8	and	O
9	1995	O
10	shows	O
11	that	O
12	there	O
13	are	O
14	some	O
15	common	O
16	factors	O
17	as	O
18	regards	O
19	the	O
20	psychological	O
21	distress	O
22	and	O
23	social	O
24	and	O
25	functional	O
26	limitations	O
27	this	O
28	group	O
29	of	O
30	patients	O
31	has	O
32	to	O
33	deal	O
34	with	O
35	.	O

1	PKC	B
2	-	I
3	gamma	I
4	,	O
5	which	O
6	is	O
7	not	O
8	present	O
9	in	O
10	keratinocytes	O
11	,	O
12	also	O
13	induces	O
14	involucrin	B
15	gene	I
16	expression	O
17	in	O
18	a	O
19	TPA	O
20	-	O
21	independent	O
22	manner	O
23	,	O
24	when	O
25	introduced	O
26	into	O
27	SVHK	O
28	cells	O
29	.	O

1	Primers	O
2	for	O
3	subsequent	O
4	rounds	O
5	of	O
6	RACE	O
7	were	O
8	designed	O
9	from	O
10	the	O
11	5	O
12	'-	O
13	ends	O
14	of	O
15	amplified	O
16	RACE	O
17	products	O
18	.	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	special	O
5	clinical	O
6	presentation	O
7	of	O
8	our	O
9	case	O
10	of	O
11	possible	O
12	Gardner	O
13	'	O
14	s	O
15	syndrome	O
16	is	O
17	discussed	O
18	.	O

1	We	O
2	have	O
3	elucidated	O
4	the	O
5	exon	O
6	-	O
7	intron	O
8	organization	O
9	of	O
10	the	O
11	entire	O
12	human	O
13	CD58	B
14	gene	I
15	,	O
16	including	O
17	approximately	O
18	2	O
19	.	O
20	5	O
21	kilobases	O
22	(	O
23	kb	O
24	)	O
25	of	O
26	5	O
27	'-	O
28	flanking	O
29	DNA	O
30	.	O

1	RESULTS	O
2	:	O
3	Using	O
4	information	O
5	in	O
6	the	O
7	dbEST	O
8	database	O
9	of	O
10	expressed	O
11	sequence	O
12	tags	O
13	,	O
14	we	O
15	isolated	O
16	an	O
17	Arabidopsis	O
18	thaliana	O
19	gene	O
20	(	O
21	GCR1	B
22	)	O
23	that	O
24	encodes	O
25	a	O
26	protein	O
27	with	O
28	seven	O
29	predicted	O
30	membrane	O
31	-	O
32	spanning	O
33	domains	O
34	and	O
35	other	O
36	features	O
37	characteristic	O
38	of	O
39	7TM	B
40	receptors	I
41	.	O

1	Alterations	O
2	in	O
3	DNase	B
4	I	I
5	reactivity	O
6	of	O
7	the	O
8	GC	O
9	-	O
10	response	O
11	element	O
12	region	O
13	suggest	O
14	that	O
15	GC	B
16	receptor	I
17	-	I
18	GC	I
19	complexes	I
20	may	O
21	associate	O
22	,	O
23	in	O
24	a	O
25	transient	O
26	manner	O
27	,	O
28	with	O
29	the	O
30	promoter	O
31	in	O
32	the	O
33	actively	O
34	transcribing	O
35	control	O
36	state	O
37	.	O

1	Ganciclovir	O
2	and	O
3	foscarnet	O
4	efficacy	O
5	in	O
6	AIDS	O
7	-	O
8	related	O
9	CMV	O
10	polyradiculopathy	O
11	.	O

1	The	O
2	study	O
3	enrolled	O
4	994	O
5	people	O
6	co	O
7	-	O
8	infected	O
9	with	O
10	CMV	O
11	and	O
12	HIV	O
13	,	O
14	with	O
15	at	O
16	least	O
17	one	O
18	CD4	B
19	count	O
20	recorded	O
21	<	O
22	100	O
23	x	O
24	10	O
25	(	O
26	6	O
27	)	O
28	cells	O
29	/	O
30	l	O
31	.	O

1	BACKGROUND	O
2	AND	O
3	OBJECTIVES	O
4	:	O
5	The	O
6	sexually	O
7	transmitted	O
8	diseases	O
9	(	O
10	STD	O
11	)	O
12	control	O
13	program	O
14	for	O
15	female	O
16	sex	O
17	workers	O
18	(	O
19	FSW	O
20	)	O
21	in	O
22	Lima	O
23	,	O
24	Peru	O
25	,	O
26	provided	O
27	periodic	O
28	serological	O
29	tests	O
30	for	O
31	syphilis	O
32	and	O
33	cervical	O
34	smears	O
35	for	O
36	gonococci	O
37	,	O
38	but	O
39	not	O
40	medication	O
41	for	O
42	STD	O
43	or	O
44	condoms	O
45	.	O

1	National	O
2	certification	O
3	:	O
4	a	O
5	vital	O
6	component	O
7	of	O
8	quality	O
9	assurance	O
10	.	O

1	A	O
2	constitutive	O
3	allele	O
4	of	O
5	GPA2	B
6	could	O
7	stimulate	O
8	growth	O
9	of	O
10	a	O
11	strain	O
12	lacking	O
13	both	O
14	RAS	B
15	genes	I
16	.	O

1	The	O
2	gene	B
3	lac	I
4	-	I
5	1	I
6	,	O
7	encoding	O
8	the	O
9	enzyme	O
10	laccase	B
11	,	O
12	is	O
13	the	O
14	best	O
15	characterized	O
16	of	O
17	a	O
18	number	O
19	of	O
20	genes	O
21	in	O
22	the	O
23	chestnut	O
24	blight	O
25	fungus	O
26	,	O
27	Cryphonectria	O
28	parasitica	O
29	,	O
30	that	O
31	are	O
32	repressed	O
33	by	O
34	hypoviruses	O
35	,	O
36	a	O
37	group	O
38	of	O
39	virulence	O
40	-	O
41	attenuating	O
42	mycoviruses	O
43	.	O
44	lac	B
45	-	I
46	1	I
47	has	O
48	also	O
49	been	O
50	shown	O
51	to	O
52	be	O
53	transcriptionally	O
54	activated	O
55	by	O
56	low	O
57	concentrations	O
58	of	O
59	the	O
60	translational	O
61	inhibitor	O
62	cycloheximide	O
63	(	O
64	CHX	O
65	)	O
66	and	O
67	by	O
68	the	O
69	immunosuppressant	O
70	cyclosporin	O
71	A	O
72	.	O

1	However	O
2	,	O
3	inhibition	O
4	of	O
5	both	O
6	the	O
7	ERK	B
8	/	O
9	RSK	B
10	and	O
11	the	O
12	p38	B
13	/	O
14	MAPKAP	B
15	kinase	I
16	2	I
17	pathways	O
18	completely	O
19	abolished	O
20	NGF	B
21	-	O
22	induced	O
23	CREB	B
24	Ser	O
25	-	O
26	133	O
27	phosphorylation	O
28	.	O

1	The	O
2	mei4	B
3	+	I
4	gene	I
5	of	O
6	the	O
7	fission	O
8	yeast	O
9	Schizosaccharomyces	O
10	pombe	O
11	was	O
12	cloned	O
13	by	O
14	functional	O
15	complementation	O
16	.	O

1	The	O
2	genomic	O
3	fragments	O
4	were	O
5	fused	O
6	upstream	O
7	of	O
8	the	O
9	luciferase	B
10	reporter	I
11	gene	I
12	.	O

1	Flap	O
2	survival	O
3	depends	O
4	on	O
5	the	O
6	development	O
7	of	O
8	a	O
9	small	O
10	number	O
11	of	O
12	vascular	O
13	connections	O
14	between	O
15	vessels	O
16	arising	O
17	from	O
18	the	O
19	pedicle	O
20	and	O
21	preexisting	O
22	dermal	O
23	vessels	O
24	.	O

1	Potential	O
2	indicators	O
3	were	O
4	assessed	O
5	for	O
6	the	O
7	two	O
8	classifications	O
9	of	O
10	protein	O
11	-	O
12	energy	O
13	malnutrition	O
14	in	O
15	the	O
16	guidelines	O
17	for	O
18	integrated	O
19	management	O
20	of	O
21	childhood	O
22	illness	O
23	:	O
24	severe	O
25	malnutrition	O
26	,	O
27	which	O
28	requires	O
29	immediate	O
30	referral	O
31	to	O
32	hospital	O
33	,	O
34	and	O
35	very	O
36	low	O
37	weight	O
38	,	O
39	which	O
40	calls	O
41	for	O
42	feeding	O
43	assessment	O
44	,	O
45	nutritional	O
46	counselling	O
47	and	O
48	follow	O
49	-	O
50	up	O
51	.	O

1	In	O
2	vitro	O
3	affinity	O
4	analyses	O
5	demonstrated	O
6	that	O
7	recombinant	O
8	130	O
9	-	O
10	kD	O
11	protein	O
12	directly	O
13	interacts	O
14	with	O
15	ZO	B
16	-	I
17	1	I
18	and	O
19	the	O
20	cytoplasmic	O
21	domain	O
22	of	O
23	occludin	B
24	,	O
25	but	O
26	not	O
27	with	O
28	ZO	B
29	-	I
30	2	I
31	.	O

1	Cytochrome	B
2	b	I
3	in	O
4	human	B
5	complex	I
6	II	I
7	(	O
8	succinate	B
9	-	I
10	ubiquinone	I
11	oxidoreductase	I
12	):	O
13	cDNA	O
14	cloning	O
15	of	O
16	the	O
17	components	O
18	in	O
19	liver	O
20	mitochondria	O
21	and	O
22	chromosome	O
23	assignment	O
24	of	O
25	the	O
26	genes	O
27	for	O
28	the	O
29	large	O
30	(	O
31	SDHC	B
32	)	O
33	and	O
34	small	O
35	(	O
36	SDHD	B
37	)	O
38	subunits	O
39	to	O
40	1q21	O
41	and	O
42	11q23	O
43	.	O

1	The	O
2	addition	O
3	of	O
4	a	O
5	Paf	B
6	-	O
7	containing	O
8	extract	O
9	does	O
10	not	O
11	lead	O
12	to	O
13	significant	O
14	protein	O
15	binding	O
16	to	O
17	these	O
18	two	O
19	hly	B
20	target	I
21	sequences	I
22	in	O
23	the	O
24	absence	O
25	of	O
26	PrfA	B
27	but	O
28	converts	O
29	the	O
30	complex	O
31	(	O
32	CIII	O
33	)	O
34	consisting	O
35	of	O
36	PrfA	B
37	and	O
38	the	O
39	109	B
40	bp	I
41	hly	I
42	DNA	I
43	fragment	I
44	to	O
45	a	O
46	slower	O
47	migrating	O
48	PrfA	B
49	-	O
50	Paf	B
51	-	O
52	DNA	O
53	complex	O
54	(	O
55	CI	O
56	).	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	B
15	product	O
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	B
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	In	O
2	a	O
3	gntR	B
4	deletion	I
5	mutant	I
6	,	O
7	the	O
8	expression	O
9	of	O
10	a	O
11	chromosomal	O
12	gntT	B
13	::	O
14	lacZ	B
15	fusion	O
16	is	O
17	both	O
18	high	O
19	and	O
20	constitutive	O
21	,	O
22	confirming	O
23	that	O
24	GntR	B
25	is	O
26	the	O
27	negative	O
28	regulator	O
29	of	O
30	gntT	B
31	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	B
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	B
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	PRL	B
2	receptor	I
3	also	O
4	activates	O
5	SHP	B
6	-	I
7	2	I
8	,	O
9	a	O
10	cytosolic	B
11	tyrosine	I
12	phosphatase	I
13	.	O

1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	B
18	-	O
19	MSH6	B
20	and	O
21	MLH1	B
22	-	O
23	PMS1	B
24	protein	O
25	complexes	O
26	.	O

1	Mutation	O
2	of	O
3	the	O
4	central	O
5	Tyr497	O
6	to	O
7	Phe	O
8	blocks	O
9	the	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	insulin	B
15	receptor	I
16	substrate	I
17	1	I
18	(	O
19	IRS1	B
20	)	O
21	and	O
22	diminishes	O
23	proliferation	O
24	in	O
25	response	O
26	to	O
27	IL	B
28	-	I
29	4	I
30	.	O

1	Instead	O
2	,	O
3	it	O
4	contained	O
5	two	O
6	tandem	O
7	kappaB	B
8	elements	I
9	and	O
10	a	O
11	variant	O
12	activating	B
13	transcription	I
14	factor	I
15	/	I
16	cAMP	I
17	response	I
18	element	I
19	site	O
20	,	O
21	which	O
22	closely	O
23	resembled	O
24	sites	O
25	in	O
26	the	O
27	E	B
28	-	I
29	selectin	I
30	gene	I
31	that	O
32	are	O
33	required	O
34	for	O
35	TNF	B
36	-	I
37	alpha	I
38	-	O
39	or	O
40	LPS	O
41	-	O
42	inducible	O
43	expression	O
44	.	O

1	The	O
2	ether	O
3	phospholipid	O
4	1	O
5	-	O
6	O	O
7	-	O
8	octadecyl	O
9	-	O
10	2	O
11	-	O
12	O	O
13	-	O
14	methyl	O
15	-	O
16	rac	O
17	-	O
18	glycero	O
19	-	O
20	3	O
21	-	O
22	phosphocholine	O
23	(	O
24	ET	O
25	-	O
26	18	O
27	-	O
28	OCH3	O
29	;	O
30	edelfosine	O
31	)	O
32	is	O
33	a	O
34	potent	O
35	inducer	O
36	of	O
37	apoptosis	O
38	in	O
39	human	O
40	tumor	O
41	cells	O
42	.	O

1	In	O
2	addition	O
3	to	O
4	a	O
5	previously	O
6	characterized	O
7	promoter	O
8	(	O
9	P1	O
10	),	O
11	we	O
12	now	O
13	show	O
14	the	O
15	existence	O
16	of	O
17	a	O
18	second	O
19	promoter	O
20	for	O
21	the	O
22	human	B
23	IL	I
24	-	I
25	5Ralpha	I
26	gene	I
27	.	O

1	Overall	O
2	agreement	O
3	between	O
4	rest	O
5	/	O
6	postnitroglycerin	O
7	technetium	O
8	-	O
9	99m	O
10	tetrofosmin	O
11	SPET	O
12	studies	O
13	and	O
14	rest	O
15	/	O
16	redistribution	O
17	or	O
18	rest	O
19	/	O
20	reinjection	O
21	thallium	O
22	-	O
23	201	O
24	SPET	O
25	studies	O
26	,	O
27	regarding	O
28	the	O
29	presence	O
30	of	O
31	myocardial	O
32	viability	O
33	,	O
34	was	O
35	87	O
36	%	O
37	and	O
38	90	O
39	%,	O
40	respectively	O
41	.	O

1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O

1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	B
27	.	O

1	The	O
2	N	O
3	-	O
4	syndecan	O
5	-	O
6	dependent	O
7	neurite	O
8	outgrowth	O
9	is	O
10	inhibited	O
11	by	O
12	the	O
13	tyrosine	B
14	kinase	I
15	inhibitors	O
16	herbimycin	O
17	A	O
18	and	O
19	PP1	B
20	.	O

1	Among	O
2	the	O
3	H	B
4	/	I
5	ACA	I
6	snoRNAs	I
7	associated	O
8	with	O
9	Gar1p	B
10	,	O
11	one	O
12	can	O
13	distinguish	O
14	a	O
15	large	O
16	group	O
17	of	O
18	snoRNAs	O
19	that	O
20	are	O
21	not	O
22	essential	O
23	in	O
24	yeast	O
25	and	O
26	serve	O
27	as	O
28	guides	O
29	for	O
30	pseudouridine	O
31	synthesis	O
32	onto	O
33	the	O
34	pre	O
35	-	O
36	rRNA	O
37	molecule	O
38	.	O

1	Specialized	O
2	actin	B
3	tails	O
4	that	O
5	propel	O
6	IEV	O
7	particles	O
8	to	O
9	the	O
10	periphery	O
11	and	O
12	virus	O
13	-	O
14	tipped	O
15	microvilli	O
16	(	O
17	both	O
18	common	O
19	in	O
20	wild	O
21	-	O
22	type	O
23	-	O
24	infected	O
25	cells	O
26	)	O
27	were	O
28	absent	O
29	in	O
30	cells	O
31	infected	O
32	with	O
33	vA33delta	O
34	.	O

1	A	O
2	cDNA	O
3	,	O
4	cak1At	B
5	,	O
6	was	O
7	isolated	O
8	that	O
9	suppressed	O
10	the	O
11	CAK	B
12	mutation	I
13	in	O
14	budding	O
15	yeast	O
16	,	O
17	and	O
18	it	O
19	also	O
20	complemented	O
21	a	O
22	fission	B
23	yeast	I
24	CAK	I
25	mutant	I
26	.	O
27	cak1At	B
28	encodes	O
29	a	O
30	protein	O
31	related	O
32	to	O
33	animal	B
34	CAKs	I
35	.	O

1	Ime1	B
2	plays	O
3	a	O
4	pivotal	O
5	role	O
6	in	O
7	the	O
8	initiation	O
9	of	O
10	meiosis	O
11	in	O
12	a	O
13	/	O
14	alpha	O
15	diploid	O
16	cells	O
17	of	O
18	Saccharomyces	O
19	cerevisiae	O
20	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	third	O
7	intracellular	O
8	loop	O
9	of	O
10	the	O
11	rat	B
12	GnRH	I
13	-	I
14	R	I
15	is	O
16	involved	O
17	in	O
18	receptor	B
19	G	I
20	(	I
21	q	I
22	/	I
23	11	I
24	)	I
25	protein	I
26	coupling	O
27	and	O
28	/	O
29	or	O
30	selectivity	O
31	,	O
32	and	O
33	in	O
34	the	O
35	GGH	O
36	(	O
37	3	O
38	)	O
39	1	O
40	'	O
41	cell	O
42	line	O
43	,	O
44	this	O
45	loop	O
46	is	O
47	also	O
48	involved	O
49	in	O
50	signal	O
51	transduction	O
52	mediated	O
53	through	O
54	the	O
55	Gs	B
56	protein	O
57	pathway	O
58	.	O

1	Another	O
2	stem	O
3	-	O
4	loop	O
5	called	O
6	structure	O
7	III	O
8	near	O
9	the	O
10	3	O
11	'-	O
12	end	O
13	of	O
14	repY	B
15	sequesters	O
16	both	O
17	the	O
18	5	O
19	'-	O
20	rCGCC	O
21	-	O
22	3	O
23	'	O
24	sequence	O
25	and	O
26	the	O
27	repZ	B
28	ribosome	I
29	-	I
30	binding	I
31	site	I
32	.	O

1	In	O
2	fus3	B
3	mutants	I
4	,	O
5	the	O
6	levels	O
7	of	O
8	Ty1	B
9	RNA	I
10	,	O
11	protein	O
12	synthesis	O
13	,	O
14	and	O
15	proteolytic	O
16	processing	O
17	were	O
18	not	O
19	altered	O
20	relative	O
21	to	O
22	those	O
23	in	O
24	FUS3	B
25	strains	O
26	but	O
27	steady	O
28	-	O
29	state	O
30	levels	O
31	of	O
32	TyA	B
33	,	O
34	integrase	B
35	,	O
36	and	O
37	reverse	B
38	transcriptase	I
39	proteins	O
40	and	O
41	Ty1	B
42	cDNA	I
43	were	O
44	all	O
45	increased	O
46	.	O

1	Posttranslational	O
2	regulation	O
3	of	O
4	Ty1	B
5	retrotransposition	O
6	by	O
7	mitogen	B
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	Fus3	I
13	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	B
17	resistance	I
18	gene	I
19	region	I
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	The	O
2	complete	O
3	exon	O
4	-	O
5	intron	O
6	organization	O
7	of	O
8	the	O
9	murine	O
10	gene	O
11	encoding	O
12	M	B
13	-	I
14	protein	I
15	,	O
16	a	O
17	structural	O
18	protein	O
19	of	O
20	sarcomeric	O
21	myofibrils	O
22	,	O
23	was	O
24	determined	O
25	.	O

1	Mean	O
2	+/-	O
3	SD	O
4	serum	B
5	VEGF	I
6	concentrations	O
7	were	O
8	significantly	O
9	higher	O
10	(	O
11	P	O
12	<	O
13	0	O
14	.	O
15	001	O
16	)	O
17	in	O
18	women	O
19	with	O
20	PCO	O
21	and	O
22	PCOS	O
23	(	O
24	3	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	7	O
31	and	O
32	3	O
33	.	O
34	2	O
35	+/-	O
36	0	O
37	.	O
38	66	O
39	ng	O
40	/	O
41	ml	O
42	respectively	O
43	)	O
44	compared	O
45	with	O
46	women	O
47	with	O
48	normal	O
49	ovaries	O
50	(	O
51	2	O
52	.	O
53	3	O
54	+/-	O
55	0	O
56	.	O
57	5	O
58	ng	O
59	/	O
60	ml	O
61	).	O

1	The	O
2	new	O
3	algorithm	O
4	,	O
5	called	O
6	RBI	O
7	-	O
8	MAP	O
9	,	O
10	is	O
11	based	O
12	on	O
13	the	O
14	rescaled	O
15	block	O
16	iterative	O
17	EM	O
18	(	O
19	RBI	O
20	-	O
21	EM	O
22	)	O
23	algorithm	O
24	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O

1	In	O
2	connective	O
3	tissue	O
4	,	O
5	cell	O
6	structure	O
7	contributes	O
8	to	O
9	type	B
10	I	I
11	collagen	I
12	expression	O
13	.	O

1	Indeed	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	it	O
8	mediates	O
9	the	O
10	formation	O
11	of	O
12	disulfide	O
13	-	O
14	linked	O
15	homodimers	O
16	and	O
17	that	O
18	the	O
19	formation	O
20	of	O
21	homo	O
22	-	O
23	and	O
24	heterodimers	O
25	are	O
26	mutually	O
27	excluded	O
28	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	B
6	,	O
7	alpha	B
8	2AP	I
9	,	O
10	and	O
11	C1	B
12	-	I
13	INH	I
14	,	O
15	should	O
16	be	O
17	considered	O
18	equine	O
19	acute	O
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	The	O
2	same	O
3	IL	B
4	-	I
5	4	I
6	-	O
7	inducible	O
8	reporter	O
9	gene	O
10	is	O
11	also	O
12	synergistically	O
13	activated	O
14	by	O
15	the	O
16	endogenous	B
17	Stat6	I
18	and	O
19	NF	B
20	-	I
21	kappaB	I
22	proteins	I
23	in	O
24	IL	B
25	-	I
26	4	I
27	-	O
28	stimulated	O
29	I	O
30	.	O
31	29mu	O
32	B	O
33	lymphoma	O
34	cells	O
35	.	O

1	However	O
2	,	O
3	a	O
4	zinc	O
5	-	O
6	depleted	O
7	enzyme	O
8	was	O
9	obtained	O
10	after	O
11	prolonged	O
12	dialysis	O
13	against	O
14	the	O
15	specific	O
16	chelating	O
17	agent	O
18	1	O
19	,	O
20	10	O
21	-	O
22	phenanthroline	O
23	.	O

1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	endothelin	B
8	-	I
9	1	I
10	(	O
11	ET	B
12	-	I
13	1	I
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	pericardial	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O

1	Roles	O
2	of	O
3	the	O
4	Candida	B
5	albicans	I
6	mitogen	I
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	homolog	I
12	,	O
13	Cek1p	B
14	,	O
15	in	O
16	hyphal	O
17	development	O
18	and	O
19	systemic	O
20	candidiasis	O
21	.	O

1	Analysis	O
2	of	O
3	a	O
4	Mac1p	B
5	mutant	I
6	,	O
7	refractile	O
8	for	O
9	copper	O
10	-	O
11	dependent	O
12	repression	O
13	of	O
14	the	O
15	Cu	B
16	(	I
17	I	I
18	)	I
19	transport	I
20	genes	I
21	,	O
22	showed	O
23	an	O
24	aberrant	O
25	pattern	O
26	of	O
27	CUP1	B
28	expression	O
29	and	O
30	copper	O
31	sensitivity	O
32	.	O

1	The	O
2	clinical	O
3	and	O
4	laboratory	O
5	features	O
6	of	O
7	72	O
8	children	O
9	with	O
10	Henoch	O
11	-	O
12	Schonlein	O
13	purpura	O
14	(	O
15	HSP	O
16	)	O
17	were	O
18	examined	O
19	to	O
20	determine	O
21	if	O
22	there	O
23	were	O
24	associations	O
25	between	O
26	the	O
27	laboratory	O
28	indices	O
29	--	O
30	including	O
31	white	O
32	blood	O
33	cell	O
34	(	O
35	WBC	O
36	)	O
37	counts	O
38	,	O
39	serum	B
40	C	I
41	-	I
42	reactive	I
43	protein	I
44	(	O
45	CRP	B
46	)	O
47	levels	O
48	,	O
49	platelet	O
50	(	O
51	PLT	O
52	)	O
53	counts	O
54	--	O
55	and	O
56	the	O
57	clinical	O
58	manifestations	O
59	of	O
60	acute	O
61	HSP	O
62	.	O

1	We	O
2	provide	O
3	community	O
4	metabolic	O
5	data	O
6	that	O
7	indicate	O
8	that	O
9	large	O
10	changes	O
11	in	O
12	CO2	O
13	concentration	O
14	can	O
15	occur	O
16	in	O
17	coral	O
18	reef	O
19	waters	O
20	via	O
21	biogeochemical	O
22	processes	O
23	not	O
24	directly	O
25	associated	O
26	with	O
27	photosynthesis	O
28	,	O
29	respiration	O
30	,	O
31	calcification	O
32	,	O
33	and	O
34	CaCO3	O
35	dissolution	O
36	.	O

1	In	O
2	contrast	O
3	to	O
4	other	O
5	known	O
6	retroviruses	O
7	,	O
8	the	O
9	FV	B
10	pol	I
11	genes	I
12	are	O
13	expressed	O
14	via	O
15	spliced	O
16	transcripts	O
17	.	O

1	Tributyltin	O
2	and	O
3	its	O
4	breakdown	O
5	products	O
6	,	O
7	mono	O
8	-	O
9	and	O
10	di	O
11	-	O
12	butyltin	O
13	,	O
14	were	O
15	determined	O
16	in	O
17	water	O
18	birds	O
19	collected	O
20	from	O
21	Lake	O
22	Huron	O
23	(	O
24	the	O
25	Great	O
26	Lakes	O
27	),	O
28	marine	O
29	coastal	O
30	United	O
31	States	O
32	,	O
33	and	O
34	the	O
35	west	O
36	coast	O
37	of	O
38	British	O
39	Columbia	O
40	,	O
41	Canada	O
42	.	O

1	GLRaV	O
2	-	O
3	2	O
4	is	O
5	the	O
6	only	O
7	closterovirus	O
8	,	O
9	so	O
10	far	O
11	,	O
12	that	O
13	matches	O
14	the	O
15	genome	O
16	organization	O
17	of	O
18	the	O
19	type	O
20	member	O
21	of	O
22	the	O
23	group	O
24	,	O
25	BYV	O
26	,	O
27	and	O
28	thus	O
29	can	O
30	be	O
31	unambiguously	O
32	classified	O
33	as	O
34	a	O
35	definitive	O
36	member	O
37	of	O
38	the	O
39	genus	O
40	Closterovirus	O
41	.	O

1	This	O
2	E	O
3	box	O
4	sequence	O
5	(	O
6	CACGTG	O
7	)	O
8	is	O
9	identical	O
10	to	O
11	the	O
12	binding	O
13	element	O
14	for	O
15	USF	B
16	(	O
17	upstream	B
18	stimulatory	I
19	factor	I
20	),	O
21	a	O
22	member	O
23	of	O
24	the	O
25	helix	B
26	-	I
27	loop	I
28	-	I
29	helix	I
30	family	I
31	of	I
32	transcription	I
33	factors	I
34	.	O

1	Interferon	B
2	beta	I
3	therapy	O
4	was	O
5	discontinued	O
6	for	O
7	4	O
8	weeks	O
9	.	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	B
8	in	O
9	nmt1	B
10	-	O
11	451Dino2	B
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O

1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	of	O
5	the	O
6	reverse	B
7	transcriptase	I
8	domain	I
9	confirms	O
10	our	O
11	differential	O
12	genetic	O
13	assessment	O
14	that	O
15	Cyclops	B
16	from	O
17	pea	O
18	is	O
19	a	O
20	novel	O
21	element	O
22	with	O
23	no	O
24	specific	O
25	relationship	O
26	to	O
27	the	O
28	previously	O
29	described	O
30	Gypsy	B
31	-	I
32	like	I
33	elements	I
34	from	O
35	plants	O
36	.	O

1	In	O
2	addition	O
3	,	O
4	insulin	B
5	induced	O
6	AP	B
7	-	I
8	1	I
9	DNA	O
10	binding	O
11	activity	O
12	,	O
13	this	O
14	effect	O
15	being	O
16	totally	O
17	prevented	O
18	in	O
19	the	O
20	presence	O
21	of	O
22	MEK	B
23	-	I
24	1	I
25	inhibitor	O
26	.	O

1	Essentially	O
2	,	O
3	2	O
4	'-	O
5	O	O
6	-	O
7	methyl	O
8	oligoribonucleotides	O
9	(	O
10	2	O
11	'	O
12	OMeRNA	O
13	)	O
14	were	O
15	delivered	O
16	to	O
17	the	O
18	nuclei	O
19	of	O
20	primary	O
21	mdx	O
22	myoblasts	O
23	in	O
24	culture	O
25	.	O

1	Regulation	O
2	of	O
3	the	O
4	human	O
5	p21	B
6	/	O
7	WAF1	B
8	/	O
9	Cip1	B
10	promoter	O
11	in	O
12	hepatic	O
13	cells	O
14	by	O
15	functional	O
16	interactions	O
17	between	O
18	Sp1	B
19	and	O
20	Smad	B
21	family	I
22	members	I
23	.	O

1	The	O
2	therapeutic	O
3	use	O
4	of	O
5	botulinum	B
6	toxin	I
7	(	O
8	Botox	B
9	)	O
10	is	O
11	increasing	O
12	in	O
13	popularity	O
14	.	O

1	The	O
2	viral	B
3	oncoprotein	I
4	E1A	I
5	inhibits	O
6	NFAT	B
7	-	O
8	dependent	O
9	transactivation	O
10	in	O
11	a	O
12	p300	B
13	-	O
14	dependent	O
15	manner	O
16	.	O

1	We	O
2	have	O
3	applied	O
4	the	O
5	mRNA	O
6	differential	O
7	display	O
8	method	O
9	to	O
10	compare	O
11	and	O
12	analyze	O
13	mRNAs	O
14	prepared	O
15	from	O
16	five	O
17	normal	O
18	nasopharyngeal	O
19	epithelial	O
20	cell	O
21	cultures	O
22	and	O
23	five	O
24	nasopharyngeal	O
25	carcinoma	O
26	cell	O
27	lines	O
28	.	O

1	The	O
2	brackets	O
3	were	O
4	bonded	O
5	to	O
6	100	O
7	freshly	O
8	extracted	O
9	bovine	O
10	incisors	O
11	,	O
12	and	O
13	,	O
14	after	O
15	storage	O
16	in	O
17	tap	O
18	water	O
19	at	O
20	room	O
21	temperature	O
22	for	O
23	24	O
24	hours	O
25	,	O
26	they	O
27	were	O
28	subsequently	O
29	tested	O
30	in	O
31	a	O
32	shear	O
33	mode	O
34	using	O
35	a	O
36	universal	O
37	testing	O
38	machine	O
39	.	O

1	Exercise	O
2	training	O
3	has	O
4	become	O
5	increasingly	O
6	important	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	heart	O
12	failure	O
13	patients	O
14	.	O

1	Regulation	O
2	of	O
3	myosin	B
4	phosphatase	I
5	activity	O
6	involves	O
7	changes	O
8	in	O
9	subunit	O
10	interactions	O
11	,	O
12	although	O
13	molecular	O
14	mechanisms	O
15	are	O
16	not	O
17	defined	O
18	.	O

1	Osteoadherin	B
2	is	O
3	a	O
4	recently	O
5	described	O
6	bone	O
7	proteoglycan	O
8	containing	O
9	keratan	O
10	sulfate	O
11	.	O

1	Moreover	O
2	,	O
3	the	O
4	mass	O
5	estimated	O
6	with	O
7	the	O
8	QCM	O
9	response	O
10	through	O
11	the	O
12	Sauerbrey	O
13	equation	O
14	and	O
15	the	O
16	mass	O
17	which	O
18	can	O
19	be	O
20	measured	O
21	thanks	O
22	to	O
23	other	O
24	analytical	O
25	techniques	O
26	,	O
27	in	O
28	our	O
29	case	O
30	an	O
31	enzymatic	O
32	assay	O
33	,	O
34	are	O
35	different	O
36	:	O
37	the	O
38	deposited	O
39	mass	O
40	is	O
41	generally	O
42	overestimated	O
43	by	O
44	the	O
45	QCM	O
46	.	O

1	The	O
2	genes	O
3	encoding	O
4	(	B
5	2Fe	I
6	-	I
7	2S	I
8	)	I
9	plant	I
10	-	I
11	like	I
12	ferredoxins	I
13	were	O
14	studied	O
15	in	O
16	the	O
17	widely	O
18	used	O
19	cyanobacterium	O
20	Synechocystis	O
21	PCC6803	O
22	.	O

1	It	O
2	can	O
3	also	O
4	be	O
5	used	O
6	to	O
7	examine	O
8	various	O
9	laryngeal	O
10	parameters	O
11	obtained	O
12	from	O
13	videotaped	O
14	endoscopic	O
15	and	O
16	stroboscopic	O
17	examinations	O
18	.	O

1	They	O
2	also	O
3	indicate	O
4	that	O
5	direct	O
6	interactions	O
7	between	O
8	C	B
9	/	I
10	EBPs	I
11	and	O
12	specific	O
13	Ets	B
14	family	O
15	members	O
16	,	O
17	together	O
18	with	O
19	GATA	B
20	-	I
21	1	I
22	,	O
23	are	O
24	important	O
25	for	O
26	eosinophil	O
27	lineage	O
28	determination	O
29	.	O

1	Recently	O
2	,	O
3	a	O
4	human	B
5	transcription	I
6	elongation	I
7	factor	I
8	P	I
9	-	I
10	TEFb	I
11	,	O
12	consisting	O
13	of	O
14	CDK9	B
15	kinase	I
16	,	O
17	cyclin	B
18	T	I
19	and	O
20	other	O
21	associated	O
22	factors	O
23	,	O
24	has	O
25	been	O
26	shown	O
27	to	O
28	interact	O
29	with	O
30	Tat	B
31	to	O
32	restore	O
33	Tat	B
34	activation	O
35	in	O
36	HeLa	O
37	nuclear	O
38	extract	O
39	depleted	O
40	of	O
41	P	B
42	-	I
43	TEFb	I
44	.	O

1	We	O
2	have	O
3	used	O
4	the	O
5	hydrophobic	O
6	repeats	O
7	of	O
8	the	O
9	HSF1	B
10	trimerization	I
11	domain	I
12	in	O
13	the	O
14	yeast	O
15	two	O
16	-	O
17	hybrid	O
18	protein	O
19	interaction	O
20	assay	O
21	to	O
22	identify	O
23	heat	B
24	shock	I
25	factor	I
26	binding	I
27	protein	I
28	1	I
29	(	O
30	HSBP1	B
31	),	O
32	a	O
33	novel	O
34	,	O
35	conserved	O
36	,	O
37	76	O
38	-	O
39	amino	O
40	-	O
41	acid	O
42	protein	O
43	that	O
44	contains	O
45	two	O
46	extended	O
47	arrays	O
48	of	O
49	hydrophobic	O
50	repeats	O
51	that	O
52	interact	O
53	with	O
54	the	O
55	HSF1	B
56	heptad	I
57	repeats	I
58	.	O

1	The	O
2	general	O
3	recombination	O
4	at	O
5	a	O
6	polarizing	O
7	voltage	O
8	of	O
9	300	O
10	V	O
11	is	O
12	less	O
13	than	O
14	2	O
15	%	O
16	for	O
17	dose	O
18	-	O
19	rates	O
20	up	O
21	to	O
22	about	O
23	100	O
24	mGy	O
25	min	O
26	-	O
27	1	O
28	.	O

1	The	O
2	DHEAS	O
3	levels	O
4	in	O
5	all	O
6	stages	O
7	of	O
8	decreased	O
9	BMD	O
10	were	O
11	significantly	O
12	lower	O
13	than	O
14	those	O
15	in	O
16	the	O
17	group	O
18	with	O
19	normal	O
20	BMD	O
21	.	O

1	Orientation	O
2	of	O
3	the	O
4	nuclear	O
5	spin	O
6	system	O
7	by	O
8	optical	O
9	pumping	O
10	causes	O
11	an	O
12	Overhauser	O
13	shift	O
14	of	O
15	the	O
16	excitonic	O
17	energy	O
18	levels	O
19	proportional	O
20	to	O
21	the	O
22	degree	O
23	of	O
24	nuclear	O
25	orientation	O
26	.	O

1	272	O
2	,	O
3	19107	O
4	-	O
5	19110	O
6	).	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	find	O
6	that	O
7	E2F	B
8	-	I
9	1	I
10	can	O
11	cause	O
12	apoptosis	O
13	in	O
14	p53	B
15	-/-	I
16	tumour	O
17	cells	O
18	and	O
19	further	O
20	p300	B
21	,	O
22	which	O
23	also	O
24	functions	O
25	as	O
26	a	O
27	co	O
28	-	O
29	activator	O
30	for	O
31	the	O
32	E2F	B
33	/	O
34	DP	B
35	heterodimer	O
36	,	O
37	enhances	O
38	the	O
39	apoptotic	O
40	activity	O
41	of	O
42	E2F	B
43	-	I
44	1	I
45	.	O

1	Human	O
2	isoforms	O
3	,	O
4	designated	O
5	1	O
6	to	O
7	4	O
8	,	O
9	differ	O
10	from	O
11	each	O
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	O
17	used	O
18	.	O

1	Five	O
2	additional	O
3	copies	O
4	of	O
5	Lian	B
6	elements	I
7	were	O
8	isolated	O
9	,	O
10	mapped	O
11	by	O
12	restriction	O
13	digestion	O
14	,	O
15	and	O
16	partially	O
17	sequenced	O
18	.	O

1	Evolutionary	O
2	relationships	O
3	among	O
4	putative	O
5	RNA	B
6	-	I
7	dependent	I
8	RNA	I
9	polymerases	I
10	encoded	O
11	by	O
12	a	O
13	mitochondrial	O
14	virus	O
15	-	O
16	like	O
17	RNA	O
18	in	O
19	the	O
20	Dutch	O
21	elm	O
22	disease	O
23	fungus	O
24	,	O
25	Ophiostoma	O
26	novo	O
27	-	O
28	ulmi	O
29	,	O
30	by	O
31	other	O
32	viruses	O
33	and	O
34	virus	O
35	-	O
36	like	O
37	RNAs	O
38	and	O
39	by	O
40	the	O
41	Arabidopsis	O
42	mitochondrial	O
43	genome	O
44	.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	O
7	core	O
8	region	O
9	and	O
10	transcription	B
11	factor	I
12	YY1	I
13	in	O
14	Rous	B
15	sarcoma	I
16	virus	I
17	long	I
18	terminal	I
19	repeat	I
20	promoter	I
21	activity	O
22	.	O

1	In	O
2	these	O
3	cells	O
4	,	O
5	ras	B
6	-	O
7	induced	O
8	transition	O
9	is	O
10	accompanied	O
11	by	O
12	a	O
13	strong	O
14	induction	O
15	of	O
16	AP	B
17	-	I
18	1	I
19	-	O
20	binding	O
21	activity	O
22	along	O
23	with	O
24	increased	O
25	expression	O
26	of	O
27	CD44	B
28	mRNA	I
29	and	O
30	protein	O
31	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	Mg2	O
6	+,	O
7	a	O
8	hydrophobic	O
9	exonuclease	O
10	site	O
11	dominates	O
12	over	O
13	the	O
14	polymerase	O
15	site	O
16	for	O
17	possession	O
18	of	O
19	the	O
20	primer	O
21	terminus	O
22	.	O

1	Each	O
2	binding	O
3	site	O
4	,	O
5	however	O
6	,	O
7	was	O
8	different	O
9	in	O
10	its	O
11	preference	O
12	for	O
13	binding	O
14	partners	O
15	.	O

1	"	O
2	Complex	O
3	partial	O
4	"	O
5	seizures	O
6	.	O

1	Chem	O
2	.,	O
3	270	O
4	:	O
5	7117	O
6	-	O
7	7124	O
8	,	O
9	1995	O
10	;	O
11	and	O
12	MT	O
13	Hartsough	O
14	et	O
15	al	O
16	.,	O
17	J	O
18	.	O

1	One	O
2	is	O
3	to	O
4	act	O
5	within	O
6	the	O
7	visceral	O
8	endoderm	O
9	to	O
10	promote	O
11	proper	O
12	streak	O
13	morphogenesis	O
14	.	O

1	We	O
2	propose	O
3	that	O
4	noi	B
5	/	O
6	pax2	B
7	.	I
8	1	I
9	participates	O
10	in	O
11	sequential	O
12	signaling	O
13	processes	O
14	as	O
15	a	O
16	key	O
17	integrator	O
18	of	O
19	midbrain	O
20	-	O
21	hindbrain	O
22	boundary	O
23	development	O
24	.	O

1	METHODS	O
2	:	O
3	Fibrotic	O
4	changes	O
5	involving	O
6	bone	O
7	marrow	O
8	were	O
9	evaluated	O
10	histologically	O
11	semiquantitatively	O
12	using	O
13	reticulin	B
14	fiber	O
15	impregnation	O
16	(	O
17	method	O
18	of	O
19	Gomori	O
20	).	O

1	Pol32Delta	B
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	The	O
2	aim	O
3	of	O
4	the	O
5	study	O
6	was	O
7	to	O
8	correlate	O
9	the	O
10	responsiveness	O
11	to	O
12	bronchoprovocation	O
13	with	O
14	methacholine	O
15	in	O
16	subjects	O
17	a	O
18	with	O
19	allergic	O
20	rhinitis	O
21	during	O
22	and	O
23	out	O
24	of	O
25	the	O
26	pollen	O
27	season	O
28	with	O
29	total	O
30	serum	O
31	IgE	B
32	and	O
33	blood	O
34	eosinophils	O
35	.	O

1	This	O
2	study	O
3	reports	O
4	the	O
5	isolation	O
6	of	O
7	a	O
8	P	O
9	.	O
10	hybrida	O
11	gene	O
12	,	O
13	jaf13	B
14	,	O
15	encoding	O
16	a	O
17	basic	B
18	helix	I
19	-	I
20	loop	I
21	-	I
22	helix	I
23	protein	I
24	that	O
25	,	O
26	on	O
27	the	O
28	basis	O
29	of	O
30	sequence	O
31	homology	O
32	and	O
33	intron	O
34	/	O
35	exon	O
36	structure	O
37	,	O
38	represents	O
39	the	O
40	P	O
41	.	O
42	hybrida	O
43	orthologue	O
44	of	O
45	the	O
46	Z	B
47	.	I
48	mays	I
49	r	I
50	genes	I
51	.	O

1	METHODS	O
2	:	O
3	Millipore	O
4	ultrafiltration	O
5	membranes	O
6	of	O
7	three	O
8	different	O
9	pore	O
10	sizes	O
11	were	O
12	used	O
13	as	O
14	model	O
15	lenticule	O
16	materials	O
17	.	O
18	The	O
19	nominal	O
20	membrane	O
21	pore	O
22	sizes	O
23	were	O
24	0	O
25	.	O
26	1	O
27	microm	O
28	,	O
29	0	O
30	.	O
31	45	O
32	microm	O
33	,	O
34	and	O
35	3	O
36	microm	O
37	;	O
38	the	O
39	surface	O
40	roughness	O
41	increased	O
42	in	O
43	the	O
44	same	O
45	order	O
46	The	O
47	membranes	O
48	were	O
49	coated	O
50	with	O
51	a	O
52	thin	O
53	layer	O
54	of	O
55	collagen	B
56	I	I
57	and	O
58	implanted	O
59	in	O
60	a	O
61	circular	O
62	pocket	O
63	of	O
64	the	O
65	anterior	O
66	cornea	O
67	of	O
68	adult	O
69	cats	O
70	,	O
71	and	O
72	were	O
73	clinically	O
74	evaluated	O
75	for	O
76	the	O
77	extent	O
78	of	O
79	epithelialization	O
80	and	O
81	the	O
82	persistence	O
83	of	O
84	epithelial	O
85	attachment	O
86	.	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	B
5	and	O
6	another	O
7	homeodomain	B
8	protein	I
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	B
24	promoter	I
25	in	O
26	transfection	O
27	assays	O
28	.	O

1	Downregulation	O
2	of	O
3	FUS	B
4	expression	O
5	in	O
6	BCR	B
7	/	O
8	ABL	B
9	-	O
10	expressing	O
11	32Dcl3	O
12	cells	O
13	was	O
14	associated	O
15	with	O
16	suppression	O
17	of	O
18	growth	O
19	factor	O
20	-	O
21	independent	O
22	colony	O
23	formation	O
24	,	O
25	restoration	O
26	of	O
27	G	B
28	-	I
29	CSF	I
30	-	O
31	induced	O
32	granulocytic	O
33	differentiation	O
34	and	O
35	reduced	O
36	tumorigenic	O
37	potential	O
38	in	O
39	vivo	O
40	.	O

1	This	O
2	repressor	O
3	is	O
4	however	O
5	unlikely	O
6	to	O
7	mediate	O
8	spi	B
9	2	I
10	.	I
11	3	I
12	3	I
13	'	I
14	UTR	I
15	silencer	I
16	action	O
17	since	O
18	it	O
19	was	O
20	not	O
21	detected	O
22	in	O
23	rat	O
24	hepatocytes	O
25	.	O

1	Specifically	O
2	,	O
3	I	O
4	use	O
5	molecular	O
6	markers	O
7	that	O
8	identify	O
9	particular	O
10	neuroectodermal	O
11	domains	O
12	,	O
13	all	O
14	neuroblasts	O
15	or	O
16	individual	O
17	neuroblasts	O
18	,	O
19	to	O
20	show	O
21	that	O
22	in	O
23	DER	B
24	mutant	I
25	embryos	O
26	(	O
27	1	O
28	)	O
29	intermediate	O
30	column	O
31	neuroblasts	O
32	do	O
33	not	O
34	form	O
35	,	O
36	(	O
37	2	O
38	)	O
39	medial	O
40	column	O
41	neuroblasts	O
42	often	O
43	acquire	O
44	identities	O
45	inappropriate	O
46	for	O
47	their	O
48	position	O
49	,	O
50	while	O
51	(	O
52	3	O
53	)	O
54	lateral	O
55	neuroblasts	O
56	develop	O
57	normally	O
58	.	O

1	The	O
2	complement	B
3	C3a	I
4	anaphylatoxin	I
5	receptor	I
6	(	O
7	C3aR	B
8	)	O
9	is	O
10	a	O
11	seven	B
12	-	I
13	transmembrane	I
14	G	I
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	B
25	peptide	I
26	ligand	I
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	Band	O
2	-	O
3	shift	O
4	assays	O
5	were	O
6	performed	O
7	using	O
8	the	O
9	LPS	B
10	-	I
11	and	I
12	IL	I
13	-	I
14	1	I
15	-	I
16	responsive	I
17	element	I
18	(	O
19	LILRE	B
20	)	O
21	oligonucleotide	O
22	,	O
23	a	O
24	gamma	B
25	interferon	I
26	activation	I
27	site	I
28	-	I
29	like	I
30	site	I
31	that	O
32	is	O
33	present	O
34	in	O
35	the	O
36	human	B
37	IL	I
38	-	I
39	1beta	I
40	promoter	I
41	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	contains	O
7	the	O
8	PTP	B
9	-	I
10	like	I
11	domain	I
12	,	O
13	whereas	O
14	the	O
15	N	O
16	-	O
17	terminal	O
18	region	O
19	shows	O
20	no	O
21	homology	O
22	to	O
23	any	O
24	known	O
25	mammalian	O
26	protein	O
27	.	O

1	In	O
2	addition	O
3	,	O
4	and	O
5	in	O
6	support	O
7	of	O
8	a	O
9	mediating	O
10	role	O
11	of	O
12	STATs	B
13	in	O
14	the	O
15	activation	O
16	of	O
17	the	O
18	p21	B
19	promoter	I
20	,	O
21	overexpression	O
22	of	O
23	Stat3	B
24	potentiated	O
25	the	O
26	cytokine	O
27	effect	O
28	on	O
29	the	O
30	p21	B
31	promoter	I
32	;	O
33	whereas	O
34	a	O
35	dominant	B
36	negative	I
37	Stat3	I
38	,	O
39	or	O
40	a	O
41	mutation	O
42	of	O
43	the	O
44	STAT	B
45	response	I
46	element	I
47	on	O
48	the	O
49	promoter	O
50	,	O
51	significantly	O
52	reduced	O
53	the	O
54	cytokine	O
55	effect	O
56	.	O

1	Randomly	O
2	selected	O
3	300	O
4	children	O
5	aged	O
6	3	O
7	months	O
8	-	O
9	3	O
10	yr	O
11	were	O
12	analysed	O
13	over	O
14	a	O
15	period	O
16	of	O
17	one	O
18	year	O
19	for	O
20	estimating	O
21	prevalence	O
22	of	O
23	nutritional	O
24	anaemia	O
25	.	O

1	Arnt3	B
2	mRNA	I
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	P19	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O

1	The	O
2	genomic	O
3	structure	O
4	and	O
5	chromosomal	O
6	location	O
7	of	O
8	the	O
9	human	B
10	TR2	I
11	orphan	I
12	receptor	I
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	steroid	B
19	receptor	I
20	superfamily	I
21	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	distribution	O
6	of	O
7	endocytic	O
8	markers	O
9	is	O
10	not	O
11	affected	O
12	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	residues	O
7	in	O
8	this	O
9	domain	O
10	(	O
11	R82A	O
12	,	O
13	K85A	O
14	,	O
15	K88A	O
16	,	O
17	and	O
18	V89A	O
19	)	O
20	resulted	O
21	in	O
22	proteins	O
23	which	O
24	failed	O
25	to	O
26	transactivate	O
27	from	O
28	the	O
29	HTLV	B
30	-	I
31	1	I
32	LTR	I
33	in	O
34	vivo	O
35	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	GluR2	B
6	gene	I
7	:	O
8	neural	O
9	-	O
10	specific	O
11	expression	O
12	,	O
13	multiple	O
14	promoters	O
15	,	O
16	and	O
17	regulatory	O
18	elements	O
19	.	O

1	Overexpression	O
2	of	O
3	MDR1	B
4	has	O
5	been	O
6	demonstrated	O
7	in	O
8	many	O
9	cancers	O
10	,	O
11	both	O
12	in	O
13	patient	O
14	tumors	O
15	and	O
16	in	O
17	cell	O
18	lines	O
19	selected	O
20	with	O
21	a	O
22	variety	O
23	of	O
24	chemotherapeutic	O
25	agents	O
26	.	O

1	The	O
2	present	O
3	study	O
4	sought	O
5	to	O
6	develop	O
7	an	O
8	equation	O
9	to	O
10	estimate	O
11	VO2peak	O
12	in	O
13	peripheral	O
14	arterial	O
15	occlusive	O
16	disease	O
17	(	O
18	PAOD	O
19	)	O
20	patients	O
21	with	O
22	intermittent	O
23	claudication	O
24	and	O
25	to	O
26	determine	O
27	independent	O
28	predictors	O
29	of	O
30	VO2peak	O
31	in	O
32	this	O
33	population	O
34	.	O

1	The	O
2	Abbreviated	O
3	Injury	O
4	Scale	O
5	(	O
6	AIS	O
7	),	O
8	Injury	O
9	Severity	O
10	Scale	O
11	and	O
12	TRISS	O
13	methodology	O
14	comprise	O
15	a	O
16	mathematically	O
17	sound	O
18	system	O
19	for	O
20	the	O
21	analysis	O
22	of	O
23	injuries	O
24	and	O
25	injured	O
26	patients	O
27	.	O

1	Seventy	O
2	-	O
3	five	O
4	percent	O
5	of	O
6	children	O
7	who	O
8	received	O
9	a	O
10	second	O
11	transplant	O
12	for	O
13	HCV	O
14	hepatitis	O
15	had	O
16	early	O
17	histologic	O
18	recurrence	O
19	that	O
20	led	O
21	to	O
22	liver	O
23	failure	O
24	and	O
25	death	O
26	.	O

1	The	O
2	PC	O
3	-	O
4	based	O
5	RTPS	O
6	is	O
7	designed	O
8	to	O
9	run	O
10	in	O
11	the	O
12	Microsoft	O
13	Windows	O
14	3	O
15	.	O
16	11	O
17	environment	O
18	(	O
19	and	O
20	later	O
21	versions	O
22	),	O
23	for	O
24	computers	O
25	equipped	O
26	with	O
27	486	O
28	or	O
29	Pentium	O
30	processors	O
31	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	functional	O
5	characterization	O
6	of	O
7	murine	B
8	sphingosine	I
9	kinase	I
10	.	O

1	A	O
2	further	O
3	mechanism	O
4	increasing	O
5	specific	O
6	activation	O
7	was	O
8	cooperation	O
9	of	O
10	receptors	O
11	at	O
12	multiple	O
13	and	O
14	weak	O
15	HREs	O
16	,	O
17	which	O
18	was	O
19	accentuated	O
20	in	O
21	the	O
22	presence	O
23	of	O
24	both	O
25	the	O
26	AR	B
27	N	O
28	terminus	O
29	and	O
30	ligand	O
31	binding	O
32	domain	O
33	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	the	O
9	cooperation	O
10	of	O
11	transcription	B
12	factors	I
13	NF	I
14	-	I
15	kappaB	I
16	and	O
17	AP	B
18	-	I
19	1	I
20	is	O
21	essential	O
22	for	O
23	transactivation	O
24	of	O
25	IL	B
26	-	I
27	8	I
28	gene	I
29	by	O
30	HTLV	B
31	-	I
32	I	I
33	Tax	I
34	.	O

1	The	O
2	defect	O
3	in	O
4	these	O
5	proteins	O
6	was	O
7	also	O
8	uniformly	O
9	suppressed	O
10	by	O
11	either	O
12	Mn2	O
13	+,	O
14	or	O
15	the	O
16	Mu	B
17	B	I
18	protein	I
19	in	O
20	the	O
21	presence	O
22	of	O
23	ATP	O
24	and	O
25	target	O
26	DNA	O
27	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	We	O
5	observed	O
6	a	O
7	congenital	O
8	skin	O
9	defect	O
10	located	O
11	exclusively	O
12	on	O
13	the	O
14	trunk	O
15	.	O

1	Surprisingly	O
2	,	O
3	double	O
4	mutants	O
5	of	O
6	the	O
7	shy2	B
8	-	I
9	1D	I
10	mutant	I
11	with	O
12	the	O
13	phytochrome	B
14	-	O
15	deficient	O
16	mutants	O
17	hy2	B
18	,	O
19	hy3	B
20	(	O
21	phyB	B
22	-	I
23	1	I
24	)	O
25	and	O
26	fre1	B
27	-	I
28	1	I
29	(	O
30	phyA	B
31	-	I
32	201	I
33	)	O
34	showed	O
35	reduced	O
36	photomorphogenic	O
37	response	O
38	in	O
39	darkness	O
40	with	O
41	a	O
42	longer	O
43	hypocotyl	O
44	,	O
45	a	O
46	longer	O
47	inflorescence	O
48	stem	O
49	,	O
50	and	O
51	a	O
52	lower	O
53	level	O
54	expression	O
55	of	O
56	the	O
57	CAB	B
58	gene	I
59	than	O
60	the	O
61	shy2	B
62	-	I
63	1D	I
64	single	I
65	mutant	I
66	.	O

1	Clone	O
2	39	O
3	was	O
4	a	O
5	homolog	O
6	of	O
7	CONSTANS	B
8	,	O
9	which	O
10	is	O
11	a	O
12	gene	O
13	involved	O
14	in	O
15	controlling	O
16	the	O
17	flowering	O
18	time	O
19	in	O
20	Arabidopsis	O
21	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	desmethyltrimebutine	O
2	was	O
3	inactive	O
4	.	O

1	The	O
2	presence	O
3	of	O
4	PDZ	B
5	and	O
6	SAM	O
7	domains	O
8	in	O
9	the	O
10	KS5	B
11	protein	I
12	suggests	O
13	that	O
14	it	O
15	may	O
16	act	O
17	as	O
18	a	O
19	molecular	O
20	adaptor	O
21	,	O
22	promoting	O
23	and	O
24	relaying	O
25	information	O
26	in	O
27	a	O
28	signal	O
29	transduction	O
30	pathway	O
31	.	O

1	However	O
2	,	O
3	while	O
4	IL	B
5	-	I
6	1beta	I
7	and	O
8	TNF	B
9	-	I
10	alpha	I
11	both	O
12	induced	O
13	nuclear	O
14	binding	O
15	of	O
16	the	O
17	Rel	B
18	proteins	I
19	p50	I
20	and	O
21	p65	B
22	to	O
23	an	O
24	NF	B
25	-	I
26	kappaB	I
27	consensus	I
28	oligonucleotide	I
29	in	O
30	gel	O
31	shift	O
32	assays	O
33	and	O
34	caused	O
35	transient	O
36	degradation	O
37	of	O
38	inhibitor	B
39	of	I
40	NF	I
41	-	I
42	kappaB	I
43	-	I
44	alpha	I
45	(	O
46	IkappaB	B
47	-	I
48	alpha	I
49	)	O
50	in	O
51	the	O
52	cytoplasm	O
53	of	O
54	myofibroblasts	O
55	,	O
56	only	O
57	IL	B
58	-	I
59	1beta	I
60	upregulated	O
61	PDGF	B
62	-	I
63	Ralpha	I
64	.	O

1	Cotransfections	O
2	with	O
3	ATF	B
4	-	I
5	2	I
6	and	O
7	HNF	B
8	-	I
9	4	I
10	expression	O
11	plasmids	O
12	resulted	O
13	in	O
14	additive	O
15	transactivation	O
16	of	O
17	the	O
18	apoCIII	B
19	promoter	I
20	.	O

1	Interestingly	O
2	,	O
3	an	O
4	antibody	O
5	against	O
6	N	B
7	-	I
8	SMase	I
9	can	O
10	abrogate	O
11	Ox	B
12	-	I
13	LDL	I
14	-	O
15	and	O
16	TNF	B
17	-	I
18	alpha	I
19	-	O
20	induced	O
21	apoptosis	O
22	and	O
23	therefore	O
24	may	O
25	be	O
26	useful	O
27	for	O
28	in	O
29	vivo	O
30	studies	O
31	of	O
32	apoptosis	O
33	in	O
34	experimental	O
35	animals	O
36	.	O

1	The	O
2	human	O
3	T	O
4	cell	O
5	lymphotropic	O
6	retrovirus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	trans	O
15	-	O
16	activator	O
17	,	O
18	Tax	B
19	,	O
20	interacts	O
21	specifically	O
22	with	O
23	the	O
24	basic	B
25	-	I
26	domain	I
27	/	I
28	leucine	I
29	-	I
30	zipper	I
31	(	I
32	bZip	I
33	)	I
34	protein	I
35	,	O
36	cAMP	B
37	response	I
38	element	I
39	binding	I
40	protein	I
41	(	O
42	CREB	B
43	),	O
44	bound	O
45	to	O
46	the	O
47	viral	B
48	Tax	I
49	-	I
50	responsive	I
51	element	I
52	consisting	O
53	of	O
54	three	O
55	imperfect	O
56	21	O
57	-	O
58	base	O
59	pair	O
60	repeats	O
61	,	O
62	each	O
63	with	O
64	a	O
65	cAMP	O
66	response	O
67	element	O
68	core	O
69	flanked	O
70	by	O
71	G	O
72	/	O
73	C	O
74	-	O
75	rich	O
76	sequences	O
77	.	O

1	Cotransfection	O
2	of	O
3	the	O
4	helicase	B
5	-	O
6	primase	B
7	proteins	O
8	,	O
9	one	O
10	of	O
11	which	O
12	was	O
13	fused	O
14	to	O
15	a	O
16	heterologous	O
17	activation	O
18	domain	O
19	,	O
20	led	O
21	to	O
22	Zta	B
23	-	O
24	dependent	O
25	superactivation	O
26	of	O
27	CAT	B
28	expression	O
29	.	O

1	This	O
2	domain	O
3	,	O
4	although	O
5	adjacent	O
6	to	O
7	the	O
8	5	O
9	'	O
10	edge	O
11	of	O
12	the	O
13	SD	O
14	sequence	O
15	,	O
16	does	O
17	not	O
18	inhibit	O
19	ribosome	O
20	binding	O
21	as	O
22	long	O
23	as	O
24	the	O
25	single	O
26	-	O
27	stranded	O
28	region	O
29	of	O
30	domain	O
31	3	O
32	is	O
33	present	O
34	.	O

1	A	O
2	technique	O
3	for	O
4	thermal	O
5	imaging	O
6	of	O
7	the	O
8	animal	O
9	and	O
10	human	O
11	brain	O
12	cortex	O
13	using	O
14	an	O
15	infrared	O
16	optical	O
17	system	O
18	is	O
19	described	O
20	.	O

1	As	O
2	PP2A	B
3	exerts	O
4	a	O
5	range	O
6	of	O
7	cellular	O
8	functions	O
9	including	O
10	cell	O
11	cycle	O
12	regulation	O
13	and	O
14	cell	O
15	fate	O
16	determination	O
17	,	O
18	we	O
19	were	O
20	surprised	O
21	to	O
22	find	O
23	that	O
24	these	O
25	embryos	O
26	develop	O
27	normally	O
28	until	O
29	postimplantation	O
30	,	O
31	around	O
32	embryonic	O
33	day	O
34	5	O
35	.	O
36	5	O
37	/	O
38	6	O
39	.	O
40	0	O
41	.	O

1	The	O
2	activated	O
3	glucocorticoid	B
4	receptor	I
5	forms	O
6	a	O
7	complex	O
8	with	O
9	Stat5	B
10	and	O
11	enhances	O
12	Stat5	B
13	-	O
14	mediated	O
15	transcriptional	O
16	induction	O
17	.	O

1	T	O
2	.,	O
3	Mahasneh	O
4	,	O
5	A	O
6	.,	O
7	and	O
8	Cote	O
9	,	O
10	G	O
11	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	portion	O
6	of	O
7	UKLF	B
8	contains	O
9	three	O
10	zinc	O
11	fingers	O
12	of	O
13	the	O
14	Cys2	O
15	-	O
16	His2	O
17	type	O
18	and	O
19	binds	O
20	in	O
21	vitro	O
22	to	O
23	the	O
24	CACCC	O
25	motif	O
26	of	O
27	the	O
28	beta	B
29	-	I
30	globin	I
31	promoter	I
32	and	O
33	to	O
34	the	O
35	Sp1	B
36	recognition	I
37	sequence	I
38	.	O

1	We	O
2	have	O
3	recently	O
4	identified	O
5	a	O
6	mouse	O
7	enzyme	O
8	termed	O
9	gamma	B
10	-	I
11	glutamyl	I
12	leukotrienase	I
13	(	O
14	GGL	B
15	)	O
16	that	O
17	converts	O
18	leukotriene	O
19	C4	O
20	(	O
21	LTC4	O
22	)	O
23	to	O
24	leukotriene	O
25	D4	O
26	(	O
27	LTD4	O
28	).	O

1	The	O
2	ARF	B
3	promoter	I
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	B
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	Observers	O
2	with	O
3	brain	O
4	injury	O
5	and	O
6	control	O
7	participants	O
8	performed	O
9	a	O
10	vigilance	O
11	task	O
12	during	O
13	which	O
14	they	O
15	received	O
16	periodic	O
17	whiffs	O
18	of	O
19	unscented	O
20	air	O
21	or	O
22	air	O
23	scented	O
24	with	O
25	peppermint	O
26	.	O

1	Some	O
2	of	O
3	the	O
4	peptide	B
5	:	I
6	MBP	I
7	fusions	I
8	were	O
9	also	O
10	analyzed	O
11	using	O
12	surface	O
13	plasmon	O
14	resonance	O
15	.	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	Analysis	O
2	of	O
3	chromosomal	O
4	DNA	O
5	sequence	O
6	immediately	O
7	downstream	O
8	of	O
9	the	O
10	transposon	O
11	insertion	O
12	identified	O
13	two	O
14	open	O
15	reading	O
16	frames	O
17	,	O
18	designated	O
19	csrR	B
20	and	O
21	csrS	B
22	,	O
23	which	O
24	exhibited	O
25	sequence	O
26	similarity	O
27	to	O
28	bacterial	O
29	two	O
30	-	O
31	component	O
32	regulatory	O
33	systems	O
34	.	O

1	J	O
2	.	O

1	PURPOSE	O
2	:	O
3	The	O
4	role	O
5	interleukin	B
6	-	I
7	6	I
8	(	O
9	IL	B
10	-	I
11	6	I
12	)	O
13	in	O
14	the	O
15	treatment	O
16	of	O
17	congenital	O
18	thrombocytopenias	O
19	is	O
20	unknown	O
21	.	O

1	Galphaq	B
2	,	O
3	Galpha12	B
4	,	O
5	and	O
6	Galpha13	B
7	,	O
8	but	O
9	not	O
10	Galphai	B
11	,	O
12	activate	O
13	SRF	B
14	through	O
15	RhoA	B
16	.	O

1	We	O
2	mapped	O
3	two	O
4	overlapping	O
5	expressed	O
6	sequence	O
7	tag	O
8	clones	O
9	within	O
10	a	O
11	genomic	O
12	contig	O
13	on	O
14	human	O
15	chromosome	O
16	5	O
17	,	O
18	band	O
19	q31	O
20	.	O

1	SRC	B
2	-	I
3	1	I
4	can	O
5	relieve	O
6	the	O
7	NF	B
8	-	I
9	kappaB	I
10	-	O
11	mediated	O
12	repression	O
13	of	O
14	GR	B
15	activity	O
16	.	O

1	However	O
2	the	O
3	sequence	O
4	surrounding	O
5	the	O
6	transcription	O
7	start	O
8	site	O
9	CTCA	O
10	(+	O
11	1	O
12	)	O
13	TTCC	O
14	was	O
15	similar	O
16	to	O
17	the	O
18	consensus	O
19	CTCA	O
20	(+	O
21	1	O
22	)	O
23	NTCT	O
24	(	O
25	N	O
26	is	O
27	any	O
28	nucleoside	O
29	)	O
30	for	O
31	an	O
32	initiator	O
33	element	O
34	found	O
35	in	O
36	terminal	B
37	deoxynucleotidyltransferase	I
38	and	O
39	a	O
40	number	O
41	of	O
42	other	O
43	highly	O
44	regulated	O
45	genes	O
46	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	total	O
7	number	O
8	of	O
9	subunit	O
10	c	O
11	in	O
12	F0	B
13	should	O
14	be	O
15	a	O
16	multiple	O
17	of	O
18	2	O
19	and	O
20	3	O
21	.	O

1	The	O
2	interaction	O
3	of	O
4	AF	O
5	-	O
6	1	O
7	with	O
8	proteins	O
9	that	O
10	regulate	O
11	distinct	O
12	steps	O
13	of	O
14	transcription	O
15	may	O
16	provide	O
17	a	O
18	mechanism	O
19	for	O
20	synergistic	O
21	activation	O
22	of	O
23	gene	O
24	expression	O
25	by	O
26	AF	O
27	-	O
28	1	O
29	.	O

1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	O
21	.	O
22	5kb	O
23	transcript	O
24	size	O
25	.	O

1	RBP56	B
2	protein	I
3	turned	O
4	out	O
5	to	O
6	be	O
7	hTAFII68	B
8	which	O
9	was	O
10	isolated	O
11	as	O
12	a	O
13	TATA	B
14	-	I
15	binding	I
16	protein	I
17	associated	I
18	factor	I
19	(	O
20	TAF	B
21	)	O
22	from	O
23	a	O
24	sub	O
25	-	O
26	population	O
27	of	O
28	TFIID	B
29	complexes	I
30	(	O
31	Bertolotti	O
32	A	O
33	.,	O
34	Lutz	O
35	,	O
36	Y	O
37	.,	O
38	Heard	O
39	,	O
40	D	O
41	.	O
42	J	O
43	.,	O
44	Chambon	O
45	,	O
46	P	O
47	.,	O
48	Tora	O
49	,	O
50	L	O
51	.,	O
52	1996	O
53	.	O
54	hTAFII68	B
55	,	O
56	a	O
57	novel	O
58	RNA	O
59	/	O
60	ssDNA	O
61	-	O
62	binding	O
63	protein	O
64	with	O
65	homology	O
66	to	O
67	the	O
68	proto	O
69	-	O
70	oncoproteins	O
71	TLS	B
72	/	O
73	FUS	B
74	and	O
75	EWS	B
76	is	O
77	associated	O
78	with	O
79	both	O
80	TFIID	B
81	and	O
82	RNA	B
83	polymerase	I
84	II	I
85	.	O

1	Gel	O
2	-	O
3	mobility	O
4	shift	O
5	analysis	O
6	was	O
7	also	O
8	performed	O
9	for	O
10	the	O
11	CCAAT	O
12	motif	O
13	at	O
14	-	O
15	67	O
16	.	O

1	Another	O
2	tentative	O
3	hotspot	O
4	mutation	O
5	in	O
6	the	O
7	third	O
8	patient	O
9	,	O
10	a	O
11	frame	O
12	shift	O
13	caused	O
14	by	O
15	a	O
16	G	O
17	nucleotide	O
18	insertion	O
19	in	O
20	a	O
21	monotonous	O
22	repeat	O
23	of	O
24	six	O
25	Gs	O
26	in	O
27	HPRT	B
28	exon	I
29	3	I
30	,	O
31	has	O
32	been	O
33	reported	O
34	previously	O
35	in	O
36	three	O
37	other	O
38	LN	O
39	patients	O
40	.	O

1	Large	O
2	-	O
3	scale	O
4	sequencing	O
5	of	O
6	two	O
7	regions	O
8	in	O
9	human	O
10	chromosome	O
11	7q22	O
12	:	O
13	analysis	O
14	of	O
15	650	O
16	kb	O
17	of	O
18	genomic	O
19	sequence	O
20	around	O
21	the	O
22	EPO	B
23	and	O
24	CUTL1	B
25	loci	I
26	reveals	O
27	17	O
28	genes	O
29	.	O

1	The	O
2	full	O
3	-	O
4	length	O
5	N	B
6	gene	I
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	O
24	-	O
25	8	O
26	.	O

1	Transcription	O
2	factors	O
3	of	O
4	the	O
5	Stat	B
6	family	I
7	are	O
8	controlled	O
9	by	O
10	protein	O
11	kinases	O
12	.	O

1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	Identification	O
2	of	O
3	a	O
4	new	O
5	gene	O
6	in	O
7	the	O
8	streptococcal	O
9	plasmid	O
10	pLS1	O
11	:	O
12	the	O
13	rnaI	B
14	gene	I
15	.	O

1	Rather	O
2	,	O
3	usp	B
4	is	O
5	required	O
6	in	O
7	late	O
8	third	O
9	instar	O
10	larvae	O
11	for	O
12	appropriate	O
13	developmental	O
14	and	O
15	transcriptional	O
16	responses	O
17	to	O
18	the	O
19	ecdysone	O
20	pulse	O
21	that	O
22	triggers	O
23	puparium	O
24	formation	O
25	.	O

1	BACKGROUND	O
2	:	O
3	Studies	O
4	in	O
5	lean	O
6	men	O
7	show	O
8	poor	O
9	regulation	O
10	of	O
11	energy	O
12	(	O
13	EB	O
14	)	O
15	and	O
16	fat	O
17	balance	O
18	(	O
19	FB	O
20	)	O
21	during	O
22	manipulation	O
23	of	O
24	dietary	O
25	ratios	O
26	of	O
27	fat	O
28	to	O
29	carbohydrate	O
30	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	-	O
6	profile	O
7	serine	O
8	substitutions	O
9	in	O
10	the	O
11	V3	B
12	loop	O
13	of	O
14	HIV	O
15	-	O
16	1	O
17	gp120	B
18	IIIB	I
19	/	O
20	LAI	B
21	on	O
22	the	O
23	immunogenicity	O
24	of	O
25	the	O
26	envelope	B
27	protein	O
28	.	O

1	Transcription	O
2	start	O
3	site	O
4	mapping	O
5	identified	O
6	the	O
7	presence	O
8	of	O
9	an	O
10	aphidicolin	O
11	-	O
12	sensitive	O
13	late	O
14	transcript	O
15	arising	O
16	from	O
17	a	O
18	TAAG	O
19	motif	O
20	located	O
21	at	O
22	-	O
23	352	O
24	nucleotides	O
25	and	O
26	an	O
27	aphidicolin	O
28	-	O
29	insensitive	O
30	early	O
31	transcript	O
32	originating	O
33	from	O
34	a	O
35	TTGT	O
36	motif	O
37	located	O
38	35	O
39	nucleotides	O
40	downstream	O
41	to	O
42	a	O
43	TATA	O
44	box	O
45	at	O
46	-	O
47	312	O
48	nucleotides	O
49	,	O
50	with	O
51	respect	O
52	to	O
53	the	O
54	+	O
55	1	O
56	ATG	O
57	of	O
58	lef2	B
59	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O

1	This	O
2	study	O
3	demonstrates	O
4	that	O
5	alteration	O
6	of	O
7	CDKN2	B
8	is	O
9	one	O
10	of	O
11	the	O
12	most	O
13	frequent	O
14	genetic	O
15	abnormalities	O
16	in	O
17	prostate	O
18	cancer	O
19	and	O
20	may	O
21	contribute	O
22	to	O
23	prostate	O
24	carcinogenesis	O
25	.	O

1	The	O
2	pharmacokinetic	O
3	parameters	O
4	which	O
5	helped	O
6	predict	O
7	these	O
8	toxicities	O
9	included	O
10	area	O
11	under	O
12	the	O
13	curve	O
14	and	O
15	peak	O
16	plasma	O
17	level	O
18	.	O

1	(	O
2	1992	O
3	)	O
4	Biochemistry	O
5	31	O
6	,	O
7	3351	O
8	-	O
9	3358	O
10	].	O

1	A	O
2	mutation	O
3	in	O
4	the	O
5	5	O
6	'	O
7	C2U4	O
8	repeat	O
9	causes	O
10	underaccumulation	O
11	of	O
12	snR13F	B
13	,	O
14	whereas	O
15	mutations	O
16	in	O
17	the	O
18	3	O
19	'	O
20	C2U4	O
21	repeat	O
22	cause	O
23	the	O
24	accumulation	O
25	of	O
26	two	O
27	novel	O
28	RNAs	O
29	that	O
30	migrate	O
31	in	O
32	the	O
33	500	O
34	-	O
35	nt	O
36	range	O
37	.	O

1	Endogenous	O
2	RMP	B
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	B
10	in	O
11	RNA	B
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	The	O
2	zona	O
3	pellucida	O
4	(	O
5	ZP	O
6	),	O
7	the	O
8	extracellular	O
9	glycocalyx	O
10	that	O
11	surrounds	O
12	the	O
13	oocyte	O
14	,	O
15	is	O
16	well	O
17	known	O
18	to	O
19	mediate	O
20	homologous	O
21	gamete	O
22	interaction	O
23	.	O

1	Quinone	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	O
12	binding	O
13	.	O

1	CONCLUSION	O
2	:	O
3	We	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	features	O
9	of	O
10	disease	O
11	likely	O
12	to	O
13	be	O
14	associated	O
15	with	O
16	a	O
17	clinically	O
18	useful	O
19	response	O
20	to	O
21	inhaled	O
22	NO	O
23	therapy	O
24	using	O
25	the	O
26	parameters	O
27	studied	O
28	.	O

1	This	O
2	core	O
3	sequence	O
4	,	O
5	along	O
6	with	O
7	additional	O
8	nonspecific	O
9	downstream	O
10	nucleotides	O
11	,	O
12	is	O
13	sufficient	O
14	for	O
15	partial	O
16	suppression	O
17	of	O
18	spliceosome	O
19	assembly	O
20	and	O
21	splicing	O
22	of	O
23	BPV	O
24	-	O
25	1	O
26	pre	O
27	-	O
28	mRNAs	O
29	.	O

1	The	O
2	Schizosaccharomyces	B
3	pombe	I
4	rad1	I
5	+	I
6	cell	I
7	cycle	I
8	checkpoint	I
9	control	I
10	gene	I
11	is	O
12	required	O
13	for	O
14	S	O
15	-	O
16	phase	O
17	and	O
18	G2	O
19	/	O
20	M	O
21	arrest	O
22	in	O
23	response	O
24	to	O
25	both	O
26	DNA	O
27	damage	O
28	and	O
29	incomplete	O
30	DNA	O
31	replication	O
32	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	established	O
6	that	O
7	progression	O
8	through	O
9	the	O
10	eukaryotic	O
11	cell	O
12	cycle	O
13	is	O
14	controlled	O
15	by	O
16	oscillations	O
17	in	O
18	the	O
19	activity	O
20	of	O
21	cyclin	B
22	-	I
23	dependent	I
24	kinases	I
25	(	O
26	CDKs	B
27	).	O

1	RT	O
2	-	O
3	PCR	O
4	analysis	O
5	showed	O
6	that	O
7	PLP	B
8	-	I
9	H	I
10	as	O
11	well	O
12	as	O
13	PLP	B
14	-	I
15	C	I
16	and	O
17	PLP	B
18	-	I
19	D	I
20	are	O
21	expressed	O
22	in	O
23	all	O
24	rat	O
25	strains	O
26	examined	O
27	,	O
28	confirming	O
29	that	O
30	PLP	B
31	diversity	O
32	is	O
33	not	O
34	due	O
35	to	O
36	strain	O
37	differences	O
38	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	characterization	O
5	of	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	rat	B
12	placental	I
13	prolactin	I
14	(	O
15	PRL	B
16	)	O
17	family	O
18	,	O
19	PRL	B
20	-	O
21	like	O
22	protein	B
23	H	I
24	.	O

1	The	O
2	retrovesical	O
3	hydatid	O
4	cyst	O
5	is	O
6	a	O
7	very	O
8	rare	O
9	site	O
10	.	O

1	Biochemical	O
2	analysis	O
3	reveals	O
4	that	O
5	KS1	B
6	is	O
7	a	O
8	nuclear	O
9	protein	O
10	containing	O
11	two	O
12	transcriptional	O
13	repressor	O
14	domains	O
15	,	O
16	R1	O
17	and	O
18	R2	O
19	.	O

1	The	O
2	results	O
3	raise	O
4	the	O
5	possibility	O
6	that	O
7	pH	O
8	induced	O
9	post	O
10	-	O
11	translational	O
12	modifications	O
13	of	O
14	DdRPA	B
15	are	O
16	involved	O
17	in	O
18	events	O
19	that	O
20	halt	O
21	cell	O
22	proliferation	O
23	and	O
24	induce	O
25	differentiation	O
26	in	O
27	Dictyostelium	O
28	.	O

1	Here	O
2	we	O
3	have	O
4	investigated	O
5	the	O
6	structural	O
7	requirements	O
8	and	O
9	consequences	O
10	of	O
11	regulatory	O
12	phosphorylation	O
13	for	O
14	the	O
15	interaction	O
16	between	O
17	c	B
18	-	I
19	Jun	I
20	and	O
21	JNK	B
22	in	O
23	vivo	O
24	.	O

1	The	O
2	method	O
3	also	O
4	eliminates	O
5	tagging	O
6	of	O
7	venous	O
8	spins	O
9	and	O
10	concern	O
11	about	O
12	asymmetric	O
13	magnetization	O
14	transfer	O
15	effects	O
16	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	provide	O
6	evidence	O
7	that	O
8	B	B
9	-	I
10	Myb	I
11	is	O
12	a	O
13	direct	O
14	physiological	O
15	target	O
16	for	O
17	cyclin	B
18	A	I
19	/	O
20	Cdk2	B
21	.	O

1	We	O
2	have	O
3	isolated	O
4	a	O
5	novel	O
6	human	B
7	cyclin	I
8	,	O
9	cyclin	B
10	E2	I
11	,	O
12	that	O
13	contains	O
14	significant	O
15	homology	O
16	to	O
17	cyclin	B
18	E	I
19	.	O

1	The	O
2	highly	O
3	amyloidogenic	O
4	42	O
5	-	O
6	residue	O
7	form	O
8	of	O
9	Abeta	B
10	(	O
11	Abeta42	B
12	)	O
13	is	O
14	the	O
15	first	O
16	species	O
17	to	O
18	be	O
19	deposited	O
20	in	O
21	both	O
22	sporadic	O
23	and	O
24	familial	O
25	AD	O
26	.	O

1	Schizosaccharomyces	O
2	pombe	O
3	cells	O
4	respond	O
5	to	O
6	nutrient	O
7	deprivation	O
8	by	O
9	altering	O
10	G2	O
11	/	O
12	M	O
13	cell	O
14	size	O
15	control	O
16	.	O

1	Raf	B
2	is	O
3	a	O
4	key	O
5	serine	B
6	-	I
7	threonine	I
8	protein	I
9	kinase	I
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	O
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O

1	In	O
2	turn	O
3	,	O
4	assembly	O
5	of	O
6	this	O
7	complex	O
8	mediates	O
9	the	O
10	enzymatic	O
11	activation	O
12	of	O
13	the	O
14	p21	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	1	I
20	and	O
21	facilitates	O
22	actin	B
23	polymerization	O
24	.	O

1	Nhp2p	B
2	is	O
3	a	O
4	highly	O
5	basic	O
6	protein	O
7	that	O
8	belongs	O
9	to	O
10	a	O
11	family	O
12	of	O
13	putative	O
14	RNA	O
15	-	O
16	binding	O
17	proteins	O
18	.	O

1	This	O
2	study	O
3	utilizes	O
4	the	O
5	mammalian	O
6	two	O
7	-	O
8	hybrid	O
9	system	O
10	to	O
11	examine	O
12	the	O
13	role	O
14	of	O
15	ligand	O
16	in	O
17	the	O
18	dimerization	O
19	of	O
20	human	B
21	progesterone	I
22	receptor	I
23	(	O
24	hPR	B
25	).	O

1	One	O
2	of	O
3	its	O
4	unique	O
5	features	O
6	appears	O
7	to	O
8	be	O
9	the	O
10	unusually	O
11	short	O
12	5	O
13	'-	O
14	untranslated	O
15	regions	O
16	(	O
17	UTR	O
18	)	O
19	(	O
20	1	O
21	-	O
22	6	O
23	nucleotides	O
24	(	O
25	nts	O
26	))	O
27	and	O
28	the	O
29	apparent	O
30	absence	O
31	of	O
32	5	O
33	'-	O
34	cap	O
35	structures	O
36	from	O
37	its	O
38	mRNAs	O
39	.	O

1	Both	O
2	the	O
3	presence	O
4	of	O
5	arginine	O
6	and	O
7	anaerobiosis	O
8	are	O
9	needed	O
10	to	O
11	trigger	O
12	induction	O
13	of	O
14	the	O
15	pathway	O
16	.	O

1	The	O
2	human	B
3	SHBG	I
4	proximal	I
5	promoter	I
6	was	O
7	analyzed	O
8	by	O
9	DNase	B
10	I	I
11	footprinting	O
12	,	O
13	and	O
14	the	O
15	functional	O
16	significance	O
17	of	O
18	6	O
19	footprinted	O
20	regions	O
21	(	O
22	FP1	O
23	-	O
24	FP6	O
25	)	O
26	within	O
27	the	O
28	proximal	O
29	promoter	O
30	was	O
31	studied	O
32	in	O
33	human	O
34	HepG2	O
35	hepatoblastoma	O
36	cells	O
37	.	O

1	In	O
2	vitro	O
3	translation	O
4	and	O
5	in	O
6	vivo	O
7	polysome	O
8	profile	O
9	analysis	O
10	indicated	O
11	that	O
12	transcripts	B
13	C	I
14	and	I
15	E	I
16	were	O
17	translated	O
18	with	O
19	similar	O
20	translational	O
21	efficiencies	O
22	that	O
23	are	O
24	substantially	O
25	greater	O
26	than	O
27	that	O
28	of	O
29	transcript	B
30	D	I
31	,	O
32	suggesting	O
33	that	O
34	5	O
35	'-	O
36	untranslated	O
37	regions	O
38	play	O
39	a	O
40	role	O
41	in	O
42	translational	O
43	control	O
44	.	O

1	Wild	O
2	type	O
3	HA	B
4	-	O
5	p190	B
6	induced	O
7	a	O
8	phenotype	O
9	of	O
10	rounded	O
11	cells	O
12	with	O
13	long	O
14	,	O
15	beaded	O
16	extensions	O
17	similar	O
18	to	O
19	that	O
20	seen	O
21	when	O
22	Rho	B
23	function	O
24	is	O
25	disrupted	O
26	by	O
27	ADP	O
28	-	O
29	ribosylation	O
30	.	O

1	Although	O
2	we	O
3	predicted	O
4	that	O
5	overexpression	O
6	of	O
7	the	O
8	COOH	O
9	-	O
10	terminal	O
11	domains	O
12	,	O
13	which	O
14	were	O
15	thought	O
16	to	O
17	be	O
18	involved	O
19	in	O
20	the	O
21	regulation	O
22	of	O
23	SREBP	B
24	processing	O
25	,	O
26	would	O
27	result	O
28	in	O
29	disruption	O
30	of	O
31	the	O
32	SREBP	B
33	-	O
34	dependent	O
35	transcriptional	O
36	regulation	O
37	of	O
38	several	O
39	genes	O
40	,	O
41	the	O
42	mRNA	O
43	levels	O
44	for	O
45	3	B
46	-	I
47	hydroxy	I
48	-	I
49	3	I
50	-	I
51	methylglutaryl	I
52	coenzyme	I
53	A	I
54	(	I
55	HMG	I
56	CoA	I
57	)	I
58	synthase	I
59	in	O
60	these	O
61	two	O
62	cell	O
63	lines	O
64	were	O
65	regulated	O
66	in	O
67	a	O
68	sterol	O
69	-	O
70	dependent	O
71	manner	O
72	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	E	O
2	.,	O
3	Scott	O
4	,	O
5	J	O
6	.	O

1	Elevated	O
2	expression	O
3	of	O
4	a	O
5	previously	O
6	uncharacterized	O
7	gene	O
8	,	O
9	SPP381	B
10	,	O
11	efficiently	O
12	suppresses	O
13	the	O
14	growth	O
15	and	O
16	splicing	O
17	defects	O
18	of	O
19	a	O
20	temperature	O
21	-	O
22	sensitive	O
23	(	O
24	Ts	O
25	)	O
26	mutant	B
27	prp38	I
28	-	I
29	1	I
30	.	O

1	Both	O
2	NUP98	B
3	-	O
4	HOXA9	B
5	chimeras	O
6	transformed	O
7	NIH	O
8	3T3	O
9	fibroblasts	O
10	,	O
11	and	O
12	this	O
13	transformation	O
14	required	O
15	the	O
16	HOXA9	B
17	domains	I
18	for	O
19	DNA	O
20	binding	O
21	and	O
22	PBX	B
23	interaction	O
24	.	O

1	Recent	O
2	studies	O
3	have	O
4	suggested	O
5	that	O
6	Y319	O
7	also	O
8	positively	O
9	regulate	O
10	ZAP	B
11	-	I
12	70	I
13	function	O
14	.	O

1	BIAcore	O
2	analysis	O
3	gave	O
4	a	O
5	Kaff	O
6	of	O
7	4	O
8	.	O
9	4	O
10	x	O
11	10	O
12	(	O
13	10	O
14	)	O
15	M	O
16	-	O
17	1	O
18	for	O
19	the	O
20	binding	O
21	of	O
22	N	B
23	-	I
24	A3	I
25	to	O
26	T84	B
27	.	I
28	1	I
29	and	O
30	2	O
31	.	O
32	2	O
33	x	O
34	10	O
35	(	O
36	10	O
37	)	O
38	M	O
39	-	O
40	1	O
41	for	O
42	the	O
43	binding	O
44	of	O
45	N	B
46	-	I
47	A3	I
48	to	O
49	T84	B
50	.	I
51	66	I
52	.	O

1	Recurrent	O
2	arterial	O
3	thrombotic	O
4	disease	O
5	on	O
6	young	O
7	onset	O
8	and	O
9	protein	B
10	S	I
11	deficiency	O
12	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	optimal	O
6	threshold	O
7	values	O
8	,	O
9	sensitivity	O
10	and	O
11	specificity	O
12	were	O
13	100	O
14	%/	O
15	97	O
16	%	O
17	and	O
18	95	O
19	%/	O
20	95	O
21	%	O
22	with	O
23	FDG	O
24	PET	O
25	,	O
26	compared	O
27	to	O
28	86	O
29	%/	O
30	92	O
31	%	O
32	and	O
33	77	O
34	%/	O
35	82	O
36	%	O
37	with	O
38	IS	O
39	,	O
40	respectively	O
41	.	O

1	Dorsal	O
2	root	O
3	ganglia	O
4	neuron	O
5	-	O
6	specific	O
7	promoter	O
8	activity	O
9	of	O
10	the	O
11	rabbit	B
12	beta	I
13	-	I
14	galactoside	I
15	alpha1	I
16	,	I
17	2	I
18	-	I
19	fucosyltransferase	I
20	gene	I
21	.	O

1	The	O
2	BAL	O
3	concentrations	O
4	of	O
5	the	O
6	nine	O
7	cytokines	O
8	evaluated	O
9	for	O
10	the	O
11	more	O
12	and	O
13	less	O
14	affected	O
15	lungs	O
16	were	O
17	compared	O
18	:	O
19	interleukin	B
20	-	I
21	6	I
22	(	O
23	IL	B
24	-	I
25	6	I
26	),	O
27	IL	B
28	-	I
29	8	I
30	,	O
31	IL	B
32	-	I
33	12	I
34	,	O
35	tumor	B
36	necrosis	I
37	factor	I
38	-	I
39	alpha	I
40	(	O
41	TNF	B
42	-	I
43	alpha	I
44	),	O
45	and	O
46	interferon	B
47	gamma	I
48	(	O
49	IFN	B
50	-	I
51	gamma	I
52	)	O
53	showed	O
54	significant	O
55	differences	O
56	(	O
57	p	O
58	ranged	O
59	between	O
60	0	O
61	.	O

1	The	O
2	orbitofrontal	O
3	,	O
4	cingulate	O
5	,	O
6	and	O
7	anteromedial	O
8	part	O
9	of	O
10	the	O
11	dorsal	O
12	premotor	O
13	areas	O
14	were	O
15	preferentially	O
16	activated	O
17	by	O
18	the	O
19	self	O
20	-	O
21	initiated	O
22	hand	O
23	movement	O
24	task	O
25	(	O
26	SELF	O
27	).	O

1	Plasma	O
2	CCK	B
3	levels	O
4	were	O
5	determined	O
6	at	O
7	regular	O
8	intervals	O
9	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	Bmp2	B
6	is	O
7	directly	O
8	regulated	O
9	by	O
10	retinoic	O
11	acid	O
12	-	O
13	bound	O
14	receptors	O
15	and	O
16	Sp1	B
17	.	O

1	Conventionally	O
2	,	O
3	four	O
4	nominal	O
5	allotypic	O
6	variants	O
7	,	O
8	b4	O
9	,	O
10	b5	O
11	,	O
12	b6	O
13	and	O
14	b9	O
15	have	O
16	been	O
17	shown	O
18	to	O
19	be	O
20	co	O
21	-	O
22	dominantly	O
23	expressed	O
24	at	O
25	the	O
26	Ckappa1	B
27	gene	I
28	locus	I
29	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	treatment	O
5	of	O
6	posttransplant	O
7	lymphoproliferative	O
8	disorder	O
9	in	O
10	recipients	O
11	of	O
12	solid	O
13	organ	O
14	transplants	O
15	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	accuracy	O
7	of	O
8	working	O
9	casts	O
10	for	O
11	crown	O
12	and	O
13	bridge	O
14	restorations	O
15	made	O
16	from	O
17	twin	O
18	mix	O
19	putty	O
20	/	O
21	wash	O
22	silicone	O
23	elastomeric	O
24	impression	O
25	materials	O
26	using	O
27	different	O
28	types	O
29	of	O
30	stock	O
31	tray	O
32	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	mouse	B
5	glycolate	I
6	oxidase	I
7	.	O

1	Additionally	O
2	,	O
3	a	O
4	variety	O
5	of	O
6	regulatory	O
7	schemes	O
8	contribute	O
9	temporal	O
10	and	O
11	/	O
12	or	O
13	spatial	O
14	restriction	O
15	to	O
16	TGF	B
17	-	I
18	beta	I
19	responses	O
20	.	O

1	Magnetically	O
2	induced	O
3	optical	O
4	self	O
5	-	O
6	pulsing	O
7	in	O
8	a	O
9	nonlinear	O
10	resonator	O
11	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	B
17	-	I
18	C	I
19	promoter	I
20	constructs	I
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	O
29	collagen	B
30	-	I
31	dependent	I
32	promoter	I
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	O
6	pgp2	B
7	/	O
8	mdr1b	B
9	gene	O
10	has	O
11	a	O
12	GC	O
13	-	O
14	rich	O
15	region	O
16	(	O
17	pgp2GC	B
18	)	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	in	O
24	mdr	B
25	genes	I
26	and	O
27	contains	O
28	an	O
29	consensus	O
30	Sp1	B
31	site	I
32	.	O

1	Sp1	B
2	'	O
3	s	O
4	role	O
5	in	O
6	transactivation	O
7	of	O
8	the	O
9	pgp2	B
10	/	O
11	mdr1b	B
12	promoter	O
13	was	O
14	tested	O
15	in	O
16	Drosophila	O
17	Schneider	O
18	cells	O
19	.	O

1	Measurements	O
2	included	O
3	bone	O
4	mineral	O
5	density	O
6	of	O
7	the	O
8	lumbar	O
9	spine	O
10	and	O
11	proximal	O
12	femur	O
13	(	O
14	by	O
15	dual	O
16	-	O
17	energy	O
18	X	O
19	-	O
20	ray	O
21	absorptiometry	O
22	)	O
23	and	O
24	biochemical	O
25	markers	O
26	of	O
27	bone	O
28	remodeling	O
29	(	O
30	serum	O
31	bone	O
32	-	O
33	specific	O
34	alkaline	B
35	phosphatase	I
36	by	O
37	immunoassay	O
38	and	O
39	urine	O
40	deoxypyridinoline	O
41	by	O
42	high	O
43	-	O
44	pressure	O
45	liquid	O
46	chromatography	O
47	).	O

1	MotA	B
2	also	O
3	binds	O
4	a	O
5	DNA	O
6	sequence	O
7	(	O
8	a	O
9	MotA	B
10	box	I
11	),	O
12	centered	O
13	at	O
14	position	O
15	-	O
16	30	O
17	.	O

1	Chem	O
2	.	O

1	However	O
2	,	O
3	C3	B
4	toxin	I
5	alone	O
6	or	O
7	in	O
8	combination	O
9	with	O
10	growth	O
11	factors	O
12	did	O
13	not	O
14	stimulate	O
15	AP	B
16	-	I
17	1	I
18	:	O
19	Luc	B
20	activity	O
21	and	O
22	actually	O
23	antagonized	O
24	the	O
25	synergistic	O
26	activation	O
27	of	O
28	AP	B
29	-	I
30	1	I
31	:	O
32	Luc	B
33	observed	O
34	in	O
35	response	O
36	to	O
37	co	O
38	-	O
39	stimulation	O
40	with	O
41	growth	O
42	factors	O
43	and	O
44	Ro	O
45	-	O
46	31	O
47	-	O
48	8220	O
49	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	Trinipatch	O
2	is	O
3	a	O
4	small	O
5	,	O
6	transparent	O
7	,	O
8	matricial	O
9	,	O
10	monolayer	O
11	patch	O
12	with	O
13	an	O
14	absorption	O
15	promoter	O
16	,	O
17	marketed	O
18	in	O
19	two	O
20	dose	O
21	-	O
22	strengths	O
23	(	O
24	5	O
25	mg	O
26	/	O
27	24	O
28	h	O
29	and	O
30	10	O
31	mg	O
32	/	O
33	24	O
34	h	O
35	)	O
36	by	O
37	Laboratoires	O
38	Synthelabo	O
39	.	O

1	Pokeweed	B
2	antiviral	I
3	protein	I
4	(	O
5	PAP	B
6	)	O
7	from	O
8	Phytolacca	O
9	americana	O
10	is	O
11	a	O
12	highly	O
13	specific	O
14	N	B
15	-	I
16	glycosidase	I
17	removing	O
18	adenine	O
19	residues	O
20	(	O
21	A4324	O
22	in	O
23	28S	B
24	rRNA	I
25	and	O
26	A2660	O
27	in	O
28	23S	B
29	rRNA	I
30	)	O
31	from	O
32	intact	O
33	ribosomes	O
34	of	O
35	both	O
36	eukaryotes	O
37	and	O
38	prokaryotes	O
39	.	O

1	Experiments	O
2	on	O
3	narcotized	O
4	cats	O
5	demonstrated	O
6	that	O
7	the	O
8	derivatives	O
9	of	O
10	2	O
11	-	O
12	mercaptobenzimidazole	O
13	possessing	O
14	the	O
15	properties	O
16	of	O
17	specific	O
18	bradycardic	O
19	agents	O
20	and	O
21	coded	O
22	as	O
23	CM	O
24	-	O
25	251	O
26	,	O
27	CM	O
28	-	O
29	266	O
30	,	O
31	and	O
32	CM	O
33	-	O
34	345	O
35	,	O
36	reduce	O
37	the	O
38	mean	O
39	rise	O
40	of	O
41	segment	O
42	ST	O
43	on	O
44	numerous	O
45	leads	O
46	of	O
47	the	O
48	epicardial	O
49	electrogram	O
50	during	O
51	5	O
52	-	O
53	min	O
54	occlusion	O
55	of	O
56	the	O
57	anterior	O
58	descending	O
59	branch	O
60	of	O
61	the	O
62	left	O
63	coronary	O
64	artery	O
65	.	O

1	Both	O
2	mutations	O
3	confer	O
4	amino	O
5	acid	O
6	substitutions	O
7	in	O
8	the	O
9	viral	B
10	coat	I
11	protein	I
12	but	O
13	differ	O
14	in	O
15	their	O
16	relative	O
17	abilities	O
18	to	O
19	utilize	O
20	the	O
21	foreign	O
22	scaffolding	B
23	protein	I
24	.	O

1	Complete	O
2	recovery	O
3	of	O
4	liver	O
5	function	O
6	after	O
7	this	O
8	surgery	O
9	tended	O
10	to	O
11	be	O
12	slow	O
13	.	O

1	Although	O
2	both	O
3	transcripts	O
4	share	O
5	the	O
6	first	O
7	nine	O
8	exons	O
9	,	O
10	exon	O
11	10	O
12	of	O
13	ZIS	B
14	-	I
15	2	I
16	is	O
17	lacking	O
18	in	O
19	ZIS	B
20	-	I
21	1	I
22	,	O
23	and	O
24	instead	O
25	,	O
26	exon	O
27	11	O
28	(	O
29	10th	O
30	exon	O
31	)	O
32	of	O
33	ZIS	B
34	-	I
35	1	I
36	is	O
37	larger	O
38	in	O
39	size	O
40	,	O
41	leading	O
42	to	O
43	the	O
44	longer	O
45	3	O
46	'-	O
47	UTR	O
48	.	O

1	The	O
2	missing	O
3	5	O
4	'	O
5	sequences	O
6	were	O
7	obtained	O
8	by	O
9	5	O
10	'-	O
11	rapid	O
12	amplification	O
13	of	O
14	cDNA	O
15	ends	O
16	and	O
17	by	O
18	analysis	O
19	of	O
20	an	O
21	NHE5	B
22	genomic	I
23	clone	I
24	,	O
25	and	O
26	the	O
27	missing	O
28	3	O
29	'	O
30	sequences	O
31	were	O
32	obtained	O
33	by	O
34	3	O
35	'-	O
36	rapid	O
37	amplification	O
38	of	O
39	cDNA	O
40	ends	O
41	.	O

1	Genoa	O
2	,	O
3	Italy	O
4	,	O
5	24	O
6	-	O
7	28	O
8	August	O
9	1997	O
10	.	O

1	Bound	O
2	-	O
3	exciton	O
4	transfer	O
5	and	O
6	photoluminescence	O
7	undulation	O
8	spectra	O
9	for	O
10	acceptors	O
11	in	O
12	ZnTe	O
13	.	O

1	Thus	O
2	,	O
3	in	O
4	normal	O
5	intestinal	O
6	epithelial	O
7	goblet	O
8	cells	O
9	,	O
10	TbetaRI	B
11	and	O
12	TbetaRII	B
13	can	O
14	respond	O
15	to	O
16	autocrine	O
17	but	O
18	not	O
19	exogenous	O
20	TGF	B
21	-	I
22	beta	I
23	without	O
24	the	O
25	participation	O
26	of	O
27	TbetaRIII	B
28	.	O

1	The	O
2	history	O
3	of	O
4	exposure	O
5	and	O
6	carboxyhemoglobin	B
7	levels	O
8	should	O
9	alert	O
10	the	O
11	physician	O
12	to	O
13	this	O
14	diagnosis	O
15	.	O

1	Scaling	O
2	of	O
3	fluctuations	O
4	in	O
5	one	O
6	-	O
7	dimensional	O
8	interface	O
9	and	O
10	hopping	O
11	models	O
12	.	O

1	Model	O
2	of	O
3	spatiotemporal	O
4	dynamics	O
5	of	O
6	stick	O
7	-	O
8	slip	O
9	motion	O
10	.	O

1	Direct	O
2	approach	O
3	to	O
4	the	O
5	study	O
6	of	O
7	soliton	O
8	perturbations	O
9	.	O

1	Several	O
2	mutations	O
3	disrupted	O
4	the	O
5	endonuclease	O
6	and	O
7	helicase	B
8	activities	O
9	;	O
10	however	O
11	,	O
12	only	O
13	one	O
14	amino	B
15	-	I
16	terminal	I
17	-	I
18	charge	I
19	cluster	I
20	mutant	I
21	protein	I
22	(	O
23	D40A	O
24	-	O
25	D42A	O
26	-	O
27	D44A	O
28	)	O
29	completely	O
30	lost	O
31	AAV	O
32	hairpin	O
33	DNA	O
34	binding	O
35	activity	O
36	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	B
15	/	I
16	Rta	I
17	gene	I
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	B
9	in	O
10	NRS	B
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	Raman	O
2	investigation	O
3	of	O
4	YBa2	O
5	-	O
6	xLaxCu3O7	O
7	ceramics	O
8	.	O

1	Chaotic	O
2	electron	O
3	dynamics	O
4	around	O
5	a	O
6	single	O
7	elliptically	O
8	shaped	O
9	antidot	O
10	.	O

1	However	O
2	,	O
3	after	O
4	PRK	O
5	at	O
6	5	O
7	weeks	O
8	of	O
9	age	O
10	,	O
11	partial	O
12	retreatment	O
13	may	O
14	be	O
15	necessary	O
16	due	O
17	to	O
18	regression	O
19	of	O
20	the	O
21	PRK	O
22	effect	O
23	.	O

1	It	O
2	was	O
3	demonstrated	O
4	that	O
5	the	O
6	processing	O
7	signals	O
8	in	O
9	the	O
10	transcript	O
11	,	O
12	i	O
13	.	O
14	e	O
15	.	O
16	both	O
17	donor	O
18	splice	O
19	sites	O
20	and	O
21	the	O
22	polyadenylation	O
23	site	O
24	located	O
25	in	O
26	the	O
27	muscle	O
28	-	O
29	specific	O
30	intron	O
31	,	O
32	have	O
33	to	O
34	be	O
35	weak	O
36	.	O

1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	O
6	CREB	B
7	binding	I
8	protein	I
9	/	O
10	p300	B
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	B
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	B
21	and	I
22	-	I
23	beta	I
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	I
35	16	I
36	promoter	I
37	in	O
38	T	O
39	cells	O
40	.	O

1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	B
6	-	O
7	dependent	O
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	B
13	ligase	I
14	(	O
15	E3	B
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O

1	Observation	O
2	of	O
3	dipolar	O
4	interactions	O
5	between	O
6	Pb0	O
7	defects	O
8	at	O
9	the	O
10	(	O
11	111	O
12	)	O
13	Si	O
14	/	O
15	SiO2	O
16	interface	O
17	.	O

1	Far	O
2	-	O
3	infrared	O
4	hopping	O
5	conductivity	O
6	in	O
7	the	O
8	CuO	O
9	chains	O
10	of	O
11	a	O
12	single	O
13	-	O
14	domain	O
15	YBa2Cu3O7	O
16	-	O
17	delta	O
18	crystal	O
19	.	O

1	Surface	O
2	spin	O
3	waves	O
4	in	O
5	a	O
6	Heisenberg	O
7	ferrimagnet	O
8	with	O
9	a	O
10	single	O
11	-	O
12	ion	O
13	anisotropy	O
14	(	O
15	uniaxial	O
16	and	O
17	nonuniaxial	O
18	).	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	O
18	beta	B
19	-	I
20	adrenergic	I
21	receptor	I
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	Factors	O
2	influencing	O
3	direct	O
4	-	O
5	immersion	O
6	(	O
7	DI	O
8	)-	O
9	SPME	O
10	process	O
11	were	O
12	also	O
13	checked	O
14	and	O
15	chosen	O
16	experimentally	O
17	.	O

1	In	O
2	contrast	O
3	,	O
4	an	O
5	amino	O
6	-	O
7	terminal	O
8	fragment	O
9	containing	O
10	the	O
11	C	O
12	/	O
13	H1	O
14	domain	O
15	was	O
16	sufficient	O
17	for	O
18	coactivation	O
19	of	O
20	Zta	B
21	transcription	O
22	and	O
23	viral	O
24	reactivation	O
25	function	O
26	.	O

1	Mammalian	O
2	Ras	B
3	GTPase	I
4	-	I
5	activating	I
6	protein	I
7	(	O
8	GAP	B
9	),	O
10	p120	B
11	Ras	I
12	-	O
13	GAP	B
14	,	O
15	has	O
16	been	O
17	implicated	O
18	as	O
19	both	O
20	a	O
21	downregulator	O
22	and	O
23	effector	O
24	of	O
25	Ras	B
26	proteins	I
27	,	O
28	but	O
29	its	O
30	precise	O
31	role	O
32	in	O
33	Ras	B
34	-	O
35	mediated	O
36	signal	O
37	transduction	O
38	pathways	O
39	is	O
40	unclear	O
41	.	O

1	Three	O
2	mog	B
3	-	I
4	1	I
5	alleles	I
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	The	O
2	Nmd3	B
3	protein	I
4	sequence	I
5	does	O
6	not	O
7	contain	O
8	readily	O
9	recognizable	O
10	motifs	O
11	of	O
12	known	O
13	function	O
14	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	The	O
2	therapy	O
3	with	O
4	a	O
5	H2	B
6	-	I
7	receptor	I
8	antagonist	O
9	is	O
10	less	O
11	effective	O
12	than	O
13	the	O
14	triple	O
15	therapies	O
16	with	O
17	omeprazole	O
18	or	O
19	lansoprazole	O
20	.	O

1	Systematic	O
2	functional	O
3	analysis	O
4	of	O
5	V1a	B
6	/	I
7	V2	I
8	hybrid	I
9	receptors	I
10	showed	O
11	that	O
12	the	O
13	second	O
14	intracellular	O
15	loop	O
16	of	O
17	the	O
18	V1a	B
19	receptor	I
20	is	O
21	required	O
22	and	O
23	sufficient	O
24	for	O
25	efficient	O
26	coupling	O
27	to	O
28	Gq	B
29	/	I
30	11	I
31	,	O
32	whereas	O
33	the	O
34	third	O
35	intracellular	O
36	loop	O
37	of	O
38	the	O
39	V2	B
40	receptor	I
41	is	O
42	required	O
43	and	O
44	sufficient	O
45	for	O
46	coupling	O
47	to	O
48	Gs	B
49	.	O

1	Depth	O
2	-	O
3	controlled	O
4	grazing	O
5	-	O
6	incidence	O
7	diffraction	O
8	of	O
9	synchrotron	O
10	x	O
11	radiation	O
12	.	O

1	Large	O
2	scale	O
3	electronic	O
4	structure	O
5	calculations	O
6	.	O

1	Analysis	O
2	of	O
3	the	O
4	consensus	O
5	binding	O
6	sequence	O
7	and	O
8	the	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	of	O
14	ZF5	B
15	.	O

1	Mutations	O
2	of	O
3	the	O
4	AP	B
5	-	I
6	1	I
7	site	I
8	of	O
9	the	O
10	TIMP	B
11	-	I
12	1	I
13	promoter	I
14	that	O
15	prevented	O
16	formation	O
17	of	O
18	HMAP	B
19	-	I
20	1	I
21	caused	O
22	a	O
23	70	O
24	%	O
25	loss	O
26	of	O
27	activity	O
28	in	O
29	transfected	O
30	activated	O
31	HSCs	O
32	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	subjects	O
7	with	O
8	air	O
9	trapping	O
10	(	O
11	residual	O
12	volume	O
13	(	O
14	RV	O
15	)/	O
16	total	O
17	lung	O
18	capacity	O
19	(	O
20	TLC	O
21	)	O
22	>	O
23	37	O
24	%)	O
25	disclosed	O
26	not	O
27	only	O
28	a	O
29	higher	O
30	n	O
31	(	O
32	mit	O
33	)	O
34	(	O
35	0	O
36	.	O
37	63	O
38	+/-	O
39	0	O
40	.	O
41	17	O
42	versus	O
43	0	O
44	.	O
45	43	O
46	+/-	O
47	0	O
48	.	O
49	07	O
50	mt	O
51	x	O
52	microm	O
53	(-	O
54	2	O
55	),	O
56	p	O
57	<	O
58	0	O
59	.	O
60	05	O
61	)	O
62	but	O
63	shorter	O
64	sarcomeres	O
65	(	O
66	L	O
67	(	O
68	sar	O
69	))	O
70	than	O
71	subjects	O
72	without	O
73	this	O
74	functional	O
75	abnormality	O
76	(	O
77	2	O
78	.	O
79	08	O
80	+/-	O
81	0	O
82	.	O
83	16	O
84	to	O
85	2	O
86	.	O
87	27	O
88	+/-	O
89	0	O
90	.	O
91	15	O
92	microm	O
93	,	O
94	p	O
95	<	O
96	0	O
97	.	O
98	05	O
99	).	O

1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	B
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O

1	The	O
2	SH2	B
3	domain	I
4	-	I
5	containing	I
6	inositol	I
7	5	I
8	'-	I
9	phosphatase	I
10	(	O
11	SHIP	B
12	)	O
13	recruits	O
14	the	O
15	p85	B
16	subunit	I
17	of	O
18	phosphoinositide	B
19	3	I
20	-	I
21	kinase	I
22	during	O
23	FcgammaRIIb1	B
24	-	O
25	mediated	O
26	inhibition	O
27	of	O
28	B	B
29	cell	I
30	receptor	I
31	signaling	O
32	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	mouse	O
6	genome	O
7	contains	O
8	four	O
9	copies	O
10	of	O
11	the	O
12	ubc	B
13	-	I
14	9	I
15	gene	I
16	.	O

1	Interestingly	O
2	,	O
3	Csx	B
4	/	O
5	Nkx2	B
6	.	O

1	We	O
2	also	O
3	identified	O
4	an	O
5	alternative	O
6	spliced	O
7	form	O
8	of	O
9	Lyp	B
10	RNA	I
11	,	O
12	Lyp2	B
13	.	O

1	The	O
2	costs	O
3	were	O
4	DM	O
5	11	O
6	,	O
7	562	O
8	for	O
9	a	O
10	PE	O
11	,	O
12	DM	O
13	12	O
14	,	O
15	477	O
16	for	O
17	a	O
18	VR	O
19	and	O
20	DM	O
21	7	O
22	,	O
23	532	O
24	for	O
25	a	O
26	MR	O
27	.	O

1	We	O
2	now	O
3	provide	O
4	evidence	O
5	for	O
6	physical	O
7	and	O
8	functional	O
9	interaction	O
10	between	O
11	Doa4	B
12	and	O
13	the	O
14	proteasome	O
15	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	IS2404	B
6	and	O
7	IS2606	B
8	:	O
9	two	O
10	distinct	O
11	repeated	O
12	sequences	O
13	for	O
14	detection	O
15	of	O
16	Mycobacterium	O
17	ulcerans	O
18	by	O
19	PCR	O
20	.	O

1	This	O
2	suggests	O
3	that	O
4	helicase	B
5	-	I
6	like	I
7	genes	I
8	may	O
9	be	O
10	involved	O
11	in	O
12	the	O
13	biosynthesis	O
14	of	O
15	nucleic	O
16	acids	O
17	and	O
18	proteins	O
19	,	O
20	and	O
21	that	O
22	the	O
23	genes	O
24	can	O
25	be	O
26	transcriptionally	O
27	activated	O
28	by	O
29	heat	O
30	shock	O
31	to	O
32	compensate	O
33	for	O
34	the	O
35	repressed	O
36	synthesis	O
37	of	O
38	mRNA	O
39	and	O
40	protein	O
41	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	B
14	and	O
15	the	O
16	MUL	B
17	genes	I
18	.	O

1	The	O
2	results	O
3	of	O
4	supershift	O
5	analysis	O
6	using	O
7	specific	O
8	antibodies	O
9	against	O
10	transcription	O
11	factors	O
12	suggested	O
13	that	O
14	both	O
15	binding	O
16	complexes	O
17	contained	O
18	the	O
19	NF	B
20	-	I
21	kappaB	I
22	components	O
23	p50	B
24	and	O
25	p65	B
26	,	O
27	and	O
28	did	O
29	not	O
30	contain	O
31	other	O
32	NF	B
33	-	I
34	kappaB	I
35	proteins	I
36	(	O
37	p52	B
38	,	O
39	c	B
40	-	I
41	Rel	I
42	,	O
43	Rel	B
44	B	I
45	),	O
46	AP	B
47	-	I
48	1	I
49	proteins	I
50	(	O
51	c	B
52	-	I
53	Fos	I
54	,	O
55	C	B
56	-	I
57	Jun	I
58	),	O
59	CREB	B
60	or	O
61	C	B
62	/	I
63	EBPbeta	I
64	(	O
65	NF	B
66	-	I
67	IL6	I
68	).	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	elucidate	O
7	signaling	O
8	pathways	O
9	induced	O
10	by	O
11	photodynamic	O
12	therapy	O
13	(	O
14	PDT	O
15	)	O
16	with	O
17	hypericin	O
18	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	B
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	B
16	.	I
17	pylori	I
18	plasmid	I
19	replication	I
20	proteins	I
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	B
31	.	I
32	pylori	I
33	plasmid	I
34	proteins	I
35	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	binding	O
7	sites	O
8	for	O
9	the	O
10	repressor	B
11	proteins	I
12	BP1	I
13	and	O
14	BP2	B
15	in	O
16	the	O
17	upstream	O
18	portion	O
19	of	O
20	the	O
21	beta	B
22	globin	I
23	gene	I
24	flanking	I
25	region	I
26	led	O
27	to	O
28	a	O
29	4	O
30	-	O
31	6	O
32	fold	O
33	increase	O
34	in	O
35	promoter	O
36	activity	O
37	.	O

1	However	O
2	,	O
3	with	O
4	the	O
5	alpha1	O
6	antagonist	O
7	prazosin	O
8	(	O
9	5	O
10	x	O
11	10	O
12	(-	O
13	8	O
14	)-	O
15	5	O
16	x	O
17	10	O
18	(-	O
19	7	O
20	)	O
21	M	O
22	),	O
23	no	O
24	relaxation	O
25	occurred	O
26	.	O

1	The	O
2	mean	O
3	value	O
4	of	O
5	the	O
6	CD79b	B
7	to	O
8	the	O
9	CD79b	B
10	internally	O
11	deleted	O
12	ratio	O
13	was	O
14	0	O
15	.	O
16	64	O
17	+/-	O
18	0	O
19	.	O
20	20	O
21	SD	O
22	in	O
23	normal	O
24	donors	O
25	and	O
26	0	O
27	.	O
28	44	O
29	+/-	O
30	0	O
31	.	O
32	27	O
33	SD	O
34	in	O
35	B	O
36	-	O
37	CLL	O
38	(	O
39	P	O
40	=.	O
41	01	O
42	).	O

1	Schwab	O
2	and	O
3	England	O
4	ADL	O
5	scores	O
6	in	O
7	the	O
8	"	O
9	off	O
10	"	O
11	state	O
12	were	O
13	improved	O
14	by	O
15	18	O
16	%	O
17	and	O
18	in	O
19	the	O
20	"	O
21	on	O
22	"	O
23	state	O
24	the	O
25	scores	O
26	declined	O
27	by	O
28	2	O
29	%.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	B
11	knuckle	I
12	9G8	I
13	variant	I
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	B
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	B
30	and	O
31	SRp20	B
32	are	O
33	similar	O
34	.	O

1	A	O
2	high	O
3	reactor	O
4	pH	O
5	(+/-	O
6	8	O
7	),	O
8	a	O
9	short	O
10	solid	O
11	retention	O
12	time	O
13	(<	O
14	150	O
15	days	O
16	),	O
17	and	O
18	the	O
19	presence	O
20	of	O
21	a	O
22	substantial	O
23	SRB	O
24	population	O
25	in	O
26	the	O
27	inoculum	O
28	may	O
29	considerably	O
30	reduce	O
31	the	O
32	time	O
33	required	O
34	for	O
35	acetate	O
36	-	O
37	utilising	O
38	SRB	O
39	to	O
40	outcompete	O
41	MB	O
42	.	O

1	A	O
2	database	O
3	search	O
4	has	O
5	revealed	O
6	as	O
7	the	O
8	most	O
9	significative	O
10	homology	O
11	a	O
12	match	O
13	with	O
14	the	O
15	human	B
16	mitochondrial	I
17	transcription	I
18	termination	I
19	factor	I
20	(	O
21	mTERF	B
22	),	O
23	a	O
24	protein	O
25	that	O
26	also	O
27	binds	O
28	DNA	O
29	as	O
30	a	O
31	monomer	O
32	and	O
33	contains	O
34	three	O
35	leucine	O
36	zippers	O
37	forming	O
38	intramolecular	O
39	interactions	O
40	.	O

1	31	O
2	,	O
3	1997	O
4	,	O
5	40	O
6	patients	O
7	had	O
8	died	O
9	(	O
10	35	O
11	in	O
12	the	O
13	ERA	O
14	-	O
15	II	O
16	group	O
17	and	O
18	5	O
19	in	O
20	the	O
21	ERA	O
22	-	O
23	III	O
24	group	O
25	),	O
26	for	O
27	a	O
28	crude	O
29	mortality	O
30	rate	O
31	of	O
32	8	O
33	.	O
34	0	O
35	%.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Holger	O
2	v	O
3	.	O

1	Hospital	O
2	hit	O
3	for	O
4	hiring	O
5	AHERF	O
6	physicians	O
7	.	O

1	This	O
2	is	O
3	in	O
4	contrast	O
5	to	O
6	PPARgamma2	B
7	,	O
8	which	O
9	was	O
10	previously	O
11	shown	O
12	to	O
13	be	O
14	phosphorylated	O
15	at	O
16	a	O
17	single	O
18	site	O
19	in	O
20	a	O
21	motif	O
22	that	O
23	is	O
24	not	O
25	homologous	O
26	to	O
27	the	O
28	sites	O
29	now	O
30	described	O
31	in	O
32	PPARalpha	B
33	.	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	B
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	B
12	family	I
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	B
20	.	O

1	We	O
2	have	O
3	screened	O
4	the	O
5	elastin	B
6	gene	I
7	for	O
8	mutations	O
9	responsible	O
10	for	O
11	supravalvular	O
12	aortic	O
13	stenosis	O
14	(	O
15	SVAS	O
16	)	O
17	in	O
18	two	O
19	large	O
20	,	O
21	independently	O
22	collected	O
23	families	O
24	with	O
25	isolated	O
26	(	O
27	nonsyndromic	O
28	)	O
29	SVAS	O
30	.	O

1	25	O
2	-	O
3	OH	O
4	-	O
5	D3	O
6	did	O
7	not	O
8	adversely	O
9	affect	O
10	animal	O
11	health	O
12	at	O
13	the	O
14	proposed	O
15	use	O
16	level	O
17	of	O
18	99	O
19	micrograms	O
20	/	O
21	kg	O
22	feed	O
23	when	O
24	replacing	O
25	vitamin	O
26	D3	O
27	in	O
28	turkey	O
29	rations	O
30	.	O

1	Voluntary	O
2	wheel	O
3	running	O
4	did	O
5	not	O
6	significantly	O
7	increase	O
8	estimated	O
9	alanine	O
10	or	O
11	pyruvate	O
12	Gneo	O
13	or	O
14	absolute	O
15	glycerol	O
16	Ra	O
17	.	O

1	The	O
2	Asian	O
3	mouse	O
4	Mus	O
5	castaneus	O
6	is	O
7	resistant	O
8	to	O
9	infection	O
10	by	O
11	the	O
12	polytropic	O
13	mink	O
14	cell	O
15	focus	O
16	-	O
17	inducing	O
18	(	O
19	MCF	O
20	)	O
21	subgroup	O
22	of	O
23	murine	O
24	leukemia	O
25	viruses	O
26	(	O
27	MuLVs	O
28	).	O

1	Plasma	O
2	glucose	O
3	,	O
4	immunoreactive	B
5	insulin	I
6	(	O
7	IRI	B
8	),	O
9	C	B
10	-	I
11	peptide	I
12	,	O
13	glucagon	B
14	,	O
15	and	O
16	GLP	B
17	-	I
18	1	I
19	levels	O
20	at	O
21	each	O
22	time	O
23	point	O
24	during	O
25	OGTT	O
26	were	O
27	measured	O
28	.	O

1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	signature	O
6	-	O
7	tagged	O
8	mutagenesis	O
9	is	O
10	a	O
11	viable	O
12	approach	O
13	to	O
14	identify	O
15	bacterial	O
16	genes	O
17	associated	O
18	with	O
19	the	O
20	ability	O
21	to	O
22	infect	O
23	the	O
24	urinary	O
25	tract	O
26	.	O

1	Pathol	O
2	.	O

1	The	O
2	GAC1	B
3	gene	I
4	encodes	O
5	the	O
6	regulatory	O
7	subunit	O
8	for	O
9	a	O
10	type	B
11	1	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	phosphatase	I
17	,	O
18	Glc7	B
19	.	O

1	The	O
2	results	O
3	demonstrate	O
4	that	O
5	the	O
6	Glc7	B
7	phosphatase	I
8	and	O
9	its	O
10	Gac1	B
11	regulatory	O
12	subunit	O
13	play	O
14	positive	O
15	roles	O
16	in	O
17	HSF	B
18	activation	O
19	of	O
20	CUP1	B
21	transcription	O
22	.	O

1	Concomitantly	O
2	,	O
3	the	O
4	total	O
5	cellular	O
6	level	O
7	of	O
8	p21	B
9	increased	O
10	severalfold	O
11	via	O
12	a	O
13	posttranscriptional	O
14	mechanism	O
15	.	O

1	Chronotherapeutics	O
2	in	O
3	cardiovascular	O
4	disease	O
5	.	O

1	Calcinosis	O
2	cutis	O
3	following	O
4	intravenous	O
5	infusion	O
6	of	O
7	calcium	O
8	gluconate	O
9	.	O

1	Solution	O
2	structure	O
3	and	O
4	mechanism	O
5	of	O
6	the	O
7	MutT	B
8	pyrophosphohydrolase	I
9	.	O

1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O

1	Constrictive	O
2	pericarditis	O
3	and	O
4	pleuropulmonary	O
5	disease	O
6	linked	O
7	to	O
8	ergot	O
9	dopamine	O
10	agonist	O
11	therapy	O
12	(	O
13	cabergoline	O
14	)	O
15	for	O
16	Parkinson	O
17	'	O
18	s	O
19	disease	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	constructed	O
7	and	O
8	expressed	O
9	chimeric	O
10	fusion	O
11	protein	O
12	that	O
13	contains	O
14	HIV	B
15	-	I
16	2	I
17	gag	I
18	with	O
19	V3	B
20	domains	O
21	of	O
22	HIV	O
23	-	O
24	1IIIB	O
25	,	O
26	HIV	O
27	-	O
28	1MN	O
29	,	O
30	HIV	O
31	-	O
32	1SF2	O
33	and	O
34	HIV	O
35	-	O
36	1RF	O
37	.	O

1	Efficacy	O
2	was	O
3	determined	O
4	by	O
5	responses	O
6	to	O
7	question	O
8	3	O
9	(	O
10	ability	O
11	to	O
12	achieve	O
13	an	O
14	erection	O
15	)	O
16	and	O
17	question	O
18	4	O
19	(	O
20	ability	O
21	to	O
22	maintain	O
23	an	O
24	erection	O
25	)	O
26	of	O
27	the	O
28	15	O
29	-	O
30	item	O
31	International	O
32	Index	O
33	of	O
34	Erectile	O
35	Function	O
36	(	O
37	IIEF	O
38	).	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	Induction	O
2	of	O
3	the	O
4	CINC	B
5	promoter	I
6	by	O
7	IL	B
8	-	I
9	17	I
10	in	O
11	IEC	O
12	-	O
13	6	O
14	cells	O
15	was	O
16	TNF	B
17	receptor	I
18	-	I
19	associated	I
20	factor	I
21	-	I
22	6	I
23	(	O
24	TRAF6	B
25	),	O
26	but	O
27	not	O
28	TRAF2	B
29	,	O
30	dependent	O
31	.	O

1	Regulatory	O
2	motifs	O
3	for	O
4	gene	O
5	expression	O
6	such	O
7	as	O
8	nuclear	B
9	-	I
10	factor	I
11	-	I
12	kappaB	I
13	-	I
14	binding	I
15	-	I
16	site	I
17	-	I
18	like	I
19	sequence	I
20	(	O
21	kappaB	B
22	site	I
23	)	O
24	and	O
25	nuclear	B
26	-	I
27	factor	I
28	-	I
29	interleukin	I
30	-	I
31	6	I
32	-	I
33	binding	I
34	-	I
35	site	I
36	-	I
37	like	I
38	sequence	I
39	(	O
40	NF	B
41	-	I
42	IL	I
43	-	I
44	6	I
45	site	I
46	)	O
47	were	O
48	found	O
49	in	O
50	the	O
51	5	O
52	'-	O
53	upstream	O
54	regulatory	O
55	region	O
56	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	B
10	sites	I
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O

1	Ischemia	O
2	and	O
3	reperfusion	O
4	markedly	O
5	increased	O
6	the	O
7	release	O
8	of	O
9	6	O
10	-	O
11	keto	O
12	-	O
13	PGF1	O
14	alpha	O
15	and	O
16	TXB2	O
17	.	O

1	Reporting	O
2	of	O
3	adverse	O
4	events	O
5	occurring	O
6	during	O
7	clinical	O
8	trials	O
9	of	O
10	investigational	O
11	drugs	O
12	is	O
13	a	O
14	complex	O
15	and	O
16	controversial	O
17	issue	O
18	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	the	O
6	current	O
7	status	O
8	of	O
9	the	O
10	understanding	O
11	of	O
12	the	O
13	interaction	O
14	mechanisms	O
15	of	O
16	ultrasound	O
17	with	O
18	biological	O
19	media	O
20	and	O
21	the	O
22	factors	O
23	that	O
24	govern	O
25	different	O
26	biological	O
27	effects	O
28	are	O
29	surveyed	O
30	.	O

1	Further	O
2	,	O
3	mutational	O
4	analysis	O
5	of	O
6	NS5A	B
7	assigned	O
8	the	O
9	SH3	B
10	-	I
11	binding	I
12	region	I
13	to	O
14	a	O
15	proline	O
16	-	O
17	rich	O
18	motif	O
19	that	O
20	is	O
21	highly	O
22	conserved	O
23	among	O
24	HCV	O
25	genotypes	O
26	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	B
9	hPRL	I
10	inhibits	O
11	the	O
12	VEGF	B
13	-	O
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	Rep63A	O
2	(	O
3	513	O
4	amino	O
5	acids	O
6	[	O
7	aa	O
8	]),	O
9	encoded	O
10	by	O
11	the	O
12	largest	O
13	ORF	O
14	,	O
15	displayed	O
16	strong	O
17	similarity	O
18	(	O
19	40	O
20	%	O
21	identity	O
22	)	O
23	to	O
24	the	O
25	replication	O
26	proteins	O
27	from	O
28	plasmids	O
29	pAMbeta1	O
30	,	O
31	pIP501	O
32	,	O
33	and	O
34	pSM19035	O
35	,	O
36	indicating	O
37	that	O
38	the	O
39	pAW63	O
40	replicon	O
41	belongs	O
42	to	O
43	the	O
44	pAMbeta1	O
45	family	O
46	of	O
47	gram	O
48	-	O
49	positive	O
50	theta	O
51	-	O
52	replicating	O
53	plasmids	O
54	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	demonstrate	O
6	that	O
7	the	O
8	production	O
9	of	O
10	active	B
11	recombinant	I
12	telomerase	I
13	requires	O
14	a	O
15	factor	O
16	in	O
17	rabbit	O
18	reticulocyte	O
19	lysate	O
20	that	O
21	promotes	O
22	ribonucleoprotein	O
23	assembly	O
24	.	O

1	The	O
2	enhanced	O
3	binding	O
4	of	O
5	c	B
6	-	I
7	Abl	I
8	to	O
9	DNA	O
10	containing	O
11	5	O
12	-	O
13	methylcytosine	O
14	residues	O
15	may	O
16	result	O
17	from	O
18	an	O
19	increased	O
20	propensity	O
21	of	O
22	the	O
23	double	O
24	helix	O
25	to	O
26	denature	O
27	locally	O
28	coupled	O
29	with	O
30	a	O
31	protein	O
32	-	O
33	induced	O
34	reduction	O
35	in	O
36	the	O
37	base	O
38	stacking	O
39	interaction	O
40	.	O

1	According	O
2	to	O
3	pilot	O
4	experiments	O
5	which	O
6	considered	O
7	various	O
8	durations	O
9	of	O
10	global	O
11	no	O
12	-	O
13	flow	O
14	ischemia	O
15	ranging	O
16	from	O
17	10	O
18	to	O
19	20	O
20	minutes	O
21	,	O
22	two	O
23	durations	O
24	were	O
25	chosen	O
26	for	O
27	the	O
28	present	O
29	study	O
30	:	O
31	20	O
32	minutes	O
33	(	O
34	group	O
35	20	O
36	)	O
37	in	O
38	which	O
39	ventricular	O
40	fibrillation	O
41	(	O
42	VF	O
43	)	O
44	was	O
45	the	O
46	predominant	O
47	form	O
48	of	O
49	arrhythmias	O
50	,	O
51	and	O
52	18	O
53	minutes	O
54	(	O
55	group	O
56	18	O
57	)	O
58	in	O
59	which	O
60	the	O
61	prevalence	O
62	of	O
63	VF	O
64	was	O
65	markedly	O
66	lower	O
67	despite	O
68	the	O
69	small	O
70	difference	O
71	in	O
72	the	O
73	duration	O
74	of	O
75	ischemia	O
76	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	the	O
6	Stress	B
7	-	I
8	Activated	I
9	-	I
10	Protein	I
11	-	I
12	Kinase	I
13	(	O
14	SAPK	B
15	)	O
16	target	O
17	sites	O
18	of	O
19	ATF2	B
20	,	O
21	Thr69	O
22	and	O
23	Thr71	O
24	are	O
25	not	O
26	required	O
27	for	O
28	the	O
29	formation	O
30	of	O
31	the	O
32	p300	B
33	/	O
34	CBP	B
35	-	O
36	ATF2	B
37	multiprotein	O
38	complex	O
39	.	O

1	Blood	O
2	samples	O
3	were	O
4	obtained	O
5	daily	O
6	during	O
7	this	O
8	supplementation	O
9	period	O
10	and	O
11	5	O
12	d	O
13	thereafter	O
14	(	O
15	d	O
16	11	O
17	to	O
18	15	O
19	).	O

1	We	O
2	also	O
3	observed	O
4	that	O
5	cell	O
6	surface	O
7	CD4	B
8	(-)	O
9	CD8	B
10	(-)	O
11	CD3	B
12	(-)	O
13	cells	O
14	with	O
15	rearranged	B
16	TCR	I
17	genes	I
18	developed	O
19	from	O
20	Id3	B
21	-	O
22	transduced	O
23	but	O
24	not	O
25	from	O
26	control	O
27	-	O
28	transduced	O
29	pre	O
30	-	O
31	T	O
32	cells	O
33	in	O
34	an	O
35	FTOC	O
36	.	O

1	This	O
2	dimer	O
3	interface	O
4	is	O
5	likely	O
6	important	O
7	for	O
8	increasing	O
9	the	O
10	DNA	O
11	-	O
12	binding	O
13	specificity	O
14	and	O
15	affinity	O
16	of	O
17	the	O
18	trimeric	O
19	form	O
20	of	O
21	HSF	B
22	,	O
23	as	O
24	well	O
25	as	O
26	for	O
27	increasing	O
28	cooperativity	O
29	between	O
30	adjacent	O
31	trimers	O
32	.	O

1	Induction	O
2	of	O
3	the	O
4	urokinase	B
5	promoter	I
6	by	O
7	HGF	B
8	/	O
9	SF	B
10	via	O
11	the	O
12	Met	B
13	receptor	I
14	was	O
15	blocked	O
16	by	O
17	co	O
18	-	O
19	expression	O
20	of	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	Grb2	B
26	and	O
27	Sos1	B
28	expression	O
29	construct	O
30	.	O

1	Nevertheless	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	the	O
7	entire	O
8	three	O
9	-	O
10	component	O
11	yeast	O
12	capping	O
13	apparatus	O
14	,	O
15	consisting	O
16	of	O
17	RNA	B
18	5	I
19	'-	I
20	triphosphatase	I
21	(	O
22	Cet1p	B
23	),	O
24	RNA	B
25	guanylyltransferase	I
26	(	O
27	Ceg1p	B
28	),	O
29	and	O
30	Abd1p	B
31	could	O
32	be	O
33	replaced	O
34	in	O
35	vivo	O
36	by	O
37	the	O
38	two	O
39	-	O
40	component	O
41	mammalian	O
42	apparatus	O
43	consisting	O
44	of	O
45	a	O
46	bifunctional	O
47	triphosphatase	B
48	-	I
49	guanylyltransferase	I
50	Mce1p	I
51	and	O
52	the	O
53	methyltransferase	B
54	Hcm1	I
55	(	I
56	121	I
57	-	I
58	476	I
59	)	I
60	p	I
61	.	O

1	The	O
2	influence	O
3	of	O
4	Epstein	O
5	-	O
6	Barr	O
7	virus	O
8	seropositivity	O
9	on	O
10	the	O
11	efficacy	O
12	of	O
13	intravenous	O
14	immune	B
15	globulin	I
16	in	O
17	children	O
18	with	O
19	immune	O
20	thrombocytopenic	O
21	purpura	O
22	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	lab	O
6	and	O
7	field	O
8	tests	O
9	yielded	O
10	high	O
11	levels	O
12	of	O
13	infestation	O
14	in	O
15	larvae	O
16	with	O
17	values	O
18	ranging	O
19	from	O
20	90	O
21	to	O
22	100	O
23	%	O
24	and	O
25	from	O
26	85	O
27	to	O
28	95	O
29	%,	O
30	respectively	O
31	.	O

1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O

1	In	O
2	addition	O
3	,	O
4	these	O
5	cells	O
6	contained	O
7	one	O
8	,	O
9	two	O
10	,	O
11	or	O
12	multiple	O
13	nuclei	O
14	indicative	O
15	of	O
16	a	O
17	G2	O
18	/	O
19	M	O
20	delay	O
21	in	O
22	nuclear	O
23	division	O
24	and	O
25	also	O
26	a	O
27	defect	O
28	in	O
29	cytokinesis	O
30	and	O
31	/	O
32	or	O
33	cell	O
34	separation	O
35	.	O

1	Both	O
2	functional	O
3	analyses	O
4	in	O
5	undifferentiated	O
6	and	O
7	differentiated	O
8	F9	O
9	cells	O
10	and	O
11	characterization	O
12	of	O
13	DNA	O
14	-	O
15	protein	O
16	complexes	O
17	in	O
18	vitro	O
19	have	O
20	identified	O
21	the	O
22	sequence	O
23	motifs	O
24	GTGACT	O
25	(	O
26	C	O
27	),	O
28	ATTGT	O
29	,	O
30	and	O
31	GATA	O
32	as	O
33	the	O
34	key	O
35	transcription	O
36	factor	O
37	binding	O
38	sites	O
39	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	O
12	perturbed	O
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	B
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	B
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	The	O
2	relatively	O
3	mild	O
4	defects	O
5	observed	O
6	in	O
7	Rpd3	B
8	mutants	I
9	suggest	O
10	that	O
11	the	O
12	recently	O
13	identified	O
14	Groucho	B
15	and	O
16	dCtBP	B
17	corepressor	I
18	proteins	I
19	do	O
20	not	O
21	function	O
22	solely	O
23	through	O
24	the	O
25	recruitment	O
26	of	O
27	histone	B
28	deacetylases	I
29	.	O

1	These	O
2	indications	O
3	of	O
4	deregulated	O
5	signalling	O
6	in	O
7	the	O
8	absence	O
9	of	O
10	tyrosine	O
11	118	O
12	were	O
13	substantiated	O
14	by	O
15	sustained	O
16	activation	O
17	of	O
18	STAT3	B
19	.	O

1	The	O
2	most	O
3	common	O
4	characteristics	O
5	of	O
6	VRE	O
7	patients	O
8	were	O
9	recent	O
10	prior	O
11	vancomycin	O
12	use	O
13	,	O
14	recent	O
15	prior	O
16	susceptible	O
17	enterococcal	O
18	infection	O
19	,	O
20	coinfection	O
21	with	O
22	other	O
23	microbial	O
24	pathogens	O
25	,	O
26	and	O
27	concurrent	O
28	fungal	O
29	infection	O
30	.	O

1	Binding	O
2	affinities	O
3	of	O
4	these	O
5	recombinant	O
6	phages	O
7	as	O
8	determined	O
9	by	O
10	the	O
11	retention	O
12	of	O
13	these	O
14	phages	O
15	by	O
16	a	O
17	His	O
18	-	O
19	tag	O
20	immobilized	O
21	gp17	B
22	column	O
23	,	O
24	and	O
25	by	O
26	co	O
27	-	O
28	immunoprecipitation	O
29	with	O
30	purified	O
31	terminase	B
32	supported	O
33	the	O
34	specific	O
35	nature	O
36	of	O
37	the	O
38	portal	B
39	protein	I
40	and	O
41	terminase	B
42	interaction	I
43	sites	I
44	.	O

1	The	O
2	exon	O
3	:	O
4	intron	O
5	structure	O
6	of	O
7	chicken	B
8	IL8	I
9	corresponds	O
10	almost	O
11	exactly	O
12	to	O
13	that	O
14	of	O
15	human	B
16	IL8	I
17	and	O
18	differs	O
19	from	O
20	those	O
21	of	O
22	other	O
23	known	O
24	mammalian	B
25	CXC	I
26	chemokine	I
27	genes	I
28	.	O

1	Interestingly	O
2	,	O
3	highly	O
4	charged	O
5	residues	O
6	were	O
7	abundantly	O
8	possessed	O
9	in	O
10	the	O
11	carboxy	O
12	-	O
13	terminal	O
14	part	O
15	of	O
16	the	O
17	MDV2	B
18	UL10	I
19	protein	I
20	.	O

1	Consistent	O
2	with	O
3	this	O
4	possibility	O
5	,	O
6	a	O
7	non	O
8	-	O
9	MBD	B
10	region	O
11	of	O
12	Bin1	B
13	was	O
14	sufficient	O
15	to	O
16	recruit	O
17	a	O
18	repression	O
19	function	O
20	to	O
21	DNA	O
22	that	O
23	was	O
24	unrelated	O
25	to	O
26	histone	B
27	deacetylase	I
28	.	O

1	The	O
2	presence	O
3	of	O
4	cutaneous	O
5	xanthomas	O
6	with	O
7	normal	O
8	serum	O
9	lipid	O
10	levels	O
11	is	O
12	due	O
13	to	O
14	the	O
15	antibetalipoproteic	O
16	activity	O
17	of	O
18	the	O
19	monoclonal	B
20	immunoglobulin	I
21	.	O

1	E2	B
2	point	O
3	mutants	O
4	unable	O
5	to	O
6	inhibit	O
7	cell	O
8	growth	O
9	did	O
10	not	O
11	repress	O
12	cdc25A	B
13	and	O
14	cdc25B	B
15	expression	O
16	,	O
17	nor	O
18	did	O
19	the	O
20	cell	O
21	cycle	O
22	inhibitors	O
23	hydroxyurea	O
24	and	O
25	mimosine	O
26	.	O

1	BACKGROUND	O
2	/	O
3	PURPOSE	O
4	:	O
5	Anomalous	O
6	arrangement	O
7	of	O
8	the	O
9	pancreaticobiliary	O
10	duct	O
11	(	O
12	AAPBD	O
13	)	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	congenital	O
19	biliary	O
20	dilatation	O
21	and	O
22	frequently	O
23	associated	O
24	with	O
25	biliary	O
26	tract	O
27	malignancy	O
28	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	B
8	protein	I
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	G	O
2	-	O
3	box	O
4	-	O
5	directed	O
6	expression	O
7	in	O
8	leaves	O
9	required	O
10	the	O
11	presence	O
12	of	O
13	an	O
14	enhancer	O
15	region	O
16	from	O
17	the	O
18	cauliflower	O
19	mosaic	O
20	virus	O
21	(	O
22	CaMV	O
23	)	O
24	35S	B
25	promoter	I
26	.	O

1	Another	O
2	element	O
3	necessary	O
4	for	O
5	augmenting	O
6	the	O
7	amplitude	O
8	of	O
9	the	O
10	oscillation	O
11	lies	O
12	between	O
13	-	O
14	178	O
15	and	O
16	-	O
17	264	O
18	.	O

1	There	O
2	was	O
3	no	O
4	competition	O
5	between	O
6	activin	B
7	A	I
8	and	O
9	OP	B
10	-	I
11	1	I
12	for	O
13	availability	O
14	of	O
15	Smad4	B
16	,	O
17	indicating	O
18	that	O
19	the	O
20	concentration	O
21	of	O
22	this	O
23	common	O
24	signal	O
25	transducer	O
26	is	O
27	not	O
28	limiting	O
29	for	O
30	generating	O
31	the	O
32	observed	O
33	biological	O
34	responses	O
35	.	O

1	A	O
2	multi	O
3	-	O
4	centre	O
5	evaluation	O
6	of	O
7	the	O
8	card	O
9	indirect	O
10	agglutination	O
11	test	O
12	for	O
13	trypanosomiasis	O
14	(	O
15	TrypTect	O
16	CIATT	O
17	).	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O

1	y	O
2	.	O

1	Auditory	O
2	clicks	O
3	were	O
4	given	O
5	at	O
6	a	O
7	rate	O
8	of	O
9	20	O
10	s	O
11	(-	O
12	1	O
13	).	O

1	Myosin	B
2	light	I
3	chain	I
4	kinase	I
5	functions	O
6	downstream	O
7	of	O
8	Ras	B
9	/	O
10	ERK	B
11	to	O
12	promote	O
13	migration	O
14	of	O
15	urokinase	B
16	-	I
17	type	I
18	plasminogen	I
19	activator	I
20	-	O
21	stimulated	O
22	cells	O
23	in	O
24	an	O
25	integrin	B
26	-	O
27	selective	O
28	manner	O
29	.	O

1	A	O
2	13	O
3	-	O
4	bp	O
5	cis	O
6	-	O
7	regulatory	O
8	element	O
9	in	O
10	the	O
11	LTR	O
12	promoter	O
13	of	O
14	the	O
15	tobacco	B
16	retrotransposon	I
17	Tto1	I
18	is	O
19	involved	O
20	in	O
21	responsiveness	O
22	to	O
23	tissue	O
24	culture	O
25	,	O
26	wounding	O
27	,	O
28	methyl	O
29	jasmonate	O
30	and	O
31	fungal	O
32	elicitors	O
33	.	O

1	G	B
2	-	I
3	CSF	I
4	(	O
5	480	O
6	micrograms	O
7	subcutaneously	O
8	(	O
9	s	O
10	.	O
11	c	O
12	.))	O
13	were	O
14	used	O
15	in	O
16	55	O
17	and	O
18	GM	B
19	-	I
20	CSF	I
21	(	O
22	400	O
23	micrograms	O
24	s	O
25	.	O
26	c	O
27	.)	O
28	in	O
29	28	O
30	chemotherapeutic	O
31	cycles	O
32	.	O

1	Human	O
2	expressed	O
3	sequence	O
4	tag	O
5	clones	O
6	were	O
7	identified	O
8	by	O
9	sequence	O
10	similarity	O
11	to	O
12	mammalian	B
13	and	I
14	yeast	I
15	oligosaccharide	I
16	-	I
17	processing	I
18	mannosidases	I
19	,	O
20	and	O
21	the	O
22	full	O
23	-	O
24	length	O
25	coding	O
26	region	O
27	of	O
28	the	O
29	putative	O
30	mannosidase	B
31	homolog	I
32	was	O
33	isolated	O
34	by	O
35	a	O
36	combination	O
37	of	O
38	5	O
39	'-	O
40	rapid	O
41	amplification	O
42	of	O
43	cDNA	O
44	ends	O
45	and	O
46	direct	O
47	polymerase	O
48	chain	O
49	reaction	O
50	from	O
51	human	O
52	placental	O
53	cDNA	O
54	.	O

1	Accumulation	O
2	of	O
3	the	O
4	U4	B
5	/	O
6	U6	B
7	duplex	O
8	was	O
9	relieved	O
10	by	O
11	overexpression	O
12	of	O
13	wild	B
14	-	I
15	type	I
16	Prp44p	I
17	.	O

1	FAK	B
2	localizes	O
3	to	O
4	sites	O
5	of	O
6	transmembrane	B
7	integrin	I
8	receptor	I
9	clustering	O
10	and	O
11	facilitates	O
12	intracellular	O
13	signaling	O
14	events	O
15	.	O

1	DESIGN	O
2	:	O
3	Comparison	O
4	of	O
5	number	O
6	of	O
7	women	O
8	with	O
9	PKU	O
10	aged	O
11	15	O
12	-	O
13	44	O
14	years	O
15	on	O
16	the	O
17	NSW	O
18	PKU	O
19	database	O
20	(	O
21	observed	O
22	number	O
23	)	O
24	with	O
25	expected	O
26	number	O
27	derived	O
28	from	O
29	population	O
30	data	O
31	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	This	O
2	report	O
3	presents	O
4	state	O
5	-	O
6	specific	O
7	MMRs	O
8	for	O
9	1987	O
10	-	O
11	1996	O
12	,	O
13	focusing	O
14	on	O
15	persistent	O
16	disparities	O
17	in	O
18	maternal	O
19	mortality	O
20	between	O
21	black	O
22	and	O
23	white	O
24	women	O
25	.	O

1	Cat	B
2	-	I
3	1	I
4	is	O
5	identical	O
6	to	O
7	the	O
8	recently	O
9	identified	O
10	binding	O
11	partner	O
12	for	O
13	the	O
14	beta	B
15	-	I
16	adrenergic	I
17	receptor	I
18	kinase	I
19	(	O
20	betaARK	B
21	or	O
22	GRK	B
23	-	I
24	2	I
25	),	O
26	which	O
27	was	O
28	shown	O
29	to	O
30	have	O
31	Arf	B
32	-	O
33	GAP	B
34	activity	O
35	.	O

1	Thus	O
2	,	O
3	elongin	B
4	C	I
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	The	O
2	molecular	O
3	mechanism	O
4	of	O
5	Tax	B
6	-	O
7	mediated	O
8	trans	O
9	-	O
10	activation	O
11	has	O
12	been	O
13	well	O
14	investigated	O
15	.	O

1	Gel	O
2	filtration	O
3	and	O
4	co	O
5	-	O
6	immunoprecipitation	O
7	analyses	O
8	reveal	O
9	that	O
10	Mad2p	B
11	tightly	O
12	associates	O
13	with	O
14	another	O
15	spindle	O
16	checkpoint	O
17	component	O
18	,	O
19	Mad1p	B
20	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	B
8	-	I
9	34	I
10	transcript	I
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	Oligonucleotide	O
2	probes	O
3	corresponding	O
4	to	O
5	wild	O
6	-	O
7	type	O
8	and	O
9	mutant	O
10	EpRE	O
11	sequences	O
12	were	O
13	used	O
14	in	O
15	gel	O
16	-	O
17	shift	O
18	and	O
19	super	O
20	-	O
21	shift	O
22	analyses	O
23	to	O
24	identify	O
25	proteins	O
26	binding	O
27	.	O

1	PDGF	B
2	A	I
3	-	I
4	chain	I
5	levels	O
6	increase	O
7	in	O
8	cultured	O
9	vascular	O
10	smooth	O
11	muscle	O
12	cells	O
13	(	O
14	SMCs	O
15	)	O
16	exposed	O
17	to	O
18	ATII	B
19	.	O

1	Deletion	O
2	mapping	O
3	of	O
4	the	O
5	human	B
6	presenilin	I
7	-	I
8	1	I
9	(	O
10	PS1	B
11	)	O
12	promoter	O
13	delineated	O
14	the	O
15	most	O
16	active	O
17	fragment	O
18	from	O
19	-	O
20	118	O
21	to	O
22	+	O
23	178	O
24	in	O
25	relation	O
26	to	O
27	the	O
28	transcription	O
29	start	O
30	site	O
31	mapped	O
32	in	O
33	this	O
34	study	O
35	,	O
36	in	O
37	both	O
38	human	O
39	neuroblastoma	O
40	SK	O
41	-	O
42	N	O
43	-	O
44	SH	O
45	and	O
46	hepatoma	O
47	HepG2	O
48	cells	O
49	.	O

1	Analysis	O
2	of	O
3	the	O
4	E2F1	B
5	gene	I
6	promoter	I
7	showed	O
8	that	O
9	the	O
10	-	O
11	146	O
12	to	O
13	-	O
14	54	O
15	region	O
16	was	O
17	required	O
18	for	O
19	E2	B
20	-	O
21	responsiveness	O
22	in	O
23	transient	O
24	transfection	O
25	assays	O
26	,	O
27	and	O
28	subsequent	O
29	deletion	O
30	/	O
31	mutation	O
32	analysis	O
33	showed	O
34	that	O
35	a	O
36	single	O
37	upstream	O
38	GC	O
39	-	O
40	rich	O
41	and	O
42	two	O
43	downstream	O
44	CCAAT	O
45	-	O
46	binding	O
47	sites	O
48	were	O
49	required	O
50	for	O
51	transactivation	O
52	by	O
53	E2	B
54	.	O

1	In	O
2	the	O
3	course	O
4	of	O
5	investigating	O
6	the	O
7	mechanisms	O
8	by	O
9	which	O
10	OF5	B
11	and	O
12	OF3	B
13	regulated	O
14	CYP11A1	B
15	transcription	O
16	,	O
17	we	O
18	found	O
19	that	O
20	OF5	B
21	and	O
22	OF3	B
23	bound	O
24	Sp1	B
25	and	O
26	Sp3	B
27	in	O
28	JEG	O
29	-	O
30	3	O
31	cells	O
32	.	O

1	Transformation	O
2	blocks	O
3	differentiation	O
4	-	O
5	induced	O
6	inhibition	O
7	of	O
8	serum	B
9	response	I
10	factor	I
11	interactions	O
12	with	O
13	serum	O
14	response	O
15	elements	O
16	.	O

1	The	O
2	median	O
3	durations	O
4	for	O
5	response	O
6	and	O
7	survival	O
8	time	O
9	in	O
10	the	O
11	late	O
12	phase	O
13	II	O
14	trial	O
15	were	O
16	2	O
17	.	O
18	3	O
19	months	O
20	and	O
21	5	O
22	.	O
23	8	O
24	months	O
25	,	O
26	respectively	O
27	.	O

1	Nuclear	O
2	hormone	O
3	receptors	O
4	(	O
5	NRs	O
6	)	O
7	are	O
8	ligand	O
9	-	O
10	inducible	O
11	transcription	O
12	factors	O
13	that	O
14	mediate	O
15	critical	O
16	functions	O
17	in	O
18	many	O
19	species	O
20	.	O

1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	B
8	might	O
9	target	O
10	Glc7	B
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	I
19	complex	I
20	.	O

1	The	O
2	analysis	O
3	of	O
4	two	O
5	distinct	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	kinase	I
11	pathways	O
12	shows	O
13	that	O
14	stress	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	-	O
20	Jun	B
21	N	I
22	-	I
23	terminal	I
24	kinase	I
25	activation	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	phosphorylation	O
31	of	O
32	ATF	B
33	-	I
34	2	I
35	,	O
36	c	B
37	-	I
38	Jun	I
39	,	O
40	and	O
41	JunD	B
42	,	O
43	is	O
44	required	O
45	not	O
46	only	O
47	for	O
48	the	O
49	IL	B
50	-	I
51	1	I
52	-	O
53	but	O
54	also	O
55	for	O
56	the	O
57	TPA	O
58	-	O
59	dependent	O
60	induction	O
61	,	O
62	while	O
63	the	O
64	extracellular	B
65	signal	I
66	-	I
67	related	I
68	kinase	I
69	1	I
70	(	O
71	ERK	B
72	-	I
73	1	I
74	)	O
75	and	O
76	ERK	B
77	-	I
78	2	I
79	activation	O
80	is	O
81	involved	O
82	in	O
83	the	O
84	TPA	O
85	-	O
86	but	O
87	not	O
88	in	O
89	the	O
90	IL	B
91	-	I
92	1	I
93	-	O
94	dependent	O
95	stimulation	O
96	of	O
97	the	O
98	uPA	B
99	enhancer	I
100	.	O

1	The	O
2	recruitment	O
3	of	O
4	constitutively	O
5	phosphorylated	O
6	p185	B
7	(	O
8	neu	B
9	)	O
10	and	O
11	the	O
12	activated	O
13	mitogenic	O
14	pathway	O
15	proteins	O
16	to	O
17	this	O
18	membrane	O
19	-	O
20	microfilament	O
21	interaction	O
22	site	O
23	provides	O
24	a	O
25	physical	O
26	model	O
27	for	O
28	integrating	O
29	the	O
30	assembly	O
31	of	O
32	the	O
33	mitogenic	O
34	pathway	O
35	with	O
36	the	O
37	transmission	O
38	of	O
39	growth	O
40	factor	O
41	signal	O
42	to	O
43	the	O
44	cytoskeleton	O
45	.	O

1	The	O
2	intron	O
3	is	O
4	capable	O
5	of	O
6	splicing	O
7	despite	O
8	the	O
9	fact	O
10	that	O
11	both	O
12	the	O
13	EBS1	B
14	/	O
15	IBS1	B
16	and	O
17	the	O
18	EBS2	B
19	/	O
20	IBS2	B
21	sequence	O
22	motifs	O
23	,	O
24	thought	O
25	to	O
26	be	O
27	necessary	O
28	for	O
29	correct	O
30	splicing	O
31	,	O
32	extend	O
33	over	O
34	5	O
35	instead	O
36	of	O
37	6	O
38	bp	O
39	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	Cross	O
2	-	O
3	linking	O
4	the	O
5	B	B
6	cell	I
7	Ag	I
8	receptor	I
9	(	O
10	BCR	B
11	)	O
12	to	O
13	surface	B
14	Fc	I
15	receptors	I
16	for	O
17	IgG	B
18	(	O
19	Fc	B
20	gamma	I
21	R	I
22	)	O
23	inhibits	O
24	G1	O
25	-	O
26	to	O
27	-	O
28	S	O
29	progression	O
30	;	O
31	the	O
32	mechanism	O
33	by	O
34	which	O
35	this	O
36	occurs	O
37	is	O
38	not	O
39	completely	O
40	known	O
41	.	O

1	TRAF2	B
2	is	O
3	a	O
4	potent	O
5	activator	O
6	of	O
7	a	O
8	95	B
9	-	I
10	kDa	I
11	serine	I
12	/	I
13	threonine	I
14	kinase	I
15	termed	O
16	germinal	B
17	center	I
18	kinase	I
19	related	I
20	(	O
21	GCKR	B
22	,	O
23	also	O
24	referred	O
25	to	O
26	as	O
27	KHS1	B
28	),	O
29	which	O
30	signals	O
31	activation	O
32	of	O
33	the	O
34	SAPK	B
35	pathway	O
36	.	O

1	The	O
2	main	O
3	issues	O
4	are	O
5	the	O
6	need	O
7	to	O
8	explain	O
9	a	O
10	number	O
11	of	O
12	still	O
13	unknown	O
14	mechanisms	O
15	,	O
16	to	O
17	determine	O
18	which	O
19	"	O
20	natural	O
21	diet	O
22	"	O
23	carries	O
24	the	O
25	minimum	O
26	coronary	O
27	risk	O
28	and	O
29	whether	O
30	"	O
31	new	O
32	"	O
33	foods	O
34	produced	O
35	by	O
36	modern	O
37	technology	O
38	are	O
39	really	O
40	needed	O
41	to	O
42	contrast	O
43	this	O
44	epidemic	O
45	.	O

1	SF	B
2	-	I
3	1	I
4	does	O
5	not	O
6	have	O
7	an	O
8	N	O
9	-	O
10	terminal	O
11	AF1	O
12	domain	O
13	.	O

1	Natural	O
2	Haemophilus	O
3	influenzae	O
4	type	O
5	b	O
6	capsular	O
7	polysaccharide	O
8	antibodies	O
9	in	O
10	412	O
11	infants	O
12	and	O
13	children	O
14	from	O
15	West	O
16	Africa	O
17	(	O
18	Burkina	O
19	-	O
20	Faso	O
21	)	O
22	and	O
23	France	O
24	:	O
25	a	O
26	cross	O
27	-	O
28	sectional	O
29	serosurvey	O
30	.	O

1	Immunohistochemical	O
2	staining	O
3	with	O
4	MIB	B
5	-	I
6	1	I
7	and	O
8	p53	B
9	antibodies	I
10	showed	O
11	low	O
12	(<	O
13	1	O
14	%)	O
15	and	O
16	negative	O
17	reaction	O
18	.	O

1	The	O
2	C2C	B
3	-	O
4	Prx	B
5	is	O
6	encoded	O
7	as	O
8	a	O
9	preprotein	O
10	of	O
11	273	O
12	amino	O
13	acids	O
14	containing	O
15	a	O
16	putative	O
17	chloroplast	O
18	-	O
19	targeting	O
20	signal	O
21	of	O
22	65	O
23	amino	O
24	acids	O
25	at	O
26	its	O
27	N	O
28	-	O
29	terminus	O
30	.	O

1	A	O
2	tyrosine	O
3	-	O
4	based	O
5	sorting	O
6	signal	O
7	in	O
8	the	O
9	beta2	B
10	integrin	I
11	cytoplasmic	I
12	domain	I
13	mediates	O
14	its	O
15	recycling	O
16	to	O
17	the	O
18	plasma	O
19	membrane	O
20	and	O
21	is	O
22	required	O
23	for	O
24	ligand	O
25	-	O
26	supported	O
27	migration	O
28	.	O

1	The	O
2	injection	O
3	of	O
4	XDRP1	B
5	protein	I
6	into	O
7	fertilized	O
8	Xenopus	O
9	eggs	O
10	blocked	O
11	embryonic	O
12	cell	O
13	division	O
14	.	O

1	In	O
2	order	O
3	to	O
4	screen	O
5	for	O
6	such	O
7	cofactors	O
8	,	O
9	we	O
10	have	O
11	used	O
12	a	O
13	transcriptionally	O
14	inactive	O
15	mutant	O
16	of	O
17	Xenopus	B
18	MEF2D	I
19	in	O
20	a	O
21	yeast	O
22	two	O
23	-	O
24	hybrid	O
25	screen	O
26	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Mutations	O
2	of	O
3	the	O
4	RET	B
5	gene	I
6	,	O
7	encoding	O
8	a	O
9	receptor	B
10	tyrosine	I
11	kinase	I
12	,	O
13	have	O
14	been	O
15	associated	O
16	with	O
17	the	O
18	inherited	O
19	cancer	O
20	syndromes	O
21	MEN	O
22	2A	O
23	and	O
24	MEN	O
25	2B	O
26	.	O

1	BCL6	B
2	encodes	O
3	a	O
4	POZ	B
5	/	I
6	Zn	I
7	finger	I
8	protein	I
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O

1	Beta	B
2	1	I
3	integrin	I
4	-	O
5	and	O
6	proteoglycan	O
7	-	O
8	mediated	O
9	stimulation	O
10	of	O
11	T	O
12	lymphoma	O
13	cell	O
14	adhesion	O
15	and	O
16	mitogen	B
17	-	I
18	activated	I
19	protein	I
20	kinase	I
21	signaling	O
22	by	O
23	thrombospondin	B
24	-	I
25	1	I
26	and	O
27	thrombospondin	B
28	-	I
29	1	I
30	peptides	I
31	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	B
16	isozymes	I
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	Serum	O
2	concentrations	O
3	of	O
4	bone	B
5	specific	I
6	alkaline	I
7	phosphatase	I
8	(	O
9	BALP	B
10	)	O
11	and	O
12	osteocalcin	B
13	(	O
14	bone	B
15	Gla	I
16	protein	I
17	,	O
18	BGP	B
19	),	O
20	urinary	O
21	levels	O
22	of	O
23	pyridinoline	O
24	(	O
25	Pyr	O
26	)	O
27	and	O
28	deoxypyridinoline	O
29	(	O
30	Dpyr	O
31	)	O
32	and	O
33	computed	O
34	tomography	O
35	(	O
36	CT	O
37	)	O
38	measurements	O
39	of	O
40	the	O
41	cross	O
42	-	O
43	sectional	O
44	areas	O
45	of	O
46	the	O
47	vertebrae	O
48	and	O
49	the	O
50	femurs	O
51	,	O
52	the	O
53	apparent	O
54	density	O
55	of	O
56	cancellous	O
57	bone	O
58	in	O
59	the	O
60	vertebrae	O
61	,	O
62	and	O
63	the	O
64	volume	O
65	and	O
66	the	O
67	material	O
68	density	O
69	of	O
70	cortical	O
71	bone	O
72	in	O
73	the	O
74	femurs	O
75	were	O
76	determined	O
77	in	O
78	126	O
79	boys	O
80	and	O
81	143	O
82	girls	O
83	,	O
84	ages	O
85	7	O
86	-	O
87	18	O
88	years	O
89	.	O

1	Prognostic	O
2	value	O
3	of	O
4	a	O
5	treadmill	O
6	exercise	O
7	score	O
8	in	O
9	symptomatic	O
10	patients	O
11	with	O
12	nonspecific	O
13	ST	O
14	-	O
15	T	O
16	abnormalities	O
17	on	O
18	resting	O
19	ECG	O
20	.	O

1	We	O
2	propose	O
3	that	O
4	Gly84	O
5	is	O
6	part	O
7	of	O
8	a	O
9	putative	O
10	"	O
11	oxyanion	O
12	hole	O
13	"	O
14	involved	O
15	in	O
16	the	O
17	stabilization	O
18	of	O
19	the	O
20	transition	O
21	state	O
22	similar	O
23	to	O
24	the	O
25	C	B
26	group	I
27	of	O
28	the	O
29	esterase	B
30	/	O
31	lipase	B
32	family	O
33	.	O

1	Since	O
2	sildenafil	O
3	came	O
4	on	O
5	the	O
6	market	O
7	,	O
8	it	O
9	seems	O
10	that	O
11	the	O
12	place	O
13	of	O
14	MUSE	O
15	is	O
16	reduced	O
17	because	O
18	comparative	O
19	studies	O
20	give	O
21	better	O
22	results	O
23	for	O
24	sildenafil	O
25	than	O
26	MUSE	O
27	(	O
28	70	O
29	%	O
30	vs	O
31	40	O
32	%)	O
33	and	O
34	of	O
35	course	O
36	with	O
37	a	O
38	better	O
39	acceptance	O
40	.	O

1	Serum	O
2	antibodies	O
3	were	O
4	detected	O
5	in	O
6	at	O
7	least	O
8	95	O
9	%	O
10	of	O
11	the	O
12	infected	O
13	guinea	O
14	pigs	O
15	between	O
16	4	O
17	-	O
18	30	O
19	WPI	O
20	and	O
21	rats	O
22	between	O
23	3	O
24	-	O
25	16	O
26	WPI	O
27	.	O

1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	B
12	-	I
13	spliceosomal	I
14	U5	I
15	snRNA	I
16	from	O
17	the	O
18	trypanosomatid	O
19	species	O
20	Leptomonas	O
21	seymouri	O
22	,	O
23	using	O
24	U5	B
25	RNA	I
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	O
10	1992	O
11	),	O
12	like	O
13	the	O
14	older	O
15	MMPI	O
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	Mammalian	B
2	M	I
3	-	I
4	Ras	I
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	O
34	p21	B
35	Ras	I
36	.	O

1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O

1	Twelve	O
2	patients	O
3	had	O
4	stage	O
5	IBG3	O
6	,	O
7	14	O
8	had	O
9	ICG1	O
10	,	O
11	9	O
12	had	O
13	ICG2	O
14	,	O
15	and	O
16	3	O
17	had	O
18	ICG3	O
19	disease	O
20	.	O

1	A	O
2	total	O
3	of	O
4	174	O
5	primer	O
6	pairs	O
7	gave	O
8	interpretable	O
9	banding	O
10	patterns	O
11	,	O
12	137	O
13	(	O
14	79	O
15	%)	O
16	of	O
17	which	O
18	revealed	O
19	at	O
20	least	O
21	two	O
22	alleles	O
23	on	O
24	native	O
25	polyacrylamide	O
26	gels	O
27	.	O

1	A	O
2	crucial	O
3	transcription	O
4	factor	O
5	in	O
6	this	O
7	process	O
8	is	O
9	STAT6	B
10	,	O
11	which	O
12	binds	O
13	to	O
14	a	O
15	specific	O
16	DNA	O
17	element	O
18	upon	O
19	cytokine	O
20	activation	O
21	.	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	B
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	Both	O
2	HERV	O
3	-	O
4	K	O
5	type	O
6	1	O
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	Duch	O
2	,	O
3	and	O
4	F	O
5	.	O

1	Efficient	O
2	phosphorylation	O
3	of	O
4	BRDG1	B
5	by	O
6	Tec	B
7	required	O
8	the	O
9	PH	B
10	and	O
11	SH2	B
12	domains	I
13	as	O
14	well	O
15	as	O
16	the	O
17	kinase	O
18	domain	O
19	of	O
20	the	O
21	latter	O
22	.	O

1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	METHODS	O
2	:	O
3	We	O
4	studied	O
5	20	O
6	symptomatic	O
7	patients	O
8	with	O
9	HOCM	O
10	(	O
11	12	O
12	men	O
13	),	O
14	mean	O
15	age	O
16	52	O
17	+/-	O
18	17	O
19	years	O
20	,	O
21	before	O
22	and	O
23	after	O
24	septal	O
25	reduction	O
26	using	O
27	echocardiography	O
28	and	O
29	electrocardiogram	O
30	(	O
31	ECG	O
32	).	O

1	Paleoceanographic	O
2	data	O
3	from	O
4	the	O
5	Laurentian	O
6	Fan	O
7	,	O
8	used	O
9	as	O
10	a	O
11	proxy	O
12	for	O
13	sea	O
14	surface	O
15	temperature	O
16	,	O
17	reveal	O
18	that	O
19	surface	O
20	slope	O
21	waters	O
22	north	O
23	of	O
24	the	O
25	Gulf	O
26	Stream	O
27	experienced	O
28	warming	O
29	during	O
30	the	O
31	Little	O
32	Ice	O
33	Age	O
34	of	O
35	the	O
36	16th	O
37	to	O
38	19th	O
39	centuries	O
40	and	O
41	support	O
42	the	O
43	notion	O
44	of	O
45	an	O
46	NAO	O
47	-	O
48	driven	O
49	coupled	O
50	system	O
51	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	Thus	O
2	,	O
3	the	O
4	nematode	O
5	genes	O
6	could	O
7	be	O
8	the	O
9	homologs	B
10	of	I
11	Hh	I
12	molecules	I
13	in	O
14	other	O
15	phyla	O
16	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	regulation	O
6	of	O
7	the	O
8	FGFR	B
9	-	I
10	1	I
11	gene	I
12	(	O
13	cek	B
14	-	I
15	1	I
16	)	O
17	in	O
18	avian	O
19	myogenic	O
20	cultures	O
21	by	O
22	immunocytochemistry	O
23	and	O
24	Northern	O
25	blot	O
26	analysis	O
27	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	RESULTS	O
2	:	O
3	Factors	O
4	associated	O
5	with	O
6	significantly	O
7	(	O
8	P	O
9	<.	O
10	05	O
11	)	O
12	increased	O
13	risk	O
14	of	O
15	treatment	O
16	failure	O
17	in	O
18	a	O
19	Cox	O
20	multivariate	O
21	analysis	O
22	included	O
23	age	O
24	older	O
25	than	O
26	45	O
27	years	O
28	(	O
29	relative	O
30	hazard	O
31	,	O
32	1	O
33	.	O
34	17	O
35	;	O
36	95	O
37	%	O
38	confidence	O
39	interval	O
40	[	O
41	CI	O
42	],	O
43	1	O
44	.	O
45	02	O
46	-	O
47	1	O
48	.	O
49	33	O
50	),	O
51	Karnofsky	O
52	performance	O
53	score	O
54	less	O
55	than	O
56	90	O
57	%	O
58	(	O
59	1	O
60	.	O
61	27	O
62	;	O
63	95	O
64	%	O
65	CI	O
66	,	O
67	1	O
68	.	O
69	07	O
70	-	O
71	1	O
72	.	O
73	51	O
74	),	O
75	absence	O
76	of	O
77	hormone	O
78	receptors	O
79	(	O
80	1	O
81	.	O
82	31	O
83	;	O
84	95	O
85	%	O
86	CI	O
87	,	O
88	1	O
89	.	O
90	15	O
91	-	O
92	1	O
93	.	O
94	51	O
95	),	O
96	prior	O
97	use	O
98	of	O
99	adjuvant	O
100	chemotherapy	O
101	(	O
102	1	O
103	.	O
104	31	O
105	;	O
106	95	O
107	%	O
108	CI	O
109	,	O
110	1	O
111	.	O
112	10	O
113	-	O
114	1	O
115	.	O
116	56	O
117	),	O
118	initial	O
119	disease	O
120	-	O
121	free	O
122	survival	O
123	interval	O
124	after	O
125	adjuvant	O
126	treatment	O
127	of	O
128	no	O
129	more	O
130	than	O
131	18	O
132	months	O
133	(	O
134	1	O
135	.	O
136	99	O
137	;	O
138	95	O
139	%	O
140	CI	O
141	,	O
142	1	O
143	.	O
144	62	O
145	-	O
146	2	O
147	.	O
148	43	O
149	),	O
150	metastases	O
151	in	O
152	the	O
153	liver	O
154	(	O
155	1	O
156	.	O
157	47	O
158	;	O
159	95	O
160	%	O
161	CI	O
162	,	O
163	1	O
164	.	O
165	20	O
166	-	O
167	1	O
168	.	O
169	80	O
170	)	O
171	or	O
172	central	O
173	nervous	O
174	system	O
175	(	O
176	1	O
177	.	O
178	56	O
179	;	O
180	95	O
181	%	O
182	CI	O
183	,	O
184	0	O
185	.	O
186	99	O
187	-	O
188	2	O
189	.	O
190	46	O
191	[	O
192	approaches	O
193	significance	O
194	])	O
195	vs	O
196	soft	O
197	tissue	O
198	,	O
199	bone	O
200	,	O
201	or	O
202	lung	O
203	,	O
204	3	O
205	or	O
206	more	O
207	sites	O
208	of	O
209	metastatic	O
210	disease	O
211	(	O
212	1	O
213	.	O
214	32	O
215	;	O
216	95	O
217	%	O
218	CI	O
219	,	O
220	1	O
221	.	O
222	13	O
223	-	O
224	1	O
225	.	O
226	54	O
227	),	O
228	and	O
229	incomplete	O
230	response	O
231	vs	O
232	complete	O
233	response	O
234	to	O
235	standard	O
236	-	O
237	dose	O
238	chemotherapy	O
239	(	O
240	1	O
241	.	O
242	65	O
243	;	O
244	95	O
245	%	O
246	CI	O
247	,	O
248	1	O
249	.	O
250	36	O
251	-	O
252	1	O
253	.	O
254	99	O
255	).	O

1	The	O
2	proteasome	O
3	is	O
4	a	O
5	large	O
6	complex	O
7	consisting	O
8	of	O
9	two	O
10	multisubunit	O
11	structures	O
12	,	O
13	the	O
14	20S	B
15	and	O
16	19S	B
17	(	O
18	PA700	B
19	)	O
20	or	O
21	P28	B
22	complexes	I
23	,	O
24	that	O
25	combine	O
26	to	O
27	form	O
28	the	O
29	26S	B
30	particles	I
31	.	O

1	Neuregulin	B
2	stimulates	O
3	ErbB2	B
4	,	O
5	ErbB3	B
6	,	O
7	and	O
8	ErbB4	B
9	,	O
10	members	O
11	of	O
12	the	O
13	ErbB	B
14	family	I
15	of	O
16	receptor	B
17	tyrosine	I
18	kinases	I
19	.	O

1	In	O
2	PC12	O
3	cells	O
4	,	O
5	nerve	B
6	growth	I
7	factor	I
8	induces	O
9	neuronal	O
10	differentiation	O
11	and	O
12	repressed	O
13	expression	O
14	of	O
15	nrg	B
16	-	I
17	1	I
18	.	O

1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	O
18	that	O
19	Spo11	B
20	expression	O
21	begins	O
22	in	O
23	early	O
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O

1	Kinase	O
2	-	O
3	deficient	O
4	erbB	B
5	proteins	I
6	reduced	O
7	epidermal	B
8	growth	I
9	factor	I
10	(	O
11	EGF	B
12	)-	O
13	induced	O
14	tyrosine	O
15	phosphorylation	O
16	of	O
17	endogenous	O
18	Shc	B
19	proteins	I
20	and	O
21	also	O
22	reduced	O
23	immediate	O
24	and	O
25	sustained	O
26	EGF	B
27	-	I
28	induced	I
29	ERK	I
30	MAPK	I
31	activities	O
32	in	O
33	human	O
34	glioblastoma	O
35	cells	O
36	,	O
37	although	O
38	basal	O
39	ERK	B
40	MAPK	I
41	activities	O
42	were	O
43	unaffected	O
44	.	O

1	Therefore	O
2	,	O
3	homozygous	O
4	co	O
5	-	O
6	deletions	O
7	of	O
8	CDKN2A	B
9	and	O
10	CDKN2B	B
11	rather	O
12	than	O
13	mutations	O
14	targeting	O
15	individual	O
16	transcripts	O
17	are	O
18	frequently	O
19	selected	O
20	for	O
21	in	O
22	these	O
23	tumors	O
24	.	O

1	The	O
2	importin	B
3	alpha	I
4	.	I
5	beta	I
6	heterodimer	I
7	mediates	O
8	nuclear	O
9	import	O
10	of	O
11	proteins	O
12	containing	O
13	classical	O
14	nuclear	O
15	localization	O
16	signals	O
17	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	per	O
10	se	O
11	of	O
12	keratan	O
13	sulfate	O
14	on	O
15	native	O
16	G1	O
17	-	O
18	G2	O
19	does	O
20	not	O
21	affect	O
22	the	O
23	activity	O
24	of	O
25	atrolysin	O
26	C	O
27	toward	O
28	the	O
29	two	O
30	sites	O
31	.	O

1	A	O
2	proportion	O
3	of	O
4	APC	B
5	wild	O
6	-	O
7	type	O
8	colon	O
9	carcinomas	O
10	and	O
11	melanomas	O
12	also	O
13	contains	O
14	constitutive	O
15	nuclear	O
16	Tcf	B
17	-	I
18	4	I
19	/	O
20	beta	B
21	-	I
22	catenin	I
23	complexes	O
24	as	O
25	a	O
26	result	O
27	of	O
28	dominant	O
29	mutations	O
30	in	O
31	the	O
32	N	O
33	terminus	O
34	of	O
35	beta	B
36	-	I
37	catenin	I
38	that	O
39	render	O
40	it	O
41	insensitive	O
42	to	O
43	downregulation	O
44	by	O
45	APC	B
46	,	O
47	GSK3	B
48	beta	I
49	,	O
50	and	O
51	Axin	B
52	/	O
53	Conductin	B
54	.	O

1	Similar	O
2	mechanisms	O
3	leading	O
4	to	O
5	deregulation	O
6	of	O
7	Tcf	B
8	target	I
9	gene	I
10	activity	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	involved	O
16	in	O
17	melanoma	O
18	and	O
19	other	O
20	forms	O
21	of	O
22	cancer	O
23	.	O

1	PURPOSE	O
2	:	O
3	Previous	O
4	WR	O
5	-	O
6	2721	O
7	human	O
8	pharmacokinetic	O
9	studies	O
10	were	O
11	limited	O
12	to	O
13	plasma	O
14	levels	O
15	in	O
16	patients	O
17	receiving	O
18	platinum	O
19	-	O
20	based	O
21	compounds	O
22	,	O
23	and	O
24	none	O
25	includes	O
26	the	O
27	effects	O
28	of	O
29	WR	O
30	-	O
31	2721	O
32	on	O
33	endogenous	O
34	thiols	O
35	.	O

1	It	O
2	consists	O
3	of	O
4	2185	O
5	amino	O
6	acid	O
7	residues	O
8	encoded	O
9	by	O
10	a	O
11	9	O
12	-	O
13	kilobase	O
14	pair	O
15	mRNA	O
16	;	O
17	several	O
18	splice	O
19	variants	O
20	have	O
21	been	O
22	detected	O
23	in	O
24	human	O
25	and	O
26	rat	O
27	cDNA	O
28	libraries	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	In	O
4	addition	O
5	to	O
6	the	O
7	superiority	O
8	of	O
9	octafluoropropane	O
10	-	O
11	filled	O
12	microspheres	O
13	to	O
14	air	O
15	-	O
16	filled	O
17	microspheres	O
18	for	O
19	LV	O
20	opacification	O
21	,	O
22	the	O
23	efficacy	O
24	of	O
25	OCTA	O
26	is	O
27	relatively	O
28	unaffected	O
29	by	O
30	impaired	O
31	LV	O
32	function	O
33	and	O
34	is	O
35	less	O
36	susceptible	O
37	to	O
38	the	O
39	effects	O
40	of	O
41	poor	O
42	echogenicity	O
43	than	O
44	AIR	O
45	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	The	O
2	more	O
3	traditional	O
4	SERMS	O
5	,	O
6	clomiphene	O
7	citrate	O
8	and	O
9	tamoxifen	O
10	,	O
11	will	O
12	be	O
13	reviewed	O
14	along	O
15	with	O
16	such	O
17	modern	O
18	drugs	O
19	as	O
20	raloxifene	O
21	and	O
22	faslodex	O
23	,	O
24	with	O
25	emphasis	O
26	upon	O
27	their	O
28	actions	O
29	on	O
30	breast	O
31	,	O
32	uterus	O
33	,	O
34	bone	O
35	and	O
36	lipids	O
37	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	B
13	-	O
14	FUT5	B
15	-	O
16	FUT6	B
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O

1	S	O
2	.,	O
3	Kim	O
4	,	O
5	S	O
6	.	O

1	The	O
2	cop	B
3	region	I
4	also	O
5	harbors	O
6	a	O
7	region	O
8	of	O
9	plasmid	O
10	incompatibility	O
11	,	O
12	inc	B
13	,	O
14	encompassing	O
15	a	O
16	stem	O
17	-	O
18	loop	O
19	structure	O
20	,	O
21	the	O
22	repA	B
23	promoter	I
24	,	O
25	Prep	B
26	,	O
27	as	O
28	well	O
29	as	O
30	two	O
31	distinct	O
32	RepA	B
33	binding	I
34	sites	I
35	,	O
36	BD	O
37	-	O
38	1	O
39	and	O
40	BD	O
41	-	O
42	2	O
43	.	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	B
19	modules	I
20	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	etr	B
6	-	I
7	1	I
8	is	O
9	essential	O
10	for	O
11	muscle	O
12	development	O
13	in	O
14	C	O
15	.	O
16	elegans	O
17	,	O
18	perhaps	O
19	by	O
20	playing	O
21	a	O
22	role	O
23	in	O
24	post	O
25	-	O
26	transcriptional	O
27	processing	O
28	of	O
29	some	O
30	muscle	O
31	component	O
32	,	O
33	and	O
34	thus	O
35	suggesting	O
36	a	O
37	possible	O
38	conservation	O
39	of	O
40	gene	O
41	function	O
42	with	O
43	human	B
44	CUG	I
45	-	I
46	bp	I
47	.	O

1	Gentamicin	O
2	given	O
3	by	O
4	DPI	O
5	and	O
6	SVN	O
7	significantly	O
8	decreased	O
9	the	O
10	sputum	O
11	Psa	O
12	density	O
13	(	O
14	p	O
15	<	O
16	0	O
17	.	O
18	05	O
19	),	O
20	by	O
21	almost	O
22	one	O
23	order	O
24	of	O
25	magnitude	O
26	.	O

1	We	O
2	have	O
3	previously	O
4	identified	O
5	mouse	B
6	and	I
7	human	I
8	cDNAs	I
9	encoding	I
10	UNC	I
11	-	I
12	51	I
13	-	I
14	like	I
15	kinase	I
16	(	O
17	ULK1	B
18	).	O

1	Connector	B
2	enhancer	I
3	of	I
4	KSR	I
5	(	O
6	CNK	B
7	)	O
8	is	O
9	a	O
10	multidomain	O
11	protein	O
12	required	O
13	for	O
14	RAS	B
15	signaling	O
16	.	O

1	Moreover	O
2	,	O
3	a	O
4	recombinant	O
5	Ad	O
6	expressing	O
7	Ad5	B
8	E4orf6	I
9	/	I
10	7	I
11	induced	O
12	apoptosis	O
13	in	O
14	rat	O
15	cells	O
16	when	O
17	coinfected	O
18	with	O
19	wild	O
20	-	O
21	type	O
22	p53	B
23	-	O
24	expressing	O
25	Ad	O
26	.	O

1	Macroscopic	O
2	researches	O
3	on	O
4	heart	O
5	vascularization	O
6	have	O
7	indicated	O
8	that	O
9	the	O
10	angioarchitecture	O
11	of	O
12	the	O
13	conducting	O
14	system	O
15	differs	O
16	from	O
17	that	O
18	of	O
19	the	O
20	normal	O
21	myocardium	O
22	.	O

1	However	O
2	,	O
3	reoperation	O
4	for	O
5	bulky	O
6	cervical	O
7	disease	O
8	(	O
9	group	O
10	3	O
11	)	O
12	rarely	O
13	results	O
14	in	O
15	normal	O
16	calcitonin	B
17	levels	O
18	and	O
19	is	O
20	associated	O
21	with	O
22	a	O
23	high	O
24	incidence	O
25	of	O
26	permanent	O
27	hypoparathyroidism	O
28	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	disease	O
7	-	O
8	free	O
9	survival	O
10	(	O
11	DFS	O
12	)	O
13	and	O
14	overall	O
15	survival	O
16	(	O
17	OS	O
18	),	O
19	prognostic	O
20	factors	O
21	,	O
22	and	O
23	treatment	O
24	-	O
25	related	O
26	mortality	O
27	of	O
28	women	O
29	with	O
30	stage	O
31	IIIB	O
32	inflammatory	O
33	breast	O
34	cancer	O
35	(	O
36	IBC	O
37	)	O
38	treated	O
39	with	O
40	combined	O
41	modality	O
42	therapy	O
43	(	O
44	CMT	O
45	)	O
46	and	O
47	high	O
48	-	O
49	dose	O
50	chemotherapy	O
51	(	O
52	HDCT	O
53	)	O
54	with	O
55	autologous	O
56	stem	O
57	-	O
58	cell	O
59	transplantation	O
60	.	O

1	The	O
2	GPI	O
3	anchor	O
4	moiety	O
5	is	O
6	either	O
7	absent	O
8	or	O
9	present	O
10	at	O
11	a	O
12	very	O
13	low	O
14	level	O
15	in	O
16	the	O
17	polypeptide	O
18	expressed	O
19	from	O
20	the	O
21	cDNA	O
22	that	O
23	contained	O
24	both	O
25	the	O
26	signal	O
27	peptide	O
28	and	O
29	GPI	O
30	signal	O
31	sequences	O
32	.	O

1	There	O
2	was	O
3	a	O
4	trend	O
5	toward	O
6	an	O
7	association	O
8	between	O
9	IENF	O
10	and	O
11	sural	O
12	nerve	O
13	unmyelinated	O
14	fiber	O
15	densities	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	32	O
22	,	O
23	p	O
24	=	O
25	0	O
26	.	O
27	054	O
28	).	O

1	In	O
2	contrast	O
3	,	O
4	AP	B
5	-	I
6	2	I
7	binding	O
8	activity	O
9	was	O
10	significantly	O
11	greater	O
12	in	O
13	T47D	O
14	cells	O
15	,	O
16	and	O
17	Western	O
18	blots	O
19	confirmed	O
20	increased	O
21	AP	B
22	-	I
23	2	I
24	protein	I
25	levels	O
26	in	O
27	these	O
28	cells	O
29	.	O

1	The	O
2	elm1	B
3	kinase	I
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O

1	Among	O
2	the	O
3	remaining	O
4	22	O
5	sites	O
6	,	O
7	six	O
8	are	O
9	in	O
10	the	O
11	promoters	O
12	of	O
13	known	O
14	alpha	O
15	-	O
16	specific	O
17	genes	O
18	and	O
19	two	O
20	other	O
21	sites	O
22	have	O
23	an	O
24	alpha2	B
25	-	O
26	Mcm1	B
27	-	O
28	dependent	O
29	role	O
30	in	O
31	determining	O
32	the	O
33	direction	O
34	of	O
35	mating	O
36	type	O
37	switching	O
38	.	O

1	A	O
2	phylogenetic	O
3	analysis	O
4	with	O
5	the	O
6	TK	B
7	domains	I
8	from	O
9	these	O
10	sequences	O
11	and	O
12	a	O
13	fourth	O
14	,	O
15	from	O
16	a	O
17	novel	O
18	scavenger	B
19	RTK	I
20	(	O
21	all	O
22	domains	O
23	comprise	O
24	the	O
25	signature	O
26	for	O
27	the	O
28	TK	B
29	class	I
30	II	I
31	receptors	I
32	),	O
33	showed	O
34	that	O
35	they	O
36	are	O
37	distantly	O
38	related	O
39	to	O
40	the	O
41	insulin	B
42	and	O
43	insulin	B
44	-	I
45	like	I
46	receptors	I
47	.	O

1	By	O
2	negatively	O
3	regulating	O
4	GRK	B
5	-	O
6	mediated	O
7	receptor	O
8	phosphorylation	O
9	,	O
10	beta	B
11	-	I
12	arrestin	I
13	-	O
14	mediated	O
15	processes	O
16	such	O
17	as	O
18	Src	B
19	recruitment	O
20	and	O
21	clathrin	B
22	-	O
23	mediated	O
24	internalization	O
25	,	O
26	which	O
27	are	O
28	required	O
29	for	O
30	GPCR	B
31	-	O
32	mediated	O
33	ERK	B
34	activation	O
35	,	O
36	are	O
37	inhibited	O
38	,	O
39	thus	O
40	dampening	O
41	further	O
42	ERK	B
43	activation	O
44	.	O

1	Supershift	O
2	EMSAs	O
3	identified	O
4	that	O
5	upstream	B
6	stimulatory	I
7	factor	I
8	-	I
9	1	I
10	and	I
11	-	I
12	2	I
13	(	O
14	USF	B
15	-	I
16	1	I
17	and	I
18	-	I
19	2	I
20	)	O
21	were	O
22	part	O
23	of	O
24	these	O
25	complexes	O
26	.	O

1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	cassettes	O
8	harboring	O
9	the	O
10	murine	B
11	D1A	I
12	gene	I
13	promoter	I
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	transgenes	O
24	in	O
25	vivo	O
26	.	O

1	Syndromes	O
2	of	O
3	abnormal	O
4	fat	O
5	redistribution	O
6	and	O
7	metabolic	O
8	complications	O
9	in	O
10	HIV	O
11	-	O
12	infected	O
13	patients	O
14	.	O

1	Taken	O
2	together	O
3	,	O
4	differences	O
5	in	O
6	signaling	O
7	and	O
8	tissue	O
9	expression	O
10	suggest	O
11	that	O
12	the	O
13	human	B
14	intermediate	I
15	PRLr	I
16	differs	O
17	from	O
18	the	O
19	long	B
20	PRLr	I
21	in	O
22	physiological	O
23	function	O
24	.	O

1	Because	O
2	the	O
3	Pit	B
4	-	I
5	1	I
6	sites	I
7	in	O
8	the	O
9	hGH	B
10	-	I
11	N	I
12	gene	I
13	promoter	I
14	are	O
15	insufficient	O
16	for	O
17	such	O
18	gene	O
19	activation	O
20	in	O
21	vivo	O
22	,	O
23	these	O
24	data	O
25	suggested	O
26	a	O
27	unique	O
28	chromatin	O
29	-	O
30	mediated	O
31	developmental	O
32	role	O
33	for	O
34	Pit	B
35	-	I
36	1	I
37	in	O
38	the	O
39	hGH	B
40	LCR	I
41	.	O

1	They	O
2	are	O
3	subdivided	O
4	into	O
5	two	O
6	types	O
7	that	O
8	activate	O
9	transduction	O
10	pathways	O
11	via	O
12	different	O
13	cell	O
14	surface	O
15	receptors	O
16	.	O

1	This	O
2	revealed	O
3	a	O
4	minimum	O
5	of	O
6	six	O
7	novel	O
8	OSBP	B
9	-	I
10	related	I
11	proteins	I
12	,	O
13	designated	O
14	ORP	B
15	-	I
16	1	I
17	to	O
18	ORP	B
19	-	I
20	6	I
21	.	O

1	A	O
2	key	O
3	event	O
4	in	O
5	this	O
6	process	O
7	is	O
8	the	O
9	selective	O
10	recognition	O
11	of	O
12	the	O
13	target	O
14	membrane	O
15	by	O
16	the	O
17	vesicle	O
18	and	O
19	the	O
20	current	O
21	view	O
22	is	O
23	that	O
24	SNARE	B
25	protein	I
26	interactions	O
27	likely	O
28	play	O
29	a	O
30	central	O
31	role	O
32	in	O
33	vesicle	O
34	-	O
35	target	O
36	recognition	O
37	and	O
38	or	O
39	membrane	O
40	fusion	O
41	.	O

1	Measurements	O
2	in	O
3	the	O
4	LWS	O
5	p	O
6	.	O
7	a	O
8	.	O
9	,	O
10	LWS	O
11	lat	O
12	.	O
13	and	O
14	at	O
15	Ward	O
16	'	O
17	s	O
18	triangle	O
19	were	O
20	made	O
21	in	O
22	a	O
23	total	O
24	of	O
25	100	O
26	patients	O
27	.	O

1	Higher	O
2	CYP3A23	B
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	B
16	that	O
17	interacts	O
18	with	O
19	USF1	B
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	The	O
2	first	O
3	one	O
4	is	O
5	a	O
6	TPA	O
7	-	O
8	responsive	O
9	element	O
10	that	O
11	controls	O
12	the	O
13	base	O
14	-	O
15	line	O
16	ST3	B
17	promoter	I
18	activity	O
19	but	O
20	is	O
21	not	O
22	required	O
23	for	O
24	its	O
25	activation	O
26	.	O

1	These	O
2	synergistic	O
3	effects	O
4	were	O
5	strongly	O
6	Jem	B
7	-	I
8	1	I
9	dose	O
10	-	O
11	dependent	O
12	.	O

1	Albumin	B
2	dialysis	O
3	:	O
4	effective	O
5	removal	O
6	of	O
7	copper	O
8	in	O
9	a	O
10	patient	O
11	with	O
12	fulminant	O
13	Wilson	O
14	disease	O
15	and	O
16	successful	O
17	bridging	O
18	to	O
19	liver	O
20	transplantation	O
21	:	O
22	a	O
23	new	O
24	possibility	O
25	for	O
26	the	O
27	elimination	O
28	of	O
29	protein	O
30	-	O
31	bound	O
32	toxins	O
33	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	beta	B
7	-	I
8	catenin	I
9	interacted	O
10	directly	O
11	with	O
12	the	O
13	RA	B
14	receptor	I
15	(	O
16	RAR	B
17	)	O
18	in	O
19	a	O
20	retinoid	O
21	-	O
22	dependent	O
23	manner	O
24	,	O
25	but	O
26	not	O
27	with	O
28	the	O
29	retinoid	B
30	X	I
31	receptor	I
32	(	O
33	RXR	B
34	),	O
35	and	O
36	RAR	B
37	competed	O
38	with	O
39	TCF	B
40	for	O
41	beta	B
42	-	I
43	catenin	I
44	binding	O
45	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	promoter	O
6	region	O
7	showed	O
8	no	O
9	TATA	O
10	box	O
11	but	O
12	identified	O
13	consensus	O
14	binding	O
15	motifs	O
16	for	O
17	Sp1	B
18	,	O
19	CREB	B
20	,	O
21	and	O
22	half	O
23	sites	O
24	of	O
25	the	O
26	estrogen	B
27	receptor	I
28	binding	I
29	site	I
30	.	O

1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O

1	Similar	O
2	to	O
3	Hp140	B
4	,	O
5	isolated	O
6	Hp55	B
7	binds	O
8	DNA	O
9	with	O
10	moderate	O
11	strength	O
12	and	O
13	was	O
14	a	O
15	specificity	O
16	for	O
17	double	O
18	-	O
19	stranded	O
20	primer	O
21	-	O
22	template	O
23	DNA	O
24	.	O

1	The	O
2	DAP5	B
3	/	O
4	p86	B
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	B
12	/	O
13	p97	B
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	In	O
2	addition	O
3	,	O
4	CaMig1	B
5	formed	O
6	specific	O
7	complexes	O
8	with	O
9	the	O
10	URS1	O
11	region	O
12	of	O
13	the	O
14	S	B
15	.	I
16	cerevisiae	I
17	FBP1	I
18	gene	I
19	.	O

1	Furthermore	O
2	,	O
3	the	O
4	wide	O
5	distribution	O
6	of	O
7	the	O
8	GFP	B
9	-	O
10	POLO	B
11	protein	O
12	to	O
13	all	O
14	compartments	O
15	of	O
16	the	O
17	mitotic	O
18	apparatus	O
19	provides	O
20	a	O
21	valuable	O
22	tool	O
23	for	O
24	future	O
25	studies	O
26	on	O
27	cell	O
28	cycle	O
29	during	O
30	development	O
31	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	We	O
2	describe	O
3	a	O
4	case	O
5	of	O
6	acetaminophen	O
7	overdose	O
8	that	O
9	was	O
10	treated	O
11	with	O
12	both	O
13	hemodialysis	O
14	(	O
15	HD	O
16	)	O
17	and	O
18	NAC	O
19	due	O
20	to	O
21	severe	O
22	intoxication	O
23	and	O
24	slow	O
25	drug	O
26	clearance	O
27	.	O

1	Downstream	O
2	of	O
3	the	O
4	G	O
5	-	O
6	A	O
7	anastomosis	O
8	,	O
9	the	O
10	RD	O
11	,	O
12	CC	O
13	,	O
14	E	O
15	(	O
16	p	O
17	)	O
18	and	O
19	loop	O
20	areas	O
21	were	O
22	significantly	O
23	different	O
24	from	O
25	REF	O
26	,	O
27	but	O
28	significantly	O
29	different	O
30	from	O
31	A	O
32	-	O
33	A	O
34	.	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	Transient	O
2	transfection	O
3	assays	O
4	using	O
5	P19	O
6	cells	O
7	revealed	O
8	that	O
9	expression	O
10	of	O
11	NDRF	B
12	/	O
13	NeuroD2	B
14	increased	O
15	the	O
16	transactivation	O
17	of	O
18	the	O
19	rat	B
20	insulin	I
21	promoter	I
22	element	I
23	3	I
24	(	O
25	RIPE3	B
26	)	O
27	enhancer	O
28	up	O
29	to	O
30	approximately	O
31	12	O
32	-	O
33	fold	O
34	and	O
35	that	O
36	co	O
37	-	O
38	expression	O
39	of	O
40	catalytically	O
41	active	O
42	form	O
43	of	O
44	PKN	B
45	,	O
46	but	O
47	not	O
48	kinase	O
49	-	O
50	deficient	O
51	derivative	O
52	,	O
53	resulted	O
54	in	O
55	a	O
56	further	O
57	threefold	O
58	increase	O
59	of	O
60	NDRF	B
61	/	O
62	NeuroD2	B
63	-	O
64	mediated	O
65	transcription	O
66	.	O

1	Two	O
2	Pax2	B
3	/	I
4	5	I
5	/	I
6	8	I
7	-	I
8	binding	I
9	sites	I
10	in	O
11	Engrailed2	B
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	AF154055	B
2	.	O

1	Alignment	O
2	of	O
3	the	O
4	cervical	O
5	spine	O
6	,	O
7	vertebral	O
8	abnormalities	O
9	,	O
10	and	O
11	disc	O
12	changes	O
13	also	O
14	were	O
15	evaluated	O
16	.	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	Overexpression	O
2	of	O
3	ICBP90	B
4	in	O
5	COS	O
6	-	O
7	1	O
8	-	O
9	transfected	O
10	cells	O
11	induced	O
12	an	O
13	enhanced	O
14	expression	O
15	of	O
16	endogenous	B
17	topoisomerase	I
18	IIalpha	I
19	.	O

1	The	O
2	study	O
3	suggests	O
4	the	O
5	presence	O
6	of	O
7	an	O
8	anatomical	O
9	sphincter	O
10	at	O
11	the	O
12	RSJ	O
13	which	O
14	seems	O
15	to	O
16	regulate	O
17	the	O
18	passage	O
19	of	O
20	stools	O
21	from	O
22	the	O
23	sigmoid	O
24	colon	O
25	to	O
26	the	O
27	rectum	O
28	.	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	Two	O
2	episodes	O
3	of	O
4	peritonitis	O
5	occurred	O
6	while	O
7	the	O
8	patient	O
9	received	O
10	CAPD	O
11	(	O
12	1	O
13	episode	O
14	/	O
15	3	O
16	.	O
17	5	O
18	patient	O
19	-	O
20	months	O
21	).	O

1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	B
8	-	I
9	Fos	I
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O

1	Electron	O
2	microscopic	O
3	and	O
4	enzymatic	O
5	analyses	O
6	revealed	O
7	that	O
8	the	O
9	A118	O
10	genome	O
11	is	O
12	a	O
13	linear	O
14	,	O
15	circularly	O
16	permuted	O
17	,	O
18	terminally	O
19	redundant	O
20	collection	O
21	of	O
22	double	O
23	-	O
24	stranded	O
25	DNA	O
26	molecules	O
27	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	B
8	-	I
9	type	I
10	Fus3	I
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	Consistently	O
2	,	O
3	activation	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	N	I
9	-	I
10	terminal	I
11	kinase	I
12	downstream	O
13	of	O
14	Rho	B
15	family	I
16	GTP	I
17	-	I
18	binding	I
19	proteins	I
20	was	O
21	also	O
22	enhanced	O
23	when	O
24	Dbl	B
25	was	O
26	tyrosine	O
27	-	O
28	phosphorylated	O
29	.	O

1	All	O
2	four	O
3	domains	O
4	were	O
5	linked	O
6	via	O
7	proline	O
8	-	O
9	threonine	O
10	-	O
11	rich	O
12	peptides	O
13	.	O

1	Transfection	O
2	experiments	O
3	demonstrated	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	(-	O
11	1894	O
12	to	O
13	+	O
14	37	O
15	)	O
16	of	O
17	the	O
18	mStaf	B
19	gene	I
20	drives	O
21	transcription	O
22	in	O
23	mouse	O
24	NMuMG	O
25	cells	O
26	and	O
27	that	O
28	a	O
29	construct	O
30	containing	O
31	a	O
32	fragment	O
33	from	O
34	-	O
35	387	O
36	to	O
37	+	O
38	37	O
39	showed	O
40	the	O
41	highest	O
42	transcriptional	O
43	activity	O
44	.	O

1	The	O
2	level	O
3	of	O
4	subclinical	O
5	infection	O
6	was	O
7	75	O
8	%	O
9	among	O
10	seropositive	O
11	dogs	O
12	.	O

1	Desmethylferrochloroquine	O
2	1a	O
3	and	O
4	didesmethylferrochloroquine	O
5	2	O
6	would	O
7	be	O
8	more	O
9	potent	O
10	against	O
11	schizontocides	O
12	than	O
13	CQ	O
14	in	O
15	vitro	O
16	against	O
17	two	O
18	strains	O
19	(	O
20	HB3	O
21	and	O
22	Dd2	O
23	)	O
24	of	O
25	Plasmodium	O
26	falciparum	O
27	.	O

1	Zebrafish	O
2	cyclops	B
3	(	O
4	cyc	B
5	)	O
6	encodes	O
7	a	O
8	Transforming	B
9	Growth	I
10	Factor	I
11	beta	I
12	(	O
13	TGFbeta	B
14	)	O
15	signaling	O
16	factor	O
17	closely	O
18	related	O
19	to	O
20	mouse	O
21	Nodal	B
22	.	O

1	Diverse	O
2	endogenous	O
3	light	O
4	chains	O
5	contribute	O
6	to	O
7	basement	O
8	membrane	O
9	reactivity	O
10	in	O
11	nonautoimmune	O
12	mice	O
13	transgenic	O
14	for	O
15	an	O
16	anti	B
17	-	I
18	laminin	I
19	Ig	I
20	heavy	I
21	chain	I
22	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O

1	ZK7	B
2	and	O
3	HZF16	B
4	genes	I
5	appear	O
6	to	O
7	be	O
8	the	O
9	splice	O
10	variants	O
11	transcribed	O
12	from	O
13	the	O
14	same	O
15	gene	O
16	.	O

1	Two	O
2	distinct	O
3	Salmonella	B
4	fimbrins	I
5	,	O
6	AgfA	B
7	and	O
8	SefA	B
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	B
15	and	O
16	SEF14	B
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	B
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	B
45	gp63	I
46	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	O
8	-	O
9	type	O
10	Salmonella	O
11	typhimurium	O
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	B
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	B
42	-	O
43	modified	O
44	RecBCD	B
45	nuclease	I
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	B
13	expression	O
14	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	B
7	I	I
8	-	I
9	mfa	I
10	domain	I
11	-	I
12	containing	I
13	protein	I
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O

1	The	O
2	encoded	O
3	amino	O
4	acid	O
5	sequences	O
6	in	O
7	the	O
8	full	O
9	-	O
10	length	O
11	bovine	O
12	and	O
13	porcine	O
14	cDNAs	O
15	were	O
16	identical	O
17	,	O
18	consisting	O
19	of	O
20	209	O
21	amino	O
22	acid	O
23	residues	O
24	,	O
25	and	O
26	were	O
27	nearly	O
28	the	O
29	same	O
30	as	O
31	the	O
32	published	O
33	sequence	O
34	determined	O
35	by	O
36	Edman	O
37	degradation	O
38	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	Acad	O
2	.	O

1	Extreme	O
2	potency	O
3	of	O
4	botulinum	B
5	toxin	I
6	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	activated	O
8	by	O
9	isoproterenol	O
10	led	O
11	to	O
12	tyrosine	O
13	phosphorylation	O
14	of	O
15	Shc	B
16	and	O
17	subsequent	O
18	Erk	B
19	activation	O
20	,	O
21	but	O
22	not	O
23	tyrosine	O
24	phosphorylation	O
25	of	O
26	cortactin	B
27	or	O
28	Stat3	B
29	.	O

1	For	O
2	wild	O
3	type	O
4	MutT	B
5	and	O
6	its	O
7	E53D	B
8	and	O
9	E44D	B
10	mutants	I
11	,	O
12	plots	O
13	of	O
14	log	O
15	(	O
16	k	O
17	(	O
18	cat	O
19	))	O
20	versus	O
21	pH	O
22	exhibited	O
23	a	O
24	limiting	O
25	slope	O
26	of	O
27	1	O
28	on	O
29	the	O
30	ascending	O
31	limb	O
32	and	O
33	then	O
34	a	O
35	hump	O
36	,	O
37	i	O
38	.	O
39	e	O
40	.,	O
41	a	O
42	sharply	O
43	defined	O
44	maximum	O
45	near	O
46	pH	O
47	8	O
48	followed	O
49	by	O
50	a	O
51	plateau	O
52	,	O
53	yielding	O
54	apparent	O
55	pK	O
56	(	O
57	a	O
58	)	O
59	values	O
60	of	O
61	7	O
62	.	O
63	6	O
64	+/-	O
65	0	O
66	.	O
67	3	O
68	and	O
69	8	O
70	.	O
71	4	O
72	+/-	O
73	0	O
74	.	O
75	4	O
76	for	O
77	an	O
78	essential	O
79	base	O
80	and	O
81	a	O
82	nonessential	O
83	acid	O
84	catalyst	O
85	,	O
86	respectively	O
87	,	O
88	in	O
89	the	O
90	active	O
91	quaternary	O
92	MutT	B
93	-	O
94	Mg	O
95	(	O
96	2	O
97	+)-	O
98	dGTP	O
99	-	O
100	Mg	O
101	(	O
102	2	O
103	+)	O
104	complex	O
105	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	O
11	activated	O
12	protein	B
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	O
30	activated	O
31	protein	B
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	We	O
2	present	O
3	evidence	O
4	that	O
5	the	O
6	upstream	O
7	open	O
8	reading	O
9	frame	O
10	(	O
11	uORF	O
12	)	O
13	represses	O
14	the	O
15	translation	O
16	of	O
17	the	O
18	downstream	O
19	major	O
20	open	O
21	reading	O
22	frame	O
23	(	O
24	mORF	O
25	).	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	It	O
2	has	O
3	also	O
4	been	O
5	shown	O
6	that	O
7	a	O
8	variety	O
9	of	O
10	extracellular	O
11	factors	O
12	stimulate	O
13	a	O
14	pair	O
15	of	O
16	MAPK	O
17	p44	B
18	and	O
19	MAPK	O
20	p42	B
21	of	O
22	MAPK	B
23	family	I
24	members	I
25	.	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	The	O
2	requirement	O
3	of	O
4	3	O
5	'	O
6	complementarity	O
7	for	O
8	a	O
9	ligation	O
10	reaction	O
11	is	O
12	reaffirmed	O
13	by	O
14	results	O
15	from	O
16	1	O
17	nt	O
18	insertions	O
19	on	O
20	either	O
21	the	O
22	3	O
23	'-	O
24	or	O
25	5	O
26	'-	O
27	side	O
28	of	O
29	the	O
30	nick	O
31	.	O

1	The	O
2	CCAAT	O
3	core	O
4	sequence	O
5	mutants	O
6	in	O
7	which	O
8	both	O
9	CIII	O
10	and	O
11	CI	O
12	/	O
13	CII	O
14	were	O
15	abolished	O
16	,	O
17	also	O
18	increased	O
19	the	O
20	promoter	O
21	activity	O
22	.	O

1	OUTCOME	O
2	:	O
3	Acetylcholine	B
4	receptor	I
5	antibodies	I
6	and	O
7	single	O
8	-	O
9	fibre	O
10	electromyogram	O
11	were	O
12	useful	O
13	in	O
14	the	O
15	diagnosis	O
16	of	O
17	myasthenia	O
18	gravis	O
19	.	O

1	The	O
2	effect	O
3	of	O
4	MIB	O
5	on	O
6	the	O
7	dose	O
8	-	O
9	response	O
10	curve	O
11	of	O
12	externally	O
13	applied	O
14	noradrenaline	O
15	was	O
16	also	O
17	studied	O
18	.	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	TIP30	B
2	has	O
3	an	O
4	intrinsic	O
5	kinase	O
6	activity	O
7	required	O
8	for	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	a	O
14	subset	O
15	of	O
16	apoptotic	O
17	genes	O
18	.	O

1	Reaction	O
2	time	O
3	(	O
4	RT	O
5	)	O
6	and	O
7	P300	O
8	were	O
9	collected	O
10	simultaneously	O
11	.	O

1	Furthermore	O
2	,	O
3	Zelen	O
4	'	O
5	s	O
6	method	O
7	is	O
8	used	O
9	to	O
10	balance	O
11	the	O
12	number	O
13	of	O
14	patients	O
15	allocated	O
16	to	O
17	the	O
18	two	O
19	groups	O
20	within	O
21	each	O
22	institution	O
23	(	O
24	M	O
25	.	O

1	RESULTS	O
2	:	O
3	In	O
4	this	O
5	group	O
6	of	O
7	patients	O
8	,	O
9	male	O
10	gender	O
11	(	O
12	P	O
13	=	O
14	0	O
15	.	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	The	O
2	patient	O
3	had	O
4	developed	O
5	left	O
6	-	O
7	sided	O
8	low	O
9	-	O
10	frequency	O
11	tremor	O
12	and	O
13	hemidystonia	O
14	after	O
15	a	O
16	severe	O
17	head	O
18	trauma	O
19	sustained	O
20	at	O
21	15	O
22	years	O
23	of	O
24	age	O
25	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	Alternatively	O
2	,	O
3	PC12	O
4	-	O
5	E2	O
6	cells	O
7	were	O
8	submitted	O
9	to	O
10	treatment	O
11	with	O
12	antibodies	O
13	to	O
14	the	O
15	fibroblast	B
16	growth	I
17	factor	I
18	(	I
19	FGF	I
20	)	I
21	receptor	I
22	,	O
23	inhibitors	O
24	of	O
25	the	O
26	nonreceptor	B
27	tyrosine	I
28	kinase	I
29	p59	I
30	(	O
31	fyn	B
32	),	O
33	PLC	B
34	,	O
35	PKC	B
36	and	O
37	MEK	B
38	and	O
39	an	O
40	activator	O
41	of	O
42	PKC	B
43	,	O
44	phorbol	O
45	-	O
46	12	O
47	-	O
48	myristate	O
49	-	O
50	13	O
51	-	O
52	acetate	O
53	(	O
54	PMA	O
55	).	O

1	Approximately	O
2	20	O
3	%	O
4	of	O
5	ALCLs	O
6	that	O
7	express	O
8	ALK	B
9	do	O
10	not	O
11	contain	O
12	the	O
13	t	O
14	(	O
15	2	O
16	;	O
17	5	O
18	),	O
19	suggesting	O
20	that	O
21	other	O
22	genetic	O
23	abnormalities	O
24	can	O
25	result	O
26	in	O
27	aberrant	O
28	ALK	B
29	expression	O
30	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	B
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	B
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	The	O
2	Mif1	B
3	5	I
4	'	I
5	flanking	I
6	region	I
7	contains	O
8	a	O
9	functional	O
10	ER	O
11	stress	O
12	-	O
13	responsive	O
14	element	O
15	which	O
16	is	O
17	sufficient	O
18	for	O
19	induction	O
20	by	O
21	tunicamycin	O
22	.	O

1	Serum	O
2	leptin	B
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	B
8	stimulation	O
9	cycles	O
10	.	O

1	Inactivation	O
2	of	O
3	Ulp2	B
4	also	O
5	suppresses	O
6	several	O
7	ulp1	B
8	(	I
9	ts	I
10	)	I
11	defects	O
12	,	O
13	and	O
14	the	O
15	double	O
16	mutant	O
17	accumulates	O
18	far	O
19	fewer	O
20	Smt3	B
21	-	I
22	protein	I
23	conjugates	O
24	than	O
25	either	O
26	single	O
27	mutant	O
28	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	O
30	/	O
31	v	O
32	)	O
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	To	O
2	determine	O
3	if	O
4	CYC2	B
5	is	O
6	found	O
7	in	O
8	a	O
9	complex	O
10	with	O
11	previously	O
12	identified	O
13	trypanosome	B
14	cdc2	I
15	-	I
16	related	I
17	kinases	I
18	(	O
19	CRKs	B
20	),	O
21	the	O
22	CYC2	B
23	gene	I
24	was	O
25	fused	O
26	to	O
27	the	O
28	TY	B
29	epitope	I
30	tag	O
31	,	O
32	integrated	O
33	into	O
34	the	O
35	trypanosome	O
36	genome	O
37	,	O
38	and	O
39	expressed	O
40	under	O
41	inducible	O
42	control	O
43	.	O

1	Additionally	O
2	,	O
3	the	O
4	mouse	O
5	promoter	O
6	contains	O
7	22	O
8	copies	O
9	of	O
10	a	O
11	CT	O
12	dinucleotide	O
13	repeat	O
14	sequence	O
15	located	O
16	approximately	O
17	155	O
18	bp	O
19	5	O
20	'	O
21	to	O
22	exon	O
23	1	O
24	.	O

1	Sequence	O
2	analyses	O
3	of	O
4	sos2	B
5	mutant	I
6	alleles	I
7	reveal	O
8	that	O
9	both	O
10	the	O
11	N	O
12	-	O
13	terminal	O
14	catalytic	O
15	domain	O
16	and	O
17	the	O
18	C	O
19	-	O
20	terminal	O
21	regulatory	O
22	domain	O
23	of	O
24	SOS2	B
25	are	O
26	functionally	O
27	essential	O
28	.	O

1	A	O
2	mutation	O
3	which	O
4	abrogates	O
5	the	O
6	binding	O
7	of	O
8	these	O
9	factors	O
10	reduces	O
11	Wp	B
12	reporter	I
13	activity	O
14	specifically	O
15	in	O
16	B	O
17	cell	O
18	lines	O
19	,	O
20	whereas	O
21	a	O
22	mutation	O
23	which	O
24	converts	O
25	the	O
26	site	O
27	to	O
28	a	O
29	consensus	O
30	CREB	B
31	-	I
32	binding	I
33	sequence	I
34	maintains	O
35	wild	O
36	-	O
37	type	O
38	promoter	O
39	function	O
40	.	O

1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	B
15	-	I
16	1	I
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O

1	The	O
2	two	O
3	contiguous	O
4	IGF2	B
5	(	O
6	human	B
7	insulin	I
8	-	I
9	like	I
10	growth	I
11	factor	I
12	II	I
13	)	O
14	and	O
15	H19	B
16	genes	I
17	are	O
18	reciprocally	O
19	imprinted	O
20	in	O
21	both	O
22	human	O
23	and	O
24	mouse	O
25	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	Preliminary	O
2	use	O
3	of	O
4	the	O
5	Nottingham	O
6	Eczema	O
7	Severity	O
8	Score	O
9	would	O
10	support	O
11	further	O
12	development	O
13	as	O
14	a	O
15	research	O
16	tool	O
17	for	O
18	a	O
19	simple	O
20	assessment	O
21	of	O
22	disease	O
23	severity	O
24	that	O
25	could	O
26	be	O
27	used	O
28	in	O
29	epidemiological	O
30	studies	O
31	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	Thus	O
2	,	O
3	both	O
4	the	O
5	hyperplasia	O
6	and	O
7	thrombotic	O
8	complications	O
9	which	O
10	often	O
11	follow	O
12	stenting	O
13	might	O
14	be	O
15	minimized	O
16	by	O
17	employing	O
18	gold	O
19	stents	O
20	,	O
21	which	O
22	have	O
23	a	O
24	greater	O
25	capacity	O
26	than	O
27	steel	O
28	in	O
29	supporting	O
30	a	O
31	functional	O
32	neo	O
33	-	O
34	endothelium	O
35	.	O

1	The	O
2	evolution	O
3	of	O
4	the	O
5	CCR5	B
6	cis	I
7	-	I
8	regulatory	I
9	region	I
10	versus	O
11	the	O
12	open	O
13	reading	O
14	frame	O
15	as	O
16	well	O
17	as	O
18	among	O
19	different	O
20	domains	O
21	of	O
22	the	O
23	open	O
24	reading	O
25	frame	O
26	differed	O
27	from	O
28	one	O
29	another	O
30	.	O

1	We	O
2	now	O
3	describe	O
4	a	O
5	second	O
6	RIM	B
7	protein	I
8	,	O
9	called	O
10	RIM2	B
11	,	O
12	that	O
13	is	O
14	highly	O
15	homologous	O
16	to	O
17	RIM1	B
18	and	O
19	also	O
20	expressed	O
21	primarily	O
22	in	O
23	brain	O
24	.	O

1	RESULTS	O
2	:	O
3	Auditory	O
4	thresholds	O
5	collected	O
6	during	O
7	audiometric	O
8	tests	O
9	increased	O
10	gradually	O
11	in	O
12	proportion	O
13	with	O
14	age	O
15	,	O
16	especially	O
17	in	O
18	the	O
19	hypertensive	O
20	group	O
21	(	O
22	p	O
23	<	O
24	0	O
25	.	O
26	05	O
27	).	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	size	O
6	,	O
7	the	O
8	CRS	O
9	sequence	O
10	to	O
11	which	O
12	it	O
13	binds	O
14	,	O
15	and	O
16	its	O
17	tentative	O
18	identification	O
19	as	O
20	a	O
21	zinc	B
22	finger	I
23	protein	I
24	,	O
25	Adx	B
26	factor	I
27	has	O
28	been	O
29	identified	O
30	as	O
31	a	O
32	Kruppel	B
33	-	I
34	like	I
35	zinc	I
36	finger	I
37	protein	I
38	(	O
39	a	O
40	mouse	B
41	ZBP	I
42	-	I
43	89	I
44	homologue	I
45	).	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Overexpression	O
2	of	O
3	mcl	B
4	-	I
5	1	I
6	is	O
7	sufficient	O
8	to	O
9	protect	O
10	against	O
11	apoptosis	O
12	,	O
13	while	O
14	transfection	O
15	of	O
16	a	O
17	mcl	B
18	-	I
19	1	I
20	antisense	O
21	plasmid	O
22	causes	O
23	cell	O
24	death	O
25	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	the	O
6	abilities	O
7	of	O
8	constitutive	O
9	and	O
10	conditional	O
11	forms	O
12	of	O
13	the	O
14	three	O
15	Raf	B
16	kinases	I
17	to	O
18	abrogate	O
19	the	O
20	cytokine	O
21	dependency	O
22	of	O
23	FDC	O
24	-	O
25	P1	O
26	cells	O
27	were	O
28	examined	O
29	.	O

1	CONCLUSIONS	O
2	:	O
3	This	O
4	randomized	O
5	study	O
6	shows	O
7	that	O
8	Vivostat	O
9	fibrin	B
10	sealant	O
11	is	O
12	effective	O
13	in	O
14	preventing	O
15	air	O
16	leakage	O
17	after	O
18	small	O
19	lung	O
20	resections	O
21	in	O
22	pigs	O
23	,	O
24	even	O
25	at	O
26	high	O
27	inspiratory	O
28	pressures	O
29	.	O

1	Hex	B
2	is	O
3	expressed	O
4	in	O
5	the	O
6	developing	O
7	liver	O
8	coincident	O
9	with	O
10	the	O
11	forkhead	B
12	/	O
13	winged	B
14	helix	I
15	transcription	O
16	factor	O
17	,	O
18	Hepatocyte	B
19	Nuclear	I
20	Factor	I
21	3beta	I
22	(	O
23	HNF3beta	B
24	).	O

1	As	O
2	an	O
3	extension	O
4	of	O
5	our	O
6	structural	O
7	characterization	O
8	of	O
9	the	O
10	exon	O
11	-	O
12	intron	O
13	organization	O
14	of	O
15	the	O
16	mouse	B
17	Pkr	I
18	gene	I
19	,	O
20	we	O
21	now	O
22	have	O
23	isolated	O
24	and	O
25	characterized	O
26	the	O
27	mouse	B
28	Pkr	I
29	promoter	I
30	region	I
31	required	O
32	for	O
33	IFN	B
34	-	O
35	inducible	O
36	transcription	O
37	.	O

1	The	O
2	CRE	O
3	,	O
4	5	O
5	'-	O
6	TGACGTCA	O
7	-	O
8	3	O
9	',	O
10	has	O
11	been	O
12	described	O
13	as	O
14	the	O
15	consensus	O
16	sequence	O
17	for	O
18	the	O
19	cis	O
20	-	O
21	element	O
22	that	O
23	directs	O
24	cAMP	O
25	-	O
26	regulated	O
27	gene	O
28	expression	O
29	.	O

1	The	O
2	clinical	O
3	stage	O
4	was	O
5	I	O
6	(	O
7	T1N0M0	O
8	),	O
9	and	O
10	S2	O
11	sleeve	O
12	segmentectomy	O
13	with	O
14	lymph	O
15	node	O
16	dissection	O
17	(	O
18	R	O
19	2	O
20	b	O
21	)	O
22	was	O
23	performed	O
24	.	O

1	The	O
2	physicians	O
3	in	O
4	charge	O
5	of	O
6	all	O
7	patients	O
8	with	O
9	evidence	O
10	of	O
11	acute	O
12	Q	O
13	fever	O
14	(	O
15	seroconversion	O
16	and	O
17	/	O
18	or	O
19	presence	O
20	of	O
21	IgM	B
22	)	O
23	or	O
24	chronic	O
25	Q	O
26	fever	O
27	(	O
28	prolonged	O
29	disease	O
30	and	O
31	/	O
32	or	O
33	IgG	B
34	antibody	I
35	titer	O
36	to	O
37	phase	O
38	I	O
39	of	O
40	Coxiella	O
41	burnetii	O
42	>	O
43	or	O
44	=	O
45	800	O
46	)	O
47	were	O
48	asked	O
49	to	O
50	complete	O
51	a	O
52	questionnaire	O
53	,	O
54	which	O
55	was	O
56	computerized	O
57	.	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	B
16	-	I
17	89	I
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	B
26	(	O
27	Mn1	B
28	)	O
29	seed	O
30	locus	O
31	that	O
32	encodes	O
33	a	O
34	seed	B
35	-	I
36	specific	I
37	cell	I
38	wall	I
39	invertase	I
40	,	O
41	INCW2	B
42	.	O

1	The	O
2	effects	O
3	of	O
4	these	O
5	mutations	O
6	on	O
7	protein	O
8	function	O
9	require	O
10	further	O
11	examination	O
12	.	O

1	Purple	O
2	photosynthetic	O
3	bacteria	O
4	are	O
5	capable	O
6	of	O
7	generating	O
8	cellular	O
9	energy	O
10	from	O
11	several	O
12	sources	O
13	,	O
14	including	O
15	photosynthesis	O
16	,	O
17	respiration	O
18	,	O
19	and	O
20	H	O
21	(	O
22	2	O
23	)	O
24	oxidation	O
25	.	O

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	B
10	-	O
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	B
12	(	O
13	mdg4	B
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	B
19	(	O
20	mdg4	B
21	),	O
22	also	O
23	known	O
24	as	O
25	E	B
26	(	I
27	var	I
28	)	I
29	3	I
30	-	I
31	93D	I
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	B
56	insulator	I
57	sequences	I
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O

1	Regulation	O
2	of	O
3	pituitary	O
4	vasopressin	B
5	V1b	I
6	receptors	I
7	plays	O
8	a	O
9	critical	O
10	role	O
11	in	O
12	regulating	O
13	pituitary	B
14	adrenocorticotropic	I
15	hormone	I
16	(	O
17	ACTH	B
18	)	O
19	secretion	O
20	during	O
21	adaptation	O
22	to	O
23	stress	O
24	.	O

1	Given	O
2	its	O
3	relative	O
4	longevity	O
5	on	O
6	the	O
7	Web	O
8	,	O
9	TIE	O
10	researchers	O
11	have	O
12	been	O
13	in	O
14	a	O
15	unique	O
16	position	O
17	to	O
18	observe	O
19	trends	O
20	in	O
21	telemedicine	O
22	.	O

1	SELECTION	O
2	CRITERIA	O
3	:	O
4	Randomised	O
5	trials	O
6	comparing	O
7	children	O
8	undergoing	O
9	systematic	O
10	therapy	O
11	focusing	O
12	on	O
13	the	O
14	family	O
15	in	O
16	conjunction	O
17	with	O
18	asthma	O
19	medication	O
20	,	O
21	with	O
22	children	O
23	taking	O
24	asthma	O
25	medication	O
26	only	O
27	.	O

1	To	O
2	test	O
3	the	O
4	hypothesis	O
5	that	O
6	progestin	O
7	-	O
8	mediated	O
9	increases	O
10	in	O
11	resting	O
12	core	O
13	temperature	O
14	and	O
15	the	O
16	core	O
17	temperature	O
18	threshold	O
19	for	O
20	sweating	O
21	onset	O
22	are	O
23	counteracted	O
24	by	O
25	estrogen	O
26	,	O
27	we	O
28	studied	O
29	eight	O
30	women	O
31	(	O
32	24	O
33	+/-	O
34	2	O
35	yr	O
36	)	O
37	at	O
38	27	O
39	degrees	O
40	C	O
41	rest	O
42	,	O
43	during	O
44	20	O
45	min	O
46	of	O
47	passive	O
48	heating	O
49	(	O
50	35	O
51	degrees	O
52	C	O
53	),	O
54	and	O
55	during	O
56	40	O
57	min	O
58	of	O
59	exercise	O
60	at	O
61	35	O
62	degrees	O
63	C	O
64	.	O

1	M	O
2	.	O

1	We	O
2	also	O
3	show	O
4	that	O
5	p65	B
6	binds	O
7	to	O
8	these	O
9	targets	O
10	with	O
11	almost	O
12	equal	O
13	affinity	O
14	and	O
15	that	O
16	different	O
17	residues	O
18	have	O
19	variable	O
20	roles	O
21	in	O
22	binding	O
23	different	O
24	kappaB	B
25	targets	I
26	.	O

1	PATIENTS	O
2	OR	O
3	OTHER	O
4	PARTICIPANTS	O
5	:	O
6	Twenty	O
7	children	O
8	met	O
9	the	O
10	criteria	O
11	for	O
12	being	O
13	learning	O
14	disabled	O
15	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	we	O
7	characterized	O
8	cis	O
9	-	O
10	elements	O
11	of	O
12	the	O
13	human	B
14	PCI	I
15	gene	I
16	required	O
17	for	O
18	expression	O
19	in	O
20	the	O
21	hepatoma	O
22	-	O
23	derived	O
24	cell	O
25	line	O
26	,	O
27	HepG2	O
28	cells	O
29	,	O
30	and	O
31	also	O
32	evaluated	O
33	rat	B
34	PCI	I
35	mRNA	I
36	expression	O
37	,	O
38	particularly	O
39	on	O
40	the	O
41	effect	O
42	of	O
43	androgen	O
44	in	O
45	rat	O
46	reproductive	O
47	tissues	O
48	.	O

1	To	O
2	illustrate	O
3	its	O
4	performance	O
5	,	O
6	measurements	O
7	of	O
8	photoluminescence	O
9	in	O
10	GaAs	O
11	/	O
12	AlGaAs	O
13	heterostructures	O
14	are	O
15	presented	O
16	.	O

1	This	O
2	activity	O
3	is	O
4	stimulated	O
5	by	O
6	complex	O
7	formation	O
8	with	O
9	the	O
10	other	O
11	eIF2B	B
12	subunits	I
13	.	O

1	Our	O
2	analysis	O
3	of	O
4	nonsense	O
5	mutations	O
6	indicates	O
7	that	O
8	the	O
9	C	O
10	terminus	O
11	of	O
12	eIF2Bepsilon	B
13	(	I
14	residues	I
15	518	I
16	to	I
17	712	I
18	)	I
19	is	O
20	required	O
21	for	O
22	both	O
23	catalytic	O
24	activity	O
25	and	O
26	interaction	O
27	with	O
28	eIF2	B
29	.	O

1	The	O
2	serine	B
3	-	I
4	threonine	I
5	kinase	I
6	gene	I
7	is	O
8	likely	O
9	functional	O
10	,	O
11	whereas	O
12	the	O
13	zinc	O
14	finger	O
15	motif	O
16	is	O
17	likely	O
18	nonfunctional	O
19	.	O

1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	B
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	B
24	-	I
25	1	I
26	.	O

1	Interestingly	O
2	,	O
3	a	O
4	decreased	O
5	transcription	O
6	from	O
7	the	O
8	endogenous	O
9	c	B
10	-	I
11	Myb	I
12	promoter	I
13	was	O
14	observed	O
15	in	O
16	several	O
17	HTLV	O
18	-	O
19	I	O
20	transformed	O
21	T	O
22	-	O
23	cell	O
24	lines	O
25	.	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	The	O
2	C	O
3	terminus	O
4	of	O
5	TRBP	B
6	binds	O
7	to	O
8	CBP	B
9	/	O
10	p300	B
11	and	O
12	DRIP130	B
13	,	O
14	a	O
15	component	O
16	of	O
17	the	O
18	DRIP	B
19	/	O
20	TRAP	B
21	/	O
22	ARC	B
23	complex	O
24	,	O
25	which	O
26	suggests	O
27	that	O
28	TRBP	B
29	may	O
30	activate	O
31	transcription	O
32	by	O
33	means	O
34	of	O
35	such	O
36	interactions	O
37	.	O

1	The	O
2	patients	O
3	who	O
4	presented	O
5	with	O
6	mucocutaneous	O
7	disease	O
8	also	O
9	had	O
10	low	O
11	CD4	B
12	+	I
13	T	O
14	lymphocyte	O
15	counts	O
16	,	O
17	and	O
18	most	O
19	of	O
20	them	O
21	had	O
22	AIDS	O
23	defining	O
24	illnesses	O
25	.	O

1	Hierarchy	O
2	of	O
3	protein	B
4	tyrosine	I
5	kinases	I
6	in	O
7	interleukin	B
8	-	I
9	2	I
10	(	O
11	IL	B
12	-	I
13	2	I
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	syk	B
20	depends	O
21	on	O
22	Jak3	B
23	;	O
24	however	O
25	,	O
26	neither	O
27	Syk	B
28	nor	O
29	Lck	B
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	I
35	2	I
36	-	O
37	mediated	O
38	STAT	B
39	activation	O
40	.	O

1	Although	O
2	the	O
3	OC	B
4	promoter	I
5	is	O
6	activated	O
7	in	O
8	a	O
9	C	O
10	terminus	O
11	dependent	O
12	manner	O
13	,	O
14	the	O
15	MDR	B
16	,	O
17	LTR	O
18	and	O
19	BSP	B
20	promoters	I
21	are	O
22	repressed	O
23	by	O
24	three	O
25	distinct	O
26	mechanisms	O
27	,	O
28	either	O
29	independent	O
30	of	O
31	or	O
32	involving	O
33	the	O
34	AML	B
35	C	I
36	terminus	I
37	,	O
38	or	O
39	requiring	O
40	only	O
41	the	O
42	conserved	O
43	C	O
44	-	O
45	terminal	O
46	pentapeptide	O
47	VWRPY	O
48	.	O

1	The	O
2	transcript	O
3	was	O
4	initially	O
5	identified	O
6	as	O
7	a	O
8	partial	O
9	cDNA	O
10	sequence	O
11	in	O
12	the	O
13	course	O
14	of	O
15	constructing	O
16	a	O
17	transcript	O
18	map	O
19	of	O
20	the	O
21	region	O
22	between	O
23	markers	O
24	D11S1765	B
25	and	O
26	uteroglobin	B
27	known	O
28	to	O
29	encompass	O
30	the	O
31	gene	O
32	causing	O
33	Best	O
34	disease	O
35	.	O

1	Biologically	O
2	significant	O
3	amounts	O
4	of	O
5	platelet	B
6	activating	I
7	factor	I
8	were	O
9	eluted	O
10	from	O
11	the	O
12	sorbent	O
13	during	O
14	the	O
15	entire	O
16	treatment	O
17	time	O
18	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	To	O
2	begin	O
3	to	O
4	characterize	O
5	the	O
6	role	O
7	of	O
8	the	O
9	RNA	O
10	subunits	O
11	in	O
12	enzyme	O
13	function	O
14	and	O
15	substrate	O
16	specificity	O
17	,	O
18	we	O
19	swapped	O
20	two	O
21	hairpin	O
22	structures	O
23	(	O
24	MRP3	O
25	and	O
26	P3	O
27	)	O
28	between	O
29	RNase	B
30	MRP	I
31	RNA	I
32	and	O
33	RNase	B
34	P	I
35	RNA	I
36	of	I
37	S	I
38	.	I
39	cerevisiae	I
40	.	O

1	Tumor	O
2	stages	O
3	were	O
4	IIB	O
5	(	O
6	T3	O
7	N0	O
8	)	O
9	in	O
10	52	O
11	%,	O
12	IIIA	O
13	in	O
14	15	O
15	%,	O
16	and	O
17	IIIB	O
18	in	O
19	27	O
20	%	O
21	of	O
22	patients	O
23	.	O

1	Mucin	B
2	gene	I
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	B
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O

1	The	O
2	model	O
3	indicates	O
4	that	O
5	a	O
6	0	O
7	.	O
8	076	O
9	%	O
10	reduction	O
11	in	O
12	cigarette	O
13	consumption	O
14	is	O
15	associated	O
16	with	O
17	the	O
18	availability	O
19	of	O
20	nicotine	O
21	patches	O
22	after	O
23	1992	O
24	.	O

1	Paper	O
2	alert	O
3	.	O

1	OBJECTIVE	O
2	:	O
3	This	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	assess	O
9	the	O
10	relative	O
11	roles	O
12	of	O
13	99mTc	O
14	-	O
15	sestamibi	O
16	scintimammography	O
17	and	O
18	sonography	O
19	in	O
20	the	O
21	evaluation	O
22	of	O
23	breast	O
24	lesions	O
25	that	O
26	are	O
27	indeterminate	O
28	or	O
29	suspicious	O
30	on	O
31	mammography	O
32	or	O
33	clinical	O
34	examination	O
35	.	O

1	Chinese	O
2	Spring	O
3	(	O
4	CS	O
5	)	O
6	carrying	O
7	the	O
8	Q	B
9	gene	I
10	to	O
11	those	O
12	of	O
13	a	O
14	chromosome	O
15	deletion	O
16	line	O
17	of	O
18	CS	O
19	,	O
20	namely	O
21	,	O
22	q5	O
23	,	O
24	which	O
25	lacks	O
26	15	O
27	%	O
28	of	O
29	5AL	O
30	including	O
31	the	O
32	Q	B
33	gene	I
34	.	O

1	Investigations	O
2	using	O
3	hippocampal	O
4	slices	O
5	maintained	O
6	in	O
7	vitro	O
8	have	O
9	demonstrated	O
10	that	O
11	bursts	O
12	of	O
13	oscillatory	O
14	field	O
15	potentials	O
16	in	O
17	the	O
18	gamma	O
19	frequency	O
20	range	O
21	(	O
22	30	O
23	-	O
24	80	O
25	Hz	O
26	)	O
27	are	O
28	followed	O
29	by	O
30	a	O
31	slower	O
32	oscillation	O
33	in	O
34	the	O
35	beta	O
36	1	O
37	range	O
38	(	O
39	12	O
40	-	O
41	20	O
42	Hz	O
43	).	O

1	Karger	O
2	AG	O
3	,	O
4	Basel	O

1	Urinary	O
2	LTE4	O
3	increased	O
4	after	O
5	both	O
6	challenges	O
7	the	O
8	rise	O
9	being	O
10	higher	O
11	following	O
12	oral	O
13	as	O
14	compared	O
15	to	O
16	inhalation	O
17	provocation	O
18	(	O
19	p	O
20	=	O
21	0	O
22	.	O
23	0001	O
24	).	O

1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	B
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	The	O
2	MRS	O
3	II	O
4	meets	O
5	a	O
6	high	O
7	methodological	O
8	standard	O
9	as	O
10	an	O
11	instrument	O
12	standardized	O
13	in	O
14	the	O
15	population	O
16	.	O

1	ECP	B
2	and	O
3	tryptase	B
4	levels	O
5	in	O
6	serum	O
7	were	O
8	measured	O
9	before	O
10	and	O
11	after	O
12	the	O
13	last	O
14	oral	O
15	challenge	O
16	.	O

1	The	O
2	presence	O
3	of	O
4	such	O
5	a	O
6	putative	O
7	RNA	O
8	-	O
9	binding	O
10	domain	O
11	suggests	O
12	a	O
13	mechanism	O
14	for	O
15	the	O
16	observed	O
17	autoregulation	O
18	of	O
19	bacteriophage	O
20	T4	B
21	DNA	I
22	polymerase	I
23	synthesis	O
24	by	O
25	binding	O
26	to	O
27	its	O
28	own	O
29	mRNA	O
30	.	O

1	Deletion	O
2	and	O
3	mutational	O
4	analyses	O
5	revealed	O
6	two	O
7	positive	O
8	cis	O
9	-	O
10	regulatory	O
11	elements	O
12	in	O
13	this	O
14	region	O
15	that	O
16	are	O
17	essential	O
18	for	O
19	CSX1	B
20	expression	O
21	in	O
22	cardiomyocytes	O
23	.	O

1	In	O
2	contrast	O
3	,	O
4	c	B
5	-	I
6	Src	I
7	-	I
8	derived	I
9	construct	I
10	(	O
11	a	B
12	-	I
13	Src	I
14	),	O
15	that	O
16	was	O
17	excluded	O
18	from	O
19	detergent	O
20	-	O
21	resistant	O
22	membranes	O
23	,	O
24	could	O
25	not	O
26	restore	O
27	the	O
28	series	O
29	of	O
30	phagocytosis	O
31	signaling	O
32	.	O

1	Franz	O
2	Schubert	O
3	--	O
4	his	O
5	life	O
6	,	O
7	music	O
8	and	O
9	diseases	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	role	O
7	of	O
8	S	O
9	.	O
10	argyrostoma	O
11	in	O
12	the	O
13	dissemination	O
14	of	O
15	Trichinella	O
16	larvae	O
17	in	O
18	nature	O
19	is	O
20	limited	O
21	in	O
22	comparison	O
23	to	O
24	the	O
25	role	O
26	played	O
27	by	O
28	mammals	O
29	with	O
30	scavenger	O
31	and	O
32	cannibalistic	O
33	behavior	O
34	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	N	O
6	-	O
7	glycans	O
8	flanking	O
9	the	O
10	receptor	O
11	-	O
12	binding	O
13	site	O
14	of	O
15	the	O
16	HA	B
17	molecule	I
18	are	O
19	potent	O
20	regulators	O
21	of	O
22	influenza	O
23	virus	O
24	growth	O
25	,	O
26	with	O
27	the	O
28	glycan	O
29	at	O
30	Asn149	O
31	being	O
32	dominant	O
33	and	O
34	that	O
35	at	O
36	Asn123	O
37	being	O
38	less	O
39	effective	O
40	.	O

1	RESULTS	O
2	:	O
3	The	O
4	introduction	O
5	of	O
6	the	O
7	PAIP	O
8	resulted	O
9	in	O
10	a	O
11	significant	O
12	(	O
13	p	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	reduction	O
20	in	O
21	contaminating	O
22	WBCs	O
23	(	O
24	median	O
25	,	O
26	30	O
27	,	O
28	000	O
29	)	O
30	from	O
31	the	O
32	numbers	O
33	seen	O
34	with	O
35	FIP	O
36	(	O
37	median	O
38	,	O
39	2	O
40	,	O
41	300	O
42	,	O
43	000	O
44	)	O
45	while	O
46	maintaining	O
47	the	O
48	separation	O
49	efficacy	O
50	(	O
51	47	O
52	%)	O
53	and	O
54	separation	O
55	time	O
56	.	O

1	The	O
2	antioxidant	O
3	agent	O
4	pyrrolidine	O
5	dithiocarbamate	O
6	(	O
7	PDTC	O
8	)	O
9	has	O
10	been	O
11	shown	O
12	to	O
13	protect	O
14	endothelial	O
15	cells	O
16	(	O
17	EC	O
18	)	O
19	from	O
20	pro	O
21	-	O
22	inflammatory	O
23	-	O
24	induced	O
25	and	O
26	pro	O
27	-	O
28	oxidant	O
29	-	O
30	induced	O
31	NF	B
32	-	I
33	kappaB	I
34	activation	O
35	.	O

1	In	O
2	contrast	O
3	to	O
4	the	O
5	morphological	O
6	criteria	O
7	,	O
8	the	O
9	few	O
10	data	O
11	available	O
12	from	O
13	recent	O
14	studies	O
15	at	O
16	the	O
17	genetic	O
18	level	O
19	have	O
20	suggested	O
21	that	O
22	EPVs	O
23	infecting	O
24	different	O
25	insect	O
26	orders	O
27	are	O
28	phylogenetically	O
29	distant	O
30	.	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	This	O
2	study	O
3	shows	O
4	that	O
5	C	B
6	/	I
7	EBPbeta	I
8	is	O
9	the	O
10	predominant	O
11	C	B
12	/	I
13	EBP	I
14	isoform	I
15	found	O
16	in	O
17	activated	O
18	stellate	O
19	cells	O
20	and	O
21	that	O
22	increased	O
23	C	B
24	/	I
25	EBPbeta	I
26	protein	I
27	and	O
28	C	B
29	/	I
30	EBPbeta	I
31	binding	O
32	to	O
33	a	O
34	proximal	O
35	C	B
36	/	I
37	EBP	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	promoter	O
43	mediates	O
44	the	O
45	activating	O
46	effect	O
47	of	O
48	acetaldehyde	O
49	.	O

1	Mutation	O
2	analysis	O
3	demonstrates	O
4	that	O
5	the	O
6	motif	O
7	TCCCCT	O
8	is	O
9	critical	O
10	for	O
11	PyRo1	B
12	interaction	O
13	.	O

1	As	O
2	with	O
3	VP16	B
4	,	O
5	the	O
6	transactivation	O
7	function	O
8	of	O
9	Luman	B
10	is	O
11	also	O
12	regulated	O
13	by	O
14	HCF	B
15	.	O

1	AIMS	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	role	O
7	of	O
8	environmental	O
9	intra	O
10	-	O
11	uterine	O
12	factors	O
13	in	O
14	determining	O
15	the	O
16	birthweights	O
17	of	O
18	twins	O
19	with	O
20	increased	O
21	susceptibility	O
22	to	O
23	diabetes	O
24	and	O
25	discordant	O
26	for	O
27	abnormal	O
28	responses	O
29	to	O
30	the	O
31	oral	O
32	glucose	O
33	tolerance	O
34	test	O
35	(	O
36	OGTT	O
37	)	O
38	and	O
39	verify	O
40	the	O
41	possible	O
42	association	O
43	of	O
44	within	O
45	-	O
46	pair	O
47	birthweight	O
48	differences	O
49	and	O
50	metabolic	O
51	abnormalities	O
52	in	O
53	adult	O
54	life	O
55	.	O

1	When	O
2	the	O
3	LCx	O
4	was	O
5	partially	O
6	occluded	O
7	,	O
8	mild	O
9	PM	O
10	-	O
11	induced	O
12	tachycardia	O
13	resulted	O
14	in	O
15	decreased	O
16	AoP	O
17	(	O
18	P	O
19	=	O
20	0	O
21	.	O
22	045	O
23	)	O
24	as	O
25	well	O
26	as	O
27	in	O
28	decreased	O
29	SV	O
30	(	O
31	P	O
32	=	O
33	0	O
34	.	O
35	048	O
36	);	O
37	the	O
38	LVEDP	O
39	remained	O
40	high	O
41	(	O
42	P	O
43	=	O
44	0	O
45	.	O
46	002	O
47	).	O

1	GAP	O
2	JUNCTIONS	O
3	IN	O
4	THE	O
5	BRAIN	O
6	:	O
7	PREFACE	O
8	.	O

1	BACKGROUND	O
2	:	O
3	Gamma	O
4	knife	O
5	radiosurgery	O
6	(	O
7	GKR	O
8	)	O
9	is	O
10	a	O
11	safe	O
12	and	O
13	effective	O
14	alternative	O
15	to	O
16	surgery	O
17	for	O
18	intracranial	O
19	lesions	O
20	.	O

1	In	O
2	hemodialyzed	O
3	patients	O
4	(	O
5	Epo	B
6	and	O
7	Non	O
8	-	O
9	Epo	B
10	group	O
11	)	O
12	leptin	B
13	levels	O
14	were	O
15	significantly	O
16	higher	O
17	when	O
18	compared	O
19	to	O
20	CAPD	O
21	patients	O
22	(	O
23	Epo	B
24	and	O
25	Non	O
26	-	O
27	Epo	B
28	group	O
29	,	O
30	respectively	O
31	).	O

1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	O
5	-	O
6	adrenergic	O
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O

1	Both	O
2	the	O
3	MVBF	O
4	and	O
5	the	O
6	maximum	O
7	EMG	O
8	activity	O
9	in	O
10	the	O
11	right	O
12	masseter	O
13	and	O
14	the	O
15	left	O
16	anterior	O
17	temporalis	O
18	muscles	O
19	were	O
20	significantly	O
21	decreased	O
22	during	O
23	muscle	O
24	pain	O
25	when	O
26	the	O
27	subjects	O
28	bit	O
29	on	O
30	the	O
31	painful	O
32	side	O
33	.	O

1	The	O
2	total	O
3	alkaloids	O
4	contained	O
5	in	O
6	the	O
7	peel	O
8	of	O
9	Atzimba	O
10	,	O
11	Lopez	O
12	,	O
13	Marciana	O
14	,	O
15	Montsama	O
16	,	O
17	Murca	O
18	,	O
19	and	O
20	Puebla	O
21	was	O
22	lower	O
23	than	O
24	the	O
25	limits	O
26	recommended	O
27	for	O
28	food	O
29	safety	O
30	.	O

1	Although	O
2	increased	O
3	expression	O
4	of	O
5	the	O
6	HMG	B
7	-	I
8	I	I
9	/	I
10	Y	I
11	proteins	I
12	is	O
13	associated	O
14	with	O
15	cellular	O
16	proliferation	O
17	,	O
18	neoplastic	O
19	transformation	O
20	,	O
21	and	O
22	several	O
23	human	O
24	cancers	O
25	,	O
26	the	O
27	role	O
28	of	O
29	these	O
30	proteins	O
31	in	O
32	the	O
33	pathogenesis	O
34	of	O
35	malignancy	O
36	remains	O
37	unclear	O
38	.	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	Bailey	O
2	Instruments	O
3	and	O
4	Owen	O
5	Mumford	O
6	filaments	O
7	were	O
8	the	O
9	most	O
10	accurate	O
11	with	O
12	100	O
13	%	O
14	buckling	O
15	within	O
16	+/-	O
17	1	O
18	.	O
19	0	O
20	g	O
21	of	O
22	10	O
23	g	O
24	.	O

1	PARTICIPANTS	O
2	:	O
3	Convenience	O
4	sample	O
5	of	O
6	ambulatory	O
7	outpatients	O
8	with	O
9	hereditary	O
10	motor	O
11	and	O
12	sensory	O
13	neuropathy	O
14	,	O
15	type	O
16	I	O
17	(	O
18	n	O
19	=	O
20	9	O
21	),	O
22	myotonic	O
23	muscular	O
24	dystrophy	O
25	(	O
26	n	O
27	=	O
28	10	O
29	),	O
30	and	O
31	able	O
32	-	O
33	bodied	O
34	controls	O
35	(	O
36	n	O
37	=	O
38	11	O
39	).	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	B
11	sequences	I
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	The	O
2	chromosomal	O
3	localization	O
4	on	O
5	distal	O
6	chromosome	O
7	7	O
8	places	O
9	it	O
10	in	O
11	a	O
12	cluster	O
13	of	O
14	imprinted	O
15	genes	O
16	,	O
17	flanked	O
18	by	O
19	the	O
20	previously	O
21	described	O
22	Tapa1	B
23	and	O
24	Kcnq1	B
25	genes	I
26	.	O

1	Double	O
2	mutant	O
3	analysis	O
4	suggests	O
5	that	O
6	Rad54p	B
7	and	O
8	Mus81p	B
9	act	O
10	in	O
11	one	O
12	pathway	O
13	for	O
14	the	O
15	repair	O
16	of	O
17	,	O
18	or	O
19	tolerance	O
20	to	O
21	,	O
22	UV	O
23	-	O
24	induced	O
25	DNA	O
26	damage	O
27	.	O

1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	action	O
6	of	O
7	GLP	B
8	-	I
9	1	I
10	at	O
11	the	O
12	CRE	O
13	was	O
14	not	O
15	blocked	O
16	by	O
17	cotransfection	O
18	with	O
19	M1	B
20	-	I
21	CREB	I
22	,	O
23	an	O
24	isoform	O
25	that	O
26	lacks	O
27	a	O
28	consensus	O
29	serine	O
30	residue	O
31	serving	O
32	as	O
33	substrate	O
34	for	O
35	PKA	B
36	-	O
37	mediated	O
38	phosphorylation	O
39	.	O

1	Because	O
2	all	O
3	PDGFbetaR	B
4	fusions	I
5	described	O
6	thus	O
7	far	O
8	result	O
9	in	O
10	splicing	O
11	to	O
12	a	O
13	common	O
14	exon	O
15	of	O
16	this	O
17	gene	O
18	,	O
19	we	O
20	performed	O
21	5	O
22	'-	O
23	rapid	O
24	amplification	O
25	of	O
26	cDNA	O
27	ends	O
28	PCR	O
29	on	O
30	patient	O
31	RNA	O
32	.	O

1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	I
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	B
24	in	O
25	vivo	O
26	.	O

1	Wnt	B
2	-	I
3	1	I
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	B
18	-	I
19	1	I
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	B
30	activity	O
31	and	O
32	cyclin	B
33	D1	I
34	levels	O
35	.	O

1	Logistic	O
2	regression	O
3	analysis	O
4	revealed	O
5	that	O
6	physicians	O
7	were	O
8	3	O
9	.	O
10	6	O
11	times	O
12	more	O
13	likely	O
14	to	O
15	detect	O
16	thin	O
17	lesions	O
18	(</=	O
19	0	O
20	.	O
21	75	O
22	mm	O
23	)	O
24	compared	O
25	with	O
26	nonphysician	O
27	detectors	O
28	(	O
29	95	O
30	%	O
31	confidence	O
32	interval	O
33	[	O
34	95	O
35	%	O
36	CI	O
37	],	O
38	2	O
39	.	O
40	1	O
41	,	O
42	6	O
43	.	O
44	5	O
45	;	O
46	P	O
47	=	O
48	0	O
49	.	O
50	0001	O
51	).	O

1	Erythema	O
2	exsudativum	O
3	multiforme	O
4	induced	O
5	by	O
6	granulocyte	B
7	colony	I
8	-	I
9	stimulating	I
10	factor	I
11	in	O
12	an	O
13	allogeneic	O
14	peripheral	O
15	blood	O
16	stem	O
17	cell	O
18	donor	O
19	.	O

1	It	O
2	is	O
3	now	O
4	well	O
5	accepted	O
6	that	O
7	the	O
8	p53	B
9	C	I
10	-	I
11	terminus	I
12	plays	O
13	a	O
14	central	O
15	role	O
16	in	O
17	controlling	O
18	the	O
19	activity	O
20	of	O
21	the	O
22	wild	O
23	-	O
24	type	O
25	molecule	O
26	.	O

1	In	O
2	contrast	O
3	to	O
4	full	B
5	-	I
6	length	I
7	E2F	I
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	I
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	authors	O
5	emphasize	O
6	that	O
7	the	O
8	initial	O
9	management	O
10	of	O
11	primary	O
12	STS	O
13	should	O
14	be	O
15	adequate	O
16	and	O
17	suggest	O
18	that	O
19	safty	O
20	margin	O
21	of	O
22	>	O
23	or	O
24	=	O
25	2	O
26	cm	O
27	should	O
28	be	O
29	adhered	O
30	to	O
31	.	O

1	Whereas	O
2	MARTA1	B
3	is	O
4	clearly	O
5	detectable	O
6	in	O
7	crude	O
8	lysates	O
9	,	O
10	cytosolic	O
11	and	O
12	ribosomal	O
13	salt	O
14	-	O
15	wash	O
16	fractions	O
17	,	O
18	and	O
19	in	O
20	nuclear	O
21	extracts	O
22	,	O
23	MARTA2	B
24	is	O
25	preferentially	O
26	found	O
27	in	O
28	the	O
29	ribosomal	O
30	salt	O
31	-	O
32	wash	O
33	preparation	O
34	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	B
5	locus	I
6	at	I
7	Xp11	I
8	.	I
9	3	I
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	CREST	O
2	syndrome	O
3	;	O
4	a	O
5	changing	O
6	clinical	O
7	significance	O

1	Troglitazone	O
2	also	O
3	induced	O
4	an	O
5	endogenous	B
6	PPARgamma	I
7	target	I
8	gene	I
9	in	O
10	T24	O
11	cells	O
12	,	O
13	adipocyte	B
14	-	I
15	type	I
16	fatty	I
17	acid	I
18	binding	I
19	protein	I
20	(	O
21	A	B
22	-	I
23	FABP	I
24	),	O
25	the	O
26	expression	O
27	of	O
28	which	O
29	correlates	O
30	with	O
31	bladder	O
32	cancer	O
33	differentiation	O
34	.	O

1	Splicing	O
2	of	O
3	the	O
4	K	B
5	-	I
6	SAM	I
7	alternative	O
8	exon	O
9	of	O
10	the	O
11	fibroblast	B
12	growth	I
13	factor	I
14	receptor	I
15	2	I
16	gene	I
17	is	O
18	heavily	O
19	dependent	O
20	on	O
21	the	O
22	U	O
23	-	O
24	rich	O
25	sequence	O
26	IAS1	B
27	lying	O
28	immediately	O
29	downstream	O
30	from	O
31	its	O
32	5	O
33	'	O
34	splice	O
35	site	O
36	.	O

1	However	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	whether	O
8	the	O
9	recently	O
10	identified	O
11	isoforms	O
12	Vav2	B
13	and	O
14	Vav3	B
15	,	O
16	which	O
17	are	O
18	broadly	O
19	expressed	O
20	,	O
21	can	O
22	couple	O
23	with	O
24	similar	O
25	classes	O
26	of	O
27	receptors	O
28	,	O
29	nor	O
30	is	O
31	it	O
32	known	O
33	whether	O
34	all	O
35	Vav	B
36	isoforms	I
37	possess	O
38	identical	O
39	functional	O
40	activities	O
41	.	O

1	Additionally	O
2	,	O
3	putative	O
4	CF1	B
5	/	O
6	USP	B
7	and	O
8	Broad	B
9	Complex	I
10	Z2	I
11	transcription	O
12	factor	O
13	elements	O
14	were	O
15	found	O
16	in	O
17	the	O
18	upstream	O
19	regions	O
20	of	O
21	MIH	B
22	and	O
23	MO	B
24	-	I
25	IH	I
26	genes	O
27	respectively	O
28	.	O

1	Mis3	B
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	After	O
2	gamma	O
3	-	O
4	irradiation	O
5	,	O
6	the	O
7	majority	O
8	of	O
9	F9	O
10	cells	O
11	undergo	O
12	apoptosis	O
13	implying	O
14	that	O
15	wt	B
16	-	I
17	p53	I
18	likely	O
19	triggers	O
20	pro	O
21	-	O
22	apoptotic	O
23	gene	O
24	expression	O
25	in	O
26	DNA	O
27	damaged	O
28	cells	O
29	.	O

1	Mobilization	O
2	with	O
3	cyclophosphamide	O
4	and	O
5	granulocyte	B
6	-	I
7	colony	I
8	stimulating	I
9	factor	I
10	was	O
11	effective	O
12	in	O
13	terms	O
14	of	O
15	CD34	B
16	+	I
17	cell	O
18	shift	O
19	to	O
20	peripheral	O
21	blood	O
22	and	O
23	the	O
24	good	O
25	quality	O
26	autograft	O
27	reliably	O
28	led	O
29	to	O
30	haematopoetic	O
31	recovery	O
32	after	O
33	megachemotherapy	O
34	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	The	O
2	reduced	O
3	efficiency	O
4	in	O
5	the	O
6	glycosylase	B
7	activity	O
8	is	O
9	also	O
10	reflected	O
11	in	O
12	a	O
13	reduced	O
14	ability	O
15	of	O
16	S120K	B
17	MutY	I
18	to	O
19	prevent	O
20	DNA	O
21	mutations	O
22	in	O
23	vivo	O
24	.	O

1	The	O
2	spacing	O
3	of	O
4	the	O
5	essential	O
6	N	O
7	-	O
8	terminal	O
9	domain	O
10	(	O
11	END	O
12	)	O
13	relative	O
14	to	O
15	the	O
16	HFD	B
17	can	O
18	be	O
19	changed	O
20	significantly	O
21	without	O
22	an	O
23	apparent	O
24	effect	O
25	on	O
26	Cse4p	B
27	function	O
28	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	relationship	O
7	between	O
8	comprehension	O
9	and	O
10	production	O
11	is	O
12	different	O
13	at	O
14	different	O
15	stages	O
16	in	O
17	development	O
18	.	O

1	The	O
2	tumor	B
3	-	I
4	suppressor	I
5	protein	I
6	p53	I
7	is	O
8	involved	O
9	in	O
10	maintaining	O
11	genomic	O
12	stability	O
13	.	O

1	Cytogenetic	O
2	analysis	O
3	of	O
4	LOH	O
5	mutants	O
6	by	O
7	chromosome	O
8	painting	O
9	indicated	O
10	a	O
11	mosaic	O
12	of	O
13	chromosomal	O
14	aberrations	O
15	involving	O
16	chromosome	O
17	17	O
18	,	O
19	in	O
20	which	O
21	partial	O
22	chromosome	O
23	deletions	O
24	,	O
25	amplifications	O
26	,	O
27	and	O
28	multiple	O
29	translocations	O
30	appeared	O
31	heterogeneously	O
32	in	O
33	a	O
34	single	O
35	mutant	O
36	.	O

1	Parathyroid	B
2	hormone	I
3	regulation	O
4	of	O
5	bone	B
6	sialoprotein	I
7	(	O
8	BSP	B
9	)	O
10	gene	O
11	transcription	O
12	is	O
13	mediated	O
14	through	O
15	a	O
16	pituitary	B
17	-	I
18	specific	I
19	transcription	I
20	factor	I
21	-	I
22	1	I
23	(	O
24	Pit	B
25	-	I
26	1	I
27	)	O
28	motif	O
29	in	O
30	the	O
31	rat	B
32	BSP	I
33	gene	I
34	promoter	I
35	.	O

1	These	O
2	include	O
3	NPF	O
4	repeats	O
5	,	O
6	a	O
7	leucine	O
8	heptad	O
9	repeat	O
10	enriched	O
11	in	O
12	charged	O
13	residues	O
14	,	O
15	and	O
16	a	O
17	proline	O
18	-	O
19	rich	O
20	SH3	B
21	-	I
22	like	I
23	and	O
24	/	O
25	or	O
26	WW	O
27	domain	O
28	-	O
29	binding	O
30	site	O
31	in	O
32	the	O
33	N	O
34	-	O
35	terminal	O
36	domain	O
37	,	O
38	which	O
39	is	O
40	followed	O
41	by	O
42	a	O
43	membrane	O
44	core	O
45	containing	O
46	four	O
47	putative	O
48	transmembrane	O
49	spans	O
50	and	O
51	three	O
52	amphiphilic	O
53	segments	O
54	that	O
55	are	O
56	the	O
57	most	O
58	highly	O
59	conserved	O
60	structural	O
61	elements	O
62	.	O

1	Mucosal	O
2	application	O
3	of	O
4	NCX	O
5	-	O
6	4016	O
7	,	O
8	however	O
9	,	O
10	did	O
11	not	O
12	cause	O
13	PD	O
14	reduction	O
15	and	O
16	luminal	O
17	H	O
18	+	O
19	loss	O
20	,	O
21	but	O
22	produced	O
23	a	O
24	marked	O
25	hyperemia	O
26	,	O
27	resulting	O
28	in	O
29	no	O
30	damage	O
31	in	O
32	the	O
33	stomach	O
34	of	O
35	both	O
36	normal	O
37	and	O
38	STZ	O
39	-	O
40	diabetic	O
41	rats	O
42	.	O

1	Functional	O
2	recognition	O
3	of	O
4	5	O
5	'	O
6	splice	O
7	site	O
8	by	O
9	U4	B
10	/	O
11	U6	B
12	.	O
13	U5	B
14	tri	O
15	-	O
16	snRNP	O
17	defines	O
18	a	O
19	novel	O
20	ATP	O
21	-	O
22	dependent	O
23	step	O
24	in	O
25	early	O
26	spliceosome	O
27	assembly	O
28	.	O

1	Analysis	O
2	of	O
3	Standard	O
4	Reference	O
5	Material	O
6	1846	O
7	,	O
8	Infant	O
9	Formula	O
10	,	O
11	gave	O
12	a	O
13	mean	O
14	value	O
15	of	O
16	0	O
17	.	O
18	95	O
19	+/-	O
20	0	O
21	.	O
22	088	O
23	mg	O
24	vitamin	O
25	K	O
26	/	O
27	kg	O
28	(	O
29	K	O
30	or	O
31	K1	O
32	?)	O
33	(	O
34	n	O
35	=	O
36	31	O
37	)	O
38	with	O
39	a	O
40	coefficient	O
41	of	O
42	variation	O
43	of	O
44	9	O
45	.	O
46	26	O
47	.	O

1	We	O
2	have	O
3	recently	O
4	discovered	O
5	that	O
6	CCAAAT	B
7	/	I
8	enhancer	I
9	-	I
10	binding	I
11	protein	I
12	-	I
13	beta	I
14	(	O
15	C	B
16	/	I
17	EBP	I
18	-	I
19	beta	I
20	)	O
21	induces	O
22	gene	O
23	transcription	O
24	through	O
25	a	O
26	novel	O
27	IFN	B
28	response	I
29	element	I
30	called	O
31	the	O
32	gamma	B
33	-	I
34	IFN	I
35	-	I
36	activated	I
37	transcriptional	I
38	element	I

1	Phylogenetic	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	ToLCV	O
7	isolates	O
8	from	O
9	Bangalore	O
10	constitute	O
11	a	O
12	group	O
13	of	O
14	viruses	O
15	separated	O
16	from	O
17	those	O
18	of	O
19	Northern	O
20	India	O
21	.	O

1	Mutating	O
2	the	O
3	Fcp1p	B
4	-	O
5	binding	O
6	motif	O
7	KEFGK	O
8	in	O
9	the	O
10	RAP74	B
11	(	O
12	Tfg1p	B
13	)	O
14	subunit	O
15	of	O
16	TFIIF	B
17	to	O
18	EEFGE	O
19	led	O
20	to	O
21	both	O
22	synthetic	O
23	phenotypes	O
24	in	O
25	certain	O
26	fcp1	B
27	tfg1	I
28	double	O
29	mutants	O
30	and	O
31	a	O
32	reduced	O
33	ability	O
34	of	O
35	Fcp1p	B
36	to	O
37	activate	O
38	transcription	O
39	when	O
40	it	O
41	is	O
42	artificially	O
43	tethered	O
44	to	O
45	a	O
46	promoter	O
47	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	B
24	endothelial	I
25	growth	I
26	factor	I
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	The	O
2	protein	B
3	-	I
4	tyrosine	I
5	kinase	I
6	fer	I
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	B
13	receptor	I
14	substrate	I
15	-	I
16	1	I
17	and	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	.	O

1	Analysis	O
2	of	O
3	intron	O
4	/	O
5	exon	O
6	boundaries	O
7	of	O
8	the	O
9	genomic	O
10	BAC	O
11	clones	O
12	demonstrate	O
13	that	O
14	junctin	B
15	,	O
16	junctate	B
17	,	O
18	and	O
19	aspartyl	B
20	beta	I
21	-	I
22	hydroxylase	I
23	result	O
24	from	O
25	alternative	O
26	splicing	O
27	of	O
28	the	O
29	same	O
30	gene	O
31	.	O

1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	B
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	O
15	all	O
16	forms	O
17	of	O
18	solid	O
19	tumors	O
20	.	O

1	The	O
2	growth	B
3	factor	I
4	receptor	I
5	-	I
6	bound	I
7	protein	I
8	2	I
9	(	O
10	Grb2	B
11	)	O
12	adaptor	O
13	when	O
14	complexed	O
15	with	O
16	Sos	B
17	(	O
18	Son	B
19	of	I
20	sevenless	I
21	),	O
22	the	O
23	exchange	O
24	factor	O
25	of	O
26	Ras	B
27	,	O
28	conveys	O
29	the	O
30	signal	O
31	induced	O
32	by	O
33	tyrosine	B
34	kinase	I
35	-	I
36	activated	I
37	receptor	I
38	to	O
39	Ras	B
40	by	O
41	recruiting	O
42	Sos	B
43	to	O
44	the	O
45	membrane	O
46	,	O
47	allowing	O
48	activation	O
49	of	O
50	Ras	B
51	.	O

1	Mutations	O
2	in	O
3	genes	O
4	encoding	O
5	PR65	B
6	/	I
7	A	I
8	subunits	I
9	have	O
10	been	O
11	identified	O
12	in	O
13	several	O
14	different	O
15	human	O
16	cancers	O
17	and	O
18	the	O
19	PP2A	B
20	inhibitor	O
21	,	O
22	termed	O
23	fostriecin	O
24	,	O
25	is	O
26	being	O
27	tested	O
28	as	O
29	an	O
30	anticancer	O
31	drug	O
32	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	segment	O
7	of	O
8	dxr	B
9	was	O
10	amplified	O
11	from	O
12	Synechococcus	O
13	leopoliensis	O
14	SAUG	O
15	1402	O
16	-	O
17	1	O
18	DNA	O
19	via	O
20	PCR	O
21	using	O
22	oligonucleotides	O
23	for	O
24	conserved	O
25	regions	O
26	.	O

1	(	O
2	1995	O
3	)	O
4	J	O
5	.	O

1	We	O
2	could	O
3	demonstrate	O
4	the	O
5	involvement	O
6	of	O
7	cAMP	B
8	-	I
9	dependent	I
10	protein	I
11	kinase	I
12	(	O
13	PKA	B
14	)	O
15	in	O
16	the	O
17	phosphorylation	O
18	of	O
19	CDC25Mm	B
20	in	O
21	fibroblasts	O
22	overexpressing	O
23	this	O
24	RasGEF	B
25	as	O
26	well	O
27	as	O
28	in	O
29	mouse	O
30	brain	O
31	synaptosomal	O
32	membranes	O
33	.	O

1	We	O
2	find	O
3	that	O
4	3T1	O
5	-	O
6	3T2	O
7	mixing	O
8	has	O
9	a	O
10	pronounced	O
11	effect	O
12	on	O
13	the	O
14	line	O
15	shape	O
16	and	O
17	radiative	O
18	decay	O
19	rate	O
20	of	O
21	emission	O
22	from	O
23	the	O
24	3T2	O
25	state	O
26	and	O
27	that	O
28	the	O
29	extent	O
30	of	O
31	mixing	O
32	depends	O
33	critically	O
34	on	O
35	the	O
36	magnitude	O
37	of	O
38	nontetrahedral	O
39	distortions	O
40	.	O

1	The	O
2	Drosophila	B
3	melanogaster	I
4	suppressor	I
5	of	I
6	sable	I
7	gene	I
8	,	O
9	su	O
10	(	O
11	s	O
12	),	O
13	encodes	O
14	a	O
15	novel	O
16	,	O
17	150	O
18	-	O
19	kDa	O
20	nuclear	O
21	RNA	O
22	binding	O
23	protein	O
24	,	O
25	SU	O
26	(	O
27	S	O
28	),	O
29	that	O
30	negatively	O
31	regulates	O
32	RNA	O
33	accumulation	O
34	from	O
35	mutant	O
36	alleles	O
37	of	O
38	other	O
39	genes	O
40	that	O
41	have	O
42	transposon	O
43	insertions	O
44	in	O
45	the	O
46	5	O
47	'	O
48	transcribed	O
49	region	O
50	.	O

1	Cost	O
2	-	O
3	effectiveness	O
4	of	O
5	interferon	B
6	beta	I
7	-	I
8	1b	I
9	in	O
10	slowing	O
11	multiple	O
12	sclerosis	O
13	disability	O
14	progression	O
15	.	O

1	Diary	O
2	.	O

1	The	O
2	LMW	B
3	FGF	I
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	B
24	isoform	I
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	B
25	-	I
26	3K	I
27	are	O
28	crucial	O
29	for	O
30	CD40	B
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	overall	O
7	performance	O
8	of	O
9	a	O
10	new	O
11	oscillometric	O
12	wrist	O
13	blood	O
14	pressure	O
15	monitor	O
16	(	O
17	Braun	O
18	PrecisionSensor	O
19	,	O
20	Braun	O
21	GmbH	O
22	,	O
23	Kronberg	O
24	,	O
25	Germany	O
26	)	O
27	as	O
28	defined	O
29	by	O
30	the	O
31	ANSI	O
32	/	O
33	AAMI	O
34	SP10	O
35	-	O
36	1992	O
37	guidelines	O
38	,	O
39	and	O
40	to	O
41	analyze	O
42	the	O
43	data	O
44	for	O
45	the	O
46	optimized	O
47	selection	O
48	of	O
49	the	O
50	algorithm	O
51	that	O
52	derives	O
53	the	O
54	blood	O
55	pressure	O
56	values	O
57	from	O
58	the	O
59	oscillometric	O
60	blood	O
61	pressure	O
62	curves	O
63	.	O

1	Methyl	O
2	formate	O
3	was	O
4	used	O
5	as	O
6	the	O
7	solvent	O
8	of	O
9	biodegradable	O
10	oligoesters	O
11	for	O
12	the	O
13	fabrication	O
14	of	O
15	microspheres	O
16	with	O
17	encapsulated	O
18	bovine	B
19	serum	I
20	albumin	I
21	(	O
22	BSA	B
23	).	O

1	The	O
2	small	B
3	monomeric	I
4	GTP	I
5	-	I
6	binding	I
7	proteins	I
8	of	O
9	the	O
10	RAB	B
11	subfamily	I
12	are	O
13	key	O
14	regulatory	O
15	elements	O
16	of	O
17	the	O
18	machinery	O
19	that	O
20	controls	O
21	membrane	O
22	traffic	O
23	in	O
24	eukaryotic	O
25	cells	O
26	.	O

1	Thus	O
2	,	O
3	methylation	O
4	of	O
5	Pph21p	B
6	is	O
7	important	O
8	for	O
9	formation	O
10	of	O
11	PP2A	B
12	trimeric	I
13	and	I
14	dimeric	I
15	complexes	I
16	,	O
17	and	O
18	consequently	O
19	,	O
20	for	O
21	PP2A	B
22	function	O
23	.	O

1	Together	O
2	,	O
3	these	O
4	results	O
5	indicate	O
6	that	O
7	IL	B
8	-	I
9	1	I
10	beta	I
11	induces	O
12	VEGF	B
13	gene	I
14	expression	O
15	at	O
16	both	O
17	transcriptional	O
18	and	O
19	post	O
20	-	O
21	transcriptional	O
22	levels	O
23	,	O
24	and	O
25	IL	B
26	-	I
27	1	I
28	beta	I
29	evokes	O
30	p38	B
31	MAPK	O
32	and	O
33	JNK	B
34	signalings	O
35	,	O
36	which	O
37	in	O
38	turn	O
39	stimulate	O
40	the	O
41	transcription	O
42	of	O
43	the	O
44	VEGF	B
45	gene	I
46	through	O
47	Sp1	B
48	-	I
49	binding	I
50	sites	I
51	.	O

1	Leptinaemia	O
2	does	O
3	not	O
4	correlate	O
5	with	O
6	the	O
7	actual	O
8	or	O
9	mean	O
10	blood	O
11	pressure	O
12	reading	O
13	nor	O
14	with	O
15	stage	O
16	of	O
17	hypertension	O
18	according	O
19	to	O
20	the	O
21	WHO	O
22	classification	O
23	.	O

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	O
11	binding	O
12	of	O
13	NFI	B
14	proteins	I
15	,	O
16	and	O
17	the	O
18	addition	O
19	of	O
20	higher	O
21	concentrations	O
22	of	O
23	dithiothreitol	O
24	to	O
25	nuclear	O
26	extracts	O
27	from	O
28	TG	B
29	-	O
30	treated	O
31	cells	O
32	restores	O
33	NFI	B
34	-	I
35	DNA	I
36	binding	O
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	O
44	.	O

1	Thromboelastography	O
2	is	O
3	a	O
4	test	O
5	that	O
6	could	O
7	potentially	O
8	correlate	O
9	with	O
10	the	O
11	degree	O
12	of	O
13	anticoagulation	O
14	produced	O
15	by	O
16	low	O
17	molecular	O
18	weight	O
19	heparin	O
20	.	O

1	A	O
2	total	O
3	of	O
4	1060	O
5	clones	O
6	were	O
7	randomly	O
8	selected	O
9	for	O
10	sequencing	O
11	of	O
12	one	O
13	end	O
14	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	B
31	(	O
32	Suvar3	B
33	-	I
34	9	I
35	,	O
36	Enhancer	B
37	-	I
38	of	I
39	-	I
40	zeste	I
41	,	O
42	Trithorax	B
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	B
51	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	XAB1	B
6	is	O
7	a	O
8	novel	O
9	cytoplasmic	B
10	GTPase	I
11	involved	O
12	in	O
13	nuclear	O
14	localization	O
15	of	O
16	XPA	B
17	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	IRF	B
7	-	I
8	2	I
9	,	O
10	was	O
11	initially	O
12	cloned	O
13	as	O
14	an	O
15	antagonistic	O
16	counterpart	O
17	to	O
18	IRF	B
19	-	I
20	1	I
21	with	O
22	oncogenic	O
23	potential	O
24	.	O

1	Among	O
2	the	O
3	total	O
4	CDSs	O
5	,	O
6	8	O
7	.	O
8	8	O
9	%	O
10	match	O
11	sequences	O
12	of	O
13	proteins	O
14	found	O
15	only	O
16	in	O
17	Bacillus	O
18	subtilis	O
19	and	O
20	66	O
21	.	O
22	7	O
23	%	O
24	are	O
25	widely	O
26	conserved	O
27	in	O
28	comparison	O
29	with	O
30	the	O
31	proteins	O
32	of	O
33	various	O
34	organisms	O
35	,	O
36	including	O
37	B	O
38	.	O
39	subtilis	O
40	.	O

1	Bacteriol	O
2	.	O

1	Thus	O
2	,	O
3	the	O
4	class	B
5	C	I
6	-	O
7	Vps	B
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	What	O
2	to	O
3	look	O
4	for	O
5	during	O
6	a	O
7	compliance	O
8	review	O
9	:	O
10	10	O
11	common	O
12	mistakes	O
13	made	O
14	by	O
15	SNFs	O
16	.	O

1	CONCLUSIONS	O
2	:	O
3	EBCT	O
4	technology	O
5	allows	O
6	minimally	O
7	invasive	O
8	evaluation	O
9	of	O
10	intramyocardial	O
11	microcirculatory	O
12	function	O
13	and	O
14	permits	O
15	assessment	O
16	of	O
17	microvascular	O
18	BV	O
19	distribution	O
20	in	O
21	different	O
22	functional	O
23	components	O
24	.	O

1	Transcription	O
2	of	O
3	the	O
4	six	O
5	EBNA	B
6	genes	I
7	,	O
8	which	O
9	are	O
10	expressed	O
11	in	O
12	EBV	O
13	-	O
14	immortalized	O
15	primary	O
16	B	O
17	cells	O
18	,	O
19	arises	O
20	from	O
21	one	O
22	of	O
23	two	O
24	promoters	O
25	,	O
26	Cp	B
27	and	O
28	Wp	B
29	,	O
30	located	O
31	near	O
32	the	O
33	left	O
34	end	O
35	of	O
36	the	O
37	viral	O
38	genome	O
39	.	O

1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	The	O
2	Tax	B
3	/	O
4	IKKgamma	B
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	B
13	catalytic	I
14	subunits	I
15	,	O
16	IKKalpha	B
17	and	O
18	IKKbeta	B
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	B
37	.	O

1	A	O
2	recently	O
3	reported	O
4	new	O
5	member	O
6	of	O
7	the	O
8	Vav	B
9	family	I
10	proteins	I
11	,	O
12	Vav3	B
13	has	O
14	been	O
15	identified	O
16	as	O
17	a	O
18	Ros	B
19	receptor	I
20	protein	I
21	tyrosine	I
22	kinase	I
23	(	O
24	RPTK	B
25	)	O
26	interacting	O
27	protein	O
28	by	O
29	yeast	O
30	two	O
31	-	O
32	hybrid	O
33	screening	O
34	.	O

1	Unlike	O
2	the	O
3	mammalian	O
4	proteins	O
5	,	O
6	XFGF3	B
7	is	O
8	efficiently	O
9	secreted	O
10	as	O
11	a	O
12	Mr	O
13	31	O
14	,	O
15	000	O
16	glycoprotein	O
17	,	O
18	gp31	B
19	,	O
20	which	O
21	undergoes	O
22	proteolytic	O
23	cleavage	O
24	to	O
25	produce	O
26	an	O
27	NH2	O
28	-	O
29	terminally	O
30	truncated	O
31	product	O
32	,	O
33	gp27	B
34	.	O

1	This	O
2	study	O
3	is	O
4	a	O
5	further	O
6	and	O
7	more	O
8	extensive	O
9	validation	O
10	of	O
11	the	O
12	clinician	O
13	rated	O
14	NIMH	O
15	-	O
16	LCM	O
17	-	O
18	p	O
19	.	O

1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	Antimicrobial	O
2	Susceptibility	O
3	of	O
4	Klebsiella	O
5	pneumoniae	O
6	Producing	O
7	Extended	B
8	-	I
9	Spectrum	I
10	beta	I
11	-	I
12	lactamase	I
13	(	O
14	ESBL	B
15	)	O
16	Isolated	O
17	in	O
18	Hospitals	O
19	in	O
20	Brazil	O
21	.	O

1	In	O
2	the	O
3	COPD	O
4	patients	O
5	,	O
6	the	O
7	variability	O
8	of	O
9	Delta	O
10	-	O
11	inst	O
12	Rrs	O
13	(	O
14	30	O
15	%)	O
16	was	O
17	greater	O
18	than	O
19	that	O
20	of	O
21	FOT	O
22	Rrs	O
23	(	O
24	21	O
25	%).	O

1	The	O
2	determination	O
3	of	O
4	the	O
5	double	O
6	bounds	O
7	in	O
8	blood	O
9	serum	O
10	lipids	O
11	by	O
12	titration	O
13	with	O
14	ozone	O
15	:	O
16	the	O
17	pathophysiology	O
18	and	O
19	diagnostic	O
20	significance	O
21	]	O
22	In	O
23	this	O
24	article	O
25	the	O
26	method	O
27	of	O
28	definition	O
29	of	O
30	double	O
31	binders	O
32	in	O
33	lipids	O
34	of	O
35	blood	O
36	serum	O
37	in	O
38	patients	O
39	with	O
40	different	O
41	diseases	O
42	basically	O
43	atherosclerosis	O
44	and	O
45	ischemic	O
46	heart	O
47	disease	O
48	,	O
49	with	O
50	use	O
51	titration	O
52	by	O
53	ozone	O
54	is	O
55	given	O
56	.	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	B
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	B
31	.	O

1	T	O
2	cells	O
3	express	O
4	two	O
5	isoforms	O
6	of	O
7	S6k1	B
8	:	O
9	a	O
10	70	O
11	kDa	O
12	cytoplasmic	O
13	kinase	O
14	and	O
15	an	O
16	85	O
17	kDa	O
18	isoform	O
19	that	O
20	has	O
21	a	O
22	classic	O
23	nuclear	O
24	localisation	O
25	.	O

1	Our	O
2	data	O
3	show	O
4	that	O
5	multiple	O
6	MLSN1	B
7	transcripts	I
8	,	O
9	both	O
10	constitutively	O
11	expressed	O
12	and	O
13	inducible	O
14	,	O
15	are	O
16	present	O
17	in	O
18	cultured	O
19	pigmented	O
20	melanoma	O
21	cells	O
22	,	O
23	and	O
24	suggest	O
25	that	O
26	MLSN1	B
27	expression	O
28	can	O
29	be	O
30	regulated	O
31	at	O
32	the	O
33	level	O
34	of	O
35	both	O
36	transcription	O
37	and	O
38	mRNA	O
39	processing	O
40	.	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	B
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	B
16	receptor	I
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	B
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	Mouse	B
2	Impact	I
3	is	O
4	a	O
5	paternally	O
6	expressed	O
7	gene	O
8	encoding	O
9	an	O
10	evolutionarily	O
11	conserved	O
12	protein	O
13	of	O
14	unknown	O
15	function	O
16	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	B
12	suppressor	I
13	ING1	I
14	with	O
15	the	O
16	mSin3	B
17	/	O
18	HDAC1	B
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	These	O
2	and	O
3	other	O
4	data	O
5	presented	O
6	suggest	O
7	that	O
8	TAg	B
9	'	O
10	re	O
11	-	O
12	models	O
13	'	O
14	host	O
15	cell	O
16	transcription	O
17	factors	O
18	that	O
19	are	O
20	used	O
21	early	O
22	in	O
23	viral	O
24	infection	O
25	,	O
26	and	O
27	thereby	O
28	mimics	O
29	an	O
30	event	O
31	that	O
32	naturally	O
33	occurs	O
34	during	O
35	transformation	O
36	.	O

1	This	O
2	sensitivity	O
3	analysis	O
4	showed	O
5	that	O
6	the	O
7	practical	O
8	limits	O
9	of	O
10	the	O
11	accuracy	O
12	of	O
13	the	O
14	used	O
15	screening	O
16	test	O
17	jeopardize	O
18	the	O
19	estimation	O
20	of	O
21	the	O
22	true	O
23	herd	O
24	prevalence	O
25	within	O
26	reasonable	O
27	confidence	O
28	limits	O
29	,	O
30	because	O
31	the	O
32	within	O
33	-	O
34	herd	O
35	PTB	O
36	true	O
37	prevalence	O
38	was	O
39	low	O
40	.	O
41	For	O
42	this	O
43	reason	O
44	we	O
45	augmented	O
46	the	O
47	herd	O
48	specificity	O
49	for	O
50	herds	O
51	with	O
52	larger	O
53	adult	O
54	herd	O
55	size	O
56	(>	O
57	5	O
58	).	O

1	Genomic	O
2	organization	O
3	of	O
4	the	O
5	human	O
6	phosphodiesterase	B
7	PDE11A	I
8	gene	I
9	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Patients	O
2	underwent	O
3	pretreatment	O
4	cystoscopy	O
5	and	O
6	detailed	O
7	tumor	O
8	mapping	O
9	,	O
10	and	O
11	were	O
12	treated	O
13	with	O
14	75	O
15	mg	O
16	.	O
17	/	O
18	m	O
19	.	O
20	2	O
21	cisplatin	O
22	on	O
23	day	O
24	1	O
25	and	O
26	1	O
27	gm	O
28	./	O
29	m	O
30	.	O
31	2	O
32	daily	O
33	,	O
34	5	O
35	-	O
36	fluorouracil	O
37	on	O
38	days	O
39	1	O
40	to	O
41	4	O
42	and	O
43	definitive	O
44	radiotherapy	O
45	.	O

1	Bupropion	O
2	to	O
3	aid	O
4	smoking	O
5	cessation	O
6	.	O

1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	O
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O

1	There	O
2	were	O
3	significant	O
4	differences	O
5	(	O
6	p	O
7	<	O
8	0	O
9	.	O
10	05	O
11	)	O
12	between	O
13	the	O
14	fracture	O
15	and	O
16	nonfracture	O
17	groups	O
18	in	O
19	the	O
20	total	O
21	femur	O
22	BMD	O
23	(	O
24	13	O
25	%),	O
26	trabecular	O
27	BMD	O
28	in	O
29	the	O
30	distal	O
31	radius	O
32	(	O
33	4	O
34	%),	O
35	and	O
36	the	O
37	fractal	O
38	dimension	O
39	in	O
40	the	O
41	radiographs	O
42	(	O
43	FD2	O
44	)	O
45	(	O
46	3	O
47	%).	O

1	Validity	O
2	of	O
3	NIR	O
4	spectroscopy	O
5	for	O
6	quantitatively	O
7	measuring	O
8	muscle	O
9	oxidative	O
10	metabolic	O
11	rate	O
12	in	O
13	exercise	O
14	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	Termination	O
2	of	O
3	induced	O
4	VT	O
5	on	O
6	the	O
7	first	O
8	attempt	O
9	was	O
10	comparable	O
11	with	O
12	BV	O
13	pacing	O
14	(	O
15	87	O
16	.	O
17	4	O
18	%)	O
19	versus	O
20	RV	O
21	pacing	O
22	(	O
23	89	O
24	.	O
25	6	O
26	%).	O

1	Changes	O
2	in	O
3	stimulation	O
4	levels	O
5	over	O
6	time	O
7	in	O
8	nucleus	O
9	22	O
10	cochlear	O
11	implant	O
12	users	O
13	.	O

1	A	O
2	marked	O
3	decrease	O
4	in	O
5	the	O
6	type	B
7	1	I
8	insulin	I
9	-	I
10	like	I
11	growth	I
12	factor	I
13	(	I
14	IGF	I
15	)	I
16	receptor	I
17	(	O
18	IGF	B
19	-	I
20	IR	I
21	)	O
22	occurs	O
23	in	O
24	prostate	O
25	epithelial	O
26	cells	O
27	during	O
28	transformation	O
29	from	O
30	the	O
31	benign	O
32	to	O
33	the	O
34	metastatic	O
35	state	O
36	.	O

